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Osteoarthritis is one of the most debilitating diseases affecting millions of people 
worldwide. However, there is no FDA approved disease modifying drug specifically 
for OA. Surgery remains an effective last resort to restore the function of the joints.  
As the aging populations increase worldwide, the number of OA patients increases 
dramatically in recent years and is expected to increase in many years to come. This 
is a book that summarizes recent advance in OA diagnosis, treatment, and surgery. 
It includes wide ranging topics from the cutting edge gene therapy to alternative 
medicine. Such multifaceted approaches are necessary to develop novel and effective 
therapy to cure OA in the future. In this book, different surgical methods are described 
to restore the function of the joints. In addition, various treatment options are 
presented, mainly to reduce the pain and enhance the life quality of the OA patients.
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Preface 
Osteoarthritis is one of the most debilitating diseases worldwide. Millions of people 
suffer from pain and disability associated with this disease. There are two major
types of OA: primary and secondary. The primary OA is associated with aging. 
While people live longer and longer, the prevalence of OA becomes more 
prominent. It is expected that the percentage of the people who suffer from OA will
continue to rise in the coming decades. The secondary OA is a consequence of injury
to the joints. It is often associated with sports injury and/or other traumatic events.
Thus, it often occurs in young people and adults who enjoy an active life style.
Although the direct damage to the joint such as rapture of the ligaments is often 
repairable by surgery, the patients nevertheless would likely suffer from
degeneration of the joint cartilage later in life. 
My connection to OA is several fold. Because of the prevalence of OA, many of us
know family members and/or friends who suffer from the disease. I am no 
exception. My mother suffered from both rheumatoid arthritis (RA) and OA.
Although she also suffered from other diseases, she complained most about arthritis.
Some of the other diseases might be more life-threatening; however, none of them 
brought as much pain and restrained her to bed on a daily basis as arthritis. She
often said that life is not worth living if there is no quality. After her RA was 
brought under control by new drug therapy and both her knees were replaced by
surgery, her pain became manageable and her mobility was regained. She was able
to perform daily routine activities by herself that many of us take for granted, such
as going to the bathroom, standing up after sitting, and walking the stairs. Her 
outlook on her life in the old age was brightened significantly because of the new
treatment and surgery.
As a biomedical researcher, I was fascinated by the intricate process of cartilage
development and aging since I was a young graduate student. The research was 
driven primarily by interest and curiosity. However, my mother’s life experience and
my interactions with other arthritis patients brought urgency as well as practicality 
into the basic research we were conducting. The basic knowledge gained from
research must be translated into new methods of diagnosis, treatment, and surgery for 
patients. That is the most direct and effective way to improve the life quality of 
patients. 
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So far, there is no FDA approved disease modified drugs for OA. Joint replacement 
surgery remains the last, and perhaps the most effective way to restore the functions of 
the joint. Due to these circumstances, a multifaceted approach is needed to improve 
the current treatment as well as to develop new therapy for the future. We need to 
emphasize the improvement not only diagnosis and treatment of OA, but also the 
surgery to restore the function of the joint. We need to consider not only 
mechanistically driven research, but also alternative medicine that has been in practice 
in treating OA related symptoms in different parts of the world for long time. 
Based on these guiding principles, we have included a variety of articles written by 
physicians and OA researchers from different parts of the world. The topics of the 
articles include general as well as alternative treatment of OA, diagnosis of OA in 
upper extremity (hand, wrist, shoulder, and elbow) as well as in lower extremity (hip, 
knee, and ankle), and common strategies for treatment as well as surgery of OA. We 
hope that this book serves as a comprehensive resource for professionals as well as 
patients who are interested in learning the state-of-the-art of OA diagnosis, treatment, 
and surgery. To borrow a Chinese proverb 抛砖引玉 (cast a brick to attract jade), we 
hope that this compilation of a variety of articles in this book, some of which are non-
traditional or even provocative, may serve as a precursor to the breakthrough in 
developing new therapy and treatment of OA in the future. 
 
Qian Chen, Ph.D. 
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Long-Term Treatment of Osteoarthritis Pain: 
Achieving a Balance Between Efficacy and 
Tolerability for a Successful Chronic Therapy 
Mila Etropolski 
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 
USA 
1. Introduction 
Throughout the world, in both developed and developing countries, arthritis is one of 
the most common causes of chronic pain (Catala et al., 2002; Elliott et al., 1999; Johannes 
et al., 2010; Tsang et al., 2008). The National Arthritis Data Workgroup estimates that 
46.4 million adults in the United States have been diagnosed with some form of arthritis 
based on analyses of data from the third National Health and Nutrition Examination 
Survey (NHANES III; 1991-1994), the 2003 to 2005 National Health Interview Survey, 
and 2005 US Census Bureau population estimates (Helmick et al., 2008; Lawrence et al., 
2008). Within this group, approximately 27 million adults have been diagnosed with 
osteoarthritis, making it the most common form of arthritis in the United States 
(Lawrence et al., 2008). 
The prevalence of osteoarthritis increases with age (Kopec et al., 2007; Lawrence et al., 2008; 
Sakalauskiene & Jauniskiene, 2010; Shane & Loeser, 2010). Based on data from 
approximately 4 million patients seen over a 1-year period in British Columbia, Canada, the 
estimated prevalence of osteoarthritis increases from approximately 7% in patients between 
40 and 44 years of age to 26% in patients between 60 and 64 years of age and to 49% in 
patients between 80 and 84 years of age (Kopec et al., 2007). The prevalence of knee 
osteoarthritis is particularly high in the elderly, and knee osteoarthritis is a major cause of 
disability in elderly patients (Shane & Loeser, 2010). Based on data from NHANES III and 
the Framingham Osteoarthritis Study, the prevalence of knee osteoarthritis in the United 
States is estimated to be 14% in adults 26 years of age or older, 19% in those 45 years of age 
or older, 37% in those 60 years of age or older, and 44% in those over 80 years of age (Dillon 
et al., 2006; Felson et al., 1987; Lawrence et al., 2008). 
Osteoarthritis can have a negative impact on health-related quality of life and psychological 
well-being (Axford et al., 2008; Breedveld, 2004; de Bock et al., 1995; Jinks et al., 2007; Majani 
et al., 2005; Salaffi et al., 2005). Patients with osteoarthritis are often limited in their ability to 
participate in main daily activities (eg, household duties, employment, body care, 
ambulation, and sleep) and to maintain their independence (de Bock et al., 1995; Hunter et 
al., 2008; Jinks et al., 2007; Segal et al., 2004). Patients’ mental health has been shown to 
decrease progressively over time, and patients with more severe osteoarthritis pain are most 
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likely to experience depression and to have difficulty coping with their disease (Axford et 
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al., 2008). In addition, patients with osteoarthritis have an increased risk of developing 
metabolic syndrome and cardiovascular disease (Breedveld, 2004; Puenpatom & Victor, 
2009). 
Osteoarthritis is also associated with a substantial economic cost (Kotlarz et al., 2009; 
Wagner, 2011; White et al., 2007). According to an analysis of a medical claims database of 
32,043 privately insured patients from 1999 to 2004, the average annual direct cost of 
osteoarthritis was $11,543 per patient, including $8,602 in direct medical costs and $2,941 in 
drug costs (White et al., 2007). Based on results of the data from the Medical Expenditure 
Panel Survey, which was conducted over a 10-year period from 1996 to 2005, osteoarthritis 
was estimated to have increased aggregate annual healthcare expenditures by $185.5 billion 
per year (in 2007 dollars; Kotlarz et al., 2009). 
Osteoarthritis can occur in any joint; however, it occurs most frequently in the knees, hips, 
and hands. Other commonly affected joints include those in the feet and the cervical or 
lumbar regions of the spine (Martel-Pelletier & Pelletier, 2010). Osteoarthritis is 
characterized by progressive degeneration of articular cartilage, bone remodeling and 
sclerosis, formation of osteophytes, synovial hypertrophy, and meniscal damage (Abramson 
& Attur, 2009; Felson, 2009; Hunter & Felson, 2006). The loss of articular cartilage, which is 
generally recognized as a defining characteristic of osteoarthritis, results from an imbalance 
in the dynamic equilibrium between the synthesis and degradation of the cartilaginous 
extracellular matrix (Abramson & Attur, 2009; Hinton et al., 2002; Michael et al., 2010). In 
normal articular cartilage, chondrocytes are responsible for the production and maintenance 
of the cartilaginous extracellular matrix; chondrocytes also act as mechano- and osmo-
sensors, altering the rate of matrix synthesis or degradation in response to local 
physiochemical changes (Loeser, 2008; Martel-Pelletier & Pelletier, 2010; Shane & Loeser, 
2010). However, in osteoarthritis, inflammatory and catabolic signals stimulate 
chondrocytes to synthesize proteolytic enzymes that actively degrade the articular cartilage 
matrix (Abramson & Attur, 2009; Shane & Loeser, 2010). In response to this increased 
degradation of cartilage matrix, chondrocytes trigger increased synthesis of the 
proteoglycan components of the matrix, but these newly synthesized proteoglycans are 
structurally altered and may have a reduced capacity to form new cartilage (Martel-Pelletier 
& Pelletier, 2010; Rizkalla et al., 1992). As osteoarthritis progresses, eventually chondrocytes 
are unable to synthesize enough proteoglycans to offset the degradation of the cartilage 
matrix. Irreversible matrix degradation and cartilage loss is followed by the development of 
synovitis, joint incongruence, and formation of subchondral cysts (Martel-Pelletier & 
Pelletier, 2010; Michael et al., 2010). 
Although the loss of articular cartilage is considered to be the physiological hallmark of 
osteoarthritis, the destruction of cartilage is not directly responsible for the joint pain that is 
considered to be the clinical hallmark of the disease (Felson, 2009). The most likely sources 
of osteoarthritis pain are the bone, muscle, ligaments, periosteum, and synovium of the 
affected joints. Bone-related changes associated with osteoarthritis joint pain may include 
bone marrow lesions, sub-articular bone attrition, periostitis associated with osteophyte 
formation, subchondral microfractures, and bone angina. Osteoarthritis joint pain has also 
been linked to synovitis and joint effusions. In cases where osteoarthritis is secondary to 
joint injury with rupture of the ligaments, the nerves themselves may be a source of pain. 
Nerve fiber regrowth is typically abnormal and disorganized, comparable to that observed 
in animal models of nerve injury (Felson, 2009; Hunter et al., 2008). 
Long-Term Treatment of Osteoarthritis Pain:  
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Pain is usually the predominant symptom of osteoarthritis. Osteoarthritis pain is often 
described as deep and aching and is typically exacerbated by physical activity and relieved 
by rest. In advanced osteoarthritis, pain may become more constant and patients may 
experience pain while at rest, resulting in sleep disturbances that can further exacerbate pain 
(Hunter et al., 2008). Traditionally, osteoarthritis pain has been attributed to local tissue 
injury, which causes mechanical nociceptive pain (Gwilym et al., 2009; Hochman et al., 
2010). However, results from several studies indicate that central sensitization (ie, increased 
response to stimulation mediated by amplification of signaling in the central nervous 
system) may also play a role in the pathophysiology of chronic osteoarthritis pain (Arendt-
Nielsen et al., 2010; Courtney et al., 2010; Hochman et al., 2010; Kidd et al., 2007; Kosek & 
Ordeberg, 2000). In patients with chronic osteoarthritis, persistent joint damage, synovial 
inflammation, and subchondral bone changes are associated with chronic nociceptor 
stimulation. This stimulation can alter the mechanisms of nociceptive processing, resulting 
in modification of central pain-transmitting neurons and enhanced pain response (Arendt-
Nielsen et al., 2010; Courtney et al., 2010; Hochman et al., 2010). Symptoms associated with 
central sensitization in patients with osteoarthritis include hypersensitivity to pain, skin 
sensitivity, and the spread of pain from the affected joint to large body areas (ie, referred 
pain; Arendt-Nielsen et al., 2010; Hochman et al., 2010; Hunter et al., 2008; Woolf, 2011). 
2. Osteoarthritis management 
There are currently no treatment options available for osteoarthritis that prevent or reverse 
disease progression or deterioration of the affected joints (Felson, 2006, 2009; Hinton et al., 
2002; Michael et al., 2010). For that reason, osteoarthritis treatment strategies are generally 
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exercise habits was associated with significant improvements in physical functioning and 
mobility (Messier et al., 2004). In a meta-analysis of changes in pain and physical function 
experienced by patients with osteoarthritis who lost weight (n = 454), Christensen and 
colleagues found that physical disability was significantly reduced in patients who lost more 
than 5.1% of their body weight at a rate of more than 0.24% per week (Christensen et al., 
2007). 
Current osteoarthritis treatment guidelines recommend that all patients participate in 
regular aerobic and muscle-strengthening exercise programs, which are intended to 
improve pain control, balance, strength, flexibility, and endurance (American College of 
Rheumatology, 2000; Coleman et al., 2010; Jordan et al., 2003; Zhang et al., 2008). The 
Physical Activity Guidelines Advisory Committee to the US Department of Health and 
Human Services found that there is strong evidence that moderate exercise, such as walking, 
can provide small to moderate improvements in pain relief and small improvements in 
function and disability in patients with osteoarthritis. These guidelines also state that 
patients with osteoarthritis can expect “significant improvements in pain, physical function, 
quality of life, and mental health” along with “delayed onset of disability” by engaging in 
low-impact physical activity 3 to 5 times per week for 30 to 60 minutes per session (Physical 
Activity Guidelines Advisory Committee, 2008). However, a recent systematic review of 
clinical trials of exercise therapy for managing hip osteoarthritis found little evidence that 
exercise therapy was effective for reducing osteoarthritis pain or improving joint function or 
quality of life (McNair et al., 2009). While the available evidence indicates that exercise can 
be beneficial for patients with knee osteoarthritis, the number of studies sufficiently 
powered to examine the effects of exercise on hip osteoarthritis is limited, and well-designed 
trials to determine joint-specific exercise recommendations are needed (McNair et al., 2009; 
Petrella, 2000). 
2.2 Pharmacologic measures 
Pharmacologic options for the management of osteoarthritis pain include acetaminophen, 
non-steroidal anti-inflammatory drugs (NSAIDs), intra-articular injections of hyaluronic 
acid or corticosteroids, the serotonin-norepinephrine reuptake inhibitor (SNRI) duloxetine, 
and opioids (Zhang et al., 2008). In addition, some nutritional supplements have shown 
efficacy in the reduction of osteoarthritis-related pain and may slow disease progression 
(Gregory et al., 2008; McAlindon et al., 2000). Topical capsaicin or lidocaine may also be 
used as adjunctive therapy for pain relief in combination with other therapies (Barron & 
Rubin, 2007; Jordan et al., 2003; Zhang et al., 2008). 
2.2.1 Dietary supplements 
A number of dietary supplements have been marketed for the management of osteoarthritis 
(Gregory et al., 2008). Supplements containing glucosamine sulfate, chondroitin sulfate, 
and/or S-adenosylmethionine may provide pain relief and functional improvement in 
patients with osteoarthritis, and these supplements may have structure-modifying effects 
that may slow disease progression. However, results from clinical studies of these 
supplements have been mixed (Gregory et al., 2008; McAlindon et al., 2000; Zhang et al., 
2008; Zhang et al., 2010). 
Glucosamine is a naturally occurring constituent of cartilage proteoglycans found in 
ligaments, synovial fluid, and other joint structures. In a pooled analysis of 20 randomized 
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controlled trials in patients with knee osteoarthritis (n = 2,570), treatment with glucosamine 
was associated with a 28% improvement in pain and a 21% improvement in function using 
the Lequesne index. However, 5 of the 20 studies analyzed failed to show that glucosamine 
was superior to placebo (Towheed et al., 2005; Towheed & Anastassiades, 2007). The 
inconsistency of results from different trials of glucosamine may be due to the use of 
different products (ie, glucosamine sulfate vs glucosamine hydrochloride), different trial 
designs, and different analysis methods (Gregory et al., 2008; McAlindon et al., 2000). In 2 
separate 3-year, randomized placebo-controlled trials of glucosamine sulfate (1,500 mg/day) 
in patients with knee osteoarthritis, patients who received glucosamine sulfate had no 
significant average change in joint-space width, while patients who received placebo had 
significant joint-space narrowing (Pavelka et al., 2002; Reginster et al., 2001). These results 
suggest that glucosamine sulfate may slow the progression of osteoarthritis in patients with 
mild to moderate disease (Zhang et al., 2008). 
Chondroitin sulfate is a glycosaminoglycan involved in the formation of cartilage and other 
joint matrix structures. Evidence supporting the clinical benefits of chondroitin sulfate for 
the improvement of osteoarthritis symptoms is inconsistent (Reichenbach et al., 2007). In a 
recent meta-analysis of 10 large-scale placebo-controlled trials of chondroitin, glucosamine, 
or their combination (n = 3,803), Wandel and colleagues found that none of these therapies 
were associated with significant improvements in pain, as measured on a 10-cm visual 
analog scale, nor were they associated with any significant reduction in joint-space 
narrowing compared with placebo (Wandel et al., 2010). 
S-Adenosylmethionine is a naturally occurring molecule involved in several different 
metabolic pathways. S-Adenosylmethionine may increase chondrocyte production and 
cartilage thickness and may decrease cytokine-induced chondrocyte damage, thus slowing the 
progression of osteoarthritis (Gregory et al., 2008). Results of clinical trials of S-
adenosylmethionine have been consistently positive, showing that the efficacy of S-
adenosylmethionine is superior to that of placebo and similar to that of NSAIDs; however, S-
adenosylmethionine has a slower onset of action compared with NSAIDs (Hardy et al., 2003; 
Kim et al., 2009; Najm et al., 2004; Sander, 2003). S-Adenosylmethionine has a short shelf-life 
and may become unstable over time, and dose-escalation may be required to maintain efficacy 
(McHughes & Lipman, 2006). For these reasons and because no studies have been conducted 
comparing the risk/benefit ratio of S-adenosylmethionine with conventional therapies, current 
treatment guidelines do not recommend the use of S-adenosylmethionine for the management 
of osteoarthritis (Gregory et al., 2008; McHughes & Lipman, 2006). 
2.2.2 Acetaminophen 
Acetaminophen (up to 4 g/day) is recommended as the first-line oral analgesic therapy for 
the management of mild to moderate osteoarthritis pain (Altman, 2009; American College of 
Rheumatology, 2000; Jordan et al., 2003; Zhang et al., 2008). It can be used for the long-term 
management of osteoarthritis pain either alone or in combination with another analgesic 
(Jordan et al., 2003; Zhang et al., 2008). 
The analgesic activity of acetaminophen is not fully understood, but is generally thought to 
result from the effects of acetaminophen on mediators of pain and inflammation in the 
central nervous system, possibly through interactions with nitric oxide, substance P 
receptors, or beta-endorphin. The anti-inflammatory properties of acetaminophen may 
block some of the inflammatory mechanisms involved in osteoarthritis pain (Flood, 2010). 
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In general, results from the published literature indicate that at standard recommended 
doses, pain relief achieved with acetaminophen is inferior to that achieved with most 
common NSAIDs (Boureau et al., 2004; Golden et al., 2004; Lee et al., 2004; Zhang et al., 
2004); however, NSAIDs are associated with more severe side effects, especially when used 
at high doses for prolonged periods of time (Flood, 2010). A meta-analysis of data from 6 
randomized placebo-controlled trials found that acetaminophen was safe and effective for 
the management of osteoarthritis pain; however, pain relief, clinical response rates, and 
health status were better with NSAIDs (including ibuprofen, diclofenac, rofecoxib, celecoxib, 
and naproxen) than with acetaminophen, and more patients preferred NSAIDs over 
acetaminophen. This meta-analysis also showed that the tolerability profile of 
acetaminophen was comparable to that of placebo, but NSAIDs were associated with more 
gastrointestinal side effects than acetaminophen or placebo (Zhang et al., 2004). 
It should also be noted that although most studies of acetaminophen for the management of 
osteoarthritis pain have found that acetaminophen is associated with a low rate of adverse 
events (AEs; Flood, 2010), some studies have found associations between acetaminophen 
use and increased risks of upper gastrointestinal complications (Garcia Rodriguez & 
Hernandez-Diaz, 2001; Rahme et al., 2002) and renal toxicity (Fored et al., 2001). To date, 
these results are considered equivocal and have not resulted in changes to the 
recommendation that acetaminophen be used as first-line therapy for osteoarthritis pain 
management (Zhang et al., 2008). 
2.2.3 NSAIDs 
NSAIDs are recommended as a second-line treatment option in patients for whom 
acetaminophen treatment has failed to provide adequate pain relief (Jordan et al., 2003; 
Zhang et al., 2008). NSAIDs should be used at the lowest effective dose to avoid the risk of 
gastrointestinal and cardiovascular AEs, and long-term use should be avoided if possible 
(Zhang et al., 2008). In the United States, all marketed prescription NSAIDs carry a boxed 
warning about their potential to cause cardiovascular and gastrointestinal side effects (US 
Food and Drug Administration, 2005; Zhang et al., 2008). 
NSAIDs are widely prescribed and are generally considered to be effective for the 
management of mild to moderate osteoarthritis pain. However, NSAIDs have a ceiling dose 
above which no additional analgesia can be achieved, which may limit their efficacy for the 
treatment of more severe pain (Fendrick & Greenberg, 2009). In a meta-analysis of the 
analgesic efficacy of NSAIDs for the short-term management of knee osteoarthritis pain (n = 
10,845), Bjordal and colleagues observed that on average, NSAIDs reduced pain intensity by 
10.1 mm (95% confidence interval [CI], 7.4-12.8) on a 10-cm visual analog scale, which was 
15.6% better than placebo. Using a random-effects model, the authors determined that the 
effect size for pain reduction associated with NSAIDs was 0.32 (95% CI, 0.24-0.39; Bjordal et 
al., 2004). 
Most common NSAIDs reduce inflammation through inhibition of the cyclo-oxygenase 
(COX) enzymes COX-1 and COX-2. COX-1 is expressed constitutively in many tissues and 
cells and may be involved in a number of physiologic functions, including protection of the 
gastrointestinal tract from its own acidity, platelet aggregation, and regulation of renal 
blood flow. In contrast, COX-2 is an inducible protein that is upregulated during 
inflammation and is primarily localized in inflamed tissue; COX-2 is not present in the 
stomach or small intestine (Crofford, 1997; Pham & Hirschberg, 2005). NSAIDs that inhibit 
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both COX-1 and COX-2 are classified as nonselective NSAIDs (eg, ibuprofen, diclofenac, 
naproxen, nabumetone, indomethacin, aspirin, etc.), whereas NSAIDs that selectively inhibit 
COX-2 are classified as selective COX-2 inhibitors or coxibs (eg, celecoxib, etoricoxib; 
Altman, 2009). 
The analgesic effects of NSAIDs are predominantly attributed to the inhibition of COX-2, 
while the gastrointestinal side effects are thought to be caused by inhibition of COX-1 
(Fendrick & Greenberg, 2009). Thus, nonselective NSAIDs are associated with an increased 
risk of severe upper gastrointestinal complications, including gastrointestinal tract bleeding, 
peptic ulcer disease, obstruction, and perforation (Pham & Hirschberg, 2005). It is estimated 
that chronic use of nonselective NSAIDs increases a patient’s risk of upper gastrointestinal 
complications by 3- to 5-fold compared with patients who do not take nonselective NSAIDs 
(Gabriel et al., 1991; Garcia Rodriguez & Hernandez-Diaz, 2001). For example, in a 5-year 
population-based cohort study of 958,397 persons in the United Kingdom, the relative risk 
of upper gastrointestinal bleeding and/or perforation was 2.4 (95% CI, 1.9-3.1) among 
patients who used low or medium doses of NSAIDs and 4.9 (95% CI, 4.1-5.8) among patients 
who used high doses of NSAIDs compared with non-users of NSAIDs. The use of 
gastroprotectants, such as proton pump inhibitors and misoprostol, reduces these risks 
(Garcia Rodriguez & Hernandez-Diaz, 2001), and many osteoarthritis treatment guidelines 
recommend the co-prescription of gastroprotectants when nonselective NSAIDs are used to 
manage pain, especially in patients who are at an increased risk of gastrointestinal 
complications (ie, elderly patients, patients with a history of gastrointestinal bleeding or 
ulcer disease, patients on a low-dose aspirin regimen, and patients with a history of alcohol 
consumption; Jordan et al., 2003; Pham & Hirschberg, 2005; Zhang et al., 2008). Because 
elderly patients have an increased risk of gastrointestinal complications associated with 
NSAIDs, the 2009 American Geriatrics Society Clinical Practice Guideline for the 
Pharmacological Management of Persistent Pain in Older Adults recommends that 
nonselective NSAIDs and COX-2 selective inhibitors be considered rarely, with caution, and 
only in highly selected individuals (American Geriatrics Society Panel on the 
Pharmacological Management of Persistent Pain in Older Persons, 2009). 
Selective COX-2 inhibitors are associated with a substantially reduced risk of 
gastrointestinal complications relative to nonselective NSAIDs (Pham & Hirschberg, 2005). 
However, selective COX-2 inhibitors are associated with an increased risk of cardiovascular 
events (eg, myocardial infarction and stroke), and 2 widely used COX-2 inhibitors, rofecoxib 
and valdecoxib, were withdrawn from the market due to concerns about their 
cardiovascular safety (Altman, 2009; Andersohn et al., 2006; Caldwell et al., 2006). The 
cardiovascular risks associated with selective COX-2 inhibitors have been confirmed by the 
results of several studies (Bombardier et al., 2000; Bresalier et al., 2005; Graham et al., 2005; 
Nussmeier et al., 2005; Solomon et al., 2005), and in recent years these findings have been 
extended to nonselective NSAIDs, particularly diclofenac (Fosbol et al., 2009; Gislason et al., 
2009; Hammad et al., 2008; McGettigan & Henry, 2006; Schjerning Olsen et al., 2011). In 
patients with a history of myocardial infarction, Schjerning Olsen and colleagues observed 
that NSAID treatment durations ranging from less than 7 days to more than 90 days were 
associated with significantly increased risks of death and recurrent myocardial infarction. 
All of the NSAIDs analyzed in this study (ie, rofecoxib, celecoxib, ibuprofen, diclofenac, 
naproxen, and other NSAIDs) were associated with a significantly increased risk of death. 
Diclofenac was associated with the earliest onset and highest relative risk of 
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gastrointestinal tract from its own acidity, platelet aggregation, and regulation of renal 
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inflammation and is primarily localized in inflamed tissue; COX-2 is not present in the 
stomach or small intestine (Crofford, 1997; Pham & Hirschberg, 2005). NSAIDs that inhibit 
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both COX-1 and COX-2 are classified as nonselective NSAIDs (eg, ibuprofen, diclofenac, 
naproxen, nabumetone, indomethacin, aspirin, etc.), whereas NSAIDs that selectively inhibit 
COX-2 are classified as selective COX-2 inhibitors or coxibs (eg, celecoxib, etoricoxib; 
Altman, 2009). 
The analgesic effects of NSAIDs are predominantly attributed to the inhibition of COX-2, 
while the gastrointestinal side effects are thought to be caused by inhibition of COX-1 
(Fendrick & Greenberg, 2009). Thus, nonselective NSAIDs are associated with an increased 
risk of severe upper gastrointestinal complications, including gastrointestinal tract bleeding, 
peptic ulcer disease, obstruction, and perforation (Pham & Hirschberg, 2005). It is estimated 
that chronic use of nonselective NSAIDs increases a patient’s risk of upper gastrointestinal 
complications by 3- to 5-fold compared with patients who do not take nonselective NSAIDs 
(Gabriel et al., 1991; Garcia Rodriguez & Hernandez-Diaz, 2001). For example, in a 5-year 
population-based cohort study of 958,397 persons in the United Kingdom, the relative risk 
of upper gastrointestinal bleeding and/or perforation was 2.4 (95% CI, 1.9-3.1) among 
patients who used low or medium doses of NSAIDs and 4.9 (95% CI, 4.1-5.8) among patients 
who used high doses of NSAIDs compared with non-users of NSAIDs. The use of 
gastroprotectants, such as proton pump inhibitors and misoprostol, reduces these risks 
(Garcia Rodriguez & Hernandez-Diaz, 2001), and many osteoarthritis treatment guidelines 
recommend the co-prescription of gastroprotectants when nonselective NSAIDs are used to 
manage pain, especially in patients who are at an increased risk of gastrointestinal 
complications (ie, elderly patients, patients with a history of gastrointestinal bleeding or 
ulcer disease, patients on a low-dose aspirin regimen, and patients with a history of alcohol 
consumption; Jordan et al., 2003; Pham & Hirschberg, 2005; Zhang et al., 2008). Because 
elderly patients have an increased risk of gastrointestinal complications associated with 
NSAIDs, the 2009 American Geriatrics Society Clinical Practice Guideline for the 
Pharmacological Management of Persistent Pain in Older Adults recommends that 
nonselective NSAIDs and COX-2 selective inhibitors be considered rarely, with caution, and 
only in highly selected individuals (American Geriatrics Society Panel on the 
Pharmacological Management of Persistent Pain in Older Persons, 2009). 
Selective COX-2 inhibitors are associated with a substantially reduced risk of 
gastrointestinal complications relative to nonselective NSAIDs (Pham & Hirschberg, 2005). 
However, selective COX-2 inhibitors are associated with an increased risk of cardiovascular 
events (eg, myocardial infarction and stroke), and 2 widely used COX-2 inhibitors, rofecoxib 
and valdecoxib, were withdrawn from the market due to concerns about their 
cardiovascular safety (Altman, 2009; Andersohn et al., 2006; Caldwell et al., 2006). The 
cardiovascular risks associated with selective COX-2 inhibitors have been confirmed by the 
results of several studies (Bombardier et al., 2000; Bresalier et al., 2005; Graham et al., 2005; 
Nussmeier et al., 2005; Solomon et al., 2005), and in recent years these findings have been 
extended to nonselective NSAIDs, particularly diclofenac (Fosbol et al., 2009; Gislason et al., 
2009; Hammad et al., 2008; McGettigan & Henry, 2006; Schjerning Olsen et al., 2011). In 
patients with a history of myocardial infarction, Schjerning Olsen and colleagues observed 
that NSAID treatment durations ranging from less than 7 days to more than 90 days were 
associated with significantly increased risks of death and recurrent myocardial infarction. 
All of the NSAIDs analyzed in this study (ie, rofecoxib, celecoxib, ibuprofen, diclofenac, 
naproxen, and other NSAIDs) were associated with a significantly increased risk of death. 
Diclofenac was associated with the earliest onset and highest relative risk of 
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death/recurrent myocardial infarction, while the lowest risks were observed with naproxen 
(Schjerning Olsen et al., 2011). 
NSAIDs are also available as topical preparations (Altman, 2010; Barthel & Oxford-Gatley, 
2010). Topical formulations are believed to provide analgesia via the same mechanisms as 
oral NSAIDs, with similar efficacy but with reduced systemic exposure and, hence, fewer 
treatment-related side effects (Barthel & Oxford-Gatley, 2010). Osteoarthritis treatment 
guidelines issued by the UK National Institute for Health and Clinical Excellence 
recommend that topical NSAIDs, possibly in combination with acetaminophen, should be 
considered as second-line therapy after acetaminophen alone and before oral nonselective 
NSAIDs, selective COX-2 inhibitors, or opioids (The National Collaborating Centre for 
Chronic Conditions, 2008). In the United States, the only 2 topical NSAID formulations 
approved for the management of osteoarthritis pain are diclofenac sodium 1% gel and 
diclofenac sodium 1.5% in 45.5% dimethylsulfoxide (Altman & Smith, 2010; Barthel & 
Oxford-Gatley, 2010). 
2.2.4 Intra-articular injections 
Intra-articular injections of hyaluronic acid have demonstrated efficacy for the management 
of knee osteoarthritis pain; however, data on the use of intra-articular hyaluronic acid in hip 
and other types of osteoarthritis are limited (Goldberg & Buckwalter, 2005; Jordan et al., 
2003; Neustadt, 2006). Hyaluronic acid is a high molecular weight glucosaminoglycan 
present in high concentrations in synovial fluid. It has lubricating and viscoelastic 
properties, which reduce articular cartilage friction. In osteoarthritis, the synthesis of 
hyaluronic acid is altered; ie, total concentration is decreased and molecular chain length is 
reduced. In patients with knee osteoarthritis, intra-articular injections of hyaluronic acid 
have been shown to reduce synovial fluid viscosity and to reduce pain by several different 
mechanisms. Hyaluronic acid may slow the progression of disease by improving synovite 
and chondrocyte function and by modifying the structure of damaged matrix proteins, 
collagen, and articular cartilage (Goldberg & Buckwalter, 2005). Injectable hyaluronic acid 
formulations are not associated with any major safety concerns; however, minor AEs, 
including transient injection-site pain, have been observed in clinical trials (Arrich et al., 
2005; Bellamy et al., 2006b). 
Intra-articular injections of corticosteroids have been used for more than 50 years for the 
treatment of osteoarthritis and other rheumatic diseases (Bannuru et al., 2011; Neustadt, 
2006). Osteoarthritis treatment guidelines recommend that intra-articular corticosteroids 
should be considered in patients with moderate to severe pain who have not responded to 
oral analgesics (Jordan et al., 2003). Intra-articular corticosteroids often provide substantial 
and lasting osteoarthritis pain relief, and may reduce the inflammatory cell-mediated 
degradation of articular cartilage (Neustadt, 2006). The short-term benefits of intra-articular 
corticosteroids are well established; however, the long-term benefits remain unclear 
(Bellamy et al., 2006a). Intra-articular corticosteroids are generally well tolerated; the most 
common side effects associated with intra-articular corticosteroid use are post-injection 
flares of pain, crystal synovitis, haemarthrosis (Bellamy et al., 2006a), joint sepsis, and 
articular atrophy. These side effects are usually not serious (Bellamy et al., 2006a; Jordan et 
al., 2003). It is important that intra-articular corticosteroid injections are placed correctly to 
avoid the possible AEs of fat necrosis and para-articular tissue atrophy (Jones et al., 1993), 
and injections should not be repeated more than 4 times per year (Jordan et al., 2003). 
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In a meta-analysis comparing the analgesic efficacy of intra-articular hyaluronic acid versus 
intra-articular corticosteroids in patients with knee osteoarthritis, Bannuru and colleagues 
found that during the first 4 weeks of treatment, corticosteroids were more effective than 
hyaluronic acid (effect size at Week 2, −0.39 [95% CI, −0.65 to −0.12]), but by Week 4, the 2 
treatments were not statistically different (effect size, −0.01 [95% CI, −0.23 to 0.21]). After 
more than 8 weeks of treatment, the efficacy of hyaluronic acid was superior to that of 
corticosteroids (effect size at Week 12, 0.35 [95% CI, 0.03-0.66]; at Week 26, 0.39 [95% CI, 
0.18-0.59]; Bannuru et al., 2011). 
2.2.5 SNRIs 
Because osteoarthritis pain perception can have a central sensitization component (Arendt-
Nielsen et al., 2010; Gwilym et al., 2009; Hochman et al., 2010; Woolf, 2011), recent studies 
have investigated the analgesic efficacy of the SNRI duloxetine for the management of 
chronic osteoarthritis pain (Chappell et al., 2009; Chappell et al., 2011; Sullivan et al., 2009). 
In 2 randomized, double-blind, placebo-controlled trials in patients with moderate to severe 
osteoarthritis knee pain (n = 231 and n = 256, respectively), 13 weeks of treatment with 
duloxetine (60-120 mg/day) was associated with significantly reduced weekly average 24-
hour pain scores and significant improvements in Western Ontario and McMaster 
Universities (WOMAC) osteoarthritis index physical functioning scores (Chappell et al., 
2009; Chappell et al., 2011). Duloxetine was associated with significantly higher incidences 
of nausea, constipation, and hyperhidrosis (all P ≤0.05) and a significantly higher rate of 
discontinuation due to AEs (P = 0.002) compared with placebo (Chappell et al., 2011). 
In August 2010, the Anesthetic and Life Support Drugs Advisory Committee (ALSDAC) of 
the US Food & Drug Administration (FDA) recommended approval of duloxetine 
hydrochloride (60 mg/day) for the management of chronic musculoskeletal pain by a vote 
of 8 to 6 (US Food and Drug Administration, 2010), and duloxetine is currently being 
marketed as a treatment for chronic osteoarthritis pain (CYMBALTA, 2011). However, at the 
same FDA meeting, the ALSDAC voted 9 to 4 (with 1 abstention) against the use of 
duloxetine for the management of chronic osteoarthritis pain. The committee expressed 
views that data from clinical trials in patients with chronic osteoarthritis pain did not 
provide adequate evidence supporting the analgesic efficacy of duloxetine in this 
population. The committee recommended that additional studies involving more patients 
should be conducted to confirm the efficacy of duloxetine for the management of chronic 
osteoarthritis pain (US Food and Drug Administration, 2010). 
While the role of SNRIs in the management of osteoarthritis pain remains unclear, results 
from duloxetine trials published to date (Chappell et al., 2009; Chappell et al., 2011; Sullivan 
et al., 2009) suggest that central sensitization may play a significant role in pain perception 
in patients with chronic osteoarthritis pain. 
2.2.6 Opioids 
Weak opioid analgesics (eg, codeine, dihydrocodeine, tramadol) are recommended for the 
management of osteoarthritis pain in patients who have failed to respond to other 
pharmacologic or nonpharmacologic treatments, or when other analgesics are 
contraindicated (Zhang et al., 2008; Zhang et al., 2010). Strong opioids (eg, oxycodone, 
morphine, fentanyl, hydromorphone, oxymorphone, buprenorphine) are recommended for 
the management of severe osteoarthritis pain only when appropriate nonpharmacologic and 
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pharmacologic treatments have been tried and referral for surgery has been considered 
(Zhang et al., 2008). Opioids can be used alone or in combination with acetaminophen or 
aspirin (Dominick et al., 2004; Jordan et al., 2003). 
In recent years, the number of prescriptions for opioid analgesics for the management of 
chronic non-cancer pain has increased dramatically (Altman & Smith, 2010). According to 
the Trends and Risks of Opioid Use for Pain study, between 2000 and 2005, among patients 
with commercial health insurance who were diagnosed with chronic back pain, neck pain, 
joint/arthritis pain, headache pain, or pain associated with HIV/AIDS, the number of 
opioid prescriptions increased by 58%. During this time period, the number of eligible 
patients diagnosed with one of these painful conditions increased by 33%, from 18% 
(485,794/2,716,163) in 2000 to 24% (897,537/3,768,223) in 2005. Thus, the increase in opioid 
prescriptions is only partially explained by an increasing incidence of chronic pain 
conditions (Sullivan et al., 2008). Further, in a 1-year study of opioid prescriptions among 
patients in the Veterans Affairs healthcare system, of 3,061 patients who visited a physician 
for osteoarthritis, 41% had at least 1 opioid prescription (Dominick et al., 2004). These results 
suggest that opioids are increasingly gaining acceptance as a treatment option for chronic 
osteoarthritis pain (Altman & Smith, 2010; Dominick et al., 2004; Sullivan et al., 2008). 
In clinical trials, opioids have demonstrated efficacy for the management of moderate to 
severe osteoarthritis pain (Altman & Smith, 2010; Avouac et al., 2007; Caldwell et al., 2002; 
Matsumoto et al., 2005; Nuesch et al., 2009; Roth et al., 2000). In a meta-analysis of 13 
randomized placebo-controlled trials of orally or transdermally administered opioids 
(oxycodone, fentanyl, morphine sulfate, tramadol, tramadol/acetaminophen, or codeine) 
that included a total of 3,733 patients with osteoarthritis pain, the pooled effect size of 
opioids compared with placebo for pain intensity reduction was −0.79 (95% CI, −0.98 to 
−0.59) based on a random-effects model (Avouac et al., 2007). 
Opioid treatment has also been associated with significant improvements in physical 
function and quality of life (Avouac et al., 2007; Caldwell et al., 2002; Hale et al., 2007; 
Matsumoto et al., 2005; Nuesch et al., 2009; Rosenthal et al., 2007; Roth et al., 2000). 
Improvements in WOMAC scores have been observed in studies of fentanyl, oxycodone, 
oxycodone/acetaminophen, morphine sulfate, oxymorphone, and hydromorphone for 
osteoarthritis pain (Caldwell et al., 2002; Hale et al., 2007; Katz et al., 2010; Langford et al., 
2006; Matsumoto et al., 2005). In addition, improvements in sleep, mood, and enjoyment of 
life have been associated with opioid analgesic therapy for the management of chronic 
osteoarthritis pain (Rosenthal et al., 2007; Roth et al., 2000). 
In spite of the improvements observed in pain intensity, physical function, and health-related 
quality of life associated with opioid analgesics, the long-term use of these agents may be 
limited by poor tolerability (Benyamin et al., 2008). In an open-label extension study lasting 6 to 
18 months (following an initial 14-day placebo-controlled study) of oxycodone controlled 
release (CR; 10 or 20 mg bid) for the treatment of moderate to severe, chronic osteoarthritis pain, 
57% (60/106) of patients discontinued treatment, and more than half of these discontinuations 
(32/60) were related to AEs (Roth et al., 2000). The most common AEs leading to 
discontinuation were constipation, nausea, pruritus, somnolence, and nervousness. These AEs 
were also among the most commonly reported treatment-emergent AEs (TEAEs). During this 6- 
to 18-month long-term extension trial, 52% (55/106) of patients taking oxycodone CR reported 
constipation, 30% (32/106) reported somnolence, 24% (25/106) reported nausea, 20% (21/106) 
reported pruritus, and 15% (16/106) reported nervousness (Roth et al., 2000). 
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In a Cochrane review of 10 trials (n = 2,268) that studied codeine, morphine, oxycodone, 
oxymorphone, or fentanyl for the management of osteoarthritis hip or knee pain, Nüesch 
and colleagues found that while opioids were more effective than controls (standardized 
mean difference, −0.36; 95% CI, −0.47 to −0.26), opioids were associated with a significantly 
increased risk of AEs (pooled risk ratio, 1.55; 95% CI, 1.41-1.70) and of dropout due to AEs 
(pooled risk ratio, 4.05; 95% CI, 3.06-5.38) compared with controls. The authors concluded 
that the small to moderate beneficial effects associated with opioids for the management of 
chronic osteoarthritis pain do not outweigh the significantly increased risk of AEs (Nuesch 
et al., 2009). 
2.2.7 New treatment option: Tapentadol extended release, a μ-opioid receptor agonist 
and norepinephrine reuptake inhibitor 
Tapentadol is a new, centrally acting analgesic that has µ-opioid receptor agonist and 
norepinephrine reuptake inhibitor activities (Tzschentke et al., 2006; Tzschentke et al., 2007). 
The opioid activity of tapentadol targets nociceptive pain at the joint level, while 
norepinephrine reuptake inhibition targets referred pain caused by central sensitization. In 
the United States, an extended-release formulation of tapentadol is in development for the 
management of moderate to severe chronic pain. In Europe, a prolonged-release 
formulation is indicated for the management of severe chronic pain in adults, which can be 
adequately managed only with opioid analgesics. 
In preclinical studies, tapentadol has demonstrated efficacy in models of both neuropathic 
and nociceptive pain (Tzschentke et al., 2007). In addition, it has been observed that 
tapentadol’s 2 mechanisms of action act synergistically to produce potent analgesia that is 
greater than the predicted additive effects of the 2 mechanisms. These synergistic effects are 
particularly notable in models of chronic pain, possibly because chronic pain is more likely 
than acute pain to have both noradrenergic and nociceptive components (Schroder et al., 
2011). The 2 mechanisms of action of tapentadol affect both the ascending and descending 
pathways of central nervous system pain control, which may make it an appropriate 
treatment option for patients with chronic osteoarthritis who experience both nociceptive 
pain and pain caused by central sensitization. 
The efficacy of tapentadol extended release (ER) has been demonstrated in patients with 
moderate to severe, chronic osteoarthritis pain (Afilalo et al., 2010). In a 15-week 
randomized, placebo- and active-controlled, phase 3 study in patients with moderate to 
severe, chronic osteoarthritis knee pain (n = 1,023), tapentadol ER (100-250 mg bid) provided 
significantly better pain relief compared with placebo (least-squares mean difference in 
average pain intensity from baseline to Week 12 measured on an 11-point numerical rating 
scale, −0.7; 95% CI, −1.04 to −0.33; Afilalo et al., 2010). Tapentadol ER was associated with 
significant improvements in overall heath, pain, and physical function compared with 
placebo based on the Short Form-36 (SF-36) and EuroQol-5 Dimension (EQ-5D) health status 
scores. Patients treated with tapentadol ER also scored significantly better on the global 
WOMAC and on pain and physical function WOMAC subscales compared with placebo, 
indicating that tapentadol ER treatment was associated with robust improvement in 
analgesia and overall physical function  (Afilalo et al., 2010). In this study, the efficacy of 
tapentadol ER was particularly notable when it was administered to patients who had not 
received opioid analgesics within the 3 months prior to the study. Opioid-naive patients 
treated with tapentadol ER achieved statistically significant improvements from baseline in 
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57% (60/106) of patients discontinued treatment, and more than half of these discontinuations 
(32/60) were related to AEs (Roth et al., 2000). The most common AEs leading to 
discontinuation were constipation, nausea, pruritus, somnolence, and nervousness. These AEs 
were also among the most commonly reported treatment-emergent AEs (TEAEs). During this 6- 
to 18-month long-term extension trial, 52% (55/106) of patients taking oxycodone CR reported 
constipation, 30% (32/106) reported somnolence, 24% (25/106) reported nausea, 20% (21/106) 
reported pruritus, and 15% (16/106) reported nervousness (Roth et al., 2000). 
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In a Cochrane review of 10 trials (n = 2,268) that studied codeine, morphine, oxycodone, 
oxymorphone, or fentanyl for the management of osteoarthritis hip or knee pain, Nüesch 
and colleagues found that while opioids were more effective than controls (standardized 
mean difference, −0.36; 95% CI, −0.47 to −0.26), opioids were associated with a significantly 
increased risk of AEs (pooled risk ratio, 1.55; 95% CI, 1.41-1.70) and of dropout due to AEs 
(pooled risk ratio, 4.05; 95% CI, 3.06-5.38) compared with controls. The authors concluded 
that the small to moderate beneficial effects associated with opioids for the management of 
chronic osteoarthritis pain do not outweigh the significantly increased risk of AEs (Nuesch 
et al., 2009). 
2.2.7 New treatment option: Tapentadol extended release, a μ-opioid receptor agonist 
and norepinephrine reuptake inhibitor 
Tapentadol is a new, centrally acting analgesic that has µ-opioid receptor agonist and 
norepinephrine reuptake inhibitor activities (Tzschentke et al., 2006; Tzschentke et al., 2007). 
The opioid activity of tapentadol targets nociceptive pain at the joint level, while 
norepinephrine reuptake inhibition targets referred pain caused by central sensitization. In 
the United States, an extended-release formulation of tapentadol is in development for the 
management of moderate to severe chronic pain. In Europe, a prolonged-release 
formulation is indicated for the management of severe chronic pain in adults, which can be 
adequately managed only with opioid analgesics. 
In preclinical studies, tapentadol has demonstrated efficacy in models of both neuropathic 
and nociceptive pain (Tzschentke et al., 2007). In addition, it has been observed that 
tapentadol’s 2 mechanisms of action act synergistically to produce potent analgesia that is 
greater than the predicted additive effects of the 2 mechanisms. These synergistic effects are 
particularly notable in models of chronic pain, possibly because chronic pain is more likely 
than acute pain to have both noradrenergic and nociceptive components (Schroder et al., 
2011). The 2 mechanisms of action of tapentadol affect both the ascending and descending 
pathways of central nervous system pain control, which may make it an appropriate 
treatment option for patients with chronic osteoarthritis who experience both nociceptive 
pain and pain caused by central sensitization. 
The efficacy of tapentadol extended release (ER) has been demonstrated in patients with 
moderate to severe, chronic osteoarthritis pain (Afilalo et al., 2010). In a 15-week 
randomized, placebo- and active-controlled, phase 3 study in patients with moderate to 
severe, chronic osteoarthritis knee pain (n = 1,023), tapentadol ER (100-250 mg bid) provided 
significantly better pain relief compared with placebo (least-squares mean difference in 
average pain intensity from baseline to Week 12 measured on an 11-point numerical rating 
scale, −0.7; 95% CI, −1.04 to −0.33; Afilalo et al., 2010). Tapentadol ER was associated with 
significant improvements in overall heath, pain, and physical function compared with 
placebo based on the Short Form-36 (SF-36) and EuroQol-5 Dimension (EQ-5D) health status 
scores. Patients treated with tapentadol ER also scored significantly better on the global 
WOMAC and on pain and physical function WOMAC subscales compared with placebo, 
indicating that tapentadol ER treatment was associated with robust improvement in 
analgesia and overall physical function  (Afilalo et al., 2010). In this study, the efficacy of 
tapentadol ER was particularly notable when it was administered to patients who had not 
received opioid analgesics within the 3 months prior to the study. Opioid-naive patients 
treated with tapentadol ER achieved statistically significant improvements from baseline in 
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average pain intensity, while patients treated with oxycodone CR did not. In opioid-naive 
patients in the tapentadol ER and oxycodone CR groups, respectively, gastrointestinal 
TEAEs were reported by 47.7% and 67.5% of patients, and 19.6% and 48.3% of patients 
discontinued due to AEs (Etropolski et al., 2009). 
In a 1-year, randomized, open-label, phase 3 long-term safety study in patients with 
moderate to severe, chronic osteoarthritis hip or knee pain or low back pain, tapentadol ER 
(100-250 mg bid) was shown to have comparable analgesic efficacy to oxycodone HCl CR 
(20-50 mg bid), but tapentadol ER was associated with better overall tolerability and lower 
incidences of side effects and TEAE-related discontinuations (Figure 1). Tapentadol ER was 
associated with particularly better gastrointestinal tolerability compared with oxycodone 
CR. Gastrointestinal TEAEs led to discontinuation in 8.6% (77/894) of patients in the 
tapentadol ER group compared with 21.5% (48/223) of patients in the oxycodone CR group 
(Wild et al., 2010). 
 
 
Fig. 1. TEAE-related discontinuations in a 1-year safety study of tapentadol ER (100-250 mg 
bid) compared with oxycodone HCl CR (20-50 mg bid). Reprinted from Pain Practice, Vol 
10, Wild JE, et al, Long-term safety and tolerability of tapentadol extended release for the 
management of chronic low back pain or osteoarthritis pain, pp. 416-427 (2010), with 
permission from John Wiley and Sons. TEAE, treatment-emergent adverse event; ER, 
extended release; CR, controlled release.  
In pooled analyses of data from 3 randomized, placebo- and active-controlled, phase 3 
studies with 15 weeks of active treatment in patients with moderate to severe, chronic 
osteoarthritis knee pain (2 studies) or low back pain (1 study), the efficacy of tapentadol ER 
(100-250 mg bid) was non-inferior to that of oxycodone HCl CR (20-50 mg bid); however, 
tapentadol ER had a superior gastrointestinal tolerability profile relative to oxycodone CR 
(Lange et al., 2010). Tapentadol ER treatment was associated with fewer discontinuations 
from treatment compared with oxycodone CR and significant improvements in function and 
quality of life based on SF-36 and EQ-5D health status questionnaire results. Improvements 
observed in 7 of 8 SF-36 domains and the EQ-5D health status index score were significantly 
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better with tapentadol ER (100-250 mg bid) compared with oxycodone HCl CR (20-50 mg 
bid; Lange et al., 2010). 
The health status and WOMAC functional improvements observed in these studies are 
likely associated with the improved tolerability profile of tapentadol ER compared with 
oxycodone CR. The superior tolerability of tapentadol ER may have allowed patients to 
maintain their therapy and to sustain the achieved analgesic effect for a longer period of 
time compared with oxycodone CR. Oxycodone CR was associated with a higher rate of 
discontinuations and worse tolerability compared with tapentadol ER (Afilalo et al., 2010; 
Lange et al., 2010). 
3. Conclusion 
Nonpharmacologic approaches, including exercise and weight-loss programs, have been 
shown to reduce pain and psychological disability in patients with osteoarthritis, and 
should be an integral part of all osteoarthritis treatment plans (Felson et al., 2000; 
Klussmann et al., 2010; Messier, 2008; Physical Activity Guidelines Advisory Committee, 
2008). Guidelines for the pharmacologic management of osteoarthritis pain recommend a 
stepwise approach to therapy, initiating with acetaminophen, then transitioning to NSAIDs 
and finally to opioids if prior therapy fails (Jordan et al., 2003; Zhang et al., 2008). However, 
the long-term utility of NSAIDs and opioid analgesics may be limited by safety and 
tolerability issues (Benyamin et al., 2008; Zhang et al., 2008). 
Tapentadol ER provides effective pain control with good tolerability and improvements in 
quality of life (Afilalo et al., 2010; Lange et al., 2010; Wild et al., 2010). The favorable 
tolerability profile of tapentadol ER compared with oxycodone CR may allow patients to 
remain on treatment for longer periods of time, resulting in consistent, effective pain relief 
and long-term improvements in quality of life and health status. Because tapentadol acts as 
both a μ-opioid receptor agonist and as a norepinephrine reuptake inhibitor, tapentadol ER 
may relieve both nociceptive pain and neuropathic pain associated with central 
sensitization. Thus, tapentadol ER may be an effective treatment option that has better 
tolerability than pure μ-opioid analgesics in patients with moderate to severe, chronic 
osteoarthritis pain. 
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1. Introduction 
Osteoarthritis (OA), the most prevalent joint disease, is characterized by the progressive loss 
of articular cartilage that leads to chronic pain and functional restrictions in affected joints 
[Goldring & Goldring, 2007]. The prior notion of OA as a bland disease related to aging and 
“wear and tear” of the joint has given way to views of a dynamic system with multiple 
pathogenic contributors, as local factors, as well as crystals and inflammation [Brandt et al., 
2006]. OA represents a major therapeutic challenge to medical and health-care providers. In 
part, this is because OA is a chronic condition in which symptoms evolve over long periods 
of time and in which symptomatic episodes are frequently separated by lengthy 
asymptomatic periods. It is likely, however, that alterations in joint structure and function 
continue during these relative periods of clinical quiescence. In addition, limited tools are 
available for the assessment of the progression of structural changes in joint tissues in 
association with the development of osteoarthritis. Importantly, the correlation between 
structural alterations and symptoms is contradictory. There is a significant difference in the 
expression levels of cartilage relevant molecules between specimens showing histological 
alterations and control samples [Lorenz et al., 2006].   A total breakdown in synthesis of 
matrix molecules leads to the end stage OA with further progression of cartilage loss. 
A number of OA models, e.g. aging animals, genetically modified mice, as well as animals 
with surgically, enzymatically, or chemically induced OA [van den Berg, 2001] have been 
developed to investigate the pathogenesis of OA and evaluate the potentials of new 
disease/structure-modifying drugs [Oegema et al., 2002]. Among these, monosodium 
iodoacetate (MIA, iodoacetic acid) model has been widely used to analyze the histological 
and biochemical changes observed during the progression of OA [Ameye, & Young, 2006]. 
Injection of the metabolic inhibitor, MIA, into joints inhibits glyceraldehye-3-phosphate 
dehydrogenase activity in chondrocytes, resulting in disruption of glycolysis and eventual 
cell death [Kalbhen, 1987]. The progressive loss of chondrocytes results in histologic and 
morphologic changes to the articular cartilage, closely resembling those seen in human OA 
[Janusz et al., 2001]. In addition, the model has been utilized by a number of investigators to 
test pharmacologic agents for their ability to preserve cartilage structure [Janusz et al., 2001]. 
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Glucosamine, a naturally-occurring amino monosaccharide, is present in the 
polysaccharides of the connective and cartilage tissues, and contributes to maintaining the 
strength, flexibility, and elasticity of these tissues. Thus, glucosamine has been widely used 
for more than two decades in humans to treat osteoarthritis [Crolle, 1980]. Several short- and 
long-term clinical trials in osteoarthritis have shown the significant symptom-modifying 
effect of glucosamine [Reginster, et al., 2001]. Moreover, the updated Osteoarthritis Research 
Society International (OARSI) recommendations for management of hip and knee OA have 
recently suggested that glucosamine has symptom-relieving and structure modifying effects 
in knee OA [Zhang et al. 2008]. Importantly, it has been previously revealed in vitro that 
glucosamine can inhibit the degradation and stimulate the synthesis of glycosaminoglycans 
(proteoglycans), thereby possibly exhibiting chondroprotective action [Fenton et al., 2000]. 
Moreover, glucosamine has been shown to reduce radiographic progression of joint space 
narrowing in knee OA [Reginster, et al., 2001]. On the other hand, Glucosamine/chondroitin 
Arthritis Intervention Trial reported that glucosamine did not reduce pain effectively in 
patients with OA [Clegg et al., 2006], and the nonsufficient number of trials cannot confirm 
statistically that glucosamine sulphite has no effect [Vlad et al., 2007]. Thus, the effect of 
glucosamine on OA is still controversial [McAlindon, 2003]. 
Thermal analysis comprises a group of techniques in which a physical property of a 
substance is measured as a function of temperature, while the substance is subjected to a 
controlled temperature programme. Differential scanning calorimetry (DSC) has been 
widely used for determining physicochemical transformations that occur during thermal 
degradation [Collett & Brown, 1998]. Calorimetry can be used to determine most 
thermodynamic properties; e.g. enthalpy changes for reactions (ΔH) and for phase changes 
[Aigner et al., 2009; Than & Lőrinczy, 2003]. The usefulness of calorimetric examination in 
the characterization of biological samples has been demonstrated by previous studies [Than 
et al., 2000; Wiegand et al., 2009]. Prior studies have demonstrated the usefulness of 
calorimetric examination in the characterization of cartilage degeneration [Wiegand et al., 
2010]. We have extended the use of thermal analysis by introducing thermogravimetric 
investigations. Thereby new information on the physicochemical properties of normal and 
OA tissues has been acquired. 
An increasing number of papers have been published with the use of calorimetric 
techniques in the examination of degenerative [Mécs et al., 2009], rheumatoid arthritis [Tóth 
et al., 2009], and healthy human hyaline cartilage [Aigner et al., 2009]. P. Than et al.  
investigated first animal hyaline cartilage using differential scanning calorimetric method 
[Than et al., 2000]. They have concluded that structural manifestation of OA causes a 
remarkable change of thermal stability of hyaline cartilage. The healthy cartilage samples 
used in these studies were of cadaver origin as waste material, pathological cartilage was 
derived as intraoperative tissue fragments. The samples were washed in sterile phosphate-
buffered saline and stored in complex solution containing fetal bovine serum, antibiotic, 
antimycotic solution, and amino acids. The measurements were conducted in 48 hours of 
sample deriving. The reported data on the calorimetric enthalpy changes proved to be 
inconsistent. In severely affected osteoarthritis, the ΔH has increased almost twofold, while 
in an earlier study, enthalpy changes in the intact hyaline cartilage altered from higher to 
lower levels in some cases [Than et al., 2000; Than et al., 2004].  
The aim of these studies was to further characterize the altered metabolisms in OA that 
promotes disease progression. Based on previous studies, we hypothesized that 
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thermodynamic findings may clearly differentiate normal and degenerated human hyaline 
`cartilage. Physicochemical transformations may provide information on the role of water 
content in OA, and enthalpy change of the process, initiated by the temperature change, 
might represent potential marker of the disease activity. Under experimental circumstances, 
calorimetric examinations were used to differentiate normal and degenerated rat hyaline 
cartilage and the effect of oral glucosamine-sulphate pre-treatment in OA was also studied. 
The purpose of this study was to elucidate complex deviations that are developed from the 
normal matrix composition during OA and OA with glucosamine-sulphate treatment in 
contributing to disease progression. 
2. Conceptual background 
2.1 Pathology 
Articular cartilage has been the focus of research into OA for decades and the literature is 
extensive. The role of the chondrocytes has been reviewed [Hunziker, 2002], and some key 
features are also briefly summarized. The mechanical properties of cartilage, including 
viscoelasticity and high resistance against load and shear stress, are controlled through the 
metabolic balance within the matrix collagen–proteoglycan network. Water is the main 
composite (60–80%) of the extracellular matrix [Armstrong & Mow, 1982; Mankin & 
Thrasher, 1975; Sandell & Hering, 2001]. Proteoglycans induce a high osmotic pressure and 
have a high water binding capacity. Between 5 and 10% of the cartilage mass are 
proteoglycans, mostly aggrecan [Eyre, 2002]. Collagen (90% collagen type II) is responsible 
for the high resistance against tensional forces. Collagen type II contributes to up to 60% of 
the dry weight [Mayne, 1989]. During inflammation or slow degeneration, the homeostasis 
within the collagen–proteoglycan network in the chondral matrix is disordered [Sandell & 
Hering, 2001].  
Theoretical and computational analyses of the contact response of cartilage under various 
loading conditions have predicted that more than 90% of the load transmitted across 
articular layers is supported by the pressurized interstitial fluid, with the remnant 
contributed by the collagen-proteoglycan solid matrix. Since the pressure of this fluid is a 
hydrostatic stress, and since cartilage has been shown to be nearly incompressible at 
physiological levels of pressures, it has become evident that the interstitial fluid shields the 
solid matrix from excessive deformations [Park et al., 2003; Soltz & Ateshian, 1998]. 
2.2 Thermal analysis 
Thermal analysis comprises a group of techniques in which a physical property of a 
substance measured as a function of temperature, while the substance is subjected to a 
controlled temperature programme. Differential scanning calorimetry (DSC) and 
thermogravimetric (TG) analysis have been widely used for determining 
physicochemical transformations that occur during thermal degradation [Bihari-Varga 
1982; Collett & Brown, 1998]. These techniques measure net changes in enthalpy and 
weight as a result of many reactions taking place simultaneously and are particularly 
useful for indicating the temperature range and the rate of thermal processes as well as 
giving considerable information on physical and chemical changes [O'Neill, 1964; 
Richardson, 1997]. Not many papers have been published on the thermal properties of 
human hyaline cartilage. 
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giving considerable information on physical and chemical changes [O'Neill, 1964; 
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Understanding the response of drugs and their formulations to thermal stresses is an 
integral part of the development of stable medicinal products. Thermal analytical methods 
have thus become important tools for the development of modern medicines. These are 
precise and accurate techniques with low sample requirements, and can provide detailed 
information about new chemical entities even at the very earliest stages of drug discovery 
and development [Clas et al., 1999]. 
2.2.1 Thermogravimetry 
Thermogravimetric analysis (TGA) is an analytical technique used to determine a material’s 
thermal stability and its fraction of volatile components by monitoring the weight change 
that occurs as a specimen is heated [Gill, 1992]. The measurement is normally carried out in 
air or in an inert atmosphere, such as Argon, and the mass is recorded as a function of 
increasing temperature. Sometimes, the measurement is performed in a lean oxygen 
atmosphere (1 to 5% O2 in N2 or He) to slow down oxidation. In addition to mass changes, 
some instruments also record the temperature difference between the specimen and one or 
more reference pans (differential thermal analysis, or DTA) or the heat flow into the 
specimen pan compared to that of the reference pan (differential scanning calorimetry, or 
DSC). The latter can be used to monitor the energy released or absorbed via chemical 
reactions during the heating process. 
In most cases, TG analysis is performed in an oxidative atmosphere (air or oxygen and inert 
gas mixtures) with a linear temperature ramp. The maximum temperature is selected so that 
the specimen mass is stable at the end of the experiment, implying that all chemical 
reactions are completed (i.e., all of the carbon is burnt off leaving behind metal oxides). This 
approach provides two important numerical informations: ash content (residual mass, Mres) 
and oxidation temperature (To). While the definition of ash content is unambiguous, 
oxidation temperature can be defined in many ways, including the temperature of the 
maximum in the weight loss rate (dm/dTmax) and the weight loss onset temperature (Tonset). 
The former refers to the temperature of the maximum rate of oxidation, while the latter 
refers to the temperature when oxidation just begins. The ability of TG to generate 
fundamental quantitative data from almost any class of materials, has led to its widespread 
use in every field of science and technology [Riesen, 1998; Rouquerol, 1989]. 
2.2.2 Calorimetry 
Differential scanning calorimetry (DSC) is a thermoanalytical technique for measuring the 
energy necessary to establish a nearly zero temperature difference between a substance and 
an inert reference material, as the two specimens are subjected to identical temperature 
regimes in an environment heated or cooled at a controlled rate. In heat-flux DSC, the 
sample and reference are connected by a low-resistance heat-flow path (a metal disc). The 
assembly is enclosed in a single furnace (Fig. 1). 
Enthalpy or heat capacity changes in the sample cause a difference in its temperature 
relative to the reference; the resulting heat flow is small as compared to that of in differential 
thermal analysis (DTA) because the sample and reference are in good thermal contact. The 
temperature difference is recorded and related to enthalpy change in the sample using 
calibration experiments [O'Neill, 1964]. 
DSC is a frequently preferred thermal analytical technique because of its ability to provide 
detailed information about both the physical and energetic properties of a substance. This 
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information cannot be obtained accurately, easily, or quickly using any other technique. 
With the development of sophisticated, modulated temperature programs, it is likely that 
DSC will retain its place at the forefront of the pharmaceutical thermal analytical sciences 
for some time to come [Clas et al., 1999]. 
 
 
Fig. 1. Heat flux DSC (S: substance, R: reference material) 
Calorimetry can be used to determine most thermodynamic properties; e.g. enthalpy 
changes for reactions (ΔH) or phase changes. Calorimetry can also be used for qualitative 
and quantitative analyses. ΔH can often be determined for an unknown reaction in a 
complex system, and the value of ΔH can then be used to assist in identifying the reaction 
[Jones, 1997]. Since calorimetry directly measures the instantaneous rate of the process, 
calorimetry is a particularly advantageous method for determination of the kinetics of slow 
processes. Calorimetric parameters provide a description of the system as a function of the 
experimental variables. Calorimetric data can also be used to gain fundamental insight into 
a process or property of a material [Hansen & Russell, 2006]. 
2.3 Thermal analysis of biological systems 
Biological samples are often expensive and scarce due to the difficulty of their isolation and 
purification [Collett & Brown, 1998; Privalovand & Plotnikov, 1989]. The biological system 
represents an aqueous environment and the water present in the specimen limits the 
amount of sample that can be investigated, when studying the bulk properties of a sample. 
Analysis of the conformational and structural changes of molecules requires the solutions to 
be sufficiently dilute so that the inter-molecular contributions can be ignored. Advantages of 
thermal analysis in biological studies: the thermal behavior of tissues, as opposed to tissue 
components, can be readily studied by thermal analysis. No preparation procedures are 
required and so the basic molecular structures can be preserved for the analysis [Burroughs 
et al., 1980]. Initially, thermal transitions were only used to gain insight into the structures of 
compounds, but subsequently, applications have also been extended to give physiological 
data [Collett & Brown, 1998; Melchior & Steim, 1976]. These interactions are probably best 
studied by thermodynamic methods. Of all the thermal analysis techniques applied to 
biological samples, DSC and TGA are the most commonly used. These applications of 
thermal analysis to the study of biological systems have obvious medical advantages 
[Melchior & Steim, 1976]. 
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2.4 Thermal analysis of connective tissue 
Connective tissue may be classified as a semifluid gel in order to explain its properties and 
functions. Thermal analysis of the material requires no preparation procedures. The material 
could thus be studied without complicated purification procedures which means that the 
basic molecular structure can be preserved [Bihari-Varga, 1982]. Bihari-Varga concluded 
that connective tissue, like other tissue, shows considerable changes as the body passes to 
older age, and that, it is affected by pathological conditions. The study revealed that both 
the amount of structurally bound water and the concentration of glycosaminoglycan's 
(GAG) decrease significantly with age in various types of connective tissues.  
More than 35 years ago in Bihari-Varga’s experiments [Bihari-Varga et al., 1975] complex 
thermoanalytical methods [Paulik et al., 1958] were applied to study various collagen-
proteoglycan-glycoprotein complexes prepared from different connective tissues. Thermal 
analysis was successfully used in their investigations for the quantitative determination of 
polysaccharides, for the characterization of protein structure, and for the estimation of age-
related [Simon et al., 1969] and pathological [Biró & Bihari-Varga, 1972] changes in 
proteoglycan- and collagen-containing biological tissues. The study was extended to 
investigate the effect of drugs on the osteoarthritic tissue [Farkas et al., 1974]. 
More recently, thermal stability and structure of cancellous bone mineral from the femoral 
head of patients with OA or osteoporosis (OP) was investigated by Mkukuma et al. 
[Mkukuma et al. 2005]. Thermogravimetric analysis was linked to mass spectrometry (MS) to 
investigate the thermal decomposition of the matrix and hence its mineral content. Thermal 
stability of the bone matrix or the mineral phase alone, was little altered by disease, though 
OA bone contained less mineral than OP or control normal bone [Mkukuma et al. 2005]. 
2.5 Cartilage water content 
Simple collagen-water systems have been examined with nuclear magnetic resonance 
(NMR) spectroscopy. It was shown that water molecules exist either as bulk water or as 
interior hydration water molecules [Chae et al., 2009]. Water within collagen fibrils consists 
of molecules involved in both inter- and intrahelical hydrogen bond formation. Based on a 
single endothermic DSC peak in cartilage, Bagratashvili et al. [Bagratashvili et al. 1997] 
found that the proportion of bound water in cartilage is around 4% using differential 
microcalorimetry and FTIR spectroscopy. Water diffusion through the tissue and from 
bound to free water transformation controlled water molecule liberation and adsorption. 
Alternating breakage and reformation of weak bonds between water molecules and 
proteoglycans directs movement of water in cartilage tissue. Both the extrafibrillar and most 
of the intrafibrillar water is freely exchangeable and behaves towards small solutes as 
available water has been independently shown by Katz and Li [Katz & Li, 1973] for other 
collagenous tissues. Furthermore Maroudas and Schneiderman have shown that the very 
major fraction of cartilage water is free, therefore the water in cartilage is completely 




In order to conduct the thermoanalytical study, 23 samples were collected from live 
surgeries of OA patients between October 2005 and April 2006. During hip arthroplasty 
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procedures performed at the Orthopedic Department, University of Szeged, 16 OA human 
hyaline cartilage samples and normal cartilage from 7 knee were obtained. There was no 
clinical meaningful difference in age between OA patients (64 ± 5.2) and controls (61 ± 4.2). 
There were no considerable sex differences between OA patients (75% females) and controls 
(70% females); Chi-square P = 0.54. 
Usually, total knee arthroplasty is performed in OA of both medial and lateral knee 
compartments. When only one compartment is affected and ligamental stability is intact, 
unicondylar prosthesis is implanted. We were able to obtain normal cartilage samples 
from those patients where one compartment of the same knee was degenerated, and the 
other one was normal. Therefore, the unaffected femoral condyle had to be sacrificed for 
the procedure because ligamental instability was the indication for total knee 
arthroplasty. 
3.1.1.2 Patients grading 
Preoperatively, the diagnosis of the patients were established on the basis of the patient 
history, clinical signs, laboratory tests, and radiological findings. The state of the hyaline 
cartilage was determined intraoperatively. All patients in the osteoarthritic group were 
considered to be 5-6 articular surface degeneration by Osteoarthritis Research Society 
International (OARSI) grade. OARSI Grade 5-6 OA is characterized by deformation and 
change in the contour of the articular surface [Pritzker et al., 2006]. This results not only 
from articular plate fractures, but also from increased metabolic activity of the articular bone 
plate, as well as from activation of connective tissue at the lateral and, sometimes, central 
cartilage/bone interfaces. Samples were considered to be normal when hyaline articular 
cartilage was uninvolved with OA (OARSI Grade 0). In these results, the cartilage surface is 
smooth, no enlargement, distortion, and no proliferative changes are observed. 
3.1.1.3 Human sample preparation for thermal analysis 
After the operation, a disc (5mm in diameter) was removed from the unhealthy and healthy 
cartilage surfaces. The samples were taken under sterile conditions, excess bone was 
removed, and only the remaining full thickness cartilage was used. The disc was first 
washed in sterile saline, then stored in 20 ml saline for transportation at room temperature. 
Mean storage time was 6 hours (min: 1 hour, max: 26 hour), 29 samples out of 35 were 
studied within four hours of preparation. Six samples were stored overnight at 5 °C. 
Preemptive control examinations did not show any change in the calorimetric and 
thermogravimetric properties after storage for 26 hours at 5 °C. 
3.1.1.4 Animal model 
Animal experiments were performed at the Physiology Department, Faculty of Medicine, 
University of Szeged. Adult male Wistar rats (Charles River strain; Bioplan, Budapest, 
Hungary), weighing 470±6 g were housed individually in ventilated cages on a 12-hour 
day/night cycle at a temperature of 22±1 °C. Water and food were provided ad libitum. The 
experiments were performed in accordance with the US National Institutes of Health 
Guidelines for the Care and Use of Laboratory Animals, and with the approval of the 
Animal Welfare Committee of the University of Szeged. Four groups of animals were 
defined as follows: 
GA, non-osteoarthritic negative control rats injected with saline but pre-treated with oral 
glucosamine-sulphate; 
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investigate the thermal decomposition of the matrix and hence its mineral content. Thermal 
stability of the bone matrix or the mineral phase alone, was little altered by disease, though 
OA bone contained less mineral than OP or control normal bone [Mkukuma et al. 2005]. 
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interior hydration water molecules [Chae et al., 2009]. Water within collagen fibrils consists 
of molecules involved in both inter- and intrahelical hydrogen bond formation. Based on a 
single endothermic DSC peak in cartilage, Bagratashvili et al. [Bagratashvili et al. 1997] 
found that the proportion of bound water in cartilage is around 4% using differential 
microcalorimetry and FTIR spectroscopy. Water diffusion through the tissue and from 
bound to free water transformation controlled water molecule liberation and adsorption. 
Alternating breakage and reformation of weak bonds between water molecules and 
proteoglycans directs movement of water in cartilage tissue. Both the extrafibrillar and most 
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In order to conduct the thermoanalytical study, 23 samples were collected from live 
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procedures performed at the Orthopedic Department, University of Szeged, 16 OA human 
hyaline cartilage samples and normal cartilage from 7 knee were obtained. There was no 
clinical meaningful difference in age between OA patients (64 ± 5.2) and controls (61 ± 4.2). 
There were no considerable sex differences between OA patients (75% females) and controls 
(70% females); Chi-square P = 0.54. 
Usually, total knee arthroplasty is performed in OA of both medial and lateral knee 
compartments. When only one compartment is affected and ligamental stability is intact, 
unicondylar prosthesis is implanted. We were able to obtain normal cartilage samples 
from those patients where one compartment of the same knee was degenerated, and the 
other one was normal. Therefore, the unaffected femoral condyle had to be sacrificed for 
the procedure because ligamental instability was the indication for total knee 
arthroplasty. 
3.1.1.2 Patients grading 
Preoperatively, the diagnosis of the patients were established on the basis of the patient 
history, clinical signs, laboratory tests, and radiological findings. The state of the hyaline 
cartilage was determined intraoperatively. All patients in the osteoarthritic group were 
considered to be 5-6 articular surface degeneration by Osteoarthritis Research Society 
International (OARSI) grade. OARSI Grade 5-6 OA is characterized by deformation and 
change in the contour of the articular surface [Pritzker et al., 2006]. This results not only 
from articular plate fractures, but also from increased metabolic activity of the articular bone 
plate, as well as from activation of connective tissue at the lateral and, sometimes, central 
cartilage/bone interfaces. Samples were considered to be normal when hyaline articular 
cartilage was uninvolved with OA (OARSI Grade 0). In these results, the cartilage surface is 
smooth, no enlargement, distortion, and no proliferative changes are observed. 
3.1.1.3 Human sample preparation for thermal analysis 
After the operation, a disc (5mm in diameter) was removed from the unhealthy and healthy 
cartilage surfaces. The samples were taken under sterile conditions, excess bone was 
removed, and only the remaining full thickness cartilage was used. The disc was first 
washed in sterile saline, then stored in 20 ml saline for transportation at room temperature. 
Mean storage time was 6 hours (min: 1 hour, max: 26 hour), 29 samples out of 35 were 
studied within four hours of preparation. Six samples were stored overnight at 5 °C. 
Preemptive control examinations did not show any change in the calorimetric and 
thermogravimetric properties after storage for 26 hours at 5 °C. 
3.1.1.4 Animal model 
Animal experiments were performed at the Physiology Department, Faculty of Medicine, 
University of Szeged. Adult male Wistar rats (Charles River strain; Bioplan, Budapest, 
Hungary), weighing 470±6 g were housed individually in ventilated cages on a 12-hour 
day/night cycle at a temperature of 22±1 °C. Water and food were provided ad libitum. The 
experiments were performed in accordance with the US National Institutes of Health 
Guidelines for the Care and Use of Laboratory Animals, and with the approval of the 
Animal Welfare Committee of the University of Szeged. Four groups of animals were 
defined as follows: 
GA, non-osteoarthritic negative control rats injected with saline but pre-treated with oral 
glucosamine-sulphate; 
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Sham, non-osteoarthritic negative control rats injected with saline and not pre-treated with 
oral glucosamine-sulphate; 
MIA, rats injected with monosodium iodioacetate and not pretreated with oral glucosamine-
sulphate; 
MIA+GA, rats injected with monosodium iodoacetate but pretreated with oral glucosamine-
sulphate. 
3.1.1.5 Compounds 
Monosodium iodoacetate was obtained from Sigma-Aldrich Kft. Budapest and dissolved in 
0.9% NaCl (Baxter) solution to get the required concentrations. 
Glucosamine sulphate was supplied by Rottapharm S.p.A., Italy. 
3.1.1.6 Induction of osteoarthritis 
Animals were briefly anesthetized with an isoflurane/O2 gas mixture and the left knee was 
shaved and disinfected with 70% ethanol followed by povidone-iodide. Osteoarthritis was 
induced by the intraarticular injection of 50 μl of 40 mg/ml monosodium iodoacetate 
solution using a 300 μl syringe fitted with a 29 G needle, as described earlier [Guingamp et 
al., 1997]. The animals of the GA and Sham groups underwent the same procedure, but were 
injected with 50 μl of 0.9% NaCl solution. 
3.1.1.7 Glucosamine-sulphate pre-treatment 
Glucosamine sulphate solution dissolved in distilled water was administered to the rat 
through a cannula daily for 8 weeks through a gastric tube (500 mg/kg dose per day in 2 ml 
volume). The control group received the same volume of distilled water. The first 
administration was applied two weeks after the MIA injection. 
3.1.1.8 Animal sample preparation 
For sample preparation, the rats were anesthetized and a disc (2 mm in diameter) was 
removed from the unhealthy and healthy cartilage surfaces. The samples were taken under 
sterile conditions, excess bone and adipose tissue was removed, and only the remaining full 
thickness cartilage was used for the experiments. The disc was first washed in sterile saline, 
then stored in 20 ml saline for transportation at room temperature for immediate 
examination. Before the measurements, all water from the surface was removed. Mean 
storage time was 4 hours (min: 1 hour, max: 12 hours), all samples were examined the same 
day of preparation. Preemptive control examinations did not show any changes in the 
calorimetric properties after storage for 24 hours at 5 °C. 
3.2 Thermal measurements 
The success of the thermal experiments depends on the careful preparation of samples and 
the judicious selection of the appropriate experimental conditions (such as scanning rate and 
sample size). In general, DSC samples are analyzed in small metal pans, designed for 
optimal thermal conductivity and minimum reaction with the samples (for example, 
aluminum alloy, platinum, stainless steel, or silver) [Clas et al., 1999]. For accurate 
quantitative work, the thermal mass of the sample and reference pans were matched. 
The calorimetric properties of samples were determined by DSC method (Mettler-Toledo 
DSC 821e apparatus, Mettler-Toledo GmbH, Switzerland). Samples were heated from 0 to 80 
°C. The heating rate was 0.3 °C/min. Conventional Hastelloy batch vessels were used with 
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40 μl sample volume. All the DSC measurements were preceded in Ar atmosphere, and the 
flow rate was 100 ml/min. From the DSC curves, the decomposition temperature (onset 
temperature), the transition temperature range (endset temperature), and the total 
calorimetric enthalpy change were calculated. Well-defined standards and calibration 
procedures are particularly important, therefore high care was taken in calibrating the 
instrument as close to the transition temperatures of interest as possible. 
The thermogravimetric analysis was performed with the use of a MOM Derivatograph 
(MOM, Budapest, Hungary), and the TG, DTG, and DTA curves were determined. The 
temperature (T) curve shows the linear increase of temperature during the process. DTG 
curve represents the first derivative of the mass change [Riesen, 1998; Rouquerol, 1989]. 
Heating was linear from 25 to 150 °C and the rate of heating was 5 °C/min. Al2O3 was used 
as reference material. In the first step, the total water loss and kinetic parameters were 
calculated. The kinetic parameters calculated by the derivatograph are the following: the 
reaction order (n), the activation energy (Ea), and the pre-exponential factor (A) [Arnold et 
al., 1987]. 
3.3 Statistics 
SPSS for Windows statistical program was used to compare enthalpy changes in the 
different groups. Data are presented as mean, ±SD, ±SEM. Statistical significance was 
assessed by the unpaired two t-test and the level of confidence interval. The results were 
considered significant, if p < 0.05. 
3.4 Ethics 
All tissues were yielded in accordance to legal regulation, international ethical concerns, and 
patients’ consent. The Human Investigation Review Board of the University of Szeged has 
decided (2006.09.18.) that the experiments comply with the ethics of research and the 
declaration of the Medical World Federation. 
4. Results 
4.1. Human hyaline cartilage study 
4.1.1 Thermogravimetry 
TG, DTG and DTA curves of the normal samples are presented on Fig. 2. Many information 
can be obtained from the T, TG, DTG and DTA curves. The temperature (T) curve shows the 
linear increase of temperature during the process. 
It was found, that the average total water content of intact (normal) cartilage is 81%, which 
was probably the interstitial water. To remove the cartilage extracellular water content, 52 
kJ/M energy was needed. 
Total water content of the OA samples was 87%, and 73 kJ/M energy was used for the 
removal of the fluid content (Table 1 and Fig. 3). 
Loss of water content in both groups are presented with a sharp step on the TG curve, 
starting on average temperature of 37 °C and ending at 116 °C. Linear part of the TG 
curve begun at around 57 °C and ended at around 104 °C (Table 1). Placing a line on this 
portion of the curve, the slope of the curve can be calculated which represents the speed 
of the water content loss (Table 2). The slope of the linear region correlated in both 
groups. 
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(MOM, Budapest, Hungary), and the TG, DTG, and DTA curves were determined. The 
temperature (T) curve shows the linear increase of temperature during the process. DTG 
curve represents the first derivative of the mass change [Riesen, 1998; Rouquerol, 1989]. 
Heating was linear from 25 to 150 °C and the rate of heating was 5 °C/min. Al2O3 was used 
as reference material. In the first step, the total water loss and kinetic parameters were 
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Fig. 2. Thermogravimetric curves of a normal sample 
 
 












Normal 7 39.1-113.8 80.79 SD: 7.09 
52.33 
SD: 6.68 
OA 16 36.4-121.9 86.71 SD: 7.84 
72.72 
SD: 23.46 
Table 1. Average mass loss and activation energy of normal and degenerated samples. 
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In case of the normal hyaline cartilage, 0.196 mg of fluid content release was observed 
(average mass of the normal samples was 15.48 mg) with increase of temperature by 1 °C, 
therefore 1.3% °C-1 loss was detected. In the osteoarthritic samples (average mass: 17.02 
mg), 0.242 mg decrease was measured which represents 1.4% °C-1 mass reduction. The 







TG step linear 
region (C) 
Mass loss 
(%) Reaction order (n) 
Slope of linear 
region 
Normal 7 62.67-102.25 -51.45 1 SD: 0.203 -0.039 
OA 16 58.0-104.6 -65.24 1.03 SD: 0.27 -0.048 
 
Table 2. Reaction kinetic parameters of normal and degenerated samples. 
4.1.2 Calorimetry 
With the rise of temperature, an endothermic reaction was observed in all of the cases 
(Fig. 4). The enthalpy change of the process initiated by the temperature change showed 





























Table 3. Thermal parameters of denaturation (mean ±SD) of normal and degenerated 
samples. 
Greater change in the enthalpy was observed in normal cartilage: 788.346 J/g 
(SD = 83.18). In case of osteoarthritis 543.838 J/g (SD = 88.57) was measured (Table 3). 
Therefore, denaturation caused by heating was larger in the normal human hyaline 
cartilage. Consequently these samples required the largest amount of energy for 
decomposition. Statistical tests proved these calculations to be significant (Fisher LSD 
method, p<0.05). Denaturation peak in normal cartilage was at 50.18 °C (SD = 3.31),  
and it was similar in osteoarthritis 50.34 °C (SD = 2.93). to that of the control results  
(Fig. 4). 
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Fig. 4. DSC curve of normal and osteoarthritic human hyaline cartilage samples, the average 
change in the enthalpy in normal cartilage: 788.346 J/g (SD = 83.18) and OA 543.838 J/g  
(SD = 88.57) respectively. (The downwards deflection means endothermic effect) 
4.2 Animal model 
With the rise of temperature an endothermic reaction was observed in all of the cases 
(Figure 5).  
 
 
Fig. 5. DSC curve of cartilage samples. (the downwards deflection means endothermic effect) 
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The enthalpy change of the process initiated by the temperature change did show marked 
























Table 4. Thermal parameters (mean, ±SD, ±SEM) of all samples 
Change in enthalpy was observed in normal cartilage at -783.65 kJ/kg (SD = 63.44), and in 
case of pre-treatment with Glucosamine-sulphate, a slight increase was seen at -848.86 kJ/kg 
(SD = 177.53). In the non-treated OA samples (MIA), the change of enthalpy was -1150.19 
kJ/kg (SD = 137.63). Further increase of the thermal parameters was measured in the OA 
group that was pre-treated with Glucosamine-sulphate (MIA+GA) -1402.92 kJ/kg (SD = 
90.74). Therefore, enthalpy change caused by the loss of water content by heating was lower 
in the normal samples than in the OA sample groups. 
The ΔH mean value of the normal samples statistically did not differ significantly from the 
treated normal group (p=0.3752). On the other hand, statistically extremely significant 
difference (p<0.0001) was observed when the calorimetric properties of the normal non-
treated hyaline samples were evaluated against either the MIA or the MIA+GA groups. 
(Table 5) Furthermore, even the low end of the confidence interval represents a difference 
large enough to be considered biologically important. 
 
Compared groups 95% confidence interval (from-to) two-tailed P value 
Sham/MIA -489.3105 to -243.7645 < 0.0001 
Sham/MIA+GA -710.4533 to -528.0925 <0.0001 
MIA/MIA+GA -385.0286 to -120.4421 0.0012 
Table 5. Statistical parameters 
Further analysis showed additional statistically significant (p<0.0012) increase in the mean 
value of the enthalpy change of the non-treated OA group to the treated OA groups. But the 
size of the confidence interval range difference is inconclusive (Table 5). 
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OA development takes place in consecutive steps of breakdown and attempted 
regeneration. Though the comprehension about OA has grown enormously over the last 
years, there is still need to extend our knowledge about the basic context of OA genesis and 
development. Several biochemical and biomechanical factors are considered for the 
pathogenesis [Abramson & Attur, 2009]. The data up to date show, however, that OA is a 
very complex disease procedure, and it can be speculated, that the context leading to the 
progressive process is not finally resolved. There might still be molecules involved which 
have not yet been studied or even identified [Kumar et al., 2001]. 
OA is widely believed to result from local mechanical factors acting within the context of 
systemic susceptibility [Goldring & Goldring, 2007]. Molecular pathology of osteoarthritis is 
under intense investigation since biomechanical factors result in chemical alteration within 
the joint. Rearrangements of intra- and intermolecular bonds in collagen molecule and 
disaggregation of proteoglycans and their elimination from OA cartilage found to be 
responsible for water accumulation [Loeuille et al., 2002]. It was also shown that the most 
part of water is free water and its quantity is increased in the osteoarthritis of the hyaline 
cartilage [Nikolaeva et al., 2000]. 
We observed increase in water content of the cartilage matrix in all cases of the investigated 
degenerative cartilages [Sohár et al., 2007]. Based on our results, it can be stated that water 
content is higher in impaired samples, meanwhile water interstitial bonding was stronger in 
these cases. Rise in water adherence was well distinguishable since higher energy was 
needed for removal. Activation energy correlated considerably with water content in the 
samples. Denaturation caused by heating was larger in the normal cartilage than in the 
diseased ones, therefore normal samples required larger amount of energy for 
decomposition [Tóth et al., 2007]. 
The purpose of our study was also to clarify the previously reported studies in the literature 
[Than & Kereskai, 2005]. By acquiring normal cartilage from live surgery and by performing 
the investigation in a relatively short period of time compared to the earlier reports [Sohár et 
al., 2007; Than et al., 2004; Than & Kereskai, 2005], similar sample environment was 
provided as with the degenerarative samples. This way, we minimized the extracorpal 
degeneration. All samples we used showed a clear denaturation peak on the calorimetric 
curve, therefore volume of the curve was easily calculated giving the enthalpy change of the 
sample. These changes correlated with the water content of the samples. Due to the 
increased number of samples acquired for our studies, the results were much better 
reproducible than results in the literature, and the difference between the normal and 
diseased samples was significant [Sohár et al., 2007; Tóth et al., 2007]. 
The newly established thermogravimetric protocol that we used was sufficient for 
compositional thermoanalytical study of normal and degenerative human hyaline cartilage. 
Water content elevation contributing to disease progression was observed in OA. 
Previously, this method has not been used for this type of investigations. The main goal of 
the thermogravimetric measurements was to identify the nature and quantity of water 
molecules in the investigated samples. Water molecules’ binding mode may have an 
important consequence in pharmacokinetics. The reaction order turned out to be 
approximately 1 in all the cases (normal and OA), and the standard deviation was low 
(Table 2). The TG curve’s slope of the linear region showed, that the rate of water loss 
depends on the water amount remaining in the tissue. Comparing the data in the presented 
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tables (Tables 1, 2) (Total mass loss: normal: 80.79% and OA: 86.71%), it can be concluded 
that the higher water content in the degenerative samples bound stronger to the matrix. 
However, the reaction order and the slope of the linear region correlated in both groups. 
This first order kinetic means that the rate of water loss depends on the water amount 
remaining in the tissue, namely if the amount of water decreases in the tissue, the rate of 
loss also decreases. 
DSC as part of thermal analysis was a reliable method for differentiating normal hyaline 
cartilage from degenerated samples. The available calorimeter proved to be adequate for 
these measurements. DSC techniques are still developing and many new variants and 
applications are reported each year. Combined techniques [Elder, 1994] with microscopic or 
spectroscopic instruments are of obvious value to the pharmaceutical scientist, although 
commercially available units are not widely used and have limited pharmaceutical 
applications. With the rapid development of atomic and molecular scale microscopy, 
hyphenated micro-thermal analysis techniques, such as atomic force microscopy-DSC, are 
also becoming commercially available. There may be many future applications of micro-
DSC measurements to pharmaceutical problems, although these are likely to be limited to 
basic research applications in the next few years until the full potential of the technique has 
been demonstrated. 
Our study has had several limitations, as many other studies on OA. First, the sample size 
was not large enough to arrive at definitive conclusions. Additional measurements are 
needed to affirm the results of our study. Secondly, we investigated those patients for 
normal cartilage samples of the knee, who underwent surgery for the other compartment 
OA. This was the only ethical and technical way of acquiring normal tissues from living 
persons for our experiments. Previous thermoanalytical studies used cadaver samples for 
the investigation as normal human hyaline cartilage. All samples that were extracted for our 
studies were obtained during live surgeries and were macroscopically intact [Sohár et al., 
2007; Tóth et al., 2007].  There is no previous report in the literature of examining normal 
cartilage from live surgery. Only full thickness cartilage was used for the normal analysis. A 
new protocol had to be established before the detailed investigation of human tissues could 
be performed. Most of the known changes in the extracellular matrix in OA come from 
animal models in the literature since human samples for investigation are not widely 
available for experiments. 
The promise of biomarkers has yet to be fulfilled in OA. Although numerous clinical studies 
have suggested that specific biomarkers or their combinations can have predictive value in 
terms of the presence and severity of the disease [Poole, 2003]. The wide variability in these 
values limits their use for individual patients. Whereas, the use of thermal analysis could be 
a simple and effective method for controlling the relationship between these markers and 
disease progression. The revised protocol for sample taking during live surgeries eliminates 
the presence of disturbing substances during the examination. 
Characterization of the altered metabolism in cartilage that promotes disease progression 
should lead to future treatment options that can prevent structural damage. Since damaged 
articular cartilage has a very limited potential for healing, prevention is fundamental in 
treatment. However, prevention is not possible without the knowledge of the basic 
pathomorphological mechanism leading to cartilage degeneration. With better 
understanding of the exact amount of water in matrix and its binding characteristics, 
preventive measures can be developed. These therapeutic steps can be adequately tested 
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commercially available units are not widely used and have limited pharmaceutical 
applications. With the rapid development of atomic and molecular scale microscopy, 
hyphenated micro-thermal analysis techniques, such as atomic force microscopy-DSC, are 
also becoming commercially available. There may be many future applications of micro-
DSC measurements to pharmaceutical problems, although these are likely to be limited to 
basic research applications in the next few years until the full potential of the technique has 
been demonstrated. 
Our study has had several limitations, as many other studies on OA. First, the sample size 
was not large enough to arrive at definitive conclusions. Additional measurements are 
needed to affirm the results of our study. Secondly, we investigated those patients for 
normal cartilage samples of the knee, who underwent surgery for the other compartment 
OA. This was the only ethical and technical way of acquiring normal tissues from living 
persons for our experiments. Previous thermoanalytical studies used cadaver samples for 
the investigation as normal human hyaline cartilage. All samples that were extracted for our 
studies were obtained during live surgeries and were macroscopically intact [Sohár et al., 
2007; Tóth et al., 2007].  There is no previous report in the literature of examining normal 
cartilage from live surgery. Only full thickness cartilage was used for the normal analysis. A 
new protocol had to be established before the detailed investigation of human tissues could 
be performed. Most of the known changes in the extracellular matrix in OA come from 
animal models in the literature since human samples for investigation are not widely 
available for experiments. 
The promise of biomarkers has yet to be fulfilled in OA. Although numerous clinical studies 
have suggested that specific biomarkers or their combinations can have predictive value in 
terms of the presence and severity of the disease [Poole, 2003]. The wide variability in these 
values limits their use for individual patients. Whereas, the use of thermal analysis could be 
a simple and effective method for controlling the relationship between these markers and 
disease progression. The revised protocol for sample taking during live surgeries eliminates 
the presence of disturbing substances during the examination. 
Characterization of the altered metabolism in cartilage that promotes disease progression 
should lead to future treatment options that can prevent structural damage. Since damaged 
articular cartilage has a very limited potential for healing, prevention is fundamental in 
treatment. However, prevention is not possible without the knowledge of the basic 
pathomorphological mechanism leading to cartilage degeneration. With better 
understanding of the exact amount of water in matrix and its binding characteristics, 
preventive measures can be developed. These therapeutic steps can be adequately tested 
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and monitored with thermal measurements. The use of these methods can also determine 
the effectiveness of currently used medications (Glucosamin, Chondroitin) for resolving 
cartilage matrix degeneration. 
The results of the experimental OA calorimetric examinations showed that physicochemical 
properties of normal samples are clearly statistically different from the MIA induced OA 
groups (treated and non-treated alike). This inequality even at the low end of the 95% 
confidence interval represents a difference large enough to be considered biologically 
important. Therefore, it can be concluded that there is a difference between treatment means 
and that the variation is large enough to be scientifically relevant. Interestingly the rats 
injected with monosodium iodoacetate and pretreated with oral glucosamine-sulphate 
showed significantly higher increase in the value of the enthalpy change than the non-
treated, but OA induced cartilage samples. However, at 95% confidence interval range (from 
-385.0286 to -120.4421) a strong conclusion can not be drawn. Therefore more data needs to 
be obtained to draw a clear conclusion. 
Further understanding of the initiating events in cartilage destruction, the relationship 
between the different pathologic influences, and the role of the chondrocyte in maintaining 
extracellular matrix homeostasis is necessary to reveal potential targets of therapy. Clinical 
trials are currently underway for a number of potential disease modifying agents that may 
significantly change the treatment approach for OA. With the use of disease-modifying OA 
drugs (DMOADs), the necessity for instruments that are sensitive to changes has become 
very apparent in clinical trials [Qvista, 2008]. 
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the effectiveness of currently used medications (Glucosamin, Chondroitin) for resolving 
cartilage matrix degeneration. 
The results of the experimental OA calorimetric examinations showed that physicochemical 
properties of normal samples are clearly statistically different from the MIA induced OA 
groups (treated and non-treated alike). This inequality even at the low end of the 95% 
confidence interval represents a difference large enough to be considered biologically 
important. Therefore, it can be concluded that there is a difference between treatment means 
and that the variation is large enough to be scientifically relevant. Interestingly the rats 
injected with monosodium iodoacetate and pretreated with oral glucosamine-sulphate 
showed significantly higher increase in the value of the enthalpy change than the non-
treated, but OA induced cartilage samples. However, at 95% confidence interval range (from 
-385.0286 to -120.4421) a strong conclusion can not be drawn. Therefore more data needs to 
be obtained to draw a clear conclusion. 
Further understanding of the initiating events in cartilage destruction, the relationship 
between the different pathologic influences, and the role of the chondrocyte in maintaining 
extracellular matrix homeostasis is necessary to reveal potential targets of therapy. Clinical 
trials are currently underway for a number of potential disease modifying agents that may 
significantly change the treatment approach for OA. With the use of disease-modifying OA 
drugs (DMOADs), the necessity for instruments that are sensitive to changes has become 
very apparent in clinical trials [Qvista, 2008]. 
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1. Introduction 
Osteoarthritis (OA) is the most common joint-related disorder. The prevalence rises steeply 
with age and is a major cause of pain and disability. In the over 65-year-old population, 12% 
suffer from symptomatic knee OA (1) while 13– 26 % suffer from symptomatic OA in at least 
one hand joint (2). Hip OA is much less common. The prevalence of radiographic change is 
much higher; in the elderly population 75% have evidence of hand OA and 30% of knee OA 
on plain radiographs (3).  
The term “osteoarthritis” is used to refer to a number of related conditions that can be 
broadly classified into two groups.  Primary OA, which can be localised or generalised and 
more commonly affects peri-menopausal woman (especially involving the hand inter-
phalangeal joints); or secondary OA which has an underlying cause such as an 
inflammatory arthritis (e.g. rheumatoid arthritis or crystal arthritis), mechanical damage 
(e.g. articular fractures), a congenital or developmental disorder or a metabolic or endocrine 
condition (4). An osteoarthritic joint may show varying degrees of inflammatory change, 
detectable clinically and histologically. It is uncertain to what degree these (and other) 
subdivisions of OA are useful in terms of therapy. 
This chapter addresses therapies for all forms of OA of limb joints. Much of the evidence 
that will be considered here does not distinguish between the various types, although where 
possible, efficacy in knee, hip and hand OA is described separately due to the differing 
natural history and prognosis of OA at these sites. 
Treatments for OA are limited. They consist of a combination of non- pharmacological and 
pharmacological approaches, which should be tailored to the individual according to their 
needs and stage of disease. They aim to relieve pain and stiffness and thereby improve 
function. It is recognised that pain arises from both intra-articular structures (bone or 
synovial tissue) and from peri-articular structures such as entheses, bursae or tendons. 
Sensitisation of peripheral nerves and central nervous system changes can also contribute to 
the persistence of pain over time. 
All patients should be offered education, advice and access to information in combination with 
physical approaches (e.g. strengthening exercises and physiotherapy, including aerobic fitness 
training) and lifestyle changes (e.g. weight reduction and dietary manipulation) as 
appropriate. Additional therapies include systemic drugs (e.g. analgesics, anti-inflammatory 
agents, supplements, and, recently, disease modifying treatment such as hydroxychloroquine) 
and surgery.   
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and surgery.   
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This chapter focuses on treatments that are administered to the joint itself, or in the region of 
the joint. Pain management techniques such as nerve block and transcutaneous electrical 
stimulation are beyond the scope of the article. 
2. Specific therapies 
2.1 Splinting/support 
Orthoses (or braces) are external devices mainly prescribed to modulate mechanical stress 
on a symptomatic joint compartment. They are used in knee and hand OA but not in hip 
OA. For knee OA, they include rest orthoses, knee sleeves and unloading braces. For hand 
OA they include thumb and wrist splints. Insoles are used in hip and knee OA: they include 
cushioned or neutral insoles, which act as shock absorbers; and wedged insoles, which also 
modulate mechanical stress.  
For lower limb OA, the main purpose of orthoses and insoles is to support an unstable joint 
and to help correct alignment (5). In doing so, they reduce pain, reduce load bearing and 
improve physical function. They can also improve proprioception (6) and possibly slow 
disease progression (7). They are particularly recommended in mild or moderate 
unicompartmental knee OA (8,9,10) where varying degrees of frontal or sagittal instability 
and varus or valgus mal-alignment occur, and ideally should be used in combination with 
other therapeutic approaches. The different interventions are described individually below. 
1. Rest orthoses are made from a stiff composite and are intended for joint 
immobilization. They are rarely used in practice however, and there are no clinical trial 
data to suggest effectiveness. Whether they would be helpful in transiently 
immobilising a swollen knee remains uninvestigated (11). 
2. Knee sleeves are functional elastic non-adhesive orthoses that can be used alone or in 
association with various devices and are aimed at patellar alignment or frontal femoro-
tibial stabilisation. Simple neoprene knee sleeves used in medial compartment OA have 
been shown to reduce pain on activity and stiffness but not physical disability in the 
short term (6 months) when compared with no sleeve (12). This does not appear related 
to a local thermic effect. They have also been shown to increase static and dynamic 
balance, which might help prevent falls (13). Heat retaining sleeves (worn for 12 hours 
per day for 4 weeks) do not offer additional therapeutic benefit over standard devices 
(14). Medial patellar strapping has also been shown to reduce pain significantly in 
patello-femoral OA associated with patellar mal-alignment (15).  
3. Unloading knee braces are functional devices indicated in patients with mal-alignment 
secondary to medial or lateral unicompartmental OA. They are composed of external 
stems, hinges and straps and are designed to decrease the compressive load transmitted 
to the diseased compartment by applying an external valgus or varus force respectively. 
Analgesic effect is achieved by improved stability, increased joint opening and possibly 
by reduction in local muscle contractions during gait (7). 
A single randomized controlled trial (RCT) of 110 patients showed that a valgus brace 
significantly improved pain, functional status and disease-specific quality of life at six 
months compared with no intervention in patients with medial compartment knee OA, 
and was more effective than a neoprene sleeve (12). However, a further RCT did not 
confirm its efficacy in pain reduction (16). A subset of patients in this trial found the 
varus brace effective for lateral compartment OA; this is the only trial result supporting 
efficacy of varus bracing. Unloading braces have been shown to improve isokinetic 
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quadriceps strength and gait symmetry (11) and while they significantly improve joint 
proprioception, this does not appear to improve postural control (6).  
The main drawbacks with unloading braces are a variable response rate (39 to 93% of 
patients notice improvement) (11), and discomfort due to heaviness, heat and mobility 
of the device. The latter can also lead to persistent joint instability. In a three-year follow 
up study of 22 patients, the most common complaint was skin irritation affecting 41% of 
patients (17). Long-term compliance is therefore a problem: 20% of patients discontinue 
their brace at 6 months and many discontinue treatment within 1 to 2 years (18). Long 
term efficacy is therefore unknown. The most serious reported side effect is venous 
thromboembolism. 
4. Insoles. There are limited data for the effectiveness of insoles (either laterally wedged or 
neutral) in reducing the symptoms of OA. In one study there was significant decrease in 
non-steroidal anti-inflammatory drug (NSAID) consumption and significantly better 
compliance in the laterally wedged insole group at 6 and 24 months compared to the 
neutral wedge group but there was no significant difference in pain, stiffness and function 
(19). Another study has shown that elastic subtalar strapping significantly reduces pain 
and femoro-tibial angulation at 6 and 24 months compared with traditional laterally 
wedged insoles (20). Adverse effects include low back, popliteal and foot sole pain (21).  
However, given their low cost and relatively better compliance, attention to footwear with 
shock-absorbing properties is worth considering (22).  
5. Thumb Splints. In patients with hand OA, pain and its anticipation is a major factor in 
loss of hand function. Pain reduction should therefore be the primary goal of treatment. 
It appears that 1st carpo-metacarpal (CMC) joint OA contributes more to pain and 
disability than inter-phalangeal joint OA (23). As heavy stresses are placed on the 1st 
CMC joint during pinching and grasping, thumb splints are useful especially if the 
patient has difficulty in performing daily tasks. 
Their efficacy was shown in a systematic review in 2010, which found high to moderate 
evidence for thumb CMC joint immobilization in improving pain and function and moderate 
evidence in improving grip strength (24). A multi-centre trial also showed strong evidence for 
efficacy at twelve months (but not at one month) in terms of improved pain and disability (25).  
There are several different designs of thumb CMC splints (from a short opponens splint 
which supports the 1st CMC and metacarpo-phalangeal (MCP) joint, to a much larger long 
opponens splint which includes both the MCP and wrist joint) (26). As yet it is unclear 
which are considered most comfortable for patients and thus will be worn long term, and 
what degree of support is required at what stage of OA in order to improve pain and 
function effectively (22).  
2.2 Topical non-steroidal anti-inflammatory drugs 
Direct application of topical non-steroidal anti-inflammatory drugs (NSAIDs) in the region 
of a painful joint is a common and recommended treatment in mild to moderate OA 
(8,9,10,22). This treatment is particularly useful in the management of a single painful 
osteoarthritic joint (especially the knee), or when a few hand joints are involved.  It can 
provide a safe and effective alternative to systemic anti-inflammatory therapy. 
Topical NSAIDs act primarily through inhibition of cyclo-oxygenases responsible for 
prostaglandin biosynthesis at the site of pain and inflammation, but might also work 
through peripheral and central desensitisation (27).  Unlike other topical treatments, the act 
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quadriceps strength and gait symmetry (11) and while they significantly improve joint 
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up study of 22 patients, the most common complaint was skin irritation affecting 41% of 
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efficacy at twelve months (but not at one month) in terms of improved pain and disability (25).  
There are several different designs of thumb CMC splints (from a short opponens splint 
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through peripheral and central desensitisation (27).  Unlike other topical treatments, the act 
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of local rubbing appears less important in achieving a therapeutic effect. Topical NSAIDs 
can be applied over the affected joint up to 2 to 4 times a day depending on the drug, but 
currently are not recommended for continuous use beyond one month.   
There are several different preparations of topical NSAID available, which differ in the 
active drug (diclofenac, ibuprofen, ketoprofen, piroxicam and felbinac), formulation (gel, 
solution, cream, plaster and patch) and the presence of a penetration enhancer to improve 
drug delivery (45.5% dimethylsulfoxide [DMSO] or menthol).  The most commonly studied 
preparations are diclofenac sodium 1% gel (DSG) and diclofenac sodium 1.5% in 45.5% 
DMSO solution (Pennsaid).  
To be effective, a topical NSAID needs to penetrate the skin and enter the circulation or 
additionally be absorbed into the underlying tissue. The formulation with respect to its lipid 
and aqueous solubility (requirements for passing through the stratum corneum and 
epidermal layer respectively) determines the degree of dermal penetration (28). 
Formulations of gels and sprays are more effective than creams.   
Studies show that penetration of the topical NSAID into the intra- and peri-articular 
structures via the local bloodstream gives rise to therapeutic concentrations within these 
tissues without significant systemic absorption (28,29). This accounts for their superior 
safety profile over oral therapy with respect to systemic renal, cardiovascular and 
gastrointestinal toxicity.  
Peak concentrations in the skin are achieved 2 hours after application, with a second peak 10 
hours after application, which is attributed to the systemic circulation. The skin appears to 
act as a ‘reservoir’ from which the drug is distributed to deeper tissues (30). Only 3-7% of 
the applied dose is systemically absorbed (29) and mean plasma concentrations are typically 
5% or less of the level reached following oral administration (31,32). Low systemic 
absorption is evidenced further by the lack of symptom relief in other joints distant to the 
site of application (33).  
With respect to knee osteoarthritis, up until recently there was no research evidence to 
support the long-term use (greater than a month) of topical NSAIDs; a systematic review in 
1998 (34) and two meta-analyses in 2004 (35,36) confirmed that topical NSAIDs were 
superior to placebo for up to two weeks in the treatment of chronically painful conditions 
but not longer. Later trials have however shown more long term efficacy, benefit beyond 4 
weeks was confirmed in a meta-analysis of trials assessing efficacy between 4 and 12 weeks 
(37), and two further recent large high quality RCTs have demonstrated a sustained 
response maintained up to 12 weeks with diclofenac (“DSG” (33) and “Pennsaid” (38)) when 
compared with placebo. A recent RCT has also found topical ibuprofen to be as effective as 
oral ibuprofen and other NSAIDs for 12 months (39).  
Currently there is insufficient evidence to compare efficacy of topical to oral administration 
of the same NSAID. The meta-analysis of RCTs in 2004 found that overall topical NSAIDs 
were less effective than oral NSAIDs (36). Two recent studies comparing topical diclofenac 
(in DMSO) with oral diclofenac in patients with knee OA have however demonstrated 
equivalent efficacy (40,41).  
Placebo controlled trials and head to head studies with oral NSAIDs also show efficacy of 
topical NSAIDs in finger joint OA: hence they are preferred to systemic therapy, especially 
for mild to moderate OA and when few joints are involved (42).  
The main side effect of topical anti-inflammatory treatment is local application site reactions 
such as dry skin, rash, pruritis and burning (36,37). They are short-lived and minor 
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however, and usually resolve when application is discontinued. Studies show that local 
adverse events are reported with equal frequency for topical NSAIDs and placebo 
preparations; hence they appear not to be related to the NSAID itself (35). Safety between 
different topical agents has not been studied. However, three 12-week trials showed a 
greater incidence (5 to 8 fold higher) of local application site reactions with diclofenac in 
DMSO solution (26-42%) compared with DSG (5.1%) (33). 
Compared to oral NSAIDs, topical therapy is associated with fewer systemic adverse events 
and gastro-intestinal side effects (33,35,40,41). However, data regarding gastro-intestinal 
safety and tolerability of topical NSAIDs in older patients (over the age of 50 years) are 
conflicting. Some studies report minor side effects to be infrequent, including the two-year 
RCT comparing topical to oral ibuprofen (39,43); but a recent systemic review has 
demonstrated gastro-intestinal adverse events in 15% and local skin reactions in 39.3% of 
patients receiving topical NSAIDs including skin sensitivity, contact dermatitis and 
photodermatitis (44). 
While topical NSAIDs should be considered with paracetamol as first line treatment ahead 
of oral NSAIDs, COX-2 inhibitors or opioids in view of their efficacy and relative safety, 
further studies are needed to confirm their long-term efficacy and use in bilateral knee OA. 
Their use in older patients also might still require a degree of caution until further data 
demonstrating their safety profile in this age group become available. 
2.3 Topical counter-irritants 
Topical counter-irritants or rubefacients are agents that are frequently applied locally to 
relieve musculoskeletal pain in the extremities. The most commonly used rubefacient is 
salicylate, but this class of agent also includes nicotinate esters. Topical capsaicin is 
commonly considered to be a rubefacient; however its mechanism of action is sufficiently 
different for this treatment to be described separately. 
The principal action of rubefacients is to act as a skin irritant. This results in reddening from 
vasodilatation and increased blood flow, but also leads to a soothing sensation of warmth 
i.e. counter-irritation. It is still unclear whether topical salicylates additionally relieve pain 
via cyclo-oxygenase inhibition, but there is little evidence that there is significant systemic 
absorption (45). This is consistent with the fact that no benefit is found using a rubefacient 
applied distal to the site of pain (46). Pain may also be offset or altered in the underlying 
muscle, joint and tendon by irritation of the sensory nerve endings (47). More recently there 
is evidence to suggest that salicylates and other rubefacients may act via the transient 
receptor potential (TRP) ion channels involved in thermal and pain sensation (48,49). 
Although topical rubefacients containing salicyclate are widely used in England (almost 1.8 
million prescriptions issued in 2006) (50), there is currently no evidence to support their 
prescription for chronic musculoskeletal pain. A Cochrane analysis in 2009 of six studies of 
rubefacients in chronic conditions such as osteoarthritis has shown that they produced 
significant benefit compared with placebo at 14 days, with 1 in 6 individuals achieving 50% 
pain relief (51). This compares poorly with topical NSAIDs however, where the number needed 
to treat (NNT) is 3.1 compared to placebo. Additionally their efficacy may be over-estimated as 
adequate blinding is not possible with any trial involving a rubefacient, the mechanism of 
action is through local irritation and any sham preparation, which attempts to mimic this, 
would be a rubefacient itself.  However, placebo gels in trials were rubbed on to the skin in the 
same way as the active treatment overcoming any additional therapeutic effect of rubbing (52). 
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however, and usually resolve when application is discontinued. Studies show that local 
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Compared to oral NSAIDs, topical therapy is associated with fewer systemic adverse events 
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demonstrated gastro-intestinal adverse events in 15% and local skin reactions in 39.3% of 
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of oral NSAIDs, COX-2 inhibitors or opioids in view of their efficacy and relative safety, 
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Their use in older patients also might still require a degree of caution until further data 
demonstrating their safety profile in this age group become available. 
2.3 Topical counter-irritants 
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relieve musculoskeletal pain in the extremities. The most commonly used rubefacient is 
salicylate, but this class of agent also includes nicotinate esters. Topical capsaicin is 
commonly considered to be a rubefacient; however its mechanism of action is sufficiently 
different for this treatment to be described separately. 
The principal action of rubefacients is to act as a skin irritant. This results in reddening from 
vasodilatation and increased blood flow, but also leads to a soothing sensation of warmth 
i.e. counter-irritation. It is still unclear whether topical salicylates additionally relieve pain 
via cyclo-oxygenase inhibition, but there is little evidence that there is significant systemic 
absorption (45). This is consistent with the fact that no benefit is found using a rubefacient 
applied distal to the site of pain (46). Pain may also be offset or altered in the underlying 
muscle, joint and tendon by irritation of the sensory nerve endings (47). More recently there 
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significant benefit compared with placebo at 14 days, with 1 in 6 individuals achieving 50% 
pain relief (51). This compares poorly with topical NSAIDs however, where the number needed 
to treat (NNT) is 3.1 compared to placebo. Additionally their efficacy may be over-estimated as 
adequate blinding is not possible with any trial involving a rubefacient, the mechanism of 
action is through local irritation and any sham preparation, which attempts to mimic this, 
would be a rubefacient itself.  However, placebo gels in trials were rubbed on to the skin in the 
same way as the active treatment overcoming any additional therapeutic effect of rubbing (52). 
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Based on limited data, rubefacients appear well tolerated and local adverse effects are 
uncommon in the short term (2% of patients) (51,52). Currently they are usually used as 
adjuvants to other therapies, such as oral analgesics, support bandages, rest, ice, and 
compression, and may be useful for patients who cannot tolerate oral analgesics (52). RCTs 
are needed to support their clinical use with respect to long-term efficacy and safety 
especially in osteoarthritis, which is a chronically painful condition. Most trials have lasted 
14 days only and the longest trial spanned 28 days (52). Consequently rubefacients are not 
recommended in the UK in osteoarthritis although this recommendation has been based on 
a small number of limited studies (22). 
2.4 Topical capsaicin 
Topical capsaicin (0.025%) cream can be used to treat pain from osteoarthritis and 
rheumatoid arthritis. A higher dose (0.075%) is used in the treatment of neuropathic pain. 
The preparations contain capsaicin, a lipophilic alkaloid extracted from chilli peppers that 
has an extremely potent irritant effect. They work by initially selectively activating and 
sensitising c-nociceptors in the skin by binding the transient receptor vanilloid type 1 (TRPV 
1) cation channel (53). Substance P is released which causes local irritation; however with 
repeated applications, levels are depleted leading to reversible desensitization of pain fibres 
and eventual degeneration of epidermal nerve fibres resulting in hypoalgesia (54). Although 
topical capsaicin is better than placebo for treatment of chronic pain, a meta-analysis of 
topical capsaicin (0.025%) or plaster for chronic musculoskeletal pain calculated the NNT at 
4 weeks to be 8.1 for a 50% reduction in pain suggesting that capsaicin is only marginally 
effective (55).  
In general therefore topical capsaicin is best employed as an adjunct to other modes of 
therapy. It should be used for 3 to 4 weeks (applied 4 times daily) to achieve maximal 
benefit. A transient local burning sensation (which can be intense), stinging or erythema at 
the application site are common (40%) (10), and lead to 1 in 10 patients discontinuing the 
treatment (55) however. Systemic events are rare. 
2.5 Thermotherapy 
The local application of heat or cold (cryotherapy) to a painful joint has been used for many 
years in the rehabilitation of patients with OA to relieve pain, stiffness and oedema. 
Cryotherapy is usually administered by application of cold packs or massage with ice over 
painful areas or acupoints (56). Cold application helps to reduce pain and swelling by 
causing temporary vasoconstriction and a reduction in local blood flow. This may in turn 
help improve range of motion and function (57). Heat therapy is used to reduce pain and 
stiffness by possibly improving circulation and relaxing muscles.  However there are 
concerns that increased blood flow may worsen inflammation and oedema. Common 
methods of superficial heat administration are electrical heating pads, application of hot 
packs, towels or wax, or immersion in warm water or wax baths. 
Supporting evidence for the efficacy of this mode of treatment remains very limited. For 
knee osteoarthritis, ice massage may be a useful adjunct for pain relief and cold packs may 
be used to lessen knee oedema  (Cochrane review of three RCTs in 2003, involving 179 
patients) (58). Ice massage for 20 minutes, 5 times a week for 3 weeks had a clinically 
significant effect on knee strength (29% improvement) with a statistically significant 
improvement in range of movement (8% relative difference) and function (11% relative 
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difference) after two weeks of treatment (59) but not at three weeks given three times a week 
(60). Ice packs did not affect pain significantly compared to controls; however ice massage 
did have a significant effect. Cold packs also lead to a significant reduction in knee swelling 
but this has not been seen with hot packs (61). Some studies have shown that heat therapy 
for knee OA used for 20 minutes every other day for four weeks can significantly improve 
pain and disability but not stiffness (62). There have been no controlled trials of cryotherapy 
in hip OA.   
There are no experimental studies to examine the role of cryotherapy in hand osteoarthritis.  
However, a systematic review in 2010 found three studies that had examined the role of heat 
therapy in 174 patients (63). There is weak evidence for the role of paraffin wax in pain 
reduction, improved range of movement and function, and moderate level evidence to 
support the use of low level continuous heat wrap and steam treatments for pain reduction 
and improved grip strength (64). Local application of heat prior to exercise may be helpful 
in knee OA; however direct research evidence for the benefit of local application of heat as a 
pretreatment or in combination with other physical therapies for hand OA is lacking (42). 
Although further studies are required to determine their efficacy, heat and cold therapies 
are easy, non-invasive treatments with very few adverse events, and therefore can be 
considered as an adjunct to core treatment in hand and knee OA.  
2.6 Joint aspiration 
Aspiration of synovial fluid from a swollen joint (e.g. aspiration of knee) can provide 
temporary relief in pain and stiffness, although effusions usually re-accumulate unless 
steroid is injected. Aspiration of cystic fluid in cystic OA of joints similarly often provides 
symptomatic relief, but again fluid tends to re-accumulate. 
2.7 Intra-articular corticosteroid 
Intra-articular (IA) corticosteroid injections have been widely used to treat symptomatic 
peripheral joint OA for many years.  The corticosteroid exerts its anti-inflammatory effect by 
interrupting the immune and inflammatory cascade at several levels. Local delivery of high 
doses of corticosteroid minimises systemic toxicity and can result in rapid improvement in 
symptoms during acute or severe symptom flares, especially in knee and hand OA. 
Corticosteroid preparations differ in solubility and potency:  more soluble preparations 
have a shorter duration of action, e.g. hydrocortisone acetate, compared to longer acting 
emulsion based preparations, which are only slightly soluble, e.g. methlyprednisolone 
acetate (MPA) or relatively insoluble, e.g.triamcinolone acetonide (TCA). Longer acting 
preparations are more effective for intra-articular injections as they remain in the joint 
longer, but there are few randomised, controlled trials comparing different IA 
corticosteroids.  In a double blind RCT of 57 patients with symptomatic knee OA 
comparing TCA 20mg with MPA 40mg, there was a greater reduction in pain compared 
with baseline at 3 weeks with TCA compared to MPA, but this was only maintained at 8 
weeks in the MPA group despite TCA being less soluble (65). In practice the choice of 
agent is usually based on local availability and cost. The dose-response relationship has 
not been systematically studied. 
Most manufacturers advise against corticosteroid dilution with local anaesthetic (e.g. 
lignocaine) because of the risk of clumping and precipitation of steroid crystals.  
However this remains common practice and provides additional benefits:  there is early 
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Corticosteroid preparations differ in solubility and potency:  more soluble preparations 
have a shorter duration of action, e.g. hydrocortisone acetate, compared to longer acting 
emulsion based preparations, which are only slightly soluble, e.g. methlyprednisolone 
acetate (MPA) or relatively insoluble, e.g.triamcinolone acetonide (TCA). Longer acting 
preparations are more effective for intra-articular injections as they remain in the joint 
longer, but there are few randomised, controlled trials comparing different IA 
corticosteroids.  In a double blind RCT of 57 patients with symptomatic knee OA 
comparing TCA 20mg with MPA 40mg, there was a greater reduction in pain compared 
with baseline at 3 weeks with TCA compared to MPA, but this was only maintained at 8 
weeks in the MPA group despite TCA being less soluble (65). In practice the choice of 
agent is usually based on local availability and cost. The dose-response relationship has 
not been systematically studied. 
Most manufacturers advise against corticosteroid dilution with local anaesthetic (e.g. 
lignocaine) because of the risk of clumping and precipitation of steroid crystals.  
However this remains common practice and provides additional benefits:  there is early 
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temporary relief of symptoms; it verifies delivery of steroid to site of pain (66); and it 
dilutes the suspension, enabling even distribution within the joint, (especially in 
shoulder joint injections), and hence avoids placement of highly concentrated fluid into a 
single area. 
Several randomised controlled trials (67-70) and one Cochrane systematic review (71) have 
shown significant short-term efficacy (between 1 to 4 weeks) in terms of pain reduction for a 
single IA corticosteroid (TCA, MPA and cortivazol) over placebo in knee OA although 
effects on function appear less marked. There was no significant benefit at 4 to 24 weeks 
post injection. Hence IA corticosteroids work rapidly, but the effects are mostly short-lived. 
The lack of a sustained response over placebo in these studies might relate to lower than 
recommended steroid doses used, and a strong beneficial effect seen in patients receiving IA 
placebo injection. In clinical practice, IA steroid injections provide rapid short-term pain 
relief to settle flares of pain and permit patients to begin other interventions such as 
quadriceps strengthening exercises.  
The benefit of IA corticosteroid injections to the hip remains inconclusive. One small RCT of 
35 patients examining the role of TCA in patients awaiting hip replacement showed good 
pain relief at one month, but this was not maintained, and in 8.5% symptoms deteriorated 
(72). Another RCT showed significant improvement by IA MPA 40mg at 2 weeks compared 
with placebo 0.9% saline injection, but efficacy was lost at 3 months (73).  
The efficacy of IA 1st CMC joint injection was evaluated in a trial of 40 patients with 
primary moderate to severe OA, randomized to either 0.25mls TCA (5mg) or an 
equivalent volume of 0.9% saline. No clinical benefit was gained compared to placebo 
injection (74). A further prospective study of 30 patients with radiographically staged 
hand OA has shown long-term benefit (18 months) with a single IA 1st CMC joint injection 
and subsequent splinting for 3 weeks, in 80% of patients with early radiographic disease 
i.e preserved joint space and minimal other changes. In patients with more 
radiographically advanced OA with osteophytes and joint space narrowing, sustained 
pain relief was less reliably achieved (75).  
While IA corticosteroids have marked anti-inflammatory effects and reduce the volume of 
synovitis in OA (73), disease factors which might relate to the presence of inflammation 
have not been found to determine clinical response including local heat and synovial 
thickening (70), and synovial fluid (SF) volume and leucocyte count (69).  Furthermore the 
presence of a knee effusion does not appear to predict response either (67,70). In one study 
prior synovial fluid aspiration did lead to a greater reduction in pain (69); however this may 
have been related to less steroid dilution by synovial fluid and more accurate placement of 
the IA injection confirmed by prior synovial fluid aspiration (76). Hence the presence of a 
knee effusion is not necessarily an indication for corticosteroid injection unless it causes 
significant restriction in movement. (22) 
Additionally a steroid response is not confined to joints with clinical evidence of 
inflammation (70). This appears not to be related to inaccuracy in detecting inflammation on 
clinical examination; a recent ultrasound scanning study showed that patients with non-
inflammatory features on ultrasound derived more prolonged benefit compared to patients 
with inflammatory features (77).  
The risks in IA steroid injection are generally small but the following potential side effects 
can occur: 
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1. Post-injection crystal-induced synovitis can occur in 2 to 6% of patients. It is usually 
observed within 24 hours of injection, and spontaneously resolves in 1 to 3 days (78). It 
is usually managed by analgesic therapy or ice packs. Flares have also been reported 
following saline injection suggesting that other factors such as injection technique may 
be responsible (67,69). 
2. Iatrogenic infection is rare, with a reported incidence between 1 in 3000 to 1 in 50 000 
(79). Symptoms usually occur within 3 to 4 days of injection. Aseptic technique and 
withholding injection in at risk patients should minimise this potential serious 
complication. 
3. Lipoatrophy secondary to subcutaneous deposition of steroid is more common with 
less soluble preparations and was found to occur in 0.6% of patients in a prospective 
study of intra- and peri-articular injections of methylprednisolone acetate (80). Hence 
longer acting preparations are generally avoided in small joint injections where accurate 
placement is technically difficult. 
4. Local effects including tendon weakening/ rupture, muscle wasting, skin pigmentation 
changes, nerve and blood vessel damage can be minimised by more accurately directed 
injections. 
5. Systemic effects vary. Facial flushing is relatively frequent (40% in one study) (81) and 
may occur after a few hours. Diabetic control may be temporarily disturbed but not 
significantly (82). Corticosteroid-induced osteoporosis does not appear to be a major 
concern due to lack of net impact on bone resorption. Anaphylaxis is extremely rare 
(81). 
Concern regarding long-term effects of repeated injection, such as risk of progressive 
articular cartilage damage, has limited the number of injections given to any particular joint: 
the general consensus is for no more than 3 to 4 per year. While animal studies have shown 
steroid induced chondrocyte degeneration (83), data to support this recommendation in 
clinical practice are lacking. In a randomised prospective trial of patients receiving TCA 
injections every 3 months for up to 2 years for knee osteoarthritis, no evidence of increased 
loss of joint space was observed (84). Similarly there are very few reports of osteonecrosis, 
with no convincing causal relationship identified.  Unpublished experience does however 
suggest that there may be an increased risk of osteonecrosis of the femoral head following 
such injections into the hip joint. 
Repeated intra-articular corticosteroid injections do not provide long-term benefit (76), and 
it is generally accepted that other treatment modalities should be sought if patients require 
frequent or numerous injections.  
2.8 Intra-articular hyaluronic acid/ hyaluronan 
Endogenous hyaluronan, previously known as hyaluronic acid (HA), is a large linear 
glycosamino-glycan.  It is a major non-structural component of both the synovial and cartilage 
extracellular matrix and of synovial fluid. Key functions in the joint are to confer viscoelasticity 
and lubrication, and to help maintain tissue hydration and protein homeostasis by preventing 
large fluid movements (22). OA is associated with a decrease of HA content in the synovial 
fluid (85). The therapeutic goal of intra-articular viscosupplementation with HA is therefore to 
restore the natural protective function of hyaluronan in the joint.  
The mechanism by which HA exerts its therapeutic effect, if any, is not certain. Intra- 
articular residency is short (hours), but the reported benefit is long (months). The short-term 
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temporary relief of symptoms; it verifies delivery of steroid to site of pain (66); and it 
dilutes the suspension, enabling even distribution within the joint, (especially in 
shoulder joint injections), and hence avoids placement of highly concentrated fluid into a 
single area. 
Several randomised controlled trials (67-70) and one Cochrane systematic review (71) have 
shown significant short-term efficacy (between 1 to 4 weeks) in terms of pain reduction for a 
single IA corticosteroid (TCA, MPA and cortivazol) over placebo in knee OA although 
effects on function appear less marked. There was no significant benefit at 4 to 24 weeks 
post injection. Hence IA corticosteroids work rapidly, but the effects are mostly short-lived. 
The lack of a sustained response over placebo in these studies might relate to lower than 
recommended steroid doses used, and a strong beneficial effect seen in patients receiving IA 
placebo injection. In clinical practice, IA steroid injections provide rapid short-term pain 
relief to settle flares of pain and permit patients to begin other interventions such as 
quadriceps strengthening exercises.  
The benefit of IA corticosteroid injections to the hip remains inconclusive. One small RCT of 
35 patients examining the role of TCA in patients awaiting hip replacement showed good 
pain relief at one month, but this was not maintained, and in 8.5% symptoms deteriorated 
(72). Another RCT showed significant improvement by IA MPA 40mg at 2 weeks compared 
with placebo 0.9% saline injection, but efficacy was lost at 3 months (73).  
The efficacy of IA 1st CMC joint injection was evaluated in a trial of 40 patients with 
primary moderate to severe OA, randomized to either 0.25mls TCA (5mg) or an 
equivalent volume of 0.9% saline. No clinical benefit was gained compared to placebo 
injection (74). A further prospective study of 30 patients with radiographically staged 
hand OA has shown long-term benefit (18 months) with a single IA 1st CMC joint injection 
and subsequent splinting for 3 weeks, in 80% of patients with early radiographic disease 
i.e preserved joint space and minimal other changes. In patients with more 
radiographically advanced OA with osteophytes and joint space narrowing, sustained 
pain relief was less reliably achieved (75).  
While IA corticosteroids have marked anti-inflammatory effects and reduce the volume of 
synovitis in OA (73), disease factors which might relate to the presence of inflammation 
have not been found to determine clinical response including local heat and synovial 
thickening (70), and synovial fluid (SF) volume and leucocyte count (69).  Furthermore the 
presence of a knee effusion does not appear to predict response either (67,70). In one study 
prior synovial fluid aspiration did lead to a greater reduction in pain (69); however this may 
have been related to less steroid dilution by synovial fluid and more accurate placement of 
the IA injection confirmed by prior synovial fluid aspiration (76). Hence the presence of a 
knee effusion is not necessarily an indication for corticosteroid injection unless it causes 
significant restriction in movement. (22) 
Additionally a steroid response is not confined to joints with clinical evidence of 
inflammation (70). This appears not to be related to inaccuracy in detecting inflammation on 
clinical examination; a recent ultrasound scanning study showed that patients with non-
inflammatory features on ultrasound derived more prolonged benefit compared to patients 
with inflammatory features (77).  
The risks in IA steroid injection are generally small but the following potential side effects 
can occur: 
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1. Post-injection crystal-induced synovitis can occur in 2 to 6% of patients. It is usually 
observed within 24 hours of injection, and spontaneously resolves in 1 to 3 days (78). It 
is usually managed by analgesic therapy or ice packs. Flares have also been reported 
following saline injection suggesting that other factors such as injection technique may 
be responsible (67,69). 
2. Iatrogenic infection is rare, with a reported incidence between 1 in 3000 to 1 in 50 000 
(79). Symptoms usually occur within 3 to 4 days of injection. Aseptic technique and 
withholding injection in at risk patients should minimise this potential serious 
complication. 
3. Lipoatrophy secondary to subcutaneous deposition of steroid is more common with 
less soluble preparations and was found to occur in 0.6% of patients in a prospective 
study of intra- and peri-articular injections of methylprednisolone acetate (80). Hence 
longer acting preparations are generally avoided in small joint injections where accurate 
placement is technically difficult. 
4. Local effects including tendon weakening/ rupture, muscle wasting, skin pigmentation 
changes, nerve and blood vessel damage can be minimised by more accurately directed 
injections. 
5. Systemic effects vary. Facial flushing is relatively frequent (40% in one study) (81) and 
may occur after a few hours. Diabetic control may be temporarily disturbed but not 
significantly (82). Corticosteroid-induced osteoporosis does not appear to be a major 
concern due to lack of net impact on bone resorption. Anaphylaxis is extremely rare 
(81). 
Concern regarding long-term effects of repeated injection, such as risk of progressive 
articular cartilage damage, has limited the number of injections given to any particular joint: 
the general consensus is for no more than 3 to 4 per year. While animal studies have shown 
steroid induced chondrocyte degeneration (83), data to support this recommendation in 
clinical practice are lacking. In a randomised prospective trial of patients receiving TCA 
injections every 3 months for up to 2 years for knee osteoarthritis, no evidence of increased 
loss of joint space was observed (84). Similarly there are very few reports of osteonecrosis, 
with no convincing causal relationship identified.  Unpublished experience does however 
suggest that there may be an increased risk of osteonecrosis of the femoral head following 
such injections into the hip joint. 
Repeated intra-articular corticosteroid injections do not provide long-term benefit (76), and 
it is generally accepted that other treatment modalities should be sought if patients require 
frequent or numerous injections.  
2.8 Intra-articular hyaluronic acid/ hyaluronan 
Endogenous hyaluronan, previously known as hyaluronic acid (HA), is a large linear 
glycosamino-glycan.  It is a major non-structural component of both the synovial and cartilage 
extracellular matrix and of synovial fluid. Key functions in the joint are to confer viscoelasticity 
and lubrication, and to help maintain tissue hydration and protein homeostasis by preventing 
large fluid movements (22). OA is associated with a decrease of HA content in the synovial 
fluid (85). The therapeutic goal of intra-articular viscosupplementation with HA is therefore to 
restore the natural protective function of hyaluronan in the joint.  
The mechanism by which HA exerts its therapeutic effect, if any, is not certain. Intra- 
articular residency is short (hours), but the reported benefit is long (months). The short-term 
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mode of action might be based on the pain relieving effect of the viscoelastic fluid in the 
affected joint. In the long term a sequence of events might be triggered which restores the 
trans-synovial flow and subsequently the metabolic and rheological homeostasis of the joint 
(86). However there is minimal evidence for a role in long term disease modification (8).  
Commercial preparations of HA have the same structure as endogenous HA, although 
cross-linked HA molecules (known as hylans) were later engineered in order to obtain 
greater elasto-viscosity and intra-articular dwell-time. There are several formulations 
available (Artz, BioHy, Durolane, Hyalgan, Synvisc, Suvenyl, Orthovisc, Replasyn and 
Suplasyn) which vary in their molecular weight (2 to over 7 million KDA).  This difference is 
thought to be of importance with respect to the volume and number of injections needed, 
and the length of time the preparation remains in the joint. Higher molecular weight 
preparations, such as Hylan G-F 20 (Synvisc), seem to be more effective than lower-
molecular-weight preparations in this respect (87).  
Although there are a large number of studies in the literature, evidence for the efficacy of 
HAs is difficult to interpret because studies have used different molecular weights of HA 
and different injection schedules, and because of poor trial design. In addition, the benefit 
from placebo saline injections was high in some of the studies. Overall, hyaluronans and 
hylan derivatives seem to be superior to placebo in terms of efficacy (including pain relief, 
function and patient global assessment) and quality of life outcomes in patients with knee 
OA at different post-injection periods, but especially at 5 to 13 weeks after the last of a series 
of 3 to 5 injections (86). Clinical trials do not suggest that sub-groups of osteoarthritis 
patients may have greater benefit; however this would be of research interest given the high 
cost of this particular treatment (22). Data from the Cochrane meta-analysis suggest that IA 
therapy with hyaluronans may have a more prolonged effect than IA corticosteroids (86). 
Adverse effects are rare but include a transient increase in pain and very rarely a frank 
arthritis flare with knee effusion. There do not appear to be any systemic side effects.  
In hip OA, no significant differences between hyaluronans and placebo were reported at any 
time point by a RCT evaluating efficacy and function outcomes, but the effect was better in 
patients without an effusion (88). There was no significant difference between hyaluronan 
and corticosteroid injection either (88). Similarly, hyaluronan and corticosteroid injections 
perform similarly with respect to efficacy and function in hand OA (89).  
Overall the evidence for HA efficacy is mostly in knee OA, with a slower onset of action but 
a more durable response than IA corticosteroid injection. It is a safe treatment.  However its 
widespread use is limited by cost. It is usually offered to patients who are not fit for or 
would like to delay surgical intervention, and in patients who require repeated IA 
corticosteroid injections. 
2.9 Acupuncture 
Accupuncture is a recommended modality of therapy for symptomatic treatment of patients 
with knee and hip OA. It involves treatment with fine filiform stainless steel needles of 0.25- 
0.35mm diameter. Typically six needles are placed near the painful area and possibly elsewhere 
and are either manipulated to produce a ‘needle sensation’ or stimulated electrically 
(electroacupuncture) for up to 20 minutes. A course of treatment usually consists of six or more 
sessions. The response can be variable, the reasons for which are not well understood. Potential 
underlying neurophysiological mechanisms are complex. The ‘gate control theory’ and release 
of endogenous opioids are possible explanations for the apparent analgesic effect (10). 
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Although an earlier systematic review of acupuncture in patients with OA at various 
peripheral sites did not show it to be any better than sham controls (90), several randomized 
trials report benefit in knee OA over sham acupuncture (91-93) and standard treatment (94).  
A systematic review in 2001 of 7 RCTs including 393 patients (95) found that acupuncture 
significantly improved pain compared with sham acupuncture, but not function (92,93). 
However, it was not found to be more effective than physical therapy or than being on a 
waiting list to receive acupuncture (94,96). The benefit appears short to medium term (6-12 
weeks); the few studies with long-term follow up did not show benefit at 26 weeks (91,94). 
Combining acupuncture with a course of advice and exercise has not been shown to provide 
any additional benefit (97). Acupuncture of peripheral joints appears safe (98). Mild adverse 
effects occur in 7% of patients (99,100), but serious side effects are rare (101).  
2.10 Trigger point injection 
In many forms of arthritis, localised areas of thickening and tenderness in cutaneous and 
other soft tissues can be found.  These have been referred to by a number of different names, 
including interstitial fibrositis, myofasciitis and myofascial trigger points (102-104).  They 
are also well described by acupuncturists (105).  Some are found clinically in cutaneous and 
subcutaneous tissue at sites near to or distant from inflamed or painful joints, typically in 
areas of a limb proximal to an affected joint, such as in the upper part of the rectus femoris 
in patients with knee pain, and in paraspinal regions in the cervical and lumbar areas (106).   
The term trigger point injection (TPI) refers to direct injection of a substance into the trigger 
point itself, or into the skin or soft tissue over the trigger point (indirect needling); or to dry 
needling of either of these areas. The main objective is to inactivate the trigger point thereby 
reducing pain and restoring function. However, the aetiology and pathogenesis of trigger 
points have yet to be elucidated, and the precise mechanism by which TPI inactivates the 
trigger point is still unknown (107). 
Optimal technique and treatment regimen for TPI varies between practitioners, and is 
largely based on clinical experience. Treatment begins with identifying the trigger point; the 
area of maximal tenderness and immobilising the muscle between the thumb and forefinger. 
Generally a sterile small gauge needle is then introduced into the trigger point. Correct 
identification is supported by a twitch in the affected muscle, exacerbation of pain and the 
presence of referred pain (108). 
Clinicians have used local anaesthetic, anti-inflammatory agents (long-acting corticosteroid, 
acetylsalicylate and ketorolac), saline and water (104,108-113). Injecting a trigger point is 
painful and the addition of a local anaesthetic to the injected fluid can help reduce pain and 
irritation (114,115).  
A systematic review of the efficacy of TPI to treat chronic non-malignant musculoskeletal 
pain (such as whiplash syndrome or chronic head, neck, shoulder, and back pain) of more 
than three months’ duration found that TPI relieved symptoms when used as a sole 
treatment for patients, regardless of the injectant used, but was not more effective than other 
less invasive treatments such as laser and ultrasound (107).  
The efficacy of TPI as a treatment for osteoarthritis is not well described; and as most studies 
have looked at its role as a sole treatment rather than in the adjunct capacity in which it is 
routinely used in clinical practice, its effectiveness might be underestimated. One study 
showed that intra-articular injection combined with lidocaine TPI of any of the 15 leg muscle 
trigger points was more effective than intra-articular injection alone in relieving pain and 
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mode of action might be based on the pain relieving effect of the viscoelastic fluid in the 
affected joint. In the long term a sequence of events might be triggered which restores the 
trans-synovial flow and subsequently the metabolic and rheological homeostasis of the joint 
(86). However there is minimal evidence for a role in long term disease modification (8).  
Commercial preparations of HA have the same structure as endogenous HA, although 
cross-linked HA molecules (known as hylans) were later engineered in order to obtain 
greater elasto-viscosity and intra-articular dwell-time. There are several formulations 
available (Artz, BioHy, Durolane, Hyalgan, Synvisc, Suvenyl, Orthovisc, Replasyn and 
Suplasyn) which vary in their molecular weight (2 to over 7 million KDA).  This difference is 
thought to be of importance with respect to the volume and number of injections needed, 
and the length of time the preparation remains in the joint. Higher molecular weight 
preparations, such as Hylan G-F 20 (Synvisc), seem to be more effective than lower-
molecular-weight preparations in this respect (87).  
Although there are a large number of studies in the literature, evidence for the efficacy of 
HAs is difficult to interpret because studies have used different molecular weights of HA 
and different injection schedules, and because of poor trial design. In addition, the benefit 
from placebo saline injections was high in some of the studies. Overall, hyaluronans and 
hylan derivatives seem to be superior to placebo in terms of efficacy (including pain relief, 
function and patient global assessment) and quality of life outcomes in patients with knee 
OA at different post-injection periods, but especially at 5 to 13 weeks after the last of a series 
of 3 to 5 injections (86). Clinical trials do not suggest that sub-groups of osteoarthritis 
patients may have greater benefit; however this would be of research interest given the high 
cost of this particular treatment (22). Data from the Cochrane meta-analysis suggest that IA 
therapy with hyaluronans may have a more prolonged effect than IA corticosteroids (86). 
Adverse effects are rare but include a transient increase in pain and very rarely a frank 
arthritis flare with knee effusion. There do not appear to be any systemic side effects.  
In hip OA, no significant differences between hyaluronans and placebo were reported at any 
time point by a RCT evaluating efficacy and function outcomes, but the effect was better in 
patients without an effusion (88). There was no significant difference between hyaluronan 
and corticosteroid injection either (88). Similarly, hyaluronan and corticosteroid injections 
perform similarly with respect to efficacy and function in hand OA (89).  
Overall the evidence for HA efficacy is mostly in knee OA, with a slower onset of action but 
a more durable response than IA corticosteroid injection. It is a safe treatment.  However its 
widespread use is limited by cost. It is usually offered to patients who are not fit for or 
would like to delay surgical intervention, and in patients who require repeated IA 
corticosteroid injections. 
2.9 Acupuncture 
Accupuncture is a recommended modality of therapy for symptomatic treatment of patients 
with knee and hip OA. It involves treatment with fine filiform stainless steel needles of 0.25- 
0.35mm diameter. Typically six needles are placed near the painful area and possibly elsewhere 
and are either manipulated to produce a ‘needle sensation’ or stimulated electrically 
(electroacupuncture) for up to 20 minutes. A course of treatment usually consists of six or more 
sessions. The response can be variable, the reasons for which are not well understood. Potential 
underlying neurophysiological mechanisms are complex. The ‘gate control theory’ and release 
of endogenous opioids are possible explanations for the apparent analgesic effect (10). 
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Although an earlier systematic review of acupuncture in patients with OA at various 
peripheral sites did not show it to be any better than sham controls (90), several randomized 
trials report benefit in knee OA over sham acupuncture (91-93) and standard treatment (94).  
A systematic review in 2001 of 7 RCTs including 393 patients (95) found that acupuncture 
significantly improved pain compared with sham acupuncture, but not function (92,93). 
However, it was not found to be more effective than physical therapy or than being on a 
waiting list to receive acupuncture (94,96). The benefit appears short to medium term (6-12 
weeks); the few studies with long-term follow up did not show benefit at 26 weeks (91,94). 
Combining acupuncture with a course of advice and exercise has not been shown to provide 
any additional benefit (97). Acupuncture of peripheral joints appears safe (98). Mild adverse 
effects occur in 7% of patients (99,100), but serious side effects are rare (101).  
2.10 Trigger point injection 
In many forms of arthritis, localised areas of thickening and tenderness in cutaneous and 
other soft tissues can be found.  These have been referred to by a number of different names, 
including interstitial fibrositis, myofasciitis and myofascial trigger points (102-104).  They 
are also well described by acupuncturists (105).  Some are found clinically in cutaneous and 
subcutaneous tissue at sites near to or distant from inflamed or painful joints, typically in 
areas of a limb proximal to an affected joint, such as in the upper part of the rectus femoris 
in patients with knee pain, and in paraspinal regions in the cervical and lumbar areas (106).   
The term trigger point injection (TPI) refers to direct injection of a substance into the trigger 
point itself, or into the skin or soft tissue over the trigger point (indirect needling); or to dry 
needling of either of these areas. The main objective is to inactivate the trigger point thereby 
reducing pain and restoring function. However, the aetiology and pathogenesis of trigger 
points have yet to be elucidated, and the precise mechanism by which TPI inactivates the 
trigger point is still unknown (107). 
Optimal technique and treatment regimen for TPI varies between practitioners, and is 
largely based on clinical experience. Treatment begins with identifying the trigger point; the 
area of maximal tenderness and immobilising the muscle between the thumb and forefinger. 
Generally a sterile small gauge needle is then introduced into the trigger point. Correct 
identification is supported by a twitch in the affected muscle, exacerbation of pain and the 
presence of referred pain (108). 
Clinicians have used local anaesthetic, anti-inflammatory agents (long-acting corticosteroid, 
acetylsalicylate and ketorolac), saline and water (104,108-113). Injecting a trigger point is 
painful and the addition of a local anaesthetic to the injected fluid can help reduce pain and 
irritation (114,115).  
A systematic review of the efficacy of TPI to treat chronic non-malignant musculoskeletal 
pain (such as whiplash syndrome or chronic head, neck, shoulder, and back pain) of more 
than three months’ duration found that TPI relieved symptoms when used as a sole 
treatment for patients, regardless of the injectant used, but was not more effective than other 
less invasive treatments such as laser and ultrasound (107).  
The efficacy of TPI as a treatment for osteoarthritis is not well described; and as most studies 
have looked at its role as a sole treatment rather than in the adjunct capacity in which it is 
routinely used in clinical practice, its effectiveness might be underestimated. One study 
showed that intra-articular injection combined with lidocaine TPI of any of the 15 leg muscle 
trigger points was more effective than intra-articular injection alone in relieving pain and 
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improving knee function in a highly selected group of older patients with knee osteoarthritis 
(116). Except for the rare occurrence of muscle atrophy at the injection site, very few adverse 
events are reported with TPI and it is currently recommended as an adjunct therapy in 
osteoarthritis. 
2.11 Subcutaneous sodium salicylate injection 
Trigger point injection using sodium salicyclate has also been studied. In a large 
uncontrolled study Fox reported a good response from injecting 0.5% sodium salicylate into 
superficial areas of tender soft tissue thickening:  using multiple injections, he recorded an 
improvement in symptoms in 79% of patients at 12 weeks (117). Most of these subjects had 
osteoarthritis. 
Following similar preliminary observations in our group, we performed a pilot study, in 
which 16 patients with OA of the first (thumb) CMC joint were treated with injections of 
0.5% sodium salicylate or saline into similar areas of superficial soft tissue thickening (118).  
There was a significant improvement in pain score in both groups.  The improvement was 
better maintained in the patients that received salicylate.  A subsequent double-blind study 
of 40 patients with the same condition showed superiority of sodium salicylate injections 
over sham injections (119).  Pain and tenderness during follow up were both significantly 
lower in the active treatment group compared with the sham group. 
The chief limitation in studies of this kind is the imperfect nature of the control treatment.  
However, in the sham-controlled study, the improvement in the active treatment group was 
sustained for as long as 13 weeks, suggesting that an effect greater than placebo was being 
observed.  Furthermore, there was no significant correlation in the active group between the 
pain of the injections and response in terms of pain in the joint. 
The mechanism of action of this treatment is uncertain.  The injected patches are distant 
from the affected joint.  It is possible that the salicylate causes a change in the control of 
pain, perhaps through a modification of central sensitisation.  This would be consistent with 
reports by patients of improvement in symptoms within minutes.  The treatment could 
modify the neurogenic control of inflammation, which may be disturbed in musculoskeletal 
disease (120,121).  One way in which this might occur could be through changes in the 
expression or transport of neurogenic peptides (122), brought about by an irritant effect of 
the salicylate, similar to that of topical capsaicin (55,123).  A systemic anti-inflammatory 
effect is unlikely, since similar injections of salicylate at other sites fail to produce any effect 
on the symptoms of osteoarthritis (Mackworth-Young C.G., personal observation). 
It could be that sodium salicylate injection therapy acts in a manner similar to acupuncture, but 
achieves a more prolonged effect because a substance is injected into the tissues that results in a 
sustained stimulus.  Many of the injected patches occur at standard acupuncture sites. 
Sodium salicylate therapy is inexpensive, and can be administered by general practitioners 
and trained nurses.  The studies on this treatment also suggest areas for further scientific 
enquiry in the regulation of pain and inflammation in osteoarthritis. 
3. Conclusions 
There are many local therapies available for the treatment of patients with limb joint OA.  
Some are well established, such as intra-articular corticosteroid. Some are relatively new, 
and show promise for further development.  
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Most of them are primarily symptomatic treatments, which need to be tailored to the 
individual’s preference and tolerance. Many of them function well as adjuncts to other 
treatments, such as systemic analgesics or anti-inflammatory agents.  Given the chronicity of 
OA however, they are likely to be required over long periods of time, either continuously or 
as episodic treatment during symptom flares. Long-term efficacy data are largely missing, 
although the therapies appear to be generally safe. Furthermore studies for costly 
interventions with proven efficacy such as hyaluronan injections are needed to identify 
subsets of patients who would benefit most from the treatment to allow more targeted use. 
It is uncertain if some treatments may modify medium or long-term outcome. For example 
in inflammatory OA of small finger joints, it is not clear whether intra-articular steroid 
injection hastens the settling down of the inflammation (which tends to happen anyway), 
and thus reduces the amount of joint damage. Similarly, effects of topical NSAIDs, 
acupuncture and subcutaneous sodium salicyclate injections on disease modulation are 
unknown. Longitudinal studies on these treatments may answer these questions. 
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and trained nurses.  The studies on this treatment also suggest areas for further scientific 
enquiry in the regulation of pain and inflammation in osteoarthritis. 
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1. Introduction 
Osteoarthritis is the most common joint disease, and is characterized by progressive loss of 
articular cartilage, subchondral bone sclerosis, osteophyte formation, synovial membrane 
changes, and an increase in synovial fluid with decreased viscosity and lubrication 
properties. Mechanical, biochemical, and genetic factors are all involved in pathogenesis of 
osteoarthritis (Chevalier, 2002; Wearing et al., 2006).  
Given the chronic and non-life-threatening nature of osteoarthritis, a good safety profile is 
essential. Characteristics of osteoarthritis vary across patients, and several definite clinical 
patterns have been identified. The choice of a suitable treatment strategy for a patient depends 
on clinical history, contraindications to specific therapies, and overall tolerability and 
acceptability of the considered treatment. This is especially true in the elderly, the major 
targeted people for osteoarthritis therapy, for whom one must consider the risk of upper 
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Osteoarthritis, distinct from many other diseases, is amenable to local intraarticular 
treatment as well as systemic treatment. Though most efforts so far have concentrated on 
development of systemic treatments, the agents used bear considerable risk of systemic side 
effects, such as the cardiovascular events and gastrointestinal adverse effects observed in 
association with most non-steroidal anti-inflammatory drugs and cyclooxygenase-2 
inhibitors for treatment of joint pain (Petit-Zeman, 2004; Topol, 2004). The chronic nature of 
the disease requires development of drugs suitable for chronic systemic treatment with 
minimal side effects, which is a challenging goal. Local drug application, i.e., injection of 
drugs directly into the affected joint, is an option for treatment of osteoarthritis which is 
already frequently used and has the potential to deliver the desired profile.  
In summary, progression of knee osteoarthritis results from local factors, which include 
synovial membrane inflammation, chondrocyte activation, and bone remodeling. Therefore, 
it appears logical to favor an intra-articular route for treatment of knee (as well as hip) 
osteoarthritis.  
1.2 Advantages and disadvantages of intraarticular administration compared to 
systemic administration 
The main advantage of intraarticular administration is that the drug reaches the cartilage, 
which includes no blood vessels, and, therefore, is not exposed to circulating drugs (Gerwin 
et al., 2006). Drugs given by systemic administration may also penetrate the joint fluid from 
blood via diffusion through the synovium, particularly in cases of active synovitis, as in 
rheumatoid arthritis. Because the superficial cartilage is altered in osteoarthritis, drugs 
present in high concentrations in the joint fluid may be able to penetrate within the cartilage 
by passive diffusion. However, short residence time due to rapid uptake by circulation 
imposes a major challenge in intra-articular delivery of solutions and correlates with the 
severity of synovitis (which accelerates drug clearance) (Gerwin et al., 2006). For instance, 
most hyaluronic acid preparations remain in the joint for only a few hours (half-life, 17 h) 
(Brandt et al., 2000). This emphasizes the need for development of sustained-release 
formulas that support continuous release of the drug from a depot in the joint space over a 
period of several weeks to months.  
In the effort to achieve an increase in drug residence time in the synovial cavity, drug 
delivery systems may be used. Among them, thermally responsive elastin-like polypeptide 
gels capable of spontaneous aggregation after intraarticular injection represent a simple and 
innovative way to prolong the intraarticular half-life of a drug. These aggregating elastin-
like polypeptides form a drug-depot, resulting in a 25-fold longer half-life than drugs 
administered with a non-aggregating protein (Betre et al., 2006). Besides the thermo-gelling 
approach, which is used to increase the retention time of a drug formulation in the joint, pH-
sensitive gels are interesting tools. For instance, an intra-articularly injected sustained-
release vehicle, such as gelatin hydrogel microspheres, for platelet rich plasma appeared to 
stimulate cartilage matrix metabolism, suggesting its potential for use in osteoarthritis 
treatment (Saito et al., 2009). 
Aspiration and injection into the knee or other joints is a common technique for both 
diagnostic and therapeutic purposes, in spite of practical difficulties, such as the lack of 
accessibility of the joint, and, thus, obstructed needle placement (Jackson et al., 2002). 
Although rare, complications of intraarticular injections, such as infection, post-injection 
flare, crystal-induced synovitis, cutaneous atrophy, and steroid arthropathy (Neustadt, 
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2001),  could result in dramatic side effects. The incidence of septic joints related to local 
steroid injection is about 1 in 10 000 injections, while for post-injection flare, a frequency of 
around 2% has been reported. Inappropriate injection technique, inexact needle placement, 
and blockage of synovial outflow by viscous injections have all been suggested as causative 
factors for development of acute pseudoseptic arthritis (Chen et al., 2002) Therefore, proper 
needle placement within the intraarticular joint deserves careful attention.  
1.3 Technical consideration of intraarticular administration 
Although an intra-articular injection of the knee is not a complex procedure, assessment of 
whether the tip of the needle lies free in the joint or is embedded in synovium or soft tissue 
before administration of the preparation of medication could be difficult. Some recent 
studies have called into question the ability of physicians to accurately localize such 
injections, finding that almost a third of knee injections are inaccurate (Jones & Doherty, 
2003). This finding emphasizes the importance of proper needle placement. Needle 
placement is easily confirmed when an effusion is present. The return of synovial fluid 
documents intra-articular placement of the needle. In the absence of an effusion, needle 
placement requires the use of anatomic landmarks and tactile feed-back to help the operator 
in positioning of the needle. Prior to performance of an injection, all landmarks for entry 
into the joints were outlined with a marking pen (Fig. 1.).  
 
 
Fig. 1. All landmarks were outlined with a marking pen. A. Landmarks for lateral and 
medial mid-patellar injections sites. B. Landmarks for anteriomedial and anteriolateral 
injections sites. C. Lateral mid-patellar injection were performed with the lower limb 
extended on the examination table. D. Anteriolateral injection were performed with the knee 
in flexed position. E. Anteriolateral injection via ultrasound guidance were performed with 
the knee in flexed position. 
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The operator then stands level with the other knee. With one hand, the patella is pushed up 
and toward the operator, which causes the lateral/medial edge to become more prominent. 
Lateral mid-patella and medial mid-patella injections were administered with the lower 
extremity extended on the examination table. The needle was advanced transversely 
between the articular surfaces of the patellofemoral joint at the midpoint of the patella. 
Jackson et al. evaluated the accuracy of needle placement in 80 obese patients undergoing 
treatment for symptomatic degenerative joint disease (Jackson et al., 2002). They reported 
difficulty in establishing anatomical landmarks about the knee due to obesity. A large 
quantity of subcutaneous fat also increases the distance between the skin and the joint space. 
They used anteromedial, anterolateral, and lateral mid-patella portals. Results of their study 
demonstrated that injection through the lateral mid-patella approach had an accuracy of 
93%. They explained that, when this route is used, the needle passes through a minimal 
amount of soft tissue in order to reach the intra-articular space; therefore, they 
recommended use of the lateral mid-patella portal with the knee extended. The extended leg 
lateral midpatellar approach has been shown to be highly accurate (93%) (Fig. 1.) (Jackson et 
al., 2002). In patients with severe osteoarthritis, the midpatellar approach may be impractical 
due to hindrance of the injection pathway by patellofemoral osteophytes (Jackson et al., 
2002). To overcome this problem, anteriolateral and anteriomedial injections were 
performed with the patient’s leg hanging over the side of the examination table with the 
knee flexed to approximately 90 degrees (Fig. 1). On the basis of careful palpation of 
anatomical landmarks, the injection site was selected inferior to the patella, one finger 
breadth proximal to the joint surface, and either medial or lateral to the patellar tendon. The 
needle was directed obliquely toward the intercondylar notch. While accessing the 
anteriolateral and anteriomedial approach with the patient in the sitting position with the 
knee bent, these approaches provide only 71-75% accuracy (Neustadt, 2006). Improvement 
of accuracy has been attempted through use of ultrasound techniques; the operator placed 
the long axis of the ultrasound transducer over the anteriomedial portion of the knee (Fig. 
1.). The modified anteriolateral bent knee approach has been reported to be an effective, 
accurate, and equivalent alternative to the standard lateral midpatellar approach for 
intraarticular injection of the knee (Chavez-Chiang et al., 2011). Therefore, any of these 
approaches might be preferred, depending on the experience of the physician. On the other 
hand, 100% accuracy could not be obtained through any approach, which should be kept in 
mind when treating knee problems with intra-articular injections. Injections were 
administered using a 5 ml syringe, with a 4 cm long needle. Injection and aspiration of the 
knee is commonly used for both diagnostic and therapeutic purposes. Determination of 
whether the needle tip lies freely within the joint or is embedded in the synovium or other 
intra-articular tissues may be difficult. In addition, clinical experience has shown that intra-
articular injection is more painful when the tip of the needle is placed in Hoffa’s fat pad. 
2. Special focus on three intraarticular administration regimens 
2.1 Current most available intraarticular injection fromulation for treatment of 
osteoarthritis: Hyaluronic acid 
2.1.1 Basic concept of hyaluronic acid 
Hyaluronic acid is a very long polysaccharide chain, consisting of repeating disaccharide 
units of N-acetyl-glucosamine and glucuronic acid. The average molecular weight of 
synovial fluid hyaluronic acid is 5 to 7 × 106 d, or 12,500 disaccharide units (Balazs & 
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Denlinger, 1993). Endogenous hyaluronic acid is synthesized by type B synoviocytes and 
fibroblasts in the synovium and released into the joint space. Hyaluronic acid is a major 
component of synovial fluid and articular cartilage, and is an important contributor to joint 
homeostasis (Balazs & Denlinger, 1993). The viscoelasticity and rheology of synovial fluid is 
due entirely to its hyaluronic acid content. 
Hyaluronic acid contributes to the viscous and elastic properties, affording the synovial fluid 
the peculiar capacity to function differently under distinct loading conditions (Simon, 1999). 
Viscosity is defined as the ability to dissipate mechanical energy as heat during low shear 
stress; elasticity is the ability of a molecule to absorb mechanical energy under increased loads. 
In the presence of low shear forces with slow joint movements, the hyraluronic acid solution 
exhibits high viscosity with reduced elasticity and acts as a joint lubricant. With increased rates 
of joint motion (high shear), this is reversed as the synovial fluid becomes more elastic and acts 
as a shock absorber (Balazs & Denlinger, 1993). The normal adult knee contains approximately 
2 mL of synovial fluid, with a hyaluronic acid concentration of 2.5 to 4.0 mg/mL (Watterson & 
Esdaile, 2000). In patients with osteoarthritis, the concentration and molecular weight of 
hyaluronic acid in synovial fluid is reduced by a factor of 2 or 3, owing to both degradation 
and dilution. Furthermore, the molecular weight of the hyaluronate that is present is reduced 
to as low as 2 × 105 d (Balazs & Denlinger, 1993). These consequences lead to dramatic changes 
in the viscoelastic properties of the synovial fluid, and, thus, altered joint mechanics. 
Decreased lubrication leads to increased stress upon the already diseased cartilage, further 
disrupting the collagen network and the integrity of the chondral surface (Marshall, 2000). 
Cartilage nutrition and waste removal are also adversely affected. Beyond these mechanical 
properties, hyaluronic acid has been reported to serve other significant functions within the 
joint (See Table 1-hyruan injection review). Higher molecular weight hyaluronic acid has been 
shown to influence a variety of leukocyte functions, including migration, chemotaxis, 
phagocytosis, adherence, and proliferation. In vitro studies have further demonstrated effects 
on levels of prostaglandins and cyclic AMP in synovial fluid. In addition to these anti-
inflammatory properties, analgesic activity of hyaluronic acid has been demonstrated in both 
in vitro and animal studies (Ghosh, 1994). This may be mediated both directly via inhibition of 
nociceptors and indirectly through decrease of synthesis of or binding to bradykinin, 
substance P, and other hyperalgesic compounds. 
Hyaluronic acid may have a chondroprotective effect, inhibiting degradation of cartilage, as 
well as encouraging its healing and repair. Ghosh (Ghosh, 1994) conducted de novo HA 
biosynthesis by fibroblasts upon in vitro exposure to exogenous hyaluronic acid. The efficacy 
of intra-articular injection can be influenced by the concentration and molecular weight of 
exogenous hyaluronic acid, with molecular weights greater than 5 × 106 being the most 
effective. Lower molecular weight hyaluronic acid compounds did not elicit a significant 
biosynthetic response. The author also reported that high molecular weight cross-linked 
derivatives of hyaluronic acid (hylans) provided a protective effect on chondrocytes exposed 
to cytokines (IL-1), oxygen-derived free radicals, or leukocyte proteinases. This effect was 
reversible and viscosity dependant; higher molecular weight hyaluronic acid may yield more 
superior protection than those with lower molecular weights.   
2.1.2 History and development of HA 
In the late 1960s, Balazs and coworkers (Balazs & Denlinger, 1993) conducted extensive 
research into joint fluid rheology and hyaluronic acid, which resulted in definition of the 
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concept of ‘‘viscosupplementation’’. Nearly 2 decades would pass before clinical application 
was achieved. Original source material for study was derived from both human umbilical 
cord tissue and rooster combs. Subsequently, the noninflammatory fraction of sodium 
hyaluronan (NIF-NaHA) was developed for therapeutic use in both joint 
viscosupplementation and ophthalmic viscosurgery. This product (marketed as Healon or 
Hyartil-Vet) was subsequently used, with some reported success, for treatment of traumatic 
joint injury in race horses beginning in 1975 (Marshall, 2000). In the late 1980s, 2 NIF-NaHA 
products, Artz (Seikagaku, Japan) and Hyalgan (Fidia,Italy), were placed on the market 
overseas for use in human arthritic joints. Because both formulations were lower in 
molecular weight, clinical recommendations were for 5 weekly injections. Hylans has been 
reported to improve viscoelastic properties and increase residual time within the joint, as a 
function of cross-linking. Two forms, a fluid (hylan A) and a gel (hylan B), were produced. 
Exogenous hylan A has been demonstrated to remain in the knee joint for approximately 1 
week after injection; hylan B may be present for as long as 30 days after injection. Hylan G-F 
20 (Synvisc) was the first (and remains the only) commercially available cross-linked 
hyaluronic acid in the United States. Hylan G-F 20 consists of a combination of the fluid and 
gel forms at a 4:1 ratio (or 20% gel). Its molecular weight is 6 × 106 d, similar to that of 
hyaluronic acid in a healthy joint. By comparison, the molecular weight of Hyalgan is 
significantly less (between 5.0 and 7.3 × 105 d). Viscosupplementation with intra-articular 
hyaluronic acid was first approved by the Food and Drug Administration in 1997. Several 
different formulations of hyaluronic acid from diverse sources, and with varying 
composition and molecular weight, are available in the United States for intra-articular 
injection. By obtaining approval under the category of a ‘‘biologic device,’’ these agents are 
indicated for treatment of pain in patients with osteoarthritis who have failed to respond to 
conservative treatment, such as non-pharmacological therapy and simple analgesics. Each of 
these agents (Table 2) has distinct properties, dosing instructions, cost, and, possibly, clinical 
outcomes. Viscosupplementation is currently indicated only for treatment of patients with 
osteoarthritis of the knee. It has been accepted as part of the American College of 
Rheumatology guidelines for treatment of osteoarthritis and the American Academy of 
Orthopedic Surgeons guidelines for treatment of osteoarthritis of the knee.  
Hyraluronic acid formulations can be obtained by prescription or directly from the 
clinician’s office, and are dispensed in 2 mL vials or 2 mL prefilled syringes. Currently, the 
recommended injection schedules are 1 injection weekly for 3 weeks for the cross linked 
higher molecular weight injection, such as hylan G-F 20. All of these products, except for 
Euflexxa, are contraindicated in patients with a hypersensitivity to poultry. Any knee 
effusion should be aspirated before injection in order to prevent dilution of the 
viscosupplement (Vad et al., 2003). Excessive weight-bearing and activity are limited for 48 
to 72 hours after each injection. Repeat courses of viscosupplementation are Food and Drug 
Administration approved, and have generally led to a 6-month interval period between 
injections (Raynauld et al., 2005) 
2.1.3 Safety profile of hyraluronic acid 
The safety profile of intra-articular hyaluronans is very favorable, and, because they are used 
as a local therapy, there are no known drug interactions-an advantage for patients receiving 
treatment for comorbid conditions. The total incidence of side effects has been reported to be 
approximately 1% to 4% per injection (Hammesfahr et al., 2003). The most frequent adverse 
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effect is local reaction in the injected knee, including mild pain, swelling, warmth, and/or 
redness at the site of injection. Such reactions are usually temporary, lasting 1 or 2 days, and 
generally respond well to physiotherapy and non-steroidal anti-inflammatory drugs. In one 
large, retrospective review of viscosupplementation with hylan G-F 20 (Synvisc), local adverse 
reactions developed in 28 of 336 patients, with an overall rate of 2.7% per injection. Incidence 
of adverse events was found to be significantly affected by the injection technique, with a side 
effects response rate of 5.2% with a medial approach in a flexed knee, versus 1.7% when 
injected laterally in extension (Hammesfahr et al., 2003). Adverse reactions may be related 
more to the accuracy of intra-articular injection than the substance itself. As previously 
mentioned, injection technique is very important. There is growing evidence that hylan G-F 20 
in particular may be associated with an adverse event, which has been termed pseudosepsis, 
or a severe acute inflammatory reaction (Goldberg & Coutts., 2004). This phenomenon has 
been associated with cross-linked hyaluroic acid. This clinical entity appears to be distinct 
from previously described minor local inflammatory reactions uncommonly seen with all 
hyaluronic acid preparations. Pseudosepsis presents as a severe inflammatory process of the 
joint, with a large effusion, and significant pain occurring within 1 to 3 days of injection. 
Differential diagnosis is requested from true sepsis or inflammatory arthritis, requiring 
synovial aspiration and examination. Aspirates of patients with pseudosepsis typically show a 
moderate cell count with high numbers of mononuclear cells (eosinophils, neutrophils, and 
macrophages), and the absence of organisms or calcium pyrophosphate crystals.  
Pseudosepsis characteristically occurs after previous injection, such as upon receiving the 
second or third injection in the first course. One report documented a 10-fold increase in the 
rate of reactions in patients 
undergoing a repeat course of hylan G-F 20 viscosupplementation (Leopold et al., 2002). As 
a result, some authors have supposed an immunologic etiology for this process (Leopold et 
al., 2002). However, in a recent prospective study comparing aspirates from 16 patients who 
presented with a severe acute inflammatory reaction after Synvisc treatment with 20 
aspirates from control patients with osteoarthritis, analysis was notably more consistent 
with a type 4 (cell-mediated) hypersensitivity reaction than with an antibody-mediated 
reaction (Marino et al., 2006). The frequent presence of eosinophils further supports these 
findings. To date, sodium hyaluronates (Hyalgan, etc) have not been reported to trigger this 
process, suggesting a link between pseudosepsis and chemical cross-linking modification of 
the hyaluronic acid molecule in hylan synthesis (Synvisc). Pseudosepsis requires 
symptomatic treatment, including use of modalities, activity modification, analgesics, and 
non-steroidal anti-inflammatory drugs. Arthrocentesis is recommended in order to rule out 
sepsis, and can be helpful in palliation. Once infection has been excluded, intra-articular 
steroids may be of value (Goldberg & Coutts., 2004). 
2.1.4 Preclinical studies 
Chondroprotective effects of hyaluronic acid were observed in vitro, e.g., that it stimulates 
production of tissue inhibitors of matrix metalloproteinases by chondrocytes, inhibits 
neutrophil-mediated cartilage degradation, and attenuates interleukin-1 induced matrix 
degeneration and chondrocyte cytotoxicity (Brockmeier & Shaffer, 2006). In several studies 
hyaluronic acid was found to enhance prostaglandin synthesis and to decrease prostaglandin  
breakdown and release from cartilage matrix (Moreland, 2003). In addition, it was shown to 
normalize endogenous hyaluronic acid synthesis by synoviocytes (Vuorio et al., 1982). 
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concept of ‘‘viscosupplementation’’. Nearly 2 decades would pass before clinical application 
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There has been considerable controversy with regard to whether hyaluronic acid has 
structure-modifying effects. A number of animal models have been conducted for 
experimental induction of changes associated with osteoarthritis, such as degradation of 
collagen and proteoglycans of articular cartilage, and increased inflammation. The most 
commonly studied models have been total or partial meniscectomy and anterior cruciate 
ligament transection; it should be noted that these models are quite aggressive in that 
degenerative changes can occur within a few months after induction. Using these 
approaches, potential structure-modifying activities of exogenously added hyaluronic acid 
have been demonstrated in several species. Wiig et al. (Wiig et al., 1990) reported that 
administration of a single injection of Healon_(sodium hyaluronate, MW 1900 - 3900 kDa) 
(Pharmacia & Upjohn, Uppsala, Sweden) immediately after anterior cruciate ligament 
transection in rabbits resulted in significantly decreased inflammation, increased collagen 
synthesis, increased angiogenesis, and enhanced tissue repair, compared with a single 
injection of saline.  
The structure-modifying effects of hyaluronic acid have been investigated using a 
meniscectomy model in rabbits and sheep. Injection of Artz (Supartz, sodium hyaluronate, 
MW 620 - 1170 kDa) after partial meniscectomy in rabbits or sheep resulted in significantly 
inhibited cartilage degeneration (Kikuchi et al., 1996; Armstrong et al., 1994). Five weekly 
intraarticular injections of sodium hyaluronate, initiated immediately after partial or total 
meniscectomy, resulted in significantly enhanced collagen remodeling, compared with 
saline injections (Sonoda et al., 1997, 2000). A course of 5 weekly injections of Artz (Supartz, 
sodium hyaluronate, MW 620 - 1170 kDa) was found to protect chondrocytes from apoptotic 
cell death following anterior cruciate ligament transection in a rabbit model (Takahashi et al, 
2000). 
Following administration to either rabbits or dogs after anterior cruciate ligament 
transaction, Artz (Supartz, sodium hyaluronate, MW 620 - 1170 kDa) was also found to 
decrease the degree of damage to femoral cartilage and aided in preservation of articular 
cartilage and integrity of synovial tissue (Yoshioka et al., 1997; Shimizu et al., 1998). 
In a study for evaluation of the effects of Synvisc (hylan G-F 20, MW >6000 kDa) (Biomatrix, 
Montreal, Canada) in a dog anterior cruciate ligament transection model, gross 
morphological and histological damage within joints that received injections was 
significantly milder than that seen in control joints (Marshall et al., 2000). Similar results 
were obtained in rabbits and dogs using Hyalgan (sodium hyaluronate, MW 500 - 730 kDa). 
A course of 5 weekly Hyalgan injections, starting at 4 or 13 weeks after anterior cruciate 
ligament transection, resulted in a significantly reduced degree of articular degeneration at 
evaluations performed 26 weeks after surgery. In this study, rabbits who received 10 
injections showed less disease progression than did rabbits treated with five injections, 
suggesting that a sequential course of Hyalgan therapy may provide long-term benefits for 
altering the disease course (Amiel et al., 2003). In dogs, initiation of weekly IA injections of 
sodium hyaluronate starting at 3, 6, or 12 weeks after anterior cruciate ligament transection 
(the Pond-Nuki model of osteoarthritis) resulted in significantly inhibited formation of a 
fibroblast-like cell layer on the articular cartilage and increased mean chondrocyte density 
and area in the middle and deep layer of the articular cartilage (Schiavinato et al., 1989). 
When given starting at 3, 6, or 12 weeks after anterior cruciate ligament transection in dogs, 
Hyalartz (sodium hyaluronate, MW 500 - 750 kDa) was found to induce a significant 
reduction in cartilaginous lesions (Pond-Nuki model of osteoarthritis) (Wenz et al., 2000). 
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On the other hand, injection of hyaluronic acid into sheep joints subjected to meniscectomy 
resulted in significantly more extensive osteophytosis and cartilage fibrillation and 
reduction in proteoglycan synthesis. A striking reduction in proteoglycan concentration in 
cartilage was also observed in dogs with anterior cruciate ligament transection who received 
prophylactic treatment with a series of hyaluronic acid injections. These findings raised 
concerns that hyaluronic acid treatment could aggravate joint damage in osteoarthritis. 
Safety and efficacy of intraarticular hyaluronic acid for treatment of pain of osteoarthritis of 
the knee have been demonstrated; preliminary work supports use of hyarluronic acid for 
osteoarthritis pain relief in other joints as well. Based on preclinical data, there is evidence to 
support the notion that all hyaluronic acids approved in the US may have some structure-
modifying characteristics. Work in these areas is ongoing. 
2.1.5 Clinical studies 
The first human clinical trial of intra-articular hyaluronic acid for treatment of arthritis was 
published by Peyron and Balazs in 1974.  
A large number of clinical trials have been conducted with different hyaluronic acid 
preparations, several of which involve large, multicenter, blinded, randomized, placebo-
controlled studies. Early clinical trials attempted to establish the clinical safety of intra-
articular hyaluronic acid and its clinical superiority in comparison with placebo (Table 2). 
Some of these studies have provided evidence that hyaluronic acid preparations are more 
effective than placebo in reducing pain associated with osteoarthritis (Dixon et al., 1988; 
Dougados et al., 1993) In contrast, others were unable to demonstrate any significant 
difference when compared with placebo groups (Henderson et al., 1993; Dahlberg et al., 
1994). 
Recent attention has focused on comparison of intra-articular viscosupplementation with 
other osteoarthritis treatment methods (such as oral anti-inflammatories and intra-articular 
steroid injections). In a multicenter trial in Canada, Adams et al compared the 3 treatment 
arms: oral non-steroidal anti-inflammatory drugs alone, hylan G-F 20 treatment (3 weekly 
injections), and combined oral non-steroidal anti-inflammatory drugs and hylan G-F 20 
treatment. Patients took their ‘‘usual’’ non-steroidal anti-inflammatory drugs in the 
appropriate arms. At 12 weeks, all 3 of the groups showed improvement, but no statistical 
difference was observed between groups. However, at the 26-week time point, both the 
hylan G-F 20 only and combined non-steroidal anti-inflammatory drugs and hylan G-F 20 
groups were statistically superior to the non-steroidal anti-inflammatory drugs only group 
(Adams et al., 1995). In another large, prospective study, Altman et al compared 5 weekly 
injections of sodium hyaluronate with a placebo group and with a group of patients treated 
with oral Naproxen. On the basis of visual analog scores and the Western Ontario and 
McMaster University Osteoarthritis Index, the hyaluronate group was found to be superior 
to the placebo group at 26 weeks. The hyaluronic acid group also tended to show improved 
outcomes, compared with the non-steroidal anti-inflammatory drugs group; however, this 
finding did not show statistical significance (Altman et al., 1998). Three recent prospective 
studies have been conducted for comparison of intra-articular hyaluronic acid to intra-
articular corticosteroids. In 1 randomized, blinded comparative trial, 63 patients were 
stratified to receive 5 weekly injections of sodium hyaluronate or 1 injection of 
triamcinolone followed by 4 placebo injections. Patients were followed for 6 months with 
VAS assessments of pain with trends suggesting some benefit of viscosupplementation over 
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intra-articular steroids. However, due to a high drop-out rate, the findings were not 
statistically significant (Jones et al,, 1995). Leopold et al conducted a prospective comparison 
of 2 cohorts of patients with knee osteoarthritis. Patients in the first group received 3 weekly 
injections with hylan G-F 20, whereas those in the second group received 1 injection of intra-
articular betamethasone, and were able to request 1 additional corticosteroid injection if 
needed, over the course of the study. Although both groups showed improvement, at 6 
months, no significant difference was noted between the 2 cohorts with respect to WOMAC 
scores, VAS, or the Knee Society Scoring System (Leopold et al., 2003). In a more recent 
report from the Synvisc 901 study group, Caborn et al used the Western Ontario and 
McMaster University Osteoarthritis Index and Visual analogue scores pain scores to 
compare the 2 groups of patients who received either 3 weekly injections of hylan G-F 20 or 
1 isolated injection of triamcinolone. This study was not blinded. In their study, maximal 
benefit was noted at week 2 for the steroid group and at week 12 for the hylan G-F 20 group. 
From week 12 through week 26, significantly superior outcomes were observed in patients 
treated with hylan G-F 20 when compared with those treated with intra-articular steroids 
(Caborn et al., 2004). 
In the most recent meta-analysis from the Cochrane database, one research study obtained 
76 randomized placebo-controlled trials that fulfilled strict study design and methodology 
criteria. On the basis of their analysis of the literature, the authors concluded that 
viscosupplementation is an effective treatment for osteoarthritis of the knee, with favorable 
effects on pain, function, and patient global assessment, particularly during weeks 5 to 13 
after the injection period (Bellamy et al., 2006).  
Conservative treatments for osteoarthritis may be characterized as symptom-modifying or 
disease-modifying drugs. As defined by the Osteoarthritis Research Society, disease-
modifying drugs are those that are intended to prevent, retard, stabilize, or reverse 
development of morphological changes of osteoarthritis (Altman et al., 1996). At present, no 
pharmacological treatments for osteoarthritis have been approved for the indication of 
modifying the rate of osteoarthritis disease progression. Intra-articular hyaluronic acid is 
currently indicated only as a symptom-modifying treatment for osteoarthritis of the knee. 
However, evaluation of novel agents and agents with established symptom-modifying 
activity for disease-modifying effects has become a major focus of research on osteoarthritis. 
In an effort to obtain evidence for disease-modifying efficacy of hyaluronic acid injections, a 
large number of clinical trials have been conducted with different hyaluronic acid 
preparations over the past 25 years. However, there is substantial evidence to suggest that 
hyaluronic acid in certain patient populations can also have disease modifying activity. This 
possibility was initially suggested by the finding that the pain-relieving benefit of 
intraarticular hyaluronic acid generally persists for considerably longer than its half-life 
within the injected joint, which has been estimated in animal studies to be as short as 18 to 
24 h (Sakamoto et al., 1984). For example, clinical efficacy in randomized, controlled trials 
has been demonstrated to last for at least 26 weeks for Hyalgan®(sodium hyaluronate, 
average molecular weight 500 -730 kDa) (Altman et al., 1998) and may last as long as a year 
or more in some patients (Kotz & Kolarz, 1999). Similarly, Synvisc_ (hylan G-F 20, average 
MW >6000 kDa) (Wobig et al., 1998) (Genzyme Biosurgery, Cambridge, MA), and Supartz® 
(sodium hyaluronate, average MW 630 - 1120 kDa) (Puhl et al., 1993) (Seikagaku 
Corporation, Tokyo, Japan) have also demonstrated months of pain relief. Although many 
of these studies were well designed, the results are difficult to interpret due to a number of 
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factors. A number of these studies used highly subjective, non-validated rating scales. 
Different formulations and treatment regimens were often used, limiting study 
comparisons. Patient treatment groups were often heterogenous, leading to stratified 
outcomes based on characteristics such as age and disease severity. 
The ideal candidate for intra-articular hyaluronic acid has yet to be clearly defined. Despite 
clinical evaluations, age, symptoms, and disease severity have not proven helpful in 
identifying patients who may best benefit. One early placebo-controlled trial indicated 
increased benefit among older patients with more significant osteoarthritis. (Lohmander et 
al., 1996) 
In another study, Dahlberg et al evaluated a group of patients with normal radiographs and 
early arthritic changes observed at arthroscopy. They reported no significant benefit from 5 
weekly injections of sodium hyaluronate (compared with placebo) (Dahlberg et al., 1994). 
Despite failure to identify the optimal cohort, there is reason to believe that the greatest 
potential benefit of hyaluronic acid would likely be among younger patients, as some 
clinical data have suggested that younger patients are more likely to respond. In a meta-
analysis by Wang et al, 35 patients older than 65 years of age and those with the most 
advanced stages of arthritic change (ie, complete loss of joint space) were found to be less 
likely to show improvement with hyaluronic acid therapy. Jubb et al., in a large, 
randomized study for evaluation of the disease-modifying effects of sodium hyaluronate in 
knee osteoarthritis, demonstrated that viscosupplementation, compared with placebo, 
significantly reduced the radiographic progression of joint space loss in the subset of 
patients with a higher joint space area at study entry. Currently, intra-articular hyaluronic 
acid therapy should be considered in patients who have failed standard non-pharmacologic 
and pharmacologic treatment options, those who have a contraindication to non-steroidal 
anti-inflammatory drugs, and those who are trying to delay or are poor candidates for 
surgical treatment. (Jubb et al., 2003) 
2.2 Candidate drugs for disease-modifying intraarticular injection regimens 
Metabolism of mature articular cartilage is regulated by a number of growth factors that are 
delivered from cellular production within the cartilage, as well as from the synovial fluid 
and surrounding tissues. As the mechanisms of action for these growth factors are obtained 
through well-defined in vitro studies, it is becoming clear that growth factors may 
eventually serve to augment current cartilage repair techniques. 
Chemotactic growth factors may be used to encourage cell migration to an injury site. Cell 
numbers can be increased and matrix production up-regulated by release of appropriate 
local growth factors via scaffolds or other methods of intra-articular administration.  
Growth factors are a group of biologically active polypeptides produced by the body, which 
can stimulate cellulardivision, growth, and differentiation. In articular cartilage, numerous 
growth factors work in concert to regulate development and homeostasis of articular 
cartilage throughout life (Goldring et al., 2009). Therefore, growth factors offer promising 
treatments for enhanced regeneration of cartilage in situations of widespread cartilage loss, 
such as those that occur in osteoarthritis. When considering an osteoarthritic joint, the 
effects of any treatment, such as growth factors, on cartilage, synovial lining, ligaments, 
tendons, meniscus, any exposed subchondral bone, as well as on mesenchymal stem cells 
that gain access to the articular environment should be collectively considered. Numerous 
anabolic growth factors stimulate chondrocyte synthesis of proteoglycans, aggrecan, and 
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intra-articular steroids. However, due to a high drop-out rate, the findings were not 
statistically significant (Jones et al,, 1995). Leopold et al conducted a prospective comparison 
of 2 cohorts of patients with knee osteoarthritis. Patients in the first group received 3 weekly 
injections with hylan G-F 20, whereas those in the second group received 1 injection of intra-
articular betamethasone, and were able to request 1 additional corticosteroid injection if 
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benefit was noted at week 2 for the steroid group and at week 12 for the hylan G-F 20 group. 
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However, evaluation of novel agents and agents with established symptom-modifying 
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In an effort to obtain evidence for disease-modifying efficacy of hyaluronic acid injections, a 
large number of clinical trials have been conducted with different hyaluronic acid 
preparations over the past 25 years. However, there is substantial evidence to suggest that 
hyaluronic acid in certain patient populations can also have disease modifying activity. This 
possibility was initially suggested by the finding that the pain-relieving benefit of 
intraarticular hyaluronic acid generally persists for considerably longer than its half-life 
within the injected joint, which has been estimated in animal studies to be as short as 18 to 
24 h (Sakamoto et al., 1984). For example, clinical efficacy in randomized, controlled trials 
has been demonstrated to last for at least 26 weeks for Hyalgan®(sodium hyaluronate, 
average molecular weight 500 -730 kDa) (Altman et al., 1998) and may last as long as a year 
or more in some patients (Kotz & Kolarz, 1999). Similarly, Synvisc_ (hylan G-F 20, average 
MW >6000 kDa) (Wobig et al., 1998) (Genzyme Biosurgery, Cambridge, MA), and Supartz® 
(sodium hyaluronate, average MW 630 - 1120 kDa) (Puhl et al., 1993) (Seikagaku 
Corporation, Tokyo, Japan) have also demonstrated months of pain relief. Although many 
of these studies were well designed, the results are difficult to interpret due to a number of 
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factors. A number of these studies used highly subjective, non-validated rating scales. 
Different formulations and treatment regimens were often used, limiting study 
comparisons. Patient treatment groups were often heterogenous, leading to stratified 
outcomes based on characteristics such as age and disease severity. 
The ideal candidate for intra-articular hyaluronic acid has yet to be clearly defined. Despite 
clinical evaluations, age, symptoms, and disease severity have not proven helpful in 
identifying patients who may best benefit. One early placebo-controlled trial indicated 
increased benefit among older patients with more significant osteoarthritis. (Lohmander et 
al., 1996) 
In another study, Dahlberg et al evaluated a group of patients with normal radiographs and 
early arthritic changes observed at arthroscopy. They reported no significant benefit from 5 
weekly injections of sodium hyaluronate (compared with placebo) (Dahlberg et al., 1994). 
Despite failure to identify the optimal cohort, there is reason to believe that the greatest 
potential benefit of hyaluronic acid would likely be among younger patients, as some 
clinical data have suggested that younger patients are more likely to respond. In a meta-
analysis by Wang et al, 35 patients older than 65 years of age and those with the most 
advanced stages of arthritic change (ie, complete loss of joint space) were found to be less 
likely to show improvement with hyaluronic acid therapy. Jubb et al., in a large, 
randomized study for evaluation of the disease-modifying effects of sodium hyaluronate in 
knee osteoarthritis, demonstrated that viscosupplementation, compared with placebo, 
significantly reduced the radiographic progression of joint space loss in the subset of 
patients with a higher joint space area at study entry. Currently, intra-articular hyaluronic 
acid therapy should be considered in patients who have failed standard non-pharmacologic 
and pharmacologic treatment options, those who have a contraindication to non-steroidal 
anti-inflammatory drugs, and those who are trying to delay or are poor candidates for 
surgical treatment. (Jubb et al., 2003) 
2.2 Candidate drugs for disease-modifying intraarticular injection regimens 
Metabolism of mature articular cartilage is regulated by a number of growth factors that are 
delivered from cellular production within the cartilage, as well as from the synovial fluid 
and surrounding tissues. As the mechanisms of action for these growth factors are obtained 
through well-defined in vitro studies, it is becoming clear that growth factors may 
eventually serve to augment current cartilage repair techniques. 
Chemotactic growth factors may be used to encourage cell migration to an injury site. Cell 
numbers can be increased and matrix production up-regulated by release of appropriate 
local growth factors via scaffolds or other methods of intra-articular administration.  
Growth factors are a group of biologically active polypeptides produced by the body, which 
can stimulate cellulardivision, growth, and differentiation. In articular cartilage, numerous 
growth factors work in concert to regulate development and homeostasis of articular 
cartilage throughout life (Goldring et al., 2009). Therefore, growth factors offer promising 
treatments for enhanced regeneration of cartilage in situations of widespread cartilage loss, 
such as those that occur in osteoarthritis. When considering an osteoarthritic joint, the 
effects of any treatment, such as growth factors, on cartilage, synovial lining, ligaments, 
tendons, meniscus, any exposed subchondral bone, as well as on mesenchymal stem cells 
that gain access to the articular environment should be collectively considered. Numerous 
anabolic growth factors stimulate chondrocyte synthesis of proteoglycans, aggrecan, and 
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type II collagen, induce synoviocyte and mesenchymal stem cell proliferation, drive 
chondrogenic differentiation of mesenchymal stem cells, and decrease the catabolic effects of 
cytokines, such as interleukin-1 and matrix metalloproteinases. In addition to being 
proanabolic and anticatabolic to restoration of cartilage in naturally occurring disease, an 
ideal growth factor for general cartilage tissue engineering or regeneration in osteoarthritis 
would be effective regardless of the patient’s age or the presence of osteoarthritis and would 
have no detrimental effects on either cartilage or the synovial lining.  
Historically, most growth factors have been evaluated on an independent basis, rather than 
in combination, in order to assess their effects on cartilage homeostasis in vitro or in vivo. 
Given the array and interactions of growth factors necessary for proper cartilage 
development and homeostasis, it is unlikely that any single growth factor will lead to 
complete cartilage repair or affect the arthritic milieu, but rather a combination approach 
will be required. 
In the following review, some key players are portrayed comprehensively. Obviously, the 
collected insights indicate a major potential for regulation of cartilage and chondrocytes in 
disease and regeneration within the organism and in tissue engineering if the structural 
properties and dynamics of natural hormone activity are carefully considered. Individual 
characteristics of growth factors are described. 
Transforming Growth Factor-b1 stimulates chondrocyte synthetic activity and decreases the 
catabolic activity of interleukin-1 (Blaney et al., 2007). In vitro, Transforming Growth Factor-
b1 stimulates chondrogenesis of synovial lining and bone marrow-derived mesenchymal 
stem cells (Fan et al., 2010; Kurth et al., 2007). In addition, promising studies in rabbits have 
demonstrated Transforming Growth Factor-b1-enhanced repair of cartilage defects (Diao et 
al., 2009). However, in mouse and rabbit animal studies, numerous deleterious side effects 
of Transforming Growth Factor-b1 supplementation have been announced, including 
stimulation of synovial proliferation and fibrosis, attraction of inflammatory leukocytes to 
the synovial lining, and induction of osteophyte formation (Bakker et al., 2001; Blaney et al., 
2007). Given these serious safety concerns, which are not components of other growth 
factor-based strategies, Transforming Growth Factor-b1 therapy is not presently a suitable 
option for use in the articular environment.  
Insulin like growth factor is a circulating cytokine that reaches articular cartilage through 
the synovial fluid. Insulin like growth factor is a single polypeptide with protein sequencing 
similar to that of insulin. Insulin like growth factor -1 is the main anabolic growth factor for 
articular cartilage. 
It plays a key role in cartilage homeostasis, balancing proteoglycan synthesis and 
breakdown by chondrocytes. In vitro studies have demonstrated that Insulin like growth 
factor -1 stimulates proteoglycan production in a dose-dependent manner, as evidenced by 
increased [35S]-sulfate incorporation (Coutts et al., 1997). Similarly, Insulin like growth 
factor -1 has been shown to slow proteoglycan catabolism in a dose-dependent fashion 
(Hickey et al., 2003). 
The role of Insulin like growth factor -I in articular cartilage metabolism in both health and 
disease has been extensively evaluated (Denko et al., 1994; MaQuillan et al., 1986; Middleton 
et al., 1996; Posever et al., 1995; Wang et al., 1995). When added exogenously to monolayer 
or explant cultures of normal articular cartilage from a variety of species, Insulin like growth 
factor-I induces a plethora of anabolic effects and decreases catabolic responses (Sah et al., 
2008; Schalkwijk et al., 1989; Tyler 1989). Chondrogenic differentiation of mesnechymal stem 
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cells is induced by Insulin like growth factor-I, but is enhanced when Insulin like growth 
factor -I and Transforming Growth Factor-b1 are used in combination (Longobardi et al., 
2006; Worster et al., 2001). The premise that Insulin like growth factor-I is required for 
maintenance of articular cartilage integrity is supported by an in vivo study in rats in which 
chronic Insulin like growth factor-I deficiency led to development of articular cartilage 
lesions (Ekenstedt et al., 2006). In animal models, Insulin like growth factor-I has led to 
enhanced repair of extensive cartilage defects and protection of the synovial membrane 
from chronic inflammation (Fortier & Miller, 2006; Goodrich et al., 2007). However, studies 
of human articular cartilage indicate that serum Insulin like growth factor-1 levels and 
chondrocyte responsiveness to Insulin like growth factor-1 diminish progressively with age 
(Ashton & Matheson, 1979; Boehm et al., 2007; Fortier & Miller, 2006; Loeser et al., 2002; 
Loeser et al., 2000; Martin et al., 1997; Trippel, 1995) This finding suggests that a 
simultaneous decrease in the amount of Insulin like growth factor-1 available and a reduced 
ability of cells to respond to the remaining Insulin like growth factor may produce cartilage 
that is less capable of maintaining its structural and functional integrity. Insulin like growth 
factor non-responsiveness has been further observed to exist in chondrocytes from arthritic 
cartilage or in the presence of inflammation (Verschure et al., 1996). The cellular response to 
Insulin like growth factor-1 is receptor mediated and Insulin like growth factor binding 
proteins in synovial fluid appear to regulate the amount of free Insulin like growth factor-1 
available for receptor binding (Trippel, 1995). 
Age-related decline in the responsiveness of chondrocytes to Insulin like growth factor-1 
appears to be due at least in part to overexpression of Insulin like growth factor binding 
proteins. Chondrocytes from patients with osteoarthritis have been observed to generate 
excessive levels of Insulin like growth factor-1 binding proteins (Martin et al., 1997; van den 
Berg et al., 1999). It has also been suggested that a defect in Insulin like growth factor 
receptor binding or postreceptor signaling may contribute to Insulin like growth factor non-
responsiveness in aged and arthritic cartilage (Verschure et al., 1996; coutts et al., 2003; 
Hickey et al., 2003). 
Evidence suggests an uncoupling of Insulin like growth factor-I responsiveness in 
osteoarthritis with Insulin like growth factor-I having the ability for robust simulation of 
matrix synthesis with an inability to decrease matrix catabolism (Morales, 2008). Despite the 
diminished ability of Insulin like growth factor-I to decrease catabolism in aged and 
osteoarthritis cartilage, studies have suggested that a combination of Insulin like growth 
factor-I and bone morphogenetic protein-7 results in greater potential for repair than either 
growth factor alone (Chubinskaya et al., 2007; Loeser et al., 2003). These studies 
demonstrated that, in general, bone morphogenetic protein-7 was more potent than Insulin 
like growth factor-I in stimulating matrix synthesis in aged and osteoarthritis cells; however, 
the greatest increase in matrix synthesis was observed after combination treatment with 
bone morphogenetic protein-7 and Insulin like growth factor-I. 
Platelet-derived growth factor is a locally produced and locally acting growth factor. It is 
synthesized by smooth muscle cells, fibroblasts, endothelial cells, and macrophages and is 
stored primarily in platelets (Lee, 2000). 
Platelet-derived growth factor plays a fundamental role in the wound healing cascade. It is 
present in high concentrations in platelets and in fluids generated during the early stage of 
wound healing (Spindler et al., 1995). Platelet-derived growth factor is a potent mitogenic 
and chemotactic factor for cells of mesenchymal origin, including fibroblasts, osteoblasts, 
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type II collagen, induce synoviocyte and mesenchymal stem cell proliferation, drive 
chondrogenic differentiation of mesenchymal stem cells, and decrease the catabolic effects of 
cytokines, such as interleukin-1 and matrix metalloproteinases. In addition to being 
proanabolic and anticatabolic to restoration of cartilage in naturally occurring disease, an 
ideal growth factor for general cartilage tissue engineering or regeneration in osteoarthritis 
would be effective regardless of the patient’s age or the presence of osteoarthritis and would 
have no detrimental effects on either cartilage or the synovial lining.  
Historically, most growth factors have been evaluated on an independent basis, rather than 
in combination, in order to assess their effects on cartilage homeostasis in vitro or in vivo. 
Given the array and interactions of growth factors necessary for proper cartilage 
development and homeostasis, it is unlikely that any single growth factor will lead to 
complete cartilage repair or affect the arthritic milieu, but rather a combination approach 
will be required. 
In the following review, some key players are portrayed comprehensively. Obviously, the 
collected insights indicate a major potential for regulation of cartilage and chondrocytes in 
disease and regeneration within the organism and in tissue engineering if the structural 
properties and dynamics of natural hormone activity are carefully considered. Individual 
characteristics of growth factors are described. 
Transforming Growth Factor-b1 stimulates chondrocyte synthetic activity and decreases the 
catabolic activity of interleukin-1 (Blaney et al., 2007). In vitro, Transforming Growth Factor-
b1 stimulates chondrogenesis of synovial lining and bone marrow-derived mesenchymal 
stem cells (Fan et al., 2010; Kurth et al., 2007). In addition, promising studies in rabbits have 
demonstrated Transforming Growth Factor-b1-enhanced repair of cartilage defects (Diao et 
al., 2009). However, in mouse and rabbit animal studies, numerous deleterious side effects 
of Transforming Growth Factor-b1 supplementation have been announced, including 
stimulation of synovial proliferation and fibrosis, attraction of inflammatory leukocytes to 
the synovial lining, and induction of osteophyte formation (Bakker et al., 2001; Blaney et al., 
2007). Given these serious safety concerns, which are not components of other growth 
factor-based strategies, Transforming Growth Factor-b1 therapy is not presently a suitable 
option for use in the articular environment.  
Insulin like growth factor is a circulating cytokine that reaches articular cartilage through 
the synovial fluid. Insulin like growth factor is a single polypeptide with protein sequencing 
similar to that of insulin. Insulin like growth factor -1 is the main anabolic growth factor for 
articular cartilage. 
It plays a key role in cartilage homeostasis, balancing proteoglycan synthesis and 
breakdown by chondrocytes. In vitro studies have demonstrated that Insulin like growth 
factor -1 stimulates proteoglycan production in a dose-dependent manner, as evidenced by 
increased [35S]-sulfate incorporation (Coutts et al., 1997). Similarly, Insulin like growth 
factor -1 has been shown to slow proteoglycan catabolism in a dose-dependent fashion 
(Hickey et al., 2003). 
The role of Insulin like growth factor -I in articular cartilage metabolism in both health and 
disease has been extensively evaluated (Denko et al., 1994; MaQuillan et al., 1986; Middleton 
et al., 1996; Posever et al., 1995; Wang et al., 1995). When added exogenously to monolayer 
or explant cultures of normal articular cartilage from a variety of species, Insulin like growth 
factor-I induces a plethora of anabolic effects and decreases catabolic responses (Sah et al., 
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cells is induced by Insulin like growth factor-I, but is enhanced when Insulin like growth 
factor -I and Transforming Growth Factor-b1 are used in combination (Longobardi et al., 
2006; Worster et al., 2001). The premise that Insulin like growth factor-I is required for 
maintenance of articular cartilage integrity is supported by an in vivo study in rats in which 
chronic Insulin like growth factor-I deficiency led to development of articular cartilage 
lesions (Ekenstedt et al., 2006). In animal models, Insulin like growth factor-I has led to 
enhanced repair of extensive cartilage defects and protection of the synovial membrane 
from chronic inflammation (Fortier & Miller, 2006; Goodrich et al., 2007). However, studies 
of human articular cartilage indicate that serum Insulin like growth factor-1 levels and 
chondrocyte responsiveness to Insulin like growth factor-1 diminish progressively with age 
(Ashton & Matheson, 1979; Boehm et al., 2007; Fortier & Miller, 2006; Loeser et al., 2002; 
Loeser et al., 2000; Martin et al., 1997; Trippel, 1995) This finding suggests that a 
simultaneous decrease in the amount of Insulin like growth factor-1 available and a reduced 
ability of cells to respond to the remaining Insulin like growth factor may produce cartilage 
that is less capable of maintaining its structural and functional integrity. Insulin like growth 
factor non-responsiveness has been further observed to exist in chondrocytes from arthritic 
cartilage or in the presence of inflammation (Verschure et al., 1996). The cellular response to 
Insulin like growth factor-1 is receptor mediated and Insulin like growth factor binding 
proteins in synovial fluid appear to regulate the amount of free Insulin like growth factor-1 
available for receptor binding (Trippel, 1995). 
Age-related decline in the responsiveness of chondrocytes to Insulin like growth factor-1 
appears to be due at least in part to overexpression of Insulin like growth factor binding 
proteins. Chondrocytes from patients with osteoarthritis have been observed to generate 
excessive levels of Insulin like growth factor-1 binding proteins (Martin et al., 1997; van den 
Berg et al., 1999). It has also been suggested that a defect in Insulin like growth factor 
receptor binding or postreceptor signaling may contribute to Insulin like growth factor non-
responsiveness in aged and arthritic cartilage (Verschure et al., 1996; coutts et al., 2003; 
Hickey et al., 2003). 
Evidence suggests an uncoupling of Insulin like growth factor-I responsiveness in 
osteoarthritis with Insulin like growth factor-I having the ability for robust simulation of 
matrix synthesis with an inability to decrease matrix catabolism (Morales, 2008). Despite the 
diminished ability of Insulin like growth factor-I to decrease catabolism in aged and 
osteoarthritis cartilage, studies have suggested that a combination of Insulin like growth 
factor-I and bone morphogenetic protein-7 results in greater potential for repair than either 
growth factor alone (Chubinskaya et al., 2007; Loeser et al., 2003). These studies 
demonstrated that, in general, bone morphogenetic protein-7 was more potent than Insulin 
like growth factor-I in stimulating matrix synthesis in aged and osteoarthritis cells; however, 
the greatest increase in matrix synthesis was observed after combination treatment with 
bone morphogenetic protein-7 and Insulin like growth factor-I. 
Platelet-derived growth factor is a locally produced and locally acting growth factor. It is 
synthesized by smooth muscle cells, fibroblasts, endothelial cells, and macrophages and is 
stored primarily in platelets (Lee, 2000). 
Platelet-derived growth factor plays a fundamental role in the wound healing cascade. It is 
present in high concentrations in platelets and in fluids generated during the early stage of 
wound healing (Spindler et al., 1995). Platelet-derived growth factor is a potent mitogenic 
and chemotactic factor for cells of mesenchymal origin, including fibroblasts, osteoblasts, 
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and chondrocytes, and is thus believed to be capable of enhancing tissue regeneration and 
repair. Platelet-derived growth factor receptors have been identified on a number of cell 
types, including chondrocytes, and the number of receptors is up-regulated by the presence 
of inflammatory cytokines, such as interleukin-1 (Smith et al., 1991). 
Indirect evidence for the role of Platelet-derived growth factor and other growth factors 
active in the wound healing process can be seen from the healing response in cartilage 
defects treated with microfracture. This procedure involves creation of microperforations in 
subchondral bone with an arthroscopic awl in and around a chondral lesion (Steadman et 
al., 2001). The mechanical integrity of the bone is maintained through careful placement of 
holes. The awl is driven to a depth of 2-4 mm to ensure that the marrow space is accessed 
and bleeding is observed. A clot forms in the defect, which is anchored to the bone by the 
increased surface roughness produced by the microperforations. Growth factors such as 
Platelet-derived growth factor are released into the defect site, exerting chemotactic and 
mitogenic effects on cells in the surrounding cartilage and infiltrating mesenchymal stem 
cells. This provides an enriched environment for new tissue formation, which may be 
augmented by placement of a scaffold seeded with autologous cells (Breinan et al., 2000; 
Dorotka et al., 2005). 
Platelet-derived growth factor exists as a homodimer (Platelet-derived growth factor-AA or 
Platelet-derived growth factor-BB) or a heterodimer (Platelet-derived growth factor-AB). 
Evidence to support the use of Platelet-derived growth factor in cartilage repair has been 
extrapolated from the role of Platelet-derived growth factor in wound healing or stimulation 
of matrix synthesis in growth plate chondrocytes (Schmidt et al., 2006). In vivo, when 
injected into the knee of skeletally immature rats, no adverse effects were noted in the 
cartilage or synovial membrane (Hulth et al., 1996). Presently, the most commonly used 
form of Platelet-derived growth factor is within the milieu of platelet-rich plasma, as 
discussed subsequently.  
2.2.1 Growth hormone 
Growth and homeostasis of cartilage tissue, particularly chondrocytes, during 
embryogenesis, postnatal development, and adulthood is governed by a significant number 
of humoral factors. Those factors may also be used during intrinsic or artificial repair and 
induced regeneration. Unfortunately, many of them also appear to accompany degenerative 
disease processes, such as osteoarthritis, and the question remains as to what extent they are 
involved in disease processes or whether they are actually a signature of ongoing 
endogenous repair pathways (Gaissmaier et al., 2008). 
Paracrine components can be delivered through typical nutrient supply mechanisms, ie, 
fluid flow under compressive loading, which also delivers blood based hormones, such as 
insulin and cytokines. Alternatively, certain elements are retained in the extracellular 
matrix, including Insulin-like growth factor Insulin like growth factor-1 and Insulin like 
growth factor-binding proteins, or ions, like potassium, which is the major counter ion for 
sulfate residues on glycosaminoglycans, and calcium (which is stored in mineralized 
cartilage) bound in part to matrix vesicles and chondrocalcin (collagen type II C-propeptide) 
(Gaissmaier et al., 2008). The insulin-like growth factor signaling axis is involved in 
maintenance of matrix metabolism in articular cartilage (McQuillan et al., 1986) A demise in 
metabolic control of cartilage matrix content is the hallmark of degenerative osteoarthritis 
(Mankin et al., 2000). 
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Growth hormone is an important regulator of skeletal growth and bone mineral density. It 
also stimulates cartilage growth, probably through local and systemic Insulin like growth 
factor-1 production, and possibly by direct stimulation of cartilage cell proliferation. 
Circulating Growth hormone or one of its mediators may accelerate healing of 
osteochondral defects through stimulation of osseous and chondral tissue formation (Adam 
et al., 1995).  
Until recently, the effect of exogenous Growth hormone administration in the process of 
skeletal repair has remained controversial. Bak et al. studied 36 rats with closed diaphyseal 
tibial fractures with intramedullary nailing. In this study, all rats received subcutaneous 
injections of recombinant human Growth hormone (1 mg) twice per day. Significant 
improvement in maximal stiffness and ultimate load-bearing were observed during 
evaluation performed after 40 days of healing (Bak et al., 1990). Kolbeck et al. studied 23 
dogs with experimentally-induced 3 cm ulnar bone defects and intramedullary fixation. 
Dogs were injected with recombinant bovine Growth hormone (1 mg), and several of these 
Growth hormone -treated dogs showed closure of these bone defects, while the remainder 
demonstrated healing. They reported that administration of homologous Growth hormone 
stimulates callus formation and ossification in the early phase of bone healing, which 
consequently results in increased mechanical strength and stiffness (Kolbeck et al., 2003). On 
the contrary, Growth hormone administration showed no measurable effects on fracture 
healing in a standardized tibia osteotomy rabbit model (Carpenter et al., 1992).  
Morphoangiogenesis was initially identified in the knees of adult rabbits undergoing intra-
articular Growth hormone injections for articulophyseal cartilage regeneration (Dunn, 2002). 
In this experiment, the regeneration cascade resulted in transformation of central arteries in 
subchondral osteones into tortuous, thin-walled fenestrated capillary structures containing 
erythrocytes, histiocytes, stem cells, and chondrocytes. This morphoangiogenesis might 
promote generative and constructive action in joints. The exact mechanisms of intra-
articular growth hormone are unclear; however, synovial fluid growth hormone could 
enhance proliferation, matrix synthesis, and differentiation of bone and cartilage cells in 
vitro (Goldspink & Goldberg, 1975). 
Kim et al. conducted a study of 30 rabbits with collagenase-induced osteoarthritis. After 
intra-articular collagenase injection, mature New Zealand white rabbits (n=30) were divided 
into 3 groups. Group 1 (control rabbits) received once-weekly intra-articular saline injections 
for 4 weeks. Group 2 rabbits received 6 mg hyaluronic acid injections, and group 3 rabbits 
were injected with 6 mg hyaluronic acid and 3 mg recombinant human growth hormone. 
These injections were initiated 4 weeks after collagenase injections. Lameness was observed 
for 9 weeks after collagenase injections. Macroscopic and histopathological knee joint 
findings were also evaluated at the end of 9 weeks after collagenase injections. Although all 
animals had lameness after collagenase injections, the duration and severity of lameness 
were significantly shorter and less severe in group 3 than in groups 1 and 2 (P<0.01) (Fig. 2.) 
Macroscopic scores showed that femoral condyles of group 3 rabbits received significantly 
less cartilage damage than those of rabbits in groups 1 and 2 (P<0.01) (Fig. 2.) 
Histopathological score was also the lowest in group 3 (P<0.01) (Fig. 2.)  
They reported that co-injection of intra-articular HA and recombinant human growth 
hormone may be more effective than hyaluronic acid injections alone in an osteoarthritis 
model. Novel combined therapy of hyaluronic acid with chondrocyte protective functions and 
recombinant human growth hormone with generative and constructive actions in 
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and chondrocytes, and is thus believed to be capable of enhancing tissue regeneration and 
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Growth hormone is an important regulator of skeletal growth and bone mineral density. It 
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osteoarthritis-affected joints may be a promising treatment option for osteoarthritis (Kim et al., 
2011). The recombinant human growth hormone used in this study is a sustained-release 
formula, which induced continuous serum Insulin like growth factor-1 elevation for 6 days 
after a single injection. This product also exhibited greater than 95% bioavailability. Sustained 
release growth hormone was used in this study. Previously-marketed daily injections have 
provided distinct peaks and troughs of growth hormone concentrations over a period of 24 
hours. The pharmacokinetic profile of recombinant Growth hormone differs from that of 
normal physiologic growth hormone, with distinct bursts (Laursen et al., 1995). Using poly 
lactic glycolic acid microparticles for the first time, Genentech and Alkermes developed the 
Nutropin Depot® as a sustained-release human growth hormone formulation. Nutropin 
Depot® appeared to achieve stable therapeutic Insulin like growth factor-1 target levels for at 
least 14 days with higher efficacy and without supraphysiological growth hormone 
concentrations at all times. Nutropin Depot® required the fewest number of injections for 
achievement of growth hormone levels within the target range, and appealed to patients in its 
convenience and compliance. However, the poly lactic glycolic acid particle size of 
microspheres was too large for efficient suspension in an injection medium. Therefore, 
injections through a 21 to 23 gauge are inevitable. Complexities with a long-acting protein 
delivery system using poly lactic glycolic acid include inflammation and protein denaturation 
by hydrophobic interactions and harsh acidic microenvironments. These complexities decrease 
the bioavailability of Nutropin Depot® (Fu et al., 2000). However, recombinant human growth 
hormone in medium chain triglycerides can be easily injected through a 26 to 27 gauge needle 
due to the small particle size and localized lecithin on the microparticle surfaces.  
 
 
Fig. 2. (A) Gross findings of the femoral condyles in Group 1 (G1), Group 2 (2), and Group 3 
(3) rabbits. (B) histologic findings of axial sections obtained at the rectangular areas shown 
in column A photographs (H&E staining, × 40). The loss of cartilage is seen on the femoral 
condyle (black arrows). (From Kim SB, Kwon DR, Kwak H, Shin YB, Han HJ, Lee JH, Choi 
SH. Additive effects of intra-articular injection of growth hormone and hyaluronic acid in 
rabbit model of collagenase-induced osteoarthritis. J Korean Med Sci. 2010 May;25(5):776-
780; with permission.) 
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Lis evaluated diagnostic usefulness of Insulin like growth factor-1 and human growth 
hormone serum level in osteoarthritis. Twenty five patients with coxarthrosis and 16 healthy 
persons were enrolled for measurement of Insulin like growth factor-1 and human growth 
hormone concentration in serum. Insulin like growth factor-1 and human growth hormone 
serum level were assayed by enzyme-linked immunosorbent assay. No significant 
correlation was observed between human growth hormone and Insulin like growth factor-1 
in serum. Insulin like growth factor-1 concentration in patient serum was found to be 
significantly lower than that in the control group. They reported that serum concentration of 
Insulin like growth factor-1 appears to be a useful laboratory marker of osteoarthritis (Lis, 
2008). 
As previously mentioned, studies of human articular cartilage indicate that serum Insulin 
like growth factor-1 levels and chondrocyte responsiveness to Insulin like growth factor-1 
diminish progressively with age (Ashton & Matheson, 1979; Boehm et al., 2007; Fortier & 
Miller, 2006; Loeser et al., 2002; Loeser et al., 2000; Martin et al., 1997; Trippel, 1995) This 
suggests that a simultaneous decrease in the amount of Insulin like growth factor-1 available 
and a reduced ability for cells to respond to the remaining Insulin like growth factor may 
cause cartilage to be less capable of maintaining its structural and functional integrity. 
Insulin like growth factor non-responsiveness has been further observed to exist in 
chondrocytes from arthritic cartilage or in the presence of inflammation (Verschure et al., 
1996). Growth hormone stimulates cartilage growth, probably through production of local 
and systemic Insulin like growth factor-1.  
Recombinant human growth hormone is produced in laboratories. Several well known 
pharmaceutical companies manufacture recombinant human growth hormone. 
Recombinant human growth hormone is pure and free of all viruses. Recombinant human 
growth hormone has been manufactured for several years and is approved by the Food and 
Drug Administration for several uses, such as inducing growth of short children to a normal 
size. However, it has not yet been approved by the Food and Drug Administration for 
injection in joints, which is an "off-label" use. There is interest in the use of growth hormone 
as a potential osteoarthritis disease-modifying treatment; however, few studies of its effects 
in humans have been conducted. 
2.3 Platelet Rich Plasma (PRP) 
2.3.1 Basic science of PRP 
Platelets were thought to act solely in the clotting cascade. In addition to local hemostasis at 
sites of vascular injury, platelets contain an abundance of growth factors and cytokines that 
are crucial in soft tissue healing and bone mineralization (Anitua et al., 2006). Besides, we 
know that platelets also discharge many bioactive proteins responsible for attracting 
macrophages, mesenchymal stem cells, and osteoblasts, which not only promote scavenging 
of necrotic tissue but also facilitate tissue regeneration and healing (Sampson, 2008). The 
concept that application of PRP would result in improvement of cartilage repair is based on 
the physiological role of platelets in wound healing (Nurden et al., 2008). Platelet rich 
plasma is composed of 3-8 times the concentration of platelets contained in whole blood; 
therefore, it contains a hyperphysiological content of autologous growth factors. Of note, a 
universally accepted definition of platelet rich plasma in terms of concentration does not 
exist. Giusti et al., postulated that the most efficacious concentration of platelets for 
stimulation of angiogenesis in vitro was 1.5  106 platelets/L. In an adult, the normal platelet 
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Insulin like growth factor-1 appears to be a useful laboratory marker of osteoarthritis (Lis, 
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and a reduced ability for cells to respond to the remaining Insulin like growth factor may 
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Insulin like growth factor non-responsiveness has been further observed to exist in 
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and systemic Insulin like growth factor-1.  
Recombinant human growth hormone is produced in laboratories. Several well known 
pharmaceutical companies manufacture recombinant human growth hormone. 
Recombinant human growth hormone is pure and free of all viruses. Recombinant human 
growth hormone has been manufactured for several years and is approved by the Food and 
Drug Administration for several uses, such as inducing growth of short children to a normal 
size. However, it has not yet been approved by the Food and Drug Administration for 
injection in joints, which is an "off-label" use. There is interest in the use of growth hormone 
as a potential osteoarthritis disease-modifying treatment; however, few studies of its effects 
in humans have been conducted. 
2.3 Platelet Rich Plasma (PRP) 
2.3.1 Basic science of PRP 
Platelets were thought to act solely in the clotting cascade. In addition to local hemostasis at 
sites of vascular injury, platelets contain an abundance of growth factors and cytokines that 
are crucial in soft tissue healing and bone mineralization (Anitua et al., 2006). Besides, we 
know that platelets also discharge many bioactive proteins responsible for attracting 
macrophages, mesenchymal stem cells, and osteoblasts, which not only promote scavenging 
of necrotic tissue but also facilitate tissue regeneration and healing (Sampson, 2008). The 
concept that application of PRP would result in improvement of cartilage repair is based on 
the physiological role of platelets in wound healing (Nurden et al., 2008). Platelet rich 
plasma is composed of 3-8 times the concentration of platelets contained in whole blood; 
therefore, it contains a hyperphysiological content of autologous growth factors. Of note, a 
universally accepted definition of platelet rich plasma in terms of concentration does not 
exist. Giusti et al., postulated that the most efficacious concentration of platelets for 
stimulation of angiogenesis in vitro was 1.5  106 platelets/L. In an adult, the normal platelet 
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count is approximately 150,000-450,000 platelets/L. (Giusti et al., 2009) There are 
classification schemes that categorize platelet concentrates based on relative concentrations 
of platelets, leucocytes, and fibrin, and, although it is important to recognize and 
understand that there are obvious differences between types of platelet concentrates that are 
being used, the general term/abbreviation, PRP, is used herein (Dohan Ehrenfest et al., 
2009). Several centrifuge devices (harvest SmartPReP APC+TM, Huons®sPRP etc) are 
commercially available for use in physicians’ offices. These devices achieve varying 
concentrations, with whole blood-to-platelet ratios ranging from 1:2 to 1:8. The ratio of 
white blood cell content also varies with the device. Obviously, the ratio of plasma to 
platelets in autologous blood is 1:1. Due to a lack of high-quality studies, the ideal ratio of 
plasma to platelets and the ideal amount of white blood cell concentrate is not well 
established at this time. 
In response to tissue injury, clots rich in platelets and fibrin form a scaffold for subsequent 
healing. There are over 1500 proteins within platelets, and, among them, are growth factors 
stored in platelets as granules, which are known to play important roles in the normal 
healing response, including Platelet-derived growth factor, vascular endothelial growth 
factor, transforming growth factor-b, fibroblast growth factor, and epidermal growth factor 
(Qureshi et al., 2009). Through modulation of the inflammatory response, promotion of local 
angiogenesis, attraction of fibroblasts and local stem cells to the site of injury, and induction 
of autocrine growth factor production by uninjured adjacent cells, platelets and their 
products are instrumental in repair and regeneration of normal tissue. 
In addition to the growth factors mentioned, there are several others that have been 
evaluated for their role in chondrogenesis, and it could be concluded that these factors will 
therefore be important during cartilage regeneration or repair. Clearly, numerous growth 
factors are needed for proper sequencing of chondrogenesis, and it is likely that more than a 
single growth factor will be needed for achievement of hyaline cartilage tissue in a 
reparative procedure. It is becoming increasingly clear that growth factors can work 
synergistically to enhance cartilage matrix synthesis, as in the case of bone morphogenetic 
protein-7 and Insulin like growth factor-I (Loeser et al., 2003), and Insulin like growth factor-
I, fibroblast growth factor-2, and transforming growth factor-b differentially regulate their 
own and each other’s gene expression and protein production in vitro (Shi et al., 2009). 
Based on the concept that a combination of bioactive growth factors is likely necessary for 
cartilage repair, and the increasing application of autogenous biologics for tissue 
engineering, recent attention has been given to the use of platelet rich plasma in cartilage 
repair techniques. Another advantage of platelet rich plasma is that on clotting; platelets 
form three-dimensional scaffolds to fill the cartilage defect and act as a guide for 
neochondrogenesis in situ. Although these issues are not insurmountable, the agents most 
likely to succeed in this regard are likely to include the polygrowth factor environment 
provided by platelet rich plasma products. 
2.3.2 History and development of PRP 
In the 1930s, Schultz demonstrated an injection technique that successfully induced 
tightening of loose temporomandibular joints; the solution injected was derived from 
psyllium seed. In the 1950s, Hackett named this technique prolotherapy to imply 
proliferation of fibrous tissue. In the early 1990s, his work was updated with articles on 
proposed mechanisms of action and use of prolotherapy (using other injectants, such as 
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dextrose and morrhuate sodium) in essentially all joints of the body. More recently, 
prolotherapy has been defined as the injection of growth factors or growth factor production 
stimulants to facilitate growth and repair of normal cells and tissue. A proliferant is any 
solution injected with the intent of growth or repair. Growth factors produced or provided 
with proliferant injection are those that are increased during the repair phase in soft tissue of 
various types; thus, connective tissue is the target for treatment. Linetsky et al proposed the 
term regenerative injection therapy to describe treatments with this goal.  
Autologous platelet rich plasma was first used in 1987 by Ferrari et al., following open heart 
surgery in order to avoid excessive transfusion of homologous blood products. Rationale: 
reversal of the blood ratio through decrease of red blood cell to 5% and increase of platelets 
to 94% for stimulation of recovery; defined as a volume of the plasma fraction of autologous 
blood having a platelet concentration above baseline; clinical efficacy with above 1 million 
platelets/ul. 
In the late 1990s, surgeons began adding platelet rich plasma to fibrin glue, forming a gel for 
placement in surgical sites. The goal was to improve healing, anchoring of implantable 
materials, and speed of recovery. In the early part of this century, physicians began injection 
of platelet rich plasma as a proliferant. The first published, nonsurgical report was a case 
series published in the podiatry field. Since 2005, the Hackett-Hemwall Foundation and the 
University of Wisconsin have sponsored an annual research forum focused on regenerative 
injection treatments. The mode of action of these therapies has been a major focus of 
discussion. Banks (Banks, 1991) has proposed that the common end point of regenerative 
therapy is formation of new collagen fibers. Growth factor stimulation by lipids released 
from cell membrane rupture and microbleeding with release of platelets have been 
proposed as potential mechanisms for such an effect (Reeves et al., 2008). Rabago et al 
discussed these proposed mechanisms of action in their review of 4 injection therapies, 
including dextrose/sodium morrhuate, polidocanol, autologous whole blood, and platelet 
rich plasma injections. They reported that the common goal of these injections is to stimulate 
a normal tissue repair cascade resulting in organized collagen fibers, not scars. Regenerative 
biomedicine is receiving progressive attention in medicine. Advancements in the study of 
these innovative bioactive therapies, such as the use of platelet rich plasma, mesenchymal 
stem cells, extracorporeal shock wave therapy, sclerosing agents, nitric oxide, and matrix 
metalloproteinase etc, have taken place during the past 2 decades.    
2.3.3 Preparation and safety of PRP 
Platelet rich plasma is prepared by centrifuging autologous, anticoagulated whole blood. 
The range of ideal concentrations is based primarily on opinion, and most publications 
differ on the platelet rich plasma concentrations cited. Citrate can be used for inhibition of 
the clotting cascade by binding ionized calcium. Centrifugation separates the following: (1) 
plasma (top layer) from (2) platelets and white blood cells (buffy coat, middle layer) and (3) 
red blood cells (bottom layer) (Fig. 3.) as a result of differences in specific gravity.  
In order to further concentrate the preparation, a second centrifugation separates the platelet 
rich plasma from platelet-poor plasma. Of note, the use of 2 spins versus 1 spin is 
controversial. Although a second spin will certainly concentrate the platelets further, the 
question of whether this step is necessary remains a subject of discussion. The platelet rich 
plasma (middle layer) is then drawn off, and addition of calcium chloride or thrombin 
activates the platelet rich plasma and results in prompt release of 70% of the growth factors 
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In order to further concentrate the preparation, a second centrifugation separates the platelet 
rich plasma from platelet-poor plasma. Of note, the use of 2 spins versus 1 spin is 
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activates the platelet rich plasma and results in prompt release of 70% of the growth factors 
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from the granules within 10 minutes (and nearly all of the contents within an hour). The 
issue of pre-activation is also controversial, and not all clinicians include this step. Presently, 
a number of different manufacturers have introduced systems for platelet rich plasma 
preparation, allowing for both intraoperative and outpatient use of platelet rich plasma for a 
variety of orthopaedic pathologies (Hall et al., 2009). The volume of platelet rich plasma and 
concentration of platelets yielded from a volume of whole blood can differ based on the 
preparation system used (Foster et al., 2009; Mishra et al., 2009; Hall et al., 2009). For 
example, in our clinic, we use the Huons® sPRP system (Huons®, Gyeonggido, Korea) (Fig. 
3.). The procedure utilizes a 50 ml venous blood sample, which is drawn using aseptic 
technique from the anticubital vein. Use of an 18-19 gauge butterfly needle is advised, in an 
effort to avoid irritation and trauma to platelets. Blood is then placed in a Korean Food and 
Drug Administration approved device (Huons®, Gyeonggido, Korea), centrifuged for 3 min 
at 3,200 rpm, and separated into platelet poor plasma, PRP, and RBC. Platelet poor plasma is 
extracted through a special port and discarded from the device. Afterward, the platelet rich 
plasma is withdrawn. Approximately 5.5 or 6.0 cc of platelet rich plasma is available.  
 
 
Fig. 3. Platelet rich plasma preparation. (1) Platelet poor plasma (top layer) (2) platelets and 
white blood cells (buffy coat, middle layer) and (3) red blood cells (bottom layer). PPP; 
platelet poor plasma, PRP; platelet rich  plasma, RBC; red blood cell. Photo courtesy of 
Huons® Technoloogies, sPRP kit.  
Platelet rich plasma is prepared from autologous blood; therefore, any concerns regarding 
immunogenic reactions or disease transfer are eliminated. Growth factors act on cell 
membranes, rather than on the cell nucleus, and activate normal gene expression. Growth 
factors are not mutagenic and act naturally through gene regulation and normal wound 
healing feed-back control mechanisms.  
2.3.4 Preclinical studies 
In a rabbit model, osteochondral defects were treated with either autogenous platelet rich 
plasma in a poly-lacticglycolic acid carrier, poly-lacticglycolic acid alone, or left untreated 
(Sun et al., 2010). The platelet rich plasma group demonstrated a higher extent of cartilage 
regeneration as well as increased production of glycosaminoglycans in the extracelluar 
matrix. 
Osteoarthritis models have also been used in study of the effects of platelet rich plasma on 
synovial cell biology. Cells from 10 patients were cultured and exposed to either a platelet-
poor or platelet-rich solution. Investigators found that the platelet rich solution in growth 
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factors enhanced hyaluronic acid secretion; therefore, they concluded that intra-articular 
injections of platelet-released growth factor may be useful in maintenance of joint 
homeostasis by contributing to hyaluronic acid restoration (Anitua et al., 2007).  
In the animal literature, results of several studies have demonstrated evidence of 
osteogenesis and formation of cartilaginous tissue with platelet rich plasma combined with 
chondrocytes or a collagen matrix (Qi et al., 2009). Sustained-release platelet rich plasma 
intra-articular injections also resulted in increased cartilage matrix metabolism (Saito et al., 
2009). Although chondrocytes and platelet rich plasma appeared to stimulate 
chondrogenesis subcutaneously, demineralized bone matrix and platelet rich plasma did 
not stimulate osteogenesis intramuscularly (Ranly et al., 2007) which prompts further 
questions about the substrates with which platelet rich plasma may have synergistic effects 
and the environment in which the composite is placed. Intra-articularly injected sustained-
release vehicles for platelet rich plasma appeared to stimulate cartilage matrix metabolism, 
which suggests potential uses in osteoarthritis management (Saito et al., 2009). In a canine 
model, a composite was created when platelet rich plasma was combined with bone marrow 
stromal cells and demineralized bone matrix, and then subsequently wrapped in a muscle 
flap containing blood vessels. This combination appeared to enhance osteogenesis and 
vascularization (Li et al., 2009). 
In a study of porcine mandibular bone defects, platelet rich plasma combined with bone 
marrow was found to stimulate osteogenesis (Lopez-Lopez et al., 2009). In another study, 
platelet rich plasma was combined with bone graft and stimulated osteogenesis in rabbit 
calvarium defects (Nagata et al., 2009). Chondrogenesis was demonstrated in rabbit knee 
cartilage defects when platelet rich plasma was used with a scaffold (Sun et al., 2010). 
platelet rich plasma alone also has been found to enhance the healing of diabetic fractures in 
rats (Gandhi et al., 2006).  
2.3.5 Clinical studies 
Blood-derived growth factors have already been studied for their potential to aid in cartilage 
repair and have been documented in the literature in both preclinical and clinical studies 
(Saito et al., 2009; Wu et al., 2007). In particular, Baltzer et al. (Tamoto et al., 1994) conducted 
an analysis of the effect of autologous conditioned serum in treatment of patients with knee 
osteoarthritis. In their prospective, randomized patient- and observer-blinded, placebo-
controlled trial, they demonstrated that autologous conditioned serum injections induced 
considerable improvement of the clinical signs and symptoms of osteoarthritis with results 
that are even superior to those of hyaluronic acid. Recently, there has been increasing 
interest in the use of another autologous blood product, platelet rich plasma, which might 
provide cellular and humoral mediators to promote tissue healing in a variety of 
applications. The rationale is based on the activity of blood growth factors carried in 
platelets, many of which have been shown to take part in regulation of articular cartilage 
(Kobayashi et al., 1994). Platelets contain storage pools of growth factors in their a-granules 
(Larsen et al., 1977), including Platelet-derived growth factor, Transforming Growth Factor-
b, Insulin like growth factor-1, fibroblast growth factor, and many others, as well as 
cytokines and chemokines (Sanzhez et al., 2009). Platelet rich plasma is derived from 
centrifugation of autologous whole blood and contains a platelet concentration that is 4 to 5 
times higher than that of normal blood, thus offering a high concentration of growth factors 
in physiological proportions. Some research findings have suggested a possible role for 
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platelet rich plasma in treatment of cartilage lesions (Saito et al., 2009). In an observational 
retrospective cohort study using hyaluronan injections as a control, Sanchez et al. (Sanchez 
et al., 2008) showed interesting preliminary results using intra-articular injections of an 
autologous preparation rich in growth factors  for treatment of knee osteoarthritis. These 
studies suggest that these potent biological regulators of chondrocytes have an important 
role in cartilage repair. However, for the time being, evidence for clinical use of platelet rich 
plasma is still in its infancy, particularly regarding treatment of degenerative knee 
conditions via multiple platelet rich plasma injections. A study was performed to explore 
this novel approach for treatment of articular cartilage degenerative lesions. The preliminary 
results indicated that this procedure was safe and had the potential to relieve pain and 
improve knee function and quality of life in younger patients with a low degree of articular 
cartilage degeneration. 
A number of studies investigating the use of platelet rich plasma and autologous blood have 
received attention in the popular press. However, there is still a lack of high-quality, 
prospective research providing definitive assistance to physicians in the appropriate use of 
these agents (Nguyen et al., 2011). That being said, early use of these agents for conditions 
that are often resistant to other treatments has been encouraging (Kazemi et. Al., 2010). In 
addition, platelet rich plasma and autologous blood have shown less potential for serious 
side effects, such as tendon rupture and fat necrosis, than corticosteroids. Autologous blood 
treatment protocols involve injection of a local anesthetic in the affected region and then 
performance of venipuncture and re-injection of the patient’s blood into the abnormal tissue. 
To date, no randomized controlled trials have been conducted in this area. We found an 
observational, retrospective clinical study that used hyaluronan as a control. The 
investigators used serial intra-articular platelet rich plasma injections, with modest 
outcomes. Another clinical study was prospective and showed more positive results, but did 
not include a control group. Investigators found promising results in patients of younger 
ages, patients with a lower body mass index, males, and cases of milder severity (Filardo et 
al., 2010). Application of platelet rich plasma in cartilage repair is relatively new; therefore, 
there have been limited publications investigating its use. Chondrocytes and mesenchymal 
stem cells exposed to platelet rich plasma have shown both increased cell proliferation and 
cartilage extracellular matrix synthesis of proteoglycans and collagen type II, compared with 
controls (Akeda et al., 2006). Synoviocytes from patients with osteoarthritis cultured in 
platelet rich plasma demonstrated increased hyaluronic acid production and secretion, 
suggesting that platelet rich plasma could potentially serve as an endogenous source of 
chondroprotection and joint lubrication after intra-articular application (Anitua et al., 2007). 
In a cohort of 30 patients for comparison of injections of platelet rich plasma with hyaluronic 
acid in management of osteoarthritis, the success rate for the pain subscale reached 33.4% 
for the platelet rich plasma group, compared with 10% for the hyaluronic acid group (p = 
0.004) (Sanchez et al., 2008). In addition, percent reductions in the physical function subscale 
and overall Westren Ontario and McMaster Universities (Bellamy et al., 1988) at 5 weeks 
were also associated solely with treatment modality in favor of platelet rich plasma, with p = 
0.043 and p = 0.010, respectively. Kon et al. reported results of a large, prospective case 
series using intraarticular platelet rich plasma injection in patients with degenerative 
chondral lesions of the knee, as seen on magnetic resonance image (Kellgren o, n = 58 knees) 
or clear osteoarthrosis on radiograph (Kellgren I-III, n = 33; Kellgre IV, n = 24. Injection of 5 
mL PRP (via a lateral approach without guidance) was administered every 21 days for a 
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total of 3 treatments. Calcium chloride was added for activation of platelets. A substantial 
improvement in International Knee Documentation Committee (Irrgang et al., 2001) and 
EuroQol-visual analogue scale scores (EuroQol, 2007) was noted at the end of therapy and at 
both the 6- and 12-month time points. International Knee Documentation Committee 
subjective scores as well as the EuroQol-visual analogue scale score also demonstrated 
major improvements at the end of therapy. The authors concluded that treatment with 
platelet rich plasma is safe and effective for improvement of pain, function, and quality of 
life in patients with degenerative articular pathology. No follow-up imaging was reported. 
The initial hypothesis was that the use of platelet rich plasma might stimulate chondral 
anabolism and produce a reduction in catabolic processes, thus leading to 
chondroprotective and chondroregenerative actions, and, therefore, symptomatic 
improvement. However, the clinical nature of this study makes it difficult to assess the 
disease-modifying properties of this approach. Moreover, despite the initial considerable 
improvement in clinical signs and symptoms of knee cartilage degeneration, the marked 
worsening observed at the 24-month follow-up indicates that improvement due to platelet 
rich plasma injections is mostly symptomatic, at least with this procedure. Platelet rich 
plasma probably influences overall joint homoeostasis, also through reduction of synovial 
membrane hyperplasia and modulation of the cytokine level, thus leading to the observed 
improvement in the clinical outcome, albeit only temporarily, and maybe without affecting 
cartilage tissue structure or progression of joint degeneration (Saito et al., 2009). Further 
studies will determine whether or not other application modalities, with different 
platelet/growth factor concentrations and injection times, may allow for achievement of 
better and more durable results. 
Treatment is most effective in younger male patients, with lower body mass index and 
lower degrees of chondral degeneration. The interesting results obtained regarding the 
safety, feasibility, and short-term efficacy of this treatment suggest that it may represent a 
minimally invasive and safe procedure that may be cyclically repeated in order to improve 
knee function and quality of life.  
Despite early optimism and the positive safety profile of platelet rich plasma and 
autologous blood, most insurance companies are reluctant to cover the use of these agents 
due to a lack of high-quality randomized, double-blinded studies. 
3. Conclusion 
When treating a patient with osteoarthritis, it is best to start with non-interventional 
approaches, such as physiotherapy, ice, and analgesics. If conservative treatment fails, 
injectable agents may help. Corticosteroid injections are effective in reducing pain associated 
with osteoarthritis and in treatment of conditions in which inflammation is present. When 
corticosteroid treatment is not effective for osteoarthritis, intra-articular injections with 
hyaluronic acid are another option. Hyaluronic acid injections provide longer-lasting pain 
relief than corticosteroids for patients with osteoarthritis; however, they are much more 
expensive. Growth hormone has not yet received Food and Drug Administration approval 
for injection in joints, which is an "off-label" use. There is interest in the use of growth 
hormone as a potential osteoarthritis disease-modifying treatment; however, studies of its 
effects in humans are lacking. Platelet-rich plasma and/or autologous blood injections are 
safer and may be more effective than corticosteroids for treatment of osteoarthritis. 
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However, physicians need to understand that high-quality prospective evidence as to the 
appropriate use of some of these treatments for certain conditions is lacking. Considering 
the limited data, no clear definition of a standardized platelet rich plasma treatment 
protocol has been established to date. Further research is needed.  
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1. Introduction 
Osteoarthritis is a very common disease, and its prevalence increases with age. According to 
the American College of Rheumatology, nearly 70 % of people over age 70 have X – ray 
evidence of osteoarthritis, although only half ever develop symptoms (Altman et al., 1991). 
Notwithstanding, due to the huge amount of persons affected, osteoarthritis is a frequent 
cause of disability (Lawrence et al., 1998). 
Several pharmaceutical approaches, such as analgesics, non steroidal anti – inflammatory 
drugs, COX – 2 inhibitors and steroids (Hochberg et al., 1995), have been proposed, with the 
aim of reducing pain and maintaining and / or improving joint function. However, none of 
these options has shown to delay the progression of osteoarthritis or reverse joint damage. 
In addition, the incidence of adverse reactions to these drugs increases with age. Data from 
epidemiological studies consistently show that the risk of gastro – intestinal complications is 
very high and largely dose – dependent (Griffin MR et al., 1991 ; Smalley & Griffin, 1996). It is 
well known that non steroidal anti – inflammatory drugs, as well as selective COX – 2 
inhibitors, may cause renal failure, hypertension and water retention and have a thrombotic 
potential, especially for high doses and long term treatments (Roughead et al., 2008; Savage, 
2005). Corticosteroids are burdened with relevant adverse reactions, when given systemically, 
and therefore are usually administered by intra – articular injection in patients who fail to 
respond to other conservative measures; in particular, patients with joint effusions and local 
tenderness may have greater benefit from this option (Flanagan et al., 1988). 
Although it has been established that corticosteroid injections are relatively safe, there are 
concerns regarding their possible adverse effects, following repeated injections. These effects 
include local tissue atrophy, particularly when small joints are injected, long – term joint 
damage, due to reduced bone formation, and risk of infection, due to suppression of 
adrenocortical function (Mader et al., 2005; Weitoft et al., 2005).  
Considering the limits of therapies at present available, drugs with minimal side effects are 
therefore warranted. 
Viscosupplementation by intra – articular injections of hyaluronic acid has been proposed as 
useful therapeutic option in the treatment of osteoarthritis in different joints (Migliore et al., 
2010). 
Aim of the chapter is to summarize the more significant results of this therapeutic approach, 
reporting the recently published data and focusing attention on issues yet unsolved. 
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2. Synovial fluid  
Synovial fluid is essential for the normal joint functioning : it acts both as a lubricant during 
slow movement (e.g. in walking), and as an elastic shock absorber during rapid movement 
(e.g. in running). It also serves as a medium for delivering nutrition, and transmitting 
cellular signals to articular cartilage.  
Hyaluronic acid, produced by synoviocytes, fibroblasts and chondrocytes, is the major 
chemical component of synovial fluid. The native hyaluronic acid has a molecular weight of 
4 – 10 millions Daltons, and is present in articular fluid in concentration about 0.35 gr / 100 
ml (Weiss & Band, 1995). It is essential for the viscoelastic properties of the fluid because of 
high viscosity, and has a protective effect on articular cartilage and soft tissue surfaces of 
joints (O' Regan et al., 1994; Van den Bekerom et al., 2008). 
In pathological conditions, the concentration and molecular weight of hyaluronic acid are 
reduced, resulting in synovial fluid of lower elasticity and viscosity : the factors which 
contribute to the low concentrations of hyaluronic acid are diluitional effects, reduced 
hyaluronan synthesis and free radical degradation (Van den Bekerom et al., 2006). When 
viscoelasticity of synovial fluid is reduced, the transmission of mechanical force to cartilage 
may increase its susceptibility to damage.  
Therefore, the restoration of the normal articular homoeostasis is the rationale for 
hyaluronic acid administration into osteoarthritic joints. Moreover, being hyaluronic acid a 
physiological component, it is very likely that it may be deprived of adverse reactions, also 
after repeated administrations. 
3. Therapeutic activities of hyaluronic acid 
The direct injection of hyaluronic acid in the joint space allows to reach a proper 
concentration with low doses, favouring a longer permanence in the joint, and therefore the 
therapeutic response. 
Hyaluronic acid preparations have a short half – life; therefore, the long term effects cannot 
solely be attributed to the substitution of molecule itself. The term viscosupplementation 
means  restoration of visco – elastic properties, such as cushioning, lubrication, elasticity 
(Kikuchi et al., 2001), while the term biosupplementation is used to indicate the  restoration 
of joint rheology, anti – inflammatory and anti – nociceptive effects, normalization of 
endogenous hyaluronic acid synthesis, and chondroprotection. These activities explain why 
the clinical efficacy is maintained for several months (Gigante & Callegari, 2010 ; Hiraoka et 
al., 2011; Julovi et al., 2011; Kumahashi et al., 2011). 
In Table 1, the main beneficial effects of hyaluronic acid in osteoarthritis are summarized. 
4. Hyaluronic acid preparations 
At present, preparations with different molecular weight are available (Low and High 
Molecular Weight), which display distinct pharmaceutical effects (Ghosh & Guidolin, 
2002). 
The enhanced penetration of low molecular weight preparations (0.5 – 1.5 millions Dalton) 
through the extracellular matrix of the synovium is thought to maximize the concentration 
and to facilitate the interaction with target synovial cells, so reducing the synovial 
inflammation (Bagga H et al., 2006). 
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ACTION TARGET RESULTS 
Inhibition Lymphocyte transformation
 
SLOW DOWN THE 
PROGRESSION OF JOINT 
DAMAGE 
 
ANTI – INFLAMMATORY 
ACTIVITY 
 







 Phagocytic activity of macrophages and leukocytes
 Adenosine triphosphate levels
 Matrix Metalloproteinase (MMP)
Promotion Release of prostaglandins
 Normalization of native hyaluronan synthesis
 Production of tissue inhibitor of MMP – 1
 Scavenging of free radicals
 Proteoglycans synthesis by chondrocytes
Protective 
Effects on chondrocytes or cartilage explants 
from degradation by enzymes, Interleukin – 1, 
and oxygen – derived free radicals 
Table 1. Beneficial effects of hyaluronic acid (modified from Carpenter & Motley (2008)) 
However, because of the low elastoviscosity of these hyaluronan compounds, compared to 
native hyaluronan in the synovial fluid, interests were shifted to a viscosupplementation 
fluid similar to the native hyaluronic acid. 
Recently, an hyaluronic acid cross – linked preparation (Hylan G – F 20), with high 
molecular weight (6 – 7 millions Dalton), has been developed (Migliore et al., 2010). 
This formulation, by means of its hydrophilic properties, retains higher amounts of fluid in 
articular space; it is also provided by a greater anti – inflammatory activity, as shown by 
studies on migration of inflammatory cells in the joint and on reduced Prostaglandin E 2 
and bradykinin concentration (Goto et al., 1999; Takahashi et al., 1999). Moreover, high 
molecular weight hyaluronic acid is considered more effective in relieving pain, compared 
to low molecular weight hyaluronic acid.  
A novel hyaluronic acid preparation, non – animal stabilised hyaluronic acid (NASHA) 
(Berg & Olsson, 2004) has been manifactured by a two stage procedure : byosinthesis of 
hyaluronic acid by cultured bacteria, followed by a mild stabilization process. Stabilisation 
does not change the biochemical properties of hyaluronic acid, but creates bio – compatible 
gel with improved viscoelastic properties and a longer residence time in joint, compared 
with non – stabilised hyaluronic acid preparation. 
Currently, with aim of favouring a longer presence of hyaluronic acid in the joint, long 
acting preparations are under study (Abate et al, 2010). Hopefully, these compounds, with 
better rheological and biological properties, could influence positively the natural history of 
osteoarthritic disease. 
5. Indications to treatment 
Viscosupplementation can be considered when the patient has not found pain relief from 
exercise, physical therapy, weight loss, use of orthotics and analgesics or non steroidal anti – 
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ACTION TARGET RESULTS 
Inhibition Lymphocyte transformation
 
SLOW DOWN THE 
PROGRESSION OF JOINT 
DAMAGE 
 
ANTI – INFLAMMATORY 
ACTIVITY 
 







 Phagocytic activity of macrophages and leukocytes
 Adenosine triphosphate levels
 Matrix Metalloproteinase (MMP)
Promotion Release of prostaglandins
 Normalization of native hyaluronan synthesis
 Production of tissue inhibitor of MMP – 1
 Scavenging of free radicals
 Proteoglycans synthesis by chondrocytes
Protective 
Effects on chondrocytes or cartilage explants 
from degradation by enzymes, Interleukin – 1, 
and oxygen – derived free radicals 
Table 1. Beneficial effects of hyaluronic acid (modified from Carpenter & Motley (2008)) 
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5. Indications to treatment 
Viscosupplementation can be considered when the patient has not found pain relief from 
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inflammatory drugs. Other indications may be the intolerance to drugs or the use of 
multiple systemic medications, as frequently happens in the elderly (Waddell, 2007). 
The treatment, in general, is offered to patients with intermediate Kellgren – Lawrence  
score (mild osteoarthritis) (Kellgren & Lawrence, 1957), who report better results in term of 
function and pain reduction (Brzusek & Petron, 2005). 
The administration of hyaluronic acid is contraindicated only in patients with known 
hypersensitivity to preparations components; patients with severe osteoarthritis 
(Kellgren – Lawrence score IV) or affected by inflammatory musculoskeletal diseases 
(rheumatoid arthritis, chondrocalcinosis, psoriasis, gout), may have limited benefit 
(Waddell, 2007). 
6. Infiltration techniques 
Intra – articular injection of hyaluronic acid must be performed in sterile conditions, to 
minimize the risk of inflammatory complications (i.e. septic arthritis). 
Moreover, the use of “image – guided” infiltration techniques is mandatory; indeed, when 
joint infiltration is performed blindly, the failure rate is high, and the drug may be 
administered in the para – articular space. In this case, treatment loses its efficacy and side 
effects, mainly pain, frequently occur (Pourbagher et al., 2005; Zwar et al., 2004). 
The ultrasound – guided injection, compared with fluoroscopy, has several advantages : it 
is simple, fast, economic and safe; it does not require the use of contrast media, allowing 
the infiltration in patients intolerant to iodized contrasts. It can be repeated without 
limits, allows an easy visualization of fluid in the articular recess (which may be 
aspirated) (Figure 1), and shows how narrow is the articular space.  
 
 
F = Femur 
Fig. 1. Ultrasound imaging (longitudinal scan). An effusion (*) is present inside the articular 
space of knee joint. 
Moreover, it is able to show the position of the needle, and, by means of continuous Color 
Doppler monitoring, to evaluate its distance from vessels. Finally, ultrasound technique 
allows the visualization of the viscous fluid injected inside the joint (Migliore et al., 2004). 
In figure 2, an example of intra – articular injections of hip joint is presented. 
 




FH = Femoral head; Fn = Femoral neck; 1 = articular space; Arrows = articular capsule 
Fig. 2. Ultrasound guided injection of hip joint (longitudinal scan). Before the injection, hip 
joint is evaluated (left panel). After the injection (right panel), the correct placement of 
hyaluronic acid (calipers) is confirmed by the presence of hyperechoic material inside the 
articular space.  
7. Clinical results 
In this section we report the main results obtained with hyaluronic acid in the treatment of 
osteoarthritis in different joints. 
7.1 Knee osteoarthritis 
Viscosupplementation with hyaluronic acid in knee osteoarthritis has been approved by 
Food and Drugs Administration (Hunter & Lo, 2008).  
Recent guidelines are based on a meta – analysis, including 5257 participants to 40 
Randomized Controlled Trials (Curran, 2010; National Collaborating Center for Chronic 
Conditions at the Royal College of Physicians, 2008). These studies were performed, single 
or double – blind, with different types of hyaluronic acid (low and high molecular weight) 
against placebo. The number of injections ranged from 3 to 5 weekly, with a maximum of 11 
in 23 weeks, the doses from 15 to 60 mg and the trials length from 4 weeks to 18 months.  
Pain was evaluated by means of Visual Analogic Scale and Western Ontario and McMaster 
Universities Osteoarthritis Index, at rest and under different load conditions. A minor 
number of studies evaluated the functional outcomes (Western Ontario and McMaster 
Universities Osteoarthritis Index [physical function], Lequesne Index, Range of motion), the 
subjective global assessment and the quality of life of the patients. The results of the 
majority of studies are in favour of hyaluronic acid, although in several randomized 
controlled trials no significant differences have been found in comparison with intra – 
articular placebo. The percentages of improvement from baseline, in all the outcomes 
measures, were 28 % to 54 % for pain, and 9 % to 32 % for function, and were similar in the 
trials where low molecular weight or high molecular weight hyaluronic acid were used 
(Aggarwal & Sempowski, 2004; Divine et al., 2007; Waddel 2007). However, the number of 
injection needed was in general lower for high molecular weight preparation and this is not 
a negligible advantage for the patients. 
A recent systematic review has compared the post – intervention time course of the effects 
of hyaluronic acid and corticosteroid (the “therapeutic trajectory”) (Bannuru et al., 2009). 
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This meta analysis highlights the therapeutic trajectory of hyaluronic acid for knee 
osteoarthritis pain over six months following the intervention. From baseline to week 4, 
intra – articular corticosteroid appear to be relatively more effective than hyaluronic acid. By 
week 4 the two approaches have equal efficacy, but beyond week 8 hyaluronic acid has 
greater efficacy. 
It should be observed that the benefit is not equally distributed among patients, some of 
them being non – responders to therapy. The characteristics of responders, at present, have 
not been clearly identified, but some authors claim that a greater benefit may be obtained in 
patients with low grade osteoarthritis (Dagenais et al., 2006). On the contrary, age does not 
influence the therapeutic response (Abate et al., 2008). 
7.2 Hip osteoarthritis 
The number of studies about viscosupplementation of hip osteoarthritis is limited, when 
compared with studies in knee osteoarthritis. The reasons can be the deeper localization of 
this joint, and the proximity of femoral vessels and nerves. 
Moreover, the level of evidence for most of these studies is low, because they are cohort 
studies and lack of a reference group (Abate et al., 2010), a score I (i.e. the highest level of 
evidence), according to the Center for Evidence Based Medicine criteria (Fletcher & Sackett, 
1979), having been assigned only to Tikiz's (Tikiz et al., 2005) and Qvistgaard's (Qvistgaard 
et al., 2006) studies. 
A new randomized controlled three – arm study, comparing intra – articular injection of 
hyaluronic acid, corticosteroid and bupivacaine, is in progress; this trial will hopefully 
provide robust information on the advantages of drugs towards the simple anaesthetic 
treatment (Colen et al., 2010). 
In the published studies, several hyaluronic acid compounds were used. The number of 
injections ranged from 1 to 3 for each patients, and only in few cases 4 or 5 injections were 
performed. In general, the injections number was lower for high molecular weight 
preparations. The length of treatments and the outcome measures were similar to those used 
in knee randomized controlled trials. 
All the trials have shown a reduction of pain, which, in general, becomes evident within 3 
months and persists in the following months. Only few studies report a precocious 
reduction of the pain : within a week, according to Brocq (Brocq et al., 2002) (– 27 %), and 
within the first 2 – 4 weeks according to Qvistgaard (Qvistgaard et al., 2001) (– 14 % and – 32 
%, respectively). The positive effects on pain after 1 – 3 months range from – 16.1 % to – 52.2 
% (mean – 37.2 %), whereas, overall, the mean Visual Analogic Scale score decreases about 
49 % after 3 – 6 months (range 31 – 80 %) (Abate et al., 2008). 
Therefore, it seems that the benefit increases in the long term. However, it must be 
underlined that only few studies report longer follow – up periods : at 12 (Migliore et al., 
2005) and at 18 months (Migliore et al., 2006a), with persistent benefit on the pain (VAS – 
36.4 %). Besides the reduction of pain, also the articular function is improved. These positive 
effects have been observed using different evaluation scales : + 11 % in the Harris Hip Score, 
+ 32 – 45 % in Western Ontario and McMaster Universities Osteoarthritis Index score, + 45 
% in Lequesne Index, and + 95 % in American Academy of Orthopaedic Association Lower 
Limb Core Scale (Abate et al., 2008). A further observation, which confirms the previous 
data, is the reduction of non steroidal anti – inflammatory drugs consumption (Migliore et 
al., 2011).  
 
Hyaluronic Acid in the Treatment of Osteoarthritis: What is New 
 
107 
7.3 Ankle osteoarthritis 
Only few studies have been performed in ankle osteoarthritis and, among these, four were 
randomized / controlled trials (level of evidence 1) (Carpenter & Motley, 2008; Cohen et al., 
2008; Karatosun et al., 2008; Salk et al., 2005, 2006), while seven studies (Hanson et al., 1999; 
Luciani et al., 2008; Mei – Dan et al., 2010; Sun et al., 2006; Valiveti et al., 2006;  Witteveen et 
al., 2008, 2010) were case series (level of evidence 4). 
In all these studies, patients suffering from post – traumatic Kellgreen – Lawrence grade II – 
IV ankle osteoarthritis were enrolled. Different hyluronic acid preparations were used, and 
patients received 1 up to 5 injections. Only in one study, the injections were performed by 
means of image guidance (fluoroscopy) (Cohen et al., 2008). Clinical benefit was evaluated 
by means of different scales (Visual Analogic Scale, Ankle Osteoarthritis Scale, American 
Orthopaedic Foot and Ankle Society, Short Form – 12, Short Form – 36, Western Ontario and 
McMaster Universities Osteoarthritis Index), and the follow – up period varied from 6 to 18 
months. 
In studies performed without control group (Hanson et al., 1999; Luciani et al., 2008; Mei – 
Dan et al., 2010; Sun et al., 2006; Valiveti et al., 2006;  Witteveen et al., 2008, 2010) (Table 
2), an improvement in all the outcome measures was reported, with the effect lasting for 
18 months (Luciani et al., 2008). However, it is not clear from reports whether the pain 
reduction was clinically significant, or could be ascribed only to a placebo effect. In 
addition, the lack of controls does not allow definitive conclusions on the efficacy of 
hyaluronic acid. 
 
Authors Patients Age HA Dose Follow up Results 
Mei – Dan 15 43 LMW 1x5 wks 7 months Positive 
Sun 75 50 LMW 1x5 wks 6 monhts Positive 
Luciani 21 45 HMW 1x3 wks 3 monhts Positive 
Witteveen(2008) 55 41 HMW 1 or 2 6 – 9 months Positive 
Witteveen(2010) 26 43 HMW 1 or 2 or 3 6 months Positive 
HA = Hyaluronic acid; LMW = Low Molecular Weight; HMW = High Molecular Weight 
Table 2. Case series studies on ankle osteoarthritis. Valiveti (2006) and Hanson (1999) 
studies' are not reported due to the small number of cases. 
The level 1 evidence studies are more qualified to assess the therapeutic efficacy, but also 
these trials show several limitations (e.g., no information on the actual number of potential 
patients, no clear patients randomization, imbalance of baseline characteristics between 
intervention and control groups, statistical weakness), and therefore have to be considered 
as low quality studies. 
In these studies (Carpenter & Motley, 2008; Cohen et al., 2008; Karatosun et al., 2008; Salk et 
al., 2005, 2006) (Table 3), the patients treated with hyaluronic acid showed a significant 
decrease in pain and disability at 6 months (Cohen et al., 2008; Salk et al., 2005, 2006), with 
the effects lasting 12 – 13 months (Carpenter & Motley, 2008; Karatosun et al., 2008). Besides 
the reduction of these parameters, an improvement in ankle sagittal range of motions, and 
gait quality was observed (Karatosun et al., 2008). 
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Authors Patients Age HA Dose Control Follow up HA vs Controls 
Carpenter 26 55 HMW 1x3 wks Arthroscopy 13 months > HA (moderate) 
Cohen 30 49 LMW 1x5 wks Saline 6 months No difference 
Karatosun 30 55 LMW 1x3 wks Exercise 12 months No difference 
Salk 17 58 LMW 1x5 wks Saline 6 months No difference 
Table 3. Randomized controlled trials on ankle osteoarthritis. Salk et al. (2006, 2005)  
presented their results in two different journals. 
In any study the authors found difference between hyaluronic acid and controls groups. In 
particular, in the studies performed by Salk (Salk et al., 2005, 2006) and Cohen (Cohen et al., 
2008), the patients, treated with a 1 – 2 ml phosphate – buffered saline solution injection, 
reported a similar improvement in all parameters evaluated. Analogously, positive results 
were observed in patients, who followed a 6 weeks exercise therapy (muscle strengthening 
and ankle range of motion exercises) (Karatosun et al., 2008), and after arthroscopic lavage 
of osteoarthritic ankle joint (Carpenter & Motley, 2008). 
On the basis of these observations, no clear evidence on the efficacy of hyaluronic acid in 
reducing pain, and improving function, in ankle osteoarthritis, is provided. 
Several factors can explain why viscosupplementation has limited efficacy in ankle 
osteoarthritis. 
Ankle joint, anatomically and functionally, is more complex than other joints, which are 
usually treated with positive results with hyaluronic acid (hip, knee) (Saltzman et al., 
2005). 
Another possible reason of the limited benefit of hyaluronic acid can be related to its use 
mostly in post – traumatic osteoarthritis (Zhang & Jordan, 2010), which has a pathogenesis  
quite different from that of primary degenerative osteoarthritis. 
Finally, it must be considered that all studies (Carpenter & Motley, 2008; Hanson et al., 1999; 
Karatosun et al., 2008; Luciani et al., 2008; Mei – Dan et al., 2010; Salk et al., 2005, 2006; Sun 
et al., 2006; Valiveti et al., 2006;  Witteveen et al., 2008, 2010), but one (Cohen et al., 2008), 
were performed blindly, with any imaging guidance. This can be a valid explanation of 
several unsatisfactory results, because there is evidence that about one third of intra – 
articular injections are not delivered into the intra – articular cavity, when performed 
without a visual aid (Cunnington et al., 2010). 
At this regard, ankle joint presents many technical difficulties of injecting intra – articularly, 
due to its complex anatomy, further complicated from the osteoarthritic joint changes (Woo 
et al., 2010). 
7.4 Gleno – Humeral osteoarthritis 
Hyaluronic acid is effective and well tolerated for the treatment of osteoarthritis and 
persistent shoulder pain refractory to other standard non operative interventions (Andrews, 
2005).  
Several authors (Blaine et al., 2008; Leardini et al., 1988) report that both 3 and 5 weekly 
intra – articular injections of low molecular weight hyaluronic acid provide significant 
improvement in terms of shoulder pain (Visual Analogic Scale score on movement), with 
the effects lasting 7 – 26 weeks (Blaine et al., 2008). 
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Similarly, in a 6 months follow – up studies (Merolla et al., 2011; Silverstain et al., 2007), a 
significant reduction in Visual Analogic Scale pain score was also provided with 3 weekly 
intra – articular high molecular weight hyaluronic acid (Hylan G – F 20) injections. In 
addition, most of the patients experienced an improvement in the shoulder function score 
and in the activities of daily living (Itokazu & Matsunaga, 1995; Merolla et al., 2011). 
A recent study comparing Hylan G – F 20 versus 6 methylprednisolone acetate shows that 
hyaluronic acid is effective in reducing pain for up to 6 months, whereas corticosteroid 
injections result in improvement at 1 month only (Merolla et al., 2011). 
Finally, the efficacy of hyaluronic acid has been demonstrated in the treatment of different 
shoulder diseases, such as subacromial bursitis, adhesive capsulitis and rotator cuff tear 
(Blaine et al., 2008; Calis et al., 2006; Fernandez – Palazzi et al., 2002; Rovetta & 
Monteforte, 1998; Tamai et al., 2004), with positive results on pain, joint mobility and 
shoulder function. 
7.5 Carpo – Metacarpal osteoarthritis 
Because carpo – metacarpal joint is essential for the closure of the first web, a loss of function 
causes an alteration of the thumb – index pinch, and therefore can lead to functional 
impairment (Spacek et al., 2004).  
Several conservative treatments have been proposed (corticosteroids, non steroidal anti – 
inflammatory drugs, prolotherapy, splinting), but none of these has shown to delay the 
progression of osteoarthritis or reverse joint damage (Fuchs et al., 2006). 
Recent studies have investigated the efficacy of hyaluronic acid in the treatment of carpo – 




MC = Metacarpal bone 
Fig. 3. Ultrasound features of carpo – metacarpal osteoarthritis (right panel) : the cortex of 
the trapezium bone (T) is irregular and an osteophyte is present (arrow); mild articular 
effusion (*) can be also appreciated. In left panel, normal features are reported.  
In particular, an early improvement in Visual Analogic Scale score was observed after 2 
weeks post treatment (Heyworth et al., 2008), with the effects lasting until 1 – 3 months 
(Coaccioli et al., 2006; Roux et al., 2007; Schumacher et al., 2004; Stahl et al., 2005). The long 
term effects of hyaluronan were demonstrated only in few studies (Fuchs et al., 2006; 
Heyworth et al., 2008;), in which the pain relief was reported at 6 months (Di Sante et al., 
2011). 
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Authors Patients Age HA Dose Control Follow up HA vs Controls 
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Cohen 30 49 LMW 1x5 wks Saline 6 months No difference 
Karatosun 30 55 LMW 1x3 wks Exercise 12 months No difference 
Salk 17 58 LMW 1x5 wks Saline 6 months No difference 
Table 3. Randomized controlled trials on ankle osteoarthritis. Salk et al. (2006, 2005)  
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Beside pain reduction, also grip strength improved significantly in some studies (Migliore et 
al., 2010), although these effects were achieved slowly, with better results observed at 6 
months (Fuchs et al., 2006; Heyworth et al., 2008; Stahl et al., 2005). 
In our experience (Table 4), a single ultrasound guided injection of hyaluronic acid is 
effective in treatment of carpo – metacarpal osteoarthritis (Salini et al., 2009). After therapy 
the Visual Analogic Scale pain score, both at rest and during common daily activities, 
decreases, while the hand function and strength are improved. The best improvement is 
observed in the pulp pinch strength, because the carpo – metacarpal joint is strongly 
stressed in this movement (Spacek et al., 2004), and therefore a better mobility and a 
reduction of pain in the joint allow evident increase in performance.  
 
 Baseline Follow – up p 
VAS rest 1,8 ± 1 0,5 ± 0,6 < 0.001 
VAS activities 8 ± 0,9 4,1 ± 1,4 < 0.001 
Dreiser Index 18,5 ± 3,3 20,7 ± 2,7 < 0.004 
Hand grip (Kg) 19,3 ± 16,5 19,6 ± 16,1 0.13 
Lateral grip (Kg) 9,5 ± 4 10 ± 3,3 0.17 
Pulp grip (Kg) 4,1 ± 1,4 5,4 ± 1,3 < 0.001 
NSAIDs (n. of subjects) 16 7  
NSAIDs (tablets / week) 2,4 ± 1,9 1,1 ± 1,3 < 0.02 
NSAID =  Non Steroidal Anti – Inflammatory Drug; VAS = Visual Analogic Scale 
Table 4. Positive results of hyaluronic acid on pain and hand function 
7.6 Temporo-mandibular joint 
At present, 19 studies have been published, and only 8 were randomized and controlled 
trials (Manfredini et al., 2010). All studies reported a decrease in pain levels 
independently by the patients’ disorder and by the adopted injection protocol. Positive 
outcomes were maintained over the follow – up period, which ranged largely from 15 
days to 24 months. The superiority of hyaluronic acid injections was shown only against 
placebo saline injections, but outcomes were comparable with those achieved with 
corticosteroid injections. 
Interestingly, in an experimental model of arthropatic temporomandibular joint, El – Hakim 
and Elyamani (El – Hakim & Elyamani 2011) found, after repeated intra – articular injections 
of hyaluronic acid, an increase in the thickness of the cartilagineous layer, suggesting that 
hyaluronic acid can inhibit the progression of osteoarthritic changes. 
A recent study, aiming to identify predictors for treatment efficacy, has shown that only 
unilateral temporomandibular joint osteoarthritis predicts better the benefit  
(Guarda – Nardini et al., 2011), while sex, age, pain duration are not provided of 
predictive power.  
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7.7 Other joints 
Encouraging results have been reported in the treatment of painful hallux rigidus (Pons et 
al., 2007), of sacroiliac joint syndrome (Calvillo et al., 2000; Srejic et al., 1999), and of nerve 
root adhesion after lumbar intervertebral disco herniation (Wang et al., 2002). 
In the treatment of elbow osteoarthritis the results are inconclusive. Positive effects have 
been observed only in two small studies (Fernandez – Palazzi et al., 2002; Hanson, 1999), 
while, in a larger study (18 patients), intra – articular hyaluronic acid was not effective in the 
treatment of post – traumatic osteoarthritis of the elbow (Van Brakel & Eygendaal, 2006). 
Controversial results have been observed also in the treatment of spine osteoarthritis. Fuchs 
et al. (Fuchs et al., 2005) reported significant pain relief and improved quality of life, also in 
the long term, in patients affected from facet joints osteoarthritis with chronic non radicular 
pain in the lumbar spine. However, these results are not in agreement with a recent study by 
Cleary et al. (Cleary et al., 2008), who have not seen any benefit of viscosupplementation in 
the management of symptomatic lumbar facet osteoarthritis. 
8. Side effects 
Several factors may contribute to the occurrence of side effects : among them, the 
characteristics and amount of hyaluronic acid preparation injected, the number of 
injections, the skill of the operator, the technique used, the local and systemic tissues 
reactions. 
In quite all the clinical trials, no general side effects were observed, and only few patients 
reported a sensation of heaviness and pain in their joint after injection (Abate M, 2009). 
These effects were more frequent in studies performed in blind conditions compared to 
those performed under imaging guidance. No differences were observed in relation to 
hyaluronic acid preparation used or to the number of injections (Abate M, 2008).  
Side effects usually disappeared after 2 – 7 days without any therapeutic intervention and 
did not limit basic or instrumental activities of daily living. 
Vascular or nervous complications were never reported, neither gout, chondrocalcinosis, 
sometimes observed after viscosupplementation of the knee (Curran, 2010). 
Septic arthritis or aseptic synovial effusion occurred in a very limited number of cases 
(Brocq et al., 2002; Chazerain et al., 1999). 
9. Hyaluronic acid vs corticosteroids 
Intra – articular corticosteroids are the alternative choice to hyaluronic acid for treatment of 
osteoarthritis. Therefore it is important to evaluate the studies, which compared these 
treatment modalities. The large majority of comparison studies has been performed between 
different hyaluronic acid preparations and steroids (methylprednisolone, triamcinolone) 
(Bellamy et al., 2006). 
In several studies, better results were observed after hyaluronic acid injection (Cohen et al., 
2008; Fuchs et al., 2005, 2006), in other no significant difference was found (Chazerain et al., 
1999; Qvistgaard et al., 2006). Steroids however offered the best results on joints with 
inflammatory effusions (Atchia et al., 2011). 
Only one study compared the clinical efficacy of hyaluronic acid versus corticosteroids and 
placebo in hip osteoarthritis. This very large trial, including 101 patients, did not show 
significant differences between the treatments in all the outcome measures, after 3 months 
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(Qvistgaard et al., 2006). However, within this time period, an improvement was found, 
which resulted clearly evident in the steroid group and moderate in hyaluronic acid group, 
compared to placebo (Qvistgaard et al., 2006). 
A comparison study on the efficacy of Hylan G – F 20 versus 6 – methylprednisolone acetate 
in shoulder osteoarthritis shows that hyaluronic acid is effective in reducing pain for up to 6 
months, whereas corticosteroids injections result in an improvement at 1 month only 
(Merolla et al., 2011). 
Analogously, Bannuru et al. (Bannuru et al., 2009) have shown in the treatment of knee 
osteoarthritis that intra – articular corticosteroids appear to be relatively more effective for 
pain that hyaluronic acid in the first four weeks, but in the long term hyaluronic acid has 
greater efficacy. 
In carpo – metacarpal joint osteoarthritis, a rapid pain relief was observed after 
triamcinolone or methylprednisolone injections (after 2 – 4 weeks), but disappeared soon 
after (Heyworth et al., 2008). Positive effects were achieved with hyaluronic acid more 
slowly, but were long – lasting and persisted 6 months after end of treatment period (Fuchs 
et al., 2006). 
Also for the treatment of temporomandibular joint osteoarthritis, the comparison between 
corticosteroids and hyaluronic acid has shown that both compounds reduce pain and 
improve articular function (Manfredini et al., 2010).  
10. Conclusions 
On the basis of the published trials, we may affirm that viscosupplementation therapy with 
hyaluronic acid is a safe and effective method in the management of osteoarthritis resistant 
to conventional therapies. This treatment has been approved by Food and Drug 
Administration for knee osteoarthritis, whereas for the other osteoarthritic joints there are 
promising results but not conclusive evidence. 
The use of hyaluronic acid is mainly recommended when non steroidal anti – inflammatory 
drugs are contraindicated or badly tolerated, when non steroidal anti – inflammatory drugs 
or corticosteroid are inefficacious, or in young patients candidate to prosthesis. 
Viscosupplementation significantly reduces pain within 3 months and this beneficial effect 
is maintained in the long term (12 – 18 months). The articular function is improved and, 
therefore, patients can rapidly come back to work and to social activities. 
Only few trials have shown a very early improvement, which has been related to the 
lubricating effect of hyaluronate in “dry” joints, as reported in studies of 
viscosupplementation in knee osteoarthritis, and / or to a short term placebo effect (Brocq et 
al., 2002). 
The reduction in non steroidal anti – inflammatory drugs consumption is another 
important clinical achievement with significant health economic consideration 
(Sturkenboom et al., 2002). Not only direct costs (non steroidal anti – inflammatory drugs 
purchasing), but also the indirect costs associated with management of non steroidal anti 
– inflammatory drugs side effects, are saved. Cost – benefit analysis is difficult in 
comparison with corticosteroids. Corticosteroids doses are cheaper than hyaluronic acid 
preparation, but the efficacy of these drugs seems to last less longer than hyaluronic acid 
preparations, with more relevant side effects, which can offset the initial saving 
(Qvistgaard et al., 2006). 
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Patients with mild morphological alterations, and with preserved articular space, are 
more responsive to treatment (Brocq et al., 2002; Gaston et al., 2007; Van den Bekerom et 
al., 2006); the results are less encouraging in patients with severe osteoarthritis (Kellgreen 
– Lawrence IV), only few studies reporting a good therapeutic effects (Migliore et al., 
2006b). 
Articular effusion usually is associated to a reduced therapeutic efficacy due to the “dilution 
effect” of the drug (Qvistgaard et al., 2006). In this situation, a better therapeutic response is 
observed with intra – articular corticosteroids, probably linked to their anti – inflammatory 
activity (Qvistgaard et al., 2006). 
The better biological activity, shown by high molecular weight hyaluronic acid preparations 
in vitro, has not been confirmed in clinical trials (Tikiz et al., 2005). In fact, the percentage of 
improvement in all the outcomes measures is similar with low molecular weight and high 
molecular weight hyaluronic acid preparations (Caglar – Yagchi et al., 2005). An advantage 
of high molecular weight hyaluronic acid may be the reduced number of the injections 
needed to obtain the therapeutic effect. 
When the therapy is delivered by appropriately trained doctors, under strict imaging 
guidance, viscosupplementation is a safe procedure, without any systemic or local side 
effect, excluding the pain of the injection and a sensation of heaviness for few hours / 
days after treatment. It is likely that persistent pain and joint swelling or major 
complications, such as septic arthritis may occur when injection is not properly 
performed. Even experienced clinicians can miss intra – articular placement of the drug, 
especially in small joints (Gaffney et al., 1995; Jones et al., 1993). The very high 
tolerability of the preparation allows the contemporary use of other drugs, which is very 
important in elderly patients with comorbid conditions and poli – pharmaceutical 
treated. 
Although these promising results, several questions are still opened. 
Inclusion and exclusion criteria vary largely in different studies and therefore the 
characteristics of patients, who are better responsive to treatment, are not clearly defined. 
The identification of these patients is, therefore, strongly recommended. 
No consensus exist about the doses of hyaluronic acid, the interval between doses and the 
number of injections, which are more effective in the different clinical situations. A 3 – 5 
doses regimen is usually recommended, but studies which compare different treatment 
schedules are lacking (Tikiz et al., 2005).  
It is also debated whether high molecular weight hyaluronic acid has to be preferred to low 
molecular weight hyaluronic acid. The better biological activity, showed by high molecular 
weight hyaluronic acid preparations in vitro, has not been confirmed in clinical trials (Tikiz 
et al., 2005). Some authors prefer to use high molecular weight hyaluronic acid because 
these preparations have a longer half – life time, so that the number of the injections needed 
to obtain the therapeutic effect may be reduced. 
Interpretation of result is made difficult by the different degree of severity of osteoarthritis, 
genetic and biological characteristics of patients enrolled in the studies and by concurrent 
therapies with other drugs and rehabilitation treatments (Brocq et al., 2002; Conrozier et al., 
2003; Migliore et al., 2003; Tikiz et al., 2005; Vad et al., 2003). 
Finally, it must be remembered that there is a strong placebo effect from joint injection, 
which may cause a nearly 30 % reduction in pain relief during the first 2 weeks (Brocq et al., 
2002; Egsmose et al., 1984; Kirwan, 2001; Ravaud et al., 1999; Tikiz et al., 2005). 
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performed. Even experienced clinicians can miss intra – articular placement of the drug, 
especially in small joints (Gaffney et al., 1995; Jones et al., 1993). The very high 
tolerability of the preparation allows the contemporary use of other drugs, which is very 
important in elderly patients with comorbid conditions and poli – pharmaceutical 
treated. 
Although these promising results, several questions are still opened. 
Inclusion and exclusion criteria vary largely in different studies and therefore the 
characteristics of patients, who are better responsive to treatment, are not clearly defined. 
The identification of these patients is, therefore, strongly recommended. 
No consensus exist about the doses of hyaluronic acid, the interval between doses and the 
number of injections, which are more effective in the different clinical situations. A 3 – 5 
doses regimen is usually recommended, but studies which compare different treatment 
schedules are lacking (Tikiz et al., 2005).  
It is also debated whether high molecular weight hyaluronic acid has to be preferred to low 
molecular weight hyaluronic acid. The better biological activity, showed by high molecular 
weight hyaluronic acid preparations in vitro, has not been confirmed in clinical trials (Tikiz 
et al., 2005). Some authors prefer to use high molecular weight hyaluronic acid because 
these preparations have a longer half – life time, so that the number of the injections needed 
to obtain the therapeutic effect may be reduced. 
Interpretation of result is made difficult by the different degree of severity of osteoarthritis, 
genetic and biological characteristics of patients enrolled in the studies and by concurrent 
therapies with other drugs and rehabilitation treatments (Brocq et al., 2002; Conrozier et al., 
2003; Migliore et al., 2003; Tikiz et al., 2005; Vad et al., 2003). 
Finally, it must be remembered that there is a strong placebo effect from joint injection, 
which may cause a nearly 30 % reduction in pain relief during the first 2 weeks (Brocq et al., 
2002; Egsmose et al., 1984; Kirwan, 2001; Ravaud et al., 1999; Tikiz et al., 2005). 
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1. Introduction 
Articular cartilage has a reduced capacity for self-regeneration. Delivery of candidate genes to 
articular chondrocytes is an attractive strategy that has the potential to allow for a durable 
reestablishment of the structural integrity in osteoarthritic (OA) cartilage. Gene transfer 
approaches might be better suited to treat a slow and irreversible disorder such as OA over 
time instead of systems that are based on the application of recombinant factors with relatively 
short pharmacological half-lives. Current approaches that aim at re-equilibrating the metabolic 
balance in OA cartilage are based on the transfer of sequences coding for agents that either 
counteract the processes of matrix degradation or enhance the synthesis of matrix components. 
Importantly for the treatment of OA, the development of effective gene treatments will 
necessitate that the gene vehicle chosen allows for high and also sustained levels of expression 
of the sequence to be delivered due to the slow and irreversible progression of this disorder. 
The method elected to administer the therapeutic composition will be also important to 
achieve successful and long-term cartilage regeneration in OA patients. 
2. Gene therapy 
Gene therapy aims at treating human diseases via gene transfer techniques that introduce 
foreign genes or sequences in various cell types. The foreign material enters the cell where it 
is transferred towards the nucleus. Once there, it either integrates in the host genome or 
stays extrachromosomal under episomal forms that generally allows only for transient 
transgene expression. Gene transfer in sufficient number of cells is essential to allow for the 
production of therapeutically relevant concentrations of transgene products. The currently 
most employed vectors used in gene therapy trials include nonviral compounds (naked 
DNA, physical and chemical methods) and different viral gene carriers including 
adenoviral, herpes simplex virus-derived, retroviral, lentiviral, and recombinant adeno-
associated viral vectors that utilize natural entry pathways in human cells (Cucchiarini et al., 
2009a; Cucchiarini & Madry, 2005; Evans, 2004; Evans et al., 2004) (Table 1). 
2.1 Nonviral vectors 
Chemical methods of complexing DNA to various macromolecules include cationic lipids 
and liposomes, polymers, polyamines and polyethylenimines, and nanoparticles, besides 
the use of calcium phosphate coprecipitates. Nonviral methods avoid the risk of acquiring 
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replication competence inherent to viral vectors. They can be repeatedly administered, have 
the capacity to deliver large therapeutic genes, and are easy to produce on a large scale. 
Also, they do not elicit immune responses in the host organism. Still, their efficacy is often 
much lower than those of viral vectors. In addition, as the transgenes remain as episomes in 
their targets, only short-term transgene expression is achievable. To overcome these 
shortcomings, nonviral gene transfer strategies in vivo are generally based on the use of ex 
vivo-modified cells for readministration in sites of damage. 
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Table 1. Gene Transfer Vectors. 
2.2 Adenoviral vectors 
Adenoviruses have been among the most employed systems so far. They allow for high 
transduction efficiencies and transgene expression in a variety of cells, allowing for direct 
approaches in vivo. Yet, there are serious concerns about their safe use in the clinics due to 
the development of strong host immune responses to the remaining adenoviral gene 
products. Another problem is the limited period of transgene expression (1-2 weeks) as the 
sequences delivered remain as episomes that are cleared shortly after being introduced in 
the cells. 
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2.3 Retroviral vectors 
An advantage of these viruses is their ability to integrate in the host genome, allowing for 
the maintenance of the transgene over extended periods of time. Nevertheless, this might 
lead to insertional mutagenesis and a potential to activate tumorigenic sequences. Also, such 
vectors transduce only dividing cells with a restricted host range (and a low efficacy) and 
are only produce at relatively low concentrations. Therefore, ex vivo approaches with pre-
selection of transduced cells are usually employed. Interestingly, lentiviral vectors, a 
subclass of retroviruses derived from the human immunodeficiency virus (HIV) that 
integrate in the genome of nondividing cells avoid the need for cell division and show 
higher levels of transduction in vivo. Nevertheless, there are still concerns associated with 
their application, including the potential for insertional mutagenesis and the psychological 
problem of introducing genetic material carrying HIV sequences. 
2.4 Herpes simplex viral vectors (HSV) 
HSV-derived vectors are large vehicles that can deliver large transgenes to almost all known 
cell types, including nondividing cells. Although first-generation vectors induced high 
levels of cytoxicity, recent work has demonstrated that second-generation HSV were less 
deleterious, in particular for cartilage gene transfer. One problem remains the transient 
nature of transgene expression mediated by this family of vectors. 
2.5 Recombinant adeno-associated viral vectors (rAAV) 
Application of viral vectors raises additional safety concerns, as potentially infectious 
agents or sequences might be introduced per se in the body. This is particularly important 
for the treatment of OA as it is not a life-threatening disorder. In this regard, rAAV 
vectors based on the nonpathogenic, replication-defective human parvovirus AAV might 
be more adequate for gene therapy settings. rAAV are produced by complete removal of 
the viral gene coding sequences, making them less immunogenic than adenoviral vectors 
and less toxic than HSV. Also, rAAV can be transcribed in their targets at very high 
efficiencies for months to years due to the stabilization of the episomal transgene cassettes 
by concatemer formation, making them strong alternatives for direct gene transfer 
approaches in vivo. Cell division and integration are not required for expression of the 
foreign material delivered via rAAV, in marked contrast with retroviral vectors. Redosing 
of vectors is practicable with rAAV, based on the use of various serotypes of the virus. For 
these reasons, rAAV became a preferred gene transfer method for experimental settings in 
vivo and for clinical applications. 
3. Osteoarthritis 
3.1 Articular cartilage 
Adult hyaline articular cartilage is an avascular and aneural tissue that does not possess a 
lymphatic drainage that allows for a smooth gliding of the articulating surfaces of a joint 
and protects the subchondral bone from mechanical stress. Hyaline articular cartilage has 
several laminar zones formed by chondrocytes surrounded by an intricate network of 
extracellular matrix rich in proteoglycans and collagen fibrils (mostly type-II collagen and 
also types type-VI, -IX, -XI, and -XIV collagens and additional macromolecules). Normal 
hyaline articular cartilage contains about 70-80% water bound to proteoglycans. The 
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lymphatic drainage that allows for a smooth gliding of the articulating surfaces of a joint 
and protects the subchondral bone from mechanical stress. Hyaline articular cartilage has 
several laminar zones formed by chondrocytes surrounded by an intricate network of 
extracellular matrix rich in proteoglycans and collagen fibrils (mostly type-II collagen and 
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chondrocytes regulate the structural and functional properties of the cartilage according to 
the applied loads by producing and degrading the extracellular matrix. 
3.2 Osteoarthritis 
Osteoarthritis (OA) is the most disabling condition and prevalent form of arthritis (80%). 
OA is a chronic disorder of diarthrodial joints, mainly characterized by a slow, progressive, 
and irreversible deterioration of the articular cartilage, with changes in the subchondral 
bone. OA also affects to a minor degree the synovial lining, ligaments, tendons, and 
muscles. 
OA is a complex disorder characterized by the activation of inflammatory cascades and 
alterations of the chondrocyte phenotype, leading ultimately to cartilage breakdown (loss of 
the major components of the cartilage matrix). Under mechanical or biochemical stress 
(interleukin-1, i.e. IL-1; tumor necrosis factor alpha, i.e. TNF-α; nitric oxide, i.e. NO, 
prostaglandins, matrix degradation products), the cells undergo pathological changes in 
gene expression patterns that impede the whole homeostasis: diminished production of 
matrix molecules, enhanced production of matrix-degrading enzymes (matrix 
metalloproteinases, i.e. MMPs; adamalysins), decreased responsiveness to reparative 
stimuli, degradation of the matrix, alteration of the cell viability, cell senescence with 
apoptosis (NO; Fas/FasL signaling). 
Several nonsurgical options are available to manage the progression of OA, including 
pharmacological treatments such as nonsteroidal anti-inflammatory drugs (NSAIDs), slow-
acting drugs in OA (SADOAs) like glucosamine, chondroitin sulfate, and diacerin, being 
either symptomatic slow-acting drugs in OA (SYSADOAs) or disease-modifying OA drugs 
(DMOADs). However, there is no convincing evidence yet that such drugs indeed modify or 
inhibit the progression of OA. Surgical interventions such as débridement, marrow 
stimulation, and osteotomy are specifically indicated in early stages of OA. Yet, restoration 
of a native cartilage that is identical in its structure to the normal cartilage and capable of 
withstanding mechanical stresses over time in OA has not been achieved to date. Causative 
treatment for OA therefore remains a problem, particularly troublesome for patients that are 
too young to undergo endoprosthetic joint replacement. 
4. Osteoarthritis gene therapy 
4.1 Target cells in OA – Gene transfer in vitro 
Target cells in the OA joint include: 
1. chondrocytes, 
2. osteocytes, 
3. cells of the synovial lining, 
4. progenitor cells, or 
5. cells of surrounding tissues (muscle, tendons, ligaments, meniscus). 
Application of nonviral (Gerich et al., 1997b; Grossin et al., 2006; Kaul et al., 2006; Madry 
et al., 2004b; Madry et al., 2005; Madry et al., 2001; Nita et al., 1996; Tsuchiya et al., 2003; 
Zhang, H. N. et al., 2009), adenoviral (Baragi et al., 1995; Brower-Toland et al., 2001; Gelse 
et al., 2001; Gerich et al., 1997a; Gerich et al., 1996; Gerich et al., 1997b; Goto et al., 1999; 
Haupt et al., 2005; Ikeda et al., 2004; Li et al., 2004; Lou et al., 1997; Mehrara et al., 1999; 
Musgrave et al., 2002; Nita et al., 1996; Nixon et al., 2000; Nixon et al., 2005; Saxer et al., 
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 2001; Shuler et al., 2000; Smith et al., 2000; Steinert et al., 2007; Steinert et al., 2009; 
Steinert et al., 2008), or retroviral vectors (Baltzer et al., 1999; Gerich et al., 1997a; Gerich et 
al., 1996; Gerich et al., 1997b; Goto et al., 2000; Gouze, J. N. et al., 2003; Hildebrand et al., 
1999; Li et al., 2004; Mason et al., 2000; Nita et al., 1996; Piera-Velazquez et al., 2002; 
Roessler et al., 1995; Tew et al., 2005) has been achieved in such cells with more or less 
success. rAAV are potent alternatives as they efficiently and durably transduce 
synoviocytes (Adriaansen et al., 2007; Apparailly et al., 2002; Goater et al., 2000; Goodrich 
et al., 2009; Hiraide et al., 2005; Traister et al., 2006; Zhang, H. G. et al., 2000), 
chondrocytes (Arai et al., 2000; Cucchiarini et al., 2005; Cucchiarini et al., 2009c; 
Cucchiarini et al., 2007; Dai & Rabie, 2007; Goodrich et al., 2009; Madry et al., 2003; Ulrich-
Vinther et al., 2002; Ulrich-Vinther et al., 2005; Yokoo et al., 2005), mesenchymal stem cells 
(MSCs) (Chamberlain et al., 2008; Chamberlain et al., 2004; Chen, M. et al., 2011; 
Cucchiarini et al., 2011; Cucchiarini et al., 2005; Dai & Rabie, 2007; Ito et al., 2004; Kim, S. 
J. et al., 2007; Pagnotto et al., 2007; Shi & Wang, 2010; Stender et al., 2007), and other cell 
types relevant of the pathogenesis of OA (Arsic et al., 2004; Basile et al., 2008; Cucchiarini 
et al., 2009b; Gerich et al., 1997a; Gerich et al., 1997b; Ito et al., 2005; Kessler et al., 1996; 
Luk et al., 2003; Madry et al., 2004a; Tang et al., 2008; Wang et al., 2007; Wang et al., 2005). 
Regeneration of a native (structural and functional) cartilage architecture might be achieved 
by: 
1. inhibiting inflammatory and catabolic pathways, 
2. stimulating anabolic pathways to rebuild the matrix, 
3. impeding cell senescence, 
4. avoiding the pathological formation of osteophytes, 
5. prevention of apoptosis, and/or 
6. influencing several of these processes. 
Inhibition of catabolic pathways has been observed when expressing inhibitors of matrix-
degrading enzymes (tissue inhibitor of MMPs, i.e. TIMP) (Kafienah et al., 2003), inhibitors of 
proinflammatory cytokines (IL-1Ra; the soluble receptors sIL-1R or sTNFR) (Attur et al., 
2002; Baragi et al., 1995; Gouze, J. N. et al., 2003; Haupt et al., 2005; Roessler et al., 1995; 
Zhang, H. G. et al., 2000; Zhang, X. et al., 2006), and chondroprotective cytokines (IL-4; IL-
10) (Kim, S. H. et al., 2001; Zhang, X. et al., 2006). Activation of anabolic processes has been 
noted by single or combined administration of components of the cartilage matrix or of the 
enzymes that synthesize them (Dharmavaram et al., 1999; Venkatesan et al., 2004), of growth 
factors and receptors (insulin-like growth factor I, i.e. IGF-I; fibroblast growth factor 2, i.e. 
FGF-2; bone morphogenetic proteins, i.e. BMPs; transforming growth factor beta, i.e. TGF-β) 
(Brower-Toland et al., 2001; Chen, B. et al., 2010; Cucchiarini et al., 2011; Cucchiarini et al., 
2005; Cucchiarini et al., 2009c; Haupt et al., 2005; Lee et al., 2005; Madry et al., 2004b; Madry 
et al., 2001; Nixon et al., 2000; Nixon et al., 2005; Saxer et al., 2001; Schmal et al., 2005; Shuler 
et al., 2000; Smith et al., 2000; Ulrich-Vinther et al., 2005), and of transcription factors (SOX 
family of DNA-binding proteins, i.e. SOX5, SOX6, SOX9) (Cucchiarini et al., 2007; Ikeda et 
al., 2004; Li et al., 2004; Tew et al., 2005; Tsuchiya et al., 2003). Restoration of cell vitality and 
activation of proliferation have been achieved by application of IGF-I or FGF-2 (Cucchiarini 
et al., 2011; Cucchiarini et al., 2005; Cucchiarini et al., 2009c; Kaul et al., 2006; Madry et al., 
2004b; Madry et al., 2001; Schmal et al., 2005), telomerase (hTERT) (Piera-Velazquez et al., 
2002), of inhibitors of apoptosis (bcl-2) (Surendran et al., 2006), or of the heat shock protein 
70 (HSP70) (Grossin et al., 2006). Remarkably, approaches that influence several of these 
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OA is a chronic disorder of diarthrodial joints, mainly characterized by a slow, progressive, 
and irreversible deterioration of the articular cartilage, with changes in the subchondral 
bone. OA also affects to a minor degree the synovial lining, ligaments, tendons, and 
muscles. 
OA is a complex disorder characterized by the activation of inflammatory cascades and 
alterations of the chondrocyte phenotype, leading ultimately to cartilage breakdown (loss of 
the major components of the cartilage matrix). Under mechanical or biochemical stress 
(interleukin-1, i.e. IL-1; tumor necrosis factor alpha, i.e. TNF-α; nitric oxide, i.e. NO, 
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gene expression patterns that impede the whole homeostasis: diminished production of 
matrix molecules, enhanced production of matrix-degrading enzymes (matrix 
metalloproteinases, i.e. MMPs; adamalysins), decreased responsiveness to reparative 
stimuli, degradation of the matrix, alteration of the cell viability, cell senescence with 
apoptosis (NO; Fas/FasL signaling). 
Several nonsurgical options are available to manage the progression of OA, including 
pharmacological treatments such as nonsteroidal anti-inflammatory drugs (NSAIDs), slow-
acting drugs in OA (SADOAs) like glucosamine, chondroitin sulfate, and diacerin, being 
either symptomatic slow-acting drugs in OA (SYSADOAs) or disease-modifying OA drugs 
(DMOADs). However, there is no convincing evidence yet that such drugs indeed modify or 
inhibit the progression of OA. Surgical interventions such as débridement, marrow 
stimulation, and osteotomy are specifically indicated in early stages of OA. Yet, restoration 
of a native cartilage that is identical in its structure to the normal cartilage and capable of 
withstanding mechanical stresses over time in OA has not been achieved to date. Causative 
treatment for OA therefore remains a problem, particularly troublesome for patients that are 
too young to undergo endoprosthetic joint replacement. 
4. Osteoarthritis gene therapy 
4.1 Target cells in OA – Gene transfer in vitro 
Target cells in the OA joint include: 
1. chondrocytes, 
2. osteocytes, 
3. cells of the synovial lining, 
4. progenitor cells, or 
5. cells of surrounding tissues (muscle, tendons, ligaments, meniscus). 
Application of nonviral (Gerich et al., 1997b; Grossin et al., 2006; Kaul et al., 2006; Madry 
et al., 2004b; Madry et al., 2005; Madry et al., 2001; Nita et al., 1996; Tsuchiya et al., 2003; 
Zhang, H. N. et al., 2009), adenoviral (Baragi et al., 1995; Brower-Toland et al., 2001; Gelse 
et al., 2001; Gerich et al., 1997a; Gerich et al., 1996; Gerich et al., 1997b; Goto et al., 1999; 
Haupt et al., 2005; Ikeda et al., 2004; Li et al., 2004; Lou et al., 1997; Mehrara et al., 1999; 
Musgrave et al., 2002; Nita et al., 1996; Nixon et al., 2000; Nixon et al., 2005; Saxer et al., 
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 2001; Shuler et al., 2000; Smith et al., 2000; Steinert et al., 2007; Steinert et al., 2009; 
Steinert et al., 2008), or retroviral vectors (Baltzer et al., 1999; Gerich et al., 1997a; Gerich et 
al., 1996; Gerich et al., 1997b; Goto et al., 2000; Gouze, J. N. et al., 2003; Hildebrand et al., 
1999; Li et al., 2004; Mason et al., 2000; Nita et al., 1996; Piera-Velazquez et al., 2002; 
Roessler et al., 1995; Tew et al., 2005) has been achieved in such cells with more or less 
success. rAAV are potent alternatives as they efficiently and durably transduce 
synoviocytes (Adriaansen et al., 2007; Apparailly et al., 2002; Goater et al., 2000; Goodrich 
et al., 2009; Hiraide et al., 2005; Traister et al., 2006; Zhang, H. G. et al., 2000), 
chondrocytes (Arai et al., 2000; Cucchiarini et al., 2005; Cucchiarini et al., 2009c; 
Cucchiarini et al., 2007; Dai & Rabie, 2007; Goodrich et al., 2009; Madry et al., 2003; Ulrich-
Vinther et al., 2002; Ulrich-Vinther et al., 2005; Yokoo et al., 2005), mesenchymal stem cells 
(MSCs) (Chamberlain et al., 2008; Chamberlain et al., 2004; Chen, M. et al., 2011; 
Cucchiarini et al., 2011; Cucchiarini et al., 2005; Dai & Rabie, 2007; Ito et al., 2004; Kim, S. 
J. et al., 2007; Pagnotto et al., 2007; Shi & Wang, 2010; Stender et al., 2007), and other cell 
types relevant of the pathogenesis of OA (Arsic et al., 2004; Basile et al., 2008; Cucchiarini 
et al., 2009b; Gerich et al., 1997a; Gerich et al., 1997b; Ito et al., 2005; Kessler et al., 1996; 
Luk et al., 2003; Madry et al., 2004a; Tang et al., 2008; Wang et al., 2007; Wang et al., 2005). 
Regeneration of a native (structural and functional) cartilage architecture might be achieved 
by: 
1. inhibiting inflammatory and catabolic pathways, 
2. stimulating anabolic pathways to rebuild the matrix, 
3. impeding cell senescence, 
4. avoiding the pathological formation of osteophytes, 
5. prevention of apoptosis, and/or 
6. influencing several of these processes. 
Inhibition of catabolic pathways has been observed when expressing inhibitors of matrix-
degrading enzymes (tissue inhibitor of MMPs, i.e. TIMP) (Kafienah et al., 2003), inhibitors of 
proinflammatory cytokines (IL-1Ra; the soluble receptors sIL-1R or sTNFR) (Attur et al., 
2002; Baragi et al., 1995; Gouze, J. N. et al., 2003; Haupt et al., 2005; Roessler et al., 1995; 
Zhang, H. G. et al., 2000; Zhang, X. et al., 2006), and chondroprotective cytokines (IL-4; IL-
10) (Kim, S. H. et al., 2001; Zhang, X. et al., 2006). Activation of anabolic processes has been 
noted by single or combined administration of components of the cartilage matrix or of the 
enzymes that synthesize them (Dharmavaram et al., 1999; Venkatesan et al., 2004), of growth 
factors and receptors (insulin-like growth factor I, i.e. IGF-I; fibroblast growth factor 2, i.e. 
FGF-2; bone morphogenetic proteins, i.e. BMPs; transforming growth factor beta, i.e. TGF-β) 
(Brower-Toland et al., 2001; Chen, B. et al., 2010; Cucchiarini et al., 2011; Cucchiarini et al., 
2005; Cucchiarini et al., 2009c; Haupt et al., 2005; Lee et al., 2005; Madry et al., 2004b; Madry 
et al., 2001; Nixon et al., 2000; Nixon et al., 2005; Saxer et al., 2001; Schmal et al., 2005; Shuler 
et al., 2000; Smith et al., 2000; Ulrich-Vinther et al., 2005), and of transcription factors (SOX 
family of DNA-binding proteins, i.e. SOX5, SOX6, SOX9) (Cucchiarini et al., 2007; Ikeda et 
al., 2004; Li et al., 2004; Tew et al., 2005; Tsuchiya et al., 2003). Restoration of cell vitality and 
activation of proliferation have been achieved by application of IGF-I or FGF-2 (Cucchiarini 
et al., 2011; Cucchiarini et al., 2005; Cucchiarini et al., 2009c; Kaul et al., 2006; Madry et al., 
2004b; Madry et al., 2001; Schmal et al., 2005), telomerase (hTERT) (Piera-Velazquez et al., 
2002), of inhibitors of apoptosis (bcl-2) (Surendran et al., 2006), or of the heat shock protein 
70 (HSP70) (Grossin et al., 2006). Remarkably, approaches that influence several of these 
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processes have been also successfully attempted, like combining the transfer of inhibitors of 
catabolism pathways and of activators of anabolic events (IGF-I/IL-1Ra) (Haupt et al., 2005; 
Nixon et al., 2005), as well as that of activators of anabolic and proliferative processes (FGF-
2/SOX9 or FGF-2/IGF-I) (Cucchiarini et al., 2009c; Orth et al., 2011). 
4.2 Gene transfer in vivo 
4.2.1 Direct gene transfer 
The key issue in establishing an efficient therapy against OA is to access the targets of the 
treatment when the cells reside in the joint cavity. The following approaches have been 
therefore developed: 
1. systemic delivery and 
2. intraarticular administration: 
2.1 by injection or 
2.2 using arthrotomy 
Systemic approaches are better suited to target diseases that are systemic in nature like 
rheumatoid arthritis (RA) (Evans et al., 2006b, 2009; Jorgensen & Apparailly, 2010). 
Local administration of components might be preferable for OA that affects only a limited 
number of joints without major systemic manifestations. Intraarticular injection of most 
vector types preferentially transduce the synovium (Ghivizzani et al., 1997; Gouze, E. et al., 
2002; Nita et al., 1996; Roessler et al., 1993), being rather suited for strategies aiming at 
inhibiting inflammatory and catabolic pathways (and a common approach employed 
against experimental RA). Direct application of gene vectors has been attempted in 
experimental OA using sequences coding for IL-1Ra (Fernandes et al., 1999; Frisbie et al., 
2002; Frisbie & McIlwraith, 2000; Zhang, X. et al., 2006), IL-10 (Zhang, X. et al., 2006), HSP70 
(Grossin et al., 2006), gene silencers (Chen, L. X. et al., 2008), or kallistatin and 
thrombospondin-1 (Hsieh et al., 2009; Hsieh et al., 2010). Yet, even if cartilage breakdown is 
contained, this may not be sufficient to fully compensate for the loss of matrix elements and 
cells noted during the disease progression. In this regard, synthesis of cartilage matrix 
components might be stimulated by providing vectors carrying genes for anabolic factors 
(FGF-2, IGF-I) (Chen, B. et al., 2010). 
4.2.2 Indirect gene transfer 
Ex vivo gene therapy is more complex but safer as no free vector particles are introduced in 
the body. Also, modified cells can be controlled, tested, and selected in culture. 
Administration of cells is also a means to increase the cellularity like needed for cases of 
severe OA. 
Synoviocytes have been mostly employed to deliver inhibitors of inflammatory and 
catabolic processes (Pelletier et al., 1997; Zhang, X. et al., 2004). Such pathways were 
regulated by injecting cells overexpressing an IL-1Ra alone (Pelletier et al., 1997; Zhang, X. et 
al., 2004) or with IL-10 (Zhang, X. et al., 2004). Again, although OA was reduced in 
association with decreased cartilage breakdown, complete resurfacing was not reported. 
Nevertheless, the use of differentiated cells is impaired by the invasive methods of 
preparation from unaffected sites with a limited supply and by common changes in cell 
phenotype observed upon passaging in culture. Also, implantation of committed cells 
generally leads to the formation of a poorly differentiated (fibrous) cartilage. Progenitor cells 
might be better suited to generate a cartilage of enhanced quality in transplantation settings. 
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They can be easily isolated from multiple tissues (bone marrow, periosteum, 
perichondrium, muscle, fat, subdermis, cartilage, bone, synovial membrane, ligaments), 
even in OA patients, maintaining a multilineage potential with a reliability for 
differentiation and a capacity for expansion (Barry & Murphy, 2004; Yoo et al., 2000). 
Remarkably, injection of muscle-derived stem cells modified by combined gene transfer of 
BMP-4 with sFlt1 (an antagonist of the vascular endothelial growth factor, i.e. VEGF) 
allowed for cartilage repair in a rat model of OA (Matsumoto et al., 2009). 
5. Clinical trials 
Preclinical data, as those described above, have encouraged the initiation of human clinical 
trials mostly for RA. The first studies were based on retroviral gene transfer of human IL-
1Ra in synoviocytes from RA patients and reinjection in the metacarpophalangeal joint 
(Evans et al., 2000a; Evans et al., 1996; Wehling et al., 2009). Transgene expression was noted 
locally without adverse events, leading to clinical improvements in some patients, 
encouraging the implementation of phase II studies (Evans, 2005; Evans et al., 2005a; Evans 
et al., 2000b; Evans et al., 2006a, 2008; Evans et al., 2004; Evans et al., 2005b; Robbins et al., 
2003). Direct intraarticular injection of rAAV carrying an sTNFR-immunoglobulin in RA 
patients revealed that the treatment was safe and well tolerated (Evans, 2005; Evans et al., 
2005a; Evans et al., 2006a, 2008; Mease et al., 2009), and a phase I/II trial was subsequently 
started. Regarding OA, a phase I protocol is ongoing, based on an ex vivo approach using the 
retroviral transfer of TGF-β (Evans et al., 2008). 
6. Conclusions 
Gene therapy holds great promise, but issues that need to be addressed include the duration 
of transgene expression, extended analyses in clinically relevant animal models, the benefit 
of ex vivo genetically modified cells versus direct approaches, and the identification of 
optimal therapeutic factors. Future studies will also have to shed light on the safety of these 
approaches regarding the nonlethal nature of OA. Successful application of gene therapy for 
OA requires a combined effort of surgeons and basic scientists in order to improve the 
currently available gene transfer systems. 
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1. Introduction 
Osteoarthritis is a group of disorders with different etiologies, but similar pathophysiologic 
changes. In primary osteoarthritis, it is believed that excessive loading cause failure of an 
otherwise normal joint (Brandt, 1996). The changes eventually involve all of the previously 
named joint tissues. In particular, the cartilage undergoes breakdown early on, especially in 
its central areas. Histologically, small tears known as fibrillations and larger tears known as 
clefts both develop. These defects begin in the superficial zone of cartilage, extend into the 
transitional zone, and are also propagated by enzymatic breakdown of cartilage. Eventually, 
large areas of cartilage loss occur, thus essentially exposing the underlying subchondral 
bone. Other changes within the cartilage include an eventual decline in the ability of the 
chondrocytes to replicate, an initial increase in the water content of cartilage, a significant 
reduction in proteoglycan content, a reduction in the size of type II collagen fibers,  a 
diminution of the keratin sulfate concentration, and an increase in the proportion of 
chondroitin-4-sulfate, consistent with immature cartilage being produced in an attempt to 
regenerate lost cartilage (Erlich at al, 1996).  
Pathogenesis of OA is closely linked to pathogenesis of cartilage degradation. (Maddison, 1998) 
Oxidative stress, defined as the imbalance between the production and degradation of ROS, is 
considered to play an important role in mechanism of cartilage degradation. Peroxidation of 
lipids, spontaneous or catalyzed by metals (iron, copper), and self-maintained by self-catalysis, 
generates the production of the reactive species of oxygen (ROS). The ROS are aggressive to 
cells and to macromolecules of cartilage. The ROS produce negative effects inducing oxidation, 
damage of membranes, modification of proteins and DNA. (Maddison, 1998)  
It’s well known that ROS have both positive effects – being involved in energy production, 
phagocytosis, regulation of cellular growth and intercellular signaling, synthesis of some 
biologically active compounds – and negative effects, initially altering membrane’s lipids, 
tissues proteins, enzymes, carbohydrates and DNA, and finally having a determinant role in 
the aging process, which characterizes degenerative diseases. Prostaglandins generated by 
inflammatory reactions contribute to this aggressive phenomenon by hyper activation of 
macrophages, which generates ROS. (Curcă, 2003-2004) 
The cytokines and growth factors produced as part of the changes that occur in OA can have 
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are prime candidates for intervention. How important they are in cartilage pathology 
remains to be more clearly established in human studies, although a mouse “knockout” 
approach points to the importance of IL-1α and IL-6 in cartilage and bone damage. A recent 
study using the Pond-Nuki dog model of OA has demonstrated that Tenidap (Pfizer Central 
Research, Groton, CT, USA), a cytokine-modulating drug, can significantly reduce cartilage 
damage and osteophyte formation, while simultaneously inhibiting the synthesis of IL-1 and 
the activity of collagenase-1 and stromelysin-1. (Pool and Webb as cited in Tsokos, 2000) 
Certain factors are supposed to have a protective role in the mechanism of cartilage 
degradation. Superoxide dismutase (SOD), for example, is an enzyme which can be found in 
different tissues and in the vascular wall. SOD catalyzes superoxide radicals in a 
neutralization reaction and protects nitrogen monoxide (NO) against inactivation. In the 
presence of high concentrations of oxygen there is an acceleration of the SOD biosynthesis 
(Olinescu, 1994). SOD participates directly and indirectly to remove excess of superoxide 
ions, by inhibiting singlet oxygen and so prevents peroxidation of unsaturated free fatty 
acids (Salo, 1990). SOD controls the superoxide anions level, thus preventing initiation of the 
formation reaction of harmful hydroxyl radicals and peroxinitrite (as a result of the reaction 
between superoxide anions and NO) (Fredovich, 1978).  
It was found that certain cytokines, as TNF, or certain lypocarbohydrates, known as 
stimulating agents of intracellular production of ROS, are also involved in some ROS 
inactivating mechanisms, from this resulting a fragile balance between production and 
destruction of ROS. Thus, through an induction mechanism, TNF can stimulate 
transcription of the Mn-SOD gene. (Pool et. al., 1995) 
Gluthatione reductase (GR) is essential for redox cycle of glutathione, which maintains 
appropriate levels of cellular reduced glutathione. Oxidized glutathione is reduced through 
a sequence of reactions. (Goldberg & Spooner, 1983) G-SH is a capital factor in the 
detoxification of the free radicals, resulted from metabolism or from self-oxidation of 
polyunsaturated fatty acids in the cell membrane. Glutathione peroxidase reduces hydro-
peroxide (H2O2) in the presence of G-SH. (Roşoiu & Verman, 2008)  
Reduced glutathione (G-SH) is one of the most important antioxidants from cells, a central 
component of adaptative system, very sofisticated. (Kidd, 1997) Glutathione exists in the cells 
both as reduced form (G-SH) and as oxidized form (GSSG), first one being predominant 
(oxidized form represents less than 10% from total glutathione). (Kosower, 1978) 
G-SH is involved in multiple reactions and processes, is an ideal compound for mantaining 
intracellular redox potential (Meister, 1994). This involvement is due to the reactivity of –SH 
group. Unlike –SH groups of other enzymes, which are protected by a polypeptidic chain, 
those from G-SH or cysteine (thyols with low molecular weight) represent „first” target for 
free radicals. 
G-SH can conjugate NO, forming S-nitroso-glutathione, which is cleaved by tioredoxine 
system, releasing G-SH and NO. Through its interaction with glutaredoxine and tioredoxine 
(thyol-proteins), G-SH is playing an important role in regulation of cellular redox 
homeostasis (Yun-Zhong Fang et al., 2002). 
Inside the protective antioxidant mechanism (Wang et al., 1998), G-SH is the substrate for 
glutathione peroxidase (is used to reduce hydrogen and organic peroxides to water and 
alcohol), it combines with toxic exogenous and endogenous compounds, reducing disulfidic 
bridges of the proteins and other molecules and, thus, it mantains reduced state of 
antioxidative enzymes, glycolitic enzymes and redox status of cells (as a major source of 
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thyols), depositing and functioning as transport mean for cysteine. G-SH-transhydrogenases 
are using reduced glutathione as cofactor for reconvert dehydroascorbate to ascorbate, 
ribonucleotides to deoxyribonucleotides, etc. G-SH is an efficient detoxifier of ROS (lipidic 
peroxil radicals, peroxinitrite and hydrogen peroxide), both on direct way and indirect 
through enzymatic reactions. (Meister, 1991) 
Because of its significant reducing potential, G-SH probably contributes to recycle other 
antioxidants (which were oxidized), as α-tocopherol and carotenoids. (Meister, 1994, 1995) 
In physiological conditions blood glucose can reduce molecular oxygen, releasing 
superoxide ions in the presence of traces of trasition metals (Fe, Cu) and forming 
cetoaldehides and intermediate oxidation products. Production of free radicals and H2O2 
after self-oxidation process of glucose can determine structural changes of proteins exposed 
to glucose in vitro.  
It has been found that harmful effect due to glucose exposure of albumin is inhibited by 
catalase, antioxidant defense enzyme, and also by metals chelating agents. It has been 
suggested that glycosylation and oxidation of proteins are correlated processes, change of 
the proteins due to glycosylation being associated with peroxidation. 
Uric acid is a substance easy to be oxidized and, due to its capacity to capture free radicals, 
is considered protective factor against continous oxidative aggression to which are exposed 
majority of body tissues. 
“In vitro” experiments showed that uric acid and some purines capture ROS, playing a role 
in inhibition of peroxidation of polyunsaturated fatty acids, in protection of red blood cells 
against singlet oxygen attack, in protection of hemoglobin against oxidative stress, in 
protection of DNA etc. (Olinescu, 1994). The uric acid acts like an antioxidant in the 
prevention of lipids peroxidation. (Curcă, 2003-2004) 
IL-1, although stimulates ROS production (especially NO and products of activated 
phagocitic cells), in certain conditions can manifest also an indirect antioxidant role, through 
stimulation of glucose-6-phosphate dehydrogenase activity, followed by an increased 
production of NADPH, which is essential in glutathion regeneration. (Mehraban, 1998) 
Glucocorticoid hormones have indirect antioxidant activity by inhibation of A2 
phospholipase, which determines an increase of arahidonic acid available in cells and, 
therefore, they produce a decrease in quantity of endoperoxides which can attack cell 
membranes, inhibition of chemotactism for activated cells involved in phagocytosis, 
inhibition of immune complexes formation, thus reducing ROS formation in active cells 
during immune response. 
Correlated with the activity of endocrine functional harmonization is, also, stimulation of 
activity of hypotalamic-hypophysis-suprarenalian shaft, resulting in optimisation of plasma 
levels of: β-endorphines, ACTH and cortisol. 
Neuro-endocrine reactivity, enzymatic and metabolic changes from endocrine glands after 
mud therapy are different with secretor type of the gland, with functional stage of the gland 
and are connected with the type of therapeutical application. Under the action of mud there 
is a harmonical stimulation of all glands, in the direction of increasing enzymatic and 
synthesis activity, but maintaining each one specificity (Zirra et al., 1964). 
The endocrine mechanism is, also, involved in induction of anti-inflammatory effects of 
mud therapy, due to modulation of activity of hypotalamic-hypophysis-suprarenalian 
shaft and to endocrine balance, effects which can be seen even after the cure (Modval et 
al., 1972).  
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2. Techirghiol mud 
Non-conventional therapies using natural factors (as mineral salted water and 
peloid/sapropelic mud from Techirghiol Lake) are used on empiric basis from ancient times 
and have unchallenged benefits in rheumatic pathology, but the intimate biological 
mechanisms of action are yet not known.  
Techirghiol therapeutic mud consists in black deposits, rich in colloidal iron hydro sulfur, 
from the bottom of the salty lake, formed under the action of micro-organisms, from the 
inorganic substance of the soil, the flora and fauna of the aquatic basin, as the consequence 
of some biological and chemical transformations, during the biological ages (Ţuculescu I., 
1965).  
2.1 Peloidogenesis 
The peloidogenesis, as a  complex process involving geological , physical, chemical, climatic 
and biological factors, it is based on organic material which forms tanatozoocenosis and 
tanatofitocenosis, with an anaerobic evolution, being generated mainly by the Artemia salina 
crustacean,  together with Haliella taurica and the Cladophora vagabunda algae, distributed 
unequally on the bottom of the lake. In the  second phase the iron sulphur is born, the black 
component of the mud, formed through the activity of the sulphur reduction bacteria, from 
the combination of the iron with the hydrogen sulphide resulted from the decomposition of 
the organic materials or, as the case of the iron, from the meteoric waters. 
Peloidogenesis runs in three stages: 
1. the phase of accumulation and alteration of organic and mineral components. In this 
stage the origin of mud is established; 
2. the sedimentation stage in which the elements are deposited on the bottom of the basin; 
3. the physical, chemical and microbiological transformation phase of the flora, fauna and 
micro-organisms - so called pelogen active agents - convert organic material and 
minerals in successive stages in the final product. Natural conditions of the lake - 
density, degree of mineralization, biogenic elements content, gas system - all influence 
the evolution, the dynamics and the microbiological population component. The dying 
phytoplankton and zooplankton generate organic substances rich in protein and fat. 
Almost every bacterium participate in this process with enzymatic equipment: 
dehydrogenase, carboxylase, catalase. The organic remains, the minerals from the 
bottom of the lake, together with the material transported by water erosion from the 
lake are transformed into peloidogen material and then peloid. Micro-organisms break 
down organic substances and mineralize them and enrich mud with their waste 
products: vitamins (C, B1, B2, B12), biostimuline, auxinic, biotin, nicotinic acid, 
carotenoids, substances such estrogenic phenols group. In the liquid phase 
carbohydrates are oxidized, proteins are decomposed, the fatty acids are desaturated 
resulting the acetic, formic and valerian acid. Bacteria are present and involved in the 
"life" of mud, not only in the training forming stage, but also afterwards when they help 
maintain the biological balance and self-purification of mud and and water basins - a 
phenomenon called bacteriophagy. (Teleki, 1984; Banciu, 1996) Micro-organisms grow 
in an environment represented by protein substances, pectin, soluble carbohydrates, 
soluble proteins, etc. The fauna and flora, as well as the microfauna and microflora 
present in the mud are: protozoa, copepods, cladocers, hemipters, diptych, beetles, 
hydrofilids, rotifers, diatomaceous, chlorofycee, cyanophycee. Peloidogenesis is a 
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complex phenomenon that takes thousands of years and never stops, being conditioned 
by the hydro-geological characteristics of the area and elements influenced by physico-
chemical, biological and microbiological (enzymatic micro equipment: catalasis, 
oxidasis, reductasis, gelatinasis), each ecosystem and each mud peloidogen resulted is 
unique. (Diaconescu, 1973) The rhythm, the amount and evolution of peloidogenesis at 
a certain time may be determined by placement and periodic control of sedimentation 
on the bottom platform in selected areas for this purpose. It is in fact an analysis of 
current status of deposit. The mud is mineralizing slowly in time, aging, a phenomenon 
called diagenesis. (Teleki, 1974). Peloids formation and maturation are slow and 
permanent processes reflected in their chemical composition. Comparison of some 
chemical compounds of peloids at different intervals and in certain circumstances 
allows the assessment of the evolution and maturation of the mud. Ratio of the crystal 
structure and structure of calcium-magnesian clay is the coefficient incarbonization of 
peloid, showing maturation stage. Its value ranges between 0.003 and 2.1. Ratio of 
sulphates and carbonates from the mud reflects its age: increased sulfate content is 
characteristic to "young" peloids, while carbonates characterise "mature, old" peloids. 
The peat age is appreciated by the ratio of humic acids / cellulose, an increased value - 
at around 2.8 - indicating a mature peat. 
The mud from the Techirghiol lake is very well hydrated, with a high content of mineral 
substances and a lower content of organic substances. It has  a great capacity of absorption of 
the ions Ca, Ng, K and Fe, which is  very important for therapeutic effects, because of the 
mobilization of these ions in the organism. 
The specificity of the therapeutic mud is given by the primary factor (H2O of the lacustrine 
basin), and by the mineral and organic substances. 
In time the mud quality depends on the balance of the three elements and on the uniformity 
of the peloidogenesis process. 
2.2 Physical characteristics of Techirghiol mud  
Techirghiol mud is an alkaline mud, pH is 8,2. 
Density value is 1,283 g/cm3 and is determined by the nature of the elements which 
compose it. 
Thermopexy is the capacity of absorption, retention/storage and release caloric energy 
(gives therapeutic value to the mud), and is the most important feature, along with 
spreading capacity; it is determined by the Denade.  
Plasticity is the feature of the mud to change its form under the action of an external force in 
time. The coefficient of flowing is 43-56% (medium). (Ţuculescu I., 1965) 
The spreading capacity depends on the size of the mud granules and for Techirghiol 
mud is 99.57%. The spreading of the mud is the capacity of fine particles (0,1 mm) to 
spread uniformly in the tube water and to adhere tightly to the tegument (Teleki et al, 
1984).  
2.3 Chemical characteristics of Techirghiol mud  
The chemical composition of Techirghiol mud consists in: water, mineral substances, 
organic substances.  
The water represents over 70% from the mud’s components and it is found as hydrating and 
colloidal water. 
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substances and a lower content of organic substances. It has  a great capacity of absorption of 
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mobilization of these ions in the organism. 
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Techirghiol mud is an alkaline mud, pH is 8,2. 
Density value is 1,283 g/cm3 and is determined by the nature of the elements which 
compose it. 
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(gives therapeutic value to the mud), and is the most important feature, along with 
spreading capacity; it is determined by the Denade.  
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time. The coefficient of flowing is 43-56% (medium). (Ţuculescu I., 1965) 
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The water represents over 70% from the mud’s components and it is found as hydrating and 
colloidal water. 
  
Osteoarthritis – Diagnosis, Treatment and Surgery 
 
148 
Mineral substances: insoluble salts (calcium sulfates and carbonates, silicates); clay 
component: SiO2 and small quantities of oxides; the colloidal component: iron hydro-sulfur, 
iron and aluminum silicates, organic-mineral complexes. 
Organic substances: from the fito-zooplakton of the aquatic basin, from vegetal remains and 
decomposed animals are represented by carbonhydrates (cellulose and hemicelluloses), 
humic and humic acids, lipids, proteins and amino-acids, the B group vitamins, nicotinic 
acid, a bituminous component which contains estrogen-like active substances. According to 
the standards of National Research Institute of Rehabilitation and Physical Medicine and 
following the procedure of Romanian Farmacopee for natural products analysis, the report 
on Techirghiol sapropelic mud is  shown in table 1. (Surdu, 2006) 
2.4 Methods of mud application 
Known and used from the antiquity, mud′s ways of applications are still the same: cold 
ointment (following the antique egyptian method), thermoneutral mud bath and 
hyperthermic mud wrapping/pack.   
Warm salted bath can be performed on a daily basis, as a single major procedure of 
hydrotherapy, or every other day alternatively with mud application or with warm bath 
containing herbal extracts. Prescribed temperature for salted bath must belong to the neutral 
field; it means around 37, 5º-38ºC. For hydro-kineto-therapy the water is heated up to 35ºC 
(Lupu, 1956; Surdu, 2006). 
Cold mud ointment is a therapeutic complex, which consists from hot-cold contrast. Cold 
mud ointment is performed in the summer time, on a specially designed beach, where fresh 
extracted mud is brought daily or every other day. After a 15-20 minutes sun exposure, the 
patient applies on the whole body surface a mud layer of 1-1. 5 cm thick. Drying of the mud 
on the skin takes 15-30 minutes, depending of the environment temperature. The patient 
enters into the lake water in order to remove dried mud, and then performs active 
movements of all body segments. In the end of the procedure the patient takes a tap water 
shower. Duration of sun exposure is increasing daily (from 5-10 minutes first day up to 30-
40 minutes in the end of the cure), as well as the number of lake immersions. The number of 
mud applications per day is constant. Meanwhile the cure one must take only one mud 
application per day. (Teleki et al., 1984) 
Thermoneutral mud bath is prepared using 10 kg of mud in 120-150 L of salted water from 
the lake. Application temperature is around 37. 5ºC -38ºC, thermoneutrality point for mud 
being at 38ºC. The mud bath takes 20-25 minutes and temperature is maintained almost 
constant adding warm water after half the time. Once the time expired, the patient takes a 
warm shower in order to remove the mud from the skin and a quick cold shower in order to 
avoid systemic vasodilatation. General mud bath is indicated once every two days, 
alternatively with salted warm bath (in the swimming pool or in the tube) or herbal extracts 
warm bath. (Onose, 2000) 
Hot mud general packing is prepared using 10-15 kg of mud heated at 42ºC – 45ºC. The mud is 
smeared all over the body surface, from neck to toes. The patient is covered with a sheet and a 
blanket, gets a cold compress on his forehead in order to avoid a strong vasodilatation of 
cerebral vessels and remains like that for 30 minutes. After time expires, the mud is washed 
with a warm shower. The procedure ends with a short cold shower, in order to prevent 
irreversible dilatation produced by heat. Mud packing is performed once two days, alternative 
with a warm salted bath or with a bath containing herbal extracts. (Surdu, 2006; Onose, 2000)  
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CRT. NR. PHYSICAL CHEMICAL PARAMETERS VALUES OBSERVATIONS 
 
GLOBAL CHEMICAL COMPOSITION ( G % )
1. Humidity (water) 71,24 g %
Reported in whole 
humid mud  
2.  Volatile substances 8,4 g %
3 Total mineralisation 20,36 g %
                                           TOTAL = 100,00 g % 
ORGANIC SUBSTANCES ( G%)
1 Total humic substances 0,9551 g %
Reported in whole 
humid mud 
2    Proteins 1,112 g %
3       Fats+ waxes+ resins 1,612 g % (ether extract) 
4 cellulose 0,4834 g %
5 bituminous 3,209 g %(benzene-alcohol extract ) 
6 Pectins + carbohydrates 2,213 g %(water extract  ) 
MINERAL CONTENT (PPM / G%)
 1 Iron 3448,332 / 0,3449 ppm / g%
Reported in whole 
dry mud 
2 Calcium 32205,91 / 3,2206 ppm / g%
3 Sodium 44608,94/ 4,4609 ppm / g%
4 Kalium  18771,12 / 1,8771 ppm / g%
5 Manganese 270,022 / 0,027 ppm / g%
6 Magnesium 39544,64 / 3,9545 ppm / g%
7 Silicates / 13,82 ppm / g% 
INDICATORS OF PELOIDOGENESIS (G% )
1 Organic carbon ( C ) 1,313 g %  
Reported in whole 
humid mud 
2 Organic azoth ( N ) 0,129 g %
3 Ratio C / N 10,18 g %
SULFUR COMPOUNDS (G%)
1 Total H2S from wich 0,1257 g % Reported in whole 
humid mud 2 H2S free 0,0449 g %
3 H2S linked 0,0808 g %
GLOBAL PHYSICAL CHARACTERISATION
1  pH 8,2 determined in whole 
humid mud 2 Density  20 1,283 g/ cm3 
3 Dry substance (DS ) 28,73 g %
4 Changeable basis  47,6 mEq / 100 g mud Reported in whole humid mud 


























Determined in whole 
dry mud 
Table 1. Physical-chemical characterisation report on Techirghiol sapropelic mud 
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Mud collection is performed from the central area of the lake, where there are three deposits 
(“islands”) of therapeutic mud. Here the mud is settled uniformly, without any foreign 
material, having a characteristic aspect: black, shiny, unctuous, very plastic, with a very fine 
granular structure and a specific smell. This is the area from where mud is extracted for over 
one hundred years and used in all sanatoriums on the seaside (Diaconescu et al., 1973; 
Ţuculescu, 1965). For mud collection is necessary a claw bucket mounted on a boat. From 
the boat mud is absorbed with a pump and loaded into a tank, which transports it inside the 
treatment area, where is deposited in special boilers provided with electric heating and 
mixing systems. Mud shelf life in the bunker is 4-6 days. From here is provided also the 
mud for cold ointments in the summer time. After collection from the lake, mud is 
transported to the solarium, where is stored in the recipients outside (Surdu et al., 2005).  
2.5 Physical mechanisms of mud action 
The thermal factor: effects are according to the temperature of the mud - the warm 
application (38° C) determines pain relief, decrease of muscles contracture and has anti-
inflammatory effects; higher temperature application has immune-stimulating, tonic, 
cardiovascular overwork effects. 
The physical component of the action of mud on the human body refers to the existing 
mechanical and thermal conditions during application. Mud thermotherapy is possible due 
to mud's properties to maintain temperature. This capability of mud allows its application at 
higher temperatures than body's temperature. There is a slow transfer of heat stored in the 
mud, allowing the body to take over an amount of this heat. Temperature affects living 
systems starting with the fundamental biophysics and molecular energy levels up to the 
most complex systems functionally speaking. The temperature influences the structure of 
cell membranes and protoplasmatic parts - non-covalent bonds (ionic, van der Waals, 
hydrogen bridges), the number of hydrogen bridges from the helix structure of nucleic acids 
and proteins, the phospholipids mezomorphysm, the state of lamellar or hexagonal phase of 
membranes, the state of oil and fatty acid chains. The temperature continues to be the one 
that influences functions and biochemical reactions in the membrane and cytosol - the 
mobility of membrane receptors (with implications in the defense processes as for instance, 
the formation of lymphocyte cap), plasmalemma vesicles formation, hydrophobic binding of 
insulin receptors, activitation of adenilcyclasis, enzymes synthesis, the presence / 
appearance or not of isoenzymes, the rate of diffusion, the Donnan equilibrium, oxygen 
consumption, etc. The temperature influences the bioenergetic cellular activity, 
multiplication, defense, various functional control and protection systems. For all biological 
processes, the temperature is one of the most important conditions for ideal development. 
For the vast majority of warm-blooded organisms the optimal functional thermal point is 
located around the temperature of 39°C +/- 1°C, but most organisms live below this heat 
value. The environmental temperature to which the request of thermoregulatory 
mechanisms is minimum represents the neutral area, that is to say the individual has no 
heat needs. The thermal field of peloidotherapy begins with cold application and goes to 
hyperthermia, each type of application having typical therapeutic effects and consequences. 
The application of cold mud is a complex heat treatment which consists of successive 
contrast hot-cold, developed in two phases: the first phase includes sun exposure on the 
solarium hot sand / beach for about 20 minutes and anointing with mud, and the second 
phase involves sun exposure for about 30 minutes in order to install a mild 
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hyperthermia, followed by a lake bath/cold shower. Under the direct influence of thermal 
contrast and indirect influence of the information from thermal receptors, the effector function 
of peripheral variable heat flow is enhanced by modulating local, partial and finally general 
circulation and by optimizing the release of self-amplification cell eicosanoids factors. Recent 
studies on the thermodynamics of soft tissue during cold applications reveal hemodynamic 
changes as a substrate of thermal changes occurring during application. The muscle tissue is 
the source of skin reheating after cold application and, even it does not suffer significant 
decreases in temperature during application, 40 minutes after the end of application it cools, 
along with the increasing of skin and subcutaneous tissue temperature. (Enwemeka et al., 
2002). Thermogenesis and thermolysis reactions are obtained through contrasting therapy, 
optimizing thus the thermal homeostatic balance. The activation of these programs, their 
hierarchy, the increasing of the anticipation and reply capacity (feed before) lead to increased 
performance of adaptive response of the body as a result of an improvement in balance and 
finally warm-blooded overall body homeostasis. (Andrieş, 1994) Thermal neutrality is the 
temperature which gives no termoestesic sensation and reduces / maintains the minimizes 
heat setting processes. This temperature is around 34-35°C for water and 38°C for mud. 
During the thermoneutral mud bath the body is subject to mechanical forces according the 
laws of physics stated by Archimedes (body weight loss equal to the weight of displaced 
liquid) and Pascal (the reduction of chest, abdomen and limbs circumferences in relation to the 
immersion due to pressure transmission in a liquid in all directions with the same intensity). 
So, besides from the thermal factor there is also a mechanical acting. During the immersion in 
mud bath gravity and termoestesic information are reduced, and therefore cortical activation is 
minimal, allowing stabilization of humoral and neuro-endocrine homeostasis stability in 
neuropsychological and biological parameters of comfort. While  reducing the gravitational 
and thermal information, information from interoceptors begin to grow, especially from the 
baroreceptors stimulated by the new hemodynamic conditions and therefore neuroendocrine 
cardiac depressant processes activate (Bainbridge effect), the Henry-Gauer reflex of inhibiting 
secretion of vasopressin sets in with its natural consequence of lowering blood pressure. The 
prolongation of the immersion in the bath over 20 minutes leads to thermoneutrality, mostly 
because of some endocrine-regulating processes, which secrete a humoral natriuretic and 
diuretic factor ANF (Atrial natriuretic factor), related with a feedback loop by vasopressin. 
The vasopressin stimulates the secretion of ANF, which in turn inhibits the secretion of 
vasopressin. Thus, a thermoneutral bath lasting for 30-40 minutes can lead to blood pressure 
decrease with about 30%. (Andrieş, 1994) Because its thermoregulatory qualities, mud can be 
used in the treatment of hyperthermia. Hyperthermia appears when core temperature 
increases over 37.3ºC by passive heat input. Increased temperature in central area and further 
in peripheral thermoregulatory area - the poikiloterm area (extremities) - has the following 
consequences: increased migration of leukocyte inhibitory factor (LIF), macrophag inhibitory 
factor (MIF), the activation of lymphoblastic transformation, the stimulation of platelet activity 
of fibrinolytic system, the increase in interferon synthesis. Not only functional, but also 
structural changes take place under the influence of temperature increase, such as formation of 
lymphocyte caps (capping) of plasmalemma vesicles, etc. Cellular defense and immunity are 
two areas with particular benefits from hyperthermia. The central serotonin core system is 
activated at a temperature of 38-39°C (which inhibits the activity of the sympathetic nervous 
system at central level), so it stimulates hypothalamic-pituitary system (with ACTH, 
endorphins, melanotropin release) and synthesis of prolactin. 
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However, under the action of mud baths, the whole body temperature is "baffled", all 
devices and systems "work transitory" in a regime requiring all means of antientropic 
control for maintaining homeostasis of internal environment (Andrieş, 1994). In conclusion, 
we should bare in mind that there are few effects under the action of the heat factor of mud 
application. 
2.6 Chemical mechanisms of mud action 
The humic acid and the humic salts are ions changeable substances, influencing ions` passage 
between skin and bath medium. They also modify the status of some skin enzymes such as: 
cytochrome-oxidase, ATP-ase, and alkaline phosphatase, that become active within skin.  
The skin pH modification increase the permeability at this level. (Teleki et al., 1984).  
Among the chemical components with proven and / or recognized action there are: the humic 
component, the estrogen bitumen component, the hydrogen sulfide, various ions, biologically 
active substances produced by microbiological flora and fauna, etc. Because of their chemical 
composition, peloids acts pharmacodynamically by ion exchange with skin or mucous 
membranes that come into contact with. Ion exchange capacity is determined mainly by 
colloidal substances: humic acids, hydrosulfuric colloidal iron. Sorption peloids capacity was 
calculated using the Mehlich-Dowexhil method, which expresses the ion exchange degree in 
mEq%. For example at 20°C, 1 kg of Techirghiol mud retains 5.48 g / l calcium, 11.50 g / l 
magnesium and 9.34 g / l iron. Ions in mud bath selectively penetrate the skin, depending on 
the electrical charge of the skin and the permeability of skin is increased by the environmental 
temperature. Soluble elements from the mud's soluble phase participate in the exchange 
between the skin and mucous membranes, and more intense is the exchange, more diluted is 
mud. In addition, a comparative study was made in order to compare effects of concentrated 
mud baths (70-150 kg mud / water in a bath tube with 300 l chlorosodic water from lake 
Techirghiol) versus diluted mud baths (1 kg mud in a valve with the same amount of water). 
The overall effects of treatment with diluted mud baths were superior to those obtained with 
concentrated mud baths and confirmed statistically. The soluble elements transfer from the 
liquid components of mud, through epithelial cells,  is activated by an "enzymatic barrier" 
represented by cytochrome, alkaline phosphatase and ATPase. In addition, if salted water 
(such as the water from Techirghiol lake),  is combined with mud to prepare mud bath, 
crystals and salts remain on the skin as a "salt sheath”, and along with the hygroscopic action 
of NaCl stimulate the nerve endings. The crystals on the skin surface retain water from 
atmosphere, thus making possible different osmotic exchanges at the skin level compared with 
basal needs. Skin acid pH gives permeability only for cations. A change in pH increases the 
permeability of skin also for anions. The alkaline hot mud baths change the skin 
electronegatively, while the acid mud baths - the only acid mud found in Romania is in Stobor 
- change the skin electropositively. Some of the ions leave the skin and pass into the bath water. 
Thus, there is a double passage of ions that alter the excitability of skin and skin reflexes 
starting points. The chemical composition of environment influences mud bath and hydro-
mineral balance of the body by various ions which can either accumulate (K+, Br+, Mg2+), or 
they can favour the retention / removal of elements such as chlorides and carbonates of 
sodium, by increased Ca and P retention in the body, or by established inter-relationships 
between  Cl¯, Br¯,K+, Na+, Ca2+, Mg2+. The action of ions can be seen as qualitative exchanges in 
the body's mineral composition by replacing certain elements with others that are in excess 
and by accumulation those with low level. The humic substances have antihyaluronidasic 
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activity, while variations in fibrinogen and fibrinolytic activity are neither parallel nor 
significant. Antihialuronidazic activity of humic acids from mud has been demonstrated in 
vitro. (Pizzoferrato, 2000) The thermal bath at 35C does not have this action, which led to the 
conclusion that inhibitory action is due to mud and not to its thermal effect. Histoenzymatic 
studies at various levels (skin, internal organs, endocrine glands) revealed differences of 
enzyme substrates in relation to different type of mud application. In this context, it is 
insufficient to mention only the enzymatic activity of mud. We can rather talk about the 
modulating role upon enzymatic that some of mud's components exercise. We have already 
mentioned the activation of enzyme systems as well as the effects of skin temperature on 
metabolic reactions. Hydrogen sulfide produces skin hyperthermia even in lower 
temperatures of mud, it enhances the activity in histaminasis tissue and increases 
histaminopexic serum activity with the effect of desensitizing the body. Estrogen-active 
elements from the bitumen component are highlighted through biological tests that revealed 
the estrogenic action of mud. The microbiological component of mud produces besides 
vitamins, growth factors, auxine - biogenic stimulators - biotine - a sulphoglicolipid with anti-
inflammatory action. (Tolomino et al., 1999) The list of the substances / active ingredients in 
mud is not complete and can not be completed. Each mud and its aquatic environment of 
formation and existence are like living organisms in a continuous dynamics. Chemical 
composition of mud is a "puzzle", that can have all the pieces but not yet arranged for us to 
create the image of the possibilities of action. 
The peloidotherapy produces an harmonic stimulation in all the glands, namely increasing 
the enzymatic activity and the glandular synthesis, and keeping the specificity of each 
gland, a persistent and post-cura stimulation. There is a  persistent after treatment 
stimulation the hypothalamus –hypofisal –suprarenalian shaft, emphasized by the 
increasing of A.C.T.H. secretion, an improvement of vasomotor reactions and of the thermo 
regulation process.  
3. Conclusion  
Evaluation of anti-inflammatory potential of sapropelic mud from Techirghiol in patients 
with osteoarthritis, through assessment of oxidative stress markers, was confirmed by a 
statistically significant increase of SOD level and by a decrease of reduced glutathione level 
under the action of mud treatment. The increase of SOD level after mud treatment suggests 
a positive response of the body, considering the positive role of enzyme in ROS 
neutralization and NO inactivation. The levels of glutathione reductase, uric acid or blood 
glucose, protective factors in oxidative stress balance, haven’t been influenced by mud 
treatment. This conclusion emphasizes the protective character of mud therapy on oxidative 
stress, the enzymes with positive effect on this metabolism increasing, as in SOD case, or 
maintaining in normal range, as in GR and TAS case (Marin et al., 2009) 
Assessment of stress hormones activity showed an optimization of plasma cortisol level and 
revealed, also, a stimulation of hypotalamic-hypophysis-suprarenalian shaft, sustained by 
significant increase of tyroid stimulating hormone (TSH) level. The increase of TSH level, for 
both warm and cold mud applications, shows a stimulation of hypotalamic-hypophysis-
suprarenalian shaft under the action of mud. So, the endocrine mechanism is involved, also, 
in induction of anti-inflammatory effects of mud therapy, by modulating of activity of 
hypotalamic-hypophysis-suprarenalian shaft and by general balancing of endocrine system, 
effects that last probably even after cure (Marin et al., 2007). 
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crystals and salts remain on the skin as a "salt sheath”, and along with the hygroscopic action 
of NaCl stimulate the nerve endings. The crystals on the skin surface retain water from 
atmosphere, thus making possible different osmotic exchanges at the skin level compared with 
basal needs. Skin acid pH gives permeability only for cations. A change in pH increases the 
permeability of skin also for anions. The alkaline hot mud baths change the skin 
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they can favour the retention / removal of elements such as chlorides and carbonates of 
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vitro. (Pizzoferrato, 2000) The thermal bath at 35C does not have this action, which led to the 
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studies at various levels (skin, internal organs, endocrine glands) revealed differences of 
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insufficient to mention only the enzymatic activity of mud. We can rather talk about the 
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elements from the bitumen component are highlighted through biological tests that revealed 
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composition of mud is a "puzzle", that can have all the pieces but not yet arranged for us to 
create the image of the possibilities of action. 
The peloidotherapy produces an harmonic stimulation in all the glands, namely increasing 
the enzymatic activity and the glandular synthesis, and keeping the specificity of each 
gland, a persistent and post-cura stimulation. There is a  persistent after treatment 
stimulation the hypothalamus –hypofisal –suprarenalian shaft, emphasized by the 
increasing of A.C.T.H. secretion, an improvement of vasomotor reactions and of the thermo 
regulation process.  
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Evaluation of anti-inflammatory potential of sapropelic mud from Techirghiol in patients 
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statistically significant increase of SOD level and by a decrease of reduced glutathione level 
under the action of mud treatment. The increase of SOD level after mud treatment suggests 
a positive response of the body, considering the positive role of enzyme in ROS 
neutralization and NO inactivation. The levels of glutathione reductase, uric acid or blood 
glucose, protective factors in oxidative stress balance, haven’t been influenced by mud 
treatment. This conclusion emphasizes the protective character of mud therapy on oxidative 
stress, the enzymes with positive effect on this metabolism increasing, as in SOD case, or 
maintaining in normal range, as in GR and TAS case (Marin et al., 2009) 
Assessment of stress hormones activity showed an optimization of plasma cortisol level and 
revealed, also, a stimulation of hypotalamic-hypophysis-suprarenalian shaft, sustained by 
significant increase of tyroid stimulating hormone (TSH) level. The increase of TSH level, for 
both warm and cold mud applications, shows a stimulation of hypotalamic-hypophysis-
suprarenalian shaft under the action of mud. So, the endocrine mechanism is involved, also, 
in induction of anti-inflammatory effects of mud therapy, by modulating of activity of 
hypotalamic-hypophysis-suprarenalian shaft and by general balancing of endocrine system, 
effects that last probably even after cure (Marin et al., 2007). 
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Assessment of anti-inflammatory potential of sapropelic mud from Techirghiol in patients 
with osteoarthritis, by measuring inflammatory cytokines levels, has confirmed this effect 
through an important decrease of TNF-α and IL-6 values in patients which had initially 
peak values. Also, it has decreased statistically significant the level of receptors for TNF-α, 
sCD27, fact that sustains the decrease of TNF-α level. (Marin et al., 2011). 
Increase of oxygen intake in peripheral blood by opening arterial-venous shunts and 
improving circulation to peripheral tissues, and osteoarticular tissue also. It was 
demonstrated the strong growth and consistent within 24 hours of oxygen saturation in the 
peripheral blood SO2%, partial pressure of oxygen at this level pO2 , the oxygen-binding 
capacity of the hemoglobin O2CAP and oxygen content of hemoglobin O2CT. A lower 
amount of lactate in the peripheral blood and a constant blood pH and carbon dioxide 
partial pressure suggests an improvement in peripheral tissue metabolism through 
increased intake of oxygen and nutrients. (Marin et al., 2011). 
The obtained results, confirming anti-inflammatory action of mud, should recommend mud 
as a therapeutic solution for osteoarthritis treatment.  
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sCD27, fact that sustains the decrease of TNF-α level. (Marin et al., 2011). 
Increase of oxygen intake in peripheral blood by opening arterial-venous shunts and 
improving circulation to peripheral tissues, and osteoarticular tissue also. It was 
demonstrated the strong growth and consistent within 24 hours of oxygen saturation in the 
peripheral blood SO2%, partial pressure of oxygen at this level pO2 , the oxygen-binding 
capacity of the hemoglobin O2CAP and oxygen content of hemoglobin O2CT. A lower 
amount of lactate in the peripheral blood and a constant blood pH and carbon dioxide 
partial pressure suggests an improvement in peripheral tissue metabolism through 
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1. Introduction 
Ginger has been used for 1000s of years as a food and medicine; it is likely one of the most 
ancient remedies valued by humans. Ancient Indian and Chinese cultures reportedly used 
ginger for a wide variety of conditions and modern day research has found it effective as an 
anti-emetic and anti-inflammatory agent, when taken internally.  Random controlled trials 
using ginger extract have been found effective in relieving symptoms of osteoarthritis. 
Osteoarthritis is the primary cause of musculoskeletal pain and disability in Western 
cultures. Current management is primarily through the use of anti-inflammatory and 
analgesic medication, with cortisone injections and joint replacements a final resort. There is 
a need for a self-administered, non-toxic, natural therapy that relieves osteoarthritis 
symptoms, with none of the disadvantages of conventional medication or surgical 
procedures. A treatment is needed to control symptoms that are: easy to administer, using 
minimal materials, comfortable to receive, with no known side effects. People with 
osteoarthritis require a simple treatment that supports the management of chronic pain, 
relieves their anxiety and improves mobility. 
This chapter introduces the significant effect on osteoarthritis symptoms, when ginger is 
applied externally rather than ingested internally. Four aspects are discussed: 1) ginger for 
arthritis, 2) ginger qualities and characteristics, 3) ginger for osteoarthritis and, 4) 
management and ginger therapy. 
2. Ginger for arthritis 
2.1 Indian medicine 
Ginger is one of the significant medicinal plants used in ancient Indian Medicine. It is found 
effective internally, when used in food preparation and herbal extracts and externally as a 
ginger compress or mixed with oil to massage around the joints (Chopra, Saluja et al., 2010; 
Ernst, Pittler et al., 2006). Ayurveda is the term given to indigenous Indian medicine that 
uses the concepts of prana, prakriti and dosha to understand illness. Prana manifests as 
movement and energy, it is the source of all existence. Prana healing is a re-vitalising of the 
body, mind and soul, the basis of ayurveda. Prakriti relates to the constitutional type, while 
dosha to the bodies elemental forces or energies. There are three dosha: 1) vata dosha 
relating to space and air, 2) pitta dosha to fire and, 3) kapha dosha to a combination of water 
and earth. When all three dosha are in balance the body is in good health. Ayurveda 
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medicine refers to osteoarthritis as sandhivata from the Sanskrit ‘sandhi’ for joint and vata 
for vata dosha. People with osteoarthritis are understood to have an imbalance of vata 
dosha that often leads to worry and anxiety, insomnia and cramping in the body, with a 
decrease of fluidity and increase of catabolic activities in the joints. In osteoarthritis there is a 
striving to rebalance the tired body and strengthen the digestive and metabolic systems. 
Ginger is considered to be a plant with qualities to rebalance symptoms of osteoarthritis. 
Ayurveda treatments are holistic using natural remedies from medicinal plants and 
minerals accompanied by changes in diet and life style.  
2.2 Chinese medicine 
Traditional Chinese Medicine (TCM) is a unique medical system using distinct terminology 
and understanding alongside the use of herbs, acupuncture and moxibustion. TCM involves 
differentiating the causes such as; emotions, climate, diet and injuries as well as selecting the 
most effective medicinal herb for a given condition. Since ancient times, ginger has been 
taken internally and used externally in China, often as a compress, patch or in combination 
with moxibustion (Lai, Chen et al., 2007; Wu, 2002; Xinangcai, 1998). ‘The yellow emperor’s 
classic of internal medicine’ written about 1000BC by a number of authors referred to as 
Huangdi, provides the first description of ginger rhizome’s medicinal use as a warming, 
stimulating agent. TCM refers to Chi, prana in ayurveda, the universal life force that is the 
source of all warmth and energy. Chi’s continual movement and variation in the natural 
world, including medicinal plants and the human body leads to the two opposing and 
interdependent poles of yin and yang; yin relating to the cold, dark, contracting forces and 
yang to the warm, light, expanding forces. The kidneys are the root of Chi, and the yin and 
yang of the body. In illness Chi becomes blocked and needs to be bought back into balance. 
Ginger’ qualities are considered to activate stagnating Chi, dispel cold and strengthen yang, 
where there is a predominance of yin activity as in osteoarthritis. Excessive cold and fear 
drives Chi downwards in the body leading to kidney/bladder weakness and bone atrophy. 
People with osteoarthritis tend to have an aversion to cold and suffer from injured and 
atrophied joints. Ginger is often the herb of choice and is used in combination with 
moxibustion or other warming herbs, as a compress and/or taken internally as a herbal 
extract for osteoarthritis.  
2.3 Macrobiotics 
Traditional Chinese medicine was bought to the West as macrobiotic healing by George 
Ohsawa in the late 1940’s. Ohsawa’s students travelled to France, Spain and Germany. In 
1950, Mischio Kushi went to the U.S.A., where his books introducing macrobiotics were 
published (Kushi, 1978, 1985). In Europe and the USA, the East West Foundation is 
committed to introducing macrobiotic medicine that requires understanding of oriental 
medicine, with treatments involving diet, life style, exercise and medicinal plants. 
Macrobiotic medicine classifies arthritis according to the cause, which dictates the treatment 
approach. Yin arthritis is caused by excessive intake of yin forces for example through the 
intake of certain foods, such as fruits, sugars and plants from the nitrate family, while yang 
arthritis is caused by excessive intake of yang foods, such as meat, eggs, salt and dairy 
products. Both yin and yang arthritis are understood to be aggravated by excessive oil and 
fat from both animal and vegetable sources, with ice cream being claimed as one of the 
major contributing causes of arthritis (Kushi, 1978). Ginger is often taken internally for yin 
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arthritis because of its strong yang qualities, while ginger compresses are used both on the 
abdomen and back to warm the body and stimulate the metabolism in both forms of 
arthritis. Arthritis is understood to be related to metabolic disturbances and when chronic 
intestinal stagnation is a contributing cause the ginger compress is often applied over the 
abdomen (Beere, 2000). 
2.4 Anthroposophic medicine 
Anthroposophic medicine was founded in the Ita Wegman Clinic, Switzerland in 1923 
under the guidance of Dr Ita Wegman (1876-1943) and inspired by the ideas of Rudolf 
Steiner (1861-1925), an Austrian scientist, philosopher and mystic (Steiner & Wegman, 
1925/1967). In 2010, in Europe there were at least 25 hospitals and clinics specialising in 
Anthroposophic medicine. Anthroposophic medicine takes cognisance of Ayurvedic, 
Traditional Chinese, herbal and allopathic medicine, with spiritual insights from the ancient 
esoteric and Christian religions. It is an integrative healing approach that encompasses the 
understanding there is an interrelation between the physical, life and emotional/sense being 
of people, which is interwoven by an individual inner organisation and life biography 
(Evans & Rodger, 1992; Therkleson, 2007). The physical is associated with the mineralising 
processes of the bone and cartilage, the life with the moving fluids that are most evident in 
the posture, the emotional with nervous and sensory perception, and the individual inner 
organisation, with the warm blood. This theoretical understanding finds expression in 
imbalances of different health conditions. For example, osteoarthritis develops, when the 
physical and life being is weakened in the joint(s), the sense being increases its activity 
causing additional tension and pain, while the individual organisation deteriorates and 
withdraws allowing excessive degeneration to continue unmanaged. The kidneys are 
considered very important metabolic organs in managing arthritis symptoms primarily due 
to their involvement in the movement of the blood and the assimilation and excretion of 
minerals in the body fluids. Typically in osteoarthritis, external treatments are selected to re-
enliven and stimulate the metabolic region, such as warm sulphur baths and ginger 
compresses over the kidneys.  
In Ayurveda, Traditional Chinese, Macrobiotic and Anthroposophic Medicine the 
relationship between a therapeutic plant substance and that of a potential recipient is 
significant. Ginger is regularly chosen as the herb of choice for people with osteoarthritis 
due to its warming and stimulating qualities.  The qualities and characteristics of ginger are 
discussed in the following section. 
3. Ginger qualities and characteristics 
Zingiber officinale (ginger) comes from the zingiberacae family, which has 1300 species of 
which about 90 comprise the zingiber species. Zingiber officinale is the only medicinal plant in 
the zingiber species. Ginger’s rhizome has been used since ancient times as a food and a 
medicine. It is taken both internally and externally for a variety of effects including 
carminative, anti-spasmodic and anti-inflammatory (Blumenthal, 1998; Castleman, 2001/2003; 
Ferry-Swainson, 2000; Newall, Anderson et al., 1996). The rhizome is the medicinal part of 
ginger and it contains: 4 - 7.5% oleoresin such as gingerols and their related dehydration 
products known as shogaols, 1 - 3.5% of volatile oils primarily sesquiterpenes such as 
bisabolene, zingi-benene, camphene and acurcumene, 6 - 10% lipids comprising triglycerides, 
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phosphatidic acid, lecithins and free fatty acids, 9 - 10% proteins and 40 - 60% carbohydrates in 
the form of silicate starches. Pharmacological and experimental studies have found the active 
principle of gingerols and shogaols have anti-inflammatory and anti-emetic qualities 
(Chrubasik, Pittler et al., 2005). Ginger rhizome is cultivated widely for commercial use in the 
warm, moist, tropical areas of Africa, Australia, China, Fiji, India, Indonesia and Sri Lanka. 
People purchasing and using ginger rarely have the opportunity to observe its cultivation and 
even more uncommon is the sighting of zingiber officinale flowers. The following description 
of the ginger plant, with a brief summary of its specific features in relation to its therapeutic 
use is an introduction to this unique healing plant. The photos were taken, whilst on an 
organic ginger farm in Northern Queensland, Australia. 
3.1 Rhizome 
The ginger rhizome is a spreading bulbous, stem that develops horizontally close to the soil 
surface. It forms regularly spaced buds that grow to either shoots or new rhizomes. The 
rounded fresh buds are about the size of a knuckle, and coloured soft lemon-green, with a 
fleck of pink. A freshly prepared rhizome reflects these colours in Fig 1.  
 
 
Fig. 1. Fresh rhizome 
The ginger rhizome has a pungent aroma, smelling fresh and sweet, and tastes hot, with a 
sharp and awakening effect. The rhizomes are harvested, when the leaves start to dry and 
contract in the winter period as shown in Fig 2. It is the rhizome that concentrates ginger’s 
nourishing, healing and reproductive qualities. Ginger is propagated in spring from stored 
rhizome stock of the previous year. 
 
 
Fig. 2. Ginger harvest 
 




Long tap roots grow from the seams of the lower buds and anchor the plant deep in the 
earth. These tap roots reach to about 80cm and are milky-white, strong and juicy; tasting 
rather like ginger radishes. The tap roots have few hairs and no lateral shoots. Thin, short 
fibrous roots also grow from the seams of the fresh buds and these are coated in loose soil 
and minute micro-organisms.  
 
 
Fig. 3. Ginger roots 
3.3 Leaf 
As the shoots emerge from the rhizome buds they are their full diameter and grow 
upwards about 4cms a day until the stalk reaches full height at about 1.5 metres after 30 
days. This growth is phenomenal and similar to that of young hollow bamboo stalks. 
Each mother rhizome develops between 10 - 14 stalks that are slender and erect with 
between 10 to 14 leaf buds on each. The lower leaf buds appear as contracted leaves, 
while the upper buds develop single stems that slowly unfurl into large spreading 
leaves. About 8 - 10 leaves rhythmically alternate up each stem and only open fully once 
the stalks have reached full height. The lower contracted leaf buds are a dark emerald 
green, while the upper buds are a soft lemon green. The upper buds open into ovate 
leaves that are light filled yellow-green, soft and smooth. Each leaf is between 18 - 20cm 
long and 3 - 4cm wide, with marked longitudinal veins running from the base to the leaf 
tip.   
3.4 Flower 
In the plant’s autumn, when conditions are dry and cool the flowering buds appear. These 
buds are positioned on stalks that grow to about 30cms. Each mother rhizome may form 
between 4 - 6 flower stalks that are dwarfed by the canopy of large drying leaves. At the end 
of each flower stalk is a green, oval, cone-like flower bud, as in Fig. 4. 
Daily in autumn, the cones relax a petal to release a small, cream coloured flower that opens 
at dusk. The flowers are delicate, 1cm across, orchid-like, with a distinct maroon red or 
purple speckled tongue, as seen in Fig. 5.  It is small wonder that these flowers are rarely 
seen, not only are they inconspicuous being shrouded by the leaves, they also open as the 
sun is going down and are spent by dawn. 
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Fig. 4. Ginger flower cones 
Ginger has specific features that relate to its selection in the therapeutic treatment of 
osteoarthritis. The ginger plant is robust, upright and balanced, with strong life giving 
forces of warmth and energy focused in the swollen stem base or rhizome. Ginger is a 
unique plant that stores all its reproductive, nourishing and medicinal forces in a rhizome, 
with the flowers and seeds being inconspicuous and often absent. Both Eastern and Western 
alternative medical approaches utilise the heat and vitality of the ginger rhizome in 
managing osteoarthritis symptoms.  
 
 
Fig. 5. Ginger flower 
4. Ginger for osteoarthritis 
The use of ginger externally and internally for osteoarthritis likely had its origins in traditional 
herbal medicine. Ginger has been applied externally to relieve painful joints for over a 1000 
years in India and China, often in combination with other hot herbs (Xinangcai, 1998). In 
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Guangzhou, China in 2006, I observed raw, grated ginger being applied to swollen ankle joints 
of travellers in street clinics. In TCM hospitals ginger slices were combined with moxibustion 
or ginger combined with other heat inducing herbs  to remove blockages in the flow of chi, 
relieve sore joints and assist chronic chest conditions (Therkleson, 2009). For decades, ginger 
has been used in external therapies in specialised Anthroposophic hospitals in Europe. More 
recently, anecdotal experiences among groups of nurses have found the ginger footbath an 
effective adjunct treatment for tired, aching muscles and joints. Modern research reports 
random controlled trials show oral ginger extract is effective in managing osteoarthritis 
symptoms (Altman & Marcussen, 2001; Bliddal, Rosetzsky et al., 2000; Haghighi, Khalvat et al., 
2005; Marcus & Suarez-Almazor, 2001). However, these studies claim that the high doses of 
ginger extract required to relieve symptoms often lead to gastrointestinal complaints. The 
external topical anti-inflammatory activity of dry ginger extracts from solutions and plasters 
looks promising, with ginger’s active ingredient gingerol permeating the epidermis 
(Minghetti, Sosa et al., 2007). It is posited that transdermal delivery of ginger is likely as 
effective as internal ginger extracts in achieving an anti- inflammatory response. 
4.1 Transdermal delivery of zingiber officinale 
Herbs were first recorded as being delivered through the skin around 1550 BC in the Egyptian 
medical text Ebers Papyrus, where the crushed castor oil plant in water is applied externally to 
treat an aching head. Chinese sources provide directions for using ginger in combination with 
other medicinal herbs in a wide variety of external applications for a number of different 
conditions ranging from chronic chest infections, musculoskeletal conditions and metabolic 
disorders (Xinangcai, 1998). Transdermal delivery is defined as, ‘a term that should be 
restricted to the situation in which a solute diffuses through various layers of the skin and into 
the systemic circulation for a therapeutic effect to be exerted’(Brown, Martin et al., 2006). This 
definition is relevant to the use of the external application of ginger in which the active 
ingredients, gingerols and/or shogaols have the potential to pass through the skin, enter the 
systemic circulation and provide a therapeutic effect. There are a number of limitations and 
some significant enhancers to transdermal delivery, which are relevant in the consideration of 
the therapeutic effect of the external application of ginger. 
The primary limitation is the skin barrier. The uppermost membrane of the skin known as 
the stratum corneum is a thousand times less permeable to water than all the other 
membranes of the body. To penetrate the stratum corneum a substance must be soluble in 
oil and water and contain fatty acids that enhance skin penetration (Potts & Lobo, 2005). 
Penetration of the skin barrier is influenced by the molecular size and the quality of fat 
solubility of a substance. When a substance has a molecular weight <500 Daltons (Da) and 
lipophilicity log P range 1 - 3 it has the potential to pass through the skin (Finnin & Morgan, 
1999; Guy & Hadgraft, 2003).  Gingerols and shogaols, the active principles of ginger, have a 
molecular weight 150 - 190 Da, a lipophilicity log P range 3.5 and moderate solubility in 
water and oil, which suggest good potential for skin penetration (Jolad, Lantz et al., 2004; 
Minghetti, Sosa et al., 2007). There are three significant factors that enhance skin absorption; 
1) thermal activity, 2) hydration and, 3) occlusion. Firstly, normal skin temperature is about 
32 0C and, when the temperature is increased to 40 - 45 0C the closely packed lipids in the 
stratum corneum become more permeable. Secondly, the application of warm fluid 
increases the fluidity of the stratum corneum lipids, with a corresponding expansion in the 
intracellular spaces. Thirdly, occlusion additionally leads to increased hydration and 
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permeability. When the skin has a warm external compress or patch firmly pressed against 
it, moisture and heat become trapped and increase the swelling and opening of the 
intracellular spaces. Permeability of the stratum corneum by the active principles of zingiber 
officinale is likely enhanced by the use of a hot moist ginger compress or patch. 
4.2 Ginger compress  
European Anthroposophic hospitals report external ginger applications are effective for 
chest, metabolic, arthritic and psychiatric conditions, especially when applied to the kidney 
region (Schurholz, Vogele et al., 1992/2002). Ginger applications to the kidney region in the 
form of ginger compresses are found to warm and reactivate the metabolic forces of the 
body, which has a corresponding positive effect on the will to be active and mobile. The 
external application of ginger to the kidney region combines both heat and relaxation 




Fig. 6. Ginger kidney compress (Fingado, 2001) 
The external application of ginger in the form of a compress to the kidney region was given 
for 7 consecutive days to 10 people with osteoarthritis. This treatment was termed ginger 
therapy and it involves having a warm footbath, resting 30 minutes supine, with a ginger 
compress in place on the kidney region (mid back), followed by a rest of 15 minutes. The 
ginger compress is a cotton cloth soaked in a hot ginger infusion, squeezed well so just 
moist and applied to the mid back. The ginger infusion comprises 10 g of ground dry ginger 
to 200 ml of very hot water. The recipient rests comfortably warm and quiet, on top of the 
compress that is held firmly in position by a thick cotton binder/towel encasing both the 
back and front.  
Warm ginger compresses applied to the back in this manner activate the movement of body 
fluids and stimulate the circulation of blood, which has a corresponding positive effect on 
the weakened joint(s) and surrounding tissues. Following a course of ginger therapy, people 
with osteoarthritis describe feeling warm and relaxed. In TCM and Anthroposophic 
medicine, the typical person selected for an external ginger application tends to react 
negatively to cold, both externally and internally. The likely characteristics of a person being 
considered for external ginger therapy are that they experience: cold impacting negatively 
on symptoms, general body tension and a lack of coping skills in times of stress  
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(Therkleson, 2009). People with osteoarthritis often have very cold extremities, of which 
they are oblivious. For this reason prior to ginger therapy, a footbath using warm water is 
generally given to activate the body’s natural warmth forces.  
4.3 Ginger footbath 
A ginger footbath is a fresh approach to applying ginger externally for musculoskeletal 
tension. This is a simple, convenient and very effective therapy. Anecdotal experiences of 
groups of nurses describe warmth penetrating through the body, activating a deep 
relaxation that enables release of mental and physical tension. 
The method involves filling a deep basin with warm water and adding 10g of ground 
dry ginger. The ginger is mixed into the water for about 30 seconds. The recipient sits in 
a relaxed position for the footbath, encompassed in a warm soft blanket/sheet that is 
large enough to wrap around the shoulders and reach to the floor. The feet are placed in 
the footbath 10 minutes, as long as the footbath is experienced as warm and comfortable 




Fig. 7. Ginger footbath 
The use of ginger externally is largely unexplored and, with current interest in alternative 
ways of managing osteoarthritis, it offers hope to those with a condition that has hitherto 
led to declining health and quality of life.   
5. Management and ginger therapy 
Osteoarthritis is a health condition that accounts for the majority of hip and knee joint 
replacements and lost efficacy at work and is the most common cause of musculoskeletal 
pain and disability in older adults in Western society (Grainger & Cicuttini, 2004). It is a 
condition that could be better managed, with increased understanding of human motivation 
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and movement. The wisdom of Eastern herbal medicine combined with Anthroposophic 
insights may well provide the answer towards a more effective approach. Conventional 
management of osteoarthritis is typically through the use of non-steroidal anti-
inflammatory drugs and analgesics (Hunt, Lanas et al., 2009). These medications are often 
rejected by people, either due to side effects from long-term use or personal preference 
(Fendrick & Greenberg, 2009). Gastro-intestinal, renal, liver and cardio-vascular risk factors 
restrict the use of non-steroidal anti-inflammatory drugs and analgesics resulting in 
osteoarthritis sufferers using a variety of non-pharmacological treatments, such as exercise, 
heat and hydrotherapy (Grainger & Cicuttini, 2004). Rheumatologists have developed 
guidelines for the management of osteoarthritis after finding there is no statistically 
significant difference between pharmacological and non-pharmacological treatments 
(Zhang, Moskowitz et al., 2008). Considering non-pharmacological treatments are found so 
effective, more attention needs to be given to alternatives. Ginger therapy is one such non-
pharmacological treatment that is worthy of further attention. 
5.1 Ginger therapy  
Ginger therapy involves a warm footbath, resting 30 minutes supine, with a ginger 
compress in place on the kidney region, followed by a rest of 15 minutes. Current 
phenomenological research indicates it is a potentially significant treatment in osteoarthritis. 
Further research is needed to assess its efficacy, with larger numbers of elderly people. In 
2011, a pilot study as preparation for a full trial is commencing in New Zealand. This pilot 
study is evaluating the feasibility of the most suitable methods and procedures to extend 
ginger therapy research. Whilst there are no known side, this study will be interested in any 
potential adverse effects. Additionally, there is a secondary interest in the feasibility and 
effectiveness of using a manufactured ginger patch that can be self-applied in the home or 
residential setting over an extended period. A prospective study is following the pilot study 
and evaluate the efficacy of self-applied ginger therapy using the ginger patch for people 
with osteoarthritis. The ginger patch has the potential to replace the ginger compress, with 
the advantage of it being manufactured for convenient application both in the research and 
clinical situation. The ginger patch would be consistently reliable and appropriately encased 
in a waterproof package that is hygienically sealed from air and light.  
Developing the research of ginger therapy for osteoarthritis will extend the possibility of 
researching its use for other relevant health conditions. Hospitals in Europe use external 
ginger applications to manage a number of different conditions such as: chronic chest 
problems, metabolic disturbances, arthritis and psychiatric conditions. Schurholz et al 
(1992/2002) is the only European research available and it is limited by the numbers of 
people involved and lack of a clearly defined methodology. Unfortunately this research has 
not been published in a recognised peer reviewed journal.  
6. Conclusion 
Ginger’s therapeutic qualities in osteoarthritis are well grounded in the experiences of 
Eastern medicine and modern research trials. Evidence suggests the high doses required for 
a positive effect in osteoarthritis often result in digestive disturbances. The external 
application of ginger avoids this negative, with ginger therapy and the ginger footbath as 
good alternatives. Ginger is a medicinal plant with strong heat activating and anti-
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inflammatory qualities, when applied to the skin in ginger therapy these qualities seem to 
magnify for people with osteoarthritis. Current research on the experiences of ginger 
therapy indicates this is a novel approach to osteoarthritis management. Further research on 
larger numbers of people receiving ginger therapy is necessary to advance the existing 
knowledge base and extend this treatment to increased numbers of osteoarthritis sufferers. 
Ginger therapy needs to be considered as a viable, non-invasive treatment option in caring 
for people with osteoarthritis symptoms. The potential socio-economic benefits are 
considerable and include a decrease in medication, surgical procedures and loss of working 
potential accompanied by improved quality of life and increased independence. 
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1. Introduction 
Our hands are a uniquely human characteristic. They have helped us throughout our 
evolution and even today they help us to live, work, and play. While osteoarthritis can cause 
great pain wherever it presents, it is a particularly crippling disease when it affects the wrist 
and the hands. Unfortunately, osteoarthritis of the wrist can result from a multitude of 
causes. One can divide these causes into two major categories: traumatic and non-traumatic. 
Trauma leading to osteoarthritis often occurs because of ligament and bone injury that 
causes instability, dyskinesis, and altered loading forces that can lead to joint degeneration. 
Intra- or extra-articular fractures can also produce abnormal joint loading and arthritis.  
For example, some prototypical patters of injury include the common scapholunate 
advanced collapse (SLAC) and the closely related scaphoid fracture and non-union (SNAC). 
When conducting a general exam on a patient with suspected wrist osteoarthritis, it is 
essential to begin with a broad differential diagnosis to avoid falling into the trap of 
premature closure. Congenital, inflammatory, vascular, post-traumatic and idiopathic 
etiologies have all been known to cause wrist pain. The goal of the history and physical 
(H&P), therefore, is to articulate the precise cause of this pain in order to design the best 
treatment plan. The patient’s age, hand dominance, aggravating and alleviating pain factors, 
prior trauma, family history, occupation, hobbies and limb functionality are all essential 
parts of a good history. The physical exam, given the close proximity and complexity of the 
intercarpal joints, is particularly important in isolating the exact source of pain. A general 
inspection should note any swelling, erythema or atrophy. Passive and active range of 
motion should be assessed with full flexion, extension, pronation and supination as well as 
radial and ulnar deviation. Physical examination should also comment on any tenderness in 
the joint in addition to the patient’s vascular and neurologic status. Additionally, other 
joints like the elbow, shoulder and neck should be inspected for injury or symptomatology. 
All tests should be bilateral. Functional measures like the Disabilities of the Arm, Shoulder 
and Hand, the Patient Evaluation Measure and the Michigan Hand Outcome Questionnaire 
have also been used to establish one’s functional status (Dias, Rajan et al. 2008). 
Joint palpation is the most useful technique in localizing articulations that produce pain. In 
addition to general palpation, there is an array of pain-producing maneuvers that can be used 
to isolate particular joints. The thumb grind can be used to show thumb carpometacarpal 
(CMC) arthritis. The scaphoid shift test will point towards a scapholunate instability (Watson, 
Ashmead et al. 1988). The shear or ballottment test indicates lunotriquestral instability 
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(Lichtman, Schneider et al. 1981). Pisiform tracking  can be used to isolate pisotriquetral 
osteoarthritis. (Nagle 2000) (Friedman and Palmer 1991). Pain on pronosupination during 
elbow flexion will help isolate a distal radioulnar joint arthritis. Pre- and post-operative pain 
scales, like the Nagy and Buchler system can also be used (Nagy and Buchler 1997). 
Strength should be evaluated and is most useful when objectively quantified with a 
goniometer. Abnormalities in grip strength can indicate pathology and its testing is most 
accurate when used with the rapid exchange grip strength technique which is best at 
determining submaximal effort (Hildreth, Breidenbach et al. 1989). In addition to the initial 
patient visit, this is a useful measure for pre-operative and post-operative comparison. 
A patient’s laboratory evaluation should include, when appropriate, plasma ESR, CRP, 
white blood cell count, uric acid, ANA and rheumatoid factor to rule out any infections or 
likely rheumatologic conditions.  
Imaging studies are another valuable tool at the physician’s disposal that allows him or her 
to better determine which joints are affected by the degenerative processes. The standard x-
ray series should include a posteroanterior (PA), oblique, and lateral view.. A wrist with 
normal anatomic relationships will show that the radial shaft, capitate, and third metacarpal 
will line up along the same vertical axis in the PA wrist x-ray. The physican’s initial 
evaluation should focus on the radioscaphoid, radioluate and capitolunate joints. A 
secondary evaluation should include assessment of the Carpometacarpal, scapho-
trapezium-trapezoid (STT), ulnocarpal and distal radioulnar joint (Weiss and Rodner 2007). 
The articular surface of the radiocarpal joints can sometimes be better seen with a 
tangeiental view. Radioscaphoid and STT joints can be seen best with radial and ulnar 
deviation views. Carpal tunnel and oblique supination views are excellent for the evaluation 
of the pisotriquetral joint (Peterson and Szabo 2006). As always, to control for normal 
anatomic variation, all findings should be compared with the contralateral wrist.  
 
 
Fig. 1. PA Radiograph of Normal Wrist 
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Sonographic imaging can be a useful tool when used by a radiologist with sufficient training 
in its application to hand anatomy. A CT scan may be useful for the evaluation of the 
smaller intra-carpal articulations as well as the pisotriquetral joint. Less obvious distal 
radioulnar joint malalignment can also be picked up with CT views in neutral, supination, 
and pronation positions. However, the CT scan is inferior when compared to the MRI for 
the evaluation of soft tissue defects (Mutimer, Green et al. 2008). An MRI is therefore better 
than a CT to evaluate for cartilage injury. Bone scintigraphy is a nonspecific scan that is best 
used to supplement inconclusive findings. A three-phase scan can be useful in determining 
the chronicity of a pathological condition; a chronic condition is indicated when technetium 
uptake is only seen in delayed images. Finally, a diagnostic injection with corticosteroid or 
anesthetic can be used to confirm the pain-generating joint in the hand. If injection of the 
suspected joint alleviates the patient’s pain, then it is highly likely that you have isolated the 
source of the problem. This technique is particularly useful in differentiating radiocarpal, 
midcarpal, and DRUJ insults. It can also confirm pisotriquetral, STT or basilar thumb 
arthritis. Injection can also distinguish an extra- versus intra-articular pain source.  
Treatment is only effective when correctly paired to an accurate diagnosis. Given the wide array 
of wrist pathologies, the exam and work up of a patient with wrist pain is crucial. All other 
causes of wrist pain must be ruled out before a diagnosis of osteoarthritis is reached. Moreover, 
the surgical treatments discussed below are only to be considered after a patient has failed other 
forms of non-pharmacologic and medical therapies. Some of the more common causes of wrist 
osteoarthritis, their pathogenesis, diagnostic workup and treatment are discussed below.  
2. Osteoarthritis of the radioscaphoid joint 
2.1 Scapholunate advanced collapse 
Scapholunate advanced collapse (SLAC) represents the most common pattern of 
degenerative wrist arthritis and accounts for 72% of the cases of wrist arthritis seen today 
(Watson and Weinzweig 1999). This pattern was first described by Watson and Ballet who 
reviewed four thousand wrist x-ray films for sequential degenerative changes and 
determined that arthritis between the scaphoid, lunate, and radius represented 57% of cases 
surveyed (Watson and Ballet 1984).  
In this disease process, the initial insult is a trauma to the scapholuate (SL) ligament which 
allows for a rotary subluxation of the distal scaphoid, resulting in progressive intercarpal 
instability and joint degeneration. Degenerative changes first affect the radial styloid and 
distal pole of the scaphoid (stage I). Arthritic changes then occur in the radioscaphoid joint 
(stage II), further progress to the capitolunate articulation (stage III), and can culminate with 
pancarpal involvement (Weiss and Rodner 2007). 
In addition to SL ligament trauma, calcium pyrophosphate dehydrate (CPPD) crystal 
deposition can also produce a SLAC wrist pattern of arthritic change (Chen, Chandnani et 
al. 1990). Also, a recent study suggested that SLAC wrist could result independently of 
trauma or CPPD. Studies suggest that congenital SL laxity may predispose certain 
individuals to develop SLAC wrist. (Pollock, Giachino et al. 2010). Other conditions like 
avascular necrosis of the scaphoid (Kienbock disease), Preiser’s disease, intra-articular 
fractures affecting the radioscaphoid or capitolunate joints, perilunate dislocation, malunion 
of a distal radius fracture and carpal instability can also produce a SLAC pattern of 
degeneration in the wrist (Vender, Watson et al. 1987).  
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Fig. 3. Lateral Radiograph of SLAC Wrist 
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As with much of orthopaedics, the anatomy of this system is implicit to its pathology. The 
proximal pole of the scaphoid is elliptical in shape and it articulates in a corresponding 
elliptical surface in the distal radius. With scaphoid instability due to SL ligament injury, the 
scaphoid will rotate causing it to sublux and articulate only on the edges of its joint 
diathasis. As a result, unequal loading forces can cause degenerative change and joint 
destruction. Imagine two nested spoons; if one were to rotate by 90 degrees, they would 
articulate on smaller contact points instead of their entire surface (Mastella, Ashmead et al. 
2009). This subluxation and rotation results in the radioscaphoid pain that designates stage 
II of SLAC. Conversely, the radiolunate joint is spherical, so that rotation of the lunate will 
not cause a change in the force distribution across the joint. It is for this reason that the 
radiolunate joint is preserved in a SLAC wrist pattern of degeneration.  This concept is 
important because it serves as the basis for surgical intervention. 
The presentation of the SLAC wrist typically involves dorsal wrist swelling and tenderness 
in a periscaphoid distribution. The patient may complain of restricted mobility of their 
wrist. Patients will demonstrate a positive “shift test” which has been described as the 
definitive test for scaphoid instability. Pain while applying pressure to the scaphoid during 
radial deviation of the wrist is a positive test result. (Watson, Ashmead et al. 1988). Wrist 
ganglia have also been known to develop in the presence of carpal instability. However, in 
the case of a SLAC wrist, as the disease becomes more advanced the structures needed to 
form ganglia are abolished. Therefore, this complication may be appreciated early on in the 
disease process, but is less apparent with advanced pathology. As always, these clinical 
symptoms should be evaluated in comparison to the contralateral wrist. Also, there have 
been reports of SLAC wrist that are not associated with pain. These are typically isolated to 
older, low-demand patients who’s arthritic disease is discovered during investigation of 
another complaint (Fassler, Stern et al. 1993). Other diagnoses to rule out include thumb 
CMC arthritis, carpal tunnel syndrome, and trigger finger. The diagnosis of SLAC wrist is 
confirmed with bilateral plain x-rays with evidence of degeneration in the affected hand. 
Nonsurgical management of a SLAC wrist or its related conditions currently lacks long term 
data. This therapy consists of non-steroidal anti-inflammatory drugs (NSAIDS), splints, and 
injections for symptomatic treatment. By decreasing inflammation with NSAIDS and 
corticosteroids, and decreasing mobility with splinting we are able to provide some pain relief. 
Anti-inflammatory medications may need to be tailored to each individual patient as some 
respond better to some medications than others. Corticosteroid injections can be particularly 
beneficial in patients who show swelling and synovitis. Moreover, intermittent injections can 
have less side effects than those associated with chronic anti-inflammatory use. Splints are to 
be worn intermittently throughout the day and during the night. One study determined that if 
pain is not limiting and grip strength is greater than or equal to 80%, managing these 
symptoms non-surgically is a reasonable option (Pilny, Kubes et al. 2006).  
Surgical contraindications are due to any pathology that affects the radiolunate joint. A 
SLAC wrist pattern represents a final common pathway in a variety of disease processes but 
a defining feature remains to be the preservation of the radiolunate joint. This joint’s 
integrity is critical because it serves as the main point of force translation through the wrist 
after several of the surgical options. Therefore, any significant degeneration of the 
radiolunate joint would qualify as a contraindication for surgery. Similarly, any ulnar 
translation of the carpus on the radius will alter the radiolunate relationship and also serve 
as a contraindication for surgery (Pellegrini, Parentis et al. 1996). 
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Surgical therapy can be accomplished through a variety of approaches. Historically, this 
consisted of scaphoid excision and replacement with a silicone arthroplasty along with 
fusion of the capitate, lunate, hamate and triquetrum by using Kirschner-wires (K-wires). 
Use of the silicone scaphoid replacement has fallen out of favor due to the fact that silicone 
wear resulted in particulate formation, synovitis, and joint collapse (Ashmead, Watson et al. 
1994). Despite the failure of the silicone scaphoid replacement, the technique of fusing the 
four aforementioned carpal bones along with scaphoid excision remains to be a popular 
surgical option for patients suffering from a SLAC wrist; this procedure is referred to as a 
scaphoid excision with a four-corner arthrodesis. This is a reliable and effective procedure 
that provides a stable column for force transfer through the radiolunate joint. Dacho has 
shown encouraging results with this technique on long-term follow-up in the treatment of 
both SLAC and SNAC wrist injury (Dacho, Grundel et al. 2006). Mid-term results using K-
wires specifically have also enjoyed similar success (Winkler, Borisch et al. 2010). 
Alternatively, a proximal row carpectomy (PRC) can be used in lieu of a four-corner 
arthrodesis. This technique calls for the removal of the proximal row of carpal bones and 
allows the distal row to collapse proximally. In this scenario, the capitate articulates with the 
lunate facet of the radius. This surgery preserves a fair amount of wrist mobility and 
requires no arthrodesis. PRC is a viable alternative to four-corner arthrodesis as it has 
shown success in long-term follow-up (Liu, Zhou et al. 2009). 
Controversy exists in determining which procedure is superior; four-corner arthrodesis with 
scaphoid excision or PRC. Studies suggest no difference in outcomes when comparing these 
two procedures. However, some patients may prefer the PRC procedure as it allows for 
greater wrist mobility. In a high demand wrist the loss of stability could become 
problematic and the four-corner arthrodesis may be the preferred technique in this patient. 
(Mulford, Ceulemans et al. 2009) (Cohen and Kozin 2001; Dacho, Baumeister et al. 2008; 
Bisneto, Freitas et al. 2011).  
Other surgical techniques include denervation, total wrist fusion, wrist arthroplasty and 
variations of intercarpal arthrodeses. Denervation can be accomplished through 
transection of all articular nerve branches or it can be limited to the anterior or posterior 
interosseous nerves proximal to the carpus. One study showed long-term data supporting 
the use of dennervation as a treatment for SLAC/SNAC wrist injury (Rothe, Rudolf et al. 
2006). 
Any symptoms of complex regional pain syndrome (intense burning pain that gets worse 
over time and spreads to adjacent or contralateral limbs) should be treated with a stress 
loading program (active exercise with minimal joint motion). Also, the patient should be 
monitored for triquetral impingement ligament tear syndrome (TILT). This syndrome 
occurs secondary to ulnar translation of the carpus due to the increased laxity of the 
radiocarpal ligaments (Watson and Weinzweig 1999). TILT will manifest as pain and 
tenderness on the ulnar aspect of the wrist. When occurring after a reconstructive surgery, 
TILT will often resolve spontaneously, however, if it persists it can be corrected by resecting 
the impinging portion of the ulnar sling. Radiolunate degeneration is a rare complication of 
reconstruction and is always seen in the context of ulnar translation of the carpus. When this 
occurs, it can be successfully repaired with total wrist arthrodesis. 
Overall, the treatment of SLAC wrist enjoys encouraging outcomes. Post operative follow 
up shows that patients generally have improved pain levels while maintaining ROM and 
grip strength. (Malerich, Clifford et al. 1999)Although controversy remains with regard to 
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the “best” procedure with which to treat a SLAC wrist, we are able to take solace in the fact 
that regardless of operative technique, patient satisfaction remains very high. 
2.2 Scaphoid nonunion advanced collapse 
It has become clear that scaphoid nonunion advanced collapse (SNAC) is a clinical entity 
similar to SLAC wrist in that it is identified by a series of predictable degenerative changes. 
In a SNAC wrist, however, the initial injury is a fracture and nonunion of the scaphoid 
rather than an SL ligament injury. A scaphoid malunion can also cause a SNAC injury. 
Interestingly, in a SNAC injury, because the SL ligament is preserved, the proximal 
scaphoid fragment is not involved in the degenerative changes and it is the scaphocapitate 
that tends to be affected (Vender, Watson et al. 1987).  
Because of its close similarity to the SLAC wrist, a SNAC injury shares a similar disease 
progression with comparable stages of joint degeneration. Stage I is associated with arthritis 
localized to the distal scaphoid and radial styloid. Stage II shows radioscaphoid and 
scaphocapitate arthritis with a preserved lunocapitate joint. Once the lunocapitate joint 
becomes involved, a stage III designation is warranted.  
Much like the presentation and evaluation of SLAC wrist, a patient with a SNAC wrist 
injury will present with wrist pain at the radioscaphoid joint and dorsal swelling. Diagnosis 
will be based on the history and physical but confirmed with an x-ray and its comparison to 
the contralateral wrist. Treatments for SNAC wrist also overlap with the SLAC wrist and are 
comprised of nonsurgical management with splinting and injections, as well as surgical 
options like arthrodesis, proximal row carpectomy, denervation, and radial styloidectomy. 
One notable difference in between the treatment plans for SLAC and SNAC wrists is that the 
SNAC wrist can be treated with the excision of the distal scaphoid fragment. One study 
noted that 13 out of 19 patients showed significant pain relief as well as improved ROM and 
grip strength with this procedure (Malerich, Clifford et al. 1999). 
In summary, a SNAC wrist injury shares a great deal with a SLAC wrist and is discerned 
through a careful history, physical, and radiographic evaluation. Treatment options are 
almost identical for the two pathologies with a notable distinction that a SNAC wrist can be 
treated with a distal scaphoid excision. 
3. Osteoarthritis of the distal radioulnar joint 
The distal radioulnar joint (DRUJ) is essential to painless pronation and supination of the 
wrist. A DRUJ that is plagued by osteoarthritis will show restriction and pain with these 
motions as well as a significantly decreased grip strength. Arthritis in this joint, therefore, 
severely limits the function of one’s entire hand. Injury can occur secondary to intra-
articular fractures involving the DRUJ or malunion of forearm fractures which result in 
altered biomechanics. The Colles’ fractures in particular can create carpal instability and 
subsequent arthritis (Cooney, Dobyns et al. 1980).  
The radius and ulna are connected by both a proximal and distal radioulnar joint which 
allow for forearm pronation and supination. Stability of the joints is conferred by a series of 
ligamentous supports. The DRUJ specifically is supported by the triangular fibrocartilage 
complex (TFCC). The TFCC is composed of the articular disc, the dorsal and volar 
radioulnar ligaments, the meniscus homologue, the ulnar collateral ligament, and the sheath 
of the extensor carpi ulnaris (Palmer and Werner 1981). The articular disc is largely an 
avascular structure. The main stabilizers of the DRUJ are dorsal and palmar radioulnar 
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ligaments (af Ekenstam, Palmer et al. 1984). The blood supply is provided by the anterior 
interosseous artery, the ulnar artery, and the medullary interosseous arteries. 
Understandably, those structures with ample blood supply, like the TFCC, are able to heal 
readily while the avascular structures, like the articular disc, are less able to do so. The 
annular ligament supports the proximal radioulnar joint and the interosseous membrane 
serves as a connection between the diathasis of the radius and ulna.  
 
Fig. 4. PA Radiograph of Osteoarthritis of the DRUJ 
The natural history of DRUJ arthritis begins with a pre-arthritic condition, usually a radial 
fracture malunion or instability of the DRUJ, which can develop into a degenerative arthritis 
over time. DRUJ instability is defined as the inability of the DRUJ to maintain its normal 
anatomic relationship under physiologic loading. Instability can be classified as either acute 
or chronic. In a case of acute DRUJ instability, the cause is often a fall on an outstretched 
hand resulting in an acute dislocation, fracture of the radial head or either bones of the 
forearm (Edwards and Jupiter 1988). This may result in injury to the joint surface, its 
supporting ligaments, or both (Bruckner, Alexander et al. 1996). In this scenario, ulna volar 
dislocation occurs secondary to hypersupination while ulna dorsal dislocations occur 
secondary to hyperpronation. Dislocations can be classified as either simple (reduced 
spontaneously or with minimal effort) or complex (irreducible or easily dislocated), the 
latter of which is usually due to a tear in the TFCC (Bruckner, Alexander et al. 1996). 
Chronic DRUJ instability can also be the result of a particular injury or it can result from a 
fracture of the radius and/or ulna, malunion or ligament injury. If left untreated, acute or 
chronic instability can progress into an arthritic degeneration of the DRUJ and can be 
associated with ulnar impaction (Kakar, Carlsen et al. 2010).  
Most patients will present with painful wrist motions and restricted mobility. If there is a 
grossly apparent acute fracture, complete radiologic evaluation is warranted (Braun 1992). 
However, with an injury of a more insidious onset (like subluxation or dislocation) then 
swelling may be the only physical finding. A volar dislocation of the DRUJ will not allow 
pronation while a dorsal dislocation will not allow supination (Hauck, Skahen et al. 1996). 
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The differential diagnosis includes piso-triquetral and triquetro-hamate arthritis. The 
presence of a piano-key sign should be assessed in patients complaining of DRUJ pain 
(Scheker, 2009). The patient places their palms down on the examination table and pushes. 
The sign is present if the head of the ulna can be seen moving up and down. Such a finding 
is indicative of damage to the triangular fibrocartilage and is more common in rheumatoid 
arthritis as opposed to osteoarthritis. A second maneuver begins with the patient placing 
their elbows on the examination table with their forearms positioned perpendicular to the 
table’s surface. Shear force is applied to the DRUJ. Any pain or displacement between the 
radius and ulna will indicate DRUJ instability. A third maneuver to be performed would be 
to apply shear force by pushing down on the patient’s forearms while the patient pronates 
and supinates. Pain may be indicative of DRUJ incongruity and/or arthritis.  
 
 
Fig. 5. PA Radiograph of Ulnar Impaction with an Ulnar –sided Lunate Cyst in Setting of DRUJ 
Arthritis 
Radiographic assessment of the DRUJ is important in diagnosis and treatment planning. 
Typically, plain radiographs are used to survey the joint for any deterioration. A PA x-rays 
should be taken with the shoulder abducted to 90 degrees, with the elbow flexed at 90 
degrees and the wrist in neutral position. The PA view is important in evaluating DRUJ 
congruency. Typically, the sigmoid notch slants towards the ulnar styloid with a 20 degree 
angle (af Ekenstam and Hagert 1985). However, evaluation of this angle is important 
because it has significant implications in ulnar shortening osteotomy as well as some of the 
other surgical treatment modalities. The lateral x-ray is also essential in determining DRUJ 
congruency. One can confirm that their scan is a true lateral view when the pisiform is in 
line with the distal third of the scaphoid. A true lateral view of the carpus will be required to 
evaluate for DRUJ subluxation. The pisotriquetral joint and hook of hamate can be 
evaluated from an oblique view with the wrist in a semipronanted and semisupinated 
position. All radiography should be compared with the contralateral side. CT scans can be 
useful when x-ray findings are unequivocal and may identify joint surface defects and 
subluxation. (Staron, Feldman et al. 1994). (Pirela-Cruz, Goll et al. 1991). An MRI is more 
useful if there is clinical suspicion of a triangular fibrocartilage tear or other cartilage defects 
(Golimbu, Firooznia et al. 1989). A bone scan is warranted in patients with a high clinical 
suspicion of DRUJ pathology who have a negative plain radiograph (Shewring, Savage et al. 
1994). While this is a very sensitive technique, unfortunately, it lacks in specificity. Infection, 
bruising, and inflammation can be readily detected with scintigraphy. 
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Treatment will obviously vary greatly depending on the presentation of either a pre-arthritic 
or arthritic joint. In the case of a simple subluxation or dislocation, treatment consists of 
immobilization in a reduced position with an above-elbow cast for 6 weeks. A closed 
reduction, if needed, should be performed under regional anesthesia. If the DRUJ remains 
unstable after reduction, surgery may be necessary to repair the torn TFCC. Open reduction 
is only indicated when a closed reduction is impossible or unsatisfactory. Fractures are to be 
evaluated individually as there are many unique patterns with an ever changing array of 
plates and screws available for repair. With regard to more chronic DRUJ instability, soft 
tissue reconstruction is usually satisfactory. Ligamentous injuries can be repaired by either 
extra-articular or intra-acricular approaches. The extra-articular approach is technicnically 
an easier surgery and is achieved by a direct radioulnar tether (Fulkerson and Watson 1978) 
or an indirect radioulnar link (with the use of a ulnocarpal sling or tenodesis) (Breen and 
Jupiter 1989). An intra-articular repair, though a more demanding procedure, can 
reconstitute the original ligamentous anatomy and can yield very satisfactory results 
(Scheker, Belliappa et al. 1994).  
In patients with evidence of joint misalignment without the presence of arthritis, treatment 
can be centered on realignment procedures through a variety of approaches, osteotomy or 
ulnar shortening osteotomy. An ulnar shortening procedure is another technique that can be 
used to re-establish stability in an otherwise lax TFCC (Nishiwaki, Nakamura et al. 2005). 
With this technique, more extensive surgery is avoided and early pre-arthritic conditions 
can be corrected before they progress further. However, it should be noted that Jupiter and 
his group determined that shortening by 6mm was enough to produce painful symptoms in 
the DRUJ (Jupiter and Masem 1988). This evidence of altered kinematics in a cadaver model 
corroborate this finding (Adams 1993). It was determined that a possible remedy for this 
cause of DRUJ arthritis is dependent on the status of the articular cartilage of the sigmoid 
notch and the ulnar seat (Hunt, Hastings et al. 1998). This study also concluded that for less 
advanced disease, where the DRUJ showed only mild arthosis, the joint stability could be 
regained with ulnar shortening osteotomy (Hunt, Hastings et al. 1998).  
Once arthritis has developed in the DRUJ, a different armamentarium is available for use. The 
Darrach resection is the oldest of these procedures and it refers to the resection of the distal end 
of the ulna; effectively eliminating the pain-generating grinding that would otherwise occur at 
the DRUJ (Darrach 1992). However, this particular technique is not without post-operative 
complications which are related to the de-stabilizing nature of the procedure (snapping the 
ulnar stump and ulnar translocation with tendon rupture). When compared to the Sauve-
Kapandji and hemiresection-interposition arthroplastic procedures, the Darrach procedure is 
less favorable and was only preferred in elderly patients with severe osteoarthritic changes 
(Minami, Iwasaki et al. 2005). The Sauve-Kapandji technique involves the fusion of the head of 
the ulna to the radius. In such a surgery, the TFCC will be preserved and the ulnar carpus will 
remain adequately supported. A recent study suggest that for moderate, but not more complex 
disease, the Sauve-Kapandji procedure showed good improvement in forearm rotation, grip 
strength, and pain reduction (Czermak, Wittemann et al. 2007).  
While the aforementioned techniques are all useful in relieving pain by removing the 
grinding contact forces responsible for that pain, they also inherently result in some 
destabilization. This may be acceptable in a patient with a low-demand lifestyle but it can 
also be problematic in someone in need of a more durable solution. Recently, prosthetic 
replacements have been developed and have outcomes as varied as their designs. 
Advantages and disadvantages of each particular device is best managed by the operating 
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surgeon. Arthrodesis of the wrist remains a viable final alternative and is usually reserved 
for malunited fractures of the carpal scapohoid and other complex pathology. However, the 
fact remains that a thorough H&P and early intervention with a skilled physician will allow 
a patient the greatest chance of a successful outcome by preventing more advanced disease. 
4. Osteoarthritis of the carpometacarpal joint 
Though the thumb carpometacarpal (CMC) joint is technically located in the hand, its close 
proximity to the carpal bone often implicates it as a pain generator when differentiating 
different causes of chronic wrist pain. Osteoarthritis(OA) of the thumb carpometacarpal 
(CMC) joint can cause debilitating pain and decreased strength and range of motion, 
making it difficult to do even the most common household tasks such as turning door-knobs 
or opening jars. CMC arthritis is the 2nd most common arthritic condition of the hand and in 
incidence, is the second only to arthritis of the distal interphalngeal joint (DIP).(Wilder, 
Barrett et al. 2006)  Furthermore, it is the most common upper extremity arthritis requiring 
surgical intervention. It commonly affects women in their 5th to 6th decade of life. 
Epidemiologic studies have shown that post menopausal women are more likely to develop 
this condition; radiographic CMC arthritis is present in 25% of men and 40% of women over 
the age of 75. (Van Heest and Kallemeier 2008)  
The thumb CMC is a biconcave-convex “saddle” joint that consists of the articular surfaces of 
the distal trapezium and the proximal thumb metacarpal.  The unique nature of the joint  
allows for flexion, extension, abduction, adduction, and oppositional movements. Stability of 
the joint is provided primarily by the bony structures and several key ligaments: anterior 
oblique, posterior oblique, dorosoradial, palmar oblique, ulnar collateral, and intermetacarpal 
ligaments.  The dorsoradial ligament, one of the thickest CMC ligaments, prevents excessive 
dorsoradial translation while the intermetacapal prevents radial translation. Excess pronation, 
abduction, and extension of the thumb are prevented by the palmar obique or “beak” ligament 
which has been regarded as the most important stabilizing structure.(Sung and Akelman 2009)  
Interestingly, this unique ability and movement of the thumb has been implicated in the 
pathophysiology of thumb CMC osteoarthritis.  
However, the specific etiology of CMC arthritis has yet to be published. Currently, experts 
believe that the pathogenesis is multifactorial. Genetic and environmental factors, 
hypermobility of the joint, ligament laxity, anatomic variations, and extrinsic trauma have 
all been implicated. It has been suggested that genetic influences play a role in the 
development of CMC arthritis, but its exact pathway has yet to be determined.(MacGregor, 
Li et al. 2009) Increased joint laxity has been associated as studies have shown that radial 
subluxation of the base of the thumb CMC joint from the trapezium predisposes patients to 
developing osteoarthritis of the joint.(Hunter, Zhang et al. 2005) Women have higher 
incidence of thumb CMC osteoarthritis, possibly suggesting hormonal influences (prolactin, 
relaxin, and estrogen) as mechanisms for hypermobility and increased joint laxity. (Sung 
and Akelman 2009). In addition to this, cadaveric studies have shown that women also have 
a smaller, less congruous trapezium that along with hypermobility and joint laxity 
contribute to increased stress on the joint.(North and Rutledge 1983; Ateshian, Rosenwasser 
et al. 1992) It is this increased focal and loading stress on joint cartilage which is believed to 
be the instigating event. Furthermore, pinching and gripping generate large loads across the 
CMC joint and may explain why people who actively sew and knit develop arthritis at a 
higher rate. (Cooney and Chao 1977)  Increased body mass index (BMI) has also been 
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Treatment will obviously vary greatly depending on the presentation of either a pre-arthritic 
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remain adequately supported. A recent study suggest that for moderate, but not more complex 
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strength, and pain reduction (Czermak, Wittemann et al. 2007).  
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surgeon. Arthrodesis of the wrist remains a viable final alternative and is usually reserved 
for malunited fractures of the carpal scapohoid and other complex pathology. However, the 
fact remains that a thorough H&P and early intervention with a skilled physician will allow 
a patient the greatest chance of a successful outcome by preventing more advanced disease. 
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which has been regarded as the most important stabilizing structure.(Sung and Akelman 2009)  
Interestingly, this unique ability and movement of the thumb has been implicated in the 
pathophysiology of thumb CMC osteoarthritis.  
However, the specific etiology of CMC arthritis has yet to be published. Currently, experts 
believe that the pathogenesis is multifactorial. Genetic and environmental factors, 
hypermobility of the joint, ligament laxity, anatomic variations, and extrinsic trauma have 
all been implicated. It has been suggested that genetic influences play a role in the 
development of CMC arthritis, but its exact pathway has yet to be determined.(MacGregor, 
Li et al. 2009) Increased joint laxity has been associated as studies have shown that radial 
subluxation of the base of the thumb CMC joint from the trapezium predisposes patients to 
developing osteoarthritis of the joint.(Hunter, Zhang et al. 2005) Women have higher 
incidence of thumb CMC osteoarthritis, possibly suggesting hormonal influences (prolactin, 
relaxin, and estrogen) as mechanisms for hypermobility and increased joint laxity. (Sung 
and Akelman 2009). In addition to this, cadaveric studies have shown that women also have 
a smaller, less congruous trapezium that along with hypermobility and joint laxity 
contribute to increased stress on the joint.(North and Rutledge 1983; Ateshian, Rosenwasser 
et al. 1992) It is this increased focal and loading stress on joint cartilage which is believed to 
be the instigating event. Furthermore, pinching and gripping generate large loads across the 
CMC joint and may explain why people who actively sew and knit develop arthritis at a 
higher rate. (Cooney and Chao 1977)  Increased body mass index (BMI) has also been 
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associated with higher rates of CMC arthritis as it is believed increased BMI generates a 
higher biomechanical load.(Haara, Heliovaara et al. 2004) Finally, prior extrinsic trauma 
such as a Bennett fracture can predispose an individual to  developing OA of the CMC joint 
and contribute to increased joint laxity and altered biomechanics.(Sung and Akelman 2009) 
Overall, it is difficult to ascertain one specific cause or risk factor for developing 
osteoarthritis of the CMC joint; rather, it is important to view the pathophysiology as 
multifactorial as ongoing research continues to develop and clarify the picture.  
Symptomatic patients typically present with diffuse pain around the thenar eminence and 
perhaps on the dorsum of the thumb base which is exacerbated by pinching and grasping 
activities. Including the previously mentioned examples, turning the key or holding onto a 
large jar are often activities that illicit pain. Early in the disease, stiffness and loss of motion are 
not the primary complaints. As the disease progresses, both symptoms can occur as 
osteophytes limit motion resulting in a subluxed joint that is adducted, dorsally fixed, and has 
limited palmar abduction. Chronic stiffness can lead to changes in the metacarpophalangeal 
(MCP) joint resulting in hyperextension to compensate for the proximal loss of motion and 
loss of the thumb index web space.(Sung and Akelman 2009) Advanced disease may have 
dorsoradial subluxation of the first metacarpal on the trapezium termed the “shoulder sign”.  
Physical examination demonstrates tenderness to palpation over the dorsal or dorsoradial 
aspect of the thumb. Erythema, edema, and calor may be present but is not a prerequisite for 
diagnosis. The “grind test” is performed by rotation the thumb metacarpal while applying 
axial compression. It is considered positive if there pain with or without crepitus. The test 
has a high specificity (80-93%) and moderate sensitivity (42-53%) making it useful in 
confirming the diagnosis of CMC osteoarthritis.(Merritt, Roddey et al. 2010) 
Radiographic imaging is the most useful initial study to evaluate and stage CMC 
osteoarthritis. In the majority of cases posterioranterior, lateral, and oblique views are all 
that are necessary. A stress view of both thumb CMC joints taken together as the patient 
pushes their thumb tips together can help assess the degree of joint space loss, but is not 
required.(Eaton and Littler 1973) The contralateral hand should also be imaged for 
comparative purposes. There are two major classification systems used for staging. The 
Eaton staging system is the most widely used and is based on degenerative changes noted 
on the radiographs. Stage 1 has normal articular cartilage with possible mild narrowing of 
the joint space secondary to joint effusion or ligament laxity. Stage 2 disease has narrowing 
of the joint space associated with subchondral sclerotic changes and the possibility of 
ostephyte formation <2 mm.  Mild to moderate subluxation of the thumb on the trapezium 
radially and dorsally may also be present. Stage 3 involves significant joint space narrowing 
with cystic and sclerotic changes with osteophytes larger than 2 mm. Stage 4 represents 
advanced degenerative changes of the CMC joint along with clear evidence scapho-trapezio-
trapizoidal (STT) joint destruction. It has also been shown that pain and stiffness do not 
exactly correlate with radiographic findings.(Eaton and Glickel 1987) The Burton system 
uses clinical signs, symptoms, and radiographic evidence of disease and can also be used.  
The differential diagnosis for pain around the base of the thumb also includes de Quervain 
tenosynovitis, flexor carpi radialis (FCR) tendonitis, radioscaphoid pathology, and carpal 
tunnel syndrome. Patients with de Quervain tenosynovitis will have tenderness at the tip of 
the radial styloid and 1st extensor compartment and may have a positive Finkelstein’s test. 
FCR tendonitis would elicit pain with flexion of the wrist and tend to be more ulnar 
compared to CMC osteoarthritis. Fracture or arthritis of the scaphoid bone can present 
similarly and a detailed history and physical investigating for recent trauma is essential in 
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differentiating the diagnosis. Finally, close to 40% of patients with CMC arthritis had 
concomitant carpal tunnel syndrome, making it important to diagnose to eliminate 
additional operations as both conditions can be repaired simultaneously.(Florack, Miller et 
al. 1992) Likewise, this condition is associated with concomitant arthritis of other carpal 
joints in the hand such as STT joint. Many times, corticosteroid intra-articular injections can 
help differentiate between different potential conditions based on subsequent pain relief.  
Initial treatment should focus on behavior modification, NSAIDS, and rest. Also, all patients 
should undergo a trial of conservative management including occupational therapy, 
splinting, and steroid injections. Occupational therapy should focus on strengthening the 
surrounding muscles to support the joint while stretching to maximize range of motion. 
Splinting can reduce the focal and load stress on the joint. The effectiveness of corticosteroid 
injections is widely debated with several studies demonstrating conflicting 
conclusions.(Day, Gelberman et al. 2004; Meenagh, Patton et al. 2004; Khan, Waseem et al. 
2009; Swindells, Logan et al. 2010) A combination of these two treatments has shown to be 
effective in stage I and stage II disease.(Swigart, Eaton et al. 1999) As the disease progresses 
and the joint undergoes further degenerative changes the results of this treatment modality 
becomes less predictable. A recent study in 2009 also demonstrated hylan injections as an 










Fig. 6. PA Radiograph of Thumb CMC Arthritis 
  
Osteoarthritis – Diagnosis, Treatment and Surgery 
 
182 
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comparative purposes. There are two major classification systems used for staging. The 
Eaton staging system is the most widely used and is based on degenerative changes noted 
on the radiographs. Stage 1 has normal articular cartilage with possible mild narrowing of 
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differentiating the diagnosis. Finally, close to 40% of patients with CMC arthritis had 
concomitant carpal tunnel syndrome, making it important to diagnose to eliminate 
additional operations as both conditions can be repaired simultaneously.(Florack, Miller et 
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joints in the hand such as STT joint. Many times, corticosteroid intra-articular injections can 
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Fig. 7. Lateral Radiograph  of Thumb CMC Arthritis 
Surgical treatment should be considered when conservative measures have failed to relieve 
pain and improve day to day thumb function. Various options exist and it is therefore essential 
to engage the patient in an informed two-way discussion regarding the relative merits and 
drawbacks of each alternative. Patients with stage 1 or 2 disease have shown good outcomes 
with arthroscopy, metacarpal extension osteotomy, and volar ligament reconstruction. 
Arthroscopy is minimally invasive and allows for direct visualization of the articular surface 
and has been shown to be effective for the treatment of early osteoarthritis of the thumb 
CMC(Badia and Khanchandani 2007). Likewise, metacarpal extension osteotomy can correct 
the alignment of the thumb and transfer the load from the diseased palmar compartment to 
the normal dorsal compartment of the trapezium.(Pellegrini, Parentis et al. 1996) Eaton and 
Littler have well described a volar ligament reconstruction using part of the FCR tendon and 
have shown excellent results in 100% of patients with stage 1 and 82%-91% of patients with 
stage 2 disease.(Eaton, Lane et al. 1984; Freedman, Eaton et al. 2000).  
For advanced disease, many surgical options exist: arthrodesis, implant arthroplasty, or 
resection arthroplasty with or without ligament reconstruction and tendon interposition.  
Arthrodesis of the thumb CMC joint provides pain relief and a strong and stable thumb 
for pinch and grasp activities. Disadvantages of the procedure include the risk of 
nonunion and altered biomechanics (Carroll and Hill 1973) Historically, surgeons have 
recommended this procedure to younger patients with high demanding jobs post 
traumatic injury; however, due to the recent success or arthroplasty this procedure may 
be falling out of favor. All the arthroplasty procedures involve either a full or partial 
trapeziectomy. Implant arthoplasty have used materials such as silicone, zircon, circonia, 
and titanium. All have  their respective disadvantages from efficacy to side effects.(Sung 
and Akelman 2009) Total prosthetic joint arthroplasty is a promising field and further 
research need to assess reproducibility and long term risks and benefits.(Ulrich-Vinther, 
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Puggaard et al. 2008) Currently, the gold standard is resection arthroplasty with or 
without ligament reconstruction and tendon interposition. This procedure requires a 
complete trapeziectomy.(Tomaino 2006; Mathoulin, Moreel et al. 2008; Sammer and 
Amadio 2010) On the other hand, there are studies that show that ligament recreation 
provides no further benefit and that trapeziectomy alone is the best and safest operation. 
(Wajon, Ada et al. 2005; Field and Buchanan 2007) Further studies need to be conducted to 
clarify this promising therapeutic modality.  
In addition to the thumb CMC joint, osteoarthritis of the second or third CMC joint can also 
cause significant wrist pain. Osteoarthritis of these joints is less common than thumb CMC 
arthritis. Typically, patients present with dorsal wrist pain and a bony prominence over the 
CMC joint that is often misdiagnosed as an isolated dorsal ganglion.  Generally, repeated 
subacute trauma from extensive radial or ulnar deviation causes degenerative changes and 
carpal bossing of the CMC joint. Nonsurgical options consist of rest, NSAIDS, splitting, and 
intra-articular corticosteroid injections. Surgical options include boss excision and 
arthrodesis.   
Thumb carpometocarpal osteoarthritis is one of the most common orthopaedic conditions a 
hand surgeon will face. The Eaton classification aids in stratifying the treatment regimen. 
Patients with early degenerative disease may benefit greatly from a regimen combining 
intra-articular corticosteroid injections and splinting. Several procedures exist for advanced 
disease and currently no one particular procedure has shown to be efficacious compared to 
another.(Wajon, Carr et al. 2009)  
5. Osteoarthritis of the scaphotrapeziotrapezoid joint 
Scaphotrapeziotrapezoid (STT) arthritis is the second most common degenerative disease of 
the wrist and often is linked with thumb CMC arthritis due to its close anatomical location. 
Isolated STT arthritis can also exist and it has been reported in 15% of wrist radiographs and 
21% of cadaveric wrists.(Watson and Ballet 1984; Viegas, Patterson et al. 1993). Higher 
incidence rates have also been published and it is believed that the age of the cadavers may 
explain the differences in values. (Bhatia, Pisoh et al. 1996; Wollstein and Carlson 2009) 
Therefore, due to differences between radiographic findings and clinical symptoms, the 
exact incidence of isolated STT arthritis is unknown. There appears to be a gender bias as it 
commonly affects postmenopausal women after the age of 50.(Moritomo, Viegas et al. 2000; 
Kapoutsis, Dardas et al. 2011) 
The scaphoid is the largest bone in the proximal carpal row and is an important link between 
the proximal and distal wrist. It articulates with the distal radius, the lunate, the capitate, the 
trapezium, and the trapezoid. The trapezium articulates with the scaphoid and first 
metacarpal via the CMC joint. The trapezoid articulates with the trapezium, scaphoid, capitate, 
and second metacarpal. Moritomo et al. described the ligaments and biomechanics of the STT 
joint.(Moritomo, Viegas et al. 2000). The capitate-trapezium ligament originates from the 
trapezium and inserts into the volar waist of the capitates and deepens the socket of the STT 
joint acting as a labrum for the distal pole of the scaphoid while reinforcing the volar  aspect of 
the joint capsule as well. The scaphotrapezial and trapeziotrapezoid ligament are two other 
volar ligaments that stabilize the joint. Dorsally, the dorsolateral STT ligament stabilizes and 
links the joint to the rest of the midcarpus. The function of the joint is to allow transfer of load 
from the thumb and radial hand to the scaphoid, capitate, and other carpal bones.  
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Surgical treatment should be considered when conservative measures have failed to relieve 
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with arthroscopy, metacarpal extension osteotomy, and volar ligament reconstruction. 
Arthroscopy is minimally invasive and allows for direct visualization of the articular surface 
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traumatic injury; however, due to the recent success or arthroplasty this procedure may 
be falling out of favor. All the arthroplasty procedures involve either a full or partial 
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and Akelman 2009) Total prosthetic joint arthroplasty is a promising field and further 
research need to assess reproducibility and long term risks and benefits.(Ulrich-Vinther, 
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Puggaard et al. 2008) Currently, the gold standard is resection arthroplasty with or 
without ligament reconstruction and tendon interposition. This procedure requires a 
complete trapeziectomy.(Tomaino 2006; Mathoulin, Moreel et al. 2008; Sammer and 
Amadio 2010) On the other hand, there are studies that show that ligament recreation 
provides no further benefit and that trapeziectomy alone is the best and safest operation. 
(Wajon, Ada et al. 2005; Field and Buchanan 2007) Further studies need to be conducted to 
clarify this promising therapeutic modality.  
In addition to the thumb CMC joint, osteoarthritis of the second or third CMC joint can also 
cause significant wrist pain. Osteoarthritis of these joints is less common than thumb CMC 
arthritis. Typically, patients present with dorsal wrist pain and a bony prominence over the 
CMC joint that is often misdiagnosed as an isolated dorsal ganglion.  Generally, repeated 
subacute trauma from extensive radial or ulnar deviation causes degenerative changes and 
carpal bossing of the CMC joint. Nonsurgical options consist of rest, NSAIDS, splitting, and 
intra-articular corticosteroid injections. Surgical options include boss excision and 
arthrodesis.   
Thumb carpometocarpal osteoarthritis is one of the most common orthopaedic conditions a 
hand surgeon will face. The Eaton classification aids in stratifying the treatment regimen. 
Patients with early degenerative disease may benefit greatly from a regimen combining 
intra-articular corticosteroid injections and splinting. Several procedures exist for advanced 
disease and currently no one particular procedure has shown to be efficacious compared to 
another.(Wajon, Carr et al. 2009)  
5. Osteoarthritis of the scaphotrapeziotrapezoid joint 
Scaphotrapeziotrapezoid (STT) arthritis is the second most common degenerative disease of 
the wrist and often is linked with thumb CMC arthritis due to its close anatomical location. 
Isolated STT arthritis can also exist and it has been reported in 15% of wrist radiographs and 
21% of cadaveric wrists.(Watson and Ballet 1984; Viegas, Patterson et al. 1993). Higher 
incidence rates have also been published and it is believed that the age of the cadavers may 
explain the differences in values. (Bhatia, Pisoh et al. 1996; Wollstein and Carlson 2009) 
Therefore, due to differences between radiographic findings and clinical symptoms, the 
exact incidence of isolated STT arthritis is unknown. There appears to be a gender bias as it 
commonly affects postmenopausal women after the age of 50.(Moritomo, Viegas et al. 2000; 
Kapoutsis, Dardas et al. 2011) 
The scaphoid is the largest bone in the proximal carpal row and is an important link between 
the proximal and distal wrist. It articulates with the distal radius, the lunate, the capitate, the 
trapezium, and the trapezoid. The trapezium articulates with the scaphoid and first 
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and second metacarpal. Moritomo et al. described the ligaments and biomechanics of the STT 
joint.(Moritomo, Viegas et al. 2000). The capitate-trapezium ligament originates from the 
trapezium and inserts into the volar waist of the capitates and deepens the socket of the STT 
joint acting as a labrum for the distal pole of the scaphoid while reinforcing the volar  aspect of 
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from the thumb and radial hand to the scaphoid, capitate, and other carpal bones.  
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The exact etiology of STT arthritis is unknown; however, there are numerous studies 
investigating the biomechanics and bony morphology as the underlying mechanism for 
degenerative change. Moritomo et al. demonstrated that underdevelopment of the capitate-
trapezium ligament has been associated with increased prevalence of STT arthritis. The 
trapezium trapezoid (TT) inclination measures the degree of bone coverage by the facets of 
each bone over the distal pole of the scaphoid. Degenerative changes of the STT joint were 
associated with a higher TT inclincation suggesting that the trapezium and trapezoid are 
more palmar relative to the scaphoid in patients with STT arthritis.(Moritomo, Viegas et al. 
2000) Interestingly, the morphology of other carpal bones, specifically the lunate, and its 
effects on wrist kinematics has also been associated with STT arthritis. Type I lunate 
morphology consist of lunates with a single distal articulation for the capitates, no 
articulation for the hamate, and a capitates to triquetrum (CT) distance of <2mm. Type II 
lunates had radial articulation for the capitates and a ulnar articulation for the hamate with 
a CT distance of ≥4mm. McLean et al. demonstrated that patients with type II lunate 
morphology had significantly higher incidences of STT arthritis compared to type I lunates 
and hypothesized that the difference in morphology make type II lunates have 
comparatively restricted range of motion creating an environment for degenerative 
change.(McLean, Turner et al. 2009) Carpal instability such as dorsal intercalated segment 
instability (DISI) has also been associated with increased prevalence of STT arthritis.(Tay, 
Moran et al. 2007) Finally, STT arthritis has been associated with prior trauma to the joint 
and surrounding structures.  
The patient typically presents with diffuse pain around the base of the thumb and thenar 
eminence. Generally, isolated STT arthritic pain tends to be more midline (ulnar) compared 
to CMC arthritis and has been reported as a deep aching pain that may not be associated 
with thumb motion.(Cannon, Pincus et al. 2008) The pain can be exacerbated by radial 
extension and flexion of the wrist.  
Physical examination generally demonstrates tenderness to palpation of the STT joint. 
Erythema, edema, and calor rarely are present unless there is significant disease of the thumb 
CMC joint as well. There is often difficulty differentiating the two clinically even with the use 
of the grind test.(Tomaino, Vogt et al. 1999) Due to the difficulty in accurate assessment from 
the history and physical exam, radiography is essential in making the proper diagnosis.  
Bilateral PA, lateral, and oblique views should be routinely obtained. Due to the plane of the 
STT joint, the oblique view appears to be the best study to evaluate the STT joint. Degenerative 
changes such as narrowing of the joint space between any of the scaphoid, trapezium, and 
trapezoid or presence of osteophytes signifies STT arthritis. Stress views of the thumb 
described earlier may also be beneficial. There have been several views that have been 
developed to specifically target the STT joint but have been difficult to readily obtain in 
practice.(Wollstein, Wandzy et al. 2005) Comparison should be made to the contra-lateral 
wrist. There have been some thoughts of using CT or MRI scan for evaluation of the STT joint, 
but there are no published studies or guidelines regarding their utility. Currently, there is no 
universal staging system. However, one such system has been proposed that describes the 
progression of the disease based on radiographic findings. In this categorization, stage I 
disease has joint space narrowing as compared to other intercarpal joints in the same hand 
with or without periarticular sclerosis. Stage II disease has the defining characteristics of stage 
I disease along with the presence of cysts and/or osteophytes. Finally, stage III disease 
demonstrates complete collapse of the joint.(Wollstein and Carlson 2009) 
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As previously mentioned, the differential diagnosis must include thumb CMC arthritis. In a 
cadaveric study, 46 % of patients with STT arthritis had concomitant thumb CMC 
arthritis.(North and Rutledge 1983) Many hand surgeons term concomitant STT and thumb 
CMC arthritis as pantrapezial arthritis. As result of its shared prevalence and clinical 
presentation, it is important to combine clinical exam with radiographic findings for the 
definitive diagnosis. De Quervain tenosynovitis can present similarly, but the tenderness 
would be at the tip of the radial styloid and along the 1st extensor compartment with a 
positive Finkelstein’s test. Direct trauma to the STT joint as the primary pain generator 
should be investigated with a thorough and detailed history. Arthroscopy of the STT joint 
can be performed as a diagnostic procedure and palmar portal has been described as safe 
and efficacious.(Bare, Graham et al. 2003) 
 
 
Fig. 8. PA Radiograph of STT Arthritis 
Treatment of STT osteoarthritis should begin with nonoperative therapy. Behavior 
modification, NSAIDS, and rest are mainstay primary therapies. Splinting can especially be 
effective if there is concomitant thumb CMC arthritis. Intra-articular corticosteroids have 
been shown to be effective along with splinting for thumb CMC arthritis but there is paucity 
of data regarding its utility specifically for isolated STT arthritis.  
Several operative techniques for management of STT arthritis exist including arthrodesis, 
resurfacing, and arthroplasty with or without implant. Historically, fusion of the STT joint 
has been the most common progression of treatment after failed conservative management. 
STT arthrodesis has been indicated for the treatment of isolated STT arthritis, scapholunate 
instability, and Kienbock disease. Nonunion complications are generally a concern with 
arthrodesis and Watson et al reported overall nonunion rate of 4% for STT arthrodesis and 
specifically 2% for patients whose primary indication was STT arthritis. They also report 
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effective if there is concomitant thumb CMC arthritis. Intra-articular corticosteroids have 
been shown to be effective along with splinting for thumb CMC arthritis but there is paucity 
of data regarding its utility specifically for isolated STT arthritis.  
Several operative techniques for management of STT arthritis exist including arthrodesis, 
resurfacing, and arthroplasty with or without implant. Historically, fusion of the STT joint 
has been the most common progression of treatment after failed conservative management. 
STT arthrodesis has been indicated for the treatment of isolated STT arthritis, scapholunate 
instability, and Kienbock disease. Nonunion complications are generally a concern with 
arthrodesis and Watson et al reported overall nonunion rate of 4% for STT arthrodesis and 
specifically 2% for patients whose primary indication was STT arthritis. They also report 
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good functionality in terms of wrist mobility, grip, key, and tip pinch strength compared to 
the unaffected side.(Wollstein and Watson 2005) Several technical aspects of the procedure 
have been shown to be associated with optimal results. The surgeon must thoroughly 
denude the articular surfaces of cartilage. As the joint is decorticated, the original joint 
height must be maintained and packed with bone graft from iliac crest or distal radius. The 
fusing of the scaphoid should be at an angle of 55 to 60 degrees of palmar flexion relative to 
the long axis of the radius as seen in a lateral radiograph. A radial styloidectomy is 
necessary and the postoperative protocol consists of long arm cast for 3 weeks followed by a 
short arm thumb spica cast for an additional 3 weeks. In addition to nonunion other 
reported complications include reflex sympathetic dystrophy and radial styloid 
impingment.(Wolf 2008) 
Resection arthroplasty refers to excision of 3 to 4 mm of the distal articulation of the 
scaphoid with or without interposition via the flexor carpi radialis (FCR) tendon. (Garcia-
Elias, Lluch et al. 1999) This procedure is an alternative to STT arthrodesis and allows for 
pain control, improvement of symptoms, and requires less postoperative 
immobilization.(Weiss and Rodner 2007) The concern with this surgical procedure is the risk 
of creating carpal instability that can lead to arthritis of other joints in the hand and wrist.  
Arthroscopic techniques have also been described.(Bare, Graham et al. 2003) 
Implant arthroplasty is another option for surgical treatment of the STT joint. Silicone 
implants have been used in the past and shown to be effective, especially for the 
treatment of the PIP joint.  It is believed that silicone cannot withstand the same amount 
of compressive forces as bone and therefore prone to fragmentation and development of 
silicone synovitis.(Swindells, Logan et al. 2010) As a result, different implants such as 
pyrocarbon and degradable polyurethanurea spacers have been used. Pyrocarbon 
implants have elastic properties similar to cortical bone and therefore may allow for better 
transfer of stress load.(Cook, Klawitter et al. 1981) Preliminary studies have shown 
significant promise for the use of pyrocarbon implants for the treatment of STT arthritis; 
however, these studies have been limited for sample size and length of follow 
up.(Pequignot, D'Asnieres de Veigy et al. 2005; Low and Edmunds 2007). Studies for 
arthroplasty with a polyurethanurea spacer (Artelon) are undergoing and perhaps a 
promising avenue for future treatment.  
STT arthritis is the second most common degenerative disease of the wrist and often coexists 
with thumb CMC arthritis. Patients present with deep pain along the base of the thumb and 
medial wrist that is exacerbated by flexion and extension. Radiographic imaging is essential 
in determining the diagnosis. Conservative management should being with activity 
modification, NSAIDS, are rest. Splinting and inrta-articular corticosteroid injections may 
also be of benefit to some patients. Surgical management includes arthrodesis, resection 
arthroplasty, and implant arthroplasty with or without interposition.  
6. Osteoarthritis of the radiolunate and radioscaphoid joint 
Arthritis at the radiolunate and radioscahpoid joints is a rare phenomenon; however, 
three common causes are avascular necrosis (including Kienbock and Preiser’s disease), 
post traumatic, and inflammatory. Inflammatory arthritis of the radiolunate and 
radioscaphoid joint can occur; however, this discussion focuses on degenerative 
osteoarthritis of the wrist.  
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6.1 Kienbock disease 
Kienbock disease, also known as avascular necrosis of the lunate, is another rare cause of 
osteoarthritis of the wrist. The classical disorder was first described in 1910 by the 
radiologist Robert Kienbock who, after a series of clinical and radiographic studies, defined 
a distinct symptomatology of volar wrist pain with isolated degeneration of the lunate that 
he termed lunatomalcia.(Kienbock 1910) Despite a century of research, the exact etiology 
and pathophysiology of this disease is unknown.  
Currently, there are many factors implicated in the pathophysiology of Kienbock disease 
and it is likely a combination of these factors that lead to its progression. Primary causes are 
generally divided into mechanical and vascular factors. Mechanical factors may be due to 
the local anatomy of the lunate and wrist and uneven distribution of stress and loading 
forces. Vascular factors imply that a primary disruption in circulation leads to secondary 
bony pathology.  
Historically, negative ulnar variance has been implicated as a mechanical cause of Kienbock 
disease. Negative ulnar variance refers to the presence of a shortened ulna compared to the 
radius in terms of distal articular surface. It is believed that a short ulna cannot share axial 
loads with the radius and therefore increases the amount of stress across the lunate.(Hulten 
1928) However, there are studies that also report no association between negative ulnar 
variance and Kienbock disease. (Gelberman, Bauman et al. 1980; Chen and Shih 1990; 
D'Hoore, De Smet et al. 1994) A meta-analysis in 2001 demonstrated that many of these 
previous studies were under powered and had flawed study designs. They concluded that 
patients with negative ulnar variance were 3.1 times more likely to develop Kienbock 
disease; however there was no statistical significance. Other mechanical factors associated 
with the development of Kienbock disease include: the size and shape of the lunate, 
“radiolunate coverage index”, and persistent trauma. Smaller sized lunates and type II 
shaped lunates are associated with the disease. Patients with a smaller contact area between 
the radius and lunate have a smaller “radiolunate coverage index” and a higher association 
with Kienbock disease. Finally, patients with repeated trauma or fracture to the joint may 
have a higher association to the disease, possibly due to compromise of the vasculature. 
(Tsuge and Nakamura 1993; Irisarri 2004; Lluch and Garcia-Elias 2011) 
Vascular impairment can be either at the external vascular net that supplies the lunate or at 
the small vessels that penetrate the subchondral bone. Studies have shown that lunates 
typically have two nutrient supplying vessels. It has been postulated that patients with 
Kienbock disease have either 1 supplying vessel or a decreased amount of penetrating 
interosseous branches.(Lluch and Garcia-Elias 2011) The mechanism of injury to these 
vessels is not known. Lack of blood supply causes necrosis of the bone with subsequent 
remodeling by osteoclasts and osteoblasts. This remodeling can cause degenerative change 
and ultimately collapse of the lunate.(Lluch and Garcia-Elias 2011) Other potential causes 
associated with Kienbock disease include coagulation disorders such as sickle cell disease, 
long term steroid use, and venous congestion.(Nagasawa, Ishii et al. 1989; Glueck, Freiberg 
et al. 2008; Lluch and Garcia-Elias 2011) 
Patient will typically present with dorsal wrist pain, decreased flexion-extension range of 
motion, and poor grip strength. Local swelling and tenderness of the lunate may be present, 
especially as the disease progresses. Radiographic imaging is necessary for the definitive 
diagnosis. MRI has shown to be more useful in diagnosis and the monitoring of treatment 
while plain radiographs are best used for staging.  
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Stage I disease demonstrates mild pain, normal radiographs, and early degenerative 
changes on MRI. Stage II disease presents with increased pain, edema, and radiographs 
show increased lunate density Stage III is divided into IIIA and IIIB. In stage IIIA 
radiographs show lunate collapse without scapholunate instability while stage IIIB disease 
shows lunate collapse with scapholuante instability. Stage IV is characteristic of pancarpal 
arthrosis.(Saunders and Lichtman 2011)  
 
 
Fig. 9. PA Radiograph of Kienbock Disease 
Current treatment recommendations are based on the classification system. Stage I disease 
is treated with rest, NSAIDS, and possible 3-6 month periods of immobilization. Stage II 
can be managed conservatively or surgically via radial and capitate osteotomies and 
lunate revascularization procedures. Radial and capitate osteotomies can change loading 
forces across the joint and lunate revascularization by transferring a vascularized pedicle 
with bone from the pisiform or distal radius has shown to be effective.(Shin and Bishop 
2002) Stage IIIA is managed with oseotomies and revascularization procedures similar to 
surgical options for stage II disease. Stage IIIB disease requires procedures that result in 
increased stability of the joint and therefore scaphocapitate and STT fusion techniques are 
preferred. Stage IV disease requires salvage procedures such as total wrist arthrodesis, 
arthroplasty, or proximal row carpectomy.(Saunders and Lichtman 2011) Patients with 
negative ulnar variance can undergo radial shortening and ulnar lengthening procedures. 
Currently, no single surgical procedure has shown to be superior.(Delaere, Dury et al. 
1998)  
Early diagnosis of Kienbock disease may help prevent progression as we continue to 
investigate the utility of bisphosphonates, stem cells, and prophylactic surgical intervention. 
The use of gadolinium infused MRI and “lunate stress tests” are techniques that may allow 
diagnosis at “stage 0” similar to that of osteonecrosis of the femoral head.(Saunders and 
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Lichtman 2011) Kienbock disease remains a partial enigma to physicians despite being 
known for over a century. However, as researchers continue to investigate its etiology and 
develop treatment modalities, the future looks promising. 
6.2 Preiser’s disease 
Similar to Kienbock disease, avascular necrosis of the scaphoid is termed Preiser’s disease. 
The exact epidemiology of Preiser’s disease is unknown, but it is considered even rarer than 
Kienbock disease. Furthermore, the exact etiology is unknown; however, physicians often 
imply a shared pathophysiology similar to Kienbock disease. Patients generally present with 
dorsoradial wrist pain, limited range of motion, and possible joint swelling and erythema. 
Patients may have tenderness to palpation along the anatomic “snuff” box. Diagnosis is 
confirmed with radiographs or MRI. Currently, a classification does not exist, perhaps due 
to the low incidence of the disease. Treatment options are similar to Kienbock disease and 
begins with conservative therapy of immobilization, NSAIDS, splinting, and intra articular 
injections. Surgical options include revascularization procedures, proximal row carpectomy, 
and four corner’s fusion with scaphoid resection(Amillo-Garayoa, Romero-Munoz et al. 
2011). 
6.3 Post distal radius fracture 
Fracture of the distal radius is one of the most common fractures in orthopaedics and can 
often cause joint instability and subsequent osteoarthritis. There are various surgical and 
nonsurgical options for the treatment of a distal radius fracture. Complications may arise 
from the traumatic injury and/or method of treatment, leading to osteoarthritis of the 
radiolunate and radioscaphoid joint.  
Osteoarthritis generally develops due to incongruity between joint surfaces. Furthermore, 
there is a potential for abnormal loading forces across a misaligned and unstable joint 
causing joint step off. Over time, this wear and tear can cause degenerative changes and 
osteophyte formation. Post traumatic chondromalacia has also been implicated as a 
potential cause of osteoarthritis status post distal radius fracture due to compression of the 
articular cartilage.  
Patients typical with pain and tenderness near the radioscaphoid and radioulnar joint.  
Previous history of distal radial fracture, clinical presentation, and radiographs help confirm 
the diagnosis. Pathology of the radiolunate joint differentiates this disorder from a 
SLAC/SNAC wrist where the radiolunate joint is preserved. Treatment options include 
conservative management with NSAIDs, splinting, physical therapy, and intra articular 
injections. Surgical options  include denervation, total wrist fusion, wrist arthroplasty and 
variations of intercarpal arthrodesis. (Nagy 2005; Handoll, Huntley et al. 2008) 
7. Osteoarthritis of the pisotriquetral joint 
Pisotriquetral (PT) arthritis is a relatively uncommon diagnosis. It is thought to be the result 
of PT joint instability which can occur after injury to the pisiform ligament complex (PLC) 
which serves to stabilize the PT joint. Injury to these PT joint stabilizers are what could 
predispose a patient to degenerative joint disease (Rayan, Jameson et al. 2005). Such a 
ligament injury is either found in the acute setting after a fall onto an outstretched hand, or 
is associated with a more chronic repetitive motion-type injury.  
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Fig. 9. PA Radiograph of Kienbock Disease 
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Lichtman 2011) Kienbock disease remains a partial enigma to physicians despite being 
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which serves to stabilize the PT joint. Injury to these PT joint stabilizers are what could 
predispose a patient to degenerative joint disease (Rayan, Jameson et al. 2005). Such a 
ligament injury is either found in the acute setting after a fall onto an outstretched hand, or 
is associated with a more chronic repetitive motion-type injury.  
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The pisiform is a sesamoid bone, nearly spherical in shape, which can be found within the 
fibers of the flexor carpi ulnaris tendon and articulates with the triquetrum. The pisiform 
forms the medial wall to Guyon’s canal and is itself bordered medially by the dorsal 
retinaculum. The pisiform ligament complex is composed of those ligaments that stabilize 
the pisiform, namely the pisometacarpal, pisohamate, radial pisotriquetral, ulnar 
pisotriquetral and transverse carpal ligaments (Rayan, Jameson et al. 2005). Its blood supply 
is obtained via the proximal and distal poles which contain branches from the ulnar artery. 
The ulnar nerve lies just radially to the pisiform in most instances. The PT joint is 
ensheathed by a joint capsule that sometimes communicates with the proximal wrist joint 
(Viegas, Patterson et al. 1993).  
The pathogenesis of PT joint pain can originate from several sources. In a study by Paley et 
al, it was noted that out of 216 cases of PT pain, primary osteoarthritis only contributed to a 
minority of the findings (2.3%) while secondary osteoarthritis and flexor carpi ulnaris 
enthesopathy contributed 48.4% and 44.6% respectively (other arthridities comprised the 
remaining 4.7%) (Paley, McMurtry et al. 1987).  Fractures, tumors, ganglions and congenital 
malformations have also been noted to contribute to ulnar volar pain (Kernohan, Beacon et 
al. 1985) (Chen, Barnwell et al. 2011) (El-Morshidy, Rabia et al. 2000). Loose bodies as well as 
PT arthrosis secondary to a triquetral fracture malunion have also been documented 
(Steinmann and Linscheid 1997) (Aiki, Wada et al. 2006). Finally, a recent case series has also 
made the suggestion that PT arthritis can develop after an intercarpal arthodesis (Gaston, 
Lourie et al. 2007). These clinical entities should be considered in a patient’s work-up 
because they each require a distinct treatment plan to alleviate pain.  
It has been hypothesized that injury to the PLC results in PT joint instability and a 
subsequent arthritis (Rayan, Jameson et al. 2005). Trauma is a likely cause of injury and 
there are multiple studies that describe a carpal injury that specifically resulted in the 
dislocation of the pisiform (Goriainov, Bayne et al. 2010) (Matsumoto, Tsunoda et al. 2005). 
Direct force to the volar hand is the most likely culprit resulting in ligament injury and 
pisiform subluxation. The insult can be an acute fall on an outstretched hand or it can be the 
result of a chronic occupational exposure or racket-sport activity. Regardless of the cause, 
instability begets incongruity and abnormal wearing of the PT joint takes place and causes 
arthritis.  
Presentation of a patient with PT joint pathology typically takes the form of either a 
chondromalacia, osteoarthritis or flexor carpi ulnaris tendinopathy. Patients will present 
with a palmar ulnar wrist pain. Exam findings of tenderness in the soft tissues distal and 
radial to the pisiform as well an ulnar volar pain that is provoked by passive wrist extension 
are all consistent with a diagnosis of PT instability. The pisiform tracking test is a useful to 
elicit PT instability: with the wrist in a fully flexed position, the examiner applies pressure to 
the pisiform in both a radial and ulnar direction (Hoepfner 2009). Crepitance and pain 
during this maneuver indicate PT pathology. Also, flexor carpi ulnaris tendinopathy 
(indicated by tenderness to palpation along the FCU tendon) may or may not coexist with 
PT dysfunction. In fact, there have been documented cases of FCU rupture in the setting of 
PT osteoarthritis (Corten, van den Broecke et al. 2004). It is thought that the PT arthritis 
resulted in impingement and attenuation of the FCU, causing its rupture. 
Radiographic analysis can be useful to supplement the physical exam findings. Several 
semilateral wrist views including (1) full wrist extension and forearm supination of 30 
degrees, (2) neutral wrist position with 30 degrees of forearm supination, (3) active and (4) 
 
Osteoarthritis of the Wrist 
 
193 
passive full wrist flexion, and (5) a 45 degree of forearm supination with thumb fully 
abducted will all be needed to isolate this joint (Jameson, Rayan et al. 2002). Dynamic 
fluoroscopy can also be a useful tool to isolate the PT joint radiographically and determine 
its “normal” position. A diagnosis of PT pathology may be confirmed with PT joint 
injection.  Other diagnoses to consider should include triangular fibrocartilage complex 
tears, ulnar impingement, lunotriquetral dysfunction, distal radioulnar joint subluxation, 
fracture/nonunion of the hook of hamate and ulnar artery thrombosis. 
Like many of the arthritic joint conditions, PT pathology can be treated medically with wrist 
splints that maintain a neutral position, NSAIDS, and intra-articular steroid injections. Only 
when a patient’s pain is refractory to these therapies, should surgery be considered. 
Although PT instability is what leads to the joint degeneration, clinically, we do not attempt 
to stabilize the pisiform by repairing the ligaments of the PLC. Instead, excision of the 
pisiform has been used to treat this condition for many years (Carroll and Coyle 1985) 
(Gomez, Renart et al. 2005) and has consistently provided pain relief without any functional 
limitations. There have been case reports, however, that promote the use of PT arthodesis in 
patients who have more high demand wrists (Abrams and Tontz 2006) (Singer, Eberl et al. 
2011). Although this does not represent the current trend in treating PT pathology, with 
further study, it could serve as a promising alternative to pisiform excision.  
In short, PT arthritis may not be a very common cause of ulnar-sided wrist pain, but it can 
be a very debilitating condition when present. It likely results from an instability due to an 
imbalance in the complex ligamentous attachments that keep the pisiform suspended in its 
proper orientation. When evaluating a patient for PT arthritis, the astute physician will keep 
a high clinical suspicion for the array of conditions that could mimic this type of wrist pain. 
Pisiform excision remains a very successful surgery for those patients who fail splinting, 
anti-inflammatories, and injection treatments. 
8. Summary 
Osteoarthritis of the wrist and hand can be a painful and debilitating disease. This chapter 
focused on the various causes, clinical presentations, and treatment options of wrist 
osteoarthritis. Many times evaluation of a patient with wrist pain reveals an extensive 
differential diagnosis. While obtaining the history, special attention should be focused on 
the patient’s age, hand dominance, location and quality of the pain, aggravating and 
relieving factors, prior trauma history, occupation, hobbies, and limb function. Physical 
exam and palpation of the carpus and hand is essential to identify and localize the pain 
source. Special maneuvers such as the grind and shift test can help navigate the differential 
diagnosis and identify the pathologic joint. Ultimately, radiographic imaging can be used 
for definitive diagnosis and staging the progression of the disease.  
SLAC and SNAC wrists are common degenerative patterns seen in osteoarthritis of the wrist 
and typically present with dorsal wrist swelling and periscaphoid tenderness. Pain and 
decreased range of motion with pronation and supination is typically indicative of arthritis of 
the DRUJ joint. Patients with arthritis of the thumb CMC and STT joint present with pain over 
the thenar eminence that is exacerbated by pinching and grasping activities. Kienbock disease 
can also present with dorsal wrist pain similar to SLAC wrist; however, the swelling and 
tenderness is along the lunate. In our discussion of wrist arthritis, degenerative change of the 
PT joint is the final cause of wrist pain and patients typically present with palmar ulnar pain.  
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PT joint is the final cause of wrist pain and patients typically present with palmar ulnar pain.  
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Conservative management should be tried on all patients with wrist pain, especially if the 
disease is identified early in its progression. Rest, NSAIDS, behavior modification, 
occupational therapy, splinting, and intra-articular corticosteroid injections are all options 
that have shown different degrees of efficacy. Furthermore, intra-articular injections can be 
used as a final tool in differentiating the diagnosis.  
Many different surgical options exist for the treatment of advanced degenerative disease. 
The common goal of surgical treatment is to remove the pain source when possible and 
stabilize the joint and its surrounding structures. Osteotomies, revascularization techniques, 
arthroscopy, resection arthroplasty, implant arthroplasty, and arthrodesis are some of the 
more common procedures used to treat the various arthropathies of the wrist. Physicians 
and patients must have an interactive discussion regarding the individual merits and 
drawbacks of each alternative to determine which procedures maximize recovery potential.  
Surgeons continue to refine and develop new techniques as arthroscopy and total joint 
arthroplasty of the small joints in the hand and wrist become more common. As long term 
data regarding the efficacy of each procedure becomes more available, the “best” procedure 
for each disease may be determined. Research in the 21st century is currently focused on 
novel treatment methods including gene therapy, cartilage regeneration, and identification 
of specific etiologic factors that cause osteoarthritis of the wrist. With time, this may allow 
the physician to prevent the development and progression of the disease altogether.  
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arthroplasty of the small joints in the hand and wrist become more common. As long term 
data regarding the efficacy of each procedure becomes more available, the “best” procedure 
for each disease may be determined. Research in the 21st century is currently focused on 
novel treatment methods including gene therapy, cartilage regeneration, and identification 
of specific etiologic factors that cause osteoarthritis of the wrist. With time, this may allow 
the physician to prevent the development and progression of the disease altogether.  
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Osteoarthritis of the Trapeziometacarpal Joint 
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1. Introduction 
Osteoarthritis (OA) of the base of the thumb is a common, painful and debilitating 
condition. It is more common in women and most commonly presents in Caucasian women 
in their late forties (Wilson and Bossley, 1983). It affects approximately 16-20% of women 
over 45 years old and 6% of men over this age (Bettinger et al., 2001). It is the site most 
frequently operated on in the upper extremity for primary osteoarthritis. (Pellegrini, 2005). 
Pain is the main presenting symptom. It is often brought on by writing, by opening jars and 
using the hand for a long time, particularly in pinching movements and there is difficulty in 
performing these activities. The patients often have weakness due to the pain that may affect 
their ability to work, perform activities of daily living and follow leisure pursuits. They may 
also have an adduction deformity of their thumb. Signs include tenderness over the 
carpometacarpal joint at the base of the thumb, thenar wasting, reduced pinch grip strength 
and crepitus on moving the thumb (Wilson and Bossley, 1983; Gwynne-Jones et al., 2006).  
The severity of basal thumb osteoarthritis can be graded according to the Eaton stages. 
Eaton Stage I basal thumb osteoarthritis indicates joint pain and symptoms but no joint 
space-narrowing or cartilage degeneration shown on X-ray. Eaton stage II is classified as 
joint space narrowing seen on X-ray with osteophytes present of less than 2mm in size. An 
osteophyte is a small outgrowth of bone which occurs at joints in association with 
degeneration of joint cartilage. Eaton Stage III osteoarthritis is characterised by osteophytes 
of greater than 2mm in size being present on x-ray and significant destruction of the joint. In 
stage IV basal thumb OA there is significant degeneration of the scaphotrapezial joint in 
addition to the trapeziometacarpal joint (Eaton at al., 1985). 
2. The anatomy of the basal joint of the thumb 
The basal joint of the thumb is formed by the articulation between the trapezium bone 
proximally and the first metacarpal bone distally. It is therefore called the 
trapeziometacarpal joint or the carpometacarpal joint of the thumb. The trapezium, a bone 
of the second carpal row, articulates with the scaphoid bone proximally, the trapezoid 
medially and the bases of the first and second metacarpal bones distally. The trapezium is 
on the palmar and radial side of the wrist. It is angled such that it projects towards the 
palmar side. It angles the first metacarpal bone (the most proximal bone of the thumb) 
radially and in a palmar direction. The articular facet of the trapezium with the first 
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palmar side. It angles the first metacarpal bone (the most proximal bone of the thumb) 
radially and in a palmar direction. The articular facet of the trapezium with the first 
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metacarpal is angled 35 degrees towards the palmar direction and 20 degrees radially. This 
results in the neutral position of the thumb being 35 degrees in a palmar direction and 20 
degrees in a radial direction (Zancolli, 1979).  
 
 
Fig. 1. Illustration of the trapeziometacarpal joint (TMJ) of the left thumb. The first (M1) and 
second (M2) metacarpals, the trapezium (T), the trapezoid (TZ), the scaphoid (S) and the 
capitate (C) bones are illustrated. Illustration courtesy of Mr Donald Sammut, Consultant 
Hand Surgeon, The Hand Clinic, Windsor. 
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The trapeziometacarpal joint is a saddle joint with wide mobility due to extensive articular 
surfaces. It is called a saddle joint because the trapezial articular surface is concave in a 
dorsopalmar direction and convex in the radioulnar direction. The first metacarpal base is 
complimentary to the trapezial articular surface. The trapezium is compared to the saddle of 
a horse and the base of the first metacarpal bone may be compared to the horse rider as it is 
mobile. It is a synovial joint and is surrounded by a joint capsule that is strengthened by 
three ligaments. The most important of these is the ulnar beak ligament. This is a very thick 
and wide ligament that runs from the crest of the trapezium and attaches to the ulnar side of 
the base of the first metacarpal. This ligament maintains the stability of the thumb and is 
tense in abduction of the first metacarpal. The other two ligaments are less widely described 
as they are believed to be less important in the stability of the thumb. The radial ligament 
originates from the radial side of the trapezium and travels dorsally and medially to attach 
to the dorsal tubercle of the first metacarpal. A palmar wide ligament is also sometimes 
described (Zancolli, 1979; Zancolli and Cozzi, 1992; Standring, 2008). A wide range of 
movement is permitted at the trapeziometacarpal joint: flexion, extension, abduction, 







Fig. 2. Dissection of the trapeziometacarpal joint showing, on the left, the base of the first 
metacarpal (M) and, on the right, the articular surface of the trapezium (T). Dissection 
courtesy of Mr Donald Sammut, Consultant Hand Surgeon, The Hand Clinic, Windsor. 
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Fig. 3. Dissection displaying the strong ulnar beak ligament (BL) of the trapeziometacarpal 
joint. Traction is applied to the first metacarpal to open and display the joint (J). The base of 
the first metacarpal (M1) is on the left side of the joint. The articular surface of the trapezium 
(T) is on the right side of the joint in this image. The base of the second metacarpal is also 
seen (M2). Dissection image courtesy of Mr Donald Sammut, Consultant Hand Surgeon, The 
Hand Clinic, Windsor. 
3. Pathophysiology of osteoarthritis of the base of the thumb 
Many authors have described theories on how osteoarthritis of the base of the thumb occurs. 
There is often degeneration of the ulnar beak ligament due to recurrent stress and overuse 
which leads to ligament and joint instability. With increased laxity there may be abnormal 
translation of the first metacarpal on the trapezium. This can result in excessive shear forces 
between the joint surfaces (Tomaino, 2000; Kapandji TG and Kapandji AI, 1993). In addition 
there is articular degeneration. This may be secondary to instability which leads to joint 
surface incongruity. The incongruity may result in areas of high contact stress developing in 
the joint. This then causes cartilage erosion and the symptoms and signs of osteoarthritis 
(Bettinger et al., 2001). It has been shown that articular degeneration occurs on the palmar 
side first and gradually progresses to dorsoradial cartilage degeneration in the later stages 
of osteoarthritis of the joint (Pellegrini, 2005; Hobby et al., 1998). Radiological studies 
looking at the angle of the trapezium compared to the second metacarpal have shown that 
there is an increased radial trapezial tilt in Eaton stages III and IV compared to Eaton stages 
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I and II osteoarthritis of the base of the thumb (Bettinger et al., 2001; Kapandji AI and Heim, 
2002). Studies have also shown accessory tendons of abductor pollicis longus inserting into 
the radial side of the metacarpal base in some people. These pull the metacarpal base 
radially and hence have a tendency to cause joint instability and may contribute to the 
development of osteoarthritis (Zancolli and Cozzi, 1992).  
4. Treatment of trapeziometacarpal osteoarthritis  
Trapeziometacarpal osteoarthritis may be treated conservatively with non-steroidal anti-
inflammatory drugs (NSAIDs) first. If these are ineffective at symptom control a splint can 
be used which holds the thumb in abduction preventing the movements of adduction and 
retroposition. This ensures that the metacarpal base is covered by the trapezium and joint 
stability is increased, reducing metacarpal subluxation and wear of the joint cartilage 
(Zancolli and Cozzi, 1992). Depending on the severity of the symptoms the splint may be 
effective if just worn nocturnally (Goubau et al., 2007; Hobby et al., 1998). 
For temporary relief of symptoms, lignocaine and steroid injections into the joint are 
effective. However, repeated injections into the joint are harmful to the joint itself and 
surrounding tissue. As well as accelerating joint damage, if the steroid leaks into the 
surrounding tissue it can lead to subcutaneous fat necrosis. This loss of the fatty tissue 
around the thumb leads to an undesirable cosmetic outcome. 
If, despite conservative measures, pain or deformity interferes with daily activities such as 
holding a key or gripping an object, surgical treatment is advocated. As already mentioned, 
the trapeziometacarpal joint is the most commonly surgically reconstructed joint for 
osteoarthritis in the upper limb (Pellegrini, 2005; Tomaino, 2000). The first operation which 
can be considered for early osteoarthritis is reconstruction of the ulnar beak ligament. This is 
achieved using a tendon slip from the flexor carpi radialis tendon. As it does not involve any 
of the articular surfaces it is reserved for patients with joint laxity without appreciable 
degenerative changes. Thumb metacarpal osteotomy is another operation which can be 
effective in early disease. It transfers load bearing from the worn volar cartilage to the more 
intact dorsal articular surface. As well as giving symptom relief it also slows the progression 
to more severe osteoarthritis (Hobby et al., 1998). Another more experimental method of 
reconfiguring the joint alignment is wedge osteotomy of the trapezium. This realigns the 
trapezial saddle reducing metacarpal subluxation. However, studies are in their early stages 
and evidence for this procedure is limited (Kapandji AI and Heim, 2002). 
For more severe disease with significant degenerative changes the surgical options include 
trapeziectomy, arthrodesis and total joint arthroplasty. Trapeziectomy is associated with 
good pain relief but can lead to weakness and instability lasting several months so is often 
reserved for Eaton Stages III and IV osteoarthritis (Hobby et al., 1998; Gwynne-Jones et al., 
2006; Wilson and Bossley, 1983). Trapeziectomy may be performed in isolation or in 
combination with tendon sling interposition or ligament reconstruction. However, the 
outcome of these operations appears to be equivalent (Davis et al 2004).  
Arthrodesis is a less frequently performed procedure in the trapeziometacarpal joint than 
other joints in the hand. It is associated with increased joint stability but longer 
immobilisation and an incidence of non-union (Hobby et al., 1998). It leaves a strong but 
rather immobile thumb.  
Total joint arthroplasty has been a less successful procedure in this joint. There is frequent 
loosening of the components, implant fracture and an increased infection rate. Revision 
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procedures of total joint replacements of this joint are common (Lanzetta and Foucher, 1995; 
Wilson and Bossley, 1983).  
The choice of surgical procedure for trapeziometacarpal arthritis is still controversial. There 
is limited evidence as to which procedure produces optimal results whilst limiting 
complications. Therefore, randomised clinical trials are awaited comparing these surgical 




Fig. 4. Plain radiograph showing Eaton Stage III osteoarthritis of the trapeziometacarpal 
joint of the right thumb 
5. Conclusion 
Trapeziometacarpal arthritis is a common, painful and debilitating condition. The complex 
anatomy allows for an extensive range of movement. However, it is this inherent instability 
within the joint that leads to wear of the articular cartilage and osteoarthritis. 
Once conservative measures have failed there are a wide variety of surgical treatment 
options.  
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1. Introduction 
Temporomandibular disorder (TMD) is a collective term for a number of clinical signs and 
symptoms involving masticatory muscles, temporomandibular joint (TMJ) and associated 
structures (De Leeuw, 2008)  
Some studies show that 3-7% of the adult population seek care for TMJ pain and 
dysfunction (Carlsson, 1999) and the range of symptom occurrence to be between 16%and 
59% and the range of clinical signs to be between 33% and 86%. Among individuals with 
TMJ disorders 11% had symptoms of TMJ arthritis. (Mejersjo & Hollender, 1984; Tanaka, 
Detamore et al., 2008) There is disagreement between the classification of degenerative joint 
disease as presented by the American Association of Orofacial Pain and the RCD/TMD( 
Research Diagnostic Criteria of Temporomandibular Disorders) (LeResche, 1997)  
1.1 Anatomy of TMJ 
Before we start discussing TMD treatments, it is important to review anatomy. 
Is the TMJ similar to other synovial joints in the human body? 
No. TMJ is the only synovial joint whose surface is not covered with hyaline cartilage but 
with fibrocartilage. One more difference is the fact that in the TMJ teeth are present as an 
intermediate structure (Schwartz & Marbach, 1965). The masticatory system is dynamic, not 
static, and it continuously changes due to the abrasion of dental surfaces 
Position of the TMJ 
Typically, the mandible has been considered to be connected to the skull by means of two 
synergically acting joints: the right and left TMJs. Both these joints are condylar synovial 
joints (diarthroses) that enable the characteristic anterior displacement (Testut, 1971). 
Because of this displacement, the TMJ has been regarded to as an atypical joint. 
Composition of the TMJ 
The TMJ is a ginglymoarthrodial synovial joint. The joint is encapsulated and immersed in 
synovial fluid, and is stress bearing and capable of both rotational and translatory 
movements. The mandibular condyle can move in a variety of directions within the 
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mandibular fossa. Condylar movements are protected from direct contact with the bony 
architecture of the fossa through an intricate system of fibrocartilage and synovial 
structures. The TMJ is structurally unique, consisting of only two joint in the body with 
vascularised tissue within the capsular ligament. Since the disc is a vascular and not 
innervated, pain from within the joint is in all probability due to inflammation or injury of 
the highly vascularised and innervated retrodiscal tissue or inflammation of the synovial 
tissues. (Loughner, Miller et al., 1997)  
Movement of the TMJ 
When the TMJ is in motion, the interarticular disc is always positioned between the 
fossa/eminence and condyle by the action of the superior lateral pterygoid muscle and 
the uppermost elastic portion of the posterior attachment known as the postero-superior 
retrodiscal lamina of the retrodiscal tissue. During function, the lateral and medial discal 






Fig. 1. Functional anatomy of TMJ. 
The superior surface of the disc translates or slides along the posterior aspect of the articular 
eminence during full mouth opening. Translation of the condyle occurs as a result of the 
action of the inferior lateral pterygoid muscle, which protrudes from the mandible, in 
concert with other mandibular depressors the infra- and suprahyoid musculature. The 
posterosuperior retrodiscal lamina acts passively to pull the disc posteriorly during opening 
as the condyle translates anteriorly. The superior lateral pterygoid muscle contracts 
eccentrically during closure, stabilizing the disc against the distal slope of the articular 
eminence. (Laskin, 1994) The two synovial membrane layers line the joint capsule and disc, 
except on the articulating surface, and produce synovial fluid, fulfilling the nutritional 
needs of the joint. (Dijkgraaf, de Bont et al., 1996)  
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Composition of the synovial fluid 
The joint space is filled by the highly viscous synovial fluid, containing hyaluronic acid and 
glycoprotein lubricant. Hyaluronic acid is a polymer of D-glucuronic acid and D-N- 
acetylglucosamine, which is highly unstable and degrades in the presence of inflammation.( 
Nitzan, Nitzan et al., 2001)  
In synovial joints is shared by the articular cartilage, the subchondral bone, and the disc. In 
synovial joints the subchondral bone shares loading with articular cartilage. Only 1-3% of load 
forces are attenuated by cartilage while the normal subchondral bone is able to attenuate about 
30% of the load through the joints.(Imhof, Sulzbacher et al., 2000) The subchondral bone 
protects the articlar cartilage from damage caused by excessive loading. The condylar ear and 
the articular fossa receive their blood supply from arteries supplying the underlying bone. In 
the TMJ, the disc, through its viscoelastic properties, functions as a stress absorber and stress 
distributor. It contributes to prevent stress concentration and excessive stress in the cartilage 
and bone components of the joint, thus protecting the joint. (Tanaka & van Eijden, 2003) 
Articular surface remodelling potential persists having the proliferative layer in the articular 
cartilage that can resume the proliferative activity if the occasion demands. 
Blood supply to the TMJ 
The articulating surfaces are free of blood vessels, but the synovial membrane is usually 
well supplied with minute vessels. The most significant blood supply enters the posterior 
aspect of the joint through the retrodiscal pad. A less significant quantity of the blood 
supply to this plexus comes from vessels within the mandible or temporal bone, which enter 
the joint at the peripheral attachment of the joint capsule. (Charles, Boyer et al., 1964)  
2. Initiating events in TMJ arthritis 
The term arthritis refers to an inflammatory condition affecting an articulation that results in 
erosion and fibrillation of articular cartilage and degeneration of adjacent sub-condral bone. 
Over recent years the term arthritis has evolved to distinguish a non inflammatory condition 
producing similar degenerative changes. 
Initiation of TMJ OA 
Wilkes (Wilkes, 1989) has suggested that TMJ arthritis is the last stage in the process of 
TMJ internal derangement, to explain the process is that as a result of joint intrinsic or 
extrinsic overloading, the lubrication system is compromised, the disc lags behind, and 
the condyle is pulled forward, away from the lagging disc. The normally firm attachment 
of the disc to the condyle becomes loose. The loose disc does not stay in its normal 
position but falls, usually anteriorly, starting the process of disc displacement (Nitzan, 
2001) When the retrodiscal area is inadaptable, it perforates on loading, thus leading to 
arthritis. Conversely, it has been suggested that TMJ arthritis may precede disc 
displacement (de Bont , Boering et al., 1986) Joint degeneration is associated with 
disintegration of the joint constituents. Many studies have shown arthritis changes prior 
to disc displacement. (de Bont & Stegenga, 1993)  
Is arthritis a reparative or a disruptive process? 
Arthritis is a reparative process in the first place, with the purpose of recovering joint 
cartilage lesions.  
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When the loading is controlled, the retrodiscal area is adaptable and becomes disk-like 
(Manfredini, 2010)  
This process of compensation unfortunately fails most of the times and a degradation takes 
place, which leads to losing normal functions in the affected joints. Early signs of TMJ arthritis 
are cellular proliferation and increased condrocytes metabolic activity. Said phenomena, when 
observed with SEM, present with a very developed wrinkled endoplasmatic reticle, a luxuriant 
Golgi apparatus and numerous secretory vescicles (de Bont & Liem, 1985). That leads to active 
reparative processes so that arthritis can remain asymptomatic for years. Next, an increase in 
the cartilage volume is observed, caused by a higher water absorption, and the cartilage 
surface becomes irregular (de Bont , Liem et al., 1985).  
Condrocytes multiply and present with an increased metabolic activity. Collagene begins to 
lose its organization presumably following the liberation of proteolitic enzymes (de Bont & 
Liem, 1985).  
After that follows a phase in which TMJ presents at first with deep surface cracks and then 
with progressive loss of the cartilage due to mechanical abrasion (de Bont , Liem et al., 1985).  
In this phase proliferated condrocytes can be observed next to the deeper cracks of the 
cartilage (de Bont , Boering et al., 1986).  
At a final stage, cracks in the cartilage appear more and more deep and the cartilage 
gradually disappears as a consequence of total destruction of collagene and proteoglycans. 
The last condrocytes die and the underlining bone becomes exposed. 
TMJ arthritis is clinically present with clicks and, less often, with limited mobility of the 
mandible. 
These descriptions, as observed with optical microscopy and SEM, are perfectly coincident 
with clinical and histological findings in great joints. Although enzymatic processes have 
not been studied in the TMJ, it can be thought that an analogy exists with the mechanisms 
described in this chapter. 
Is TMJ arthritis a rare event? 
It is not a rare event. It is not typical of the adult age and it can present  in both adults and 
young subjects. 
2.1 Local and systemic risk factors of arthritis 
The TMJ function will remain normal as long as its adaptive capacity is not compromised. 
The changes in the joint associated with the adaptation process are considered as 
asymptomatic arthritis. The failure of the joint to adjust may cause symptoms such as pain 
and/or limitation depending on the presence of risk factors, thus confirming the cyclic 
nature of arthritis. Local and systemic risk factors (micro- and macro-trauma, parafunction, 
joint laxity, abnormal alignment, occlusal changes etc.) may results in overloading and/or 
immobilization, thus jeopardizing TMJ integrity.  
Which are the risks factors of TMJ overloading? 
Causes that lead to loading of the joint include clenching, occlusal changes (eg premature 
contact, teeth extractions, posterior bite collapse, teeth inclination) etc. These may set off 
abnormal compressive and shear forces.  
On the other hand, it has an intra-articular origin, eg inflammation, infection, and 
hemarthritis, in which there is an increase in intra-articular pressure that consequently 
increases the joint loading. 
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Macro-trauma such as whiplash, for example, involves both extrinsic and intrinsic joint 
overloading. By stretching the joint ligaments, the joint’s stability to withstand extrinsic 
loading is affected, and the initiation of an inflammatory reaction within the joint increases 
the intrinsic loading (Manfredini, 2010). Abnormal alignment, joint laxity, and disc 
displacement all decrease the joint’s ability to cope with increased joint loading. 
Which are the risks factors of TMJ immobilization? 
TMJ immobilization is considered to be one of the principal causes of joint deterioration, 
mainly due to inability of the body to eliminate the harmful effects of inflammation. 
Immobilization might be caused by extrinsic or intrinsic factors and rehabilitation is possible 
only when the correct diagnosis is made. Extrinsic or extra-articular causes included 
myofascial pain disorder, extra-articular infection, coronoid hyperplasia, or other 
pathologies. Intra-articular inflammatory perfusion, infection, and hemarthritis are all 
intrinsic causes of immobilization. Advancing age, sex, hormonal factors, genetics, nutrition, 
obesity, and systemic illnesses such as atherosclerosis, diabetes, or osteoporosis may affect 
the host’s adaptive capacity. These factors may contribute to dysfunctional remodelling of 
the TMJ, even when the biomechanical stresses are within a normal physiologic range. 
(Laskin , 1994; Arnett, Miliam , Miliam et al., 1996)  
3. TMJ diagnosis 
TMJ arthritis is a disorder represented by variable combinations of signs and symptoms 
including pain, limitation in movements, joint noises, malocclusion etc that may be 
uncovered by means of several type of examination. 
The TMJ diagnosis  
3.1 Clinical extraoral and intraoral examination 
Pain may not necessarily be present, when it occurs, it might be severe and localized to the 
joint. Mouth opening may not be limited or may present limitation originating in the 
affected joint. Noise such as cliking and or crepitus may or may not be present. Lateral 
movements, protrusive mandibular movements, existence of deviation, and the exact 
location of pain during each movement are considered. Intraorally, occlusal findings, such 
as deviation of dental midline, crossbites, ipsi or controlateral open bite, missing teeth, and 
posterior bite collapse are recorded. 
Auscultation for joint noises (cliking, crepitus) and eliciting pain on palpation of TMJ, head 
and neck muscles are recommended. 
3.2 Imaging 
Imaging has played an important role in the diagnosis of TMJ arthritis, however there is 
only a limited correlation between clinical and radiographic findings. Severe symptoms may 
be associated with imaging changes or, alternatively severe changes on radiographs may be 
associated with an asymptomatic joint. 
For radiologic evaluation panoramic radiographs can be obtained for initial screening 
purposes. Computed tomography (CT) provides a three dimensional view of the 
morphologic changes in the TMJ and bone mineral density in the mandibular condyle. 
Imaging of an osteoarthritic joint in the advanced stages typically shows erosion of the 
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cortical outline, osteophytes, subcortical cysts, reduced joint space, and the presence of 
condylar deformities and osteophytes (Fig. 2, 3).  
 
 
Fig. 2. CT of TMJ arthritis (coronal section) 
 
 
Fig. 3. CT of TMJ arthritis (sagittal section) 
MRI imaging shows TMJ soft tissue abnormalities such as disc displacement, join perfusion 
and bone marrow signal changes related to TMJ arthritis (fig. 4).  
 
 
Fig. 4. MRI of TMJ arthritis (sagittal section) 
4. Treatment of TMJ arthritis 
A correct evaluation of the patient is the key for appropriate treatment. The prognosis of 
arthritis following conservative management has been shown to be good and stable. 
Although, radiologically, bone may show deterioration, clinical sign and symptoms tend to 
improve. 
Treatment, in general, should address the rehabilitation of the joint defence mechanisms 
such as blood supply, movements, shock absorbance, and remodelling potential by coping 
with the patient’s risk factors. 
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4.1 Non surgical treatment 
A large variety of non-steroidal anti-inflammatory drugs (NSAIDs) can be used to reduce 
TMJ inflammation and the associated pain. They should be used at an early stage before any 
other treatment. However, they are not a long-term remedy for TMJ arthritis. 
4.1.1 Local treatments 
Physical therapy for the TMJ 
Reduced mandibular mobility is caused by intra-articular restriction or by muscular 
dysfunction, physical exercises are beneficial to prevent formation of intra-articular 
adhesions and to increase the blood flow and strength of the jaw muscles. Physical therapy 
is a valuable adjunct to other treatments for TMJ arthritis aimed at normalizing the 
functional capability of temporomandibular system 
 In difficult cases or when cooperation is not achieved, it is the physician’s responsibility to 
refer the patient to a professional physical therapist; exercises include passive and active 
symmetric movements in all directions, further stretching on maximal movement exercises, 
as well as movements against resistence. 
4.1.2 Acupuncture 
Acupuncture has been used as an adjunct to other therapy for pain relief in patients with 
OA. Furthermore, acupuncture has not effect on joint pain and tenderness or on the acute 
phase reactants and disease activity (Casimiro ,Barnsley et al., 2004).  
Iontophoresis and Phonophoresi 
Iontophoresis and Phonophoresi are techniques to enhance the transport of drug ions across 
a tissue barrier. The effects of iontophoretically-applied dexamethasone in combination with 
lidocaine were evaluated in patients with painful TMJ disc displacement, with or without 
reduction and in patients with OA. Iontophoretically-applied dexamethasone was effective 
in improving mandibular function, mobility but not in reducing pain. 
4.1.3 Bite appliances  
Muscular hyperfunction or occlusal trauma can be a primary cause of OA, and these 
factors might also be detrimental and accelerate tissue destruction in the case of systemic 
inflammatory joint disease involving the TMJ. Treatment with occlusal bite appliances has 
been advocated mainly in patients with pain of muscular origin due to muscle 
hyperfunction or tension (Major & Nebbe, 1997; Ekberg , Vallon et al., 2003).  
But there is no evidence of the efficacy of treating TMJ OA with occlusal appliance (Al –Ani , 
Davies et al., 2004). 
4.1.4 Low-level laser therapy 
Superpulsed low-level laser therapy (LLLT) seems to be a good choice as a non-invasive 
treatment for tempomandibular joint pain while exhibiting a low cost for the patient. 
Many authors have reported significant pain reduction with low-level laser therapy in 
acute and chronic musculoskeletal pain conditions (Bjordal, Couppè et al., 2003; 
Ninomiya, Hosoya et al., 2007). 
The results of many works show no statistical improvements for any of following: localized 
swelling, muscle strength, functional status, or global assessments with laser treatment. The 
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major limitation of the systematic meta-analyses about LLLT is the heterogeneity of clinical 
application, including different dosages, wavelengths and types of LLLT. 
Which are the evidence-based proves of the efficacy of LLLT in the treatment of TMJ 
ARTHRITIS? 
Our superiority randomized double-blind clinical trial in parallel arms was carried out with 
the aim to investigate the efficacy of the new superpulsed low-level laser therapy versus 
anti-inflammatory and placebo therapy in the treatment of TMD, and to determine the 
optimal time and exposure application to LLLT for treating arthritis with pain. (Marini, 
Gatto et al., 2010) 
How was the trial designed? 
A total of 99 patients with temporomandibular joint disorders, secondary to disc 
displacement without reduction (Fig. 5) or arthritis with articular effusion (Fig. 6) were 
randomly divided into 3 groups. Thirty-nine patients received LLLT in 10 sessions over 2 
weeks, 30 patients received ibuprofen 800 mg twice a day for 10 days, and 30 patients 
received sham laser as placebo in 10 sessions over 2 weeks. Pain intensity was measured by 
visual analogue scale at baseline, 2, 5, 10, and 15 days of treatment. Mandibular function 
was evaluated by monitoring active and passive mouth openings and right and left lateral 
motions at baseline, 15 days, and 1 month of treatment. Magnetic resonance imaging was 
performed at baseline and the end of therapy. 
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Fig. 6. MRI of TMJ arthritis with articular effusion (sagittal section) 
Which were the results? 
Mean visual analogue scale pain scores in LLLT group was significantly lower than in non-
steroidal anti-inflammatory drug group and control group (P=0.0001) from fifth day up to 
the end of the observation period. As for active and passive mouth openings and right and 
left lateral motions, superiority of LLLT was evident 1 month after treatment (interaction 
time treatment, P=0.0001). 
Therefore mandibular function improved in all LLLT patients proving the effectiveness in 
the treatment of pain, as demonstrated by a significant improvement in clinical signs and 
symptoms of temporomandibular joint disc displacement without reduction and arthritis at 
the end of treatment and stability over a period of 1 month. 
Which were doses and times of LLLT? 
Each patient received laser therapy, gallium-arsenide diode superpulsed laser, (LUMIX 2 
HFPL Fisioline, Verduno, Italy) with time pulsation<200 ns; frequency range 1 to 50 kHz, 
wave length 910 nm, mean power 400 mW, and peak power 45W. The affected TMJ areas of 
these patients were treated daily in 3 steps: 
1. 20 kHz for 10 minutes 
2. 18 kHz for 5 minutes 
3. 16 kHz for 5 minutes 
All patients were treated for 10 consecutive days (5 d/wk) in right and left TMJ,. Laser test 
was performed at the end of every application to measure the laser output. The laser 
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parameters selected were based pragmatically on those used in everyday practice by a 




Fig. 7. Low-Level Laser device. 
Which were the main differences between LLLT and NSAIDs treatment, observed in our 
study?  
The laser group showed an increase in pain, which then disappeared for a long time; the 
increased pain could be explained with an increased local hyperemia. 
Patients treated with NSAIDs showed an improvement in pain and mandibular function 
during the time of treatment but returned to more or less the same level as pretreatment 
conditions after treatment terminated. It is hard to compare our outcomes with those of 
other studies that obtained similar results despite differences in design, dosage, intensity, 
and frequency. In Italy, administration of NSAIDs is suggested for not more than 7 to 10 
days, except for rheumatoid arthritis, whereas in many countries this therapy can be 
prolonged from 4 to 6 weeks. 
Real hazards of long-term administration of NSAIDs have been recognized lately as 
involving renal disease and serious toxicity to the gastrointestinal tract, as well as increasing 
the risks of adverse cardiovascular events. A comprehensive review of the primary 
literature reveals modest scientific support for the assertion that the daily use of NSAIDs 
offers benefits for patients with chronic TMD pain. (List , Axellson et al., 2003)  
Does laser treatment influence active and passive mouth opening and right and left 
lateral motion? 
These parameters are always significantly different between patients treated with laser and 
patients treated with NSAIDs (Table 1 and 2). Superiority of laser is mostly evident one 
month after treatment (interaction time-treatment p=0.0001)  
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Active mouth opening Passive mouth opening 
Comparison p-values atBaseline 15 days 1 month
p-values at
Baseline 15 days 1 month 
Laser vs 
NSAIDs 0.001 0.001 0.001 0.001 0.001 0.001 
Laser vs 
Control 0.031 0.001 0.001 0.012 0.001 0.001 
NSAIDs vs 
Control 0.026 0.083 0.003 0.041 0.069 0.001 
(1) Marini, Ida MD, DDS; Gatto, Maria Rosaria PhD; Bonetti, Giulio Alessandri MD, DDS* Effects of 
Superpulsed Low-level Laser Therapy on Temporomandibular Joint Pain The Clinical Journal of Pain 
Issue: Volume 26(7), September 2010, pp 611-616 (http://lww.com) 
Table 1. Comparisons of the difference of active and passive mouth opening, right and left 
lateral motion between the groups . α = 0.02 
 
Right lateral motion Left lateral motion 
Comparison p-values atBaseline 15 days 1 month
p-values at 
Baseline 15days 1 month 
Laser vs 
NSAIDs 0.013 0.001 0.001 0.001 0.001 0.0010 
Laser vs 
Control 0.683 0.228 0.001 0.631 0.001 0.001 
NSAIDs vs 
Control 0.296 0.232 0.741 0.411 0.123 0.412 
(1)α = 0.02 
Table 2. Comparisons of the difference of right and left lateral motion between the groups.  
Does time influence active and passive mouth opening and right and left lateral motion 
in patients treated with laser and patients treated with NSAIDs ? 
Mean values of these parameters remain stable across the times (Table 3).  
 
 Baseline After treatment 1 month after treatment 
Active mouth 
opening(mm) 
L 36,28 ± 3.44
A 39.85 ± 2.89 
C 38.06 ± 3.19
L 43.24 ± 2.71
A 41,27 ± 2.49 
C 39.77 ± 3.96
L 45.89 ± 2.13 
A 40.90 ± 3.37 
C 37.46 ± 4.94 
Passive mouth 
opening (mm) 
L 37.97 ± 3.22
A 41.68 ± 3.01 
C 40.00 ± 3.21
L 45.28 ± 2.37
A 42.43 ± 2.77 
C 40.77 ± 4.06
L 47.22 ± 2.31 
A 42.54 ± 2.20 
C 38.28 ± 4.67 
Right lateral 
motion (mm) 
L 6,37 ± 1.08
A 7.10 ± 1.28 
C 6.57 ± 2.43
L 8.54 ± 1.41
A 8.63 ± 1.97 
C 7,98 ± 2.20
L 12.20 ± 1.08 
A 8.22 ± 1.92 
C 8.04 ± 2.26 
Left lateral 
Motion (mm) 
L 6.67 ± 1.14
A 6.87 ± 1.57 
C 6.44 ± 2.39
L 13.01 ± 1.57
A 8.82 ± 1.78 
C 8.01 ± 2.19
L 13.19 ± 1.54 
A 8.43 ± 1.97 
C 7.98 ± 2.21 
Table 3. Active and passive mouth opening, right and left lateral motion at baseline, after 
treatment and one month after treatment (mean±SD) (1) 
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May be hypothesized the mechanism of action of LLLT? 
It is interesting to observe that patients examined with MRI at the end of treatment showed 
a more or less abundant effusion within the intra-articular, which disappeared after laser 
therapy, whereas it remained stable in the other 2 groups, control and patients treated with 
NSAIDs. This reabsorption could explain the disappearance of pain through a wash out of 
the algogenic metabolites and the functional improvement through the elimination of the 
mechanical obstacle created by the liquid. In the case of arthritis, a series of pathologic 
phenomenon is present, which results in a synovial inflammation inducing a cascade of 
reactions and, in particular, prostaglandins and leukotrienes. LLLT might act on the synovia 
and stimulate cellular energy processes that appear. It could be hypothesized that in the 
condyle-meniscus coordination a synovitis could arise, even without the evident signs of 
arthritis, which could result in arthritis as indicated by an author (Stegenga , de Bont et al., 
1991)  
Which are the main advantages in using LLLT? 
Our therapeutic protocol and the characteristics of LLLT (highest peak power for a few 
seconds) are suggested in the treatment of painful TMD. An important adjunctive factor is 
the low cost of the therapy. 
4.2 Surgical treatment 
Surgical procedure is available for the treatment of TMD, ranging from simple 
arthrocentesis and lavage to more complex open joint surgical procedures. 
The general indication for TMJ arthritis surgery is significant TMJ pain and or dysfunction 
that originates in the joint and worsens during jaw functions, such as talking or clewing on 
the contralateral side and is refractory to non surgical treatment. 
Arthrocentesis and arthroscopy should resolve limited mouth opening, and pain associated 
with OA .  
Condylotomy should be used for high intensity of pain with restriction of opening the 
mouth. Whereas TMJ surgery should be reserved for advances cases of TMJ arthritis.  
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1. Introduction 
Osteoarthritis (OA) is a degenerative chronic condition that involves degradation of 
joints―primarily articular cartilage, synovium, and subchondral bones, producing joint 
pain, tenderness and stiffness. It can occur in any joint but knees, hips and small hand joints 
are the most commonly affected. Although OA can occur in any age group, its prevalence 
increases with age especially after the 4th or 5th decades of life (Jordan et al., 2007; Lawrence 
et al., 2008). OA is one of the most prevalent chronic conditions in Western countries, 
although prevalence rates vary depending on whether symptomatic or radiographic criteria 
were used (Busija et al., 2010; Comas et al., 2010), as it is well known that the severity of a 
patient's symptoms often is not correlated to the degree of disease progression evaluated on 
radiographs (Hannan et al., 2000). Women show, in general, a greater risk of prevalent OA 
and more severe symptoms, particularly after menopausal age (Srikanth et al., 2005). 
OA is a leading cause of disability and decreased quality of life, as it produces important 
functional limitations in daily activities (Elliot et al., 2007; van Dijk et al., 2008; Salaffi et al., 
2005). The socioeconomic burden of the condition is immense and is not only the leading 
cause of disability in Western countries but is also responsible for a large number of 
physician visits, hospitalisations, and time lost from work (Kotlarz et al., 2009; Bitton, 2009). 
There is no known cure for OA, so available treatments aim to relieve symptoms and 
improve or maintain functional capacity. Therapeutic options include nonpharmacologic, 
pharmacologic, and surgical interventions. Nonpharmacologic therapies, such as exercise, 
weight loss, physiotherapy, heat and cold application, or assistive devices entail no inherent 
risks and therefore they are recommended at all levels of severity, although they have 
revealed a modest effect in reducing symptoms (Scott & Kowalczyk, 2006).  
Acetaminophen is also a safe core treatment recommended as a first line option for pain 
relief. At more severe levels of symptoms, oral non-steroidal anti-inflammatory drugs 
(NSAIDs) should be considered, although they have shown a higher risk of adverse effects 
(gastrointestinal, liver and cardio-renal) than acetaminophen or topical NSAIDs. Therefore, 
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improve or maintain functional capacity. Therapeutic options include nonpharmacologic, 
pharmacologic, and surgical interventions. Nonpharmacologic therapies, such as exercise, 
weight loss, physiotherapy, heat and cold application, or assistive devices entail no inherent 
risks and therefore they are recommended at all levels of severity, although they have 
revealed a modest effect in reducing symptoms (Scott & Kowalczyk, 2006).  
Acetaminophen is also a safe core treatment recommended as a first line option for pain 
relief. At more severe levels of symptoms, oral non-steroidal anti-inflammatory drugs 
(NSAIDs) should be considered, although they have shown a higher risk of adverse effects 
(gastrointestinal, liver and cardio-renal) than acetaminophen or topical NSAIDs. Therefore, 
when selecting the agent and dose, healthcare professionals must take into account 
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individual patient risk factors, including age, and they should be used at the lowest effective 
dose for the shortest possible period of time.  
When nonsurgical treatments are ineffective at relieving symptoms and there is prolonged 
and established functional limitation and severe pain, referral for joint replacement surgery 
is recommended. This is a highly efficacious and cost-effective procedure for the treatment 
of advanced OA in its capability to relieve pain, increase mobility, and improve the quality 
of life (Losina et al., 2009). 
In the last two decades there has been increasing interest in shared decision-making (SDM) 
as a collaborative model of health care (Charles et al., 1997; Edwards & Elwyn, 2009). SDM, 
as opposed to a more traditional authoritative and paternalistic patient-practitioner 
relationship, requires information exchange between patients and professionals, where the 
latter offer technical information about the disease and available treatments, while patients 
offer their personal knowledge about their concerns, expectations and preferences about 
treatments, their efficacy and potential risks, in order to reach a consensus about medical 
decisions. SDM is especially applicable in those situations where there is uncertainty about 
the probability of outcomes, or when there are two or more treatment options that offer a 
similar balance between benefits and risks. From this perspective, taking into account 
patients’ preferences is increasingly advocated as an optimal model of collaborative care. 
In the case of OA, as commented above, clinical recommendations vary depending on 
symptoms severity and prior experience with other treatments. In spite of this, OA is a 
clinical condition that is highly sensitive to patient preferences at all stages of severity. 
Treatments recommended for mild symptoms (exercise, physiotherapy, acetanomiphen, etc) 
have modest efficacy but no inherent risks of adverse effects, while more effective options 
which reduce pain and increase functionality, such as NSAIDs or opioid analgesics, present 
a higher risk of side effects. Even a highly effective procedure such as total joint replacement 
(TJR) is subjected to relevant trade-offs between its demonstrated benefits and risks 
associated with every surgical intervention, or other factors such as convalescence or costs, 
in those societies without universal healthcare systems. Therefore, patients with OA are 
continually faced with decisions that imply relevant trade-offs between benefits and the risk 
of undesired outcomes, so their personal preferences should be incorporated during 
deliberations and decisions about treatment of their condition. 
Although research and implementation of SDM in OA remains scarce (Weng et al., 2007; 
Fraenkel et al., 2007), in the last decade an increasing number of studies have been 
performed that assessed patients’ preferences about treatment options for OA and its 
characteristics. The aim of this article is to present an overview about the research on 
preferences and use of treatments by patients with hip and/or knee OA. 
2. Patients’ awareness, use and satisfaction with treatments 
Several studies have analyzed patient awareness, prior utilization and/or satisfaction with 
treatments for OA, using survey measures. With some exceptions, results show that 
medications represent the most frequently used option in the treatment of OA. For instance, 
Juby et al. (2005) observed patients with clinical and radiographic evidence of OA (either hip 
or knee), and found a good awareness of 12 treatments, with diet modification and 
viscosupplementation being the less known (and used) options, with approximately 40% of 
the sample. Medications (non-narcotic and narcotic analgesics, NSAIDs, cyclooxygenase 
inhibitors COXIBs, steroid injections) were the most frequently known (more than 85% of 
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the sample) and used treatments (50% to 75%), and between half and two-thirds of the 
patients who have taken them reported to be satisfied with their efficacy. Tallon et al. (2000) 
also found medications to be the most frequently used treatment among knee OA patients, 
with more than 70% of participants considering them moderately or extremely helpful. In 
both the studies commented, nonpharmacological treatment options such as physical 
therapy or aids/adaptations were used by 40% to 60% of participants, and of these, a similar 
percentage considered them satisfactory. Joint replacement surgery was the least frequently 
used treatment, as it is recommended only for those with high severity, but among those 
who have undergone this procedure it was the most valuated. 
Mitchell & Hurley (2008), with 415 patients who consulted a primary care physician for knee 
pain of more than 6 months duration also found drugs (analgesic or NSAIDs) to be the 
treatment most frequently received (83%), followed by physiotherapy (41%), with other 
therapies showing rates of use lower than 10%. Sixty per cent of participants reported their 
preferences, and among these, physiotherapy was the most preferred treatment (41%), while 
only 4% reported drugs as their primary option.  
Blake et al. (2002) obtained quite a different result, with rates of treatments tried more 
equally distributed, exercise being the most frequently used (35%), while oral medications 
were tried by approximately 25% of respondents (only over-the-counter-medication was 
included in the survey). This study was population-based and data on treatment use refer to 
those participants who reported knee or hip pain (37% of the sample) and therefore, 
although a small subsample was required to present verifiable radiographic evidence of OA, 
it cannot be assured that other rheumatic conditions were not present in the sample. The fact 
that only use of over-the-counter medication was assessed was possibly responsible for the 
discrepancies with the studies previously commented. 
Other studies have analyzed patients’ preferences when two specific treatments are compared. 
For instance, Wolfe et al. (2000) studied a cohort of patients with OA, rheumatoid arthritis and 
fibromyalgia, assessing their preferences for acetaminophen versus NSAIDs. Among OA 
patients, 56% of them considered acetaminophen significantly or somewhat less effective than 
NSAIDs, and 30% stated that the efficacy of both drugs was about the same. When considering 
overall satisfaction with the drugs also taking into account their side effects, results were 
almost identical. In the context of a randomised trial comparing treatments for knee OA, three 
studies reported patients’ preferences for the treatments implemented. Underwood et al. 
(2007) offered patients the possibility of participating in a randomised trial or a preference 
study comparing topical versus oral ibuprofen for chronic knee pain. Among those who 
decided to participate in the preference study, 74% opted for the topical modality of the drug. 
Denegar et al. (2010) randomised 34 patients, in a crossover design, to heat, cold or contrast 
therapy, and after trial termination 47% of participants stated a preference for warm treatment, 
while equal preferences were observed for cold and contrast (24% in both cases). Foster et al. 
(2010), in a trial comparing physiotherapy advice and exercise versus the same condition plus 
acupuncture, assessed treatment preferences (not only for those implemented in the trial) 
before treatment was commenced, and found that only 20% of the participants stated a 
treatment preference; of these, 10% stated advice and exercise, 13% acupuncture and 44% both. 
3. Studies that use preferences elicitation techniques 
A number of studies have used different techniques to elicit patients’ preferences about 
treatments or its characteristics. The most frequently used technique has been Conjoint 
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Analysis (CA), a task where patients construct their treatment preferences by making trade-
offs between competing treatment characteristics (e.g., efficacy, risks or route of 
administration) in a series of rating tasks. Preferences are then predicted based on trade-offs 
between specific treatment characteristics and not the treatment itself. CA enables both 
health-related and nonhealth-related attributes, taking into account a wider range of 
outcomes. 
Byrne et al. (2006) used CA to assess racial differences in preferences for TJR in a sample that 
includes general population and patients with knee OA. Participants were faced with 
different hypothetical scenarios of surgical and nonsurgical states for OA, developed from 
combinations of several attributes with different levels: pain, walking, costs, death, 
complications and failure of the surgical procedure. Results showed that all attributes except 
failure of TJR significantly predicts participants’ choices: as differences between surgical and 
nonsurgical scenarios were smaller for pain and walking ability, and when the attribute of 
surgery (costs, death, complications) is larger participants were less likely to opt for surgery. 
Regarding participant characteristics, women, African-American and older individuals were 
less likely to choose surgery, while income level or kind of sample (public or patient) did not 
have a significant effect on choice. 
Fraenkel et al. (2004) also used CA to assess knee patients’ preferences for medications 
commonly prescribed for OA when an inadequate response for acetaminophen is obtained 
(nonselective NSAIDs, COXIBs, opioid analgesics) as well as other agents such as 
glucosamine and/or chondroitin sulphate, and capsaicine. Seven characteristics (with 
different levels) of medication were combined in the CA tasks: label, administration route, 
time to benefit, response rate, common adverse effects, risk of ulcer and monthly 
copayments. Results showed that the risk of adverse effects had the greatest impact on 
patient preferences; nonselective NSAIDs were almost never preferred, while topical 
capsaicine was the most preferred option even when it was reported as much less effective 
than the other alternatives. No significant associations between patients’ demographic or 
clinical characteristics and treatment preferences were obtained.  
In a more recent article, Fraenkel et al. (2008) also used CA to compare knee patient 
preferences for characteristics corresponding to four treatment options: topical capsaicin, 
oral medications (acetanomiphen, NSAIDs), intra-articular injections and exercise. Once 
again, patients’ preferences were more strongly influenced by the risk of side effects 
compared to the chance of benefit. Exercise and NSAIDs were the most and least preferred 
options respectively, whether this latter option was described as 20% (base case) or 50% 
(benefits maximized) more effective compared to the other options.  
In Ratcliffe et al. (2004), however, physical mobility was the most important attribute 
influencing patients’ preferences, although risk of serious adverse effects and level of joint 
aches were also significant predictors (level of joint pains and risk of mild to moderate side 
effects did not attain statistical significance in the prediction of patients’ choices). These 
results were moderated by factors such as symptoms severity, age or income; for instance, 
the importance attached to the level of mobility achieved decreased as the severity of 
symptoms increased. Chang et al. (2005), when combining health states for OA with 
different gastrointestinal side effects profiles (using a visual analogue scale, VAS), also 
found that the influence of side effects depends on the severity of the disease: it is lower 
when OA pain is severe and higher when OA pain is milder.  
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Kopec et al. (2007) analyzed patients’ maximum acceptable risk increments (MARI) for 
different adverse effects from OA medication, using a probabilistic threshold technique. In 
this task, patients are presented with two treatment options that only differ in one attribute 
(e.g., pain relief), so most patients would logically opt for the more effective one. Then, the 
task proceeds by increasing (in the most favourable option) by small units the probability of 
one of the side effects presented, until the respondent switches to accepting the alternative 
option. Results showed that the lowest MARI was observed for heart attack/stroke (3% to 
5%, depending on the level of pain relief and initial risk) and highest for dyspepsia (23% to 
35%). Higher initial-risk levels correlated with greater subsequent willingness to run 
additional risk to obtain a benefit in pain relief. 
4. Willingness and use of total joint replacement 
Total joint arthroplasty has been revealed to be an effective procedure for the management 
of end-stage hip and knee OA (Losina el at., 2009). Ninety per cent of those who undergo 
TJR experience relief of pain and functional improvement, and the probability of associated 
risks is lower than 1%. In spite of this, significant variations in the rates of utilisation of TJR 
have been found (Jones et al., 2005; Skinner et al., 2003). Race was the most frequently 
studied variable to explain these disparities, as numerous studies have shown that white 
patients are more likely than Afro-American patients to have TJR, results that can be 
extrapolated to other ethnic minorities (Escalante et al., 2000; Oishi et al., 1998). These 
disparities cannot be accounted for by differences in disease prevalence or in access to 
healthcare, since most of the candidates for these procedures are older persons with access 
to public health insurance, and studies in universal health care systems have also found 
ethnic disparities in utilisation. Haussman et al. (2010) have found that TJR 
recommendations were lower for Afro-American than white patients of similar age and 
disease severity, but after adjusting for patients’ preference for TJR this difference was no 
longer significant. Therefore, it seems that patient-level factors may be responsible, at least 
in part, for these disparities.  
Several studies have analyzed which variables, both at system and patient level, predict 
willingness to undergo TJR. Hawker et al. (2001, 2002, 2004) have demonstrated that some 
sociodemographic, clinical and psychological variables (patients’ beliefs and/or 
expectations about TJR) significantly predict their willingness for surgery: younger age, 
having spoken to the physician about having surgery, higher perceived severity, less 
comorbidities, considering friends as the best information source, perceiving the risk of TJR 
revision acceptable, or some perceived indications for treatments. Income and educational 
level are significantly related to the potential need for TJR, but not with willingness to 
undergo the procedure. Suarez-Almanzor et al. (2005) observed that when patients were 
asked whether they had considered knee replacement in the past, the most powerful 
predictor of an affirmative response was to have a previous recommendation by their 
physicians, followed by not being Afro-American, being male, higher perceived efficacy, 
and more confidence in the physician. When the question referred to considering TJR in the 
future if it was recommended by the physician, only ethnicity and perceived efficacy were 
significant predictors. To date, studies strongly suggest that less willingness of Afro–
Americans to undergo TJR compared with white patients is accounted for by several 
psychological factors: they have worse expectations about TJR outcomes (Ibrahim et al., 
2002a), expect a longer hospital stay (Ibrahim et al., 2002b), are more likely to perceive 
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one of the side effects presented, until the respondent switches to accepting the alternative 
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have been found (Jones et al., 2005; Skinner et al., 2003). Race was the most frequently 
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recommendations were lower for Afro-American than white patients of similar age and 
disease severity, but after adjusting for patients’ preference for TJR this difference was no 
longer significant. Therefore, it seems that patient-level factors may be responsible, at least 
in part, for these disparities.  
Several studies have analyzed which variables, both at system and patient level, predict 
willingness to undergo TJR. Hawker et al. (2001, 2002, 2004) have demonstrated that some 
sociodemographic, clinical and psychological variables (patients’ beliefs and/or 
expectations about TJR) significantly predict their willingness for surgery: younger age, 
having spoken to the physician about having surgery, higher perceived severity, less 
comorbidities, considering friends as the best information source, perceiving the risk of TJR 
revision acceptable, or some perceived indications for treatments. Income and educational 
level are significantly related to the potential need for TJR, but not with willingness to 
undergo the procedure. Suarez-Almanzor et al. (2005) observed that when patients were 
asked whether they had considered knee replacement in the past, the most powerful 
predictor of an affirmative response was to have a previous recommendation by their 
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and more confidence in the physician. When the question referred to considering TJR in the 
future if it was recommended by the physician, only ethnicity and perceived efficacy were 
significant predictors. To date, studies strongly suggest that less willingness of Afro–
Americans to undergo TJR compared with white patients is accounted for by several 
psychological factors: they have worse expectations about TJR outcomes (Ibrahim et al., 
2002a), expect a longer hospital stay (Ibrahim et al., 2002b), are more likely to perceive 
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various traditional and complementary care modalities as efficacious (Ibrahim et al., 2001), 
and consider that prayer is a helpful option to face up to OA disability (Ang et al., 2002). 
These beliefs and expectations may have important historical roots; discrimination against 
African Americans, for example, may have created cultural expectations of avoiding 
medical interventions in favour of home remedies. In any case, these data reflect the 
importance of taking patients’ preferences into account when making decisions about 
treatment, and the necessity of implementing interventions that could correct erroneous 
perceptions about the efficacy of medical procedures. 
It seems logical that physician recommendation of surgery was the most powerful predictor 
to undergo TJR, as found by Hawker et al. (2006). This study only reported unadjusted 
analyses in the prediction of undergoing TJR and also found that age between 62-82, higher 
education level, higher body mass index, worse perceived severity, and a better perceived 
general health significantly predict the use of TJR. In Hamel et al. (2008), age was a 
significant predictor in unadjusted analyses, but not when the remaining predictors were 
introduced in the regression model. Independent significant predictors of receiving the 
procedure were higher income level, higher perceived severity and less concern about dying 
or having complications from surgery. 
5. Qualitative studies 
Qualitative studies may help to obtain a more in depth viewpoint on the experiences of 
patients with the disease, in addition to their beliefs, perceptions and concerns about 
therapies to follow and in general their relationship with the health system. In the case of 
OA, a considerable number of studies have been performed which analyse various issues 
related to living with the disease and the treatment options.  
As for sociodemographic variables which might have an influence on patients' preferences 
and decisions, in accordance with the results obtained in some of these studies, sex is one of 
the variables which may lead to differences in the way to live with OA and its possible 
treatments. Chang et al. (2004), observed that in general women generate more topics of 
interest than men (while in the sample there were twice as many women as men); some 
were exclusive to women: anatomy of OA, disadvantages of surgery, pain following surgery 
and methods to relieve this pain. In the case of intra-operative issues, women focused more 
on anaesthesia, and men on surgical technique. The study by Karlsson et al. (1997) focused 
specifically on sex-based differences. The results highlighted that women were more 
concerned about their function in basic activities, and tended to attain a worse functional 
level prior to considering surgery; they prefer to endure the suffering instigated by OA. 
They were more sceptical regarding the results of the arthroplasty and had less confidence 
in the doctor. The reasons provided for having more reservations towards surgery refer to 
expecting better technology to exist, their responsibilities as carers or concerns on becoming 
a burden to others. 
Just as for the quantitative studies, race also seems to differentially affect living with OA 
and treatment preferences. In Chang et al. (2004), Afro-American patients generated less 
topics (especially men), and these dealt with more issues related to financial aspects, the 
ideal nature of the treatment or lack of trust in the doctor and health system in general. In 
Kroll et al. (2007), racial differences focused especially on four categories: causes of the 
disease (Afro-Americans tended to offer internal explanations, related to wear of the body 
and ageing, whilst Caucasians and Hispanics referred more frequently to external variables, 
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such as lesions or accidents), lifestyle changes (Afro-Americans report the disease as more 
debilitating, while white people and Hispanics, although they recognise the functional 
impairment, more frequently name the ways in which they try to overcome these 
limitations), trust and scepticism (Hispanics reveal less trust in the doctor, not so much in 
their skill as in their professional integrity. Afro-Americans were more sceptical as to 
technological progress), paying for surgery (Afro-Americans mention this topic more 
frequently, and are more concerned with obtaining money lent to be able to pay for the 
operation, while Hispanics mention the possibility of first undergoing the operation and 
then paying later on). Ibrahim et al. (2004), in a sample of Afro-American men, found that in 
relation to the category “cultural aspects of the care of arthrosis”, the emerging topics 
referred to religious beliefs of the doctor and patient, in addition to the doctor's sex and race. 
For the latter aspect, the majority of the sample said they felt indifferent towards the 
doctor's race as the important thing is their professional skill; however, approximately 10% 
of the sample preferred a doctor of their same race, arguing that in this way they could 
better understand their problems. Regarding the sex of the doctor, one fifth of people who 
mentioned this topic preferred a doctor of the same sex as they were uncomfortable 
discussing private issues with someone of the opposite sex. 
Other studies have offered information on various clinical factors or related to the health 
system which also has an influence on patient preferences and taking decisions. The study by 
Ballantyne et al. (2007) reveals how the assessment of the severity of OA is performed in 
general in a framework of comorbidity; although OA is considered as debilitating, it is not 
usually the primary health concern. The impact of the symptoms of OA (pain, lack of 
functionality), and their possible relief following the operation are essential topics for 
consideration of arthroplasty, in addition to the risks or side effects of the treatments, and they 
appear like this in most studies (Bower et al., 2006; Campbell et al., 2001; Chang et al., 2004; 
Karlsson et al., 1997; Kroll et al., 2007; Thorstensson et al., 2006). Waiting lists are debated in 
the study by O´Neill et al. (2007). Although participants confide in arthroplasty as a means to 
relieve symptoms, the uncertainty generated by waiting time once they have decided to 
operate has a negative effect on patient quality of life. Examples of other emerging topics 
regarding medical aspects of the disease and treatment were: anatomy of OA and duration of 
the prosthesis (Chang et al., 2004), body abnormality (Kroll et al., 2007), surgical techniques 
and indication for surgery (Chang et al., 2004; Karlsson et al., 1997), or improvements to 
general physical function (Thorstensson et al., 2006). 
The social networks of patients are also a very important aspect in the decision to operate 
(Ballantyne et al., 2007; Bower et al., 2006; Kroll et al., 2007); family members or other people 
relevant for patients play a notable influence on their decisions to handle the disease, both 
by means of instrumental and emotional support, in addition to strengthening or 
contravening the beliefs of patients or providing them with new information. The role of the 
spouse is decisive in one sense or the other, to the extent that this is the person who will 
adopt the role of carer, and who in some way “shares” the psycho-emotional impact 
produced by OA; in many cases decisions are taken in part based on the capacity of the 
spouse to face up to the disease (Ballantyne et al., 2007; O´Neill et al., 2007). In the same 
way, the knowledge of other people who have undergone arthroplasty and the results 
obtained from this process are important when taking decisions on treatment (Chang et al., 
2004). In some cases, however, the validity of friends as a source of information is 
questioned by patients themselves (Bower et al., 2006). 
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such as lesions or accidents), lifestyle changes (Afro-Americans report the disease as more 
debilitating, while white people and Hispanics, although they recognise the functional 
impairment, more frequently name the ways in which they try to overcome these 
limitations), trust and scepticism (Hispanics reveal less trust in the doctor, not so much in 
their skill as in their professional integrity. Afro-Americans were more sceptical as to 
technological progress), paying for surgery (Afro-Americans mention this topic more 
frequently, and are more concerned with obtaining money lent to be able to pay for the 
operation, while Hispanics mention the possibility of first undergoing the operation and 
then paying later on). Ibrahim et al. (2004), in a sample of Afro-American men, found that in 
relation to the category “cultural aspects of the care of arthrosis”, the emerging topics 
referred to religious beliefs of the doctor and patient, in addition to the doctor's sex and race. 
For the latter aspect, the majority of the sample said they felt indifferent towards the 
doctor's race as the important thing is their professional skill; however, approximately 10% 
of the sample preferred a doctor of their same race, arguing that in this way they could 
better understand their problems. Regarding the sex of the doctor, one fifth of people who 
mentioned this topic preferred a doctor of the same sex as they were uncomfortable 
discussing private issues with someone of the opposite sex. 
Other studies have offered information on various clinical factors or related to the health 
system which also has an influence on patient preferences and taking decisions. The study by 
Ballantyne et al. (2007) reveals how the assessment of the severity of OA is performed in 
general in a framework of comorbidity; although OA is considered as debilitating, it is not 
usually the primary health concern. The impact of the symptoms of OA (pain, lack of 
functionality), and their possible relief following the operation are essential topics for 
consideration of arthroplasty, in addition to the risks or side effects of the treatments, and they 
appear like this in most studies (Bower et al., 2006; Campbell et al., 2001; Chang et al., 2004; 
Karlsson et al., 1997; Kroll et al., 2007; Thorstensson et al., 2006). Waiting lists are debated in 
the study by O´Neill et al. (2007). Although participants confide in arthroplasty as a means to 
relieve symptoms, the uncertainty generated by waiting time once they have decided to 
operate has a negative effect on patient quality of life. Examples of other emerging topics 
regarding medical aspects of the disease and treatment were: anatomy of OA and duration of 
the prosthesis (Chang et al., 2004), body abnormality (Kroll et al., 2007), surgical techniques 
and indication for surgery (Chang et al., 2004; Karlsson et al., 1997), or improvements to 
general physical function (Thorstensson et al., 2006). 
The social networks of patients are also a very important aspect in the decision to operate 
(Ballantyne et al., 2007; Bower et al., 2006; Kroll et al., 2007); family members or other people 
relevant for patients play a notable influence on their decisions to handle the disease, both 
by means of instrumental and emotional support, in addition to strengthening or 
contravening the beliefs of patients or providing them with new information. The role of the 
spouse is decisive in one sense or the other, to the extent that this is the person who will 
adopt the role of carer, and who in some way “shares” the psycho-emotional impact 
produced by OA; in many cases decisions are taken in part based on the capacity of the 
spouse to face up to the disease (Ballantyne et al., 2007; O´Neill et al., 2007). In the same 
way, the knowledge of other people who have undergone arthroplasty and the results 
obtained from this process are important when taking decisions on treatment (Chang et al., 
2004). In some cases, however, the validity of friends as a source of information is 
questioned by patients themselves (Bower et al., 2006). 
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Prior experience with the health system is also a highly determinant factor, to the extent that 
negative experiences may affect patient beliefs or expectations (Ballantyne et al., 2007). 
Other factors which will be included in this section would be financial/work-related aspects 
such as the effect of OA and/or the operation on working life (e.g. early retirement; Kroll et 
al., 2007), the cost of the operation (Chang et al., 2004; Ibrahim et al., 2004; Kroll et al., 2007), 
technical and structural support (accessibility to the health system, or specific contexts 
related to treatment; Thorstensson et al, 2006), etc. 
Psychological variables comprise most topics generated in different studies, including 
knowledge, beliefs, expectations or emotional reactions to living with OA and its 
treatment. Beliefs on the nature of OA seem important when considering surgery. In 
many cases patients consider that OA is a natural age-related process and this belief has a 
negative effect on the expected success of the treatment (Ballantyne et al., 2007; Campbell 
et al., 2001; O´Neill et al., 2007). However, one possible positive consequence of these 
kinds of beliefs could be the fact that OA is not a threat to the sense of own identity, to the 
extent that it is considered “suitable” at one's current age and therefore integrates easily 
into one's own identity (Ballantyne et al., 2007). In other cases, however, the alterations in 
roles and social relationships, or the lack of autonomy and independence produced by OA 
represent an invasive characteristic of own identity which affects self-identity and self-
esteem. 
Beliefs about who is eligible for the operation also play an important role in their selection 
(O´Neill et al., 2007). Some people believe that to consider surgery, the pain should be 
constant and the incapacity to move, total; obviously, this reduces the probabilities of 
considering arthroplasty, although the expectations on their results are positive. In the same 
sense, it may also occur that patients consider there should be people in worse physical 
conditions, for which reason they should be priority for surgery. The experience of pain and 
incapacity produced by the OA has a strong subjective component (O´Neill et al., 2007). In 
this sense, it has been seen that there are differences in the way these aspects are assessed; 
for example, Afro-Americans report the disease as more disabling than Caucasians (Kroll et 
al., 2007). However, as mentioned above, this greater disability perceived is not translated 
into a greater disposition to operate, quite on the contrary. Expectations on the results of 
treatments whether on their benefits or on their risks/side effects, also play a determining 
role when taking decisions on OA (Bower et al., 2006; Kroll et al., 2007; O´Neill et al., 2007). 
These expectations may come from external sources (doctors, friends, acquaintances) or the 
patient's own experience, for example over medication (Bower et al., 2006) or practicing 
exercise (Thorstensson et al., 2006). 
Different kinds of reaction to OA symptoms have also been detected (Karlsson et al., 1997). 
Reacting by means of adaptation would refer to the psychological acceptance of the disease 
by means of regulating one's own emotions with a positive attitude and trying to adapt 
lifestyle to the new physical condition. A response by means of action would also refer to 
trying out new treatments.  
6. Conclusions 
In the last few decades there has been a gradual change in models of healthcare and the way 
to understand the doctor-patient relationship. From a medical model based on the disease 
and symptoms there has been a gradual progression towards what has been called patient-
focused care whose main features would be respect for the patient's choices and values, 
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emotional support, providing information and education, coordination of clinical care or the 
involvement of the patient's family and friends (Gerteis et al., 1993) 
From this new point of view, the patient's psychological attitude, reflected in beliefs and 
expectations on the disease, healthcare or the doctor-patient relationship, as well as 
emotional response and the establishment of socio-affective links with health professionals, 
turns into a highly relevant aspect which is necessary to incorporate into the healthcare 
process. Patient attitudes, beliefs, preferences and expectations are considered factors which 
may have an important influence on the treatment process and its results whether by means 
of behavioural factors such as compliance with treatment procedures or putting into practice 
certain lifestyles which may favour or, on the contrary, hinder the onset or development of 
the disease, whether because of the direct effect that beliefs and expectations could have on 
the results of medical interventions by means of psychological mechanisms still not well 
understood.  
Regarding taking medical decisions, this new way of understanding the role of the patient 
and their relationship with health professionals has led to the concept of shared decision-
making, a joint process of deliberation between the doctor and patient where preferences are 
incorporated into taking decisions on diagnostic or therapeutic procedures within a process 
of mutual communication between both, where the professional provides information based 
on scientific evidence on the efficacy and safety of available treatment options, while the 
patient incorporates their psychological experiences, concerns, preferences and expectations 
over reaching a consensual decision on the procedure to follow. 
In the case of OA, research performed to date has been delimiting a series of factors which 
determine patient choices as to different treatment options for their disease. Race was the 
most frequently studied variable because of the consistent results on less frequent use of TJR 
by ethnic minorities, especially Afro-Americans. Other studies report sex-based differences 
in living with the disease, patient concerns regarding their quality of life and on the results 
of treatments. These studies have revealed the importance of dealing with the beliefs and 
expectations of patients on the disease and available treatment options to the extent that 
these factors account for a substantial part of the behaviour of patients regarding their 
disease and quest for healthcare.  
The studies commented in this article used different methodologies which hinder the 
integration of results, which on the other hand lead to discrepancies in some cases. For 
example, studies which use preference elicitation techniques found, in general, that patients' 
preferences are more influenced by the risk of adverse effects than potential benefits (while 
this effect is moderated by variables such as severity level, as patients with more serious 
symptoms tend to agree to run a greater risk in exchange for obtaining symptomatic relief). 
This data is clearly reflected in the investigation by Fraenkel et al. (2004, 2008) regarding 
NSAIDs, which because of a greater possibility of adverse effects are less preferred by 
patients given less effective but safer options. However, studies which have analysed by 
means of self-reporting techniques patients' use and preferences on the different treatments 
find that NSAIDs are not only among the most frequently used but they also reveal a high 
degree of acceptance by patients. Studies which use Conjoint Analysis propose explicit 
trade-offs to patients between risks and benefits of treatments while preferences are made 
on the characteristics of treatments and not on these by themselves; therefore, the possibility 
of bias because of recognition of the product or commercial brand and the experience of 
patients with these treatments is removed. For their part, studies such as those by Wolfe et 
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al. (2000) and Juby et al. (2005) ask patients about the use they have made of different 
therapeutic options and their satisfaction with these and do not oblige participants to 
establish trade-offs between treatment characteristics. In this sense, preference elicitation 
techniques enable a more "pure" measure of these, in the sense of not being explicitly 
influenced by experience (and satisfaction) of patients with the treatment assessed. 
However, we can ask ourselves to what extent these procedures offer a somewhat 
“artefactual” image of patients' preferences derived from trade-offs between the 
consequences of treatments based on population-related probabilities, compared to 
assessments made by people who have experienced both adverse effects and the benefits of 
treatments. Prior investigations have reported that people from the general population 
assess certain states of health more negatively than those patients who suffer them. In this 
context it would be interesting to analyse the results of the CA separately for people who 
have experienced adverse effects of treatments compared to those who have not suffered 
from them. Studies on communication of risks both in the health and other fields have also 
revealed that people are more insensitive to major variations in the likelihood of very life-
threatening emotional events, such as cancer or a nuclear accident (Slovic et al., 2005; 
Rottenstreich & Hsee, 2001).  
Participation of the patient in taking decisions on their own health has turned into an object 
of debate and research in the last few decades. Calls to involve the patient in the process of 
taking decisions is based on practical arguments, in the sense of achieving more quality and 
efficiency in health services, and from an ethical point of view as a consequence of the 
emphasis on rights of autonomy and patient participation. In this sense, the preferences and 
values of patients have to occupy a relevant place in the process of healthcare and both 
investigators and health professionals should develop strategies to incorporate these 
preferences into taking medical decisions. Although currently there is no absolute 
unanimity on the meaning of “shared decision-making”, it may be generally accepted that 
this refers to a process of communication between patients and health professionals 
regarding reaching a consensus on diagnostic or therapeutic procedures to follow―a 
dynamic process both from a non-historical and historical point of view where the 
information, concerns, values and preferences are shared and debated for which, in fact, 
they may be modified during this process. This does not mean the patient lays down their 
own preferences; in fact, these may be based on erroneous perceptions of medical 
procedures. Therefore, for example, it has been commented that racial differences over 
disposition to undergo TJR are in large part explained by the worse expectations of Afro-
American patients over the results of this operation when scientific evidence reveals that 
this is a highly effective procedure with a low level of risk. These erroneous perceptions 
may be modified during the process of communication which suggests SDM, but this will 
not occur unless they are debated explicitly by the actors in the healthcare process. These 
difficulties may be overcome by means of implementing interventions promoted by SDM, 
such as training professionals on a consultatory style which promotes participation of the 
patient or the use of patient decision aids (PtDAs). These are instruments designed to set out 
the scientific evidence in a understandable way for patients in addition to helping them 
clarify their values and preferences regarding the features of the diagnosis or treatment 
procedures in terms of efficacy, safety or other relevant aspects, with the aim of facilitating 
taking decisions alongside their doctor. There are few studies which have analysed the effect 
of the application of these tools to patients with OA, but results are promising. Therefore, 
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Weng et al. (2007), in an uncontrolled study, found an improvement in the expectations of 
the results of TJR in Afro-American patients in addition to a reduction in decision-related 
conflict in the overall sample following the application of a PtDA consisting of a video and 
booklet on OA and its treatments. In a randomised controlled trial where patients from the 
intervention group received the results of their scores in a CA test, Fraenkel et al. (2007) 
observed a significant increase in self-efficacy in the handling of OA and in preparedness to 
participate in decision-making with their physicians. Therefore, these tools represent a 
resource of major interest to encourage a more active role for patients, thereby improving 
their knowledge on the medical procedures in which they are involved, in addition to 
communication with their health professional on their values and preferences. 
Healthcare in the 21st century must respond to new challenges in an increasingly complex 
society where the increase in life expectancy also entails an increase in chronic diseases with 
a more educated population and where the sources of information on health have quickly 
multiplied with the onset of new technologies. The change from a paternalistic model of 
healthcare to another where the patient adopts a more autonomous and active role seems 
unstoppable. The assessment and understanding of patients' values and preferences 
regarding their states of health and available medical procedures represents only part of the 
process of involving the patient in taking decisions on their health, but this is fundamental 
in order for this process to be successful. In the case of OA, research has shown that patients’ 
preferences are influenced by a wide number of factors. Experimental tasks such as CA have 
pointed out the importance of treatment risks in patients’ choices, since participants in those 
tasks tend to prefer options with lower risks although they involve a lower probability of 
benefit. However, survey based studies show that when patients are asked based on their 
experience, they are quite satisfied with more effective options although they involve a 
higher risk. Furthermore, these results are moderated by demographic or clinical variables 
such as age or disease severity. Future research must clarify these questions. Psychological 
and psychosocial variables such as beliefs about the disease and treatments, expectations 
about outcomes, trust in health professionals, previous experience with the Health System, 
social networks and perceived social support, conform a complex interaction of factors that 
play an important role in patients’ preferences and choices, and therefore they should not be 
neglected in the health care of patients with OA. 
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they may be modified during this process. This does not mean the patient lays down their 
own preferences; in fact, these may be based on erroneous perceptions of medical 
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play an important role in patients’ preferences and choices, and therefore they should not be 
neglected in the health care of patients with OA. 
7. References 
Ang, D., Ibrahim, S., Burant, C., Siminoff, L. & Kwoh, C. (2002). Ethnic differences in the 
perception of prayer and consideration of joint arthroplasty, Medical Care Vol. 40 
(No. 6): 471-476. 
Ballantyne, P., Gignac, M. & Hawker, G. (2007). A patient-centered perspective on surgery 
avoidance for hip or knee arthritis: lessons for the future, Arthritis & Rheumatism 
Vol. 57 (No. 1): 27-34. 
Bitton, R. (2009). The Economic Burden of Osteoarthritis, The American journal of managed care 
Vol. 15 (Suppl 8):230-235. 
Blake, V., Allegrante, J., Robbins, L., Mancuso, C., Peterson, M., Esdaile, J., Paget, S. & 
Charlson, M. (2002). Racial differences in social network experience and 
perceptions of benefit of arthritis treatments among New York City medicare 
  
Osteoarthritis – Diagnosis, Treatment and Surgery 
 
238 
beneficiaries with self-reported hip and knee pain, Arthritis & Rheumatism Vol. 47 
(No. 4): 366–371. 
Bower, K., Frail, D., Twohig, P. & Putnam W. (2006). What influences seniors´choice of 
medications for osteoarthritis? Qualitative inquiry, Canadian Family Physician Vol. 
52: 342-343. 
Busija, L., Bridgett, L., Williams, S., Osborne, R., Buchbinder, R., March, L. & Fransen, M. 
(2010). Osteoarthritis, Best practice & research. Clinical rheumatology Vol. 24 (No. 6): 
757–768. 
Byrne, M., Souchek, J., Richardson, M. & Suarez-Almazor M. (2006). Racial/ethnic 
differences in preferences for total knee replacement surgery, Journal of clinical 
epidemiology Vol. 59: 1078-1086. 
Campbell, R., Evans, M., Tucker, M., Quilty, B., Dieppe, P. & Donovan, J. (2001). Why don´t 
patients do their exercises? Understanding non-compliance with physiotherapy in 
patients with osteoarthritis of the knee, Journal of epidemiology and community health 
Vol. 55 (No. 2): 132-138. 
Chang, J., Kauf, T., Mahajan, S., Jordan, J., Kraus, V., Vail, T., Reed, S., Omar, M., Kahler, K. 
& Schulman, K. (2005). Impact of disease severity and gastrointestinal side effects 
on the health state preferences of patients with osteoarthritis, Arthritis and 
rheumatism Vol. 52 (No. 8): 2366–2375. 
Chang, H., Mehta, P., Rosenberg, A. & Scrimsham, S. (2004). Concerns of patiens actively 
contemplating total knee replacement: diferences by race and gender, Arthritis care 
& research Vol. 51 (No. 1): 117-123. 
Charles, C., Gafni, A. & Whelan, T. (1997). Shared decision-making in the medical 
encounter: What does it mean? (Or it takes at least two to tango), Social science & 
medicine Vol. 44 (No. 5): 681-692. 
Denegar, C., Dougherty, D., Friedman, J., Schimizzi, M., Clark, J., Comstock, B. & 
Kraemer, W. (2010). Preferences for heat, cold, or contrast in patients with knee 
osteoarthritis affect treatment response, Clinical interventions in aging Vol. 5: 199–
206 
Edwards, A. & Elwyn, G. Decision-Making in health care. Achieving evidence-based patient 
choice. Second edition, New York: Oxford University press; 2009; 17-22. 
Comas, M., Sala, M., Román, R., Hoffmeister, L. & Castells, X. (2010). Variaciones en la 
estimación de la prevalencia de artrosis de rodilla según los criterios 
diagnósticos utilizados en los estudios poblacionales, Gaceta sanitaria Vol. 24 
(No. 1): 28–32. 
Elliott, A., Kraus, V., Fang, F., Renner, J., Schwartz, T., Salazar, A., Huguenin, T., Hochberg, 
M., Helmick, C. & Jordan J. (2007). Joint-specific hand symptoms and self-reported 
and performance-based functional status in African Americans and Caucasians: the 
Johnston County Osteoarthritis Project. Annals of the rheumatic diseases Vol. 66 (No. 
12): 1622-1626.  
Escalante, A., Espinosa-Morales, R., del Rincon, I., Arroyo, R. & Older, S. (2000). Recipients 
of hip replacement for arthritis are less likely to be Hispanic, independent of access 
to health care and socioeconomic status, Arthritis and rheumatism Vol. 43 (No. 2): 
390-399. 
 
Treatment Preferences in Patients with Knee or Hip Osteoarthritis: An Overview 
 
239 
Foster, N., Thomas, E., Hill, J. & Hay, E. (2010). The relationship between patient and 
practitioner expectations and preferences and clinical outcomes in a trial of exercise 
and acupuncture for knee osteoarthritis, European journal of pain Vol. 14 (No. 4): 
402–409. 
Fraenkel, L., Bogardus, Jr., S., Concato, J. & Wittink, D. (2004). Treatment options in knee 
osteoarthritis: the patient’s perspective, Archives of internal medicine Vol. 164 (No. 
12): 1299-1304 
Fraenkel, L., Rabidou, N., Wittink, D. & Fried, T. (2007). Improving informed decision-
making for patients with knee pain, The Journal of rheumatology Vol. 34 (No. 9): 1894-
1898. 
Fraenkel, L. & Fried, T. (2008). If You Want Patients with Knee Osteoarthritis (OA) to 
Exercise: Tell them about NSAIDS, Patient Vol. 1 (No. 1): 21–26. 
Gerteis, M., Edgman-Levitan, S., Daley, J., Delbanco, T. Through the Patient's Eyes: 
Understanding and Promoting Patient-Centered Care. San Francisco: Jossey-Bass; 
1993. 
Hawker, G., Wright, J., Coyte, P., Williams, J., Harvey, B., Glazier, R., Wilkins, A. & 
Badley, E., (2001). Determining the need for hip and knee arthroplasty: the role 
of clinical severity and patients' preferences, Medical Care Vol. 39 (No.3): 206-
216. 
Hawker, G., Wright, J., Badley, E. & Coyte, P. (2004). Perceptions of, and willingness to 
consider, total joint arthroplasty in a population-based cohort of individuals 
with disabling hip and knee arthritis, Arthritis and rheumatism Vol. 51 (No. 4): 
635-641. 
Hawker, G., Wright, J., Glazier, R., Coyte, P., Harvey, B., Williams, J. & Badley, E. (2002). 
The effect of education and income on need and willingness to undergo total joint 
arthroplasty, Arthritis and rheumatism Vol. 46 (No. 12): 3331-3339. 
Hawker, G., Guan, J., Croxford, R., Coyte, P., Glazier, R., Harvey, B., Wright, J., Williams, J. 
& Badley, E. (2006). A prospective population-based study of the predictors of 
undergoing total joint arthroplasty, Arthritis and rheumatism Vol. 54 (No. 10): 3212–
3220. 
Hannan, M., Felson, D. & Pincus, T. (2000). Analysis of the discordance between 
radiographic changes and knee pain in osteoarthritis of the knee. The Journal of 
rheumatology Vol. 27 (No. 6): 1513-1517. 
Hausmann, L., Mor, M., Hanusa, B., Zickmund, S., Cohen, P., Grant, R., Kresevic, D., 
Gordon, H., Ling, B., Kwoh, C. & Ibrahim, S. (2010). The effect of patient race on 
total joint replacement: recommendations and utilization in the orthopedic setting, 
Journal of general internal medicine Vol. 25 (No. 9): 982-989.  
Ibrahim, S., Siminoff, L., Burant, C. & Kwoh, C. (2002a). Understanding ethnic differences in 
the utilization of joint replacement for osteoarthritis: the role of patient-level 
factors, Medical care Vol. 40 (Suppl 1): 144-151.  
Ibrahim, S., Siminoff, L., Burant, C. & Kwoh, C. (2002b). Differences in expectations of 
outcome mediate African American/white patient differences in “willingness” 
to consider joint replacement, Arthritis and rheumatism Vol. 46 (No. 9): 2429-
2435. 
  
Osteoarthritis – Diagnosis, Treatment and Surgery 
 
238 
beneficiaries with self-reported hip and knee pain, Arthritis & Rheumatism Vol. 47 
(No. 4): 366–371. 
Bower, K., Frail, D., Twohig, P. & Putnam W. (2006). What influences seniors´choice of 
medications for osteoarthritis? Qualitative inquiry, Canadian Family Physician Vol. 
52: 342-343. 
Busija, L., Bridgett, L., Williams, S., Osborne, R., Buchbinder, R., March, L. & Fransen, M. 
(2010). Osteoarthritis, Best practice & research. Clinical rheumatology Vol. 24 (No. 6): 
757–768. 
Byrne, M., Souchek, J., Richardson, M. & Suarez-Almazor M. (2006). Racial/ethnic 
differences in preferences for total knee replacement surgery, Journal of clinical 
epidemiology Vol. 59: 1078-1086. 
Campbell, R., Evans, M., Tucker, M., Quilty, B., Dieppe, P. & Donovan, J. (2001). Why don´t 
patients do their exercises? Understanding non-compliance with physiotherapy in 
patients with osteoarthritis of the knee, Journal of epidemiology and community health 
Vol. 55 (No. 2): 132-138. 
Chang, J., Kauf, T., Mahajan, S., Jordan, J., Kraus, V., Vail, T., Reed, S., Omar, M., Kahler, K. 
& Schulman, K. (2005). Impact of disease severity and gastrointestinal side effects 
on the health state preferences of patients with osteoarthritis, Arthritis and 
rheumatism Vol. 52 (No. 8): 2366–2375. 
Chang, H., Mehta, P., Rosenberg, A. & Scrimsham, S. (2004). Concerns of patiens actively 
contemplating total knee replacement: diferences by race and gender, Arthritis care 
& research Vol. 51 (No. 1): 117-123. 
Charles, C., Gafni, A. & Whelan, T. (1997). Shared decision-making in the medical 
encounter: What does it mean? (Or it takes at least two to tango), Social science & 
medicine Vol. 44 (No. 5): 681-692. 
Denegar, C., Dougherty, D., Friedman, J., Schimizzi, M., Clark, J., Comstock, B. & 
Kraemer, W. (2010). Preferences for heat, cold, or contrast in patients with knee 
osteoarthritis affect treatment response, Clinical interventions in aging Vol. 5: 199–
206 
Edwards, A. & Elwyn, G. Decision-Making in health care. Achieving evidence-based patient 
choice. Second edition, New York: Oxford University press; 2009; 17-22. 
Comas, M., Sala, M., Román, R., Hoffmeister, L. & Castells, X. (2010). Variaciones en la 
estimación de la prevalencia de artrosis de rodilla según los criterios 
diagnósticos utilizados en los estudios poblacionales, Gaceta sanitaria Vol. 24 
(No. 1): 28–32. 
Elliott, A., Kraus, V., Fang, F., Renner, J., Schwartz, T., Salazar, A., Huguenin, T., Hochberg, 
M., Helmick, C. & Jordan J. (2007). Joint-specific hand symptoms and self-reported 
and performance-based functional status in African Americans and Caucasians: the 
Johnston County Osteoarthritis Project. Annals of the rheumatic diseases Vol. 66 (No. 
12): 1622-1626.  
Escalante, A., Espinosa-Morales, R., del Rincon, I., Arroyo, R. & Older, S. (2000). Recipients 
of hip replacement for arthritis are less likely to be Hispanic, independent of access 
to health care and socioeconomic status, Arthritis and rheumatism Vol. 43 (No. 2): 
390-399. 
 
Treatment Preferences in Patients with Knee or Hip Osteoarthritis: An Overview 
 
239 
Foster, N., Thomas, E., Hill, J. & Hay, E. (2010). The relationship between patient and 
practitioner expectations and preferences and clinical outcomes in a trial of exercise 
and acupuncture for knee osteoarthritis, European journal of pain Vol. 14 (No. 4): 
402–409. 
Fraenkel, L., Bogardus, Jr., S., Concato, J. & Wittink, D. (2004). Treatment options in knee 
osteoarthritis: the patient’s perspective, Archives of internal medicine Vol. 164 (No. 
12): 1299-1304 
Fraenkel, L., Rabidou, N., Wittink, D. & Fried, T. (2007). Improving informed decision-
making for patients with knee pain, The Journal of rheumatology Vol. 34 (No. 9): 1894-
1898. 
Fraenkel, L. & Fried, T. (2008). If You Want Patients with Knee Osteoarthritis (OA) to 
Exercise: Tell them about NSAIDS, Patient Vol. 1 (No. 1): 21–26. 
Gerteis, M., Edgman-Levitan, S., Daley, J., Delbanco, T. Through the Patient's Eyes: 
Understanding and Promoting Patient-Centered Care. San Francisco: Jossey-Bass; 
1993. 
Hawker, G., Wright, J., Coyte, P., Williams, J., Harvey, B., Glazier, R., Wilkins, A. & 
Badley, E., (2001). Determining the need for hip and knee arthroplasty: the role 
of clinical severity and patients' preferences, Medical Care Vol. 39 (No.3): 206-
216. 
Hawker, G., Wright, J., Badley, E. & Coyte, P. (2004). Perceptions of, and willingness to 
consider, total joint arthroplasty in a population-based cohort of individuals 
with disabling hip and knee arthritis, Arthritis and rheumatism Vol. 51 (No. 4): 
635-641. 
Hawker, G., Wright, J., Glazier, R., Coyte, P., Harvey, B., Williams, J. & Badley, E. (2002). 
The effect of education and income on need and willingness to undergo total joint 
arthroplasty, Arthritis and rheumatism Vol. 46 (No. 12): 3331-3339. 
Hawker, G., Guan, J., Croxford, R., Coyte, P., Glazier, R., Harvey, B., Wright, J., Williams, J. 
& Badley, E. (2006). A prospective population-based study of the predictors of 
undergoing total joint arthroplasty, Arthritis and rheumatism Vol. 54 (No. 10): 3212–
3220. 
Hannan, M., Felson, D. & Pincus, T. (2000). Analysis of the discordance between 
radiographic changes and knee pain in osteoarthritis of the knee. The Journal of 
rheumatology Vol. 27 (No. 6): 1513-1517. 
Hausmann, L., Mor, M., Hanusa, B., Zickmund, S., Cohen, P., Grant, R., Kresevic, D., 
Gordon, H., Ling, B., Kwoh, C. & Ibrahim, S. (2010). The effect of patient race on 
total joint replacement: recommendations and utilization in the orthopedic setting, 
Journal of general internal medicine Vol. 25 (No. 9): 982-989.  
Ibrahim, S., Siminoff, L., Burant, C. & Kwoh, C. (2002a). Understanding ethnic differences in 
the utilization of joint replacement for osteoarthritis: the role of patient-level 
factors, Medical care Vol. 40 (Suppl 1): 144-151.  
Ibrahim, S., Siminoff, L., Burant, C. & Kwoh, C. (2002b). Differences in expectations of 
outcome mediate African American/white patient differences in “willingness” 
to consider joint replacement, Arthritis and rheumatism Vol. 46 (No. 9): 2429-
2435. 
  
Osteoarthritis – Diagnosis, Treatment and Surgery 
 
240 
Ibrahim, S., Zhang, A., Mercer, M., Baughman, M. & Kwoh, C. (2004). Inner city African-
american elderly patients´ perceptions and preferences for the care of chronic knee 
and hip pain: findings from focus groups, Journal of gerontology Vol. 59 (No. 12): 
1318-1322. 
Ibrahim, S., Siminoff, L., Burant, C. & Kwoh, C. (2001). Variation in perceptions of 
treatment and self-care practices in elderly with osteoarthritis: a comparison 
between African American and white patients, Arthritis care & research Vol. 45 
(No. 4): 340–345. 
Jordan, J., Helmick, C., Renner, J., Luta, G., Dragomir, A., Woodard, J., Fang, F., Schwartz, 
T., Abbate, L., Callahan, L., Kalsbeek, W. & Hochberg, M. (2007). Prevalence of 
knee symptoms and radiographic and symptomatic knee osteoarthritis in African 
Americans and Caucasians: the Johnston County Osteoarthritis Project, The Journal 
of rheumatology Vol. 34 (No. 1): 172-180. 
Juby, A., Skeith, K. & Davis, P. (2005). Patients’ awareness, utilization, and satisfaction with 
treatment modalities for the management of their osteoarthritis, Clinical 
rheumatology Vol. 24 (No. 5): 535–538. 
Jones, A., Kwoh, C., Kelley, M. & Ibrahim, S. (2005). Racial disparity in knee arthroplasty 
utilization in the veterans health administration, Arthritis and rheumatism Vol. 53 
(No. 6): 979-981. 
Karlson, E., Daltroy, L., Liang, M., Eaton, H. & Katz, J. (1997). Gender differences in patient 
preferences may underlie differential utilization of elective surgery. The American 
journal of medicine Vol. 102 (No. 6): 524-530. 
Kopec, J., Richardson, C., Llewellyn-Thomas, H., Klinkhoff, A., Carswell, A. & 
Chalmers, A. (2007). Probabilistic threshold technique showed that patients' 
preferences for specific trade-offs between pain relief and each side effect of 
treatment in osteoarthritis varied, Journal of clinical epidemiology Vol. 60 (No. 9): 
929-938. 
Kotlarz, H., Gunnarsson, C., Fang, H. & Rizzo, J. (2009). Insurer and out-of-pocket costs of 
osteoarthritis in the US: evidence from national survey data, Arthritis and 
rheumatism Vol. 60 (No. 12): 3546-3553. 
Kroll, T., Richardson, M., Sharf, B. & Suarez-Almazor, M. (2007). "Keep on truckin''' or 
''it's got you in this little vacuum'': race-based perceptions in decision-making 
for total knee arthroplasty, The Journal of rheumatology Vol. 34 (No. 5): 1069-
1075. 
Lawrence, R., Felson, D., Helmick, C., Arnold, L., Choi, H., Deyo, R., Gabriel, S., Hirsch, 
R., Hochberg, M., Hunder, G., Jordan, J., Katz, J., Kremers, H. & Wolfe, F. 
(2008). Estimates of the prevalence of arthritis and other rheumatic  
conditions in the United States. Part II, Arthritis and rheumatism Vol. 58 (No. 1): 
26-35. 
Losina, E., Walensky, R., Kessler, C., Emrani, P., Reichmann, W., Wright, E., Holt, H., 
Solomon, D., Yelin, E., Paltiel, A. & Katz, J. (2009). Cost-effectiveness of total knee 
arthroplasty in the United States: patient risk and hospital volume, Archives of 
internal medicine Vol. 169 (No. 12): 1113-1121. 
 
Treatment Preferences in Patients with Knee or Hip Osteoarthritis: An Overview 
 
241 
Mitchell, H. & Hurley, M. (2008). Management of chronic knee pain: survey of patient 
preferences and treatment received, BMC musculoskeletal disorders Vol. 9: 123. 
Oishi, C., Hoaglund, F., Gordon, L. & Ross, P. (1998). Total hip replacement rates are higher 
among Caucasians than Asians in Hawaii, Clinical orthopaedics and related research 
Vol. 353: 166-174. 
O'Neill, T., Jinks, C. & Ong, B. (2007) Decision-making regarding total knee replacement 
surgery: a qualitative meta-synthesis, BMC health services research Vol. 7: 52. 
Ratcliffe, J., Buxton, M., McGarry, T., Sheldon, R. & Chancellor, J. (2004). Patient´s 
preferences for characteristics associated with treatment for osteoarthritis, 
Rheumatology Vol. 43 (No. 3): 337-345. 
Rottenstreich, Y., & Hsee, C. (2001). Money, kisses and electric shocks: On the affective 
psychology of probability weighting, Psychological science Vol. 12 (No. 3): 185–
190. 
Salaffi, F., Carotti, M., Stancati, A. & Grassi, W. (2005). Health-related quality of life in 
older adults with symptomatic hip and knee osteoarthritis: a comparison with 
matched healthy controls, Aging clinical and experimental research Vol. 17 (No. 4): 
255-263. 
Scott, D. & Kowalczyk, A. (2007). Osteoarthritis of the knee, Clinical evidence Vol. 12:1121 
Skinner, J., Weinstein, J., Sporer, S. & Wennberg, J. (2003). Racial, ethnic, and geographic 
disparities in rates of knee arthroplasty among Medicare patients, The New England 
journal of medicine Vol. 349 (No. 14): 1350–1359. 
Slovic, P., Peters, E., Finucane, M. & MacGregor-Bates, D. (2005). Affect, Risk, and Decision 
Making, Health psychology Vol. 24 (Suppl): 35-40 
Srikanth, V., Fryer, J., Zhai, G., Winzenberg, T., Hosmer, D. & Jones G. (2005). A meta-
analysis of sex differences prevalence, incidence and severity of osteoarthritis, 
Osteoarthritis and cartilage Vol. 13 (No. 9): 769-781. 
Suarez-Almanzor, M., Souchek, J., Kelly, P., O´Malley, K., Byrne, M., Richardson, M. & Pak, 
C. (2005). Ethnic variations in knee replacement: patients preferences or 
uninformed disparity?, Archives of internal medicine Vol. 165 (No. 10): 1117-1124. 
Tallon, D., Chard, J., & Dieppe, P. (2000). Exploring the priorities of patients with 
osteoarthritis of the knee, Arthritis care & research.Vol. 13 (No. 5): 312-319. 
Thorstensson, C., Roos, E., Petersson, I. & Arvidsson, B. (2006). How do middle-aged 
patients conceive exercise as a form of treatment for knee osteoarthritis? Disability 
and rehabilitation Vol. 28 (No. 1): 51-59. 
Underwood, M., Ashby, D., Cross, P., Hennesy, E., Letley, L., Martin, J., Mt-Isa, S., Parsons, 
S., Vickers, M. & Whyte, K. (2007). Advice to use topical or oral ibuprofen for 
chronic knee pain in older people: randomised controlled trial and patient 
preference study, British Medical Association Vol. 336 (No. 7636): 138-142.  
van Dijk, G., Veenhof, C., Schellevis, F., Hulsmans, H., Bakker, J., Arwert, H., Dekker, J., 
Lankhorst, G. & Dekker, J. (2008). Comorbidity, limitations in activities and pain in 
patients with osteoarthritis of the hip or knee, BMC musculoskeletal disorders Vol. 9: 
95. 
  
Osteoarthritis – Diagnosis, Treatment and Surgery 
 
240 
Ibrahim, S., Zhang, A., Mercer, M., Baughman, M. & Kwoh, C. (2004). Inner city African-
american elderly patients´ perceptions and preferences for the care of chronic knee 
and hip pain: findings from focus groups, Journal of gerontology Vol. 59 (No. 12): 
1318-1322. 
Ibrahim, S., Siminoff, L., Burant, C. & Kwoh, C. (2001). Variation in perceptions of 
treatment and self-care practices in elderly with osteoarthritis: a comparison 
between African American and white patients, Arthritis care & research Vol. 45 
(No. 4): 340–345. 
Jordan, J., Helmick, C., Renner, J., Luta, G., Dragomir, A., Woodard, J., Fang, F., Schwartz, 
T., Abbate, L., Callahan, L., Kalsbeek, W. & Hochberg, M. (2007). Prevalence of 
knee symptoms and radiographic and symptomatic knee osteoarthritis in African 
Americans and Caucasians: the Johnston County Osteoarthritis Project, The Journal 
of rheumatology Vol. 34 (No. 1): 172-180. 
Juby, A., Skeith, K. & Davis, P. (2005). Patients’ awareness, utilization, and satisfaction with 
treatment modalities for the management of their osteoarthritis, Clinical 
rheumatology Vol. 24 (No. 5): 535–538. 
Jones, A., Kwoh, C., Kelley, M. & Ibrahim, S. (2005). Racial disparity in knee arthroplasty 
utilization in the veterans health administration, Arthritis and rheumatism Vol. 53 
(No. 6): 979-981. 
Karlson, E., Daltroy, L., Liang, M., Eaton, H. & Katz, J. (1997). Gender differences in patient 
preferences may underlie differential utilization of elective surgery. The American 
journal of medicine Vol. 102 (No. 6): 524-530. 
Kopec, J., Richardson, C., Llewellyn-Thomas, H., Klinkhoff, A., Carswell, A. & 
Chalmers, A. (2007). Probabilistic threshold technique showed that patients' 
preferences for specific trade-offs between pain relief and each side effect of 
treatment in osteoarthritis varied, Journal of clinical epidemiology Vol. 60 (No. 9): 
929-938. 
Kotlarz, H., Gunnarsson, C., Fang, H. & Rizzo, J. (2009). Insurer and out-of-pocket costs of 
osteoarthritis in the US: evidence from national survey data, Arthritis and 
rheumatism Vol. 60 (No. 12): 3546-3553. 
Kroll, T., Richardson, M., Sharf, B. & Suarez-Almazor, M. (2007). "Keep on truckin''' or 
''it's got you in this little vacuum'': race-based perceptions in decision-making 
for total knee arthroplasty, The Journal of rheumatology Vol. 34 (No. 5): 1069-
1075. 
Lawrence, R., Felson, D., Helmick, C., Arnold, L., Choi, H., Deyo, R., Gabriel, S., Hirsch, 
R., Hochberg, M., Hunder, G., Jordan, J., Katz, J., Kremers, H. & Wolfe, F. 
(2008). Estimates of the prevalence of arthritis and other rheumatic  
conditions in the United States. Part II, Arthritis and rheumatism Vol. 58 (No. 1): 
26-35. 
Losina, E., Walensky, R., Kessler, C., Emrani, P., Reichmann, W., Wright, E., Holt, H., 
Solomon, D., Yelin, E., Paltiel, A. & Katz, J. (2009). Cost-effectiveness of total knee 
arthroplasty in the United States: patient risk and hospital volume, Archives of 
internal medicine Vol. 169 (No. 12): 1113-1121. 
 
Treatment Preferences in Patients with Knee or Hip Osteoarthritis: An Overview 
 
241 
Mitchell, H. & Hurley, M. (2008). Management of chronic knee pain: survey of patient 
preferences and treatment received, BMC musculoskeletal disorders Vol. 9: 123. 
Oishi, C., Hoaglund, F., Gordon, L. & Ross, P. (1998). Total hip replacement rates are higher 
among Caucasians than Asians in Hawaii, Clinical orthopaedics and related research 
Vol. 353: 166-174. 
O'Neill, T., Jinks, C. & Ong, B. (2007) Decision-making regarding total knee replacement 
surgery: a qualitative meta-synthesis, BMC health services research Vol. 7: 52. 
Ratcliffe, J., Buxton, M., McGarry, T., Sheldon, R. & Chancellor, J. (2004). Patient´s 
preferences for characteristics associated with treatment for osteoarthritis, 
Rheumatology Vol. 43 (No. 3): 337-345. 
Rottenstreich, Y., & Hsee, C. (2001). Money, kisses and electric shocks: On the affective 
psychology of probability weighting, Psychological science Vol. 12 (No. 3): 185–
190. 
Salaffi, F., Carotti, M., Stancati, A. & Grassi, W. (2005). Health-related quality of life in 
older adults with symptomatic hip and knee osteoarthritis: a comparison with 
matched healthy controls, Aging clinical and experimental research Vol. 17 (No. 4): 
255-263. 
Scott, D. & Kowalczyk, A. (2007). Osteoarthritis of the knee, Clinical evidence Vol. 12:1121 
Skinner, J., Weinstein, J., Sporer, S. & Wennberg, J. (2003). Racial, ethnic, and geographic 
disparities in rates of knee arthroplasty among Medicare patients, The New England 
journal of medicine Vol. 349 (No. 14): 1350–1359. 
Slovic, P., Peters, E., Finucane, M. & MacGregor-Bates, D. (2005). Affect, Risk, and Decision 
Making, Health psychology Vol. 24 (Suppl): 35-40 
Srikanth, V., Fryer, J., Zhai, G., Winzenberg, T., Hosmer, D. & Jones G. (2005). A meta-
analysis of sex differences prevalence, incidence and severity of osteoarthritis, 
Osteoarthritis and cartilage Vol. 13 (No. 9): 769-781. 
Suarez-Almanzor, M., Souchek, J., Kelly, P., O´Malley, K., Byrne, M., Richardson, M. & Pak, 
C. (2005). Ethnic variations in knee replacement: patients preferences or 
uninformed disparity?, Archives of internal medicine Vol. 165 (No. 10): 1117-1124. 
Tallon, D., Chard, J., & Dieppe, P. (2000). Exploring the priorities of patients with 
osteoarthritis of the knee, Arthritis care & research.Vol. 13 (No. 5): 312-319. 
Thorstensson, C., Roos, E., Petersson, I. & Arvidsson, B. (2006). How do middle-aged 
patients conceive exercise as a form of treatment for knee osteoarthritis? Disability 
and rehabilitation Vol. 28 (No. 1): 51-59. 
Underwood, M., Ashby, D., Cross, P., Hennesy, E., Letley, L., Martin, J., Mt-Isa, S., Parsons, 
S., Vickers, M. & Whyte, K. (2007). Advice to use topical or oral ibuprofen for 
chronic knee pain in older people: randomised controlled trial and patient 
preference study, British Medical Association Vol. 336 (No. 7636): 138-142.  
van Dijk, G., Veenhof, C., Schellevis, F., Hulsmans, H., Bakker, J., Arwert, H., Dekker, J., 
Lankhorst, G. & Dekker, J. (2008). Comorbidity, limitations in activities and pain in 
patients with osteoarthritis of the hip or knee, BMC musculoskeletal disorders Vol. 9: 
95. 
  
Osteoarthritis – Diagnosis, Treatment and Surgery 
 
242 
Weng, H., Kaplan, R., Boscardin, W., Maclean, C., Lee, I., Chen, W. & Fitzgerald, J. (2007). 
Development of a decision aid to address racial disparities in utilization of knee 
replacement surgery, Arthritis and rheumatism. Vol. 57 (No. 4): 568-575. 
Wolfe, F., Zhao, S. & Lane, N. (2000). Preference for nonsteroidal antiinflammatory drugs 
over acetaminophen by rheumatic disease patients, Arthritis and rheumatism. Vol. 43 
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Turkey 
1. Introduction 
Osteoarthritis is one of the most important diseases in the eld of orthopedics 
worldwide. The disease is characterized by progressive loss of articular cartilage and 
formation of osteophytes, which lead to chronic pain and functional restrictions in the 
affected joints.  
Different factors can be involved in the development of osteoarthritis including 
traumatic events, genetic predisposition, defective position of joints, and ageing and 
malnutrition. 
The plica is the generic name of the ruins or folds of the synovial membrane in the knee 
joint. The incidence of the plicas in the knee joint is between 18,5-87 %. These plicas are 
named and classified according to their settlements in the knee joint (1-6). 
The plicas sometimes come to a pathologic state, which gains clinical importance and causes 
the plica syndrome (7). When plica is symptomatic, the condition is called plica syndrome.   
The plicas are considered to be one of the potential causes of the complaints around the knee 
joint (8). 
It is known that medial plica causes to degeneration of cartilage around the medial femoral 
condyle of the knee joint and / or the medial pole of the patella (2,8-14). Owing to the 
anatomic location of the medial plica, a loss of normal elasticity can cause it to impinge on 
the femoral medial condyle or the medial facet of the patella during flexion–extension 
motion of the knee.  This kind of repetitive contact may result in a chondral lesion of 
varying severity, sometimes referred to as an impingement lesion (2,7,8,14-18). 
It has also been suggested that normal-looking medial plica, not impinging on the articular 
surfaces, could be symptomatic as well . This is supported by recent findings which have 
demonstrated an increase in the amount of nerve endings in the plica after trauma or 
overuse, indicating increased pain sensitivity and sensation of pain (19,20). 
The anatomy of the plicas or synovial folds was first described by Mayeda in 1918. In 1939,  
Lino first described the appearance of arthroscopic synovial folds in the cadaveric knees. In 
1950 and 1971, Pipkin reported that the plicas should be distinguished from adhesions in the 
knee joint and those might cause clinical symptoms (21,22). 
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2. Embryology  
The knee embryologically develops from mesoderm in several developement stages. At the 
first weeks of the fetal development, the mesenchymal origined intra-articular knee joint 
membrane separates the knee joint into three compartments, the medial and lateral 
tibiofemoral compartment, and the suprapatellar bursa. This membrane is usually resorbed 
between the weeks of 9.5 and 12. Later on, these compartments coalesce to form a single 
large cavity. However, if this membrane is not completely resorbed, membranous structure 
forms in different locations in the knee joint. These membranous structures, when persist as 
normal folds of synovial membrane in the knee joint, are termed as plica (10,22,23). 
3. Anatomy, classification and incidence 
Generally plicas have been classified into three predominant types based on their 
anatomical location; the infrapatellar plica or ligamentum mucosum, the suprapatellar plica 
and the medial patellar plica or the medial shelf. Lateral plica have also been described but 
are considered a much more rare entity. These can vary in morphology and can exist in 
combinations. Arthroscope is a boon in visualizing intra-articular anatomy and pathology, 
and it also allows precise assessment and dynamic examination of the plica (24). 
3.1 Suprapatellar plica 
This type of plica takes origin from the inferior face of tendon of quadriceps and lies 
transversly in the suprapatellar pouch and attaches to the superomedial and lateral walls of 
the knee joint. Different anatomical variations of the suprapatellar plica have been 
described. According to Kim and collegues there are different types, such as; absence of 
plica, vestigial shaped, medially cited, laterally cited, arch shaped, hole shaped and total 
septum. The most seen type of this group is medial suprapatellar plica (1,2).  
Most arthroscopic studies have reported an incidence of some form of plica between 70% 
and 91%. Dandy in a study of 500 knees attempted to classify the suprapatellar plica 
arthroscopically. He described 10 variations with an overall incidence of 91% (1,2,4). 
3.2 Mediopatellar plica 
The medial plica has been given many names as it may reflect many variations of size, 
configurations, and attachments: Plica synovialis mediopatellaris, mediopatellar plica, 
medial shelf, Lino’s band, Aoki’s ledge, plica alaris elongata, medial intra-articular band 
meniscus of patella (2,8,12). 
It originates on the medial wall of the knee joint and may or may not cross the 
suprapatellar plica passing obliquely, from the medial side of patella through to the distal, 
downward in the coronal plane to insert into the synovium surrounding the infrapatellar 
fat pad (1,2,7). 
Lino first described four types of plica in 1939. And then Sakibara arranged these four 
types such as; Type A is a cord like structure in the synovial wall that can be traced to the 
fat 
pad. Type B has a shelf like appearance but does not cover the femoral condyle. Type C has 
a large shelf like structure and can be seen to cover the anterior surface of the medial 
femoral condyle. Type D is a variation in which two insertions into the medial wall can be 
seen. There is a defect of plica that covers the whole medial femoral condyle (16). 
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Dandy reported difficulty in creating a classification to describe the medial patella plica and 
settled for a classification based upon the maximum width and position along with the 
incidence of each.  
Dandy classification: type A, absence of any medial plica; type B, a narrow ridge at the 
medial wall of the knee joint; type C, width of the plica < 1 cm; type D, width of the plica 1–
2 cm; type E, width of the plica >2 cm; type F, presence of a defect within the plica; type G, 
plica is high type but not contacting the medial femoral condyle; and type H, the plica is re-
duplicated (4). 
There are large variations in the reported incidence of medial plica ranging from 17 to 75%. 
The incidence of the medial patella plica is difficult to define as different interpretations of 
its presence have been used with some authors considering a small fold of synovium as a 
plica and others indicating this as absent. The more recent arthroscopic studies where a fold 
of tissue was considered a plica give an overall incidence of 92%  and 72% (1,4,25). 
The medial plica is considered the most problematic by many authors (Muse et al,1985; 
Patel, 1986; Kim and Choe, 1996; Dupont, 1997) due to its close proximity to the medial 
border of the patella and medial femoral condyle where it can be‘impinged’(1,2,24,26). 
3.3 Infrapatellar plica 
The infrapatellar plica is more commonly known as the ligamentum mucosum. It originates 
from the intercondylar notch, spreads paralel to the anterior cruciat ligament and inserts 
into the synovium around the infrapatellar fat pad.    
The infrapatellar plica is a common finding at knee arthroscopy with Kim and Choe 
reporting an overall incidence of 86%. Kim et al. have been the first to describe an 
arthroscopic classification of the infrapatellar plica and used its relation to the ACL and 
morphology to classify it(1,25,27).  
According to this classification; 
Absent: no synovial fold between the condyles of the femur. 
Separated: A complete synovial fold that was separate from the anterior cruciate 
ligament (ACL). 
Split : Synovial fold that is separate from the ACL but is also divided into 
two or more cords. 
Vertical septum: A complete synovial fold tht is attached to the ACL and divided the 
joint into medial and lateral compartments. 
Fenestra: A vertical septum pattern that contains a hole or defect. 
3.4 Lateral plica 
The lateral plica is considered to be rare. Overall incidence was found 1,3% by Kim and 
collegues. It originates from the lateral wall of the knee above the popliteal hiatus and 
inserts into the synovium around the infrapatellar fat pad (1,2). 
4. Pathophysiology 
Normally plica exists as thin flexible soft tissue structures, mainly composed of elastic and 
areolar tissue. Due to this property, it changes its shape and length with knee movements 
(7). Inflammation of the synovial tissue makes plica edematous and thickened, and in 
chronic cases, it looses its inherent elastic nature and becomes thick and fibrosed. And even 
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it hyalinize and rarely becomes calcified. Then plica can cause secondary mechanical 
synovitis around the femoral condyles. Mediopatellar plica is trapped between the 
anteromedial portion of the medial femoral condyle and the medial pole of the patella with 
flexion of the knee. This pathologic thickness of plica causes articular cartilage degeneration 
the anteromedial portion of the medial femoral condyle and the medial pole of the patella 
by the continuity of knee movements (2,9,28-32). 
Plica become pathological when thickening and fibrosis occurs giving rise to relative 
inelasticity that can lead to it snapping over the femoral condyle causing synovitis, chondral 
damage and pain. The plica syndrome was described by Hardaker and defined as a painful 
impairment of knee function inwhich the only findingwas the presence of a thickened, 
hypertrophic plica (7). 
Generally, direct injury to the knee leading to synovial hematoma and post-traumatic transient 
synovitis is one of the commonest factors coupled with the development of pathological 
medial plica (24). In some cases, repetitive and overuse of knee as per task-specific demands or 
athletic activities associated with minor irregularities of knee mechanics cause progressive 
inflammation with recurrent synovitis, edema, thickening, and fibrosis of plica (33).  
It can also get involved in any primary disorder of knee capable of producing synovitis such 
as torn meniscus, loose bodies, and osteochondritis dissecans. Many authors accept that 
wider plicas are more often symptomatic and more frequently demonstrate pathologic 
changes at histological analysis than thinner plica (34). Normally, medial plica slides 
smoothly over medial femoral condyle in flexion and extension, and it remains in contact 
with the condyleduring whole range of motion. Thus, pathological plica, with movement of 
knee may generate some shearing force acting on the condyle, has a role in the pathogenesis 
of degeneration of the cartilage on the medial femoral condyle (35). 
Being in close proximity to medial femoral condyle, plica may provoke secondary 
mechanical synovitis about the margins of condyle. The fibrotic plica can bowstring across 
the trochlea and condyle or can get impinged between the patella and medial femoral 
condyle, altering the patello-femoral mechanics (32,36).  
However, this aberrant mechanics is directly related to degeneration of articular cartilage of 
patello-femoral joint. And there are high incidences of chondromalacia reported in  pathological 
medial plica involving medial femoral condyle and medial patellar facet (37,38).  
The severity of the degeneration was positively correlated with the severity of the medial 
plica and patients’age (15). 
In the arthroscopy study of Christoforakis and Strachan on 1,000 patients, a total of 319 
mediopatellar plicas were identified, and cartilage degeneration was found at medial 
femoral condyle and/or medial pole of patella in 24.7% of these cases (13). 
In that study, isolated patellofemoral cartilage degeneration was present in 15.5% of knees 
not having mediopatellar plica. Authors concluded that mediopatellar plica leads to 
patellofemoral joint degeneration.  
In an another study, cartilage degeneration was found in higher degrees patients at medial 
femoral condyle and medial pole of patella. Significant clinical and functional 
improvements were observed early after plica excision in patients with mediopatellar plica 
and associated cartilage degeneration. Pain score, physical function score, total score and the 
mean score of WOMAC were all decreased at 6 weeks compared to baseline (39). 
Excessive exercises, sports activities and the chronic hyperflexion of the knee due to life 
style can cause the plica syndrome.  
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Even if plica does not touch the bone structures, it may disrupt the function of quadriceps 
tendon due to its tension and may cause pain by applying traction to the synovium and fat 
pad.  
The function of plica has not been fully understood. However, plicas have neural elements 
according to some studies. 
Quadriceps atrophy can occur in up to 45% of patients with a pathological plica. This 
concurs with the current view that atrophy is caused by chondromalacia and develops soon 
after the plica irritation (6,7). 
In the case of medial plica trauma, biomechanical factors may cause it to enlarge, resulting 
in impingement between the medial border of the trochlea’s medial facet and the medial 
facet of the patella. Impingement occurs during flexion of the knee between 40° and 80° 
when the gap between the patella and femoral joint is at its closest. Continued impingement 
of the plica with repeated flexion may cause chondromalacia, groove formation within the 
articular cartilage and a thickening of the plica. This is associated with a clicking or loud 
snapping sound on flexion/extension of the knee (2,26,40). 
5. Clinical signs and symptoms 
The most frequent complaint is pain (8). Most common presentation of medial plica 
syndrome is anteromedial knee pain. The pain is usually in front of the knee but it may also 
be on the  the antero-medial and anterior-lateral, medial and lateral joint space. The pain is 
usually intermittent, and occurs with activity. Pain is significant while climbing stairs like 
other patellofemoral problems (10). 
The cinema sign is positive. The increase of the pain when the knee is flexed for a long time, 
and then a relief by extension of the knee is decribed as positive cinema sign. 
A pathological plica produces popping or catching in knee by snapping across patella or 
medial femoral condyle. Other symptoms associated with anteromedial pain include 
swelling of knee, feeling of tightness, and stiffness (7,24,36,37). 
Sometimes pain and clicking of previously asymptomatic medial plica starts as a result of tear, 
due to rubbing of torned portion of plica over medial femoral condyle. Thus, one cause of 
anterior knee pain can be tear of plica along with thickening and fibrotic changes. A very rare 
presentation, hemearthrosis, caused by large medial plica has also been reported (41,42). 
In physical examination when the knee is in extension posture, pain with the palpation of 
the medial lower pole of patella is specific. Sensitivity can be found in the medial joint space 
when the knee is in flexion. 
Examination remains unreliable in most patients but common findings are quadriceps 
wasting, effusion, medial condyle tenderness, crepitus and decreased range of motion (26,37).   
Provocative tests for meniscal tears are often positive but have poor specificity. Signs 
forpatellofemoral pathology are also often positive but again offer poor specificity (8). It is 
occasionally possible to palpate the thickened plica as a tight band mostly superomedially 
which will be tender to palpate and can be felt to click or catch with movement (43).  
A number of provocative tests for pathological plica have been described. 
Plica can be rolled over medial femoral condyle as it is thickened and fibrosed. A palpable 
or sometimes audible snap is present when knee passes from 30° to 60° of flexion(7,24).  
Pipkin has described the pop that occurs, as the knee is extended from 90° of flexion with foot 
internally rotated and the patella pressed medially, between 60° and 45° of flexion of knee (22). 
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it hyalinize and rarely becomes calcified. Then plica can cause secondary mechanical 
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by the continuity of knee movements (2,9,28-32). 
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damage and pain. The plica syndrome was described by Hardaker and defined as a painful 
impairment of knee function inwhich the only findingwas the presence of a thickened, 
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Generally, direct injury to the knee leading to synovial hematoma and post-traumatic transient 
synovitis is one of the commonest factors coupled with the development of pathological 
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athletic activities associated with minor irregularities of knee mechanics cause progressive 
inflammation with recurrent synovitis, edema, thickening, and fibrosis of plica (33).  
It can also get involved in any primary disorder of knee capable of producing synovitis such 
as torn meniscus, loose bodies, and osteochondritis dissecans. Many authors accept that 
wider plicas are more often symptomatic and more frequently demonstrate pathologic 
changes at histological analysis than thinner plica (34). Normally, medial plica slides 
smoothly over medial femoral condyle in flexion and extension, and it remains in contact 
with the condyleduring whole range of motion. Thus, pathological plica, with movement of 
knee may generate some shearing force acting on the condyle, has a role in the pathogenesis 
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mechanical synovitis about the margins of condyle. The fibrotic plica can bowstring across 
the trochlea and condyle or can get impinged between the patella and medial femoral 
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However, this aberrant mechanics is directly related to degeneration of articular cartilage of 
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Even if plica does not touch the bone structures, it may disrupt the function of quadriceps 
tendon due to its tension and may cause pain by applying traction to the synovium and fat 
pad.  
The function of plica has not been fully understood. However, plicas have neural elements 
according to some studies. 
Quadriceps atrophy can occur in up to 45% of patients with a pathological plica. This 
concurs with the current view that atrophy is caused by chondromalacia and develops soon 
after the plica irritation (6,7). 
In the case of medial plica trauma, biomechanical factors may cause it to enlarge, resulting 
in impingement between the medial border of the trochlea’s medial facet and the medial 
facet of the patella. Impingement occurs during flexion of the knee between 40° and 80° 
when the gap between the patella and femoral joint is at its closest. Continued impingement 
of the plica with repeated flexion may cause chondromalacia, groove formation within the 
articular cartilage and a thickening of the plica. This is associated with a clicking or loud 
snapping sound on flexion/extension of the knee (2,26,40). 
5. Clinical signs and symptoms 
The most frequent complaint is pain (8). Most common presentation of medial plica 
syndrome is anteromedial knee pain. The pain is usually in front of the knee but it may also 
be on the  the antero-medial and anterior-lateral, medial and lateral joint space. The pain is 
usually intermittent, and occurs with activity. Pain is significant while climbing stairs like 
other patellofemoral problems (10). 
The cinema sign is positive. The increase of the pain when the knee is flexed for a long time, 
and then a relief by extension of the knee is decribed as positive cinema sign. 
A pathological plica produces popping or catching in knee by snapping across patella or 
medial femoral condyle. Other symptoms associated with anteromedial pain include 
swelling of knee, feeling of tightness, and stiffness (7,24,36,37). 
Sometimes pain and clicking of previously asymptomatic medial plica starts as a result of tear, 
due to rubbing of torned portion of plica over medial femoral condyle. Thus, one cause of 
anterior knee pain can be tear of plica along with thickening and fibrotic changes. A very rare 
presentation, hemearthrosis, caused by large medial plica has also been reported (41,42). 
In physical examination when the knee is in extension posture, pain with the palpation of 
the medial lower pole of patella is specific. Sensitivity can be found in the medial joint space 
when the knee is in flexion. 
Examination remains unreliable in most patients but common findings are quadriceps 
wasting, effusion, medial condyle tenderness, crepitus and decreased range of motion (26,37).   
Provocative tests for meniscal tears are often positive but have poor specificity. Signs 
forpatellofemoral pathology are also often positive but again offer poor specificity (8). It is 
occasionally possible to palpate the thickened plica as a tight band mostly superomedially 
which will be tender to palpate and can be felt to click or catch with movement (43).  
A number of provocative tests for pathological plica have been described. 
Plica can be rolled over medial femoral condyle as it is thickened and fibrosed. A palpable 
or sometimes audible snap is present when knee passes from 30° to 60° of flexion(7,24).  
Pipkin has described the pop that occurs, as the knee is extended from 90° of flexion with foot 
internally rotated and the patella pressed medially, between 60° and 45° of flexion of knee (22). 
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Two provocative tests described by Koshino and Okamato are helpful in diagnosing 
pathological medial plica. Rotation valgus test is elicited by flexing the knee and applying a 
valgus force on internally and externally rotating the tibia while simultaneously attempting 
to displace the patella medially. The other one is holding test, done by attempting to flex the 
knee against active resistance. If either test elicits pain, with or without a click, it is 
considered positive (32,44). 
Kim et al. named his the medial patella plica test or MPP test (45). It is performed by 
applying a manual force to the infero-medial portion of the patellofemoral joint. Whilst 
maintaining the force the knee is flexed to 90 degrees. A positive test occurs when the 
patient experiences pain in extension but this is eliminated at 90 degrees of flexion. 
Other provocative tests have previously been described by Pipkin, but this test relied upon 
no effusion being present and was often found to be negative later in the day, it therefore 
became dubbed the ‘morning test’(22). 
Shetty et al. in their prospective study over 66 knees, devised a system to diagnose 
symptomatic medial plica based on history and clinical examination. It includes five essential 
and four desirable criteria. Essential criteria are as follows: [1]. history of anteromedial knee 
pain, [2]. Pain primarily over medial femoral condyle, [3]. visible or palpable plica, [4]. 
tenderness over palpable plica, [5]. Exclusion of other causes of anteromedial knee pain. 
Desirable criteria are as follows: [1] onset blunt or trivial trauma, [2] Duvet test (use of a duvet 
placed between knees to prevent pain while sleeping, [3] audible snap during active range of 
motion, and [4] palpable snap during flexion. This systemHas diagnostic accuracy of 91.7%, 
sensitivity of 100%, and positive predictive value of 91.7% (32,38). 
Diagnosis with routine blood tests may often be unhelpful as inflammatory markers almost 
invariably are normal. Radiographs of the knee do not demonstrate a plica but help to 
exclude other pathology. Double contrast arthrograms have historically been used and are 
able to demonstrate plica reliably but are unable to distinguish between pathological  
and non-pathological plica. It had been hoped that the advent of MRI would be useful in 
aiding the diagnosis of a pathological plica. Although it has been able to demonstrate plica 
reliably, it has not been able to predict the necessity of excision of that plica at arthroscopy, 
which limits its use as a screening tool (46-51). 
Arthroscopy is still the gold standard modality to diagnose pathological medial plica. 
Definitive diagnosis can only be made by arthroscopy, and it allows precise assessment of 
plica including dynamic examination. The normal plica is thin, pink, and pliable, 
whereaspathological plica is white, thickened, and fibrotic (7,32). 
6. Treatment 
6.1 Conservative treatment 
In all cases, conservative treatment should be tried first (2,7-9). Rest and nonsteroidal anti-
inflammatory drugs are used to resolve the pain and, after the removal of acute painful period 
rehabilitation program starts. Physical therapy is given in the form of local heat, ultrasound, 
short-wave diathermy, along with quadriceps and hamstring stretching exercises. 
The basis of rehabilitation program includes quadriceps and hamstring strengthening and 
stretching exercises (3,28). 
Objective of physiotherapy is to increase the structural flexibility of tissues and decrease 
compressive forces on the knee.  
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The response taken from the case determines the duration of the conservative treatment. 
Even if the improvement is visible partially with the treatment for two or three months, 
conservative treatment should be continued. If there is no reduction in pain, surgical 
treatment should be started. With the increase of pain in patients, early surgical treatment 
could be planned (3). 
In addition injection of local anesthetic and corticosteroid can be given into the plica and 
surrounding synovial tissues. Rovere et al. reported overall success rate of 73% and poor 
results were obtained in chronic fibrotic plica (52). 
Patients who do not respond to conservative therapy or have recurrence of symptoms are 
essentially the candidates for arthroscopic examination of knee joint. 
6.2 Surgical treatment 
The medial patella plica is most commonly associated with symptoms and is frequently 
considered to be pathological. There are very few reports in the literature of the infrapatellar 
plica being pathological. On the other hand, the suprapatellar plica has been implicated 
more commonly in pathology. Kyung Bae reported a series of 30 complete type 
suprapatellar plicae with 90% of the patients reporting good or excellent results following 
arthroscopic excision (53). 
Patients who do not respond to conservative treatment, surgical treatment is applied. If a 
plica causes friction on medial femoral condyle or pinches between the patella and medial 
femoral condyle, it should be excised. But arthrotomy should not be done for excision. 
According to Patel's surgical indications are as follows; 
1. Palpation of clinically painful and sensitive band 
2. Determination of thickened and subluxated mediopatellar plica existance with or 
without cartilage lesions at patella or femur 
3. If arthroscopy is performed under local anesthesy, streching plica with a hook causes 
complaints of patient  
4. Without the determination of other pathologies clinically and arthroscopically (2,3). 
For arthroscopic surgery, usually standard portals like antero-medial, antero-lateral are 
used. Brief et al. described superolateral approach as a better arthroscopic portal for medial 
plica, and it offers a sweeping, unobstructed view of entire plica, and also good 
visualization of patello-femoral joint (7,54). 
Visualisation of all the compartments of the knee and probing of the menisci should also be 
performed to ensure no other pathological cause of pain is present within the knee. 
Accessory portals can be created to allow better visualisation of the patellofemoral and 
suprapatellar compartments. If any other pathology isfound, it needs to be treated 
appropriately (32). 
Arthroscopic excision of medial plica is carried out as a day procedure. Complete resection 
of pathological plica to the capsular attachment is advisable. Many studies reported good to 
excellent results with this procedure(8,24,36-38). However, extensive excision of medial plica 
can lead to patellar subluxation (55,56). 
During the medial plica surgery, knee should be in full extension. Mild flexion of the knee 
complicates the surgery. 
The amount of excision is controversial. The main operations in the literature are; the 
division of the plica just as band, total excision and segmental resection. The division of the 
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placed between knees to prevent pain while sleeping, [3] audible snap during active range of 
motion, and [4] palpable snap during flexion. This systemHas diagnostic accuracy of 91.7%, 
sensitivity of 100%, and positive predictive value of 91.7% (32,38). 
Diagnosis with routine blood tests may often be unhelpful as inflammatory markers almost 
invariably are normal. Radiographs of the knee do not demonstrate a plica but help to 
exclude other pathology. Double contrast arthrograms have historically been used and are 
able to demonstrate plica reliably but are unable to distinguish between pathological  
and non-pathological plica. It had been hoped that the advent of MRI would be useful in 
aiding the diagnosis of a pathological plica. Although it has been able to demonstrate plica 
reliably, it has not been able to predict the necessity of excision of that plica at arthroscopy, 
which limits its use as a screening tool (46-51). 
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whereaspathological plica is white, thickened, and fibrotic (7,32). 
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The response taken from the case determines the duration of the conservative treatment. 
Even if the improvement is visible partially with the treatment for two or three months, 
conservative treatment should be continued. If there is no reduction in pain, surgical 
treatment should be started. With the increase of pain in patients, early surgical treatment 
could be planned (3). 
In addition injection of local anesthetic and corticosteroid can be given into the plica and 
surrounding synovial tissues. Rovere et al. reported overall success rate of 73% and poor 
results were obtained in chronic fibrotic plica (52). 
Patients who do not respond to conservative therapy or have recurrence of symptoms are 
essentially the candidates for arthroscopic examination of knee joint. 
6.2 Surgical treatment 
The medial patella plica is most commonly associated with symptoms and is frequently 
considered to be pathological. There are very few reports in the literature of the infrapatellar 
plica being pathological. On the other hand, the suprapatellar plica has been implicated 
more commonly in pathology. Kyung Bae reported a series of 30 complete type 
suprapatellar plicae with 90% of the patients reporting good or excellent results following 
arthroscopic excision (53). 
Patients who do not respond to conservative treatment, surgical treatment is applied. If a 
plica causes friction on medial femoral condyle or pinches between the patella and medial 
femoral condyle, it should be excised. But arthrotomy should not be done for excision. 
According to Patel's surgical indications are as follows; 
1. Palpation of clinically painful and sensitive band 
2. Determination of thickened and subluxated mediopatellar plica existance with or 
without cartilage lesions at patella or femur 
3. If arthroscopy is performed under local anesthesy, streching plica with a hook causes 
complaints of patient  
4. Without the determination of other pathologies clinically and arthroscopically (2,3). 
For arthroscopic surgery, usually standard portals like antero-medial, antero-lateral are 
used. Brief et al. described superolateral approach as a better arthroscopic portal for medial 
plica, and it offers a sweeping, unobstructed view of entire plica, and also good 
visualization of patello-femoral joint (7,54). 
Visualisation of all the compartments of the knee and probing of the menisci should also be 
performed to ensure no other pathological cause of pain is present within the knee. 
Accessory portals can be created to allow better visualisation of the patellofemoral and 
suprapatellar compartments. If any other pathology isfound, it needs to be treated 
appropriately (32). 
Arthroscopic excision of medial plica is carried out as a day procedure. Complete resection 
of pathological plica to the capsular attachment is advisable. Many studies reported good to 
excellent results with this procedure(8,24,36-38). However, extensive excision of medial plica 
can lead to patellar subluxation (55,56). 
During the medial plica surgery, knee should be in full extension. Mild flexion of the knee 
complicates the surgery. 
The amount of excision is controversial. The main operations in the literature are; the 
division of the plica just as band, total excision and segmental resection. The division of the 
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plica may cause recurrances. The radical resection may lead to formation of tense fibrotic 
tissue through the capsule and subcutaneous fat tissue. A thin peripheric edge is left in the 
procedure of subtotal resection. In this way capsule and synovium is not traumatised and 
because of this formation of fibrous tissue is not seen. As described by Dandy, segmental 
resection may be insufficent for large and hard plicas (4,9,28,29,36,37). 
The normal or asymptomatic plicas should not be excised which are detected incidentally. 
Some researchers suggest the excision of plicas to prevent the complaints in the future 
except thin and distant plicas from bony structures.  
Plicas have copious blood supply around the synovial attachments, and thus it is necessary to 
achieve hemostasis to prevent complications of intra-articular bleed post-operatively (10,54). 
Post-operatively, compression bandage is applied over the joint. Mobilization is started on 
same day with the help of physical therapist, and early knee physiotherapy is encouraged to 
prevent stiffness and scarring of plica (7,10,55). 
Plicas around the knee are common findings at arthroscopy but are rarely pathological. The 
plica syndrome is a cause of anterior knee pain and can be debilitating for patients. 
Inflammation and synovitis causes fibrosis and thickening of the plica. And then plica starts 
to behave like a bowstring causing to impingement and cartilage damage.  
If a thickened and hypertrophic pathological plica is found at arthroscopy and completely 
excised good results from the artroscopical excision can be expected in the majority of the 
patients.  
Surgical excision of mediopatellar plica associated with cartilage degeneration appears to 
result in substantial clinical improvement, thus representing an effective treatment modality 
for this group of patients. 
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plica may cause recurrances. The radical resection may lead to formation of tense fibrotic 
tissue through the capsule and subcutaneous fat tissue. A thin peripheric edge is left in the 
procedure of subtotal resection. In this way capsule and synovium is not traumatised and 
because of this formation of fibrous tissue is not seen. As described by Dandy, segmental 
resection may be insufficent for large and hard plicas (4,9,28,29,36,37). 
The normal or asymptomatic plicas should not be excised which are detected incidentally. 
Some researchers suggest the excision of plicas to prevent the complaints in the future 
except thin and distant plicas from bony structures.  
Plicas have copious blood supply around the synovial attachments, and thus it is necessary to 
achieve hemostasis to prevent complications of intra-articular bleed post-operatively (10,54). 
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If a thickened and hypertrophic pathological plica is found at arthroscopy and completely 
excised good results from the artroscopical excision can be expected in the majority of the 
patients.  
Surgical excision of mediopatellar plica associated with cartilage degeneration appears to 
result in substantial clinical improvement, thus representing an effective treatment modality 
for this group of patients. 
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Osteoarthritis (OA) is a highly prevalent disease with markedly increasing impact 
worldwide because of the aging of populations (Center for disease control and prevention 
(CDC); Murphy L.et al., 2008). It affects more than 21 milion people in the U.S. (Handout on 
Health: Osteoarthritis), with 36% of elderly aged 70 or older having some degree of 
radiographic knee OA (D’Ambrosia et al., 2005; Felson et al., 1987). It is a major public 
health problem, with prevalence in the knee of approximately 30% in those over 65 years old 
(Felson et al., 1987).  
The cause of knee pain in patients with OA remains unclear. Because hyaline cartilage has 
no innervations (Dye et al., 1998), the primary pathologic abnormality in OA (hyaline 
cartilage loss) could occur without pain. In MRI studies is reported an increase the 
prevalence of subchondral bone marrow edema, knee joint effusion, and synovial thickening 
in patients with symptomatic knee OA compared with patients with no symptoms (Hill et 
al., 2001; Felson et al., 2001). Knee with OA are biomechanically altered, and these changes 
may put stress on ligament and tendon insertion sites in and around the knee joint, creating 
pain (Hill et al., 2003). Some of the pain does not emanate from the joint itself but rather 
from the structures near the joint that contain pain fibers. Wide ranges of periarticular 
lesions occur around the knee joint, including popliteal Baker cyst (BC) (Vasilevska et.al., 
2008, Janzen et al., 1994) and friction of the iliotibial band (ITBF) (Vasilevska et al., 2009). 
Iliotibial band friction syndrome (ITBFS) is an inflammatory overuse disorder affecting 
soft tissue, interposed between the iliotibial band and the lateral femoral condyle, caused 
by chronic friction (Muhle et al., 1999). Recently, an anatomic study disclosed a fibrous 
anchorage of the iliotibial band to the femur preventing rolling over the epicondyle; 
therefore ITBFS is mainly caused by increased pressure to the richly innervated and 
vascularized fat and loose connective tissue beneath the tract (Fairclough et al., 2006, 
2007). Either ITBFS has been shown to cause lateral knee pain in athletes, it may be a 
consequence of gait changes induced by knee OA and may occur together with 
symptomatic knee OA (presented only 3 cases with low grade ITBF, only one with 
symptom) (Hill et al., 2003). 
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by chronic friction (Muhle et al., 1999). Recently, an anatomic study disclosed a fibrous 
anchorage of the iliotibial band to the femur preventing rolling over the epicondyle; 
therefore ITBFS is mainly caused by increased pressure to the richly innervated and 
vascularized fat and loose connective tissue beneath the tract (Fairclough et al., 2006, 
2007). Either ITBFS has been shown to cause lateral knee pain in athletes, it may be a 
consequence of gait changes induced by knee OA and may occur together with 
symptomatic knee OA (presented only 3 cases with low grade ITBF, only one with 
symptom) (Hill et al., 2003). 
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Recent reports have suggested a 60% reduction in cartilage volume in severe knee 
osteoarthritis (Vahlensieck et al., 2001; Fritschy et al., 2006). Medial compartment cartilage 
loss leads to varus deformity, which can affect knee biomechanics by altering the 
relationship of the iliotibial band and the lateral epicondyle with the possibility of an 
increased friction and pressure between these structures.  
In contrary it is well known that popliteal (Baker) cyst is the most frequent encountered 
lesion around the knee. Among older individual with asymptomatic OA, popliteal cyst have 
a high prevalence (20,8%) (Hill et al., 2001). Cystic lesions around the knee may present as a 
painless palpable mass (Kornaat et al., 2006; Hill et al., 2003), with pain, with symptoms of 
tenderness in the posterior fossa (Hill et al., 2003) or to be detected during the routine MR 
imaging of the knee with suspected internal joint derangement (Mc Carthy et al., 2004), 
eventually when is large can be painful. 
Multiple studies confirmed that intraarticular derangement play an important role in 
pathogenesis of popliteal cyst. MR studies of popliteal cyst demonstrated connection to one 
or more intraarticular lesions in 87-98% of the cases, like osteoarthritis or inflammatory 
arthritis; often joint effusion, meniscus tear and degenerative disease of the joint are found 
(Miller et al., 1996). 
During the routine practice in cases with advanced isolated medial osteoarthritis (with 
subsequent genu varum) presence of MR signs of friction of ITB have been noted. The 
purpose of the study was to describe the frequency of fibrovascular tissue between the 
iliotibial tract and the lateral epicondyle in patients with severe isolated medial 
compartment osteoarthritis of the knee (Vasilevska et al., 2009). From this cases were 
selected those with Baker cyst, and the correlation between sizes of Baker cyst in patients 
suffering from medial compartment osteoarthritis of the knee was recognized and 
evaluated. The purpose was to describe the significance of the associated medial 
compartment knee osteoarthritis: cartilage degeneration, different degree of medial 
meniscus degeneration, bone edema and knee effusion. 
In a study which was done 2009, in a 128 patients retrospectively selected from 700 MR 
examinations of patients with advanced medial compartment osteoarthritis of the knee, with 
> 80% loss of articular cartilage at the femur and the tibia, a relationship with MR signs of 
ITBF was presented. In this study MR signs for ITBF were present in 95 patients (74.2%). Out 
of them 91 patient had moderate signs for ITBF and 4 had severe MR signs for presence of 
fibrovascular tissue (Table 1) (Vasilevska et al., 2009).  
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Table 1. Presence of MR signs of ITBF in the study group with severe medial compartment 
osteoarthritis and in the control group (consensus reading).  
Patients with complete cartilage loss as well as patients with subtotal cartilage loss showed 
tendency to further increase the incidence of MR signs of ITBF, when advanced 
degeneration of the medial meniscus was present (Table 2).  
Knee Osteoarthritis and Associated  








0 - absent 
ITBF 
1 - present 
ITBF 
2 - severe Total 
complete loss 1st degree 0 2 0 2 
complete loss 2nd degree 2 7 0 9 
complete loss 3rd degree 14 42 2 58 
 total 16 (12.5%) 51 (39.8%) 2 (1.6%) 69 (53.9%) 
subtotal 
loss 1
st degree 3 9 0 12 
subtotal 
loss 2
nd degree 3 12 1 16 
subtotal 
loss 3
rd degree 11 19 1 31 
 total 17 (13.3%) 40 (31.3%) 2 (1.6%) 59 (46.1%) 
 Column Total 33 (25.8%) 91 (71.1%) 4 (3.1%) 128 
Table 2. Presence of MRI signs of ITBF in the group with severe medial compartment 
osteoarthritis correlated with cartilage degeneration and meniscal lesions.  
Clinically, patients with medial sided osteoarthritis of the knee, occasionally also complain 
of laterally located pain. ITBF is unrecognized cause for lateral knee pain in patients with 
medial compartment knee osteoarthritis (Vasilevska et al., 2009). 
When severe cartilage damage is associated with advanced degeneration of the medial 
meniscus, altered biomechanics probably with varus deformity, may contribute to the 
development of fibrovascular tissue between the iliotibial band and the lateral epicondyle 
on MR images as a recognized sign of ITBF (Fig.1) (Vasilevska et al., 2009). 
 
   
Fig. 1. A 72 y.o. woman with MR imaging signs of iliotibial band friction (ITBF) and medial 
osteoarthritis of the knee. Fibrovascular tissue (arrow) is seen between the lateral epicondyle 
and the ITB on PDw fatsat image (A). Some slices posterior the complete loss of hyaline 
cartilage at the medial femoral condyle and the tibia plateau with advanced degeneration of 
the medial meniscus is obvious. The lateral compartment is normal (B). On axial PDw fatsat 
image minor effusion and extensive firbovascular tissue between the lateral epicondyle and 
the ITB is present (arrow, C) (Vasilevska et al., 2009). 
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Recent reports have suggested a 60% reduction in cartilage volume in severe knee 
osteoarthritis (Vahlensieck et al., 2001; Fritschy et al., 2006). Medial compartment cartilage 
loss leads to varus deformity, which can affect knee biomechanics by altering the 
relationship of the iliotibial band and the lateral epicondyle with the possibility of an 
increased friction and pressure between these structures.  
In contrary it is well known that popliteal (Baker) cyst is the most frequent encountered 
lesion around the knee. Among older individual with asymptomatic OA, popliteal cyst have 
a high prevalence (20,8%) (Hill et al., 2001). Cystic lesions around the knee may present as a 
painless palpable mass (Kornaat et al., 2006; Hill et al., 2003), with pain, with symptoms of 
tenderness in the posterior fossa (Hill et al., 2003) or to be detected during the routine MR 
imaging of the knee with suspected internal joint derangement (Mc Carthy et al., 2004), 
eventually when is large can be painful. 
Multiple studies confirmed that intraarticular derangement play an important role in 
pathogenesis of popliteal cyst. MR studies of popliteal cyst demonstrated connection to one 
or more intraarticular lesions in 87-98% of the cases, like osteoarthritis or inflammatory 
arthritis; often joint effusion, meniscus tear and degenerative disease of the joint are found 
(Miller et al., 1996). 
During the routine practice in cases with advanced isolated medial osteoarthritis (with 
subsequent genu varum) presence of MR signs of friction of ITB have been noted. The 
purpose of the study was to describe the frequency of fibrovascular tissue between the 
iliotibial tract and the lateral epicondyle in patients with severe isolated medial 
compartment osteoarthritis of the knee (Vasilevska et al., 2009). From this cases were 
selected those with Baker cyst, and the correlation between sizes of Baker cyst in patients 
suffering from medial compartment osteoarthritis of the knee was recognized and 
evaluated. The purpose was to describe the significance of the associated medial 
compartment knee osteoarthritis: cartilage degeneration, different degree of medial 
meniscus degeneration, bone edema and knee effusion. 
In a study which was done 2009, in a 128 patients retrospectively selected from 700 MR 
examinations of patients with advanced medial compartment osteoarthritis of the knee, with 
> 80% loss of articular cartilage at the femur and the tibia, a relationship with MR signs of 
ITBF was presented. In this study MR signs for ITBF were present in 95 patients (74.2%). Out 
of them 91 patient had moderate signs for ITBF and 4 had severe MR signs for presence of 
fibrovascular tissue (Table 1) (Vasilevska et al., 2009).  
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In another study 66 cases were retrospectively evaluated its MR study of the knee with 
medial compartment knee osteoarthritis and MR signs of Baker cyst. The median age was 
56,42 years, (age range 34-84 years). We selected two groups according to the size of the 
Baker cyst on MRI. The first group was with palpable soft tissue mass on medial aspect of 
popliteal fosa with a large Baker cyst, and in the other group the Baker cyst was small and 
detected only on MRI (Table 3). 
 
 Number of cases Male/Female Age (age range) 
Large Baker Cyst 31 11/20 54 (37-78) 
Small Baker Cyst 35 12/23 59 (34-84) 
total: 66 23/43 56 (34-84) 
Table 3. Sex and age distribution in cases with large and small Baker cysts 
2. Imaging features 
Magnetic resonance imaging (MRI) has enhanced our ability to examine patients non-
invasively. This allows us to assess structural changes of osteoarthritis (OA) without risk to 
the patient. MRI enables to visualize and quantitate the changes in articular cartilage, the 
menisci, and other periarticular structures non-invasively (Wluka et al., 2001; Baranyay et 
al., 2007). MRI use in healthy populations and those with OA will detect a significant 
number of incidental lesions, some which are clinically significant and will require further 
imaging and clinical management (Grainger et al., 2008). 
MRI may eventually eclipse plain radiography as the modality of choice for documenting 
structural progression of OA. Plain radiography remains the standard method for assessing 
progression. The measurement of radiographic joint space width is the most accepted and 
widely-used method of OA progression (Ravaud et al., 2008). 
On MR images, cartilage thickness of the medial and lateral compartment should be 
measured centrally in the weight bearing zone. Degeneration of the medial meniscus had to 
be assessed, as well as subchondral bone marrow edema and effusion (Vasilevska et al., 
2009). 
The thickness of residual cartilage is measuring separately at the femur and at the tibia. The 
degree of degeneration of the meniscus is graded: 0- normal meniscus, 1- moderate 
degeneration with focal signal increase, 2- severe degeneration with some residual normal 
tissue and shape, 3-advanced degeneration of the meniscus with destroyed shape and no 
functional meniscal tissue.  
Presence of MR signs for ITBF to be evaluated as well. For evaluation of MR signs of ITBF to 
be evaluated as well. 
For evaluation of MR signs of ITBF (0-not present, 1-present, 2 severe changes) the following 
criteria can be used (Ekman et al., 1994; Muhle et al., 1999; Murphy et al., 1992; Nishimura et 
al., 1997; Vasilevska et al., 2009): 
- poorly defined signal intensity abnormalities lateral, distal or proximal to the lateral 
epicondyle; 
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- signal intensity abnormalities superficial or deep to the ITT; 
- localized fluid collection lateral, distal or proximal to the lateral epicondyle; (Fig.2).  
To conclude that the reason of the lateral knee pain is ITBF in patients with osteoarthritis of 
the knee, which showed advanced medial compartment osteoarthritis with complete or 
subtotal (>80%) loss of articular cartilage at the femur and the tibia, lateral compartment 
should be normal including the articular cartilage and the lateral meniscus, without 
meniscal lesion or cartilage abnormalities (Vasilevska et al., 2009). 
MR imaging allows confirmation of diagnosis of ITBFS and exclusion of other causes of 
lateral knee pain - such as meniscal tears or ligament injuries. Axial images are necessary to 
differentiate intraarticular fluid from ITBFS (Murphy et al., 1992). 
Popliteal cysts on MR imaging are usually well defined, extending between the tendon of 
semimembranosus and the medial head of gastrocnemius into the gastrocnemius-
semimembranosus bursa, situated superficial to the medial gastrocnemius muscle, along the 
medial side of the popliteal fosa (Torreggiani et al., 2002; Steiner et al., 1996). As cyst 
enlarge, the cystic fluid may extend in any direction. Inferomedial expansion is relatively 
common with a superficial location, which results in cysts becoming palpable (Torreggiani 
et al., 2002; Steiner et al., 1996). Baker cyst can be presented as a palpable soft tissue masses 
on the medial aspect of the popliteal fossa when it is distended and large (Fig.3) (Vasilevska 
et al., 2008). 
On MRI, Baker cyst is presenting as a circumscribed mass with low signal on T1-weigted 
image, intermedal signal intensity on proton density (PD) image and high signal intensity 
comparing with skeletal muscle on PD-weithed fatsat image. The size of Baker cyst can be 
assessed by measuring the distension of the cyst, and when is thickened more than 1cm is a 
large cyst (Fig.4) (Vasilevska et al., 2008). 
 
   
 
Fig. 2. A 61 y.o. man, medial sided osteoarthritis of the knee, associated with ITBF. 
Fibrovascular tissue and fluid collections (arrow) are located between the lateral epicondyle 
and the ITB at the lateral aspect of the left knee on PDw fatsat coronal image (A). Better seen 
on a section more posterior, osteoarthritis of the medial compartment is advanced with 
cartilage loss, vacuum phenomenon in the medial compartment and advanced degenerative 
desintegration of the medial meniscus (B). Axial PDw fatsat image again shows 
extraarticular fibrovascular tissues between the lateral epicondyle and the ITB (arrow, C) 
(Vasilevska et al., 2009). 
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Fig. 3. Large Baker’s cyst in a 59-year old woman; A) Coronal PDw fatsat image shows 
complete cartilage lose on the medial knee compartment with 3th degree medial meniscus 
degeneration with degenerative disintegration (arrows), the lateral compartment is normal 
including the hyaline cartilage and the lateral meniscus. B) Axial PDw fatsat image 





Fig. 4. Small Baker’s cyst in a 35-year-old women; A) Axial fatsat PDw images. Small Baker 
cyst is shown with its subgastrocnemius bursa and gastrocnemius-semimembranosus bursa 
connected by a tin neck (arrow); B) Coronal PD fatsat image of the same patient exhibits 
normal hyaline cartilage thickness without defects. Minor mucoid degeneration is shown of 
posterior horn of the medial meniscus at its base without tear (Vasilevska et al., 2008). 
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Some studies report an incidence of Baker cysts on MR images done for internal 
derangement of the knee of 5-58% with an increase in the prevalence with age, presence of 
arthritis, internal derangement and/or effusion (Miller et al., 1996; Ward et al., 2001). 
Sansone at al. noted that Baker’s cyst were associated with one or more disorders detected 
by MRI in 94% of cases (Sansone et al., 1995). The results confirmed a strong association 
between popliteal cysts and intra-articular pathology (Sansone et al., 1995, 1999). 
The popliteal cyst is almost never an isolated pathology in an adult knee (Fritschy et al., 
2006). The probability of popliteal cysts increase with increasing number of associated knee 
conditions (Miller et al., 1996). Of 77 MRI-observed cysts, a statistical correlation existed 
with effusion, meniscus tears or ”degenerative” arthropathy, or combination of these 3 
maladies (Miller et al., 1996). 
For fluid filled bursa have two etiological factors, knee joint effusion and persistence of one 
way valvular mechanism (Takahashi et al., 2005). Vahlensieck et al. mention that there is a 
communication with the joint in half of all cases, according to the anatomy literature. 
Therefore, a joint effusion may increase the size of the gastrocnemius bursae (Vahlensieck et 
al., 2001). Sowers MF et al. detected presence of joint effusion in 70% (507) in cases with the 
knee OA. They observed large baker cyst in 6,1% of the knee (Sowers et al., 2011). Marti-
Bonmati L.et al. (2000) reported that the volume of Baker cyst was statistically related with 
presence of joint effusion in 70%. The presence and volume of the cyst is directly related 
with the quantity of the joint effusion, and the presence and type of meniscal lesion but not 
to the cartilage lesion (Marti-Bonmati et al., 2000). In isolated medial compartment knee 
osteoarthritis, there is no statistically significant difference between the size of the Baker cyst 
and degree of joint effusion (Vasilevska et al. 2008). 
Other studies, in contrary, reported that there is a statistically significant correlation 
between Baker cyst and internal derangement of the joint without joint effusion. Internal 
derangement results from disturbed biomechanics with increased pressure to shift normal 
joint fluid into the bursa (Miller et al. 1996). The intraarticular pressure of the knee is 
increased with abnormal meniscus compared to healthy knees (Miller et al. 1996). 
Almost all popliteal cyst are secondary cyst and degenerative cartilage lesions are 
responsible in 30-60% of the cases (Miller et al. 1996; Sansone et al. 1999). Articular cartilage 
lesion was the most frequent accompanying lesion with popliteal cysts and suggested an 
influence in pathogenesis of popliteal cyst (Rupp et al. 2002). An isolated degenerative 
alteration of the cartilage was present in 43% of the cases with Baker cyst (Sansone et al. 
1995, 1999). Cartilage lesion, inflamatory and degenerative arthropaty are associated 
pathology with Baker cyst (Miller et al., 1996; Torreggiani et al., 2002; Ward et al., 2001; 
Handy et al., 2001; Vasilevska et al. 2008). In contrary, Marti-Bonmati et al. (2000) reported 
that they have not observed any statistically significant relation with presence and degree of 
the cartilage lesions.  
In referred study of 30 patients with popliteal cyst in 90% had lesion of the posterior horn of 
medial meniscus (Sansone et al., 1999). Meniscal lesion was also directly related to the 
presence and quantity of fluid inside Baker cyst (Sansone et al. 1995; Marti-Bonmati et al., 
2000). Although Baker cyst are more frequent with meniscus tear, their presence is also 
associated with menisci degeneration, especially of the posterior horn (Miller et al., 1996; 
Marti-Bonmati et al., 2000). Majority of cases with a Baker cyst usually were involved the 
medial meniscus (90%) and less frequently both menisci (17%) (Sansone et al., 1999). 
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Authors in study of 66 Baker cyst in cases with isolated medial compartment knee 
osteoarthritis concluded that in the cases with large Baker cyst, there is statistically 
significant difference between different degree of medial meniscus degeneration and 
distension of the cyst. The degree of medial meniscal degeneration has no influence on the 
distension of Baker cyst generally but an influence was found, when there is significant 
cartilage degeneration (Vasilevska et al., 2008). The same authors reported that the 
combination of medial compartment cartilage degeneration and medial meniscus 
degeneration are associated with large Baker cyst in 84%, but only 48% with small Baker 
cyst. In the group with large Baker cyst, isolated medial meniscus degeneration is present in 
16%, comparing with association of medial meniscus degeneration in 52% from the cases 
with small cyst (Vasilevska et al., 2008). 
Bone edema on medial compartment in isolated medial compartment osteoarthritis, can be 
present in 65% of the cases with large Baker cyst, only when cartilage degeneration is 
present. In cases with small Baker cyst, bone edema is present in 37% of the cases (Fig.5) 
(Vasilevska et al., 2008). In cases with both compartments knee OA, Sowers MF et al. 
reported the prevalence of bone marrow lesion in the medial compartment in 21,3% and in 
lateral 13,4 % (Sowers et al., 2011).  
 
  
Fig. 5. Large Baker’s cyst in a 67-year –old man; A) On a sagittal and B) coronal PDw fatsat 
image; complete cartilage lose on the femoral condyle and the tibial plateau of the medial 
compartment (arrows), with 3th degree of medial meniscus degeneration. Bone marrow 
edema (arrow heads) and effusion is present (Vasilevska et al., 2008). 
There is a strong association between popliteal cysts and the severity of isolated medial 
compartment osteoarthritis, emphasizing the importance of cartilage degeneration for the 
distension of Baker cysts (Vasilevska et al., 2008). 
It is well known that ITBFS is associated with overuse in long distance runners, cyclists, 
military personnel, football players, and weight lifters (Barber et al., 2007; Kirk et al., 2000; 
Fredericson et al., 2006,2007;). In runners the reported incidence is as high as 22,2% of all 
lower extremity injuries (Linenger et al., 1992), and it is 15% of all overuse injuries of the 
knee from cycling (Holmes et al., 1993). Excessive running in the same direction on a track, 
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downhill running, a lack of running experience, long distance running are the most often 
mentioned etiologic factors for ITBFS (Linenger et al., 1992; Messier et al., 1995). Weakness 
of the hip abductor muscles is also believed to play a role in the development of ITBFS 
(Fredericson et al., 2006; MacMahon et al., 2000). Football players and weight lifters can also 
suffer from chronic inflammation and fibrovascular tissue at the ITB proximal to its 
insertion into the anterolateral tibia. The causes of the ITBFS can be extrinsic (related to 
training technique) or intrinsic (related to the patient’s anatomic alignment) (Farell et al., 
2003; Fredericson et al., 2006; Nishimura et al., 2003).  
Farell et al. (2003) emphasized that ITBFS usually occurs as a result of overuse. If, however, 
the patient has certain anatomical conditions (leg length discrepancies, varus knee 
alignment or excessive pronation and external tibial rotation of more than 20%), he/she will 
be more inclined to experience ITBFS. They concluded that knee-flexion repetition was more 
likely to result in the onset of the overuse injury ITBFS during cycling (Farell et al., 2003). 
ITBFS is predominantly a clinical diagnosis. 
Several other anatomical abnormalities, including leg length discrepancy and functional 
overpronation of the food have been postulated as predisposing factors (Nishimura et al., 
2003). Nishimura et al. (2003) described also two no athletic patients with ITBFS. 
As a possible factor contributing to the development of ITBFS, genus varus has been 
described, in runners and in athlete that may increase the tension and thus a frictional force 
over the lateral femoral condyle (Jones et al., 1987; Sutker et al., 1981).  
The finding of predominant cartilage degeneration on the medial rather than the lateral tibia 
plateau side suggests a close relation to the varus- knee osteoarthritis present in most of the 
cases (Kleemann et al., 2005). Recent reports have suggested a 60% reduction in cartilage 
volume in severe knee osteoarthritis (Burgkart et al., 2001; Cicuttini et al., 2001).  
Significant correlation between joint space narrowing and cartilage volume was reported 
(Cicuttini et al., 2001). Medial compartment cartilage loss leads to varus deformity, which 
can affect knee biomechanics by altering the relationship of the iliotibial band and the lateral 
epicondyle with the possibility of an increased friction and pressure between these 
structures. An association of ITBFS with genu varum in runners has been previously 
established (Farell et al., 2001). 
There is only one study in literature of 128 MR of the knee, we published a 2009, that 
describe the correlation of advanced isolated medial compartment knee osteoarthritis (with 
subsequent genu varum) and MR signs of friction of ITB (Vasilevska et al., 2009). Cartilage 
volume was not measured but the cartilage thickness in the weight bearing zone, to assess if 
there was a significant difference on cartilage thickness between the medial and the lateral 
compartment. There was a significant difference in cartilage thickness between medial and 
lateral compartment which led to joint space narrowing when standing and varus deformity 
of the knee. Varus knee alignment may be one of the causes for permanent stretching of the 
ITB and even during walking, to cause friction of the ITB on the femoral lateral condyle 
which leads to inflammation of the fibrovascular tissue, thus presenting signs of ITBF on 
MRI (Vasilevska et al., 2009). 
4. Conclusion 
Advanced reduction of cartilage thickness combined with severe degeneration of the 
meniscus at the medial compartment probably leads to biomechanical changes, and varus 
knee alignment. It may be the cause for stretching of the ITB, and may be one of the reasons 
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Authors in study of 66 Baker cyst in cases with isolated medial compartment knee 
osteoarthritis concluded that in the cases with large Baker cyst, there is statistically 
significant difference between different degree of medial meniscus degeneration and 
distension of the cyst. The degree of medial meniscal degeneration has no influence on the 
distension of Baker cyst generally but an influence was found, when there is significant 
cartilage degeneration (Vasilevska et al., 2008). The same authors reported that the 
combination of medial compartment cartilage degeneration and medial meniscus 
degeneration are associated with large Baker cyst in 84%, but only 48% with small Baker 
cyst. In the group with large Baker cyst, isolated medial meniscus degeneration is present in 
16%, comparing with association of medial meniscus degeneration in 52% from the cases 
with small cyst (Vasilevska et al., 2008). 
Bone edema on medial compartment in isolated medial compartment osteoarthritis, can be 
present in 65% of the cases with large Baker cyst, only when cartilage degeneration is 
present. In cases with small Baker cyst, bone edema is present in 37% of the cases (Fig.5) 
(Vasilevska et al., 2008). In cases with both compartments knee OA, Sowers MF et al. 
reported the prevalence of bone marrow lesion in the medial compartment in 21,3% and in 
lateral 13,4 % (Sowers et al., 2011).  
 
  
Fig. 5. Large Baker’s cyst in a 67-year –old man; A) On a sagittal and B) coronal PDw fatsat 
image; complete cartilage lose on the femoral condyle and the tibial plateau of the medial 
compartment (arrows), with 3th degree of medial meniscus degeneration. Bone marrow 
edema (arrow heads) and effusion is present (Vasilevska et al., 2008). 
There is a strong association between popliteal cysts and the severity of isolated medial 
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distension of Baker cysts (Vasilevska et al., 2008). 
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2003; Fredericson et al., 2006; Nishimura et al., 2003).  
Farell et al. (2003) emphasized that ITBFS usually occurs as a result of overuse. If, however, 
the patient has certain anatomical conditions (leg length discrepancies, varus knee 
alignment or excessive pronation and external tibial rotation of more than 20%), he/she will 
be more inclined to experience ITBFS. They concluded that knee-flexion repetition was more 
likely to result in the onset of the overuse injury ITBFS during cycling (Farell et al., 2003). 
ITBFS is predominantly a clinical diagnosis. 
Several other anatomical abnormalities, including leg length discrepancy and functional 
overpronation of the food have been postulated as predisposing factors (Nishimura et al., 
2003). Nishimura et al. (2003) described also two no athletic patients with ITBFS. 
As a possible factor contributing to the development of ITBFS, genus varus has been 
described, in runners and in athlete that may increase the tension and thus a frictional force 
over the lateral femoral condyle (Jones et al., 1987; Sutker et al., 1981).  
The finding of predominant cartilage degeneration on the medial rather than the lateral tibia 
plateau side suggests a close relation to the varus- knee osteoarthritis present in most of the 
cases (Kleemann et al., 2005). Recent reports have suggested a 60% reduction in cartilage 
volume in severe knee osteoarthritis (Burgkart et al., 2001; Cicuttini et al., 2001).  
Significant correlation between joint space narrowing and cartilage volume was reported 
(Cicuttini et al., 2001). Medial compartment cartilage loss leads to varus deformity, which 
can affect knee biomechanics by altering the relationship of the iliotibial band and the lateral 
epicondyle with the possibility of an increased friction and pressure between these 
structures. An association of ITBFS with genu varum in runners has been previously 
established (Farell et al., 2001). 
There is only one study in literature of 128 MR of the knee, we published a 2009, that 
describe the correlation of advanced isolated medial compartment knee osteoarthritis (with 
subsequent genu varum) and MR signs of friction of ITB (Vasilevska et al., 2009). Cartilage 
volume was not measured but the cartilage thickness in the weight bearing zone, to assess if 
there was a significant difference on cartilage thickness between the medial and the lateral 
compartment. There was a significant difference in cartilage thickness between medial and 
lateral compartment which led to joint space narrowing when standing and varus deformity 
of the knee. Varus knee alignment may be one of the causes for permanent stretching of the 
ITB and even during walking, to cause friction of the ITB on the femoral lateral condyle 
which leads to inflammation of the fibrovascular tissue, thus presenting signs of ITBF on 
MRI (Vasilevska et al., 2009). 
4. Conclusion 
Advanced reduction of cartilage thickness combined with severe degeneration of the 
meniscus at the medial compartment probably leads to biomechanical changes, and varus 
knee alignment. It may be the cause for stretching of the ITB, and may be one of the reasons 
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for ITBF. A latest statement for the so frequent presence of MR signs of ITBF in patients with 
isolated medial compartment knee osteoarthritis, give us a rights to put this entity in the list 
of an important associated entities with knee osteoarthritis. We should always think about it 
as the reason for lateral knee pain in those cases. This can be an explanation for the presence 
of lateral knee pain, when lateral knee compartment is unaffected. 
Baker cyst is not a single joint lesion, but it is associated with cartilage and meniscus 
degeneration on the medial compartment of the knee joint. Its size is strongly correlated 
with degenerative changes of the cartilage on the medial compartment and medial meniscus 
degeneration. It is not connected with a joint effusion. The size of Baker cyst had a strong 
correlation with degenerative changes of the cartilage and with the degree of meniscus 
degeneration on the medial compartment of the knee joint. Presence of distended Baker cyst 
can be one of the reasons of the pain and discomfort in the posterior aspect of the knee.  
5. References 
Baranyay FJ, Wang Y, Wluka AE, English DR, Giles GG, Sullivan RO, Cicuttini FM. (2007) 
Association of bone marrow lesions with knee structures and risk factors of bone 
marrow lesions in the knee of clinically healthy, community-based adults. Semin 
Arthritis Reum 37:112-118. 
Barber FA, Boothby MH, Troop RL. (2007) Z-plasty lengthening for iliotibial band friction 
syndrome. J Knee Surg 20:281-284 
Burgkart R, Glaser C, Hyhlik-Drr A, Englmeier K, Reiser M, Eckstein F. (2001) Magnetic 
resonance imaging based assessment of cartilage loss in severe osteoarthritis: 
accuracy, precision and diagnostic value. 44:2072-2077 
Center for disease control and prevention (CDC). (2003) Public health and aging: projected 
prevalence of self reported arthritis or chronic joint symptoms among persons aged 
>65-United States,2005-2030.MMWR Morb Mortal Wkly Rep.52:489-91. 
Cicuttini FM, Wluka AE, Stuckey SL. (2001) Tibial and femoral cartilage changes in knee 
osteoarthritis. ANN Rheum Dis 60:977-980 
D’Ambrosia RD. (2005) Epidemiology of osteoarthritis. Orthopedics 28(suppl.):s201-205 
Dye SF, Vaupel GL, Dye CC. (1998) Conscious neurosurgery mapping of the internal 
structures of the human knee without intraarticular anesthesia. Am J Sports Med 
26:773-7 
Ekman EF, Pope T, Martin DF, Curl WW. (1994) Magnetic resonance imaging of iliotibial 
band syndrome. Am J Sports Med 22:851-854 
Fairclough J, Hayashi K, Toumi H, Lyons K, Bydder G, Phillips N, Best TM, Benjamin M. 
(2006) The functional anatomy of the iliotibial band during flexion and extension of 
the knee: implications for understanding iliotibial band syndrome. J Anat 208:309-
316 
Fairclough J, Hayashi K, Toumi H, Lyons K, Bydder G, Phillips N, Best TM, Benjamin M. 
(2007) Is iliotibial band syndrome really a friction syndrome? J Sci Med Sport 10:74-
76 
Farell KC, Reisinger KD, Tillman MD. (2003) Force and repetition in cycling: possible 
implications for iliotibial band friction syndrome. The Knee 10:103-109 
Felson DT, Naimark A, Anderson J, Kazis L, Castelli W, Meenan RF. (1987) The prevalence 
of knee osteoarthritis in elderly. The Framingham Osteoarthritis Study. Arthritis 
Rheum 30(8):914-918 
Knee Osteoarthritis and Associated  
Periarticular Conditions: Iliotibial Band Friction and Baker Cyst 
 
263 
Felson DT, Chaisson CE, Hill CL, Totterman SM, Gale ME, Skinner KM, et al. (2001) The 
association of bone marrow lesion with pain in knee osteoarthritis. Ann Intern Med 
134:541-9. 
Fredericson M, Weir A. (2006) Practical management of iliotibial band friction syndrome in 
runners. Clin J Sport Med 16:261-268 
Fredericson M, Misra AK. (2007) Epidemiology and aetiology of marathon running injuries. 
Sports Med 37:437-439 
Fritschy D, Fasel J, Umbert JC, Bianchi S, Verdonk R, Wirth CJ. (2006) The popliteal cyst. 
Knee Surg Sport Traumatol Arthrosc 14:623-628. 
Grainger R, Stuckey S, O’Sullivan R, Davis SR, Ebeling PR, Wluka AE. (2008) What is the 
clinical and ethical importance of incidental abnormalities found by knee MRI? 
Arthritis Research & Therapy 10:R18 
Handout on Health: Osteoarthritis. www.niams.nih.gov 
Handy JR. (2001) Popliteal cysts in adults: a review. Semin Arthritis Rheum 31:108-118. 
Hill CL, Gale DG, Chaisson CE, Skinner K, Kazis L, Gale ME, et al. (2001) Knee effusion, 
popliteal cyst, and synovial thickening : association with knee pain in osteoarthritis. 
J Reumatol28:1330-7. 
Hill CL, Gale DG, Chaisson CE, Skinner K, Kazis L, Gale ME, Felson DT. (2003) Periarticular 
lesions detected on magnetic resonance imaging. prevalence in knees with and 
without symptoms. Arthritis & Reumatism 48:2836-2844. 
Holmes JC, Pruitt AL, Whalen NJ. (1993)Iliotibial band syndrome inIliotibial band friction 
syndrome in cyclists. Am Orthop Soc Sports Med 21:419-424 
Janzen DL, Peterfy CG, Forbes JR, Tirman PF, Genant HK. (1994) Cystic lesions around the 
knee joint: MR imaging findings. AJR Am J Roendgenol163:155-61 
Jones DC, James SL. (1987) Overuse injuries of the lower extremity: shin splints, iliotibial 
band friction syndrome and exertional compartment syndromes. Clin Sports Med 
6:273-290 
Kirk LK, Kuklo T, Klemme W. (2000) Iliotibial band friction syndrome. Orthopedics 23:1209-
1214 
Kleemann RU, Krocker D, Cedraro A, Tuischer J, Duda GN. (2005) Altered cartilage 
mechanics and histology in the knee osteoarthritis: relation to clinical assessment 
(ICRS Grade). OsteoArthritis and Cartilage 13:958-963 
Kornaat PR, Bloem JL, Ceulemans RY, Riyazi N, Rosendaal FR, Nelissen RG, Carter WO, Le 
Graverand MPH, Kloppenburg M. (2006) Osteoarthritis of the knee: Association 
between Clinical Features and MR Imaging Findings. Radiology vol.239: No 3-June. 
Linenger IMCC. (1992) Is iliotibial band syndrome overlooked? Phys Sport Med 20:98-108 
MacMahon JM, Chaudhari AM, Andriacchi TP. (2000) Biomechanical injury predictors for 
marathon runners; striding towards iliotibial band syndrome injury prevention. 
Conference of the International Society of Biomechanics in Sports, Hong Kong.  
Marti-Bonmati L, Molla E, Dosda R, Casillas C, Ferrer P. (2000) MR imaging of Baker cyst-
prevalence and relation to internal derangement of the knee. Magnetic Resonance 
Materials in Physics, Biology and Medicine 10:205-210. 
Mc Carthy C.L., Mc Nally E.G. (2004) The MRI appearance of cystic lesions around the knee. 
Skeletal Radiol 33: 187-209. 
Messier SP, Edwards DG, Martin DF, et al. (1995) Etiology of iliotibial band friction 
syndrome in distance runners. Med Sci Sports Exerc 27:951-960 
  
Osteoarthritis – Diagnosis, Treatment and Surgery 
 
262 
for ITBF. A latest statement for the so frequent presence of MR signs of ITBF in patients with 
isolated medial compartment knee osteoarthritis, give us a rights to put this entity in the list 
of an important associated entities with knee osteoarthritis. We should always think about it 
as the reason for lateral knee pain in those cases. This can be an explanation for the presence 
of lateral knee pain, when lateral knee compartment is unaffected. 
Baker cyst is not a single joint lesion, but it is associated with cartilage and meniscus 
degeneration on the medial compartment of the knee joint. Its size is strongly correlated 
with degenerative changes of the cartilage on the medial compartment and medial meniscus 
degeneration. It is not connected with a joint effusion. The size of Baker cyst had a strong 
correlation with degenerative changes of the cartilage and with the degree of meniscus 
degeneration on the medial compartment of the knee joint. Presence of distended Baker cyst 
can be one of the reasons of the pain and discomfort in the posterior aspect of the knee.  
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1. Introduction 
Osteoarthritis (OA) is a degenerative articular disease primarily observed in older adults, 
and is the leading cause of physical disability and impaired quality of life. OA is 
characterized by softening, fibrillation, erosion, defect of the articular cartilage, bone 
hypertrophy at the margins with osteophyte formation, subchondral sclerosis, and chronic 
inflammation of the synovial membrane and joint capsule (Zhang et al., 2010). 
These alterations are thought to be caused by biochemical and biomechanical factors leading 
to a failure in the balance of synthesis and degradation (Martel-Pelletier et al., 2010). 
Pathogenesis of OA is based on an imbalance of the functional requirements and 
morphologic alterations, and these statuses progressively and chronically evoke subsequent 
alterations (Lorenz et al., 2005). 
Although the etiology of OA is not completely understood, the accompanying biochemical, 
structural, and metabolic alterations of the articular cartilage have been well described (de 
Seny et al., 2011; Kraus 2010; Reeves et al., 2011; Sobczak et al., 2010). Recently, it has been 
revealed that proteolytic enzymes, cytokines, biomechanical stress, and altered genetics are 
involved in its pathogenesis, and proteolytic activity is particularly important in regards to 
the morphologic alterations of the articular structures, and is considered as an internal-
factor of the disease (Takei et al., 1999; Kevorkian et al., 2004). It has been suggested that 
proteolytic activity in the constituent of the joint, such as synovium, joint fluid, cartilage, is 
continuously involved in the articular alterations of the disease, as its progression is 
gradual.  
Although it is extremely difficult to accurately predict future articular OA alterations, it is 
possible to evaluate the present phenomenon, which may lead to speculation of possible 
further alterations by evaluating proteolytic activity in the joint. 
2. Evaluation of in vivo proteolytic activiy 
2.1 In situ zymography 
There have been many studies of proteolytic activity, using gelatin zymography. This 
method is a valuable and effective tool for examining and analyzing proteolytic activity, 
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1. Introduction 
Osteoarthritis (OA) is a degenerative articular disease primarily observed in older adults, 
and is the leading cause of physical disability and impaired quality of life. OA is 
characterized by softening, fibrillation, erosion, defect of the articular cartilage, bone 
hypertrophy at the margins with osteophyte formation, subchondral sclerosis, and chronic 
inflammation of the synovial membrane and joint capsule (Zhang et al., 2010). 
These alterations are thought to be caused by biochemical and biomechanical factors leading 
to a failure in the balance of synthesis and degradation (Martel-Pelletier et al., 2010). 
Pathogenesis of OA is based on an imbalance of the functional requirements and 
morphologic alterations, and these statuses progressively and chronically evoke subsequent 
alterations (Lorenz et al., 2005). 
Although the etiology of OA is not completely understood, the accompanying biochemical, 
structural, and metabolic alterations of the articular cartilage have been well described (de 
Seny et al., 2011; Kraus 2010; Reeves et al., 2011; Sobczak et al., 2010). Recently, it has been 
revealed that proteolytic enzymes, cytokines, biomechanical stress, and altered genetics are 
involved in its pathogenesis, and proteolytic activity is particularly important in regards to 
the morphologic alterations of the articular structures, and is considered as an internal-
factor of the disease (Takei et al., 1999; Kevorkian et al., 2004). It has been suggested that 
proteolytic activity in the constituent of the joint, such as synovium, joint fluid, cartilage, is 
continuously involved in the articular alterations of the disease, as its progression is 
gradual.  
Although it is extremely difficult to accurately predict future articular OA alterations, it is 
possible to evaluate the present phenomenon, which may lead to speculation of possible 
further alterations by evaluating proteolytic activity in the joint. 
2. Evaluation of in vivo proteolytic activiy 
2.1 In situ zymography 
There have been many studies of proteolytic activity, using gelatin zymography. This 
method is a valuable and effective tool for examining and analyzing proteolytic activity, 
as gelatin degrades over the course of the disease (Hattori et al., 2003; Cha et al., 2004; Sun 
et al., 2003). However, most current zymography methods are used to qualitatively 
examine this activity, and are thus not adequate for histological evaluation or 
quantification. 
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In situ zymography was developed to determine the in vivo proteolytic activity and 
determine its histological location. However, this method has only been used to 
demonstrate a qualitative analysis as the gelatin does not sufficiently coat the film with a 
uniform thickness of substrate to allow precise quantification of the in vivo proteolytic 
activity (Senzaki et al., 2000; Yi et al., 2001; Galis et al., 1995; Viemard-Barone et al., 2000; 
Goodall et al., 2001). 
A newly method, “film in situ zymography (FIZ)”, has been developed specially to evaluate 
the histological distribution the in vivo proteolytic activity (Ikeda et al., 2000; Takano et al., 
2001; Zheng et al., 2002; Kaji et al., 2003) .  
This new method works by applying unfixed frozen tissues (or fluid) to the recently 
developed FIZ film (Fuji Film. Co., Tokyo, Japan) which is uniformly coated with cross-bridge 
gelatin at a thickness of 7 μm. In our study, the synovial tissue specimens were embedded in 
Tissue-Tek OCT Compound (Lab-Tek Products, Elkhart, IN, USA) and frozen in the cryostat’s 
refrigerated chamber. Then, frozen sections were cut at 4 μm, and applied to the FIZ film, 
followed by flushing with water for a few seconds. After incubation for 6 hours at 37°C, the 
film was stained with 0.2% Ponceau solution (which is commonly used for protein staining), 
(Sigma-Aldrich, St. Louis, MO, USA) for 3 minutes and fixed with 1% acetate for 5 minutes. 
After flushing with water for 15 minutes, the film was stained with hematoxylin for nuclear 
staining. Gelatinolyzed areas caused by the proteolytic activity in the synovium were detected 
as pale in color, and non-gelatinolyzed areas were stained red (Figure 1). In several studies, 
this method was successful in achieving reproducible quantification of gelatinolyed areas 
(Iwata et al., 2001; Furuya et al., 2001; Yamanaka et al., 2000). 
 
 
Fig. 1. Film in situ zymography of OA synovium. Arrows indicate the proteolytic lesions as 
pale in color in the Ponceau-stained FIZ film.  
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2.2 Quantification by image analyzer 
Furthermore, it is possible to quantify the degree of this activity using a digital image 
analyzer (Image Processor for Analytical Pathology, IPAP, Sumitomo Tech, Osaka, Japan). 
The IPAP system is comprised of a conventional microscope, a CCD color video camera, an 
IBM-compatible microcomputer and a specialized image analysis board, Matrox Image-1280 
(Dorval, Quevec, Canada) to convert microscopic photographic images into digital images, 
and allows us to analyze many samples, fields and parameters (Figure 2). For each Ponceau-
stained FIZ film image, the analyzer can measure the approximate optical density of 
gelatinolyzed area as optical density of gelatinolyzed area (ODG) and ratio of gelatinolyzed 
area (RGA). The ODG is the mean optical density of the red-stained component at 50 
random points in the gelatinolyzed area. The RGA is the ratio of the gelatinolyzed area to 
the entire synovium stained on the FIZ films as background reference (ODG and RGA were 
measured blindly at a magnification of ×4). As such, implementing both FIZ and IPAP 
enable the histological evaluation and quantification of the in vivo proteolytic activity to 
analyze the gelatinolyzed area (Uzuki et al., 1999; Yoshida et al., 2009). 
 
 
Fig. 2. IPAP system. This system is comprised of a microscope, a CCD color video camera 
and an analyzing computer for converting microscopic photographic images into digital 
images. 
3. In vivo proteolytic activity on OA synovium 
It was revealed through FIZ the in vivo proteolytic activity on OA synovium was mainly 
distributed in the layer of the lining rather than in the stroma, although this histological 
feature is predominant and consisted of uniform fibrous proliferation with chronic 
inflammation. Furthermore, distribution of the proteolytic area in rheumatoid arthritis (RA) 
synovium, which showed obvious inflammatory changes, also detected in layer of the lining 
(Yoshida et al., 2009). 
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Comparing the in vivo proteolytic activity using FIZ and IPAP, there was a significant 
difference between OA and RA synovium in regards to the ODG (Figure 3) and RGA 
(Figure 4)(Yoshida et al., 2009). These findings suggest that there is also a difference on the 
proteolytic potential per one active-cell and the proteolytic-cell number between OA and RA 
synovium, and this might reflect that the articular alteration in OA is less progressive than 
in RA. 
Furthermore, the proteolytic area is mostly localized in the layer of the lining and similar to 
both OA and RA articular disease, although they have different degrees of activity. The 
proteolytic area is constantly exposed to the articular space, and this finding suggests that 
the in vivo proteolytic activity in synovium might be affected in the interaction with the 
constituents of articular space as an internal-factor of the articular alterations. 
 
 
Fig. 3. Optical density of the gelatinolyzed area (ODG) as produced by FIZ and IPAP the 
synovium of OA and RA. OA synovium had a significantly higher ODG (0.864±0.037) than 
RA synovium (0.758±0.019). All OA cases were classified as grade 4 using Kellgren and 
Lawrence classification and all RA cases were classified as stage IV using the Steinbrocker 
classification. 
 




Fig. 4. Ratio of gelatinolyzed areas (RGA) as produced by FIZ and IPAP the synovium of 
OA and RA. The synovium of OA had a significantly lower RGA (3.5±1.1%) than RA 
synovium (9.7±3.1%). All OA cases were classified as grade 4 using Kellgren and Lawrence 
classification and all RA cases were classified as stage IV using the Steinbrocker 
classification. 
In examination of enzyme expression by immunohistochemistry using serial sections, 
matrix metalloproteinase (MMP)-2, MMP-9, also known as gelatinase-A and -B, were mainly 
expressed by fibroblast- or macrophage-like cells of the synovial-lining layer (Figures 5a and 
5b). Interestingly, these same cells also expressed tissue inhibitor of metalloproteinase 
(TIMP) -1 and TIMP-2 (Figures 5c and 5d). In addition, the distribution of cells expressing 
MMPs and TIMPs corresponded to the proteolytic areas detected by FIZ investigation 
(Figure 5a, 5b, 5c, and 5d as serial sections showed the expression of the enzymes by 
immunohistochemisty in lining layer of RA synovium). These findings indicate that 
synovial cells simultaneously produce proteolytic enzymes and their inhibitors, and suggest 
that the in vivo proteolytic activity might be dependent on “imbalances” in enzymes-
inhibitors production of the individual cells. 
Utilizing FIZ and IPAP may further help to understand biological enzymatic activity on 
articular manifestations of OA. 
  
Osteoarthritis – Diagnosis, Treatment and Surgery 
 
268 
Comparing the in vivo proteolytic activity using FIZ and IPAP, there was a significant 
difference between OA and RA synovium in regards to the ODG (Figure 3) and RGA 
(Figure 4)(Yoshida et al., 2009). These findings suggest that there is also a difference on the 
proteolytic potential per one active-cell and the proteolytic-cell number between OA and RA 
synovium, and this might reflect that the articular alteration in OA is less progressive than 
in RA. 
Furthermore, the proteolytic area is mostly localized in the layer of the lining and similar to 
both OA and RA articular disease, although they have different degrees of activity. The 
proteolytic area is constantly exposed to the articular space, and this finding suggests that 
the in vivo proteolytic activity in synovium might be affected in the interaction with the 
constituents of articular space as an internal-factor of the articular alterations. 
 
 
Fig. 3. Optical density of the gelatinolyzed area (ODG) as produced by FIZ and IPAP the 
synovium of OA and RA. OA synovium had a significantly higher ODG (0.864±0.037) than 
RA synovium (0.758±0.019). All OA cases were classified as grade 4 using Kellgren and 
Lawrence classification and all RA cases were classified as stage IV using the Steinbrocker 
classification. 
 




Fig. 4. Ratio of gelatinolyzed areas (RGA) as produced by FIZ and IPAP the synovium of 
OA and RA. The synovium of OA had a significantly lower RGA (3.5±1.1%) than RA 
synovium (9.7±3.1%). All OA cases were classified as grade 4 using Kellgren and Lawrence 
classification and all RA cases were classified as stage IV using the Steinbrocker 
classification. 
In examination of enzyme expression by immunohistochemistry using serial sections, 
matrix metalloproteinase (MMP)-2, MMP-9, also known as gelatinase-A and -B, were mainly 
expressed by fibroblast- or macrophage-like cells of the synovial-lining layer (Figures 5a and 
5b). Interestingly, these same cells also expressed tissue inhibitor of metalloproteinase 
(TIMP) -1 and TIMP-2 (Figures 5c and 5d). In addition, the distribution of cells expressing 
MMPs and TIMPs corresponded to the proteolytic areas detected by FIZ investigation 
(Figure 5a, 5b, 5c, and 5d as serial sections showed the expression of the enzymes by 
immunohistochemisty in lining layer of RA synovium). These findings indicate that 
synovial cells simultaneously produce proteolytic enzymes and their inhibitors, and suggest 
that the in vivo proteolytic activity might be dependent on “imbalances” in enzymes-
inhibitors production of the individual cells. 
Utilizing FIZ and IPAP may further help to understand biological enzymatic activity on 
articular manifestations of OA. 
  
















Fig. 5b. Expression of MMP-9 by immunohistochemistry. 
 
















Fig. 5d. Expression of TIMP-2 by immunohistochemisry. 
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Fig. 5d. Expression of TIMP-2 by immunohistochemisry. 
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Phonoarthrography: A New Technique  
for Recording Joint Sounds 




In Medicine there are a lot of sounds emerging from the human body. Many of them are 
used either for diagnosing the condition such as heart murmurs or following up cases of 
ileus by hearing nascent intestinal borboregmi or even hearing bruits traversing the skull 
in cases with brain angiomatous malformation and many more. There is one sound of 
interest to both rheumatologists and orthopedic surgeons which  is the one heard and felt 
when osteoarthritic knees are moved. As knee sounds were regarded as an 
accompaniment to OA, the idea of recording knee sounds seemed interesting and 
plausible to many investigators. 
The historical background was handsomely written before (Mollan et al, 1982). An early 
report dates back to 1882, when Heuter  reported the first study involving the evaluation of 
sounds from the locomotory system, as he described hearing and localizing loose bodies 
within the knee, using a stethoscope. Blodgett reported in 1902 his experiences on 
auscultation of the knee using a stethoscope fitted with a rubber diaphragm to prevent 
slipping and skin friction noises. He could classify different joint sounds, graphically linking 
each to joint position .In 1906, Ludloff claimed a possible diagnosis on spinal arthritis on 
auscultatory basis .Bircher in 1913 investigated meniscal lesions of the knee and concluded 
that each type of injury had a specific sound emission .Walters in 1929, reported the 
auscultation of 1600 joints and suggested that these sounds might be a sign of early arthritis 
and promoted the use of joint auscultation in early phases of arthritis . Later, microphones 
have been used to reduce subjectivity; that step was taken by Erb (1933), when he used a 
contact microphone obtaining the clearest sound, with the exception of cases of meniscal 
tears, when he placed the sensor over the patella. 
Most of the joints recorded were the knees (M H Bassiouni & El-Feki, 1986;M H  Bassiouni 
et al., 1995; Krishnan et al., 2000; Nagata, 1988) and temporomandibular joints 
(Ciancaglini et al., 1987; Guler et al., 2003). The first reason, they are superficial thus 
perfect for auscultation and recording and the second reason is that they produce sounds 
when diseased. 
In 1986, a detailed report was published on phonoarthrography, performed using a special 
sensor, amplifier, special recorder tape, and a memory oscilloscope (M H Bassiouni & El-
Feki, 1986). This device, however, had many disadvantages, such as tape noise imposed on 
the knee signal; the limited memory storage of the oscilloscope, which did not allow storage 
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of the full motion of the knee; and finally, the incapacity of auto-analysis of the obtained 
signals. 
In 1995 a full report was published on a computerized program used to record knee 
sounds with a sensor; the results were reproducible and were expressed as average 
amplitude (units/recording) or frequency/second (M H Bassiouni et al., 1995). The 
average amplitude was calculated per 2 seconds of recording, while the frequency was 
measured per 1 second. 
When sound engineers deal with this specific area of research, they prefer to name it,  
externally detected vibroarthrographic signals (VAG) .They concentrate basically on the 
study of sound definitions rather on the medical point of view. In a paper of that kind, the 
authors concluded that VAG could provide quantitative indices for non-invasive 
diagnosis of knee osteoarthritis. They also proposed the use of statistical parameters of 
VAG signals including the form factor involving the variance of the signal and its 
derivatives, skewness, kurtosis and entropy to classify the VAG signals into normal or 
abnormal (Krishnan et al.,2000). Unfortunately, this may not serve rheumatologists as it is 
not clearly related to the pathophysiology of the disease, or to other investigative tools 
and treatment impacts. 
2. Nomenclature 
All sounds are vibrations, but not all vibrations are sounds, that is why the nomenclatures 
given to the technique included  the word vibration such as joint vibrational analysis (JVA) 
and vibroarthrographic signals (VAG) (Krishnan et al.,2000). Phonoarthrography is the most 
widely accepted term to describe the medical process as it refers to sounds (phono), 
originating from joints (arthro) and appearing on a graph. 
3. Briefing on sounds 
3.1 Definition 
Sound is a mechanical wave that is an oscillation of pressure transmitted through a solid, 
liquid, or gas, composed of frequencies within the range of hearing and of a level 
sufficiently strong to be heard, or the sensation stimulated in organs of hearing by such 
vibrations (The American Heritage Dictionary, 2008). 
3.2 Propagation of sound inside a joint 
Sound is a sequence of waves of pressure that propagates through compressible media such 
as air or water. Inside the joint the tissues will allow propagation of sounds easily even 
through the thin patella. During propagation, waves can be reflected, refracted, or 
attenuated by the medium (The propagation of sound). 
Sound propagation during phonoarthrography may be affected by the relationship between 
density and pressure. This relationship, affected by temperature, determines the speed of 
sound within the medium. For joint recording, the density of structures do not seem to vary 
between individuals, nevertheless the intra-articular pressure is increased in cases of OA 
due to effusion (H M Bassiouni et al., 1992). That is why it is recommended to aspirate 
excess synovial fluid before recording. The propagation of sound may be affected by the 
motion of the medium which is not applicable to recording of joint sounds since there is no 
medium to be moving during recording. 
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3.3 Sound wave properties and characteristics 
Sound waves are often simplified to a description in terms of sinusoidal waves, with some 
characteristics such as: 
 Frequency 
 Wavelength 
 Wave number 
 Amplitude 
The important ones used by investigators were the frequency/second,  and the amplitude. 
The wavelength and individual  wave number carry no importance to researchers recording 
joint sounds. 
3.4 Speed of sound 
The speed of sound depends on the medium traversed by  the waves . In general, the speed 
of sound is proportional to the square root of the ratio of the elastic modulus (stiffness) of 
the medium to its density. And since the velocity of sound in water is approximately 1,482 
m/s then it is assumed that the sound originating from the cartilage surface would take a 
negligible time to reach the sensor (http://library.thinkquest.org/19537/Physics4.html). 
3.5 Noise 
Noise is a term often used to refer to an unwanted sound. In science and engineering, noise 
is an undesirable component that obscures a wanted signal. The problem of noise recording 
during the process of recording the joint sounds has been dealt with properly. The solution 
to avoiding the noise background level is either to record in an anechoic chamber or 
recording first the noise then subtracting it from the joint recording. 
3.6 Equipment for dealing with sound 
Equipment for generating or recording sound includes transducers such as microphones 
and loudspeakers. The latter may help to listen to the joint recording afterwards.  
4. Joint tissues producing sounds 
4.1 Cartilage 
Cartilage friction is the mostly accused of producing sounds. If it wears out it produces a 
complex sound known as crepitus (figure 4) but if there is a torn meniscus it produces one 
sharp sound during flexion and same on extension (figure 5). The cartilage covering the 
patella and the femur is also incriminated in sound production together with the femoro-
tibial articulations in the knee joint. In the temporomandibular joint, the articulating disc is 
usually the source of sound production in disorders of mastication, while pain and 
tenderness come from the synovial lining of the joint. 
4.2 Muscles 
Muscles acting on knee for flexion and extension as well as those for mastication in the 
temporomandibular joint may produce sounds during contraction. That is why during 
recording of the knee sounds flexion and extension are done passively by the examiner 
to annul the muscle noise. Recording the sounds originating from the 
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temporomandibular joint necessitate active opening and closure of the mouth, while the 
microphone is put directly on the superficial part of the joint far from the 4 muscles 
causing jaw movements. 
4.3 Ligaments 
Ligaments do not move hence they are not major sound contributors. 
5. Different recording techniques 
The use of a special sensor together with a recording tape and a memory oscilloscope was 
done in 1986 with many disadvantages such as the inability to get rid of the background 
noise; also the oscilloscope had a small memory insufficient to complete the full recording of 
knee flexion- extension at one time. The Inability to analyze the waves was also a 
disappointment (M H Bassiouni & El-Feki, 1986). A couple of years later another work was 
able to analyze the joint sounds using a narrow-band spectrum analyzer and a computer. 
The authors could subtract the spectrum of background noise from the linear averaged 
spectrum to obtain the phopnoarthrograph (Nagata, 1988). Nevertheless; this work carried 
some disadvantages. First the authors had to divide the sounds into two levels, the (L type) 
representing the low level less than 2.5 kHz and the high frequency sound (H type) lower 
than 3.5 kHz. This did not permit enough flexibility for diagnosing the cartilage condition 
regarding degeneration, and furthermore it did not help to classify the degree of 
degeneration. The authors concluded that the sounds emerging were due to thickness and 
hardness of the cartilage surface. 
In 1987, a study was conducted to evaluate the dysfunctional temporomandibular joint 
(TMJ) by recording the joint sounds heard by a microphone during full mouth opening then 
closure done repeatedly. The main objective of the authors being dentists was to evaluate 
masticatory disorders attributed to TMJ disorders. They also correlated the 
phonoarthrographic values with pain in the TMJ area and also the radiological arthropathic 
index finding a high degree of correlation between the phonoarthrographic values and the 
arthropathic index (Ciancaglini et al., 1987). 
The first report on phonoarthrography using a sensitive microphone and a computer with a 
special program came in 1995 with me as a co-author (M H Bassiouni et al., 1995). We 
proposed the following steps for recording the knee joint: 
1. The selected and fixed time for the recording was two seconds. One second for flexion 
and the other for extension. It was done to be similar to what we do in clinical 
examination of the knee to feel the crepitus. 
2. The patient was seated on a chair with the knee bent in order to fix a constant load (that 
of the lower limb) and to avoid noises coming from the hip joint Figure 1. 
3. A recording of the background noise in the room was done. After its analysis, a 
standard value for the noise is now obtained. If the device is placed in a sound-proof 
room (anechoic), there will be no need for standardization of the noise. 
4. Ultrasound gel was applied over the shaved patellar skin to avoid friction noises. 
5. The sensor was put over the center of the patella in a fixed point. 
6. The signals now appear on the monitor after flexing and extending the knee in two 
seconds. 
7. Signals are analyzed and printed. 
 




Fig. 1. Showing the microphone attached to a rubber band fixed around the knee so as to be 
centered on the patella. A –The knee is resting at 90°flexion.  B- The knee is fully extended 
passively.  C- Return to resting 90° flexion. 
In another work done by some researchers from a department of electronics engineering 
(Kim et al., 2010), the authors recorded the knee sounds in 2 sec as stated above but they 
repeated the motion of knee flexion extension during a 20 seconds period. Unfortunately, 
this method did not add to the outcome of the recording, not to mention muscle fatigue and 
change in the velocity of movement which renders the test not precisely reproducible. The 
authors also did the recording using 2 postures the first while the patient is sitting and the 
second while the patient was standing. The values obtained while on standing were larger 
than those obtained while sitting; the authors attributed this result to the effect of the 
patient’s weight or stress or both on the knee joint. During knee flexion and extension in 
standing mode, the different agonist muscles contributed to these movements, such as the 
hamstrings, biceps femoris, quadriceps femoris, muscles needed a more forceful contraction 
than in sitting position which increased the sounds recorded. Additionally, during these 
movements, the exposed area within the patella (which generates the knee sounds due to 
friction), could become relatively larger producing more waves. 
For all researchers working in this field, reproducibility of phonoarthrographic values was a 
major concern. For that purpose ten knees were selected randomly and recorded 5 
consecutive times. The mean values for every single reading were obtained and then 
readings were compared. The P values were insignificant between the readings assuring 
reproducibility (M H Bassiouni, 1995). 
In an attempt to link modern therapies with phonoarthrography, recording the knee sounds 
was done before and after hyaluronic acid intraarticular injections (Matsuura & Masatoshi, 
2000) two microphones were used in this piece of work, the authors placed them over the 
patella, 10 mm apart. The work was done on cases with end stage OA of the knees 
patellofemoral disorders and bucket-handle meniscal tears. The patients were divided into 
two groups, the first was given hyaluronic acid injections and the second was given steroid 
injections, both intraarticular. It was found that the sound frequency was significantly 
reduced (p=0.001) immediately and 24 hours after the hyaluronic acid administration while 
it did not differ after steroid injections. The frequency returned to pre-administrative levels 
when the recording was done 48h and 1 week after the administration of hyaluronic acid. 
The authors attributed the frequency lowering to a better joint lubrication. 
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In an attempt to explain the previous results, it must be remembered that the molecular 
structure of glycosaminoglycans allows them to attract and hold countless water 
molecules through electrostatic forces and weak chemical interactions as hydrogen bonds, 
which are easily formed and broken. The water-holding capacity of these 
glycosaminoglycans is so great that, when they are incorporated into the molecular 
complex, they can hold up to 50 times its own weight in water. This enables the complex 
to cushion the effects of physical impacts, which when occur, water is squeezed out of the 
glycosaminoglycans, and when the compressive force dissipates, the water rebinds to 
these thirsty molecules (Kawano et al., 2003). An important finding also is the fast return 
of frequency to pre-administrative levels which may suggest a short action of the injected 
hyaluronic acid. 
6. Calibration of signals 
The waves obtained in phonoarthrography like others have a frequency/recording and 
amplitude. Figure 2 shows a control case while figure 3 and 4 show moderate and severe 
case of osteoarthritis respectively. The frequency will be the number of waves crossing the 
midline every second and will be measured as number of waves/second. When the 
number gets higher it means directly more degenerated areas in cartilage.  As for the 
amplitude, it is simply the difference between the highest and lowest points of the wave. 
The specially designed software has the capability to analyze the waves in average and 
extreme amplitude. Analogue scale divided into units was used to compare the different 
amplitudes. When using the amplitude, it is best to use the average values for the all 
waves in the same recording and this is known as the average amplitude (M H Bassiouni 
et al. 1995). In some cases where the click of a torn meniscus is recorded, the sound will 
appear once during flexion and repeated again during extension. The rest of the recording 
time will not record any other sounds if the knee was healthy until the meniscal problem 




Fig. 2. Phonoarthrography of a control knee with average amplitude of 27.55 
units/recording. 
 




Fig. 3. Phonoarthrography of a moderate case of osteoarthritis (OA), with average amplitude 
of 47.53 units/recording. 
 
 




Fig. 5. Phonoarthrograph of a case of torn meniscus showing the sharp sound wave 
appearing twice during the recording of flexion and extension. 
  
Osteoarthritis – Diagnosis, Treatment and Surgery 
 
280 
In an attempt to explain the previous results, it must be remembered that the molecular 
structure of glycosaminoglycans allows them to attract and hold countless water 
molecules through electrostatic forces and weak chemical interactions as hydrogen bonds, 
which are easily formed and broken. The water-holding capacity of these 
glycosaminoglycans is so great that, when they are incorporated into the molecular 
complex, they can hold up to 50 times its own weight in water. This enables the complex 
to cushion the effects of physical impacts, which when occur, water is squeezed out of the 
glycosaminoglycans, and when the compressive force dissipates, the water rebinds to 
these thirsty molecules (Kawano et al., 2003). An important finding also is the fast return 
of frequency to pre-administrative levels which may suggest a short action of the injected 
hyaluronic acid. 
6. Calibration of signals 
The waves obtained in phonoarthrography like others have a frequency/recording and 
amplitude. Figure 2 shows a control case while figure 3 and 4 show moderate and severe 
case of osteoarthritis respectively. The frequency will be the number of waves crossing the 
midline every second and will be measured as number of waves/second. When the 
number gets higher it means directly more degenerated areas in cartilage.  As for the 
amplitude, it is simply the difference between the highest and lowest points of the wave. 
The specially designed software has the capability to analyze the waves in average and 
extreme amplitude. Analogue scale divided into units was used to compare the different 
amplitudes. When using the amplitude, it is best to use the average values for the all 
waves in the same recording and this is known as the average amplitude (M H Bassiouni 
et al. 1995). In some cases where the click of a torn meniscus is recorded, the sound will 
appear once during flexion and repeated again during extension. The rest of the recording 
time will not record any other sounds if the knee was healthy until the meniscal problem 




Fig. 2. Phonoarthrography of a control knee with average amplitude of 27.55 
units/recording. 
 




Fig. 3. Phonoarthrography of a moderate case of osteoarthritis (OA), with average amplitude 
of 47.53 units/recording. 
 
 




Fig. 5. Phonoarthrograph of a case of torn meniscus showing the sharp sound wave 
appearing twice during the recording of flexion and extension. 
  
Osteoarthritis – Diagnosis, Treatment and Surgery 
 
282 
7. Cracking knee sounds 
These sounds may be confusing with others. Actually what we call “normal joint sounds” 
may be produced through a mechanism different from a degenerated cartilage. When the 
two articulating surfaces, of a synovial joint are forcefully separated from each other, the 
volume within the joint capsule increases suddenly, creating a negative pressure within. 
Synovial fluid normally present cannot fill the created extra space and the gases dissolved in 
the synovial fluid- such as carbon dioxide) are liberated swiftly to fill the space leading to 
the formation of a bubble (Unsworth et al, 1971). This process is known as cavitation. 
Cavitation in synovial joints results in a high frequency 'cracking' sound (Watson et al., 
1989). 
8. Phonoarthrography, a simple parameter for cartilage degeneration 
Aging must impose its print on cartilage as it does to many other organs in the human 
body. In a previous work that performed phonoarthrography on normal controls, rising 
values went side by side with advancement of age (Figure 6). Logically thinking, this 
could be expected, however, it still was statistically less than those who had clinically 
symptomatic osteoarthritis. Another important observation in the same work was that 
phonoarthrography was found to show abnormally high values in all cases with 
radiological OA, proving to be 100% sensitive for radiology. Positive values were also 
present in 32.5% of cases with normal radiology, giving more credit to 
phonoarthrography as being more sensitive than radiology for detecting cartilage 
degeneration. All Cases with clinically felt crepitus had abnormal phonoarthrographic 
values while in those with no felt crepitus, 13% had high phonoarthrographic values (M H 
Bassiouni et al., 1995). 
9. Relating phonoarthrography to other standard investigative tools 
9.1 Phonoarthrography versus standard knee radiology 
Being relatively a new parameter, phonoarthrography had to be tested against standard used 
parameters such as radiology in order to discover its potentials  properly. The work done by M 
H Bassiouni et al in 1995, dealt with this point; as the patients had their knees 
phonoarthrographied and classified using the radiological Kellgren-Lawrence classification 
grades (K-L) (Kellgren & Lawrence, 1957). The K-L classification as previously known is 
presented into 4 grades according to radiological severity of the knee joints. The average 
amplitude and frequency were defined for each K-L grade. A marked statistical difference was 
found between the phonoarthrography values in each grade and the following grade (P 
=0.0001) denoting a positive correlation between both parameters (M H Bassiouni et al., 1995). 
In a recent work (H M Bassiouni et al., 2011), comparing phonoarthrographic values 
obtained from patients with bilateral OA of the knees with K-L classification, the authors 
plotted the average amplitude against each grade and found that it rose steadily with higher 
radiological grades (35.04 in grade 1, 39.55 in grade 2, 44.27 in grade 3, 50.53 in grade 4) 
(table 1). 
TMJ has a clinico-radiologicalarthropathic index (CRAI) that includes the duration of the 
occurrence of noise, pain in the TMJ area, the tenderness on lateral palpation of the TMJ, and 
linear and computer tomography of the craniomandibular complex. The CRAI ranged from 
 
 





























Fig. 6. Showing the frequency/sec from normal controls and from OA patients in different 
age groups.   
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O (no arthropathy) to 13 (severe arthropathy). A previous paper where the authors used 
clinical exam, tomograms and JVA to diagnose TMJ internal derangement versus an 
artificial neural network (ANN) program trained to recognize vibration patterns. The results 
of this work showed that ANN correctly identified 98.2% of the diagnosis made previously 
(Knutson & Radke, 1995). 
9.2 Phonoarthrography versus musculoskeletal ultrasonography and MRI 
Musculoskeletal ultrasonography (MSUS) has been  proposed previously for assessing 
periarticular and intra-  articular abnormalities involved in the pathophysiology of  knee OA 
(Naredo et al., 2005).Before linking parameters to each other, one must know what the 
capabilities of each are. Musculoskeletal ultrasonography (MSUS) has the capability of 
studying many structures around the knee joint; it can also measure the thickness of the 
cartilage peripherally but cannot give information about the surface of the cartilage. On the 
other hand Phonoarthrography provides an evaluation about the smoothness or roughness 
of the articular cartilage. 
The cartilage thickness from the 4 condyles was measured by MSUS in cases of OA of the 
knees and Phonoarthrography was performed to same patients (H M Bassiouni et al., 2011). 
The study provides important information about the thickness of cartilage in both OA 
patients and control groups and it shows clearly that there was a high statistical difference 
between the thickness in both groups (P=0.0001). This difference was present in all 4 
condyles. Table 1 shows the cartilage thickness from the patients group measured from the 4 
condyles in each grade of OA. There was also an inverse correlation between thickness of 
cartilage and radiological grading. 
Phonoarthrography inversely correlated with the thickness of cartilage i.e. the lesser 
thickness (denoting more degeneration), the higher the average amplitude. An example 
correlating the medial femoral cartilage thickness to the average amplitude shows r =-0.77, 
p=0.01. 
In a single work in literature that was done to correlate magnetic resonance imaging (MRI) 
findings of effusion, disc displacement, condylar bony changes and disc form with clinical 
findings of pain and sounds in patients with bruxing and non-bruxing behavior, the authors 
found that a higher prevalence of condylar bony changes occurred in reducing joints in 
patients with bruxing behavior and also they highlighted the importance of 
phonoarthrography in diagnosing unilaterally affected joints. In non-reducing joints, 30% of 
painful joints in the patient group and 59% of controls showed a strong signal in the joint 
space on T2 weighted imaging (Guler et al., 2003). 
9.3 Phonoarthrography versus cartilage biomarkers 
In the same work where the authors correlated the cartilage thickness with the average 
amplitudes (H M Bassiouni net al., 2011); they also measured the MMP-3 and TIMP-1 as to 
detect if changes in these markers would influence the outcome of phonoarthrography 
(table 1). MMp-3 was selected because many proteolytic enzymes, secreted by chondrocytes 
and synovial cells, cause degeneration and destruction of the cartilage matrix of the joints. 
Matrix metalloproteinase-3 (MMP-3) (stromelysin) is a major player in cartilage destruction; 
it degrades proteoglycan and collagen types II, IX, and XI (Wu et al., 1991), and also 
activates other MMPs (Okada et al., 1989). 
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Table 1. This table shows the 4 OA grades in relation to biomarkers (MMp-3 and TIMP-1), 
phonoarthrography, and cartilage thickness from the 4 condyles. 
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Interestingly,  MMP-3 did not correlate with the real-time status of cartilage elaborated 
by phonoarthrography, and the reason for that is that this  marker denotes only  
episodes of joint destruction, while Phonoarthrography  describe the present cartilage 
condition.  
10. Conclusion 
Phonoarthrography is a simple, non-invasive tool that should be present in any 
rheumatology clinic. A trained doctor or nurse can perform the test easily. A point of 
strength for Phonoarthrography is that it provides early and sensitive information about 
cartilage that other imaging machines cannot do, except when the disease is prominent. This 
information is related to motion, which involves two articulating surfaces gliding over each 
other at the same time. Magnetic resonance imaging (MRI), a known strong tool for the 
diagnosis and follow-up of OA, remains handicapped in the domain of detecting any 
changes related to cartilage surfaces’ functioning together, which is provided by 
Phonoarthrography. 
So far only 2 joints have been studied which are the knees and temporomandibular joints. 
Other joints such as the elbow, metacarpophalangeal, shoulder and other articulations 
should be candidates for phonoarthrography. 
More works are needed to prove that we can use phonoarthrography in diagnosis and 
follow ups of patients in diseases where the etiologies are different from OA such as in 
rheumatoid arthritis. 
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1. Introduction 
Osteoarthritis (OA) of the knee is a common joint disorder affecting nearly a third of the 
elderly population.  
[Felson 1987] The chance of suffering from knee OA increases with advancing age. In a world 
with an aging population, the prevalence is set to increase further. Conservative management 
for Osteoarthritis of the knee is often successful and should always be considered initially. 
However, it is not uncommon for the situation to arise where conservative management has 
failed or indeed is futile. This chapter will outline, categorize and detail the surgical options 
available for knee OA. Key results from the literature will be used to demonstrate the current 
reasoning behind evidence-based practice in surgery for knee Osteoarthritis. In particular we 
shall focus on evidence comparing surgical options for knee OA.  
2. Definition, aetiology and diagnosis  
Osteoarthritis (OA), also known as osteoarthrosis and degenerative joint disease is a progressive 
disorder of the articular cartilage. The aetiology of knee OA is multifactorial. Contributory 
factors include age, sex, obesity and previous trauma. There is a genetic component to the 
aetiology of knee OA. It is thought that genetic variations lead to chondrocyte abnormalities 
resulting in osteoarthritis. [Valdes 2010] Twin studies have demonstrated an increase in 
prevalence independent of other confounding factors. [Spector 1996] 
Diagnosis of knee OA is generally made from a combination of history, examination and 
radiographic findings. Plain radiographs are usually diagnostic, particularly if they are 
weight-bearing views. The four classic features are joint space narrowing, osteophyte 
formation, subchondral sclerosis and the presence of subchondral cysts. Not all of these are 
required for the diagnosis to be made. In some situations, additional imaging in the form of 
Computer Tomography (CT), Magnetic Resonance Imaging (MRI) and isotope bone scans 
can be helpful in providing further diagnostic information. 
3. Basic science of articular cartilage 
Osteoarthritis is principally a disorder of articular cartilage. The proteoglycan structure of 
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inflammation or infection. If this occurs, the water holding ability of articular cartilage is 
disturbed. This in turn leads to progressive breakdown of the collagen meshwork exposing 
the subchondral bone beneath the articular cartilage. It is this exposure of bone, which is 
responsible for the symptoms of pain in OA.  
 
 
Fig. 1. Knee Osteoarthritis. Medial joint space narrowing, subchondral sclerosis and 
osteophyte formation. 
Articular cartilage is avascular, aneural and alymphatic. Nutrition is derived by diffusion 
from the synovial fluid or via the blood vessels in the subchondral bone. Articular cartilage 
unfortunately cannot significantly repair once damaged.  Partial thickness injuries do not 
heal as they stimulate only a minimal reaction in adjacent chondrocytes. Full thickness 
injuries penetrating the subchondral bone cause bleeding and heal with fibrocartilage as 
opposed to hyaline cartilage. Unfortunately, the mechanical properties of fibrocartilage are 
inferior to the specialized hyaline cartilage. The above-described mechanism of 
fibrocartilage production is the surgical goal of the marrow stimulation techniques, which 
will be described later.  
4. When is surgical intervention warranted in knee OA? 
Initial treatment of knee OA is with non-operative measures. When these measures fail, 
surgical options can be considered. The choice of procedure is based on the symptoms, the 
severity of OA and patient factors such comorbidities and physical demands on the knee. 
The radiological findings are helpful in making an overall assessment of the patient, but do 
not dictate the treatment option alone. Many patients have severe radiological OA changes 
but with minimal symptoms. Similarly, some patients can be severely disabled by their knee 
OA symptoms with minimal changes on plain radiographs.  
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Pain that is not responding to conservative measures along with decreasing function and 
mobility are the predominant features in the history that help guide when surgical 
treatment is required. Inability to sleep due to pain is used by many surgeons as a guide, but 
occasionally progressive deformity or instability symptoms dictate when the time is chosen 
for surgery. 
There is no globally accepted timing point for surgery to be performed. Patient and surgeon 
factors along with availability of local resources all play their part. 
This chapter will identify and discuss the surgical treatment options in knee OA. 
5. Surgical options 
5.1 Arthroscopy 
Arthroscopy or “key hole” surgery involves the examination and treatment of intra-articular 
conditions of the knee. Small incisions or portals are made to allow the insertion of an 
arthroscope.  A camera within the arthroscope, a fibre optic light source and irrigation allow 
visualization of the articular surfaces of the knee. Small instruments that are capable of 
probing, cutting, shaving and ablating can be passed through the portals to allow 
assessment and treatment of the osteoarthritic knee. 
 
 
Fig. 2. Normal knee arthroscopic appearances 
5.1.1 Classification of cartilaginous lesions 
In 1961, Outerbridge [Outerbridge 1961] detailed a grading for patellar chondral lesions. 
Since then it has become accepted for lesions in other areas of the knee and remains a useful 
classification in the assessment of cartilaginous lesions of the knee. 
Grade 1: Softening and swelling 
Grade 2: Fragmentation and fissuring of 0.5 inch or less 
Grade 3: Fragmentation and fissuring of 0.5 inch or more 
Grade 4: Erosion of cartilage to bone 
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Fig. 3. Erosion of cartilage to bone. Medial femoral condyle. 
5.1.2 Arthroscopic lavage and debridement 
Arthroscopic lavage involves simply irrigating and washing out the knee joint. The lavage 
effect was first noted by Burman in 1934. [Burman 1934] Theoretically, it has been proposed 
that lavage is effective by removing debris and inflammatory cytokines that can cause 
synovitis. [Chang 1993] [OgilvieHarris 1991] 
Arthroscopic debridement can remove loose chondral flaps. The removal of mechanical 
irritants by debridement of any roughened surface was pioneered by Magnuson in 1941. 
[Magnuson 1941]  
In well-selected middle-aged patients with grade 3 or 4 changes in the medial femoral 
condyle, a better outcome can be expected with arthroscopic debridement as opposed to 
arthroscopic lavage. [Hubbard 1996] 
It remains controversial as to whether arthroscopic lavage or debridement has a 
significant role to play in the treatment of knee OA. [Zhang 2007] [Zhang 2008] [Zhang 
2010] 
Moseley demonstrated no significant benefit to arthroscopic lavage or debridement 
compared to placebo surgery. [Moseley 2002]  The placebo effect was also shown to be 
significant in the treatment of OA in a systematic literature review.  [Zhang 2008a] 
A recent Cochrane review of arthroscopic debridement and lavage concluded from these 
that the procedure has no benefit for OA arising from mechanical or inflammatory changes. 
[Laupattarakasem 2008] 
Despite the lack of evidence in favour for this procedure, it is easy to see why it continues to 
part of the surgical armamentarium for knee OA for many patients and surgeons. It is 
evident that it cannot prevent the progression of OA, but it may offer some temporary 
symptomatic relief. It is a low risk procedure with a short postoperative recovery and 
doesn’t “burn any bridges” in terms of further procedures.   
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5.1.3 Arthroscopic bone marrow stimulating techniques 
The following procedures are not curative. They all aim to create bleeding which in turn will 
produce a fibrin clot on the exposed bony surface. Undifferentiated cells from the bone 
marrow proliferate with an end result a fibrocartilage (scar tissue).  The procedures do not 
address the issue of why a weight bearing area of articular cartilage has been denuded. If 
there is an underlying element of instability or malalignment, the fibrocartilage layer filling 
the defect is likely to fail.  
5.1.4 Drilling 
Pridie first described this technique using an arthrotomy incision. [Pridie 1959] He used a 
0.25 inch drill bit to penetrate the vascular cancellous bone beneath the sclerotic subchondral 
lamina. This technique has been adapted to the use of a kirschner wire via arthroscopic 
portals. Two studies using this technique in rabbits have failed to demonstrate long-term 
coverage of the denuded bone. [Meachim 1971] [Mitchell 1976] 
5.1.5 Abrasion arthroplasty 
In this technique a motorized burr is used to create an intracortical abrasion in areas where 
the chondral surface is deficient. Similar in nature to the drilling technique, the process 
causes localized bleeding and consequent healing with fibrocartilaginous tissue. During the 
immediate postoperative phase, the healing fibrocartiaginous tissue is protected from 
shearing forces by a period of non-weight bearing for the patient. 
One study found abrasion arthroplasty was beneficial in the short term in 60% of 110 
patients who had full thickness cartilage defects in the knee. Better results were noticed in 
patients less than 40 years of age. [Friedman 1984]  
A comparative 5 year retrospective review of 126 patients with unicompartmental 
osteoarthritis, undergoing arthroscopic treatment, demonstrated a satisfactory result in only 
67% of 59 patients who had been managed with abrasion arthroplasty with debridement as 
opposed to a satisfactory result in 79% of 67 patients who had been managed with 
arthroscopic debridement alone. [Bert 1989]  
5.1.6 Microfracture 
This technique is currently the most widely accepted of the bone marrow stimulating 
techniques. 
Microfracture is the process of making multiple small holes in an area of denuded articular 
surface with small picks by hand rather than using drills or pins under power. In this low 
energy technique the awl theoretically causes microfracture of the trabeculae rather than 
destruction of the bone. Steadman et al [Steadman 1997] describe the technique where the 
exposed bone is debrided of loose articular cartilage to a stable articular margin. The base of 
the defect should also be debrided to remove the calcified layer of cartilage. Three to four 
perforations per square centimeter are made at a depth of approximately 4 mm and spaced 
3-4 mm apart. Post operatively range of movement exercises are encouraged, but weight 
bearing is restricted to protect the healing cartilaginous zone. Histological evaluation of the 
healed tissue following second look arthroscopy has demonstrated a hybrid of 
fibrocartilaginous and hyaline-like cartilage. [Bae 2006]  
This is a relatively simple, low cost arthroscopic technique. Steadman [Steadman 2002] 
[Steadman 2003] reported 80% of 75 knees were improved by microfracture with respect to 
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the chondral surface is deficient. Similar in nature to the drilling technique, the process 
causes localized bleeding and consequent healing with fibrocartilaginous tissue. During the 
immediate postoperative phase, the healing fibrocartiaginous tissue is protected from 
shearing forces by a period of non-weight bearing for the patient. 
One study found abrasion arthroplasty was beneficial in the short term in 60% of 110 
patients who had full thickness cartilage defects in the knee. Better results were noticed in 
patients less than 40 years of age. [Friedman 1984]  
A comparative 5 year retrospective review of 126 patients with unicompartmental 
osteoarthritis, undergoing arthroscopic treatment, demonstrated a satisfactory result in only 
67% of 59 patients who had been managed with abrasion arthroplasty with debridement as 
opposed to a satisfactory result in 79% of 67 patients who had been managed with 
arthroscopic debridement alone. [Bert 1989]  
5.1.6 Microfracture 
This technique is currently the most widely accepted of the bone marrow stimulating 
techniques. 
Microfracture is the process of making multiple small holes in an area of denuded articular 
surface with small picks by hand rather than using drills or pins under power. In this low 
energy technique the awl theoretically causes microfracture of the trabeculae rather than 
destruction of the bone. Steadman et al [Steadman 1997] describe the technique where the 
exposed bone is debrided of loose articular cartilage to a stable articular margin. The base of 
the defect should also be debrided to remove the calcified layer of cartilage. Three to four 
perforations per square centimeter are made at a depth of approximately 4 mm and spaced 
3-4 mm apart. Post operatively range of movement exercises are encouraged, but weight 
bearing is restricted to protect the healing cartilaginous zone. Histological evaluation of the 
healed tissue following second look arthroscopy has demonstrated a hybrid of 
fibrocartilaginous and hyaline-like cartilage. [Bae 2006]  
This is a relatively simple, low cost arthroscopic technique. Steadman [Steadman 2002] 
[Steadman 2003] reported 80% of 75 knees were improved by microfracture with respect to 
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function and pain at a minimum of 7 years follow up. Other studies suggest a shorter 
duration of improvement. Kreuz et al found that in their 85 patients, a deterioration in 
results began at 18 months post surgery.  They also reported that the clinical results appear 
age dependent with better results in patients less than 40 years of age. [Kreuz 2006]  
With the development of chondrocyte implantation techniques, inevitably the question 
arises as to which technique is superior in terms of clinical results. Numerous studies have 
attempted to address this. A recent systematic review [Harris 2010] evaluated 7 studies 
[Basad 2010] [Basad 2004] [Knutsen 2007] [Knutsen 2004] [Saris 2009] [Saris 2008]  [Kon 
2009] comparing autologous chondrocyte implantation with microfracture. Intermediate 
term (with follow up times ranging from 1 to 5 years) clinical outcome analysis 
demonstrated a trend towards autologous chondrocyte implantation having improved 
outcomes as compared with microfracture. 
 
 
Fig. 4. Microfracture technique. 
5.1.7 Arthroscopic Osteochondral Autograft Transplantation System (OATS or 
Mosaicplasty)  
Transplantation of hyaline cartilage from one area of the knee to another will not heal to the 
underlying bone. An osteochondral graft provides a bony surface to anchor the attached 
cartilage to the recipient area. The bony area can then be replaced by creeping substitution.  
This technique was first described in 1993 by Matsusue et al. [Matsusue 1993] Single or 
multiple cylindrical plugs from a relatively non weight-bearing region of the knee are 
harvested. These plugs are then inserted into the chondral surface defect. It is possible to 
perform the procedure either as an open procedure or arthroscopically. 
The main disadvantages are donor site morbidity and the limited options for donor site. The 
donor site is usually the edge of the patellar groove or the area just proximal to the 
intercondylar notch. Although larger grafts have been performed, [Karataglis 2005] the 
limited possible donor sites available, generally restrict the use of this technique to small 
focal areas of articular cartilage loss.  
Outerbridge [Outerbridge 1995] demonstrated an improvement in knee function and 
symptoms at an average of 6.5 years following osteochondral grafts for defects of the 
femoral condyle. The procedure does not seem to disturb the main nutritional pattern of 
articular cartilage.  The donor sites fill in with fibrocartilage.   
Hangody [Hangody 2003] reported the results of a large series of mosaicplasty. 597 femoral 
condyles, 76 tibial plateau and 118 patellofemoral joints at up to 10 years postoperatively 
were assessed. Good or excellent results were reported in 92%, 87%, and 79% of patients 
who underwent mosaicplasty of the femoral condyle, tibial plateau and patellofemoral joint 
respectively. 
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When compared to other cartilage repair techniques, a randomized study by Gudas et al 
[Gudas 2005] demonstrated a more reliable improvement in clinical outcome with OATS 
compared to microfracture. In a recent systematic review [Harris 2010] autologous 
chondrocyte implantation and mosaicplasty were compared in 2 studies. [Dozin 2005] 
[Horas 2003] Analysis demonstrated equivalent clinical outcomes, but a more rapid 
treatment response was seen with the mosaicplasty patients. 
5.1.8 Autologous chondrocyte implantation 
In 1994 Brittberg [Brittberg 1994] described the technique whereby cultivated and 
proliferated autologous chondrocytes are re-implanted underneath a periosteal flap. An 
initial arthroscopy following visualization of the chondral defect provides the opportunity 
to harvest chondrocytes with a small probe. The harvested cells are then grown in a 
monolayer culture enriched with growth factors over a 3-4 week period. The cells can be 
suspended in a liquid medium or cultured directly into a three-dimensional collagen 
scaffold which itself can be implanted. A collagen membrane now replaces the periosteal 
flap that was initially described. The second stage of the procedure is performed through an 
open arthrotomy. The main advantage of the procedure is the potential for the restoration of 
normal hyaline cartilage. The disadvantages are the need for 2 procedures and the cost of 
the cell culture.  
Similar to other cartilage repair techniques, success depends on patient selection. The ideal 
candidate is a young patient, with a short duration of symptoms and an isolated small 
chondral defect. [Krishnan 2006]  
Instability, malalignment and patellofemoral maltracking will almost certainly jeopardize 
the final result. An improvement over recent years in Magnetic Resonance Imaging 
techniques is helpful in patient selection and assessment.  [Potter 2009] 
Histological analysis studies [Roberts 2003] have demonstrated tissue which is hyaline-like, 
but the tissue is not morphologically or histochemically identical to normal hyaline cartilage 
and may include some fibrocartilage.  
In a clinical review of 244 patients [Brittberg 2003] with 2-10 years’ follow up, subjective and 
objective improvements were seen in high numbers of patients with femoral condyle 
lesions. There was a high percentage of good to excellent results (84-90%) in patients with 
different types of single femoral condyle lesions while other types of lesions had a lower 
degree of success. Other reports have shown similar levels if success in terms of 
symptomatic improvement [Erggelet 2003] [Gillogly 2006]. However it has been suggested 
[Lohmander 2003] that results should be compared with other cartilage repair techniques in 
randomized trials. 
In a randomized trial of 100 patients comparing autologous chondrocyte implantation (58 
patients) with mosaicplasty (42 patients), Bentley [Bentley 2003] demonstrated a significant 
difference between the 2 groups with 88% excellent or good results in the autologous 
chondrocyte implantation group and 69% excellent or good in the mosaicplasty group. A 
recent systematic review [Harris 2010] comparing these two techniques, looked at two other 
studies [Horas 2003] [Dozin 2005] concluding that clinical outcomes were similar. 
The same systematic review [Harris 2010] evaluated 7 studies [Basad 2010] [Basad 2004] 
[Knutsen 2007] [Knutsen 2004] [Saris 2009] [Saris 2008]  [Kon 2009]  comparing autologous 
chondrocyte implantation with microfracture. Intermediate term (with follow up times 
ranging from 1 to 5 years) clinical outcome analysis demonstrated a trend towards 
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function and pain at a minimum of 7 years follow up. Other studies suggest a shorter 
duration of improvement. Kreuz et al found that in their 85 patients, a deterioration in 
results began at 18 months post surgery.  They also reported that the clinical results appear 
age dependent with better results in patients less than 40 years of age. [Kreuz 2006]  
With the development of chondrocyte implantation techniques, inevitably the question 
arises as to which technique is superior in terms of clinical results. Numerous studies have 
attempted to address this. A recent systematic review [Harris 2010] evaluated 7 studies 
[Basad 2010] [Basad 2004] [Knutsen 2007] [Knutsen 2004] [Saris 2009] [Saris 2008]  [Kon 
2009] comparing autologous chondrocyte implantation with microfracture. Intermediate 
term (with follow up times ranging from 1 to 5 years) clinical outcome analysis 
demonstrated a trend towards autologous chondrocyte implantation having improved 
outcomes as compared with microfracture. 
 
 
Fig. 4. Microfracture technique. 
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Transplantation of hyaline cartilage from one area of the knee to another will not heal to the 
underlying bone. An osteochondral graft provides a bony surface to anchor the attached 
cartilage to the recipient area. The bony area can then be replaced by creeping substitution.  
This technique was first described in 1993 by Matsusue et al. [Matsusue 1993] Single or 
multiple cylindrical plugs from a relatively non weight-bearing region of the knee are 
harvested. These plugs are then inserted into the chondral surface defect. It is possible to 
perform the procedure either as an open procedure or arthroscopically. 
The main disadvantages are donor site morbidity and the limited options for donor site. The 
donor site is usually the edge of the patellar groove or the area just proximal to the 
intercondylar notch. Although larger grafts have been performed, [Karataglis 2005] the 
limited possible donor sites available, generally restrict the use of this technique to small 
focal areas of articular cartilage loss.  
Outerbridge [Outerbridge 1995] demonstrated an improvement in knee function and 
symptoms at an average of 6.5 years following osteochondral grafts for defects of the 
femoral condyle. The procedure does not seem to disturb the main nutritional pattern of 
articular cartilage.  The donor sites fill in with fibrocartilage.   
Hangody [Hangody 2003] reported the results of a large series of mosaicplasty. 597 femoral 
condyles, 76 tibial plateau and 118 patellofemoral joints at up to 10 years postoperatively 
were assessed. Good or excellent results were reported in 92%, 87%, and 79% of patients 
who underwent mosaicplasty of the femoral condyle, tibial plateau and patellofemoral joint 
respectively. 
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When compared to other cartilage repair techniques, a randomized study by Gudas et al 
[Gudas 2005] demonstrated a more reliable improvement in clinical outcome with OATS 
compared to microfracture. In a recent systematic review [Harris 2010] autologous 
chondrocyte implantation and mosaicplasty were compared in 2 studies. [Dozin 2005] 
[Horas 2003] Analysis demonstrated equivalent clinical outcomes, but a more rapid 
treatment response was seen with the mosaicplasty patients. 
5.1.8 Autologous chondrocyte implantation 
In 1994 Brittberg [Brittberg 1994] described the technique whereby cultivated and 
proliferated autologous chondrocytes are re-implanted underneath a periosteal flap. An 
initial arthroscopy following visualization of the chondral defect provides the opportunity 
to harvest chondrocytes with a small probe. The harvested cells are then grown in a 
monolayer culture enriched with growth factors over a 3-4 week period. The cells can be 
suspended in a liquid medium or cultured directly into a three-dimensional collagen 
scaffold which itself can be implanted. A collagen membrane now replaces the periosteal 
flap that was initially described. The second stage of the procedure is performed through an 
open arthrotomy. The main advantage of the procedure is the potential for the restoration of 
normal hyaline cartilage. The disadvantages are the need for 2 procedures and the cost of 
the cell culture.  
Similar to other cartilage repair techniques, success depends on patient selection. The ideal 
candidate is a young patient, with a short duration of symptoms and an isolated small 
chondral defect. [Krishnan 2006]  
Instability, malalignment and patellofemoral maltracking will almost certainly jeopardize 
the final result. An improvement over recent years in Magnetic Resonance Imaging 
techniques is helpful in patient selection and assessment.  [Potter 2009] 
Histological analysis studies [Roberts 2003] have demonstrated tissue which is hyaline-like, 
but the tissue is not morphologically or histochemically identical to normal hyaline cartilage 
and may include some fibrocartilage.  
In a clinical review of 244 patients [Brittberg 2003] with 2-10 years’ follow up, subjective and 
objective improvements were seen in high numbers of patients with femoral condyle 
lesions. There was a high percentage of good to excellent results (84-90%) in patients with 
different types of single femoral condyle lesions while other types of lesions had a lower 
degree of success. Other reports have shown similar levels if success in terms of 
symptomatic improvement [Erggelet 2003] [Gillogly 2006]. However it has been suggested 
[Lohmander 2003] that results should be compared with other cartilage repair techniques in 
randomized trials. 
In a randomized trial of 100 patients comparing autologous chondrocyte implantation (58 
patients) with mosaicplasty (42 patients), Bentley [Bentley 2003] demonstrated a significant 
difference between the 2 groups with 88% excellent or good results in the autologous 
chondrocyte implantation group and 69% excellent or good in the mosaicplasty group. A 
recent systematic review [Harris 2010] comparing these two techniques, looked at two other 
studies [Horas 2003] [Dozin 2005] concluding that clinical outcomes were similar. 
The same systematic review [Harris 2010] evaluated 7 studies [Basad 2010] [Basad 2004] 
[Knutsen 2007] [Knutsen 2004] [Saris 2009] [Saris 2008]  [Kon 2009]  comparing autologous 
chondrocyte implantation with microfracture. Intermediate term (with follow up times 
ranging from 1 to 5 years) clinical outcome analysis demonstrated a trend towards 
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autologous chondrocyte implantation having improved outcomes as compared with 
microfracture. 
Despite the increasingly widespread use of autologous chondrocyte implantation, it remains 
unclear as to whether there is a significant difference between this and other cartilage repair 
techniques. A Cochrane Database Systematic Review [Vasiliadis 2010] concluded that there 
was insufficient evidence to draw conclusions on the use of autologous chondrocyte 
implantation in the knee. 
5.2 Osteotomy 
Osteotomies around the knee alter the weight-bearing axis of the lower extremity. The 
surgical goal is to unload the damaged compartment and to transfer the weight load from 
the affected areas by slightly overcorrecting into a valgus or varus alignment. The aims of 
the procedure are to reduce pain, slow the degenerative process and delay joint 
replacement. 
The concept gained acceptance in the 1960s after studies by Jackson and Waugh [Jackson 
1961].  They demonstrated that a correction in the knee deformity relieved the pain. Many 
surgeons believe that the mechanism for symptomatic improvement is entirely mechanical 
[Harris 1970]. Others believe that this biomechanical concept is spurious. Shaw and Moulton 
demonstrated in their biomechanical cadaveric study, that to unload the medial 
compartment, a valgus correction of 25 degrees would be required. [Shaw 1996]  
During the 1960s and 1970s, the use of osteotomy was the recommended surgical treatment 
for osteoarthritis of the knee. As the mid term and long-term excellent results of knee 
replacements became apparent, the use of osteotomy became less widespread. 
The advantages of osteotomy over total joint arthroplasty are the preservation of bone stock 
and intra-articular structures. The classic indication is an osteoarthritic knee with single 
compartment disease (most commonly the medial compartment) accompanied by a varus or 
valgus alignment. Patient selection is fundamental to achieving a satisfactory result. The 
knee should have a good range of movement. The patellofemoral joint should not be 
significantly involved. Ligamentous stability is ideal, but cruciate ligament instability is not 
an absolute contraindication. Combining an osteotomy with a cruciate ligament 
reconstruction is possible. Changing the slope of the proximal tibia at the time of the 
osteotomy can also improve cruciate ligament laxity. [Aqueskirchner 2002] [Paley 2000] 
Osteotomies around the knee have generally been suited to young active patients in place of 
joint replacement. An osteotomy once united allows unlimited activity. The polyethylene is 
a cause for concern in highly active patients with knee joint replacements. High loads from 
running and jumping may exceed the tolerance of polyethylene. Repetitive loading may 
loosen or damage a total knee replacement.  
In unicompartmental osteoarthritis, it is possible to correct the mechanical axis with 
different techniques. These include proximal tibia and supracondylar distal femoral 
osteotomies. Both can be performed with an additive (opening wedge) or subtractive 
(closing wedge) technique. Most commonly, the osteotomy is performed on the proximal 
tibia for varus medial compartment osteoarthritis. This can be a lateral closing wedge or a 
medial opening wedge osteotomy.  
Traditionally, a closing wedge, valgising osteotomy was performed for medial compartment 
osteoarthritis. Described by Coventry  [Coventry 1965], the osteotomy is made proximal to 
the tibial tuberosity and incorporates a fibula osteotomy also.  
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One disadvantage of a lateral closing proximal tibial osteotomy is the associated risk of 
peroneal nerve injury at the time of fibula osteotomy. This is reported to be as high as 11%. 
[Staubli 2003] Other concerns are the propensity for loss of bone stock, patella baja and 
leaving the joint line in an oblique position, making subsequent joint replacement more 
challenging.  
For these reasons, the medial opening wedge osteotomy has gained in popularity.  
5.2.1 Outcome following high tibial osteotomy 
There are numerous studies available on the outcome following high tibial osteotomy. 
Differing techniques and evaluation methods make pooling and comparison of this data 
challenging. A Cochrane review [Brouwer 2007] concluded that there is “silver” level 
evidence that a valgising high tibial osteotomy improves knee function and reduced pain, 
but there is no evidence whether an osteotomy is more effective than conservative 
treatment. 
Coventry describes good results in several studies. [Coventry 1979] [Coventry 1982] 
[Coventry 1993] Coventry also states that high tibial osteotomy not only improves the knee 
function, but also allows healing of the articular cartilage. [Coventry 1984] 
Multiple studies have demonstrated that the early good results of high tibial osteotomy 
gradually deteriorate with time. A meta-analysis [Virolainen 2004] demonstrated good or 
excellent results in 75% of patients after 60 months and 60% of patients after 100 months. 
Unchanged and mild pain were defined as unsatisfactory results. 
It is generally accepted that age is an important factor in predicting outcome. Patients 
greater than 50 years old are less likely to have a satisfactory result. [Naudie 1999] [Flecher 
2006] 
The degree of correction has repeatedly been shown to correlate with survivorship. 
Overcorrecting the femorotibial angle to more than 15 degrees has been shown to give a 
better clinical outcome, but the cosmetic appearance is generally not acceptable to patients. 
[Rudan 1990]  Under correction is associated with a poorer outcome. [Naudie 1999] 
[Ivarsson 1990] [Matthews 1988] [Sprenger 2003]. Consequently, most surgeons aim for a 
correction of between 5 and 12 degrees. 
5.2.2 Closing versus opening wedge high tibial osteotomy 
For many years, the closing wedge osteotomy was considered the gold standard. Over 
recent years the medial open wedge osteotomy technique has been developed. This 
procedure is considered technically less demanding and more precise. The use of modern 
angular stable locking plates for fixation of the osteotomy makes the need for bone grafting 
potentially dispensable. [Lobenhoffer 2003] [Staubli 2003]. Long-term results for open 
wedge techniques, with modern implants using locking screws are not yet available. One 
randomized controlled trial [Brouwer 2006] comparing the two techniques reports at one 
year follow up, an improvement in knee function and pain in both groups but no significant 
differences. Until further studies become available, it is not possible to state which technique 
should be preferred. 
5.2.3 Total knee replacement after high tibial osteotomy 
Understandably, the outcome of Total Knee Replacement following High Tibial Osteotomy 
raises concerns amongst surgeons and patients. The two concerns generally raised, relate to 
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autologous chondrocyte implantation having improved outcomes as compared with 
microfracture. 
Despite the increasingly widespread use of autologous chondrocyte implantation, it remains 
unclear as to whether there is a significant difference between this and other cartilage repair 
techniques. A Cochrane Database Systematic Review [Vasiliadis 2010] concluded that there 
was insufficient evidence to draw conclusions on the use of autologous chondrocyte 
implantation in the knee. 
5.2 Osteotomy 
Osteotomies around the knee alter the weight-bearing axis of the lower extremity. The 
surgical goal is to unload the damaged compartment and to transfer the weight load from 
the affected areas by slightly overcorrecting into a valgus or varus alignment. The aims of 
the procedure are to reduce pain, slow the degenerative process and delay joint 
replacement. 
The concept gained acceptance in the 1960s after studies by Jackson and Waugh [Jackson 
1961].  They demonstrated that a correction in the knee deformity relieved the pain. Many 
surgeons believe that the mechanism for symptomatic improvement is entirely mechanical 
[Harris 1970]. Others believe that this biomechanical concept is spurious. Shaw and Moulton 
demonstrated in their biomechanical cadaveric study, that to unload the medial 
compartment, a valgus correction of 25 degrees would be required. [Shaw 1996]  
During the 1960s and 1970s, the use of osteotomy was the recommended surgical treatment 
for osteoarthritis of the knee. As the mid term and long-term excellent results of knee 
replacements became apparent, the use of osteotomy became less widespread. 
The advantages of osteotomy over total joint arthroplasty are the preservation of bone stock 
and intra-articular structures. The classic indication is an osteoarthritic knee with single 
compartment disease (most commonly the medial compartment) accompanied by a varus or 
valgus alignment. Patient selection is fundamental to achieving a satisfactory result. The 
knee should have a good range of movement. The patellofemoral joint should not be 
significantly involved. Ligamentous stability is ideal, but cruciate ligament instability is not 
an absolute contraindication. Combining an osteotomy with a cruciate ligament 
reconstruction is possible. Changing the slope of the proximal tibia at the time of the 
osteotomy can also improve cruciate ligament laxity. [Aqueskirchner 2002] [Paley 2000] 
Osteotomies around the knee have generally been suited to young active patients in place of 
joint replacement. An osteotomy once united allows unlimited activity. The polyethylene is 
a cause for concern in highly active patients with knee joint replacements. High loads from 
running and jumping may exceed the tolerance of polyethylene. Repetitive loading may 
loosen or damage a total knee replacement.  
In unicompartmental osteoarthritis, it is possible to correct the mechanical axis with 
different techniques. These include proximal tibia and supracondylar distal femoral 
osteotomies. Both can be performed with an additive (opening wedge) or subtractive 
(closing wedge) technique. Most commonly, the osteotomy is performed on the proximal 
tibia for varus medial compartment osteoarthritis. This can be a lateral closing wedge or a 
medial opening wedge osteotomy.  
Traditionally, a closing wedge, valgising osteotomy was performed for medial compartment 
osteoarthritis. Described by Coventry  [Coventry 1965], the osteotomy is made proximal to 
the tibial tuberosity and incorporates a fibula osteotomy also.  
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One disadvantage of a lateral closing proximal tibial osteotomy is the associated risk of 
peroneal nerve injury at the time of fibula osteotomy. This is reported to be as high as 11%. 
[Staubli 2003] Other concerns are the propensity for loss of bone stock, patella baja and 
leaving the joint line in an oblique position, making subsequent joint replacement more 
challenging.  
For these reasons, the medial opening wedge osteotomy has gained in popularity.  
5.2.1 Outcome following high tibial osteotomy 
There are numerous studies available on the outcome following high tibial osteotomy. 
Differing techniques and evaluation methods make pooling and comparison of this data 
challenging. A Cochrane review [Brouwer 2007] concluded that there is “silver” level 
evidence that a valgising high tibial osteotomy improves knee function and reduced pain, 
but there is no evidence whether an osteotomy is more effective than conservative 
treatment. 
Coventry describes good results in several studies. [Coventry 1979] [Coventry 1982] 
[Coventry 1993] Coventry also states that high tibial osteotomy not only improves the knee 
function, but also allows healing of the articular cartilage. [Coventry 1984] 
Multiple studies have demonstrated that the early good results of high tibial osteotomy 
gradually deteriorate with time. A meta-analysis [Virolainen 2004] demonstrated good or 
excellent results in 75% of patients after 60 months and 60% of patients after 100 months. 
Unchanged and mild pain were defined as unsatisfactory results. 
It is generally accepted that age is an important factor in predicting outcome. Patients 
greater than 50 years old are less likely to have a satisfactory result. [Naudie 1999] [Flecher 
2006] 
The degree of correction has repeatedly been shown to correlate with survivorship. 
Overcorrecting the femorotibial angle to more than 15 degrees has been shown to give a 
better clinical outcome, but the cosmetic appearance is generally not acceptable to patients. 
[Rudan 1990]  Under correction is associated with a poorer outcome. [Naudie 1999] 
[Ivarsson 1990] [Matthews 1988] [Sprenger 2003]. Consequently, most surgeons aim for a 
correction of between 5 and 12 degrees. 
5.2.2 Closing versus opening wedge high tibial osteotomy 
For many years, the closing wedge osteotomy was considered the gold standard. Over 
recent years the medial open wedge osteotomy technique has been developed. This 
procedure is considered technically less demanding and more precise. The use of modern 
angular stable locking plates for fixation of the osteotomy makes the need for bone grafting 
potentially dispensable. [Lobenhoffer 2003] [Staubli 2003]. Long-term results for open 
wedge techniques, with modern implants using locking screws are not yet available. One 
randomized controlled trial [Brouwer 2006] comparing the two techniques reports at one 
year follow up, an improvement in knee function and pain in both groups but no significant 
differences. Until further studies become available, it is not possible to state which technique 
should be preferred. 
5.2.3 Total knee replacement after high tibial osteotomy 
Understandably, the outcome of Total Knee Replacement following High Tibial Osteotomy 
raises concerns amongst surgeons and patients. The two concerns generally raised, relate to 
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the technical difficulty of total knee replacement following high tibial osteotomy and the 
whether there is a negative effect on functional outcome of total knee replacement if there 
has been a previous high tibial osteotomy.  
It is generally accepted that Total Knee Replacement can be more challenging following 
lateral closing wedge High Tibial Osteotomy. [Mont 1994] [Karabatsos 2002] The difficulties 
relate to loss of bone stock, surgical exposure, obliquity of the joint line, soft tissue balancing 
and patella baja. 
Amendola [Amendola 2010] reviewed all published data relating to this and concluded that 
there is no statistically significant difference between patients treated with a primary total 
knee replacement or with a total knee replacement following a high tibial osteotomy. A 
systematic review by Van Raaij [VanRaaij 2009] also concluded that previous osteotomy 
does not compromise subsequent total knee replacement. 
There have been no studies reporting Total Knee Replacement results following opening 
wedge high tibial osteotomy. 
5.2.4 Unicompartmental knee arthroplasty versus high tibial osteotomy 
Although there is a large difference in the philosophy between these two procedures, the 
indications can overlap. Consequently, a number of comparative studies have been 
performed. Most of these studies compare Unicompartmental Knee Arthroplasty to lateral 
closing wedge high tibial osteotomy.  
A retrospective review of 49 lateral closing wedge high tibial osteotomies and 42 
unicompartmental knee arthroplasties reported 76% good results with Unicompartmental 
Knee arthroplasty and 43% with high tibial osteotomy at 5-10 years. [Broughton 1986] 
 
 
Fig. 5. Closing and opening wedge osteotomies of the proximal tibia 
A prospective randomised comparison between 32 high tibial osteotomies and 28 
unicompartmental knee arthroplasties reported improved long term success with 
unicompartmental knee arthroplasty with 77% 10 year survival compared with 60% in the 
osteotomy group. [StukenborgColsman 2001] 
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A comparison of 54 consecutive opening wedge high tibial osteotomies and 56 
unicompartmental knee arthroplasties found no difference in the midterm clinical or 
radiological results. [Dettoni 2010] 
The latest Cochrane review [Brouwer 2007] states that there is no significant difference in 
pain, function and gait analysis between HTO and UKA.  
5.3 Arthroplasty 
Arthroplasty or joint replacement is a well-accepted and effective treatment modality for 
advanced knee osteoarthritis. The number of knee arthroplasties performed has increased 
exponentially over the last few decades.  
5.3.1 History of knee arthroplasty 
Themistocles Gluck implanted a primitive hinge joint made of ivory in 1860. The next 
significant step was the acrylic Walldius hinge joint in 1951, followed by a cobalt and 
chrome implant in 1958. [Walldius 1953] 
Gunston in the 1960s designed an unhinged knee that that incorporated separate medial and 
lateral condylar components. [Gunston 1971] Gunston recognized that the knee does not 
rotate on a single axis and has more complex kinematics than a simple hinge. By preserving 
the cruciate ligaments, the polycentric knee design allowed the femoral condyles to roll and 
glide on the tibia with multiple instant centres of rotation. The failure mechanism related to 
inadequate fixation of prosthesis to bone. 
The so-called “kinematic conflict” arose as further designs became available. Some designers 
opting to follow Gunston’s principle of attempting to recreate normal knee kinematics. 
Others opting for a conforming articulation and constraint. A highly conforming design acts 
like a simple hinge, which increases the torsional stress across the joint leading to loosening 
of the prosthesis. 
Insall designed and introduced the Total Condylar Prosthesis at the Hospital for Special 
Surgery in 1973. This initial design did not attempt to recreate normal knee kinematics. 
Subsequently, the design was altered to improve knee range of movement. Improvements in 
component geometry, instrumentation, bearing materials and fixation techniques continue 
to be made.  
5.3.2 Indications and assessment for knee arthroplasty  
The functional impact of the knee osteoarthritis is the key factor in determining the timing 
of knee replacement surgery. Severity of symptoms are classically assessed by how 
disabling the pain is, noting a decreased walking distance, increased analgesic use and 
disturbance of sleep. 
Examination should assess gait, limb alignment, range of movement and the neurovascular 
status of the limb. Other sources of knee pain such as the hip and lumbar spine should 
routinely be assessed to exclude dual pathology.  
Up to date radiographs should be available including weight bearing anteroposterior views 
as well as a true lateral and skyline view. Radiographs of the ipsilateral hip are necessary if 
clinical examination raises the suspicion of hip pathology.  
5.3.3 Total knee arthroplasty – Current designs 
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the technical difficulty of total knee replacement following high tibial osteotomy and the 
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Fig. 5. Closing and opening wedge osteotomies of the proximal tibia 
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osteotomy group. [StukenborgColsman 2001] 
 
Surgery for Osteoarthritis of the Knee 
 
301 
A comparison of 54 consecutive opening wedge high tibial osteotomies and 56 
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5.3.2 Indications and assessment for knee arthroplasty  
The functional impact of the knee osteoarthritis is the key factor in determining the timing 
of knee replacement surgery. Severity of symptoms are classically assessed by how 
disabling the pain is, noting a decreased walking distance, increased analgesic use and 
disturbance of sleep. 
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Up to date radiographs should be available including weight bearing anteroposterior views 
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replacements. There are two design types in this category: the posterior cruciate retaining 
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and the posterior cruciate substituting (or posterior stabilized) implants. Both types include 
a metal femoral component, a metal tibial component with a polyethylene insert (or an all 
polyethylene tibial component) and if used a polyethylene patella component. The implants 
can be cemented or uncemented. 
The posterior cruciate retaining design is controversially thought to replicate knee 
kinematics more closely because the native posterior cruciate ligament causes femoral 
rollback. They have low conformity with a round femoral surface and a relatively flat tibial 
polyethylene surface. 
The posterior cruciate substituting designs have increased conformity. They employ a tibial 
polyethylene post in the middle of the knee together with a cam situated between the 
femoral condyles. During flexion the femoral cam engages against the tibial post. With 
further flexion controlled mechanical rollback is achieved. 
 
 
Fig. 6. Cruciate substituting Total Knee Replacement prosthesis 
5.3.4 Total knee arthroplasty – Surgical goals 
A pain free, mobile, stable joint replacement with a long life span is the overall aim of knee 
replacement surgery. The achievement of several biomechanical goals can contribute 
towards this overall aim. Implant design and surgical technique are crucial in how these 
goals are achieved. 
5.3.4.1 Restoration of mechanical axis 
The proximal tibia and distal femur are cut in such a way that at the end of the operation the 
mechanical axis of the limb should pass from the centre of the hip through the centre of the 
knee to the centre of the ankle. This allows the equal passage of forces through the joint 
replacement optimizing its longevity. [Fang 2009] 
5.3.4.2 Preserve the level of the joint line 
The femur and tibia are cut at a depth that is equal to the thickness of the prosthesis that is 
inserted. Optimal function of ligaments, muscles and tendons can be expected if the joint 
line level is preserved.  
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5.3.4.3 Soft tissue balancing in the coronal plane 
An osteoarthritic knee with a varus or valgus deformity has soft tissues that are contracted 
on one side of the joint and stretched on the other side. If the deformity is not corrected by 
the bony cuts, a soft tissue release is performed on the concave side of the deformity. If the 
knee is well balanced at the end of the procedure, load transmission should be 
approximately equal through both sides of the joint. 
5.3.4.4 Balancing the flexion and extension gaps in the sagittal plane 
At the end of the procedure, the gap between the tibia and femur should be the same in 
extension and in flexion. A gap that is too tight in extension or flexion will prevent full 
extension or flexion respectively. A gap too loose in extension will allow hyperextension of 
the knee; too loose in flexion will allow instability in flexion.  
5.3.4.5 Maintenance of Q angle 
The most common complication in Total Knee replacement involves the patellofemoral 
articulation. 
The Q angle is the angle formed by a line drawn from the Anterior Superior Iliac Spine to 
the central patella and a second line drawn from the central patella to the tibial tubercle. An 
increased Q angle is a risk factor for patellar subluxation. 
Positioning of the femoral, tibial and patella component (if used) all can influence the 
stability of the patellofemoral articulation.  
5.3.5 Total knee arthroplasty – Results 
Total knee arthroplasty is an effective treatment for advanced knee osteoarthritis, resulting 
in substantial improvement in patient function and health related quality of life. [Buly 1995]  
The success of the procedure can be judged by patient satisfaction and by the lifespan of the 
implant before a revision procedure is required. (Survivorship) 
Patient satisfaction can be assessed by questionnaires. A study using data from the British 
National Joint Registry demonstrated 81.8% of 8095 patients were satisfied, 11.2% (906 of 
8095) were unsure and 7% (566 of 8095) were not satisfied with their new knee. [Baker 2007] 
The total condylar knee design continues to be successful. At 15 years follow up, 
survivorship can be expected to be as high as 95%. [Ranawat 1993] [Ritter 2001]. 
5.3.6 Total knee arthroplasty – Controversial topics and recent developments   
5.3.6.1 Cemented versus uncemented fixation 
Cemented fixation of total knee replacement is a standard procedure with good long-term 
durability. Despite the predominance of cemented fixation, there is increasing interest in 
using cementless fixation. The principal advantage to using uncemented implants is the 
shorter operating times.  
A meta-analysis compared the two techniques by outcome. [Gandhi 2009] For implant 
survival without aseptic loosening, cemented prostheses lasted longer. Both designs shared 
similar complications and produced similar results.  
The advantages of cemented fixation are that it is less costly and gives immediate stable 
fixation, preventing early migration. [Nilsson 1999] Cemented fixation has the added 
advantage of filling in small voids, whereas uncemented fixation requires perfect bony cuts 
to allow a perfect fit between prosthesis and bone. 
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stability of the patellofemoral articulation.  
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in substantial improvement in patient function and health related quality of life. [Buly 1995]  
The success of the procedure can be judged by patient satisfaction and by the lifespan of the 
implant before a revision procedure is required. (Survivorship) 
Patient satisfaction can be assessed by questionnaires. A study using data from the British 
National Joint Registry demonstrated 81.8% of 8095 patients were satisfied, 11.2% (906 of 
8095) were unsure and 7% (566 of 8095) were not satisfied with their new knee. [Baker 2007] 
The total condylar knee design continues to be successful. At 15 years follow up, 
survivorship can be expected to be as high as 95%. [Ranawat 1993] [Ritter 2001]. 
5.3.6 Total knee arthroplasty – Controversial topics and recent developments   
5.3.6.1 Cemented versus uncemented fixation 
Cemented fixation of total knee replacement is a standard procedure with good long-term 
durability. Despite the predominance of cemented fixation, there is increasing interest in 
using cementless fixation. The principal advantage to using uncemented implants is the 
shorter operating times.  
A meta-analysis compared the two techniques by outcome. [Gandhi 2009] For implant 
survival without aseptic loosening, cemented prostheses lasted longer. Both designs shared 
similar complications and produced similar results.  
The advantages of cemented fixation are that it is less costly and gives immediate stable 
fixation, preventing early migration. [Nilsson 1999] Cemented fixation has the added 
advantage of filling in small voids, whereas uncemented fixation requires perfect bony cuts 
to allow a perfect fit between prosthesis and bone. 
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5.3.6.2 Cruciate retaining versus cruciate sacrificing design 
Good long-term results are reported in both posterior cruciate retaining (CR) and posterior 
cruciate substituting (PS) Total Knee Replacement designs. [Ritter 2007] [Bourne 2007] 
The role of the posterior cruciate ligament (PCL) in total knee replacement remains 
controversial. Those in favour of retaining the PCL propose maintenance of normal knee 
kinematics, particularly with reference to femoral rollback. Others believe that the PCL’s 
proprioceptive properties should encourage its retention. [Scott 1986] [Conditt 2004] 
[Insall 1988] [Swanik 2004] Those in favour of sacrificing the PCL argue that the ligament 
is degenerative in arthritic knees and that removing it makes soft tissue balancing more 
straight forward. If the PCL is excised, most surgeons will use a posterior cruciate 
substituting design, although this is not essential as long as a reasonably conforming 
insert is used. [Straw 2003] Proponents of the PS design argue that the central 
polyethylene post engages on the femoral cam during flexion providing mechanical 
femoral rollback. [Dennis 1996]The central post may also provide some additional 
stability in the anteroposterior plane and act as a secondary stabiliser to varus or valgus 
stress. [Matsuda 1996] 
Multiple comparative studies have shown no demonstrable difference in knee scores, 
patient satisfaction or radiographic parameters. [Dorr 1988] [Clark 2001] [Tanzer 2002] A 
systematic literature review within the Cochrane framework [Jacobs 2005] identified an 
increased average range of motion in the posterior stabilised group (113 degrees) compared 
with the PCL retention group (105 degrees). No other differences were found. The review 
does not conclude superiority of one technique over the other. 
5.3.6.3 Patella resurfacing versus non-resurfacing  
Management of the patella in Total Knee Replacement for osteoarthritis remains 
controversial. Currently, there are three options available: Routine resurfacing, non-
resurfacing and selective resurfacing. Proponents of patellar resurfacing propose that this 
procedure will decrease the incidence of anterior knee pain postoperatively and lower the 
risk of reoperation following Total Knee Replacement.  
Some surgeons avoid routine resurfacing on the basis of a variety of complications that have 
been attributed to the procedure. These include instability of the patellofemoral joint, 
avascular necrosis, patellar fracture, patella tendon injury, aseptic loosening and 
polyethylene wear of the patella component. These complications although relatively 
uncommon have been associated with difficult revision procedures. [Barrack 1998] [Rand 
2005] 
Some surgeons opt to selectively resurface the patella, but it has been shown that the 
appearance of the articular cartilage is an unreliable predictor for a successful outcome. 
[Waters 2003] 
There have been a substantial number of comparative studies on this subject. Indeed, several 
meta-analyses have collated this evidence, demonstrating a lower risk of reoperation for 
resurfaced implants, but not demonstrating firm evidence of superiority of one technique 
over the other. [Nizard 2005] [Forster 2004] [Pakos 2005] [Parvizi 2005] A critical appraisal of 
the available evidence suggests that patellar resurfacing reduces the risk of anterior knee 
pain and patella related reoperation, but found methodological limitations in all the studies 
examined. It concludes that no single option for patella treatment in total knee replacement 
is clearly superior. [Calvisi 2009] 
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5.3.6.4 Computer assisted surgery  
Over recent years, there has been considerable development in computer-assisted 
navigation systems for total knee replacement.   
Current navigation systems are comprised of several components. An optical tracking 
system measures the position and orientation of optical reference frames that are attached to 
the femur and tibia, typically with bicortical threaded pins. The camera also tracks a stylus 
that the surgeon uses to digitize bony landmarks and an instrumented plate that records the 
position and orientation of the cutting blocks and bone surfaces. The navigation system is 
controlled by a computer and accompanying software. Anatomical reference frames are 
created that relate the position mad orientation of the optical reference frames to the 
underlying bony anatomy.  
Although navigation in total knee replacement has increased in popularity over recent 
years, it remains controversial as to whether it is superior to traditional mechanical 
instrumentation techniques.  
Most would accept that demonstrating improvements in results for a successful procedure 
such as total knee replacement is not easy.  
The main arguments against the routine use of computer-assisted navigation relate to cost 
and time. The cost is variable, but has been shown to be in the region of an additional 200 to 
1400 Euros per case, compared with the manual technique [Cerha 2009]. Cost effectiveness is 
difficult to judge until long-term outcome studies are available. It has been estimated that an 
annual reduction in revision rates of 2 % would be required over 20 years in a centre 
performing 250 navigated total knee replacements per year, in order to be cost effective 
[Slover 2008]. Additional operating time is required. This has been demonstrated as being 
between 8 to 14 minutes per case. [Bäthis 2004] [Jenny 2005] [Haaker 2005] 
A fundamental premise of computer-assisted navigation relates to one of the surgical goals 
of total knee replacement surgery. It has been proposed that more accurately restoring the 
mechanical axis of the limb will promote greater implant durability. Previous studies have 
suggested that restoring overall limb alignment to a mechanical axis of less than 3° 
varus/valgus will improve the longevity of the implant [Jeffery 1991] [Ritter 1994]. 
Consequently, several studies have focused on this and demonstrated that the use of 
computer navigation can lead to a significant reduction in the number of outliers outside of 
this range. [Jenny 2005] [Bäthis 2004] A systematic review incorporating twenty nine studies 
comparing alignment outcomes in computer assisted knee replacements with conventional 
techniques demonstrated a 3° varus/valgus malalignment occurred in 9% of computer 
assisted cases and 32% in conventional knee replacements.  
More recently, this concept this has been contested with evidence to suggest that fifteen year 
survival of knee replacements is unaffected by variations in the postoperative limb 
mechanical axis. [Parratte 2010] 
Some surgeons favour physiological reasons rather than alignment reasons in their 
reasoning to navigate a total knee replacement. Computer navigation techniques can avoid 
the need to instrument the femoral or tibial canals as with intramedullary jigs. Studies have 
demonstrated decreases in blood loss, systemic emboli and generalized systemic 
inflammatory response with the use of navigation techniques. [Kalairajah 2005] [Kalairajah 
2006] [Church 2007] [Shen 2009]. 
Definitive conclusions regarding differences in clinical outcome between navigated and 
conventional techniques can only be made with long-term results of well-conducted 
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randomised controlled trials. These are not yet available, but there is some evidence 
suggesting that rehabilitation is quicker and short-term function within the first 
postoperative year is improved with a greater accuracy in implant alignment. [Choong 2009] 
[Longstaff 2009] 
5.3.6.5 Mobile versus fixed bearing inserts 
Surgeons make a choice between monoblock all polyethylene tibial components and 
metallic tibial components with a modular polyethylene insert. The insert as described 
earlier can either be posterior stabilizing (with a post, to articulate with a cam on the femoral 
component) or cruciate retaining (no post). Either way, the insert can be of fixed bearing or 
mobile bearing design. 
Mobile-bearing inserts can be further subdivided into rotating platform types or meniscal 
bearing types. A rotating platform rotates by utilizing a peg on its undersurface that fits into 
a socket on the base plate. In contrast to this, meniscal bearing inserts also allow anterior –
posterior translation of the insert over the base plate. 
Theoretically, mobile bearing designs have greater total congruency of the femur/tibial 
articulation. This leads to less contact stress and potentially less polyethylene wear. Knee 
simulation studies have demonstrated less wear with rotating platform designs. [Mcewen 
2001] The other proposed advantage is that the freedom of movement at the 
polyethylene/tibial tray interface should decrease the stresses at the tibial tray/bone 
interface. 
There have been a large number of publications attempting to determine whether the 
theoretical advantages of a mobile bearing insert are transformed into clinical advantages. 
These studies consistently fail to demonstrate any significant advantage for either design. 
[Evans 2006] [Biau 2006] [Kim 2007] [Kim 2007a] 
5.3.6.6 Patient specific cutting blocks   
This new technique relies on patient specific cutting blocks. These are engineered by using a 
computer template of the patient’s own anatomy. Preoperative imaging with a Magnetic 
Resonance Imaging scan and mechanical axis radiographs are used. These individualized 
cutting blocks allow precise bone resections to be made, allowing implantation of standard 
knee replacement implants. Advantages are a shortened operation time and a smaller 
surgical inventory requirement (sizes of implants determined preoperatively). 
Disadvantages are the additional costs for the preoperative imaging and the production of 
the custom made cutting blocks. Long-term results using this technique are awaited.   
5.3.7 Unicompartmental Knee Arthroplasty (UKA) 
UKA is the partial surface replacement of the knee joint. Osteoarthritic changes can be 
predominantly confined to one of the three compartments of the knee. In this scenario, a 
UKA can be performed in the medial tibiofemoral joint, the lateral tibiofemoral joint or the 
patellofemoral joint. By far the most common site for osteoarthritis in the knee is the medial 
tibiofemoral joint. The biggest experience to date with UKA has been with the medial 
tibiofemoral joint. Here, a metallic femoral component and a metallic tibial component 
replace the medial side of the knee joint. The components can be cemented or uncemented. 
In between the two metal components, a polyethylene insert is positioned. This can be a 
mobile bearing or a fixed bearing design. In the mobile bearing design, the polyethylene 
insert has a flat undersurface to allow it to slide over the flat tibial component. The top 
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surface is concave allowing a congruent articulation with the spherical femoral component 
above. The proposed benefits of this articulation are larger contact areas; resulting in lower 
contact pressures and decreased polyethylene wear rates. The disadvantages of the mobile 
bearing design are that it is technically more challenging to implant and the potential risk 
for bearing dislocation. The fixed bearing design has a polyethylene insert which locks into 
the tibial tray.  A meta-analysis pooling data from five studies concluded that there was no 
significant difference in outcome or complication rates between mobile and fixed bearing 
UKAs. [Smith 2009] 
The ideal indications for UKA include unicompartmental osteoarthritis; age over 60 years; 
low demand patient; no obesity; range of motion arc over 90 degrees with less than 5 
degrees fixed flexion contracture; less than 10 degrees of axial malalignment in the coronal 
plane which is passively correctable. [Borus 2008] 
One perceived advantage of UKA over Total Knee Replacement is a less extensive surgical 
dissection. Generally, there is no need for eversion of the patella and the soft tissue 
disruption is less. Preservation of bone stock, decreased blood loss and an end result with 
more normal knee kinematics are also quoted as advantages. [Robinson 2003] 
Unicompartmental knee arthroplasty (UKA), total knee arthroplasty (TKA) and high tibial 
osteotomy (HTO) may all be used to treat unicompartmental osteoarthritis, but they are 
often used for different patient groups. However, there is considerable overlap in 
indications for all three options.  
A systematic review [Griffin 2007] focused on the safety and efficacy of UKA compared with 
TKA and HTO in unicompartmental osteoarthritis. Studies that compared UKA with either 
TKA or HTO were identified and included for review. They conclude that UKA is 
considered at least as safe as TKA and HTO. For function, UKA appears to be at least as 
efficacious as TKA and HTO. The survival of UKA compared with TKA and HTO could not 
be determined based on the available evidence. 
The first published series of UKA documented a 70% 10-year survival rate. [Marmor 1988] 
[Marmor 1988a]  
Improvements in implant design; materials and instrumentation combined with clearer 
patient selection criteria may have been partially responsible for some of the better-reported 
results. Up to 98% survivorship has been reported at 10 years in both fixed and mobile 
bearing designs. [Berger 1999] [Murray 1998] 
On the other hand a prospective study of 1819 patients from the Finnish Arthroplasty 
Register demonstrated an overall 10-year survival of 73% between four different implants. 
This supports the view of many, that the long-term survival of UKAs remains significantly 
poorer than that of TKA. [Koskinen 2007] 
Isolated lateral compartment osteoarthritis of the knee is less common. Consequently, 
outcome studies reporting results of lateral UKA are less abundant. Results appear to be less 
predictable with a higher complication rate than the medial UKA. [Gunther 1996] 
Isolated patellofemoral osteoarthritis occurs in approximately 10% of patients with knee 
osteoarthritis. There is often a previous diagnosis of trauma, patellar maltracking or 
trochlear dysplasia. Arthroplasty options include TKA with patellar resurfacing, TKA 
without patella resurfacing [Thompson 2001] and isolated patellofemoral replacement. 
The number of isolated patellofemoral replacements is increasing. The commonest 
complication identified is radiological progression of arthritis. [Ackroyd 2007] 
[Odumenya 2010] 
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randomised controlled trials. These are not yet available, but there is some evidence 
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[Longstaff 2009] 
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surgical inventory requirement (sizes of implants determined preoperatively). 
Disadvantages are the additional costs for the preoperative imaging and the production of 
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bearing design are that it is technically more challenging to implant and the potential risk 
for bearing dislocation. The fixed bearing design has a polyethylene insert which locks into 
the tibial tray.  A meta-analysis pooling data from five studies concluded that there was no 
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plane which is passively correctable. [Borus 2008] 
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dissection. Generally, there is no need for eversion of the patella and the soft tissue 
disruption is less. Preservation of bone stock, decreased blood loss and an end result with 
more normal knee kinematics are also quoted as advantages. [Robinson 2003] 
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osteotomy (HTO) may all be used to treat unicompartmental osteoarthritis, but they are 
often used for different patient groups. However, there is considerable overlap in 
indications for all three options.  
A systematic review [Griffin 2007] focused on the safety and efficacy of UKA compared with 
TKA and HTO in unicompartmental osteoarthritis. Studies that compared UKA with either 
TKA or HTO were identified and included for review. They conclude that UKA is 
considered at least as safe as TKA and HTO. For function, UKA appears to be at least as 
efficacious as TKA and HTO. The survival of UKA compared with TKA and HTO could not 
be determined based on the available evidence. 
The first published series of UKA documented a 70% 10-year survival rate. [Marmor 1988] 
[Marmor 1988a]  
Improvements in implant design; materials and instrumentation combined with clearer 
patient selection criteria may have been partially responsible for some of the better-reported 
results. Up to 98% survivorship has been reported at 10 years in both fixed and mobile 
bearing designs. [Berger 1999] [Murray 1998] 
On the other hand a prospective study of 1819 patients from the Finnish Arthroplasty 
Register demonstrated an overall 10-year survival of 73% between four different implants. 
This supports the view of many, that the long-term survival of UKAs remains significantly 
poorer than that of TKA. [Koskinen 2007] 
Isolated lateral compartment osteoarthritis of the knee is less common. Consequently, 
outcome studies reporting results of lateral UKA are less abundant. Results appear to be less 
predictable with a higher complication rate than the medial UKA. [Gunther 1996] 
Isolated patellofemoral osteoarthritis occurs in approximately 10% of patients with knee 
osteoarthritis. There is often a previous diagnosis of trauma, patellar maltracking or 
trochlear dysplasia. Arthroplasty options include TKA with patellar resurfacing, TKA 
without patella resurfacing [Thompson 2001] and isolated patellofemoral replacement. 
The number of isolated patellofemoral replacements is increasing. The commonest 
complication identified is radiological progression of arthritis. [Ackroyd 2007] 
[Odumenya 2010] 
  




Fig. 7. Unicompartmental Knee Arthroplasty (UKA) and Total Knee Replacement (TKR) 
6. Conclusion 
Osteoarthritis of the knee is a common condition. The chances of developing symptoms 
increase with age. Initially treatment is with non-operative measures. Surgical options are 
considered when conservative measures have failed. We have discussed the options of 
arthroscopy, bone marrow stimulating techniques, chondrocyte transplantation, osteotomy 
and arthroplasty. Determining which of these procedures is most appropriate depends on a 
number of different variables. Age, comorbidities, patient activity levels and expectations, 
severity of symptoms and surgeon expertise and preference all contribute to the decision 
process.  
Arthroscopic lavage and debridement is a procedure that is often carried out, but it does not 
alter the disease progression. Single compartment disease may be amenable to offloading 
osteotomy or unicompartmental knee arthroplasty. Total knee arthroplasty is a reliable 
treatment option for end stage osteoarthritis of the knee. 
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1. Introduction 
High tibial osteotomy was first described by Langenbeck in 1854 (Langenbeck 1854). It is an 
efficient method to treat unicondylar osteoarthrosis. High tibial osteotomy allows one to 
interrupt the circular reasoning of unicondylar osteoarthrosis (Fig. 1) (Jakob & Jacobi, 2004).  
 
 
Fig. 1. The circular reasoning of unicondylar arthrosis (from Jakob & Jacobi, 2004). 
Following high tibial osteotomy, osteosclerosis in the medial compartment of the arthritic knee 
is significantly reduced, and the degenerated portions of the articular surface are completely 
covered by a fibrocartilagenous layer (Akamatsu et al., 1997; Fujisawa et al., 1979; Koshino, & 
Tsuchiya, 1979; Koshino, 2010; Odenbring et al. 1992; Takahashi et al. 2002-2003).  
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An open-wedge high tibial osteotomy proximal to the tibial tuberosity was first described 
by Debeyre and Patte in 1951 (Debeyre & Patte, 1962). A disadvantage of this method is the 
need for bone grafts and the resulting risk of donor-site morbidity (Becker et al., 2011). Thus, 
because of its inherent stability, closed-wedge osteotomy has become the treatment of choice 
for unicompartmental osteoarthritis (Coventry, 1965). 
Unicompartmental (or total knee) arthroplasty has been the treatment of choice because 
osteotomy is considered a demanding procedure with an unpredictable outcome and is 
associated with significant complications. The biological internal fixation of fractures using 
the indirect reduction technique could improve the outcome in treating fractures (Mast et 
al., 1989). The “minimally invasive plate osteosynthesis (MIPO) technique” further improves 
the results of plate osteosynthesis . Locked-plate fixators significantly improve the stability 
of plate osteosynthesis. The combination of locked-plate fixators and the MIPO technique 
makes it possible to perform plateosteosynthesis without the need for bone grafts. Menisceal 
and chondral lesions both as ligament instabilities have an increased risk for osteoarthritis  
(Hofmann et al., 2009). In young patients with a varus malalignment, the treatment of 
menisceal or chondral lesions both as ligament instabilites can be combined with a high 
tibial osteotomy (Noyes et al., 1993; Imhoff et al., 2004). The combination of varus 
malalignment with chronic posterolateral instability was defined as triple varus by Noyes 
and Simon (Noyes & Simon, 1994).  
The keys to a successful osteotomy are basic biomechanics, careful patient selection, and 
precise planning combined with a skilful surgical technique and stable osteosynthesis for 
early mobilisation (Hanssen, 2001; Hofmann et al., 2009). Remarkably, the patient selection 
process and the specific indications for osteotomy are more standardised than the various 
preoperative planning methods and operative techniques currently being used (Hanssen, 
2001). Given the positive long-term outcome of osteotomy when strict selection criteria are 
implemented and the compliance with a rigorous technique, it appears that these 
procedures have their place in the treatment of the early stages of gonarthrosis that arise 
from axial deviation (Poilvache, 2001). Careful planning of the axis of correction and the 
osteotomy, the degree of correction and the implant allow one to avoid complications such 
as nerve injury, instability and pseudoarthrosis (Lichte et al. 2010).   
Periarticular corrective osteotomies have grown in importance since the advent of locking 
compression plates (Köck et al., 2011) 
New planning methods as well as new techniques for open-wedge high tibial osteotomies and 
custom-designed internal fixators have improved upon the early results and have led to a 
trend towards high tibial open-wedge osteotomy. Medial open-wedge high tibial osteotomy 
secured by a TomoFix plate (Synthes, West Chester, Pennsylvania) provides stability that is 
equal to the lateral closing-wedge technique (Luites et al., 2009). The TomoFix plate is an 
anatomically pre-contoured locked plate for the medial aspect of the tibia and is inserted into a 
subcutaneous tunnel with minimal bone exposure (Kolb et al., 2009). 
The aim of this report is to (1) describe new planning  methods and (2) describe new 
techniques for open-wedge high tibial osteotomy.  
2. Indication  
The typical indication for deformity correction is a combination of morphological, 
functional and radiographic results in terms of both the personal situation of the patient 
(e.g., expectation, compliance, general factors such as smoking, peripheral vascular 
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status, nutritional status, comorbidities such as diabetes, occupational situation and 
sports activities) and the length of rehabilitation (Hofmann et al., 2009; Tunggal et al., 
2010). The primary indications are active patients who are between 40 and 60 years of 
age with varus malalignment of the limb with no radiographic evidence of subluxation, 
no patellofemoral symptoms, isolated medial activity-related joint line pain, full 
extension, and a knee arc of motion that is >100°. In reality, however, there are many 
other patients who would benefit from osteotomy but fall short of these idealised criteria 
(Hanssen & Chao, 1994) (Table 1).  
 
Absolute Indications Relative Indications Absolute Contraindications 
Patients 40-60 years of age Patients >60 or <40 yearsof age Open growth plates 
Varus malalignment of the 
limb <15° 











related joint line pain  Lateral joint line pain 
Full extension Flexion contracture >15° Flexion contracture >25° 
Range of motion >100° Range of motion >90° Range of motion <75°  
Medial soft tissue coverage Previous infection Inflammatory disease 
Stable knee ACL, PCL or PLC insufficiency Mediolateral insufficiency 
No patellofemoral arthrosis Patellofemoral arthrosis grade II – III*
Patellofemoral arthrosis 
grade IV-V*
Non-smoker Smoker (<15 cigarettes/day) Smoker (>15 cigarettes/day) 
BMI<30 BMI 30-40 BMI >40
High-demand activity but 
no running or jumping
Wish to continue all 
sports Severe osteoporosis 
Metaphyseal tibial varus 
(TBVA+ >5°) 
Metaphyseal femoral 
varus and tibial valgus Extraarticular deformity 
Normal lateral component, 
arthrosis grade I-III* 
medial component
Arthrosis grade IV* 
medial 
Lateral gonarthrosis, 
Arthrosis grade V* medial 
No meniscectomy Partial medial meniscectomy Lateral meniscectomy 
No cupula Osteochondritis dissecans Bad peripheral vascular status (no foot pulse) 
 Condylar osteonecrosis Bone healing disorders 
*Ahlbäck Grading System for Degenerative Arthritis 
+ tibial bone varus angle  
Table 1. Ideal and possible patients for high tibial osteotomy and patients not suited for the 
procedure, modified from the International Society of Arthroscopy, Knee Surgery and 
Orthopaedic Sports Medicine (Brinkman et al., 2008; Frey et al., 2008; Hofmann et al., 2009; 
Kolb et al., 2009; Rand & Neyret, 2005; Song et al., 2010)  
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3. Preoperative evaluation 
A preoperative clinical evaluation of the knee and adjacent joints is mandatory. The gait 
pattern of the patient, including additional varus, must be assessed (Müller, 2001). Limited 
mobility of the hip-, especially its rotation, -may influence both the gait pattern and dynamic 
load (Müller, 2001). A varus knee with internal rotation requires more valgus correction than 
in cases in which the foot is in its normal position (Müller, 2001). A preoperative gait analysis 
should become part of the routine preoperative patient assessment (Lind et al., 2011). High 
tibial osteotomy can reduce significantly the external adduction moment (Bhatnagar & Jenkyn, 
2010). According to the magnitude of the knee-adduction moment, (Prodomos et al., 1985) 
classified patients into low and high adduction moment groups, and patients with a low 
preoperative adduction moment had substantially better clinical results than did patients with 
high adduction moments. The dynamic situation may therefore be an important consideration 
in helping to explain certain failures or recurrences despite a good initial correction, as the 
static alignment of the knee cannot account for dynamic loading  (Tunggal et al., 2010).  
Radiographic assessment includes standard knee radiographs, full-length A-P view 
standing radiographs with the patella facing directly anterior with the patient standing on 
both legs, a lateral view, a flexed weightbearing tunnel view (Rosenberg’s view) and skyline 
views of the patella with both knees in 30° flexion (Merchant’s view, Table 2). Patients with 
a positive varus stress test, increased varus during thrust, increased tibial external rotation 
at 30° of flexion, or varus recurvatum during standing or walking should receive stress 
radiographs (Dugdale et al., 1992). If the radiographs are positive, the patient should receive 
supine full-length A-P radiographs of both legs to evaluate their true alignment (Noyes et 
al., 2000). The routine use of magnetic resonance imaging (MRI) to evaluate and manage 
meniscal tears, cartilage lesions or ligament injuries in patients with osteoarthritis of the 
knee is recommended (Bhattacharyya et al., 2003; Jakob & Jacob, 2004; Englund et al., 2008). 
Bone marrow oedema in MRI is a potent risk factor for structural deterioration in knee 
osteoarthritis, and its relation to progression is explained in part by its association with limb 
alignment (Felson et al., 2003). Preoperative planning of the osteotomy using the MRI data is 
not recommended, as full-length views of the leg are not possible. 
 
Standard radiograph Purpose
Full-length double stance A-P-radiograph (Moreland et 
al., 1987) To evaluate the femorotibial alignment  
Full-length double supine A-P-radiograph (Moreland et 
al., 1987) 
To eliminate the added varus due to deficiency of the 
lateral and PL structures 
Real lateral view radiograph (Dejour & Bonnin, 1994) To evaluate the posterior tibial slope
Merchant’s view radiograph (Merchant et al., 1974) To evaluate the patellofemoral joint
Rosenberg’s view (Rosenberg et al., 1988) To evaluate the lateral compartment of the knee 
Stress radiograph Purpose
Lateral stress view according to the Telos method 
(Jacobsen, 1976; Strobel et al., 2002)
To evaluate the anterior and posterior tibial translation 
with respect to the femur
Lateral stress view according to the kneeling method
(Louisia et al., 2005) 
To evaluate the anterior and posterior tibial translation 
with respect to the femur
Lateral stress view with hamstring contraction method 
(Chassaing et al., 1995) 
To evaluate the anterior and posterior tibial translation 
with respect to femur
Lateral stress view according to the gravity method 
(Stäubli & Jakob, 1990)
To evaluate the anterior and posterior tibial translation 
with respect to the femur
Axial stress view (Puddu et al., 2000) To evaluate the anterior and posterior tibial translation with respect to the femur
Table 2. Imaging views and their purpose for standard and stress radiographs (Savarese et 
al., 2011). 
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4. Preoperative planning 
Preoperative planning of the osteotomy is mandatory (Freiling et al., 2010; Pape et al., 2007). 
The outcome will depend strongly on achieving an optimal and exact degree of correction 
(Pape et al., 2004). An analysis of knee malalignment includes 5 criteria as listed in Table 3 
(Hofmann & Pietsch, 2007). 
 
1. Frontal mechanical axis 
2. Joint line 
3. Sagittal mechanical axis 
4. Patellofemoral joint 
5. Malrotation 
Table 3. The 5 criteria for analysing knee deformities (Hofmann & Pietsch, 2007). 
The malalignment test is used for cases in which there is a frontal mechanical axis deviation 
(Paley et al., 1994). The normal axis passes 10 mm medial of the centre of the knee joint in 
the region of the tibial spine (ranging from 3 to 17 mm) (Paley et al., 1992) (Table 4). Frontal 
malalignment may result from a femoral deformity, a tibial deformity, knee joint laxity and 
luxation, an intra-articular condylar deficiency of the knee joint, reduced joint space due to 
meniscus or cartilage lesions, or any combination of the above (Dugdale et al., 1992; Paley et 
al., 1994). The intersection point of the proximal and distal mechanical axes is called the 
centre of rotation of angulation (CORA) (Paley et al., 1994). The axis of correction of 
angulation and the osteotomy should pass through the same CORA to avoid displacement 
of the bone ends. The osteotomy should maintain neutral joint-line obliquity and thus not 
increase the shear stresses at the joint surface (Babis et al., 2002). Excessive obliquity 
prevents the shift of weight bearing to the lateral compartment and may cause a recurrence 
of the varus deformity following high tibial osteotomy (Terauchi et al., 2002). (Levigne and 
Bonnin, 1991) differentiated congenital tibial bone varus (TBVA) from acquired tibial varus 
malalignment, which results from bone wear in medial gonarthrosis. A high tibial 
osteotomy can cure tibial bone varus, whereas in acquired tibial varus malalignment it is 
only a palliative procedure (Bonnin & Chambat, 2004). Patients with varus malalignment 
and normal TBVA (<5°) and medial proximal tibial angle (MPTA, 85-90°) have a bone varus 
of the distal femur (lateral distal femoral angle, LDFA >90°) (Hofmann et al., 2009).   
 
1. Mechanical tibiofemoral angle 
2. Mechanical axis (Mikulicz-line) 
3. The total transverse line through the knee (joint line is given as 100%) 
4. Lateral distal femoral angle (LDFA) 88° (85-90°) 
5. Medial proximal tibial angle (MPTA) 87° (85-90°)  
6. Joint line convergence angle (JLCA) 2° (1-3°) 
7. Joint line (JL) 87° (84-90°) 
8. Mechanical axis deviation (MAD) 10 mm medial (3-17 mm) 
9. Centre of rotation of angulation (CORA) 
10. Tibial bone varus angle (TBVA) 0° (<0-5°) 
Table 4. Biomechanical parameters in the frontal plane (Bonnin & Chambat, 2004; Brown & 
Amendola, 2000; Fick, 1911; Hofmann & Pietsch, 2007; Paley et al., 1994)  
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To eliminate the added varus due to deficiency of the 
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Stress radiograph Purpose
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4. Preoperative planning 
Preoperative planning of the osteotomy is mandatory (Freiling et al., 2010; Pape et al., 2007). 
The outcome will depend strongly on achieving an optimal and exact degree of correction 
(Pape et al., 2004). An analysis of knee malalignment includes 5 criteria as listed in Table 3 
(Hofmann & Pietsch, 2007). 
 
1. Frontal mechanical axis 
2. Joint line 
3. Sagittal mechanical axis 
4. Patellofemoral joint 
5. Malrotation 
Table 3. The 5 criteria for analysing knee deformities (Hofmann & Pietsch, 2007). 
The malalignment test is used for cases in which there is a frontal mechanical axis deviation 
(Paley et al., 1994). The normal axis passes 10 mm medial of the centre of the knee joint in 
the region of the tibial spine (ranging from 3 to 17 mm) (Paley et al., 1992) (Table 4). Frontal 
malalignment may result from a femoral deformity, a tibial deformity, knee joint laxity and 
luxation, an intra-articular condylar deficiency of the knee joint, reduced joint space due to 
meniscus or cartilage lesions, or any combination of the above (Dugdale et al., 1992; Paley et 
al., 1994). The intersection point of the proximal and distal mechanical axes is called the 
centre of rotation of angulation (CORA) (Paley et al., 1994). The axis of correction of 
angulation and the osteotomy should pass through the same CORA to avoid displacement 
of the bone ends. The osteotomy should maintain neutral joint-line obliquity and thus not 
increase the shear stresses at the joint surface (Babis et al., 2002). Excessive obliquity 
prevents the shift of weight bearing to the lateral compartment and may cause a recurrence 
of the varus deformity following high tibial osteotomy (Terauchi et al., 2002). (Levigne and 
Bonnin, 1991) differentiated congenital tibial bone varus (TBVA) from acquired tibial varus 
malalignment, which results from bone wear in medial gonarthrosis. A high tibial 
osteotomy can cure tibial bone varus, whereas in acquired tibial varus malalignment it is 
only a palliative procedure (Bonnin & Chambat, 2004). Patients with varus malalignment 
and normal TBVA (<5°) and medial proximal tibial angle (MPTA, 85-90°) have a bone varus 
of the distal femur (lateral distal femoral angle, LDFA >90°) (Hofmann et al., 2009).   
 
1. Mechanical tibiofemoral angle 
2. Mechanical axis (Mikulicz-line) 
3. The total transverse line through the knee (joint line is given as 100%) 
4. Lateral distal femoral angle (LDFA) 88° (85-90°) 
5. Medial proximal tibial angle (MPTA) 87° (85-90°)  
6. Joint line convergence angle (JLCA) 2° (1-3°) 
7. Joint line (JL) 87° (84-90°) 
8. Mechanical axis deviation (MAD) 10 mm medial (3-17 mm) 
9. Centre of rotation of angulation (CORA) 
10. Tibial bone varus angle (TBVA) 0° (<0-5°) 
Table 4. Biomechanical parameters in the frontal plane (Bonnin & Chambat, 2004; Brown & 
Amendola, 2000; Fick, 1911; Hofmann & Pietsch, 2007; Paley et al., 1994)  
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The posterior distal femoral angle (PDFA) helps one to differentiate between bone- and soft 
tissue-dependant hyperextension or a flexion contracture (Bonin et al., 2004). Changes in the 
posterior proximal tibial angle (PPTA) or the posterior tibial slope have a strong effect on 
cartilage pressure and kinematics of the knee (Agneskirchner et al., 2004). With the 
exception of rare circumstances, the normal tibial slope should not be changed (Hofmann et 
al., 2009) (Table 5).  
 
Posterior distal femoral angle (PDFA) 83° (79-87°) 
Posterior proximal tibial angle (PPTA, posterior tibial slope) 81° (77-84°) 
Table 5. Biomechanical parameters in the sagittal plane (Paley et al., 1994) 
A closing-wedge high tibial osteotomy decreases the posterior slope, translates the tibia in 
the posterior direction and stabilises a knee that has anterior instability, whereas a medial 
opening wedge high tibial osteotomy increases the posterior tibial slope, translates the tibia 
in the anterior direction, and stabilises a knee that has posterior instability (Giffin et al., 
2007; Hohmann et al., 2006; Lerat et al., 1993; Savarese et al., 2011). The slope must be raised 
only slightly, as an elevation in the slope of more than 10° can cause a chronic insufficiency 
in the anterior cruciate ligament (Dejour et al., 2000). 
Changes in the mechanics of the patellofemoral joint can also result in changes in the 
tibiofemoral compartments (Feller et al., 2007) (Table 6). A medial open-wedge high 
tibial osteotomy improves the symptoms of patellofemoral osteoarthritis because the 
anterior translation of the tibia reduces the tension on the patellar tendon, the patella 
becomes less horizontal, and pressure decreases in the lateral facet (Kumagai et al., 2002; 
Li et al., 2002; Savarese et al., 2011). When faced with a patellofemoral malfunction, it is 
important to check all of the soft tissues and the articular geometry factors that relate to 
the patella locally and to not neglect the overall alignment and function of the lower limb 
(Feller et al., 2007). Weight bearing skyline views of the patella with both knees at 30° 
flexion, both as the tibial tuberosity-trochlear groove (TT-TG) distance that measured 
with the CT-scan is an important factor for analysing patellofemoral malfunction (Dejour 
et al., 1994). 
 
No trochlear dysplasia (no crossing sign with trochlea bump >3 mm and trochlea depth 
<4 mm)  
No quadriceps dysplasia with no patellar tilt >20% in extension  
Caton-Deschamps Index 1.0 (0.8-1.2) (Caton, 1989) 
Insall-Salvati Index 1.0 (0.8-1.2) (Insall & Salvati, 1971) 
Blackburne-Peel Index 0.8 (0.5-1.0) (Blackburne & Peel, 1977) 
Tibial tuberosity-trochlea groove (TT-TG) distance <15 mm 
Congruence angle -6° + 11° (Merchant et al., 1974) 
Axial linear patellar displacement (Urch et al., 2009) 
Patellar tilt angle 2° + 5° (Grelsamer et al., 1993) 
Sulcus angle (Brattstroem, 1964) 
Table 6. Biomechanical parameters in the patellofemoral joint 
A CT scan or MRI of the leg is recommended in malrotations during the preoperative 
clinical evaluation.      
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5. Planning of post-operative correction 
The post-operative correction is typically planned with the use of full-length A-P view standing 
radiographs with the patella facing directly anterior with the patient standing on both legs 
according to the method of Miniaci et al. (M Galla & Lobenhoffer, 2004; Miniaci et al., 1989).  
Alternatively, the post-operative correction can be planned according to the methods of 
(Dugdale et al., 1992 or Coventry, 1985). (Coventry, 1985) recommended a postoperative 
anatomical valgus of at least 8°. The correction that is achieved can also be verified by 
measuring the mechanical tibiofemoral angle (Hernigou et al., 1987; Ivarsson et al., 1990). The 
point where the mechanical axis crosses the transverse diameter of the tibial plateau is the 
recommended planning method (Pape et al., 2007) Table 6 (Noyes et al., 1993). The mechanical 
axis is shifted to a point that is 62% of the transverse diameter of the tibial plateau (Fujisawa et 
al., 1979) (Table 7). In a biomechanical study under reproducible dynamic loading conditions 
using pressure-sensitive films with the corrected axis running through the “Fujisawa point”, 
the load changed only after the complete release of the MCL from medial to lateral (64%) 
(Agneskirchner et al., 2007). An individual correction of varus deformities between 0° and 6° 
of the mechanical valgus or shifting the mechanical axis to a point between 55% and 67.5%  on 
the transverse diameter of the tibial plateau according to the intra-articular disease is also 
recommended (Fig. 2 and Table 8). Post-operative correction can also be planned with an 
arthroscopy before the osteotomy based on the Outerbridge classification (Fig. 3) (Müller & 
Strecker, 2008; Outerbridge, 1961). Digital radiographs require calibration before planning 
(Freiling et al., 2010). A large flexion deformity in varus knees precludes the precise planning 
of deformity correction, as the degree of the varus malalignment will be overestimated (Pape 
et al., 2004). To support planning deformities with TomoFix (Synthes, West Chester, 
Pennsylvania), the tool PreOp-Plan was developed by Siemens.  
 




Point where the 
mechanical axis crosses 
the tibial plateau (%) 
Coventry (Coventry, 1985) Anatomical tibiofemoral angle 8-10 - 
Koshino et al. (Koshino et 
al., 1989) 
Anatomical tibiofemoral 
angle 6-15 - 
Engel & Lippert  
(Engel & Lippert, 1981) 
Anatomical tibiofemoral 
angle 5-10 - 
Kettelkamp (Kettelkamp 
et al., 1976)  
Anatomical tibiofemoral 
angle >5 - 
Aglietti et al.  
(Aglietti et al., 2003)
Anatomical tibiofemoral 
angle 8-15  
Hernigou et al. (Hernigou 
et al., 1987) 
Mechanical tibiofemoral 
angle 3-6 - 
Ivarson et al.  
(Ivarson et al., 1990)
Mechanical tibiofemoral 




angle 3-7 - 
Miniaci et al.  
(Miniaci et al., 1989) Mechanical axis - 60-70 
Dugdale  
(Dugdale et al., 1992) Mechanical axis - 50-75 
Noyes  
(Noyes et al. 1993) Mechanical axis - 62 
Table 7. Recommended correction angles and lines (Pape et al., 2004; Pape et al., 2007) 
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Fig. 2. Correction of varus deformities (Marti et al., 2004; Jakob &Jacobi, 2004)  
 
 
Fig. 3. Planned correction in high tibial valgus osteotomies. The load bearing distribution at 
the medial knee depending on the frontal axis of the leg (normal 75% according to Hsu et 
al., 1990) is in red, and the correction angle depending on CCartilage lesion) according 
to the Outerbridge classification (Outerbridge, 1961) is in blue. The planned correction 
angles were as follow: at CM=IV° 5° of valgus, at CM=III° the Fujisawa point (3.3° of 
valgus) and at CM =II° 1.7° of valgus (Müller & Strecker, 2008; Strecker et al. 2009). 
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Posttraumatic malalignment without 
osteoarthritis  0-2° 
ACL insufficiency 0-2° 
PCL insufficiency 2-4 (5)° 
Surgery of chondral lesions 3-5° 
Table 8. Correction angles of varus deformities for the different types of disorders (Müller, 
2001; Hofmann et al., 2009) 
The first step is to draw the z-line from the centre of the femoral head to the centre of the talus 
(Fig. 4). In varus malalignment, the mechanical axis passes the tibial plateau more medially 
than the physiological mechanical axis deviation (MAD) of 10 mm (ranging from 3 to 17 mm). 
Next, a line that is parallel to the tibial plateau is drawn. A third line is drawn with the desired 
mechanical axis from the centre of the femoral head to a point 62% lateral on the transverse 
diameter of the tibial plateau (Fujisawa et al., 1979). The desired mechanical axis is continued 
to the centre of the ankle in its postoperative position. The centre of rotation of angulation 
(CORA) lies in the lateral cortex at the tip of the fibula. Line 1 connects CORA with the middle 
of the ankle joint. Line 2 is drawn from CORA to the centre of the ankle in its postoperative 
position and crosses the desired mechanical axis at the centre of the ankle. The angle between 
lines 1 and 2 forms the correction angle. The degree of lateral separation (the joint line 
convergence angle, or JLCA) from the apparent deformity in the preoperative planning of the 
correction angle is subtracted (Kolb et al., 2010). 
Alternatively the JLCA can be determined preoperatively from the full-length A-P view 
standing radiographs of both knees. The difference a between both JLCAs is measured 
(Pape et al., 2004). By taking the width of the tibial plateaus (WTP) and a constant K (76.4) 
into consideration, the varus malalignment that is caused by the ligamentous instability 
(can be determined using the following equation:  = K x (a)/WTP (Galla & 
Lobenhoffer, 2004). The angle is then subtracted from the measured angle of correction 
(Pape et al., 2004; Galla & Lobenhoffer, 2004).  
Ideal correction of the leg of the leg is difficult to achieve, and postoperative malalignment 
is often observed following high tibial osteotomy (Dahl, 2000; Noyes et al., 2000). The 
challenge for achieving a permanent surgical solution is to achieve the planned axis 
intraoperatively (Gebhard et al., 2011). Computer-assisted navigation systems may improve 
the precision and accuracy of the leg axis correction while offering simulation tools that can 
predict the postoperative alignment (Gebhard et al., 2011) (Fig. 5). The integration of 
“computer-aided design/computer-aided manufacturing (CAD/CAM)” planning into 
computer-assisted surgery allows one to plan complex orthopaedic surgical procedures 
(Wong et al., 2010). 
6. Surgical technique 
An arthroscopy is first performed to check the indication for an osteotomy, to modify the 
planned correction according to the intra-articular findings and to rule out and treat the intra-
articular pathologies (Fig. 3) (Strecker et al., 2009). Meniscal tears, loose bodies, osteophytic 
spurs, and chondral flaps can cause mechanical symptoms that can be treated successfully 
with arthroscopy (Iorio & Healy, 2003). In 51 out of 300 cases (17%), the procedure was 
changed to a total knee arthroplasty due to finding of advanced osteoarthritis in the intended 
compartment during the preoperative arthroscopy (Strecker et al., 2009).  
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Fig. 4. Planning of post-operative correction for an open wedge high tibial osteotomy. 
 




Fig. 5. High tibial osteotomy with a computer-assisted navigation system (From BRAINLAB 
with permission) 
Lateral open-wedge high tibial osteotomies are rarely performed. There is a paucity reports 
regarding the use of a reconstructive osteotomy to treat depression and valgus malunions of 
the proximal tibia (Kerkhoffs et al., 2008). 
Barrel-vault (dome) osteotomies, lateral-closed-wedge, medial open-wedge high tibial 
osteotomies or a procedure that combines these techniques are used to treat varus 
deformities of the knee (Coventry, 1965; M Galla & Lobenhoffer, 2004; Hernigou et al. 1987; 
Maquet, 1976; Nagi et al., 2007; Watanabe et al., 2008; Weber & Wörsdörfer, 1980). 
Patellofemoral pain due to patella baja, large deformities or high tibial slope is an indication 
for performing a closed-wedge osteotomy (Marti et al., 2004). Small deformities and medial 
instability are indications for open-wedge osteotomies.    
Lateral closed-wedge high tibial osteotomies have been the treatment of choice since 1965 
(Coventry, 1965). The closed wedge is the most stable high tibial osteotomy technique when 
compared with the open-wedge osteotomy and the barrel-vault (dome) osteotomy, as the 
periosteum and cortex adjacent to the apex of the removed wedge act as a tether when the 
osteotomy is closed (Hansen & Chao, 1994, Kolb et al., 2009). Several lateral tensioning 
systems such as 1/3 tubular plates with cortical bone screws, a 4.5-mm L-plate, bone staples, 
external fixation devices, Giebel plates and locked plates are used (Billings et al., 2000; 
Coventry, 1969; Giebel et al., 1985; Jackson & Waugh, 1961; Kessler et al. 2002; Luites et al., 
2009; Perusi et al., 1994; Weber & Wörsdörfer, 1980). 
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periosteum and cortex adjacent to the apex of the removed wedge act as a tether when the 
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We have used the modified Weber-technique (Weber & Wörsdörfer, 1980), which 
provides several advantages, including high stability of the osteotomy through the 
tension band principle with large bone contact areas and the possibility of bone 
impaction, intraoperative correction of the osteotomy, no large implant (in particular, no 
removal of the implant is necessary), no increase in pressure in the medial compartment 
through tensioning of the MCL, no increase of pressure in the patellofemoral joint and no 
bone graft (Frey et al., 2008).  
The most common problems associated with this procedure are difficulty in achieving an 
accurate correction of the osseous malalignment, the need for fibular osteotomy or 
separation of the proximal tibiofibular joint, contracture of the patellar tendon leading to 
patellar baja, leg shortening, and a high rate of other complications (Aydogdu et al., 2000;  
Kirgis & Albrecht, 1992; Tunggal et al., 2010) (Tables 9 and 10). Large corrections may 
cause marked shortening of the leg and a large offset of the tibia, which may compromise 
the later placement of the tibial component during a total knee replacement (Brinkman et 
al., 2008).  
(Shaw et al., 2004) conducted an anatomical study and found that an osteotomy angle 
greater than 10° rendered the lateral collateral ligament non-functional and allowed the 
knee to swing back to its native alignment with varus loading, thus negating much of the 
bony correction.  
 
Infection 0.8-10.4% 
Thromboembolic disease 2-5% 
Compartment syndrome Rare 
Fracture of the medial cortex 82% 
Intra-articular fractures 0-20% 
Non-union 1-5% 
Delayed union 4-8.5% 
Peroneal nerve palsy 0-27% 
Table 9. Complications (and their incidence) of closed-wedge high tibial osteotomy (Staubli 
& Jacob, 2010, Tunggal et al., 2010) 
 
- No difference in the incidence of infection, deep vein thrombosis, peroneal nerve 
palsy, non-union or revision to knee arthroplasty (p>0.05)  
- Significantly greater posterior tibial slope and mean angle of correction, reduced 
patellar height and hip-knee-ankle angle following opening-wedge HTO (p<0.05)  
- No significant difference was found for any clinical outcome including pain, 
functional score or complications (p>0.05)  
Table 10. Differences in complications between Open- or closed-wedge high tibial 
osteotomies (Smith et al. 2010). 
The open-wedge high tibial osteotomy gained recognition after the encouraging reports of 
(Hernigou et al., 1987). A medial open-wedge osteotomy proximal to the tibial tubercle 
was performed, and appropriate-size wedges of bone that were obtained from the iliac 
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crest were inserted into the defect (Hernigou et al., 1987; Poignard et al., 2010). No 
internal fixation or plaster was used. A crack in the lateral cortex during or after the 
osteotomy may cause a displacement and a subsequent loss of correction (Hernigou et al., 
1987). Therefore, we now perform internal fixation using a plate and screws for all 
osteotomies (Poignard et al., 2010). Modern techniques involve sawing and chiselling 
through the bone and the application of an internal (or external) splint to fix the 
fragments in the required juxtaposition until bone healing is complete (Staubli & Jacob, 
2010; Merian et al., 2005; Weale et al., 2001). Because of the well-known morbidity of the 
relevant donor site, bone substitutes such as DUOWEDGE (from Intrauma, Rivoli, Italy) 
can be employed (Poignard et al., 2010). However, the outcome often falls short of the 
expected result, and much effort is currently being expended to improve this outcome. 
The surgical technique was improved by applying a combination of the MIPO-technique 
with a V-shaped osteotomy and an internal fixator. The V-shaped osteotomy provides 
additional room for the adequate fixation of any device to the proximal fragment (i.e., 5 
cm distal to the joint line rather than only 3.5 cm) (Hernigou et al., 1987; Lobenhoffer et 
al., 2002). The V-shaped osteotomy further improves the rotational and sagittal stability 
(Lobenhoffer et al., 2002). The anterior bone contact supports healing of the osteotomy 
and prevents intraoperative malrotation, forward slipping and tilting (Freiling et al., 2010; 
Van Heerwarden et al., 2007). Lastly, the force transmission of the patellar tendon is not 
compromised (Staubli & Jacob, 2010).  
The TomoFix internal fixator is anatomically pre-contoured for the proximal-medial aspect 
of the tibia, which allows healing of the osteotomy without compression between the plate 
and bone and promotes osteogenesis through angular stable fixation with the precise 
amount of elasticity (Brinkman et al., 2008; Kolb et al., 2009; Nelissen et al., 2010). The angle 
of correction is maintained, thereby avoiding a later loss of correction (Kolb et al., 2009; 
Staubli et al., 2003; Stoffel et al., 2004).     
The following surgical technique was developed by Lobenhoffer et al., 2002 and Staubli et 
al., 2003 (Kolb et al., 2009, 2010) 
The procedure is performed with the patient placed in a supine position on a radiolucent 
table with a lateral support. With the knee held at 90° of flexion, the medial side of the 
proximal tibia is exposed by a 6 to 8 cm oblique incision 4 cm distal to the joint line 
extending from the medial aspect of the tibial tuberosity to the posterior border of the tibial 
plateau.  
The superficial fibres of the medial collateral ligament are mobilised and released (Fig. 6). 
The knee is then extended, and two 2.5-mm Kirschner wires mark the oblique osteotomy 
starting proximal to the pes anserinus 5 cm distal to the joint line (Figs. 6 and 7). 
The wires then extend to the tip of the fibula. A V-shaped osteotomy is then performed with 
the knee flexed again. The oblique osteotomy is performed in the posterior two-thirds of the 
tibia while leaving a 10-mm lateral bone bridge intact. To prevent an unintentded increase 
in the posterior tibial slope, special attention should be paid in locating the intact cortical 
hinge on the lateral - not posterolateral - side of the tibia (Wang et al., 2009) 
The second osteotomy begins in the anterior one-third of the tibia at an angle of 135° while 
leaving the tibial tuberosity intact (a proximal-tuberosity osteotomy, or PTO, Fig. 8). When 
jigs are not available, a significant improvement in cutting accuracy can be achieved using a 
navigating system or an industrial robot that is integrated into the freehand bone-cutting 
(Cartiaux et al., 2010). 
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proximal tibia is exposed by a 6 to 8 cm oblique incision 4 cm distal to the joint line 
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Fig. 6. 2.5 mm Kirschner wire mark the oblique osteotomy 
 
 
Fig. 7. 2.5 mm Kirschner wire mark the oblique osteotomy 
 




Fig. 8. V-shaped open-wedge high tibial osteotomy 
We open the oblique osteotomy stepwise using three stacked osteotomes and a calibrated 
wedge spreader. The alignment is verified using the cable method (Krettek et al., 1997) or, 
alternatively, a rigid bar (Brinkman et al., 2008) or an axis-board (Liodakis et al., 2010). The 
axis-board is a simple and convenient option for intraoperative evaluation of the mechanical 
axis (Liodakis et al., 2010); however, for complex corrections, the use of navigation systems 
is still recommended (Liodakis et al. 2010). In recent studies, computer-assisted surgery has 
proven to be a helpful tool for the intraoperative control of the leg axis (Bae et al., 2009; 
Lützner et al., 2010; Gebhard et al., 2011), as it provides additional information regarding the 
lateral plane, ligaments and extension (Heijens et al., 2009). Moreover, 3D navigation can 
provide surgeons with reliable information both to determine the appropriate coronal 
alignment and to maintain the anatomical tibial slope during the open-wedge high tibial 
osteotomy procedure (Yamamoto et al., 2008). With the addition of arthroscopy, the 
anatomy and landmarks of the proximal tibia can be fully utilised to determine the frontal 
alignment and tibial slope (Lo et al., 2009). In a first prospective case series, approximately 
85%, of patients achieved perfect result in terms of deviaton of the planned mechanical axis 
using computer assistance as an intraoperative guiding tool (Gebhard et al., 2011).   
The alignment is checked with the knee fully extended. The TomoFix internal fixator is 
inserted into a subcutaneous tunnel on the anteromedial aspect of the tibia (Fig. 9).  
The posterior tibial slope depends on the position of the plate that is used to stabilise the 
osteotomy (Rodner et al., 2006, Saverese et al., 2011). An anterior plate position results in an 
increase in the posterior tibial slope by an average of 6.6° (Rodner et al., 2006). In a large open-
wedge correction (i.e., >8° to 10°) or in the cases of a preoperative patella infera, the tibial 
tuberosity is cut distally with a modified distal-tuberosity osteotomy (DTO) (Gaasbeek et al., 
2004; Brinkman et al., 2008). (Poignard et al., 2010) recommend open medially and posteriorly 
to avoid increasing the posterior slope and unducing patella baja. We use cancellous bone 
grafts for open-wedge osteotomies that exceed 15 mm, whereas (Brinkman et al. 2008) uses 
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these bone grafts when the open-wedge osteotomy exceeds 20 mm. (Poignard et al., 2010) 
recently reported the use of the porous beta-tricalcium phosphate (Beta-TCP) DOUWEDGE.   
 
 
Fig. 9. The TomoFix is inserted into a subcutaneous tunnel 
6.1 Postoperative care 
Beginning on their first postoperative day, the patient is limited to partial weight bearing (15 
kg to 20 kg) for six weeks, after which the patient can begin full weightbearing. According to 
(Brinkman et al., 2010) patients can typically begin full weight bearing-depending on pain-
after two to three weeks (Brinkman et al., 2010).  
7. Results 
The open-wedge high tibial osteotomy with the MIPO technique using the TomoFix internal 
fixator obtained significant improved clinical results after a short to medium term follow-up 
(Table 10). Postoperatively, the infection rate, the rate of delayed and non-unions, the intra-
articular fracture rate and the rate of implant failures were low (Table 11). Smokers had a higher 
rate of non-unions (Meidinger et al., 2009) (Table 12). The reason for the low complication rate 
of the MIPO technique with the TomoFix internal fixator was its high stability that allows a 
larger distance between the two screws that are adjacent to the osteotomy, thereby resulting in 
less elastic deformation of the plate and interfragmantary tissue. A high percentage of patients 
(41%) complained of local irritation that was associated with the implant in the clinical course 
after high tibial osteotomy (Table 13, Meidinger et al., 2011). In all cases, irritation disappeared 
after implant removal upon consolidation of the osteotomy gap (Meidinger et al., 2011). In the 
meantime, the design of the TomoFix has been modified.  
 







































healing ND ND ND 
Takeuchi  






months 50.9  12.3 







Valkering et al., 
2009 40/40 (100%)
Mean 10.4 
months ND ND ND 









22 (17-31)  
(p < 0.05) 
82 (45-92)  
(p < 0.05) 
75 (50-95)  






















72.72  17.15 
(p < .001) 
79.14 + 16.63 




et al., 2011 
51/50 (98%), 
45.4  8.6 (22-
59) 
6 weeks ND ND ND 
Meidinger  
et al., 2011 
182, 142 men, 
40.3  10.6 
years, 40 
women, 43.7 
 8.9 years 
3 months ND ND ND 
ND means not determined 
Table 11. The results of open-wedge high tibial osteotomy with the TomoFix internal fixator 
from various studies. 
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Author Nerve lesion (n, %) Total knee arthroplasty (n, %) 
Implant removal 
(n, %) 
Staubli et al., 2003 
10 hyposensitivity of 
the saphenous nerve 
(11%) 
3 TKA (3%) 37 (41%) after 12 (2.5-17) months 
Galla & Lobenhoffer, 
2004, Lobenhoffer  
et al., 2004 
ND ND 10 (38%) 
Takeuchi et al., 2009 ND ND ND 
Valkering et al., 2009 ND ND ND 
Zaki & Rae, 2009 ND 1 (2%) ND 
Kolb et al., 2009 ND 4 (8%) 2 (4%) 
Niemeyer et al., 2010 ND ND 68 (93%) 
Gebhard et al., 2011 ND ND ND 
Meidinger et al. 2011 ND ND ND 
Table 13. Complications from open-wedge high tibial osteotomy with the TomoFix internal 
fixator II from various studies. 
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Tibio-femoral 7 (5-8)° 
varus pre-op, 6 (5-8)° 
valgus p.o. 
 2 superficial infections (4%) ND ND 
Kolb et al., 
2009 
9.5 (15-0)° varus pre-op, 












with bone graft 
(2%) 
Niemeyer  
et al., 2010 
3 (4%) overcorrection 
mechanical axis >70% 
transverse diameter of 
proximal tibia, 









due to the 
implant 




fracture, 2 (3%) 






et al., 2011 
p.o. mean leg axis 
deviation 1.5° (22 (48%) 
patients <2.5°, 39 (85%) 
patients <3.5°








et al. 2011 







10 (5%) revision 
surgery with 
debridement 
and bone graft 
including 4 (2%) 
plate exchanged 
ND means not determined 
Table 12. Complications from open-wedge high tibial osteotomy with the TomoFix internal 
fixator I from various studies. 
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Author Nerve lesion (n, %) Total knee arthroplasty (n, %) 
Implant removal 
(n, %) 
Staubli et al., 2003 
10 hyposensitivity of 
the saphenous nerve 
(11%) 
3 TKA (3%) 37 (41%) after 12 (2.5-17) months 
Galla & Lobenhoffer, 
2004, Lobenhoffer  
et al., 2004 
ND ND 10 (38%) 
Takeuchi et al., 2009 ND ND ND 
Valkering et al., 2009 ND ND ND 
Zaki & Rae, 2009 ND 1 (2%) ND 
Kolb et al., 2009 ND 4 (8%) 2 (4%) 
Niemeyer et al., 2010 ND ND 68 (93%) 
Gebhard et al., 2011 ND ND ND 
Meidinger et al. 2011 ND ND ND 
Table 13. Complications from open-wedge high tibial osteotomy with the TomoFix internal 
fixator II from various studies. 
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1. Introduction  
Current development of medical practice has shown that imaging-guided interventional 
invasive techniques are superior to blind manoeuvres. Moreover, a safe nonradiant and 
cheap imaging guidance method is always preferred (Aliabadi P et al., 1988; Ozonoff MB, 
1973; Sofka CM et al., 2005; Picano & Matucci Cerinic, 2010). In addition to its primary use as 
a very useful diagnostic tool and natural extension of the clinical examination, 
musculoskeletal ultrasound is now frequently used in clinical rheumatological practice for 
guiding interventional manoeuvres.   
Interventional musculoskeletal ultrasound guided manoeuvres refer to a variety of invasive 
procedures performed percutaneously covering diagnostic as well as therapeutic injection of 
joints, tendon sheats or other peri-articular structures up to more complex manoeuvres like 
biopsies, removal of foreign bodies and intratumoral therapeutic injections. 
Ultrasonography has a very important advantage over other imaging methods because it 
allows the concomitant visualization of the target structure, the needle penetration and tip 
positioning as well as the drug deposition (Bradley MJ, 2001). Indeed, musculoskeletal 
ultrasound evaluation is an accurate and reliable method in depicting articular and 
periarticular lesions, has no radiation, is cheap and quick to perform and allows repeated 
examinations at baseline and during follow up (Bierma-Zeinstra et al., 2001; Koski JM et al., 
1989; Iagnocco A et al., 2006; Qvistgaard E et al., 2001). Moreover, a modular flexible 
training strategy to achieve competence in diagnostic as well as in interventional 
musculoskeletal ultrasound  showed a fast learning curve among  rheumatologists, thus 
encouraging its employment  in daily practice (Atchia I et al., 2007). 
Hip joint pathology is very frequently encountered in clinical practice. Hip joint pain is the 
main symptom generated by several pathological conditions including primary 
osteoarthritis (OA), inflammatory diseases like rheumatoid arthritis, spondylarthropaties, 
crystal deposition diseases as well as congenital and traumatic disorders with potential 
evolution to secondary OA.  
Recently, several studies have shown an increase in the general population of hip OA 
incidence in parallel with an increase of obesity incidence and higher life expectancy 
worldwide. Chronic hip pain on walking is the most important factor impacting on patient 
quality of life and is complicated by functional disability due to structural damage. The 
management of hip pain is therefore burdened by long term high treatment costs. In fact, the 
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increasing number of total hip replacements with elevated surgery costs and prolonged 
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rehabilitation procedures are challenging the health care systems all over the world (Birrell 
F et al., 2003; Brooks PM, 2006). For this reason, various diagnostic and treatment strategies 
are continuously tested in order to obtain maximum efficacy and minimize the total 
management costs  .  
In the outpatient rheumatological setting, diagnostic aspiration and therapeutic intra-
articular hip joint injections are frequently required.  In fact, the guided aspiration of the 
fluid from the coxofemoral joint is of paramount importance to obtain laboratory analyses 
(microscopy-culture and Gram stain) that may rapidly differentiate septic arthritis from 
other inflammatory joint conditions like rheumatoid arthritis, spondilarthropaties and 
crystal deposition diseases. Other imaging techniques do not differentiate a septic effusion 
from other kind of effusions because of the non-specific appearance. (Foldes K et al., 1995) 
The current Osteoarthritis Research Society International (OARSI)  and Assessment of 
SpondyloArthritis International Society (ASAS) / European League Against Rheumatism 
(EULAR)  therapeutic guidelines include hip corticosteroid injection, which is still a rare 
therapeutic approach because standardized criteria for patients selection are still missing 
and because of the small number of performing physicians. These are clear limitation in 
using the method. (Zhang W et al., 2005, 2008) On the other hand, the use of intraarticular 
hip viscosupplementation is still under study because of the low number of existing trials, 
most of them with contradictory results and is still waiting for approval in some countries. 
(Migliore A et al., 2004; Qvistgaard E et al., 2006; Richette P et al., 2009) 
It is well known that deep joints, like the hip, are difficult to reach and inject and therefore 
require imaging guided needle techniques that are currently preferred to the blind injections 
guided only by anatomical landmarks. In fact, musculoskeletal ultrasound guided technique 
allows a correct needle penetration (avoiding neurovascular structures injury), joint 
aspiration, and a more accurate drug deposition which assures a higher efficacy. (Leopold 
SS et al., 2001 ; Iagnocco A & Naredo E , 2010; Naredo E et al., 2005) 
The first data about the use of musculoskeletal ultrasound guided hip aspiration of synovial 
fluid were reported by Komppa in 1985. (Komppa GH et al., 1985) Ultrasound guided 
injections were introduced much later in clinical trials and practice, when it became evident 
that joint ultrasound facilitates a quick, accurate diagnosis and operative safe local treatment 
showing extraordinary advantages over the other imaging techniques. Despite several 
efforts made in many countries to implement the invasive musculoskeletal ultrasound 
guided techniques as a part of the rheumatology curriculum, this procedure still remains 
insufficiently exploited among rheumatologists. 
The aim of this chapter is to describe the basic techniques of the ultrasound guided hip joint 
injection and to update the therapeutic standards, indications and contraindications, efficacy 
and safety of the method. 
2. Anatomy of the hip 
The hip is a “ball and socket” synovium lined joint between the spherical femoral head 
covered by hyaline articular cartilage and the cup- shaped acetabulum. The capsule, 
superficially reinforced in the anterior aspect by the ilio- femoral ligament and covered by 
synovial tissue, extends around the joint attaching superiorly to the acetabulum and labrum 
and inferiorly to the intertrochanteric area. The deep synovial layer reflects back from the 
intertrochanteric area to the head neck junction delineating the anterior joint recess. The ilio-
psoas muscle is superficial to the anterior aspect of the capsule. 
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3. Sonoanatomy, patient position and scanning technique 
To perform an ultrasound guided procedure, the patient should be supine with the heels 
together and slightly (10-20 ºdegrees) externally rotated legs. The examination is performed 
with a low frequency 3.5- 7.5 MHz linear array probe or a convex one (2.5-5 MHz) for obese 
or muscular patients, following EULAR ultrasound evaluation guidelines with multiplanar 
structure scanning, in grey scale and Doppler mode. (Iagnocco A & Naredo E, 2010; Leopold 
SS et al., 2001; Naredo E et al., 2005; Qvistgaard E et al., 2006) The anterior longitudinal view 
as well as the transversal one are fundamental.  
The anterior (superior collicular recess) and the supero- anterior recesses are the most 
important in musculoskeletal ultrasound assessment because of the sensitivity in depicting 
synovitis. (Backhaus M et al., 2001; Iagnocco A et al., 2006; Qvistgaard E et al., 2001) Femoral 
neuro- vascular structures are located medial to the joint and easily depicted in transversal 









Figure 1  
 
 
Fig. 1. Anterior longitudinal scanning and view of the hip. Patient photo in scanning 
position and correct position of the probe; drawing of the hip region showing the probe 
position parallel to the femoral neck ( red line); sonoanatomy of the hip in trapezoidal view- 
anterior joint recess ( black arrow). Legend:  B- bone (femoral head), AC- acetabulum, RF- 
rectus femoris muscle, IPM- ilio-psoas muscle, Sa- sartorius muscle, iliac b- iliac bone. 
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rehabilitation procedures are challenging the health care systems all over the world (Birrell 
F et al., 2003; Brooks PM, 2006). For this reason, various diagnostic and treatment strategies 
are continuously tested in order to obtain maximum efficacy and minimize the total 
management costs  .  
In the outpatient rheumatological setting, diagnostic aspiration and therapeutic intra-
articular hip joint injections are frequently required.  In fact, the guided aspiration of the 
fluid from the coxofemoral joint is of paramount importance to obtain laboratory analyses 
(microscopy-culture and Gram stain) that may rapidly differentiate septic arthritis from 
other inflammatory joint conditions like rheumatoid arthritis, spondilarthropaties and 
crystal deposition diseases. Other imaging techniques do not differentiate a septic effusion 
from other kind of effusions because of the non-specific appearance. (Foldes K et al., 1995) 
The current Osteoarthritis Research Society International (OARSI)  and Assessment of 
SpondyloArthritis International Society (ASAS) / European League Against Rheumatism 
(EULAR)  therapeutic guidelines include hip corticosteroid injection, which is still a rare 
therapeutic approach because standardized criteria for patients selection are still missing 
and because of the small number of performing physicians. These are clear limitation in 
using the method. (Zhang W et al., 2005, 2008) On the other hand, the use of intraarticular 
hip viscosupplementation is still under study because of the low number of existing trials, 
most of them with contradictory results and is still waiting for approval in some countries. 
(Migliore A et al., 2004; Qvistgaard E et al., 2006; Richette P et al., 2009) 
It is well known that deep joints, like the hip, are difficult to reach and inject and therefore 
require imaging guided needle techniques that are currently preferred to the blind injections 
guided only by anatomical landmarks. In fact, musculoskeletal ultrasound guided technique 
allows a correct needle penetration (avoiding neurovascular structures injury), joint 
aspiration, and a more accurate drug deposition which assures a higher efficacy. (Leopold 
SS et al., 2001 ; Iagnocco A & Naredo E , 2010; Naredo E et al., 2005) 
The first data about the use of musculoskeletal ultrasound guided hip aspiration of synovial 
fluid were reported by Komppa in 1985. (Komppa GH et al., 1985) Ultrasound guided 
injections were introduced much later in clinical trials and practice, when it became evident 
that joint ultrasound facilitates a quick, accurate diagnosis and operative safe local treatment 
showing extraordinary advantages over the other imaging techniques. Despite several 
efforts made in many countries to implement the invasive musculoskeletal ultrasound 
guided techniques as a part of the rheumatology curriculum, this procedure still remains 
insufficiently exploited among rheumatologists. 
The aim of this chapter is to describe the basic techniques of the ultrasound guided hip joint 
injection and to update the therapeutic standards, indications and contraindications, efficacy 
and safety of the method. 
2. Anatomy of the hip 
The hip is a “ball and socket” synovium lined joint between the spherical femoral head 
covered by hyaline articular cartilage and the cup- shaped acetabulum. The capsule, 
superficially reinforced in the anterior aspect by the ilio- femoral ligament and covered by 
synovial tissue, extends around the joint attaching superiorly to the acetabulum and labrum 
and inferiorly to the intertrochanteric area. The deep synovial layer reflects back from the 
intertrochanteric area to the head neck junction delineating the anterior joint recess. The ilio-
psoas muscle is superficial to the anterior aspect of the capsule. 
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3. Sonoanatomy, patient position and scanning technique 
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or muscular patients, following EULAR ultrasound evaluation guidelines with multiplanar 
structure scanning, in grey scale and Doppler mode. (Iagnocco A & Naredo E, 2010; Leopold 
SS et al., 2001; Naredo E et al., 2005; Qvistgaard E et al., 2006) The anterior longitudinal view 
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The anterior (superior collicular recess) and the supero- anterior recesses are the most 
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synovitis. (Backhaus M et al., 2001; Iagnocco A et al., 2006; Qvistgaard E et al., 2001) Femoral 
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position parallel to the femoral neck ( red line); sonoanatomy of the hip in trapezoidal view- 
anterior joint recess ( black arrow). Legend:  B- bone (femoral head), AC- acetabulum, RF- 
rectus femoris muscle, IPM- ilio-psoas muscle, Sa- sartorius muscle, iliac b- iliac bone. 
  
Osteoarthritis – Diagnosis, Treatment and Surgery 
 
352 
4. Ultrasound guided hip injection 
Generally, two types of US joint injection techniques may be performed: an indirect method 
(half blind) and a real time procedure which may be further divided in a “hand free“ 
technique and a device guided one.  
4.1 Indirect method 
The indirect method uses ultrasound for establishing the puncture site, the depth of the 
target structure but without following the needle penetration. After performing two 
perpendicular scans, the site of the needle insertion is marked with a skin marking pen and 
the dept of the target is measured with the ultrasound machine callipers. After the probe 
removal and proper skin disinfection, the needle is perpendicularly inserted progressing 
blindly up to the depth previously measured, followed by aspiration and/or drug injection. 
The blind injection, despite previous imaging location of the target structure, may expose to 







Figure 2  
 
Fig. 2. Anterior transversal scanning and view of the hip. Patient photo and correct position 
of the probe perpendicular to the femoral neck ( red line); drawing of the hip region and 
sonoanatomy of the hip. Medial to the joint ( right side of the ultrasound image), the 
neurovascular structures can be recognized. Legend: B- bone, IPM- ilio-psoas muscle, N- 
femoral nerve, A- femoral artery, V- femoral vein, iliac b- iliac bone. 
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4.2 Real time method 
With the real time injection methods, the probe is placed in close proximity of the puncture 
site and the progression of the needle is followed having direct ultrasound control of the 
position and depth.  
4.2.1 Device guided technique 
The device guided technique is used less frequently in clinical practice because of the 
supplementary cost of the biopsy device and further sterile preparation before each 
punction manoeuvre. Instead, the penetration of the needle is more precisely and easier to 
use even for beginners in the field of invasive guided manoeuvres, the insertion of the 
needle is made always from the lateral side of the probe, in older models. Attachable 
guiding kits are easier to use and became more popular in the last years. The procedure can 
be easily performed by a single person , but the method has a certain limitation due to the 
fixed angle relative to the transducer. 
4.2.2 Hand free technique 
The “hand free“ technique requires more experienced practitioners but is more flexible, 
allows multiple angle repositioning of the probe and may allow, if necessary, to redirect the 
needle during the manoeuvre. The site of needle insertion can be placed in fact anywhere in 
relation with the probe and allows the choice of the most convenient position for the 
performing doctor. The method is performed usually by two or, more rarely, by a single 
physician but is burdened by higher learning costs. 
5. Approach to the hip joint 
Nowadays, two real time musculoskeletal ultrasound guided hip injection approaches are 
used (Migliore A et al., 2001, 2004).  The longitudinal antero- inferior approach, suggested 
mostly for aspiration of synovial fluid and corticosteroid deposition and the longitudinal 
antero- superior approach having the femoral head as target, proposed for 
viscosupplementation drug deposition.  
As a rule, before starting the interventional procedure, an ultrasound evaluation of the hip 
joint must be repeated in order to reconfirm the diagnostic selection criteria for the invasive 
manoeuvre and to choose the most appropriate approach. An adequate but also comfortable 
scanning position is required for the patient as well as for the doctor.  
6. Written consent of the patient 
The patient must be informed about the injection indication, about potential side effects or 
complications and must sign a written consent.  
7. Antiseptic rules 
All punction techniques must fulfil the antiseptic rules. After wearing of sterile gloves, 
the preparation of the skin above the hip with  iodine or  clorhexidine  gluconate is  
made. In addition to these requests, a large variation in using supple-mentary antiseptic 
methods is present among doctors. Some use a sterile condom to isolate the transducer 
followed by application of sterile gel on the scanning area. The needle insertion is possible 
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4.2 Real time method 
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site and the progression of the needle is followed having direct ultrasound control of the 
position and depth.  
4.2.1 Device guided technique 
The device guided technique is used less frequently in clinical practice because of the 
supplementary cost of the biopsy device and further sterile preparation before each 
punction manoeuvre. Instead, the penetration of the needle is more precisely and easier to 
use even for beginners in the field of invasive guided manoeuvres, the insertion of the 
needle is made always from the lateral side of the probe, in older models. Attachable 
guiding kits are easier to use and became more popular in the last years. The procedure can 
be easily performed by a single person , but the method has a certain limitation due to the 
fixed angle relative to the transducer. 
4.2.2 Hand free technique 
The “hand free“ technique requires more experienced practitioners but is more flexible, 
allows multiple angle repositioning of the probe and may allow, if necessary, to redirect the 
needle during the manoeuvre. The site of needle insertion can be placed in fact anywhere in 
relation with the probe and allows the choice of the most convenient position for the 
performing doctor. The method is performed usually by two or, more rarely, by a single 
physician but is burdened by higher learning costs. 
5. Approach to the hip joint 
Nowadays, two real time musculoskeletal ultrasound guided hip injection approaches are 
used (Migliore A et al., 2001, 2004).  The longitudinal antero- inferior approach, suggested 
mostly for aspiration of synovial fluid and corticosteroid deposition and the longitudinal 
antero- superior approach having the femoral head as target, proposed for 
viscosupplementation drug deposition.  
As a rule, before starting the interventional procedure, an ultrasound evaluation of the hip 
joint must be repeated in order to reconfirm the diagnostic selection criteria for the invasive 
manoeuvre and to choose the most appropriate approach. An adequate but also comfortable 
scanning position is required for the patient as well as for the doctor.  
6. Written consent of the patient 
The patient must be informed about the injection indication, about potential side effects or 
complications and must sign a written consent.  
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All punction techniques must fulfil the antiseptic rules. After wearing of sterile gloves, 
the preparation of the skin above the hip with  iodine or  clorhexidine  gluconate is  
made. In addition to these requests, a large variation in using supple-mentary antiseptic 
methods is present among doctors. Some use a sterile condom to isolate the transducer 
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through it. Other practitioners prefer nonsterile gel commonly used for musculoskeletal 
ultrasound evaluations, with application strictly under the probe footprint and needle 
insertion at a distance of 1-2 cm from the transducer margin through previous disinfected 
skin surface.  
8. Visualisation of the needle 
The progression of the needle through different tissue layers (fat tissue, rectus femoris and 
ilio- psoas muscle, capsule) can be followed if it is kept inside the ultrasound beam, with 
maximum accuracy if the penetration direction is perpendicular to the ultrasound beam. 
When linear array probes are used in standard view, the horizontal position of the needle 
allows a better visualisation of the progression in the tissues but in deep structures, like the 
hip joint, it is impossible to position the needle horizontal. The use of very long needles has 
a breaking risk during tissue penetration. Today, new developed steering based imaging 
techniques obtained by activating consecutive elements in the linear array are now able to 
generate oblique lines of sights along the dept axis creating the trapezoid shaped image 
display. In this case, due to the characteristics of the ultrasound beam or by using 
curvilinear probes, the 45° up to 60º degree angulation of the needle obtains good 
visualisation of the needle position. In clinical practice, it is proven that the visualisation of 
the relationship between the needle tip and target structure is more important in 
comparison to the visualisation of the entire needle body. 
For aspiration, spinal-needle gauge 18-20 are used, while for injection only, a 22 gauge 
needle is sufficient. For better visualisation due to increased reflectivity, some performing 
physicians scratch the needle surface with a sterile scalpel and keep the mandrin inside 
while inserting the needle. (Sofka CM et al., 2005)  
9. Artifacts 
Some artefacts, like anisotropy can occur, creating difficulties in needle visualisation. This 
artefact may appear when the needle is not strictly perpendicular to the ultrasound beam: in 
this case, the needle is not visualised as a shiny hyperechoic line but it appears as a hypo- 
anechoic line. Also the comet tail artefact characteristic for the needle insertion in a fluid 
collection can be very much attenuated while penetrating a solid structure. Some 
practitioners activate the Doppler mode while penetrating the skin and underlying layers   
to follow the needle tip up to the bony cortex. (Hamper UM et al., 1991) 
10. Hip injection techniques 
10.1 Antero- inferior longitudinal approach 
The antero- inferior longitudinal approach is designed for hip aspiration of the anterior recess 
content in inflammatory or septic conditions as well as for corticosteroid injections in cases 
of synovitis refractory to traditional treatment. (Iagnocco A et al., 2006; Micu MC et al., 2010; 
Zhang W et al., 2005, 2008)  
In our daily practice, the “free hand” technique is used with the following steps: the patient 
lays in supine position and legs slightly external rotated , the image of the hip is obtained in 
longitudinal view ( probe placed parallel to the femoral neck and lateral to the femoral 
neuro- vascular structures) and transversal view for the last check. After proper disinfection 
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of the area, the image is obtained in longitudinal view by placing nonsterile gel exactly 
under the probe footprint, the needle is inserted 2 cm from the distal part of the probe with 
an angle of 45° degrees to the horizontal skin plane having as target the head neck junction. 
The needle insertion can be traced from the moment it enters in the ultrasound beam, 
approximately 1 cm below the skin, through the fat tissue, rectus femoris and ilio-psoas 


















Fig. 3. Anterior longitudinal view of the hip; visualisation of the needle as a hyperechoic line 
penetrating the rectus femoris muscle (white arrows) 
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of the area, the image is obtained in longitudinal view by placing nonsterile gel exactly 
under the probe footprint, the needle is inserted 2 cm from the distal part of the probe with 
an angle of 45° degrees to the horizontal skin plane having as target the head neck junction. 
The needle insertion can be traced from the moment it enters in the ultrasound beam, 
approximately 1 cm below the skin, through the fat tissue, rectus femoris and ilio-psoas 


















Fig. 3. Anterior longitudinal view of the hip; visualisation of the needle as a hyperechoic line 
penetrating the rectus femoris muscle (white arrows) 
  



























Fig. 4. Anterior longitudinal view of the hip; visualisation of the needle as a hyperechoic line 
penetrating the rectus femoris and ilio-psoas muscle (white arrows) 
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After bony cortex contact, the needle is retracted 3-4 mm in order to avoid engaging the tip 
in the posterior synovial layer and facilitate the tip placement inside the anterior joint recess. 
In this position, the effusion can be aspirated and/ or corticosteroids can be injected. (Micu 


















Fig. 5. Anterior longitudinal view of the hip; irregularities of the bony cortex and synovitis 
with capsule distension can be seen. 
  



























Fig. 4. Anterior longitudinal view of the hip; visualisation of the needle as a hyperechoic line 
penetrating the rectus femoris and ilio-psoas muscle (white arrows) 
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After bony cortex contact, the needle is retracted 3-4 mm in order to avoid engaging the tip 
in the posterior synovial layer and facilitate the tip placement inside the anterior joint recess. 
In this position, the effusion can be aspirated and/ or corticosteroids can be injected. (Micu 


















Fig. 5. Anterior longitudinal view of the hip; irregularities of the bony cortex and synovitis 
with capsule distension can be seen. 
  
























Fig. 6. Anterior longitudinal view of the hip; the needle tip can be identified as a 
hyperechoic dot inside the anterior recess (black arrow). 
 






Figure 7  
 
 
Fig. 7. Anterior longitudinal view of the hip; visualisation of the corticosteroid drug as a 
hyperechoic mass while being injected ( black punctured arrow); distension of the capsule 
after corticosteroid deposition in direction of the white arrow. 
It is extremely important to visualize the progression of the needle through the capsule 
because sometimes this structure can become very thick after repeated inflammatory 
episodes, giving the sensation of bony contact inducing subsequent extracapsular drug 
deposition. A potential advantage of the antero- inferior longitudinal approach is the 
anatomical position of the ilio- femoral ligament with and inverted “Y” shape so that the 
needle can be inserted between the two ligament branches, in a thinner part of the capsule. 
This allows a less traumatic perforation.  
The aspiration of hip effusions is possible only in some cases, partly explicable due to its 
gravitational movement inside the recess while laying supine (Iagnocco A et al., 2006; Micu 
MC et al., 2010).  The injection of different corticosteroid products alone or with Lidocaine, 
with or without a small amount of air, is visualized in real time as a growing hyperechoic 
mass generated by the injected drug crystals and air bubbles creating the reverberation and 
ring down artifacts. The detection of the antigravitational movement of the drugs in the 
supero- anterior recess is also possible.  (Figures 8, 9)  
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Fig. 8. Anterior longitudinal view of the hip- trapezoidal view; progressive antigravitational 
movement of the corticosteroid drug after intraarticular deposition (black punctured 
arrows) at the beginning of the injecting manoeuvre. 
 





Fig. 9. Anterior longitudinal view of the hip- trapezoidal view; progressive antigravitational 
movement of the corticosteroid drug after intraarticular deposition generating comet tail 
artefact and partially blocking the ultrasound beam penetration ( black punctured arrows), 
at the end of the injecting manoeuvre. 
Sometimes, hyperechoic traces of CS can be visualized while retracting the needle, 
indicating the direction of previous needle penetration. Some authors suggest to flush the 
syringe and needle with lidocaine or saline solution at the end of the injection avoiding the 
reflux of corticosteroids into the shaft during the retraction of the needle (Bianchi , 2007). 
10.2 Antero- superior longitudinal approach 
The antero- superior longitudinal approach is used mainly for viscosuplementation products 
injection and allows deposition of the drug as close as possible to the femoral cartilage 
(Migliore A et al., 2004). It is not known if there is a real benefit of this kind of drug deposition 
and if the drug remains in the cartilage proximity after the patients regain vertical position. 
Other authors use also the antero- inferior approach for viscosupplementation drug 
deposition. (Qvistgaard E et al., 2006)  The position of the patient, the scanning technique, and 
skin preparation procedure follow the same steps as described before and a spinal puncture 
needle of 22 gauge is inserted usually using a biopsy guiding device. The needle is introduced 
inside the anterior capsular recess at the level of the femoral head and after femoral head 
contact, retraction of the needle tip of 1 mm is requested and drug is injected under direct 
visualisation of the drug in grey scale or Doppler.  
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11. Patients selection criteria 
The physician must be aware of the current selection criteria for diagnostic and therapeutic 
hip injection. For diagnostic purposes, aspiration of hip synovial fluid is important for 
differentiating septic arthritis from other inflammatory joint involvement, especially in 
monoarthritis. Aspiration can be of benefit also due to mechanical decompression and 
cleaning of the joint recess by pathologic fluid removal. 
11.1 Corticosteroid intraarticular hip injection 
The selection for corticosteroid hip intraarticular injection is made for patients with 
symptomatic hip OA, refractory to conventional pain killers, with synovitis and sometimes 
also for patients with advanced OA with contraindication for total hip replacement. (Kruse 
DW, 2008) 
11.2 Intraarticular hip viscosupplementation 
Hip intraarticular viscosupplementation is recommended in patients refractory to other 
non-invasive-nonsurgical treatment options, not yet candidates for hip replacement, with 
contraindication for NSAIDs, and refractory to corticosteroids (Migliore A et al., 2010). 
11.3 Exclusion criteria 
There are important exclusion criteria for hip injection techniques to be considered. Most of 
the contraindications are temporary and relative, such as suspected or known hip joint 
infection, joint fracture, anticoagulant therapy to avoid intra/ peri- capsular bleeding, 
extensive skin pathology in the area of injection, presence of joint prosthesis, uncontrolled 
high blood pressure and diabetes mellitus, glaucoma, severe congestive heart failure, some 
severe liver or bone marrow diseases with negative impact on coagulation. Drug(s) allergy 
may represent an absolute contraindication. Severe hip OA with total absence of 
radiological joint space contraindicates the use of intraarticular viscosupplementation drugs 
(Kruse DW, 2008; Migliore A et al., 2010). 
12. Efficacy of intraarticular guided injections 
Recent trials have demonstrated clear clinical benefit of intraarticular hip injection with 
corticosteroids and viscosupplementation in hip OA treatment. The imaging techniques 
currently used for guiding needle insertion are musculoskeletal ultrasound and fluoroscopy, 
in different protocols, praparates and dosage ( Atchia I et al., 2011; Flanagan J et al., 1988; 
Kullenberg B et al., 2004; 2005; Lambert RGW et al., 2001; Leopold SS et al., 2005; Margules 
KR , 2001; Migliore A et al., 2004, 2010; Micu MC et al., 2010; Qvistgaard E et al., 2006; 
Robinson P et al., 2007; Sofka CM et al., 2005).  
13. Side effects 
As with any other joint injections, various and well known side effects may occur with hip 
intraarticular joint injection. There are three major concerns for the hip- septic arthritis, 
osteonecrosis and risk of joint infection after total hip replacement following pre-operative 
intraarticular corticosteroid injection in a close interval up to the surgical event. In fact, there 
are just a few cases published in the medical literature reporting the occurrence of local side 
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effects. Intraarticular viscosupplementation drug deposition is well tolerated and without 
significant systemic side effects. There are by now eight reported cases of intraarticular 
granulomatosus inflammation developed after a series of three hyaluronic acid injection 
(Hyalgan GF 20). Intraarticular corticosteroid deposition may have mild systemic effects like 
transient facial rash, increase of blood pressure or hyperglicemia and local secondary 
crystalline synovitis which leads to rapid postprocedural local pain. In the literature, there 
are only two case reports mentioning septic hip involvement following intraarticular 
corticosteroid injection (Kruse DW, 2008) and four cases of hip aseptic osteonecrosis, but in 
three of them, corticosteroid deposition was made in another joint. (Kruse DW, 2008; 
Migliore A et al., 2010) Significant increase in arthroplasty revision secondary to infection in 
patients who received intraarticular corticosteroid injection prior to surgery is reported in a 
study performed in 2005 (Kaspar S & de V de Beer j, 2005), but other studies did not confirm 
any relationship between intraarticular corticosteroid injection prior to total hip 
arthroplasty. (Chitre AR et al., 2007) As caution, a gap of two months prior to the surgical 
event is recommended. 
14. Post- procedural monitoring 
Regardless of the procedure type, aspiration and/ or drug intraarticular injection, the 
patient must inform the performing physician if any local disturbance or fever occurs within 
the first 48-72 hours suggesting postprocedural infection. Musculoskeletal ultrasound 
evaluation for hip joint and periarticular structures can be repeated anytime during follow 
up without restriction. 
15. Conclusions 
Ultrasound guided hip injections is ideal for clinical practice because it is rapid, safe and 
cheap. The method allows precise aspiration even of small amounts of intraarticular fluid 
and accurate deposition of corticosteroids and viscosupplementation drugs increasing the 
treatment efficacy. The increasing evidence that musculoskeletal ultrasound is of paramount 
importance in the rheumatological practice is a further support for its use in guiding the 
intrarticular  injections in order to avoid damage of the structures, misplacing of drugs and 
help fluid aspiration for diagnostic purposes. 
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1. Introduction 
Ankle osteoarthritis (OA) is a degenerative joint disease that can cause substantial pain, 
muscle weakness and functional limitations. Due chiefly to its post-traumatic origin and 
appearance in young patients, ankle OA has a high impact on socioeconomics and patients’ 
quality of life. Approximately 6% to 13% of all cases of OA involve the ankle joint (Thomas 
and Daniels, 2003). Recent research also identify that a larger number of patients are being 
diagnosed with ankle OA (Saltzman et al, 2005). Currently, no curative therapy is available 
for OA, and thus the overall goals of management are to reduce pain and prevent disability. 
Treatment options include simple analgesics, nonsteroidal anti-inflammatory drugs 
(NSAIDs), weight reduction, physical and occupational therapy, activity modification, 
orthotic devices, shoe modifications, intraarticular corticosteroid injections, and surgery. 
Although some cases can be treated successfully with surgery, many patients are either not 
good candidates for surgery or may want to avoid or delay it if possible. There is a need for 
a treatment that reduces chronic joint pain and improves function yet avoids toxic effects of 
medications and the morbidity and mortality risks of surgery. One such option for these 
patients may be the intraarticular injection of hyaluronate. 
Hyaluronate, a high molecular weight polysaccharide, is a principal component of synovial 
fluid and extracellular matrix of articular cartilage. It contributes to the elasticity and 
viscosity of synovial fluid. In addition to providing joint lubrication and shock absorbancy, 
hyaluronate helps to maintain the structural and functional characteristics of the cartilage 
matrix. It also inhibits the formation and release of prostaglandins, induces proteoglycan 
aggregation and synthesis, and modulates the inflammatory response (Frizziero, 1998). In 
OA, the concentration and molecular weight of hyaluronate are reduced, limiting its role in 
maintaining normal joint biomechanics (Engström-Laurent A, 1997). Viscosupplementation 
with intraarticular injections of hyaluronate was approved by the Food and Drug 
Administration (FDA) in 1997 for treating pain associated with knee OA. Although the exact 
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1. Introduction 
Ankle osteoarthritis (OA) is a degenerative joint disease that can cause substantial pain, 
muscle weakness and functional limitations. Due chiefly to its post-traumatic origin and 
appearance in young patients, ankle OA has a high impact on socioeconomics and patients’ 
quality of life. Approximately 6% to 13% of all cases of OA involve the ankle joint (Thomas 
and Daniels, 2003). Recent research also identify that a larger number of patients are being 
diagnosed with ankle OA (Saltzman et al, 2005). Currently, no curative therapy is available 
for OA, and thus the overall goals of management are to reduce pain and prevent disability. 
Treatment options include simple analgesics, nonsteroidal anti-inflammatory drugs 
(NSAIDs), weight reduction, physical and occupational therapy, activity modification, 
orthotic devices, shoe modifications, intraarticular corticosteroid injections, and surgery. 
Although some cases can be treated successfully with surgery, many patients are either not 
good candidates for surgery or may want to avoid or delay it if possible. There is a need for 
a treatment that reduces chronic joint pain and improves function yet avoids toxic effects of 
medications and the morbidity and mortality risks of surgery. One such option for these 
patients may be the intraarticular injection of hyaluronate. 
Hyaluronate, a high molecular weight polysaccharide, is a principal component of synovial 
fluid and extracellular matrix of articular cartilage. It contributes to the elasticity and 
viscosity of synovial fluid. In addition to providing joint lubrication and shock absorbancy, 
hyaluronate helps to maintain the structural and functional characteristics of the cartilage 
matrix. It also inhibits the formation and release of prostaglandins, induces proteoglycan 
aggregation and synthesis, and modulates the inflammatory response (Frizziero, 1998). In 
OA, the concentration and molecular weight of hyaluronate are reduced, limiting its role in 
maintaining normal joint biomechanics (Engström-Laurent A, 1997). Viscosupplementation 
with intraarticular injections of hyaluronate was approved by the Food and Drug 
Administration (FDA) in 1997 for treating pain associated with knee OA. Although the exact 
mechanism of action is not understood with certainty, recent research suggests that it exerts 
anti-inflammatory, analgesic, anabolic and possibly chondroprotective effects on the 
articular cartilage and joint synovium that reduce pain and disability and improve joint 
function. 
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There are five injectable forms of hyaluronate approved for use in the United States, 
including Hyalgan, Supartz, Orthovisc, Synvisc and Euflexxa (Table 1). Each of these 
hyaluronate products differ in their origin, method of production, molecular weight, 
dosing instructions, rheologic properties, cost, pharmacodynamics and possibly clinical 
outcomes.  
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500-730 6000 620-1170 1000-2900 2400-3600 
Amount  


















3 or 5 weekly 
3 weekly 
(In 2009, FDA 
approved single-
dose Synvisc-
One™ 6 mL 
injection for the 
treatment of knee 
OA) 
5 weekly 3 or 4 weekly 3 weekly 
Table 1. Characteristics of five formulations of intraarticular Hyaluronans available in the 
United States 
All products are manufactured from rooster combs except for Euflexxa, which is the only 
non-avian derived hyaluronan approved in the United States. Also, Synvisc undergoes 
additional chemical crosslinking to create hylans with increased molecular weight and 
increased elastoviscous properties. The differing molecular weights of the products lead 
to different half-lives; the half-life of Hyalgan or Supartz is estimated at 24 hours, while 
the half-life of Synvisc may range up to several days. There is no consistent evidence from 
well-controlled clinical studies that documents the superior efficacy of one product over 
another. 
Although viscosupplementation is a well-established treatment option in knee OA and is 
included in the professional guidelines by European League of Arthritis & Rheumatism 
(EULAR) and American College of Rheumatology (ACR), evidence regarding its use in 
ankle OA is limited. Recently, several studies attempting to evaluate the use of hyaluronate 
in the ankle have been published. In this chapter, we discuss our experiences, the 
indications, injection technique and review the clinical outcomes on hyaluronate use in 
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patients with ankle OA. Additionally, future directions for the use of hyaluronate in the 
management of ankle OA and areas of active research in hyaluronate are discussed. 
2. Indications 
The exact indications for viscosupplementation are still evolving, but it currently can be 
considered for use in patients who have significant residual symptoms despite traditional 
nonpharmacologic and pharmacologic treatments. In addition, patients who have 
gastrointestinal or renal intolerance to NSAIDs, and those who wish to postpone surgical 
intervention or are poor candidates for surgery can be considered for these injections. 
Contraindications to hyaluronate injection include protein/avian allergy (except Euflexxa), 
active skin disease and joint infections at the injection site. Patients with substantial venous 
or lymphatic stasis in the legs, bleeding disorder or treatment with anticoagulants are 
relatively contraindicated. Hyaluronate is not recommended to pregnant women, lactating 
women and children under 18, because the safety and effectiveness have not been 
established.  
The ideal candidate for viscosupplementation has yet to be defined. Studies are inconclusive 
regarding the best responders with respect to age, level of OA as defined radiographically, 
level of symptoms and level of physical activity. We previously reported (Sun et al, 2006a) 
that patients with Kellgren-Lawrence grade 1and 2 ankle OA had good response to 
viscosupplementation (grade 1, doubtful narrowing of joint space and possible osteophytic 
lipping; grade 2, definite osteophytes and possible narrowing of joint space). This suggested 
that viscosupplementation was effective in mild to moderate ankle OA. Whether severe 
cases would likely respond to viscosupplementation remained unknown. In another case 
series by our study group (Sun et al, 2011), we stratified patients by age and radiographic 
severity to determine whether these factors would influence the treatment response. 
Subgroup analysis results showed that there was no significant difference in outcomes 
between patients with grade 2 and grade 3 OA in each study period. However, we found 
difference in clinical balance tests between patients of the younger age-group and the older 
age-group at different time points. As the subgroup analysis was not sufficiently powered, 
definite conclusion could not be drawn.  
As the treatment group increases, the ideal subgroup of patients who are best candidates for 
ankle viscosupplementation should be identified. 
3. Injection technique  
In our experience, intraarticular injection of the ankle joint is easy to perform and requires 
no radiologic guidance. The two approaches for performing an ankle joint injection are the 
anterior medial and anterior lateral (Figure 1). For the anterior medial approach, we position 
the patient in the supine position, with the knee flexed and the foot flat on the examination 
table. The ankle is placed in a degree of plantarflexion, which opens the anterior aspect of 
the joint. We identify the space between the anterior border of the medial malleolus and the 
medial border of the tibialis anterior tendon and palpate this space for the articulation of the 
talus and tibia to locate a suitable entry point into the ankle joint. The injections are 
performed in aseptic conditions. We insert a 21-23 gauge needle into the identified space 
and direct posterolaterally to run parallel to the upper surface of the talus, which is slightly 
convex . Joint effusion, if present, should be aspirated before injection. Alternatively, the 
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The exact indications for viscosupplementation are still evolving, but it currently can be 
considered for use in patients who have significant residual symptoms despite traditional 
nonpharmacologic and pharmacologic treatments. In addition, patients who have 
gastrointestinal or renal intolerance to NSAIDs, and those who wish to postpone surgical 
intervention or are poor candidates for surgery can be considered for these injections. 
Contraindications to hyaluronate injection include protein/avian allergy (except Euflexxa), 
active skin disease and joint infections at the injection site. Patients with substantial venous 
or lymphatic stasis in the legs, bleeding disorder or treatment with anticoagulants are 
relatively contraindicated. Hyaluronate is not recommended to pregnant women, lactating 
women and children under 18, because the safety and effectiveness have not been 
established.  
The ideal candidate for viscosupplementation has yet to be defined. Studies are inconclusive 
regarding the best responders with respect to age, level of OA as defined radiographically, 
level of symptoms and level of physical activity. We previously reported (Sun et al, 2006a) 
that patients with Kellgren-Lawrence grade 1and 2 ankle OA had good response to 
viscosupplementation (grade 1, doubtful narrowing of joint space and possible osteophytic 
lipping; grade 2, definite osteophytes and possible narrowing of joint space). This suggested 
that viscosupplementation was effective in mild to moderate ankle OA. Whether severe 
cases would likely respond to viscosupplementation remained unknown. In another case 
series by our study group (Sun et al, 2011), we stratified patients by age and radiographic 
severity to determine whether these factors would influence the treatment response. 
Subgroup analysis results showed that there was no significant difference in outcomes 
between patients with grade 2 and grade 3 OA in each study period. However, we found 
difference in clinical balance tests between patients of the younger age-group and the older 
age-group at different time points. As the subgroup analysis was not sufficiently powered, 
definite conclusion could not be drawn.  
As the treatment group increases, the ideal subgroup of patients who are best candidates for 
ankle viscosupplementation should be identified. 
3. Injection technique  
In our experience, intraarticular injection of the ankle joint is easy to perform and requires 
no radiologic guidance. The two approaches for performing an ankle joint injection are the 
anterior medial and anterior lateral (Figure 1). For the anterior medial approach, we position 
the patient in the supine position, with the knee flexed and the foot flat on the examination 
table. The ankle is placed in a degree of plantarflexion, which opens the anterior aspect of 
the joint. We identify the space between the anterior border of the medial malleolus and the 
medial border of the tibialis anterior tendon and palpate this space for the articulation of the 
talus and tibia to locate a suitable entry point into the ankle joint. The injections are 
performed in aseptic conditions. We insert a 21-23 gauge needle into the identified space 
and direct posterolaterally to run parallel to the upper surface of the talus, which is slightly 
convex . Joint effusion, if present, should be aspirated before injection. Alternatively, the 
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anterior lateral approach is done with the patient positioned with the foot in plantar flexion. 
The needle is inserted from the anterior lateral position and directed posteriorly toward the 
medial malleolus. The needle is advanced until there is a drop in tissue resistance 
confirming entry into the joint. Excessive weight bearing and strenuous activity are 
discouraged within 2 days following injection. Otherwise, no specific post-injection 
instructions are necessary. 
Most injection in the ankle joint was performed without any instrumental guide in the 
literature. One of the limitations of hyaluronate therapy is that it can be difficult to ensure 
that intraarticular injections are actually given into the joint capsule. In clinical trials with 
ankle viscosupplementation, only one trial used a fluoroscopic guide for the injection 
(Cohen et al, 2008). Ultrasound has been used to guide hyaluronate injection in hip and 
hand OA, however, no ultrasound guide has been used in ankle OA studies. The aim for the 
future is to encourage the ultrasound-guided intraarticular injection because it is simple, 
fast, economic and safe; it does not require the use of contrast, allowing the intraarticular 
injection in patients intolerant to iodized contrasts. It can be repeated without limits, allows 
an easy visualization of fluid in the articular recess, the correct position of the needle and the 
distance from the vessels. 
 
 
Fig. 1. The two approaches for ankle joint injection: the anterior medial and anterior lateral 
approaches 
4. Overview of clinical outcomes 
The potential for treating ankle OA by viscosupplementation has been suggested in the 
literature. To date, there are only 3 randomized controlled, double-blind trials ( Salt et al, 
2006; Cohen et al , 2008; Karatosun et al, 2008) (Table 2) and a few case series in the search of 
the literature on viscosupplementation therapy for ankle OA (Table 3). Two recent reviews 
(Migliore et al, 2011; Sun et al, 2009) have provided an overview of clinical trials with 
hyaluronate therapy in ankle OA.  
Salk et al. performed the first randomized, double-blind, saline solution-controlled trial in 
patients with grade 2, 3 and 4 (Kellgren–Lawrence) ankle OA (Salk et al, 2006), assessing the 
efficacy and safety of hyaluronate for the treatment of ankle OA. Patients were randomized 
to receive 5 weekly intraarticular injections of either 1 mL of sodium hyaluronate (10 
mg/mL) or 1 mL of phosphate-buffered saline solution into the ankle joint. The primary 
outcome measure was the ankle osteoarthritis score (AOS) pain and disability assessment 
(Domsic and Saltzman, 1998). At 6-month follow-up, trends toward greater improvement in 
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the hyaluronate group compared with sham injection control were noted. The benefit with 
hyaluronate in the treatment of ankle OA is consistent with previous published studies 
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Abbreviations in the table: 
HA=hyaluronic acid 
AOS= ankle osteoarthritis score 
AOFAS= American Orthopaedic Foot and Ankle Society 
VAS= visual analog scale 
WOMAC= Western Ontario and McMaster Universities Arthritis Index 
Table 2. Randomized controlled trials of Viscosupplementation in the Treatment of Ankle 
Osteoarthritis 
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Author Year Viscosupplement Study Patients Outcome Measures Outcomes 
Sun et al 
(2006) 
Artz (5 injections), 














Safe and efficacious, 
effects rapid at 1 week 
post the fifth injection, 
lasting for 6 months  in 
patients with  Kellgren-
Lawrence grade 1 or 2 
ankle OA. 
High patients’ 
satisfaction rate.  
Significant reduction in 
analgesics consumption 
Witteveen 




2 ml per injection 
51 one 
injection 






Safe and effective for 6 
months in patients with 
grade 2 ankle OA (van 
Dijk et al scale).  
Carpenter  
et al (2008) 
Sinvisc (3 
injections), 
2 ml per injection 
26 






The mean pain score of 
the HA+arthroscopy 
group was 1, the score 
for the arthroscopy  
alone group was 3 on a 
10 point VAS scale in 
patients with Kellgren-
Lawrence grade 2-4 




et al (2008) 
Sinvisc  
(3 injections), 






improvement in AOS 
from baseline in 
patients with Kellgren-
Lawrence grade 2 ankle 
OA after 6 months, 




et al. (2010) 
Adant (5 
injections) 









Improvement of 20% in 
the ROM, significant 
reduction in VAS scale 
and ankle-hindfoot 
scores in patients with 
Kellgren-Lawrence 
grade 2-4 ankle OA for 7 
months 
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Author Year Viscosupplement Study Patients Outcome Measures Outcomes 


















Safe and effective, 
improve physical 
function and balance 
with high patients’ 
satisfaction in patients 
with unilateral 
Kellgren-Lawrence 
grade 2 or 3 ankle OA. 
Abbreviations in the table: 
HA=hyaluronic acid 
AOS= ankle osteoarthritis score 
AOFAS= American Orthopaedic Foot and Ankle Society 
ROM=range of motion 
VAS= visual analog scale 
Table 3. Case Series of Viscosupplementation in the Treatment of Ankle Osteoarthritis 
Cohen et al. performed a randomized, double blind, saline solution-controlled trial of 
patients with grade 2, 3 and 4 (Kellgren–Lawrence) ankle OA (Cohen et al, 2008). Patients 
were randomized to receive 5 weekly injections of either 2 mL of sodium hyaluronate 
(Hyalgan) or 2 mL of phosphate-buffered saline solution in the ankle joint. All injections 
were fluoroscopically guided. The primary endpoint was pain on movement and weight 
bearing using the AOS 3 months after injection. At month 3, the patients in the hyaluronate 
group showed a significant improvement from baseline in AOS total score than those in the 
control group.  
Karatosun et al. performed a prospective randomized trial with 12-months follow-up, to 
evaluate the efficacy of intraarticular injection of sodium hyaluronate (Adant®) 
compared with exercise therapy (Karatosun et al, 2008). Patients with grade 3 (Kellgren–
Laurence) ankle OA were randomized to receive 3 weekly intraarticular injections of 
hyaluronate or an exercise cycle therapy, which included a series of progressive, 
isometric, isotonic range of motion, resistance, closed kinetic chain and proprioceptive 
exercise, for 6 weeks. Outcomes, including the American Orthopaedic Foot and Ankle 
Society (AOFAS) Ankle-Hind Foot score(Kitaoka et al,1994), gait, pain with VAS scale 
were evaluated and analyzed. At 12 months, both groups improve in pain score, walking 
surface, gait quality and total ankle–hind foot score. The authors concluded that the 
patients benefit either by 3 injection of hyaluronate or by 6 weeks of exercise therapy. 
The advantage of exercise therapy may be its non-invasive nature being preferred by 
both the physicians and the patients; however, while exercise therapy last 6 weeks, 
hyaluronate injections stop at 3 weeks. This point may be an advantage for the 
preference of hyaluronate injections. 
In a relatively large case series by our group (Sun et al, 2006a), we reported outcomes of 75 
patients with unilateral grade 1 or 2 (Kellgren–Lawrence) ankle OA. We concluded similarly 
that a regimen of 5 weekly intraarticular injection of sodium hyaluronate was safe and 
effective in the areas of pain and ankle function. Patients expressed a high level of 
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Author Year Viscosupplement Study Patients Outcome Measures Outcomes 
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Laurence) ankle OA were randomized to receive 3 weekly intraarticular injections of 
hyaluronate or an exercise cycle therapy, which included a series of progressive, 
isometric, isotonic range of motion, resistance, closed kinetic chain and proprioceptive 
exercise, for 6 weeks. Outcomes, including the American Orthopaedic Foot and Ankle 
Society (AOFAS) Ankle-Hind Foot score(Kitaoka et al,1994), gait, pain with VAS scale 
were evaluated and analyzed. At 12 months, both groups improve in pain score, walking 
surface, gait quality and total ankle–hind foot score. The authors concluded that the 
patients benefit either by 3 injection of hyaluronate or by 6 weeks of exercise therapy. 
The advantage of exercise therapy may be its non-invasive nature being preferred by 
both the physicians and the patients; however, while exercise therapy last 6 weeks, 
hyaluronate injections stop at 3 weeks. This point may be an advantage for the 
preference of hyaluronate injections. 
In a relatively large case series by our group (Sun et al, 2006a), we reported outcomes of 75 
patients with unilateral grade 1 or 2 (Kellgren–Lawrence) ankle OA. We concluded similarly 
that a regimen of 5 weekly intraarticular injection of sodium hyaluronate was safe and 
effective in the areas of pain and ankle function. Patients expressed a high level of 
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satisfaction, with only relatively few local adverse events. These effects were rapid at 1 week 
post the fifth injection and could last for 6 months. One limitation in this trial includes the 
absence of a control group, thus the placebo effects associated with joint injections per se 
were not analyzed.  
In the prospective case series by Witteveen et al, patients with symptomatic grade 2 (van 
Dijk et al scale) ankle OA (>50 and <90 mm on a 100 mm visual analog scale (VAS), were 
treated with intraarticular injection of Hylan GF-20 (Synvisc, 2 mL) plus an optional second 
injection if pain remained at baseline level after 1, 2 or 3 months, with 6–9-months follow-up 
period (Witteveen et al, 2008). The primary efficacy endpoint was the change from baseline 
in the Pain VAS Score at 3 months. The results showed a statistically significant decrease in 
the mean Pain VAS score from 68.0 mm at baseline to 33.8 mm at month 3. They reported 
that a regimen of one single intraarticular injection of hyaluronate (Synvisc), with the option 
of a second injection after 1–3 months if pain relief is inadequate, is an efficacious treatment 
of patients with symptomatic ankle OA.  
Carpenter et al. conducted a controlled trial investigating the effectiveness of Hylan G-F 20 
in reducing pain following ankle arthroscopy in patients with grade 2, 3 and 4 (Kellgren–
Laurence) ankle OA (Carpenter and Motley, 2008). Fourteen patients received 3 weekly 
injections of Hylan G-F 20 post ankle arthroscopy, while 12 patients received only ankle 
arthroscopy. At 3 months, the mean pain score of the Hylan G-F 20 plus arthroscopy group 
was 1, while the score for the arthroscopy alone group was 3 on a 10 point VAS scale, and 
this difference was statistically significant.  
In a case series by Luciani et al, 21 patients with a grade 2 (Kellgren–Laurence) ankle OA 
had 3 weekly intraarticular injections of 2 ml of synvisc into the ankle joint (Luciani et al, 
2008). The primary clinical outcome measurement was the AOS. The results showed 
significant improvement of the AOS from baseline after 6 months and this improvement 
was maintained at 12- and 18-month follow-ups.  
Mei-Dan et al. have studied 16 patients with grade 2-4 (Kellgren-Lawrence) ankle OA who 
received intraarticular injections of 25mg of sodium hyaluronate for 5 consecutive weeks 
(Mei-Dan et al, 2010). There was a significant reduction in pain assessed by VAS scale and 
ankle-hindfoot scores and an improvement of 20% in the range of motion. 
Previous ankle viscosupplementation studies reported that five weekly intraarticular 
injections of hyaluronate were safe and effective; however, the effect of three weekly 
injections has rarely been investigated. Our study group (Sun et al, 2011) conducted another 
prospective case series with a 6-month follow-up period and reported that three weekly 
injections of sodium hyaluronate are well tolerated, can provide pain relief, improve 
function and balance in patients with unilateral grade 2 or 3 (Kellgren–Lawrence) ankle OA. 
OA remains by far the most common disease of joints and represents a huge burden to 
society in terms of personal suffering and health resource utilization. The three-injection 
regimen may possibly represent a cost-saving therapy. Besides, pain associated with ankle 
OA may cause loss of balance, leading to falls, more injuries and higher costs to the patient 
and society. This study was the first that examined the effect of hyaluronate on balance in 
patients with ankle OA, as we had previously reported significant improvements in pain, 
physical function and balance tests after five weekly hyaluronate injections in geriatric 
patients with knee OA (Sun et al,2006b). Although the mechanism by which hyaluronate 
results in a clinical benefit in balance remains unknown and it remain an area important for 
future research, we thought pain reduction might be one of the major contributing factor.   
 




Because use of hyaluronate in the ankle is an “off label” application of this agent, patient 
safety is a key issue considering this treatment. Clinical studies have demonstrated that 
viscosupplementation is generally safe and well tolerated. Although significant 
complications are rare, mild adverse effects have been reported. Because there are no 
known hyaluronate–medication interactions, it is a good option for patients on multiple 
medications, particularly the elderly. Mild injection-site pain and swelling are the most 
common adverse events in the injected joints. These reactions are usually transient, 
resolving without intervention within 1 to 3 days. Other adverse events included rash, 
muscle cramps, dizziness, nausea, headache, local ecchymosis and pruritus. The overall 
incidence of adverse reactions in knee studies has been reported to be approximately 1% 
to 4%. Rare cases of post-injection pseudogout with sodium hyaluronate and Synvisc have 
been reported. It is unclear whether these reactions were caused by the hyaluronate itself 
or by the injection procedure. There is growing evidence that Synvisc may be associated 
with an adverse event termed pseudosepsis or a severe acute inflammatory reaction. 
Pseudosepsis presents as severe inflammation of the joint, with a large effusion, and 
significant pain occurring within 1 to 3 days post injection. It requires symptomatic 
treatment, including use of modalities, activity modification, analgesics, and NSAIDs. 
Once infection has been excluded, intraarticular steroids may be of value. Despite a lack 
of understanding of both the etiology of pseudosepsis and the long-term effects of these 
local immunological reactions, such events would be expected to incur additional 
socioeconomic costs. Additional study is required to enable the treating physician to 
identify patients at risk for this injection related complication and to determine whether 
patients with a history of a pseudosepsis after hyaluronate injection can safely receive 
further hyaluronate therapy. 
The safety in the treatment of ankle OA appears to be similar to the injections widely 
performed in the treatment of knee OA. No systemic adverse events were reported in the 
literature relating to ankle viscosupplementation; however, cases of local adverse 
reactions do exist. In study by Salt et al (Salk et al, 2006), injection site pain was noted in 5 
(29%) of the 17 patients, with no significant difference between the groups. In our case 
series (Sun et al, 2006a), local pain and erythema at the injection site occurred in 5 of 75 
patients, it was mild and resolved within 48 hours without sequela. The adverse reaction 
rate was 5.3% per injection and 6.7% per patient. We observed that these adverse events 
sometimes occurred after several injections without any reaction previously, and 
sometimes they did not occur in subsequent injections. Interestingly, local adverse 
reactions did not predict treatment failure. All of these patient received subsequent 
injections and they still improved clinically and reported high satisfaction. The incidence 
of adverse events was also low in the study by Cohen et al (Cohen et al, 2008), only one 
case of pseudogout, resolved without therapy, was observed in the Hyalgan group. 
Witteveen et al (Witteveen et al, 2008) reported 35 patients (63.6%) experienced a total of 
89 adverse events in their study, which was relatively high compared with other studies. 
The majority of adverse events were arthralgia, injection site pain, and joint swelling, 
which were reported to be mild or moderate in intensity and transient in nature. Luciani 
et al. reported 11 patients (52%) in their case series presented transient pain and erythema 
in the injection site that resolved within 2 days and did not interfere with remaining 
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injections (Luciani et al, 2008). In the case series by Carpenter et al.  (Carpenter and 
Motley, 2008), they did not observe any local or systemic adverse events.  
6. Further studies needed 
Despite the fact that hyaluronate has been proposed as a useful treatment of symptomatic 
knee OA, its role in the treatment of ankle OA is still not clear, due fundamentally to the 
dearth of large, well-controlled studies and to the methodologic limitations of those that 
have been published. Most studies included small cohorts, short follow-up periods and an 
overall level of evidence is low. The clinical effects of the hyaluronate products have 
considerable heterogeneity and therapeutic variability, as most studies use different 
dosages, injection frequencies, different outcome measures, especially at different time 
points.  Conclusions regarding the clinical effectiveness of each hyaluronate product could 
not be drawn. There was no evidence for differential effects according to subgroups defined 
by age, gender, primary/secondary disease, body mass index/weight, or disease severity. 
The exact mechanisms of viscosupplementation action on osteoarthritic joints are uncertain. 
Although recent attention has focused on the disease-modifying potential of hyaluronate, 
especially the chondroprotective mechanism, definitive evidence is still lacking. We believe 
that hyaluronate can be used as an adjunct therapy, after failure of one or more courses of 
oral pain medications, or perhaps as a first choice in the treatment of ankle OA before 
prescription of pain medications.  
Future studies regarding optimal dosing regimen, injection frequency and injection technique, 
optimal number of injections in a course of treatment, favorable prognostic factors, duration of 
benefits, effectiveness and safety of repeated courses of therapy, longer term trials, head-to-
head comparisons of the various hyaluronate products, as well as the biochemical, 
morphologic, and histopathologic effects on cartilage are warranted. Cost-effectiveness needs 
to be addressed. Comparison studies or combination therapies with other treatment options, 
such as intraarticular steroid injections, NSAIDs and therapeutic exercise, are also needed to 
help determine the best overall treatment plan for patients with ankle OA.  
7. Conclusion 
The published data suggest that viscosupplementation may potentially be a safe and 
effective alternative in treating patients with ankle OA. However, there are still inadequate 
data to provide definitive conclusions on the efficacy of hyaluronate in reducing pain or 
improvement of function among patients with ankle OA. The FDA has not approved 
intraarticular hyaluronate for joints other than the knee. To date ankle viscosupplementation 
should only be used under careful supervision by the clinician. Many uncertainties on the 
use of hyaluronate remain. The use of standardized outcome measures is encouraged to 
facilitate meta-analyses and between trial comparisons. Additional studies are required 
before viscosupplementation should be included into the treatment paradigm for patients 
with ankle OA. 
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1. Introduction  
Although articular hyaline cartilage was typically considered having no or low potential for 
regeneration (Zhang L et al., 2009), some still thought that it does have the capacity to grow 
and remodel extensively during pre- and post-natal development and after trauma 
(Onyekwelu I et al., 2009). Both direct and indirect evidence of articular cartilage 
regeneration have been observed by some authors after correction of varus deformity for 
osteoarthritis of the knee (Kanamiya T et al., 2002; Koshino T et al., 2003). Moreover, unlike 
the first impression of a more or less static tissue, articular cartilage shows a slow turnover. 
Anabolic and catabolic pathways were thought to be very much intermingled in articular 
cartilage (Aigner T et al., 2006). Thus, one of the most important questions in osteoarthritis 
research is to understand the balance of catabolic and anabolic factors in articular cartilage 
as this is the key to understand the biology of cartilage maintenance and degeneration. 
Osteoarthritis (OA) of the knee is the major cause of chronic musculoskeletal pain and is 
ranked as a main cause of mobility disability in elderly population. It is a disease process of 
uncertain multifactorial etiology, which eventually affects the entire joint. Various etiologic 
risk factors have been proposed, but the exact pathogenesis for OA knee is still unknown. 
Many literatures mentioned medial compartment is more commonly involved than the 
lateral one and the pathogenesis may be different (Neame R et al., 2004; Nunez M et al., 
2008). 
In 2006, we reported that in patients with medial compartment osteoarthritic knees, the 
prevalence of medial plica was significantly higher than that of others and that two distinct 
foci of cartilaginous lesion were found on the facing medial femoral condyle in almost all of 
the patients who had the structure of medial plica (Lyu SR and Hsu CC, 2006). Our further 
study disclosed the kinematic relationship of the medial plica with the medial femoral 
condyle during knee motion in vivo (Lyu SR, 2007). In that study, it was revealed that all 
medial plicae, regardless of their size, would move reciprocally and would keep in touch 
with the medial femoral condyle and therefore might cause some degree of abrasion on the 
facing medial femoral condyle during knee motion. Another histomorphological study of 
the medial plica also implied the close interplay between this structure and the medial 
femoral condyle (Lyu SR et al., 2009). Moreover, our recent study (Wang HS et al., 2011) 
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2008). 
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prevalence of medial plica was significantly higher than that of others and that two distinct 
foci of cartilaginous lesion were found on the facing medial femoral condyle in almost all of 
the patients who had the structure of medial plica (Lyu SR and Hsu CC, 2006). Our further 
study disclosed the kinematic relationship of the medial plica with the medial femoral 
condyle during knee motion in vivo (Lyu SR, 2007). In that study, it was revealed that all 
medial plicae, regardless of their size, would move reciprocally and would keep in touch 
with the medial femoral condyle and therefore might cause some degree of abrasion on the 
facing medial femoral condyle during knee motion. Another histomorphological study of 
the medial plica also implied the close interplay between this structure and the medial 
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found that the repeated injuries elicited by this abrasion phenomenon might trigger 
interleukin-1 (IL-1) production in medial plica, thus enhance the expression of matrix 
metalloproteinase-3 (MMP-3). Based on these findings, we developed a concept of 
arthroscopic medial release (AMR) for the treatment of osteoarthritis of the medial 
compartment of the knee joint (Lyu SR, 2008). The clinical outcome of this procedure lured 
us to believe that, by eradication of the abrasion phenomenon between the tight, fibrotic and 
hypertrophied medial structure and the adjacent medial femoral condyle, the pain of most 
patients could be reduced and the degenerative process in the medial compartment of some 
patients might be decelerated or arrested. Recently, we proposed a concept of arthroscopic 
cartilage regeneration facilitating procedure (ACRFP) that combines arthroscopic medial 
release (AMR) with conventional arthroscopic procedures including synovectomy, 
chondroplasty, partial meniscectomy and percutaneous lateral release (PLR) as a rationale 
for the deliberate arthroscopic management of OA knee. We’ve found that the elimination of 
the existing detrimental factors will provide a preferable environment for regeneration of 
the damaged cartilage. 
The main scheme of this chapter will be a step-by-step presentation of the development of a 
global approach which we call “knee health promotion option (KHPO)” for OA knee. In 
section 2, a new entity “medial abrasion syndrome (MAS)” and the related hidden lesions 
will be defined. Its role in the pathogenesis of medial compartmental OA knee will be 
discussed based on our series of studies. The techniques and clinical outcomes of two novel 
arthroscopic procedures: arthroscopic medial release (AMR) and arthroscopic cartilage 
regeneration facilitating procedure (ACRFP) which have been developed according to the 
rationale conceptualized from the results of our basic research will be described in section 3 
and 4. In section 5, a concept of total management of OA knee (KHPO) will be proposed. 
Finally, conclusions and discussions for the future prospect are presented in section 6. 
2. Medial abrasion syndrome (MAS) and the hidden lesions 
Medial abrasion syndrome is an unrecognized but common clinical entity caused by the 
repeated impingement between mediopatellar plica (medial shelf) and the opposite medial 
femoral condyle during knee motion. This syndrome could explain most of the symptoms 
and signs of the medial compartment OA knee. In this section, the definition, clinical 
manifestations and relavant studies to investigate the role of MAS and the correlated hidden 
lesions in the pathogenesis of OA knee will be presented.  
2.1 Medial plica and MAS 
The mediopatellar plica is a fold in the synovium representing an embryologic remnant in 
the development of the synovial cavity of the knee. It is found along the medial wall of the 
joint originating superiorly, extending obliquely and inferiorly, and inserting on the 
synovial lining of the infrapatellar fat pad (Dandy DJ, 1990). It is generally agreed that this 
structure can produce knee symptoms and could be successfully treated by arthroscopic 
resection when it becomes inflamed, thickened, and less elastic (Dorchak JD et al., 1991; 
Flanagan JP et al.). 
During arthroscopic examination, different degrees of cartilaginous degeneration on the 
surface of the medial femoral condyle facing the medial plica has been noticed by many 
authors (Tasker T et al., 1982; Broom MJ et al., 1986; Dupont JY, 1997). According to a study 
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conducted in 2006 (Lyu SR and Hsu CC, 2006), the incidence of the medial plica was 
significantly higher in subjects with osteoarthritis of their knees. Degenerative cartilaginous 
lesions on the facing medial femoral condyle were found in almost all of the patients who 
had the structure of medial plica. This study also found that the severity of these lesions has 
obvious correlation with patient’s age and the severity of their plical lesions. In daily clinical 
practice, we likewise get an impression that the severity of the plical lesions present positive 




Fig. 1. Arthroscopic findings of the effect of medial abrasion syndrome, the severity of the 
osteoarthritis of the medial compartment seems to have positive correlation with the 
severity of gross appearance of the medial plica. 
2.2 Clinical manifestations of MAS  
In 2004, we conducted an unpublished investigation in order to find out the predisposing 
factors and presenting symptoms and signs of MAS in a series of 163 patients older then 40 
years with 232 knees proven to have medial plica related MAS by arthroscopy. The 
sensitivity and specificity of each parameter about predisposing factors, symptoms and 
signs for the diagnosis of the medial plica related medial abrasion syndrome were analyzed. 
This study conceptualized the following clinical manifestations of MAS. 
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2.2.1 Predisposing factors 
Injuries 
The presentation of a single episode of injury, such as a falling down with sudden bending 
of the knee, direct blunt injury over the anterior-medial aspect of the knee, unexpected 
twisting of the knee or change of position when kneeling. 
Activities need bending knee 
History of repeated or prolonged bending of the involved knee, such as squatting, kneeling, 
climbing stairs, hiking along slopes, climbing mountains or bicycling, either due to 
occupational or recreational needs. Prolonged driving or riding any transportation vehicle.  
Female 
Females tend to bend their knee more than males do in their daily activities. 
Religion 
Some religious worship needs repeated squatting or kneeling. 
2.2.2 Symptoms 
Pain 
It is always described as deep-seated, throbbing or cutting ache and would  get worse when 
climbing stairs, sitting with the knees flexed for a long time, rising from a sitting position, or 
extending the knee against resistance. Night pain or soreness and difficult to find a suitable 
position when sleeping are also common complaints. Some patients might point out the 
location of pain over the anterior-medial aspect of the knee. 
Crepitus 
The presentation of the feeling or hearing of a click or crepitus when the involved knee is 
flexed or extended after prolonged sitting. It may or may not be accompanied by pain. 
Snapping or locking 
Patients might incidentally experience the feeling of giving way, a sense of insecurity or 
pseudolocking in some particular position. Mostly it occurs when the knee is partially 
bended during weight-bearing. Sometimes, locking will occur when patients try to walk 
after sitting or lying for a long time. It will get unlocked after standing for a few minutes. 
2.2.3 Signs 
Localized tenderness    
Precise tender area could be identified over the region between the inferior-medial margin 
of the lower pole of the patella and the ridge of the medial femoral condyle.  
Palpable band 
A palpable band with snapping or crepitation might be found over the above-mentioned 
tender area.  
Provocative test 
A provocative test to reproduce the characteristic pain and snapping of the band might be 
conducted by compressing the tender point with the thumb of one hand and repeatedly 
bend the knee with the other hand. 
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2.2.4 Radiographic findings 
Various degrees of rentgenographic manifestation of medial abrasion syndrome could be 
evaluated by axial view (Merchant’s view) of the patello-femoral joint. In the early stage, it 
is always difficult to be diagnosed due to the concurrent lateral deviation or subluxation of 
the patella.  Sometimes, narrowing of the medial patello-femoral joint space that represents 
as the clue of abrasion phenomenon might be found by careful evaluation. In more 
advanced cases, eburnation and bone attrition of the medial femoral condyle and/or medial 
facet of patella with obvious narrowing of the medial patello-femoral joint space could also 
be visualized as shown in figure 2.  
Progressive narrowing of the medial patello-femoral joint space accompanied by 
osteophytes formation over the medial margin of patella and medial femoral condyle is the 
typical findings of severe cases. Subchondral cysts and hypersclerosis sometimes could be 












   





Fig. 2. A, narrowing of the medial patello-femoral joint is obvious; B, thicken medial plica 
with synovitis causing medial abrasion syndrome of left knee; C, after arthroscopic medial 
release, fibrillation of the cartilage surfaces are obvious over medial patello-femoral joint 
compared to that of the lateral one as was shown in D.  
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Fig. 3. Rentgenographic and gross appearance of the late effect of medial abrasion 
syndrome, A, marked narrowing of the medial patello-femoral joint with osteophytes, 
hypersclerosis and subchondral cysts; B, severe cartilage destruction over medial facet (MF) 
of patella and medial femoral condyle (MC) compared to lateral ones (LF and LC) could be 
visualized in this patient received arthroplasty. 
2.3 The hidden lesions 
Medial abrasion syndrome could give rise to different degrees of cartilagenous degeneration 
on the surface of medial femoral condyle facing the medial plica. We call it “hidden lesion” 
because that in most occasions, either due to synovitis or tightness of the joint space in 
osteoarthritic knees, these lesions are difficult to be found in routine arthroscopic 
examination. Only after adequate synovectomy could they be clearly visualized by special 
view as shown in figure 4.  
 
   
A                                                    B                                                     C 
Fig. 4. The unveiling of the hidden lesion, A, the space between medial patellar facet and 
medial femoral condyle is obliterated by focal synovial tissue; B, during arthroscopic medial 
release, the hypertrophied medial plica and related tissue were debrided and removed; C, 
after this procedure, the “hidden lesion” could be visualized. 
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After proper synovectomy and release of the infero-medial area of patella and the medial 
gutter, two distinct foci (A and B in figure 5A) of cartilaginous lesions which we call the 
“hidden lesions“ could be found on the edge and anterior part of the medial femoral condyle. 
The appearance of these focal cartilaginous lesions was unique and different from what has 
been described by the classical arthroscopic classification of cartilaginous lesions. We classify 
these lesions into five stages according to the gross appearance of their severity (figure 5). In a 
retrospective reviewing of the arthroscopic findings of 1587 knees, we found that the severity 
of the hidden lesions was positively correlated with the severity of the pathologic medial plica, 
total degeneration score of the knee and patient’s age (Lyu SR and Hsu CC, 2006). 
2.4 MAS as a cause of medial compartment osteoarthritis of the knee 
The aforementioned clinical findings strongly suggest that the medial abrasion syndrome 
might play a role in the pathogenesis of medial compartment osteoarthritis of the knee. In 
2002, we collaborated a research team and began to conduct a series of investigations 
focusing on the following subjects: establishment of a finite element model of the medial 
abrasion phenomenon for biomechanical analysis of the possible mechanical effect elicited 
by this abrasion phenomenon; histopathological study of the gross and histological 
presentation of the pathological medial plica itself; biochemical analysis of the medial plica 
and the related pannus-like tissue, and compartment specified joint fluid analysis. In this 
section, we will describe and summarize the results of these studies and make a conclusive 
assumption for the role of the medial abrasion phenomenon as an important etiologic factor 
of medial compartment osteoarthritis of the knee.  
2.4.1 Mechanical factor – The finite element model 
In order to establish a finite element model for the study of the relationship of medial plica 
with the facing medial femoral condyle, two pilot experiments were conducted.  
First, an experimental study on the tensile strength of mediopatellar plica was undertaken 
using high precision micro-force tensile tests (Lyu SR et al, 2006). These tests were 
conducted with plica specimens taken from 61 knees of patients of different ages. The force-
deflection curves resulting from these tests were recorded and transferred to stress-stain 
curves to get the Young’s moduli of these specimens. In addition, pathological tissue dye 
tests were used to assess the fiber content ratio (FCR) of each specimen. The value of the 
Young’s modulus was plotted versus FCR, and the relation between them was fitted 
properly using a quadratic regression model. The test results indicated that the value of 
Young’s modulus sharply increased when FCR exceeded 80%. This may lead to higher 
contact pressure between the medial plica and the adjacent articular cartilage. This study 
also found that the Young’s modulus of the medial plica was positively correlated with the 
severity of the plica lesion and the patient’s age.  
In the second study (Lyu SR, 2007), the inner margins of the medial plicae of 30 knees were 
located by inserting needles percutaneously under direct vision during arthroscopic 
examination. The topographic changes of the margins of these plicae during knee motion were 
recorded by fluoroscopy and analyzed. In all types of the medial plicae, regardless of their sizes, 
shifting (rubbing, sliding) medially was found when the knee was moved from extension to 
flexion. They remained in contact with the medial femoral condyles during the whole range of 
motion. This observation disclosed the kinematic relationship of the medial plica with the 
medial femoral condyle during knee motion in vivo. This pattern of medial-lateral motion may 
generate some shearing force acting on the cartilage of the medial femoral condyle.  
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Fig. 5. The hidden lesions, A, gross appearance of the typical hidden lesions (foci A and B); 
arthroscopic findings of different stage of focus A lesion: A-1, in the stage I cartilaginous 
lesion, neovascularization and pannus formation are found over the margin of the lesion. 
Softening of the cartilage could be confirmed by palpation with a probe; A-2, the stage II 
lesion has all the findings of the stage I lesion. Moreover, flattening and indentation of the 
cartilage could be identified; A-3, the stage III lesion is a partial thickness cartilaginous 
damage. The cartilage becomes fissured and fibrillated; A-4, in a stage IV lesion, some areas 
of subchondral bone are exposed. A shallow gutter representing the imprint of abrasion 
caused by the medial plica can be identified; A-5, in a stage V lesion, the subchondral bone 
is completely exposed to form a deep gutter; B, the arthroscopic picture of focus B 
cartilaginous lesion related to medial abrasion syndrome. 
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Based on the findings of these pilot studies, a three-dimension dynamic finite element 
model composed of femur, tibia, cartilage layers and medial plica was recently developed 
(Lyu SR and Liu DS, unpublished). This validated model was used to investigate and 
compare the level of cyclic pressures acting on the cartilage of the medial femoral condyles 
by three different types of medial plicae with various Young’s moduli. We found that all 
types of medial plicae remained in contact with the medial femoral condyles and shift 
medially when the knee moved from extension to flexion.  
 
 
Fig. 6. The distribution of contact pressure on the medial femoral condyle elicited by 
different types of medial plica with Young’s modulus set at 110 MPa and the knee model is 
flexed to 90 degrees. The high-pressure zones (red areas) are well correlated with our 
clinical findings. 
This 3D model (figure 6) demonstrated that the contact pressures were positively correlated 
with the Young’s moduli of the medial plicae. When the Young’s moduli of the medial 
plicae were set greater than 40 MPa, all types of medial plicae would elicit contact pressures 
higher than 10 MPa on medial femoral condyles, and that is enough to cause apoptosis of 
chondrocytes in the cartilage tissue according to previous study using a bovine cartilage 
explant system to evaluate the effects of injurious compression on chondrocyte apoptosis 
(Loening et al., 2000).  
In conclusion, according to the findings of this 3D dynamic finite element model, the close 
relationship and possible high contact pressure between fibrotic medial plica and medial 
femoral condyle during knee motion may be an crucial cause of the degenerative change of 
the cartilage on the medial femoral condyle. 
2.4.2 MAS and abnormal gait  
Successively, we have conducted an histomorphological study focusing on the gross 
appearance and histological features of the medial plicae removed from 48 consecutive 
patients who had received total knee replacement for severe medial compartment 
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Based on the findings of these pilot studies, a three-dimension dynamic finite element 
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explant system to evaluate the effects of injurious compression on chondrocyte apoptosis 
(Loening et al., 2000).  
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osteoarthritis of their knees (Lyu SR et al., 2010).  Histologically, the majority of advanced 
pathologic presentation was found at the middle and distal portion of the medial plica that 
might abrade on the articular cartilage of the medial femoral condyle and noticeable 
cartilaginous lesion was found on the facing medial femoral condyle in all knees. In 
addition, a small branch of skeletal muscle originating from articularis genu inserting into 
the proximal synovial stroma of the medial plica was found in all knees (figure 7 A, B). The 
synovial fold of the distal part of the medial plica was disclosed to have a close relationship 
with the gracilis tendon sheath (figure 7 C, D). 
 
    
A                                                                          B 
 
    
C                                                                          D 
(Reproduced and adapted with permission and copyright © of the Springer [Lyu SR et al., 2010]) 
Fig. 7. A. A branch of skeletal muscle (SMB) originating from articularis genus was noticed 
inserting into the proximal part (P) of this medial plica. (A: abrasion portion) B. 
Microscopically, skeletal muscular fibers (arrows) could be found in the alveolar 
fibroadipose tissue of this medial plica (×40; H & E stain). C. The synovial fold of the distal 
part (D) of the medial plica was disclosed originating from the tendon sheath of the gracilis 
tendon (G). D. After the medial plica was removed, the gracilis tendon (G) could be 
visualized clearly. (P: proximal and A: abrasion parts of the medial plica)  
It has been suggested that abnormal gait pattern may lead to the development of knee OA 
(Lynn SK et al., 2007). Several studies (Baliunas AJ et al., 2002; Gok H et al., 2002; Landry SC 
et al., 2007) have noticed that an increased knee adduction and internal rotation moment 
during the stance phase of gait is associated with knee OA. It was also detected that among 
individuals with mild radiographic knee OA, those who are symptomatic have significantly 
higher medial compartment loads than those who are asymptomatic (Thorp LE et al., 2007). 
The linkage of medial plica with the medial muscle group of the thigh found in this study 
might give answer to these literature findings which suggested the relationship of gaits with 
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medial compartment OA knee. During the walking cycle, the irritation of the inflamed 
medial plicae by the abrasion phenomenon with the medial femoral condyle might evoke 
reflex contracture of the medial muscle group including vastus intermedialis and gracilis 
and therefore increase the adduction and internal rotation moment and the medial 
compartment load of the knee. This correlation could further be proven by subjective 
improvement of gait pattern claimed by many of our OA knee patients who have received 
arthroscopic resection of the inflamed medial plica.  
The histomorphological findings of this study imply the close interplay between the medial 
plica and the medial femoral condyle that might play a role in the pathogenesis of medial 
compartment osteoarthritis of the knee. 
2.4.3 Biochemical analysis of medial plica and pannus tissue 
The most significant pathological change in OA of the knee is the progressive loss of hyaline 
cartilage of the articular surface. The expression of IL-1 and matrix metalloproteinase-3 
(MMP-3) by pannus-like tissue in the knees of patients with advanced OA suggests that 
MMP-3 contributes to cartilage degradation (Shibakawa A et al., 2003; Yuan GH et al., 2004). 
MMP-3 is produced by both chondrocytes and synoviocytes, especially when stimulated by 
IL-1 (Tetlow LC et al., 2001). Synovial tissue inflammation has been predicted as a 
pathogenesis factor in early OA (Haywood L et al., 2003; Ayral C et al., 2005; Benito MJ et 
al., 2005; Ikeuchi M et al., 2005).  Joint injury-induced IL-1 expression has been found to 
enhance MMP-3 release (Techetverikov I et al., 2005; Daheshia M and Yao JQ, 2008; Eder C, 
2009), resulting in matrix degradation (van den Berg WB 2001). IL-1 levels in the knee joint 
were found to be associated with the severity of chondral damage (Marks PH and 
Konaldson ML, 2005).  
In our previous study, pannus-like tissue (figures 5 and 8C) was also observed on the 
cartilage of the medial femoral condyle opposite the inflamed medial plica in early stage 
medial compartment OA of the knee (Lyu SR and Hsu CC, 2006).  Further observation 
found that pathologic medial plica could be discovered in every patient suffering from 
medial compartment OA knee. This study also declared that various degrees of 
inflammation could be observed in the medial plicae of patients with medial compartment 
OA of the knee and removal of this structure by arthroscopic medial release could relieve 
their symptoms or even modify their disease process (Lyu SR, 2008).  
In order to determine the role of medial plica and pannus-like tissue (figure 8C) in the 
pathogenesis of OA knee, expression of MMP-3 in the control synovial membrane, pannus-like 
tissue and medial plica obtained from early stage OA knee patients were investigated by 
immunohistochemical staining (Wang HS et al 2011). We found that MMP-3 was highly 
expressed in the pannus-like tissue (p in figure 8B-b) and medial plica (figure 8B-c), but not in 
the cartilage (ca in figure 8B-b) or control synovial membrane (figure 8B-a). Immunofluorescent 
staining also showed that MMP-3 was intensively expressed in medial plica tissue (figure 8C). 
In this study, the effect of IL-1 on cells isolated from pannus-like tissue and medial plica from 
early stage OA knees was also determined. Our results demonstrated that these cells expressed 
significant amount of MMP-3 mRNA and MMP-3 was found being released into the culture 
medium consequently.  Moreover, similar to what were found in both medial plica and pannus-
like tissue of late stage OA knees, significant high levels of IL1- mRNA expression was found 
in medial plica of early stage OA knees. All of these findings suggest that IL1- might be the 
triggering factor in MMP-3 expression by these tissues. Since MMP-3 plays a significant role in 
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medial compartment OA knee. During the walking cycle, the irritation of the inflamed 
medial plicae by the abrasion phenomenon with the medial femoral condyle might evoke 
reflex contracture of the medial muscle group including vastus intermedialis and gracilis 
and therefore increase the adduction and internal rotation moment and the medial 
compartment load of the knee. This correlation could further be proven by subjective 
improvement of gait pattern claimed by many of our OA knee patients who have received 
arthroscopic resection of the inflamed medial plica.  
The histomorphological findings of this study imply the close interplay between the medial 
plica and the medial femoral condyle that might play a role in the pathogenesis of medial 
compartment osteoarthritis of the knee. 
2.4.3 Biochemical analysis of medial plica and pannus tissue 
The most significant pathological change in OA of the knee is the progressive loss of hyaline 
cartilage of the articular surface. The expression of IL-1 and matrix metalloproteinase-3 
(MMP-3) by pannus-like tissue in the knees of patients with advanced OA suggests that 
MMP-3 contributes to cartilage degradation (Shibakawa A et al., 2003; Yuan GH et al., 2004). 
MMP-3 is produced by both chondrocytes and synoviocytes, especially when stimulated by 
IL-1 (Tetlow LC et al., 2001). Synovial tissue inflammation has been predicted as a 
pathogenesis factor in early OA (Haywood L et al., 2003; Ayral C et al., 2005; Benito MJ et 
al., 2005; Ikeuchi M et al., 2005).  Joint injury-induced IL-1 expression has been found to 
enhance MMP-3 release (Techetverikov I et al., 2005; Daheshia M and Yao JQ, 2008; Eder C, 
2009), resulting in matrix degradation (van den Berg WB 2001). IL-1 levels in the knee joint 
were found to be associated with the severity of chondral damage (Marks PH and 
Konaldson ML, 2005).  
In our previous study, pannus-like tissue (figures 5 and 8C) was also observed on the 
cartilage of the medial femoral condyle opposite the inflamed medial plica in early stage 
medial compartment OA of the knee (Lyu SR and Hsu CC, 2006).  Further observation 
found that pathologic medial plica could be discovered in every patient suffering from 
medial compartment OA knee. This study also declared that various degrees of 
inflammation could be observed in the medial plicae of patients with medial compartment 
OA of the knee and removal of this structure by arthroscopic medial release could relieve 
their symptoms or even modify their disease process (Lyu SR, 2008).  
In order to determine the role of medial plica and pannus-like tissue (figure 8C) in the 
pathogenesis of OA knee, expression of MMP-3 in the control synovial membrane, pannus-like 
tissue and medial plica obtained from early stage OA knee patients were investigated by 
immunohistochemical staining (Wang HS et al 2011). We found that MMP-3 was highly 
expressed in the pannus-like tissue (p in figure 8B-b) and medial plica (figure 8B-c), but not in 
the cartilage (ca in figure 8B-b) or control synovial membrane (figure 8B-a). Immunofluorescent 
staining also showed that MMP-3 was intensively expressed in medial plica tissue (figure 8C). 
In this study, the effect of IL-1 on cells isolated from pannus-like tissue and medial plica from 
early stage OA knees was also determined. Our results demonstrated that these cells expressed 
significant amount of MMP-3 mRNA and MMP-3 was found being released into the culture 
medium consequently.  Moreover, similar to what were found in both medial plica and pannus-
like tissue of late stage OA knees, significant high levels of IL1- mRNA expression was found 
in medial plica of early stage OA knees. All of these findings suggest that IL1- might be the 
triggering factor in MMP-3 expression by these tissues. Since MMP-3 plays a significant role in 
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the progression of OA, our investigation bring to light that medial plica might be involved in 
the pathogenesis of medial compartment OA of the knee.  
 
 
           C 
 
Fig. 8. A, immunohistochemical staining for MMP-3 in pannus-like tissue, cartilage and 
medial plica. (a) control synovial membrane, (b) pannus-like tissue (“p”) or cartilage (“ca”) 
or (c) medial plica. The bar is 20 μm in (a) and (b) and 10 μm in (c). B, Immunofluorescent 
staining for MMP-3 in medial plica. (a) Nuclei stained with DAPI (blue), (b) cells stained for 
MMP-3 (red) and (c) merged image. The bar represents 10 μm. The results are typical of 
those from 16 knees. C, Anatomical location of tissue biopsy in a typical right knee with 
stage II OA. MP is medial plica, P pannus and C cartilage. (Reproduced and adapted with 
permission and copyright © of the John Wiley and Sons [Wang HS et al 2011]) 
We propose that the abrasion between medial plica and the opposite medial femoral 
condyle may be the cause of inflammation in patients with medial compartment OA of the 
knee. This repeated abrasion injuries might trigger IL-1 production in medial plica, thus 
enhance the expression of MMP-3. Our finding of highly expressed MMP-3 mRNA in 
medial plica than in the control synovial membrane by real-time PCR analysis further 
supports this hypothesis. Recently, we found that inflammation in patients with medial 
compartment OA of the knee may also induce the production of other MMPs involved in 
the pathogenesis of OA knees (Wang HS et al., unpublished data). These findings agree with 
the observation that removal of pathologic medial plica and its related inflammatory 
structure by arthroscopy can be effective in symptom relief or even can modify the disease 
process of medial compartment OA knee (Ikeuchi M et al., 2005; Lyu SR 2008).  
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2.4.4 Analysis of joint fluid 
There are a variety of proteins in the synovial fluid of osteoarthritic knee. These proteins 
include glycoprotein debris and collagen fragments derived from destructed cartilaginous 
tissue and enzymes such as metalloproteinase, collagenase and proinflammatory cytokines 
(interleukin-1, interleukin-1, tumour necrosis factor , etc) (Yoshihara Y et al., 2000; 
Hedbom E and Hauselmann HJ, 2002; Tchetverikov I et al., 2005). All of these proteins in 
synovial fluid might reflect the pathological status of the knees.  
Since the aforementioned abrasion phenomenon between fibrotic medial plica and the 
opposite medial femoral condyle may continuously produce cartilage debris and give rise to 
various degree of synovitis, it is interesting to see whether the concentrations of total 
protein, IL-1 and MMP-3 are different in medial and lateral compartments of these knees. 
Recently, we have conducted a study (Lyu SR and Chau LC, unpublished) to analyze total 
protein, interleukin (IL)-1β and Matrix Metalloproteinase-3 concentrations in synovial fluid 
of medial and lateral compartments from 14 knees with medial compartment OA received 
unicompartmental arthroplasty due to medial compartment osteoarthritis. All of these knees 
were found to have fibrotic medial plica demonstrating abrasion phenomenon with the 
opposite medial femoral condyle. Figure 9 shows the total protein, IL-1, and MMP-3 
concentrations in the synovial fluid obtained from the medial and lateral compartments of 
these knees. All sets of sample analyzed revealed significant higher concentration of total 
protein, IL-1, and MMP-3 in the medial compartment.  
 
       
(a)                                                                            (b) 
Fig. 9. (a) The total protein concentration and (b) the concentrations of IL-1 and MMP-3 
measured by enzyme-linked immunosorbent assay (ELISA) in samples of synovial fluid in 
medial and lateral compartments of osteoarthritic knees. *The difference between medial  
(n = 14) and lateral (n = 14) was statistically significant at P < 0.01 in the Mann Whitney U test. 
In contrast to the common point of view that molecules should be evenly distributed within 
joint cavity, the above findings revealed the existence of big differences of total protein 
concentration, IL-1 concentration, and MMP-3 concentration between medial and lateral 
compartments of osteoarthritic knees. The discrepancy in the total protein distribution in 
synovial fluids may be attributed to the size of the protein molecules. Owing to the gravity 
and the contour of the tibial plateau, the debris or tissue fragments generated from the 
medial compartment may not pass freely between medial and lateral compartments of the 
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the progression of OA, our investigation bring to light that medial plica might be involved in 
the pathogenesis of medial compartment OA of the knee.  
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the observation that removal of pathologic medial plica and its related inflammatory 
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knee joint and accumulate in the particular compartment. On the other hand, the local 
higher concentrations of IL-1 and MMP-3 are likely due to the medial abrasion 
phenomenon related ongoing pathologic progress in the medial compartment of these 
knees. Furthermore, the self-abrasion of the rough degenerated cartilaginous surfaces might 
also be the source of debris generation during daily activities. These findings might be 
important in the unveiling of pathogenesis or progression of medial compartment OA knee. 
2.4.5 MAS as an important etiologic factor for medial compartment OA knee 
In summary, as shown in figure 10, our series of studies have discovered the possible 
mechanism by which the medial abrasion syndrome cause progressive degradation of the 
cartilage over the medial compartment of the knee.  
 
 
Fig. 10. Medial abrasion syndrome as an etiologic factor for medial compartment OA knee, 
the repeated abrasion (millions times per year) between medial plica (represented by yellow 
curved line) and the medial femoral condyle will cause: A, chondrocyte and matrix damage 
due to direct mechanical shearing force; B, synovitis around medial plica due to trauma will 
produce cytokines (such as IL-1) and cartilage degradating enzymes (such as MMP-3); C, 
the debris and particles shedding down from the damaged cartilage accumulate in the 
medial compartment, further elicit third party abrasion over the weight bearing area.  
Depending on the size and the severity of fibrosis of the medial plica, the abrasion itself will 
produce abnormal shearing force on the opposite cartilage of the medial femoral condyle and 
cause various degree of cartilaginous damage. On the other side, this abrasion phenomenon 
elicits repeated injury to the medial plica itself and results in focal synovitis that will trigger 
the production of cytokines such as IL-1 and then upgrades the production of cartilage 
degradating enzymes such as MMP-3. The continuous shedding of cartilaginous debris and 
production of cartilage drgradating enzymes make the whole medial compartment in a 
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consistently detrimental condition for the maintainance of normal cartilage metabolism and 
thus progressive “degeneration” results.  Moreover, the painful sensation of inflammation of 
medial plica might evoke a reflex contracture of the pes anserinus muscle group and increase 
the loading of the medial compartment thus further jeopadize the cartilage. 
According to our theory, medial abrasion syndrome, if present, might produce life long 
harmful effects on the general environment of medial compartment of the involved knee 
and disturb normal cartilage metabolism thus bring about the process of  “degeneration”. 
3. Surgical treatment of MAS 
In order to remove the detrimental medial abrasion syndrome, we have developed a novel 
arthroscopic procedure that we called arthroscopic medial release (AMR) for capsular release 
(Lyu SR, 2008). The target of the capsular release was the layer III, so called “true capsule” of 
the 3-layers medial supporting structure (Warren LF and Marshall JL, 1979). As shown in 
figure 11, the capsulectomy extends superiorly to the midline of suprapatellar pouch. 
Inferiorly, it extends to the upper margin of medial meniscus. Anteriorly, it extends to the 
medial margin of patella. Posteriorly, it is undertaken to remove  portion of the conjoined part 
of layer II and III till the gracilis tendon is visualized. Only the deep medial ligament was 
severed by this procedure and the medial stability should not be disturbed much.  
 
 
Fig. 11. A: The extent of the medial capsulectomy is shown in the hatched area of the line 
drawing of the lateral view of the knee joint. The line marked by ＊ is the level of cross 
section above the meniscus as shown in B.  B: The crossed-hatched area indicates the extent 
of the capsulectomy above the medial meniscus. Note that only the deep medial ligament is 
severed. The tendon of gracilis could be visualized after the procedure. (Reproduced and 
adapted with permission and copyright © of the British Editorial Society of Bone and Joint 
Surgery [Lyu SR, 2008]) 
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consistently detrimental condition for the maintainance of normal cartilage metabolism and 
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Fig. 11. A: The extent of the medial capsulectomy is shown in the hatched area of the line 
drawing of the lateral view of the knee joint. The line marked by ＊ is the level of cross 
section above the meniscus as shown in B.  B: The crossed-hatched area indicates the extent 
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severed. The tendon of gracilis could be visualized after the procedure. (Reproduced and 
adapted with permission and copyright © of the British Editorial Society of Bone and Joint 
Surgery [Lyu SR, 2008]) 
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The adequacy of the medial release could be checked by passing the scope under the patella 
and verified if the previously tightly closed medial patellofemoral joint space could be easily 
opened and the medial retinaculum visualized when the knee was put in full extension 
position. 
 
   
A                                                   B                                                  C 
 
  
D                                                   E 
 
  
F                                                  G 
Fig. 12. For a complete arthroscopic medial release (MAS), A, proximally, the genu 
articularis muscle attachment (arrow) should be released; B, the anterior synoviomeniscal 
junction (arrow) should be release; C, the medial gutter should be cleared to its posterior 
corner (arrow); D, the synoviomeniscal junction of the medial meniscus (arrow) should be 
clearly seen; E, in some case, release of the fascia of pes anserinus (arrow) should be 
performed; F, before medial release; G, after medial release. 
According to our experience of performing this procedure (Lyu SR, 2008), the outcome of 
255 knees in 173 patients for varying stages of osteoarthritis involving the medial 
compartment supports our contention that AMR is a good modality for the treatment of 
osteoarthritis of the medial knee joint in the aspect of symptom relief. It can reduce the pain 
in the majority of OA patients over a period of at least 4 years. In some cases, we also found 
the evidence that AMR could modify the disease process and satisfied the patients.  
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4. Arthroscopic cartilage regeneration facilitating procedure (ACRFP)  
The clinical outcome of the AMR lured us to believe that, by eradication of the abrasion 
phenomenon between the tight, fibrotic and hypertrophied medial plica related structure 
and the opposite  medial femoral condyle, the pain of most patients could be reduced and 
the degenerative process in the medial compartment of some patients might be decelerated 
or arrested. Therefore, we propose a concept of arthroscopic cartilage regeneration 
facilitating procedure (ACRFP) that combines arthroscopic medial release (AMR) with 
synovectomy, abrasional chondroplasthy, partial meniscectomy or percutaneous lateral 
release (PLR) as a rationale for the deliberate arthroscopic management of OA knee. We 
believed that the elimination of the detrimental factors including medial abrasion 
phenomenon, focal or generalized synovitis, chondral flaps, meniscus flaps or lateral 
compression phenomenon will provide a preferable environment for the regeneration of the 
damaged cartilage. 
In the year of 2005, 571 knees of 367 patients having medial compartment osteoarthritis 
with or without patellofemoral compartment involvement received this procedure. There 
were 95 (26%) male and 272 (74%) female and the mean age was 60 years (range, 29 to 
82). The Knee Society score and the knee injury and osteoarthritis outcome score were 
used for subjective outcome study. The roentgenographic changes of femoral-tibial angle 
and joint space width were evaluated for objective outcome. The mean follow-up period 
was 38 months (range, 36 to 49). There were 505 knees in 326 patients (88.8%) available 
with more than 3 years follow-up. The subjective satisfactory rate for the whole series 
was 85.5%. For 134 knees with complete follow-up evaluation, the Knee Society score 
and all subscales of the knee injury and osteoarthritis outcome score improved 
statistically. The femoral-tibial angle improved from 1.52 degrees (95% confidence 
interval, 0.84~2.19) to 1.93 degrees (1.21~2.64) (p=0.03). The joint space width increased 
from 2.03 millimeters (1.81~2.24) to 2.18 millimeters (1.97~2.38) (p=0.01). The 
degeneration process of the medial compartment was found being reversed in 82.1% of 
these knees according to the radiographic evaluation. Examples of cartilage regeneration 
are shown in figures 13~16. 
 
      
A                                                                B 
Fig. 13. Cartilage regeneration demonstrated in the medial compartment of the left knee of a 
56 years old lady having stage II OA; A, cartilage erosion was found over the medial 
femoral condyle opposite the removed pathologic medial plica; B, the defect was found 
regenerated during the second-look arthroscopy 3 years later when the same knee suffered 
from hemoarthrosis after a falling down accident. 
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Fig. 14. A self-control example showing the benefit of ACRFP: A, pre-operative AP standing 
view of a 61 years old male with grade III OA over medial compartment of right knee and 
grade II OA over medial compartment of left knee, ACRFP was performed for his right 
knee; B, 46 months later, he came back due to marked disability over his left knee, the 
condition of his right knee was excellent and the degenerative process ceased compared to 
the progressively degenerated left knee; C, unicompartmental arthroplasty was necessary 
for his left knee that hadn’t received ACRFP.  
 
   
A                                                                               B 
 
Fig. 15. An example of reversal of natural degenerative course by ACRFP in a 70 years old 
male patient having grade IV OA over his right knee: A, pre-operative standing AP view 
showing grade IV OA over medial compartment of his right knee; B, three years after 
ACRFP, the joint space reopened and the FTA improved from 7 degrees varus to 3 degrees 
varus.  
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Fig. 16. Another example of reversal of natural course by ACRFP: A, AP standing view of a 
58 years old female patient having bilateral grade IV OA with subluxation of medial femoral 
condyle; B, three years after ACRFP, obvious improvement of the radiographic 
manifestation could be observed. 
Based on this constitutional study, we proposed a concept that by a purposeful 
eradication of all prejudicial factors in the degenerative knee, the jeopardized cartilage 
will have the chance to regenerate by its natural character. In comparison with the 
uncertain beneficial mechanism and the diversity of outcomes of current popular 
arthroscopic techniques for osteoarthritis of the knee, this concept of ACRFP has more 
precise rationale of treatment. The main theme of ACRFP is to remove any abnormal 
abrasion or impingement phenomenon and reestablish soft tissue balance in medial 
compartment and patellofemoral joint. For knees demonstrating medial abrasion 
phenomenon, medial release (Lyu SR, 2008) was performed to relieve the tension and 
abrasion between the tight, fibrotic and hypertrophied medial plica and the adjacent 
medial femoral condyle that have been described in previous studies (Lyu SR and Hsu 
CC, 2006; Lyu et al., 2006; Lyu SR, 2007; Lyu et al., 2010). On the other hand, in knees 
demonstrating lateral compression syndrome over patellofemoral joint, percutaneous 
lateral capsular release that has the benefits of tension release and denervation (Calpur 
OU et al., 2005; Paulos LE et al., 2008) was added.  
The immediate effect of ACRFP is to release the strain caused by chronically inflamed soft 
tissue and to eradicate the hypertrophied synovium that may cause pain in the degenerative 
knees over the medial compartment and patellofemoral joint. Furthermore, this procedure 
might also bring forth to long-term favorable effects as a consequence of the global 
improvement of the environment of the knee joint for cartilaginous regeneration.  
According to the experience of performing this procedure, the radiographic evaluations and 
clinical outcome studies have demonstrated that, by removal of all existed catabolic factors, 
the anabolic pathway of the damaged cartilage might become dominant and regeneration 
unveiled. The data support our contention that arthroscopic cartilage regeneration 
facilitating procedure is a good modality for the treatment of medial compartment 
osteoarthritis of the knee joint with/without patellofemoral joint involvement. It could 
modify the disease process of this common disease.  
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5. The future: Knee health promotion option (KHPO) for OA knee 
Based on the findings of our research regarding MAS and the clinical outcome of ACRFP, an 
integrated protocol shown in figure 17 for the treatment of OA knee that we call “knee 
health promotion option (KHPO)” has been developed and put into practice in our center 
since 2007. The details of this protocol for global management of OA knee will be presented 
in this section. 
 
 
ACRFP: arthroscopic cartilage regeneration facilitating procedure 
PCRFM: post-operative cartilage regeneration facilitating modalities 
Fig. 17. Protocol of KHPO, the key determinant of success is to obtain complete consensus 
from the patient about this novel concept before enrolling him/her into this protocol. In our 
practice, the patients will be put under strict surveillance from case manager and nursing 
specialist during the whole process. 
5.1 Clinical staging 
The first step of knee health promotion option for the treatment of OA knee is thorough 
evaluation of the patient’s general condition and establishing the clinical staging for each 
compartment of the knee by standard rentgenographic examination including standing 
anteroposterior, lateral, and Merchant’s views. The degree of joint space narrowing, 
presentation of osteophytes and alignment measured by femorotibial angle were the main 
parameters evaluated. The staging of OA of the whole knee is given as the most advanced 
stage of the three compartments. We have been using this staging system since 2000 and 
noticed its high correlation with the corresponding arthroscopic findings (as the example of 
medial compartment shown in table 1).  
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Stage Joint Space Narrowing Osteophyte
FT 
angle Arthroscopic findings 
I Doubtful No Normal Smooth surface, loss of normal elasticity 
II Definite, no more than 1/2 Doubtful > 0 
Uneven surface, superficial to 
moderate cartilage damage 
(bubbling, fibrillation) 
III Marked, more than 1/2 Definite 
Around 
0 
Deep cartilage damage 
(chondral flap, subchondral 
bone exposed < ½ area) 
IV Complete obliterated Marked < 0 
Full thickness cartilage damage    
(subchondral bone exposed > ½ 
area) 
Table 1. Clinical staging for medial compartment based on the rentgenographic findings and 
possible correlated arthroscopic findings. 
5.2 Decision making for treatment option 
Once the clinical staging of each compartment has been made, the decision of treatment 
option for idividual patient could be made according to the guideline listed in table 2. For 
stage I ~ III patients, KHPO is the best choice compared to osteotomy and arthroplasty. In 
stage IV patients, although arthroplasty is usually recommended, KHPO sometimes still has 
its value considering patients’ preference and biopsychosocial condition. 
 
Stage KHPO Osteotomy Arthroplasty 
I ++++ - - 
II ++++ - - 
III +++ ++ + 
IV ++ ++ ++++ 
Table 2. Recommendation of treatment option for different stage of OA knee. 
5.3 Conservative treatment before ACRFP 
All of the stage I and II patients and some of the stage III patients should be recommended 
to encounter into this supervised conservative treatment for at least 3 months. The sine qua 
non for a successful conservative treatment is to make patients and the family completely 
understand the concept of treatment. The medial abrasion phenomenon as an important 
etiologic factor should be emphasized. Daily activities, job and exercise modification could 
then be tailored for individual patient focusing on the avoidance of the medial abrasion 
phenomenon. In general, activities and exercises need repeated knee bending are regarded 
as harmful. The following recommendation shown in table 3 for activities and exercises is an 
example according to this principle. 
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Suitable  Harmful 
Walking Stairs or mountains  climbing 
Jogging Squatting (e.g. gardening) 
Golf Bicycling 
Swimming using freestyle or butterfly 
stroke Swimming using breaststroke 
Table 3. Recommendation for suitable or harmful activities and exercises for OA knee 
Home-based rehabilitation exercises including muscle strengthening and soft tissue 
stretching around the knee should be instructed and followed up under close surveillance 
from special personnels such as case managers or nursing specialists. 
5.4 Post-operative cartilage regeneration facilitating modalities (PCRFM) 
After the detrimental factors including medial abrasion syndrome, lateral compression 
syndrome, synovitis, chondral debris and meniscus flaps that have been proven as the main 
causes of cartilage damage are eliminated by ACRFP, the purpose of the post-operative care 
is to unveil and facilitate the natural repairing ability of the degenerated cartilage.  
During the first 3 months after ACRFP, the aim of rehabilitation is to prevent scar 
contracture and consequent recurrent medial abrasion phenomenon. Gentle deep bending 
stretching exercise is encouraged after each session of quadriceps strengthening exercise.  
To facilitate cartilage regeneration, strict rules about engaging into appropriate daily 
activites and exercises as listed in table 3 should be followed during the first post-operative 
year. The rationale of this precaution is to avoid repeated bending of the knee that might 
produce shearing force harmful for cartilage regeneration. Muscle strengthening and soft 
tissue stretching exercises around the knee should be conducted as long as possible.  
6. Conclusion  
The concept of knee health promotion option (KHPO) for the treatment of OA knee could be 
summarized in figure 18. From our series of studies and long-term clinical observation, we 
have defined a new entity - medial abrasion syndrome (MAS) and realized that it might be 
the main etiologic factor for the idiopathic medial compartment osteoarthritis of the knee 
joint. This syndrome could clarify most of the recognized symptoms, signs and risk factors 
of this common disease. Combined with other detrimental factors such as lateral 
compression syndrome, focal synovitis, chondral debris and meniscus flaps, the normal 
metabolism balance of articular cartilage is jeopadized and the knee “degenerates”. If these 
detrimental factors could be eliminated by ACRFP in time and KHPO undertaken, the 
natural repairing power of the articular cartilage could be revived and the “degenerated” 
knee might “regenerate”. In our clinical outcome study, the radiographic evaluations have 
demonstrated that, by removal of all existing catabolic factors, the anabolic pathway of the 
damaged cartilage might become dominant and regeneration unveiled. 
In conclusion, we have conceptualized a novel theory for the global management of OA 
knee. We propose that, by a purposeful eradication of all prejudicial factors in the 
degenerative knee, the jeopardized cartilage will have the potential to regenerate. In 
comparison with the uncertain beneficial mechanism and the diversity of outcomes of 
current popular arthroscopic techniques for osteoarthritis of the knee, our concepts of AMR, 
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ACRFP and KHPO have more precise rationale for the treatment and could bring hope to 
the majority of patients.  
 
 
A                                                                      A-1 
 
 
B                                                                     B-1 
MAS: medial abrasion syndrome; LCS: lateral compression syndrom; 
KHPO: knee health promotion option 
Fig. 18. A, multiple detrimental factors cause imbalance of cartilage metabolism and the 
knee continue “degeneration”; A-1, different life span of normal (yellowish green line) and 
degenerated knee (purple line); B, KHPO could revive the natural repairing capacity of 
cartilage and “regeneration” could be anticipated, B-1, KHPO could reverse the 
“degeneration” process and change the direction of purple line. 
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current popular arthroscopic techniques for osteoarthritis of the knee, our concepts of AMR, 
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ACRFP and KHPO have more precise rationale for the treatment and could bring hope to 
the majority of patients.  
 
 
A                                                                      A-1 
 
 
B                                                                     B-1 
MAS: medial abrasion syndrome; LCS: lateral compression syndrom; 
KHPO: knee health promotion option 
Fig. 18. A, multiple detrimental factors cause imbalance of cartilage metabolism and the 
knee continue “degeneration”; A-1, different life span of normal (yellowish green line) and 
degenerated knee (purple line); B, KHPO could revive the natural repairing capacity of 
cartilage and “regeneration” could be anticipated, B-1, KHPO could reverse the 
“degeneration” process and change the direction of purple line. 
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